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KL1
Ending the HIV/AIDS pandemic: follow the science
Anthony Fauci
National Institute of Allergy and Infectious Diseases
(NIAID)//National Institutes of Health (NIH), Bethesda, MD, USA
Scientific advances over the 35 years since AIDS was first recognized
as a new disease, have put us on a clear path towards ending the
HIV/AIDS pandemic. Scaling-up access to antiretroviral therapy (ART)
and HIV prevention strategies, such as pre-exposure prophylaxis,
could dramatically decrease HIV-related deaths and the rate of new
HIV infections. Current and future scientific advances, notably in HIV
vaccine and cure research, will accelerate this process. Two major
directions in HIV vaccine development will be discussed: building on
the results from RV 144, the clinical trial in Thailand that resulted in
the first modest signal of efficacy for a HIV vaccine; and structure-
based immunogen design to elicit broadly neutralizing antibodies.
Cure research has accelerated greatly over the past few years in two
areas. The first is the prospect of eradicating the HIV reservoir
altogether (i.e. a classic cure), which might involve novel latency-
reversing and immunotoxic regimens and gene editing techniques to
create a host cellular environment that does not allow HIV replication.
The second approach involves controlling viral rebound following
discontinuation of ART to achieve sustained virological remission
employing strategies, such as passive transfer of broadly neutralizing
antibodies and therapeutic vaccination. In 2016, the arsenal of scien-
tifically proven interventions available, as well as the hope of others
to come, offer unprecedented opportunities to make major gains
in the fight against HIV/AIDS. With a major global commitment to
implement these scientific advances, the end of the HIV/AIDS
pandemic is now achievable.
KL2
Treatment for cancer, HIV and viral hepatitis in Europe using
low-cost generic drugs: what could be done?
Andrew Hill
St Stephens AIDS Trust, Chelsea and Westminster Hospital,
London, UK
Across Europe, high drug prices can limit access to treatment for
hepatitis C, cancer and pre-exposure prophylaxis for HIV. Fifteen years
ago, it was shown that antiretrovirals for HIV/AIDS could be mass
produced at very low costs. This led to treatment programmes which
now supply drugs to more than 17 million people with HIV worldwide.
Similar analyses of drug production show that viral hepatitis,
tuberculosis and certain cancers could also be treated at very
low costs. Several key drugs will become generic in Europe within
the next 5 years.There is a potential to expand treatment coverage for
key diseases, while lowering overall costs of treatment. For mass
treatment with low-cost generic drugs to be successful, five key
conditions need to be met:
1. When any drug becomes generic, it should become available to
publicly run health services at prices close to the cost of production,
with an acceptable profit margin. These prices are freely available
from India.
2. Pharmaceutical companies should not be able to inflate the prices
of drugs after initial approval.
3. When a drug becomes generic and a low price is established, the
effects of this lower price on the value of other drugs should be
evaluated. Higher prices for newer drugs may no longer be justified.
4. Any secondary patent on a drug should be carefully evaluated for
validity.
5. Pharmaceutical companies involved in bribery, false advertising or
suppression of clinical trial results should pay significant fines, which
are then used to sponsor national treatment access schemes.
KL3
Revolution in prevention in low- and middle-income
settings
Linda-Gail Bekker
The Desmond Tutu HIV Centre, University of Cape Town, Cape Town,
South Africa
After 2000, we saw a remarkable era of HIV treatment roll out with
consequent notable public health gains. This will be remembered as a
treatment revolution. Most recently, with a number of important
human trials marking at least partial efficacy with male circumcision,
topical and systemic antiretroviral-based prophylaxis, HIV vaccines and
other promising primary prevention modalities in the pipeline, this
next decade could well be thought of as the prevention revolution.
How the prevention revolution plays out in resource-constrained
settings will depend on political will, resources and the competing
need to reach the other half of the treatment pool effectively.
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O11 - Antiretrovirals: Progress and
Remaining Challenges
O111
HIV treatment as prevention, from a research hypothesis to
a new global target and beyond
Julio Montaner
British Columbia Centre for Excellence in HIV/AIDS, and University of
British Columbia, Vancouver, Canada
Antiretroviral therapy (ART) has dramatically reduced pro-
gression to AIDS and premature death among people living with HIV
(PLHIV). Furthermore, ART is highly effective in preventing HIV
transmission. We refer to this combined effect of ART as treatment
as prevention (TasP). HIV TasP has proven cost-effective, because
beyond its impact on morbidity and mortality, TasP decreases HIV
incidence, which acts as a multiplier on the return-on-investment. In
2014, under the Joint United Nations Programme on HIV/AIDS
leadership, we developed the 909090 target, a new TasP-inspired
ambitious goal for global HIV treatment to ‘‘End the AIDS Pandemic’’ as
a public health threat by 2030. The 909090 target, proposes by
2020, ]90% of all PLHIV will know their HIV status; ]90% of them
will have access to ART; and]90% of themwill achieve sustained HIV
viral suppression. The success of HIV-TasP has fuelled enthusiasm that
this approach could be successfully exported and adapted to other
infectious diseases, such as hepatitis C infection. Similarly, there is
growing interest regarding a possible role TasP may play dealing with
conditions where there is ‘‘social contagion’’ (i.e. any condition where
increased prevalence is associated with increased incidence through
behavioural contagion; including smoking, addiction or obesity-related
diseases).We believe that TasP offers a unique means to optimize the
management of selected high burden conditions, with a view to
reduce morbidity and mortality, as well as prevalence and incidence
within a highly cost-effective framework, and as such, to promote
healthcare sustainability.
O112
Initiation of ART early in HIV infection: START to Finish
Jens Lundgren
Initiation of CHIP and PERSIMUNE, Rigshospitalet, University of
Copenhagen, Copenhagen, Denmark
The strategic question on when to initiate antiretroviral therapy (ART)
was finally resolved in 2015: since all HIV-positive persons stand to
benefit from ART, this treatment should be offered to all. The START
study provided key evidence by demonstrating a substantial reduction
in risk of disease progression by early versus deferred initiation of ART
in early HIV infection (i.e. before the CD4 cell count had decreased
below 500 cells/mL). A series of sub studies and secondary analysis
from START has subsequently been reported. The key findings from
this portfolio of research will be reviewed and will include the
identification of key subgroups with varying absolute risk reduction
from the early use of ART, immunological correlates of ART-induced
clinical protection, ART-induced depletion of bonemineral density, the
lack of benefit on arterial elasticity, pulmonary and neurocognitive
function, beneficial effects fromARTon opportunistic disease, invasive
bacterial infections, cancer, and kidney and bone marrow function.
Overall, the data demonstrate that the balance of benefits versus risks
from early ART favours the benefit across a wide spectrum of
pathophysiological processes. In conclusion, global consensus on
evidence for universal access to ART now exists; implementation
research is key, as only half of the infected population is currently
receiving ART.
O113
Transition to adult care
Pablo Rojo
Paediatric Infectious Diseases, Hospital 12 de Octubre, Complutense
University, Madrid, Spain
The presentation is given by a Spanish paediatrician, who will
be directing his presentation mainly to European adult HIV
physicians. This presentation will refer to the situation of HIV-infected
adolescents and young adults, mainly perinatally infected, being
transferred from paediatric HIV clinics to adult HIV clinics in Europe.
The presentation will focus specifically on three issues: 1) the
special pattern of adolescence and young adulthood in relation to
neurocognitive development, behaviour and chronic illness; 2) to
review what are the main clinical, immunovirological, psychological
and social characteristics of the adolescents and young adults who are
being transferred currently and in the near future to the adult
HIV clinics. Special attention will be on the differences between
the children born before and after combined antiretroviral
treatment, which was available in the paediatric population; and 3)
the system where they come from: the insights of a paediatric HIV
clinic in Europe.
O114
Persistent disparities in meeting WHO/UNAIDS targets
for ART coverage and ART-induced HIV RNA suppression
across Europe
Kamilla Grønborg Laut1,2; Leah Shepherd3; Roxana Radoi4;
Igor Karpov5; Milosz Parczewski6; Cristina Mussini7;
Fernando Maltez8; Marcelo Losso9; Nikoloz Chkhartishvili10;
Hila Elinav11; Helen Kovari12; Anders Blaxhult13; Robert Zangerle14;
Tatiana Trofimora15; Brygida Knysz16; Kai Zilmer17;
Elena Kuzovatova18; Therese Staub19; Dorthe Raben1,2;
Jens Lundgren1,2; Amanda Mocroft3 and Ole Kirk1,2
1CHIP-Centre for Health and Infectious Disease Research,
Rigshospitalet, University of Copenhagen, København, Denmark.
2Department of Infectious Diseases, Rigshospitalet, University of
Copenhagen, København, Denmark. 3Department of Infection and
Population Health, University College London, London, UK. 4Spitalul
de Boli Infectioase si Tropical, Dr Victor Babes Hospital, Bucharest,
Romania. 5Department of Infectious Diseases, Belarus State Medical
University, Minsk, Belarus. 6Department of Infectious and Tropical
Diseases, and Immune Deficiency, Pomeranian Medical University,
Szczecin, Poland. 7Department of Infectious and Tropical Diseases,
University of Modena and Reggio Emilia, Modena, Italy. 8Servico de
Doencas Infecciosas, Hospital de Curry Cabral, Lisbon, Portugal.
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9Servicio de Immunocomprometidos, Hospital JM Ramos Mejia, Buenos
Aires, Argentina. 10Infectious Diseases, AIDS & Clinical Immunology
Research Center, Tbilisi, Georgia. 11Department of Clinical
Microbiology and Infectious Diseases, Hadassah Hospital, Jerusalem,
Israel. 12Division of Infectious Diseases and Hospital Epidemiology,
University Hospital Zu¨rich, Zu¨rich, Switzerland. 13Department of
Infectious Diseases, So¨dersjukhuset, Venha¨lsan, Stockholm, Sweden.
14Department of Dermatology and Venerology, Medical University
Innsbruck, Innsbruck, Austria. 15Infectious Diseases, Novgorod Centre
for AIDS Prevention and Control, Velikij Novgorod, Russian
Federation. 16Department of Infectious Diseases, Wroclaw Medical
University, Wroclaw, Poland. 17Centre of Infectious Diseases, West-
Tallin Central Hospital, Tallin, Estonia. 18Nizhny Novgorod Scientific
and Research Institute of Epidemiology and Microbiology named
after Academician IN Blokhina, Privolzhsky Fed Dist AIDS Control and
Prevention C, Nizhny Novgorod, Russian Federation. 19Service des
Maladies Infectieuses, Centre Hospitalier de Luxembourg,
Luxembourg City, Luxembourg
Introduction: Direct comparisons between countries in core HIV care
parameters are often hampered by different data collection. We
compared temporal changes in country-specific rates of the UNAIDS/
WHO targets of90%ARTcoverage and90%ART-induced HIV RNA
suppression for a given population.
Materials and methods: EuroSIDA participants under follow-up
between the periods 1 January 2004 to 31 December 2005 and 1
January 2014 to 31 December 2015 were followed from first visit
until latest of CD4, HIV RNA or follow-up visit. Based on the included
EuroSIDA centres, country-specific proportions of persons on ART
(]3 antiretrovirals) and HIV RNA suppression (B500 copies/mL)
among patients on ART were assessed. Missing HIV RNA was
considered as unsuppressed. Temporal changes were analyzed using
generalized estimating equations, accounting for repeated measure-
ments and adjusting for age, gender, mode of infection, CD4 at first
visit, HBV and HCV status.
Results: A total of 11,975 people were under follow-up in the 2014/15
cohort (n8978 in 2004/05), in 105 clinics in Eastern Europe (EE)
(n1748), East Central (EC) Europe (n1884),Western Europe (WE)
(n2512), Southern Europe (SE) (n3109) and Northern Europe
(NE) (n2722). Overall ARTcoverage within EuroSIDA increased from
68.0% in 2004/05 to 82.4% in 2014/15 [adjusted odds ratio (aOR) of
being on ART in 2014/15 versus 2004/05: 1.90 (95% CI 1.772.03)],
and among those on ART, the proportion with suppressed HIV RNA
increased from 74.5 to 86.9% [aOR 2.09 (1.912.27)]. Overall odds of
being on ART and virologically suppressed doubled from 2004/05 to
2014/15 [aOR 2.13 (2.002.26)]. Improvements in ART coverage and
HIV RNA suppression varied significantly across regions (pB0.001)
and were greatest in EE where ARTcoverage and HIV RNA suppression
was low in 2004/05: in EE, aOR of being on ART and virologically
suppressed in 2014/15 versus 2004/05 was 15.78 (11.7521.19),
compared with EC aOR 2.39 (2.042.80),WE aOR 2.69 (2.383.04), SE
aOR 1.97 (1.772.19) and NE aOR 1.75 (1.531.99). In 2014/15, 6/35
(17%) countries had90% ARTcoverage and90% ART-induced HIV
RNA suppression [0/7 (0%) EE, 1/8 (13%) EC, 1/6 (17%) WE, 4/8 (50%)
NE and 0/6 (0%) SE countries]. However, the pattern differed
significantly between participating clinics across countries, with
country-specific proportions of ART coverage ranging from 63 to
98%, and viral suppression from 31 to 100% of those on ART (Figure 1).
Conclusions: Despite marked improvements over the last decade, we
observed persistent large variation among countries in our cohort in
meeting the UNAIDS/WHO targets for treatment coverage and
virological suppression. The representativeness of clinics and patients,
Abstract O114Figure 1. Unadjusted estimates of ART coverage and proportion with ART-induced HIV RNA suppression by EuroSIDA
country and region in two different time periods. Each bubble represents a country. The area of the bubble is proportional to the number of
people under follow-up in each country. The two dotted lines indicate 90% ART coverage (x-axis) and 90% ART-induced HIV RNA
suppression (y-axis). Eastern Europe: Belarus, Estonia, Georgia*, Latvia, Lithuania, Russia, Ukraine. East Central Europe: Bosnia-Herzegovina*,
Croatia*, Czech Republic, Hungary, Poland, Romania, Serbia, Slovakia$, Slovenia*. Western Europe: Austria, Belgium, France, Germany,
Luxembourg, Switzerland. Southern Europe: Argentina, Greece, Israel, Italy, Portugal, Spain. Northern Europe: Denmark, Finland, Iceland*,
Ireland, Netherlands, Norway, Sweden, UK. *included only in 2014/15 cohort; $included only in 2004/05 cohort.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Oral Abstracts
3
as well as underlying factors differentiating individual countries’ ability
to meet the targets, are under investigation.
O12 - Treatment Strategies
O121
Simplification to atazanavir/ritonavirlamivudine versus
maintaining atazanavir/ritonavir2NRTIs in virologically
suppressed HIV-infected patients: 96-week data of the
ATLAS-M trial
Roberta Gagliardini1; Massimiliano Fabbiani1; Eugenia Quiros
Roldan2; Alessandra Latini3; Gabriella D’Ettorre4; Andrea Antinori5;
Antonella Castagna6; Giancarlo Orofino7; Daniela Francisci8;
Pierangelo Chinello9; Giordano Madeddu10; Pierfrancesco Grima11;
Stefano Rusconi12; Barbara Del Pin13; Annalisa Mondi1;
Alberto Borghetti1; Emanuele Foca`2; Manuela Colafigli14;
Roberto Cauda1; Simona Di Giambenedetto1 and Andrea De Luca15
1Institute of Clinical Infectious Diseases, Catholic University of Sacred
Heart, Rome, Italy. 2Division of Infectious and Tropical Diseases,
University of Brescia, Brescia, Italy. 3Infectious Dermatology and
Allergology, IFO San Gallicano Institute (IRCCS), Rome, Italy.
4Department of Infectious Diseases, La Sapienza University, Rome,
Italy. 5Department of Infectious Diseases, National Institute for
Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
6Department of Infectious and Tropical Diseases, San Raffaele
Hospital, Vita-Salute San Raffaele University, Milan, Italy. 7Infectious
and Tropical Diseases Unit, Amedeo di Savoia Hospital, Torino, Italy.
8Infectious Diseases Clinic, University of Perugia, Perugia, Italy.
9Systemic Infections and Immunodeficiency Unit, National Institute
for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
10Department of Clinical and Experimental Medicine, University of
Sassari, Sassari, Italy. 11Division of Infectious Diseases, S. Caterina
Novella Hospital, Galatina, Italy. 12Dipartimento di Scienze
Biomediche e Cliniche, Luigi Sacco, Infectious Disease Unit, University
of Milan, Milan, Italy. 13Unit of Infectious Diseases, M. Annunziata
Hospital, Florence, Italy. 14Infectious Dermatology and Allergology
Unit, IFO San Gallicano Institute (IRCCS), Rome, Italy. 15Infectious
Diseases Unit, Siena University Hospital, Siena, Italy
Objectives: To explore 96-week non-inferior efficacy of treatment
simplification to atazanavir/ritonavirlamivudine versus continuing
atazanavir/ritonavir 2NRTI.
Materials and methods: ATLAS-M is a 96-week, multicentre, open-
label, randomized study. Subjects on atazanavir/ritonavir2NRTIs,
without previous virologic failures, with HIV RNA B50 copies/mL for
3 months and CD4 200 cells/mm3 for 6 months were eligible. At
baseline, ’ atazanavir/ritonavirlamivudine (dual therapy, DT) or to
continue the baseline regimen (triple therapy, TT). At 48 weeks, DT
showed a higher proportion of patients free of treatment failure
(primary study endpoint) when compared to TT, demonstrating super-
iority of DT strategy. Here we analyze the treatment failure, including
virologic failure (two consecutive HIV RNA 50 copies/mL or a single
value 1000 copies/mL), and other outcomes at 96 weeks.
Results: A total of 266 patients (78% males, median age 44 years,
median CD4 603 cells/mL, 79% treated with tenofovir) were enrolled.
Ninety-six-week data were available for 254 (126 in DT and 128 in
TT). At baseline, subjects in the two arms did not differ for the main
characteristics (Table 1). At 96 weeks, the proportion of patients free
of TF were 77.8% (95% CI 70.585.1) in the DT and 65.6% (95% CI
57.473.8) in the TT arm (difference12.2%, 95% CI1.2,23.2).
VF was observed in two (1.6%) patients randomized to DT and eight
(6.3%) to TT (p0.056). Clinical adverse events occurred at similar
rates in the two arms, mostly transient and not leading to treatment
discontinuation. More frequent in the DT arm were new-onset grade
3 to 4 hypertriglyceridemia (7.6% vs. 1.6%, p0.027) and hyperbi-
lirubinemia (59.6% vs. 35.8%, p0.001). No significant differences in
CD4 changes from baseline at week 96 were observed between the
two arms (mean 83 cells/mL in DT vs. 49 in TT, p0.233). A
greater increase in total cholesterol (15 vs.0 mg/dL, p0.005)
and HDL (5 vs.0 mg/dL, p0.002) was observed in the DT arm
without differences of other lipid parameters. Change from baseline
estimated glomerular filtration rate was significantly better in the
DT arm as compared to the TT arm (5 vs. 3 mL/min/1.73 m2,
pB0.001). No significant differences in other laboratory parameters
were observed between the study arms.
Conclusions: This 96-week data demonstrated non-inferiority and
even superior efficacy of treatment simplification to atazanavir/
ritonavirlamivudine as compared to continuation of atazanavir/
ritonavir2NRTIs in virologically suppressed patients. A numerically
higher rate of VF was observed in the TT arm. Switch to DT was
Abstract O121Table 1. Baseline patients characteristics based on randomization arm (interim 96-week population n254)
ATV/r3TC (DT arm) n126 ATV/r2NRTIs (TT arm) n128 p
Age, yearsa 43.4 (35.749.2) 44.2 (36.251.0) 0.963
Male gender 107 (84.9) 96 (75.0) 0.069
IDU (risk factor) 8 (6.3) 11 (8.6) 0.659
HCV co-infection 12 (9.5) 14 (10.9) 0.836
Previous AIDS events 17 (13.5) 11 (8.6) 0.961
Years from HIV diagnosisa 4.2 (2.18.6) 4.9 (2.510.4) 0.102
Years from first cART initiationa 2.7 (1.74.8) 2.7 (1.66.5) 0.207
Therapeutic linea 2 (13) 2 (13) 0.628
Months from last regimen initiationa 27.6 (17.952.5) 28.7 (16.152.0) 0.352
TDF-containing backbone 100 (79.4) 109 (85.2) 0.296
CD4 nadir, cells/mLa 277 (132359) 257 (144349) 0.848
CD4, cells/mLa 621 (466777) 614 (485784) 0.806
Months with viral load B50 copies/mLa 23.4 (12.646.7) 21.0 (12.544.9) 0.403
Values are expressed as n (%) except for amedian (interquartile range, IQR). 3TC, lamivudine; ATV/r, atazanavir/ritonavir; HCV, hepatitis C virus;
NRTI, nucleos(t)ide reverse transcriptase inhibitors; TDF, tenofovir.
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associatedwith improved renal function over TTcontinuation, but also
with increased total cholesterol and bilirubin levels.
O122
Dual therapy with a boosted protease inhibitor plus
lamivudine is an effective maintenance strategy in patients
on second-line antiretroviral therapy in Africa: the ANRS
12286/MOBIDIP trial
Laura Ciaffi1; Sinata Koulla-Shiro2; Adrien Sawadogo3;
N Fatou Ngom Gueye4; Vincent Le Moing1; Sabrina Eymard-
Duvernay1; Suzanne Izard1; Jacques Zoungrana3; Pretty Mbouyap5;
Mamadou Diallo6; Guillaume Bado3; Koumba Toure Kane7;
Avelin Aghokeng8; Martine Peeters1; Jacques Reynes9 and
Eric Delaporte1
1IRD INSERM, UMI 233, Montpellier, France. 2Faculty of Medicine
and Biomedical Sciences, University of Yaounde 1, Yaounde,
Cameroon. 3Hoˆpital de Jour, Centre Hospitalier Universitaire de
Souro Sanou, Bobo Dioulasso, Burkina Faso. 4Hoˆpital de Jour, Centre
Hospitalier Universitaire de Fann, Dakar, Senegal. 5Projet MOBIDIP,
Agence Nationale de Recherche sur le SIDA et les he´patites virales
(Cameroun Site), Yaounde, Cameroon. 6Centre Hospitalier
Universitaire de Fann, CRCF, Dakar, Senegal. 7Laboratoire de
Bacte´riologie-Virologie, Centre Hospitalier Universitaire Aristide Le
Dantec, Dakar, Senegal. 8Virology laboratory IMPM-IRD, Centre de
Recherche sur les Maladies Emergentes et, Yaounde, Cameroon.
9Maladies Infectieuses, Centre Hospitalier Universitaire Montpellier,
Montpellier, France
Introduction: Second-line ART regimens with ritonavir-boosted pro-
tease inhibitor (PI/r) plus nucleoside reverse-transcriptase inhibitors
(NRTIs) have shown good efficacy in resource-limited settings [13].
But issues of costs, toxicity and future options make a simplified
maintenance treatment a strategy of interest. We aimed to compare
two maintenance treatments with PI/r in mono- or dual therapy [plus
lamivudine (3TC)] in a group of virally suppressed patients on second-
line ART.
Material and methods: A randomized, open-label, multicentre clinical
trial was conducted in Cameroon, Senegal and Burkina Faso. HIV-1
positive patients followed in the ANRS 12186 2LADY trial [3] on stable
PI plus NRTIs second-line ART with HIV-1 RNA [viral load (VL)] below
200 copies/mL, CD4 above 100 cells/mm3 and adherence]90%,were
included in a two arms trial comparing monotherapy with the ongoing
PI/r: darunavir (DRV/r) or lopinavir (LPV/r)  mono arm  with the
same PI/r associated with 3TC 300 mg  dual arm. The primary
outcomewas failure rate at 96weeks.Treatment failure was defined as
1) a confirmed VL above 500 copies/mL, 2) reintroduction of the NRTI
backbone or 3) the interruption of PI.
Results: From March 2014 to January 2015, 265 patients were
randomized (133 in mono arm and 132 in dual arm). Included patients
were mainly women (73%), with a median age of 42 years
[interquartile range (IQR) 3650]; median CD4 was 475 cells/mm3
(IQR 379652) and median time on second line was 37 months (IQR
3047). At the failure of first line, 96% had the M184V mutation. For
the Data Safety Board meeting in March 2016, week 48 data were
analyzed. The Board advised for the interruption of the mono arm. In
the ITT analysis, 3.0% (95% CI 0.87.6) and 22.6% (95% CI 15.830.6)
of patients failed in the dual and mono arm respectively (pB0.001).
Median time to failure was 24 weeks. All failing patients, except one,
resuppressed to less than 200 copies/mL in amedian time of 12 weeks
after reintroduction of the NRTI backbone. Increase in CD4 was
significantly higher in the dual arm (48 vs. 7 cells/mm3). No differences
in adverse events were observed. Neither adherence, nor nadir CD4
count, nor PI drug were associated with failure.
Conclusions: After viral suppression with PI plus NRTIs in second-line
therapy, maintenance with PI/r plus 3TC is associated with a high
rate of success despite the presence of M184V while PI/r mono-
therapy cannot be recommended.
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O123
Resistance profile analysis of treatment-experienced HIV-1-
infected patients switching to elvitegravir/cobicistat/
emtricitabine/tenofovir alafenamide (E/C/F/TAF) plus
darunavir (DRV)
Nicolas Margot1; Renee Ram1; Moupali Das2; Marshall Fordyce2;
Scott McCallister2; Michael Miller1 and Christian Callebaut1
1Clinical Virology, Gilead, Foster City, CA, USA. 2Clinical Research,
Gilead, Foster City, CA, USA
Introduction: In study GS-US-292-0119, virologically suppressed,
treatment-experienced patients on complex multi-tablet regimens
[1] were switched to a simpler, more convenient antiretroviral
regimen. After 48 weeks, viral suppression was maintained in 94.4%
of patients who switched to E/C/F/TAFDRV compared to 76.1% in
the DRV-containing ‘‘Stay on Baseline Regimen’’ arm. All patients had
documented resistance to 2 classes of antiretroviral (ARV) agents
at baseline. Detailed ARV regimens and the resistance profile of the
study population are described.
Methods: Historical genotypic reports were analyzed for resistance-
associated mutations (RAMs) to ARVs. The Stanford HIVdb algorithm
version 8.01 was used to calculate genotypic susceptibility scores
(GSS). For each drug, a 5-point scale was used: susceptible, potential
low-level resistance, low-level resistance, intermediate-level resis-
tance and high-level resistance were scored as 1, 0.75, 0.5, 0.25 and
0, respectively. The total GSS for a given regimen was calculated as
the sum of the scores for each individual drug.
Results: A total of 94.8% had documented resistance to 2 classes
of ARVs, including protease inhibitors (PIs; 34.8%), non-nucleoside RT
inhibitors (NNRTIs; 88.1%) and NRTIs (94.8%). The most common PI-
RAMs were L90M (15.6%) and V82A/F/L/S/T (14.8%), the most
common NNRTI-RAMs were K103N/S (63%) and Y181C/I/V (19.3%)
and the most common NRTI-RAMs were M184V/I (83%) and K65R
(23.7%). Thymidine analog mutations (TAMs) were present in 42.2%
of patients (59.6% with one or two TAMs and 40.4% with three
TAMs). The distribution of GSS at study entry was similar across
treatment groups. Patients in the E/C/F/TAFDRV arm maintained
virologic suppression similarly, regardless of the DRV dosage received
before switching (33/33 and 51/56 with treatment success in the 600
mg BID and 800 mg QD groups, respectively). In the E/C/F/TAFDRV
arm, 11/89 patients (12.4%) had GSS B2, 51/89 patients (57.3%)
had GSS ]2 and B3, and 27/89 patients (30.3%) had GSS ]3.
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Within each treatment group, patients maintained virologic suppres-
sion similarly regardless of their GSS at study entry.
Conclusions: Despite the high incidence of pre-existing re-
sistance in this population, including resistance to ]2 classes of
ARVagents and presence of K65R or53 TAMs, strategic simplification
to E/C/F/TAFDRVwas statistically superior to staying on the baseline
regimen. Patients benefited from switching regimen regardless of their
prior DRVdose and their GSS.Treatment with E/C/F/TAFDRVoffers a
simpler and more convenient option for treatment-experienced
patients on complex multi-tablet regimens.
Reference
1. Huhn G, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, et al. Strategic
simplification: the efficacy and safety of switching to Elvitegravir/
Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Plus Daruna-
vir (DRV) in treatment-experienced HIV-1-infected adults [Oral Presenta-
tion #726]. IDWeekTM, Oct 711 2015, San Diego, CA.
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Switching from rilpivirine/emtricitabine/tenofovir
disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/
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safety and efficacy through 48 weeks
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Introduction: Tenofovir alafenamide (TAF) is a novel tenofovir (TFV)
prodrug that achieves 91% lower plasma TFV levels than seen with
TDF, reducing the risks of renal and bone toxicities. The impact of
switching from TDF (300 mg) to TAF (25 mg), as a fixed-dose
combination with RPV (25 mg) and FTC (200 mg), was evaluated in
this first phase 3 clinical trial of RPV/FTC/TAF. Primary endpoint
(week 48) results are presented.
Materials and methods: A randomized (1:1), double-blind, active-
controlled, phase 3 study was conducted in virologically suppressed
(HIV-1 RNA B50 copies/mL) and HIV-infected adults with estimated
glomerular filtration rate (eGFR)50mL/min taking RPV/FTC/TDF for
at least 6 months. Eligible study participants were randomized to
switch to RPV/FTC/TAF or to continue RPV/FTC/TDF. Primary endpoint
was virologic suppression (HIV-1 RNA B50 copies/mL) at week 48 by
FDA snapshot algorithm with a pre-specified non-inferiority margin of
8%. Bone and renal safety, and tolerability endpoints were evaluated.
Results: A total of 630 patients were enrolled (RPV/FTC/TAF 316 vs.
RPV/FTC/TDF 314): median age 45 years, 10% women and 19% black.
Through week 48, switching to RPV/FTC/TAF was non-inferior to
remaining on RPV/FTC/TDF (94% vs. 94%; exact difference: 0.3%;
95% CI 4.2% to 3.7%). General safety was similar between the
arms with low rates of grade 3 to 4 adverse events (AEs). The rate of
discontinuations due to AEs was 0.1% in both groups. Improvement in
bone mineral density was observed in the RPV/FTC/TAF group com-
pared to the RPV/FTC/TDF group, with higher mean changes from
baseline: hip1.04% versus 0.25% (pB0.001) and spine1.61%
versus 0.08% (pB0.001), respectively. Median eGFR increased
4.5 mL/min for RPV/FTC/TAF and 0.7 mL/min for RPV/FTC/TDF
(p0.002). Improvements in quantitative proteinuria, including
tubular proteinuria, were seen in patients switching to RPV/FTC/TAF
(pB0.001) (Table 1). No cases of Fanconi syndrome or proximal renal
tubulopathy were reported.
Conclusion: Through 48 weeks, virologically suppressed patients
switching to RPV/FTC/TAF maintained high rates of virologic
suppression, with improved markers of bone and renal safety
compared to those remaining on RPV/FTC/TDF.
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Long-term (96-week) efficacy and safety after switching from
tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
(TAF) in HIV-infected, virologically suppressed adults
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Table 1. Changes in proteinuria at week 48
PV/FTC/
TAF
RPV/
FTC/TDF p
Urine protein: creatinine ratio
Median baseline value (mg/g) 53.2 50.0 0.69
Median % changes at week 48 18.8 7.3 B0.001
Urine albumin: creatinine ratio
Median baseline value (mg/g) 5.5 5.4 0.98
Median % changes at week 48 7.8 16.8 B0.001
Urine retinol binding protein: creatinine ratio
Median baseline value (mg/g) 101.2 111.1 0.12
Median % changes at week 48 18.0 21.5 B0.001
Urine beta-2-microglobulin: creatinine ratio
Median baseline value (mg/g) 111.6 116.1 0.72
Median % changes at week 48 29.0 12.0 B0.001
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Introduction: Recent HIV treatment guidelines have either replaced
TDF with TAF or included both as part of recommended initial
regimens. This study assesses long-term efficacy, safety and toler-
ability of switching emtricitabine FTC/TDF to FTC/TAF, each with
various third agents, through Week (W) 96.
Methods: In this double-blind, active-controlled study, virologically
suppressed HIV-infected participants receiving FTC/TDF-containing
regimens were randomized (1:1) to switch to FTC/TAF versus
continue FTC/TDF while remaining on the same third agent. Virologic
suppression (HIV-1 RNA B50 c/mL) by FDA snapshot analysis,
markers of bone and renal safety, and safety and tolerability were
assessed up to W96.
Results: A total of 663 participants were randomized and treated (FTC/
TAF N333, FTC/TDF N330): median age 49 years, 15% women,
median estimated glomerular filtration rate (eGFR, Cockcroft Gault)
100 mL/min. Third agents included boosted protease inhibitors (46%),
integrase inhibitors (28%) and non-nucleoside reverse transcriptase
inhibitors (25%). Median duration of FTC/TDF use prior to enrolment
was 5.1 years. Through W96, virologic suppression was maintained in
89% of participants in both groups [difference 0.5%; 95%CI
(5.3%, 4.4%)]. One FTC/TAF participant developed M184V in the
first 48 weeks. Drug-related serious adverse events (AEs) were rare
(FTC/TAF: 0 vs. FTC/TDF: 0.3%). Drug discontinuation due to AEs was
low (FTC/TAF: 2.4% vs. FTC/TDF: 1.2%). No cases of Fanconi syndrome
or proximal renal tubulopathy occurred with FTC/TAF; one FTC/TDF
participant discontinued study drug due to proximal tubulopathy.
Biomarkers of renal safety favoured FTC/TAF (Table 1). Lumbar spine
and hip bone mineral density (BMD) increased in the FTC/TAF group,
while decreasing in the FTC/TDF group (Table 1), with ]3%
improvement at W96: lumbar spine BMD 40% versus 18%, hip BMD
29% versus 11%, respectively. There were greater increases in lipids
[including high-density lipoproteins (HDL)] with FTC/TAF versus FTC/
TDF but no difference in total cholesterol to HDL ratio (Table 1) or
initiation of lipid-lowering agents (FTC/TAF: 7% vs. FTC/TDF: 6%).
Conclusion: In virologically suppressed participants switching from
FTC/TDF to FTC/TAF high rates of virologic suppression were
maintained, while renal and bone safety parameters improved. These
long-term data support FTC/TAF as a safe and durable backbone,
which can be used in combination with various third agents for
treatment of HIV-1 infection.
O13 - Keeping the Patient in the Centre
of Quality Care: What Matters?
O131
Confidentiality matters: innovative HIV testing
Cheryl Johnson
World Health Organization, Geneva, Switzerland
The global scale-up of HIV testing services (HTS) has been
tremendous; however, many of these tests never reach those with
undiagnosed HIV and at high ongoing risk, for example, key
populations, men and adolescents. Approximately 40% of people
with HIV remain undiagnosed, and thus unable to receive life-saving
treatment or effective prevention to stop onward transmission. To
achieve the United Nation’s 909090 goals, greater efforts and
innovations are needed, starting with the first 90 goal, which calls for
the diagnosis of 90% of all people with HIV by 2020. Globally, 35% of
new HIV infections are among key populations and their partners.
Yet, HTS coverage and uptake among key populations remains poor
and irregular worldwide. Men also remain unreached and untested,
and evidence shows men present late in disease stage and have
higher HIV-related mortality compared with women. Young people in
high incidence settings, particularly sub-Saharan Africa, also remain
untested and unlinked to prevention and treatment. It is well
documented that among these populations, unfriendly services, fear
of stigma and discrimination, and lack of privacy and confidentiality
are barriers to HTS uptake. In many environments, this is further
exacerbated by restrictive policies, such as age of consent laws and
policies which criminalise key populations for their behaviour;
deterring HTS uptake among those with greatest need. HTS
approaches must evolve and utilize innovative methods that are
effective, acceptable and meet the patient’s need for confidentiality,
such as HIV self-testing, anonymous and assisted HIV partner
notification, and community- and facility-based models which take
place in discreet locations, offer night-time hours, use trusted peers
and lay providers, and are designed to be friendly and attractive to
key populations, men and adolescents. Placing people at the highest
risk of HIV at the centre of HIV testing programmes is essential, and
this is the only way to reach and go beyond the first 90 goal.
O132
Convenience matters: catalogue STI testing and PrEP
Patrick S Sullivan
Rollins School of Public Health, Emory University, Atlanta, USA
Mathematical modelling suggests that reducing HIV incidence among
men who have sex with men (MSM) will require achieving high
coverage of multiple HIV prevention interventions [e.g. HIV testing,
sexually transmitted infections (STI) testing, condom promotion and
pre-exposure prophylaxis (PrEP)]. For reasons of convenience and to
minimise the burden on healthcare providers, we have developed
Table 1. Changes in renal, bone and lipid parameters from
baseline to week 96
Parametersa,b
FTC/TAF
(N333)
FTC/TDF
(N330)
eGFR, mL/min (Cockcroft Gault) 10.0 4.0
Urine protein: creatinine ratio, % 26.0 2.7
Urine albumin: creatinine ratio, % 3.4 27.0
Urine beta-2-microglobulin:
creatinine ratio, %
29.7 46.8
Urine retinol binding protein:
creatinine ratio, %
4.1 42.6
Lumbar spine BMD, % 2.153 0.167
Hip BMD, % 1.853 0.331
Total cholesterol, mg/dL 14 1
LDL cholesterol, mg/dL 14 4
HDL cholesterol, mg/dL 1 1
Triglycerides, mg/dL 11 2
Total cholesterol: HDL ratio 0.1 0.1
aMean is used to summarize BMD; otherwise, median is used;
bp-values were B0.05 for all, except total cholesterol to HDL ratio
(p0.26).
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systems to offer self-service options for HIV self-testing with
telemedicine counselling, if requested; home specimen collection
with mail-in processing of tests for HIV, urethral and rectal STIs; and
at-home self-monitoring of behaviours and laboratory screens for
MSM on PrEP. Acceptability has been high among MSM and their
healthcare providers for these programmes. However, some chal-
lenges remain in the evaluation of programmes and in bringing
programmes to a broader scale in the United States. Mail-out kits for
STI testing and for PrEP monitoring offer important options to reach
the highest risk MSM with a higher frequency of STI testing, and to
lower the burden of follow-up PrEP care.
O133
Context matters: one-stop medical care from Eastern
Europe to downtown London
Jeffrey V Lazarus
CHIP, Centre for Health and Infectious Disease Research and WHO
Collaborating Centre on HIV and Viral Hepatitis, Rigshospitalet,
University of Copenhagen, Copenhagen, Denmark
Despite great advances in HIVmedicine, people living with HIV (PLHIV)
in many European settings are not attaining optimal health outcomes.
This situation raises important questions about how well national and
local health systems are meeting the full spectrum of PLHIV health
needs. The public health community’s increasing interest in health
system performance in recent years presents important opportunities
for researchers, policy-makers, community stakeholders and others to
explore how PLHIV healthcare can be advanced in tandemwith efforts
to improve overall health system functioning. A key issue in this realm
is the goal of making health systems more people-centred. As health
system experts continue to explore what constitutes a ‘‘people-
centred health system’’ in theory and in practice, the HIV field stands
poised to make unique contributions to this emerging body of
knowledge, which is greatly needed by policy-makers who seek to
make health systems more cost-efficient and more equitable.
Providing integrated ‘‘one-stop’’ medical care is one important aspect
of people-centred health systems, but how can critical practices
stemming from integrated care be transferred to HIV care and applied
effectively in markedly different settings within and across countries?
This presentation draws on the paradigm of people-centred health
systems to provide strategic thinking into how to utilize local and
national healthcare contexts to drive forward this next step in HIV
care, which includes how to improve the quality of life of PLHIV.
O134
Choice matters: differentiated models of care
Helen Bygrave
SAMU (Southern Africa Medical Unit), Me´decins Sans Frontie`res,
Cape Town, South Africa
Differentiated care is a patient-centred approach that simplifies and
adapts HIV services across the cascade to reflect the preferences and
expectations of various groups of people living with HIV, while
reducing unnecessary burdens on the health system. By providing
differentiated care, the health system can refocus resources to those
most in need. Antiretroviral therapy (ART) delivery may be
differentiated according to the medical needs of the patient,
subpopulation and contextual factors. Using the ‘‘building blocks’’
of differentiated care, a model may be built to determine where,
how often and to whom ART is provided to. Differentiated ART
delivery for stable patients has demonstrated positive outcomes for
both health systems and patients. In South Africa, HIV Adherence
Clubs, where groups of 20 to 30 patients meet at either a facility or
community location to receive their ART, have demonstrated higher
rates of both retention (97% vs. 85%), virological uptake and
suppression than those in conventional care. Community ART groups
in Tete, Mozambique, where self-formed groups of patients on ART
collect medication for each other, demonstrated retention within the
model of 98%, 96%, 93% and 91% at 12, 24, 36 and 48 months,
respectively. Such group models of ART delivery have also demon-
strated an impact on reducing clinical visits, along with enhancing
peer and community support. Moving forward, differentiated ART
delivery must be adapted beyond stable patients and the principles
applied across the HIV cascade. By adopting such patient-centred
approaches, differentiated care will be a part of the solution to reach
the United Nation’s 909090 target in the era of start all.
O21 - Co-morbidities andHIVManagement
O211
Helping the HIV physician through the challenges of co-
morbidities
Edouard Battegay
Center of Competence Multimorbidity, University Hospital Zurich,
Zurich, Switzerland
Between 20 and 30% of the population and about 90% of inpatients
hospitalized in General Internal Medicine have multiple concurrent
acute or chronic diseases, that is, multi-morbidity (MM). Complexity
increases proportionally with the number of concurrent diseases,
probably partially due to diseasedisease interactions (DDIs). Risk
factors for HIV, such as intravenous (IV) drug use and successful near-
normalization of life expectancy in HIV, have increased the likelihood
of other concurrent diseases to occur and to determine life
expectancy. In one study, people living with HIV/AIDS had a
prevalence of one or more co-morbidity of 29%, a rate similar to
the population at large. Concurrent diseases associated with IV drug
use include hepatitis and sometimes severe mental disorders.
However, in ageing HIV patients especially, diseases constitute very
typical MM clusters that include vascular risk factors and disease,
heart and pulmonary disease, major mental disorders and a broad
array of various other medical diseases and conditions. These occur
sometimes in characteristic dyadic or triadic, or higher combinations
(painful syndromes and depression; non-adherence and depression,
and hypertension and HIV; pain treatment for arthritis and hyperten-
sion; non-adherence and mental disorders, etc.). Some of these
conditions and combinations of interactions interact with HIV to
worsen the prognosis. There are limited evidence-based guidelines for
MM, be it without or with HIV, even for more prevalent forms of MM
and frequent interacting combinations (mentioned earlier). This
leaves MM care heavily reliant upon clinical guidelines intended for
the treatment of single diseases. However, these guidelines do not
adequately address the combined risk to multi-morbid patients and
tend to ignore adverse DDI’s (diseasedisease, drugdisease and
drugdrug interactions, due to multiple drug regimens, i.e. poly-
pharmacy), especially if a condition is outside the usual realm of those
specialists from the same field of expertise that wrote the guidelines.
Decision-making concerning therapeutic conflicts due to adversely
interacting treatments usually remains to be resolved at the dis-
cretion of involved clinicians. These conflicts typically demand priori-
tizing and reconciling adverse DDIs with the most suitable, best
acceptable and sometimes surprising therapeutic strategy. They also
require medical doctors to communicate these dilemmas and the
corresponding lack of evidence-based security to patients in order to
allow for shared decision-making, if possible and if wished. Further-
more, decision-making in dilemma situations can induce psychological
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stress upon patients, especially on conscientious medical doctors that
they need to consciously deal with.
O212
HIV patients today and 10 years ago: do they have the same
needs? Results from cross-sectional analysis of ANRS CO3
Aquitaine cohort
Fabrice Bonnet1; Fabien Le Marec2; Olivier Leleux2;
Charles Cazanave3; Estibaliz Lazaro1; Pierre Duffau1; Marie-
Anne Vandenhende1; Patrick Mercie1; Didier Neau3 and
Franc¸ois Dabis2
1Service de Me´decine Interne et Maladies Infectieus, Centre
Hospitalier Universitaire de Bordeaux, Bordeaux, France. 2INSERM
U1219, ISPED, Universite´ de Bordeaux, Bordeaux, France. 3Service de
Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire
de Bordeaux, Bordeaux, France
Introduction: Nowadays, people living with HIV (PLHIV) live longer,
due to highly effective ART. Also, due to age, risk factors exposure,
ART and HIV-related factors, they are more likely to develop
comorbidities, potentially requiring different, long-term healthcare
management. This study aimed to describe the PLHIV characteristics,
HIV markers, comorbidities and their risk factors and scores, in the
same patients 10 years apart.
Materials andmethods: The ANRSCO3Aquitaine cohort prospectively
collects epidemiological, clinical, biological and therapeutic data on
PLHIV in the French Aquitaine region. Inclusion criterion for this
analysis was ]1 visit in both calendar years. Two cross-sectional
analysis were performed (2004 and 2014), regarding patient char-
acteristics, HIV markers, the prevalence of comorbidities [chronic
kidney disease (CKD), fractures, cardiovascular disease (CVD), dia-
betes, dyslipidaemia and hypertension, defined via ICD-10 diagnosis
code, treatments or values for these comorbidities] and treat-
ment (ART and comedication).
Results: A total of 3289 PLHIV had at least a visit registered in the
cohort in 2004 and 3880 in 2014, out of which 2138 had a visit in both
years. Seventy-one percent of those were male, and in 2014 the
median age was 52.2 (IQR 47.658.1). When compared to 2004, in
2014 thereweremore patients virologically suppressed (91.5% in 2014
vs. 50.9%; pB0.0001) and 72.0% in 2014 versus 43.6% patients in
2004 had CD4 count ]500 cells/mL (pB0.0001). Table 1 shows a
statistically significant increase in the prevalence of diagnosed CKD,
fractures (anywhere), CVD events, hypertension, diabetes and dysli-
pidaemia, but also for their treatment: statins use for dyslipidaemia
(9.2% in 2004 vs. 24.0% in 2014; pB0.0001); clopidogrel and aspirin
use for CVD events prevention (clopidogrel: 0.8% vs. 4.1%; pB0.0001;
aspirin: 0.9% vs. 8.0%; pB0.0001; 2004 and 2014, respectively).This is
also reflected in the higher proportion of patients in the high risk or
very high groups in the different disease risk scores for CKD, CVD and
bone fracture score.
Conclusions: As PLHIV life expectancy increases, age-related comor-
bidities are increasing, leading to different needs in today’s HIV
disease management. Even for the patients in this analysis who
present favourable HIV disease progression, there is still a significant
increase on the comorbidity burden, and therefore a need for a more
holistic, long-term, multidisciplinary approach that considers not only
the ART, but also lifestyle, to manage HIV patients, potentially
leading to improved outcomes.
O213
Long-term impact of lipodystrophy on the risk of
morbidity and mortality: a 20-year longitudinal
cohort study
Gemma Sanchez; Ana Gonzalez-Cordon; Jhon Rojas; Jose Blanco;
Jordi Blanch; Montserrat Lonca; Berta Torres; Maria Martinez-
Rebollar; Montserrat Laguno; Amparo Tricas; Ana Rodriguez;
Josep Mallolas; Jose Gatell; Judit Pen˜afiel; Elisa de Lazzari and
Esteban Martinez
Hospital Clı´nic-Institut d’Investigacions Biome`diques August
Pi i Sunyer, University of Barcelona, Infectious Diseases Unit,
Barcelona, Spain
Abstract O212Table 1. Prevalence of comorbidities, their treatments and risk factors in 2004 and 2014
2004; N2,138 2014; N2,138 p
Patients with CD4 count ]500 cells/mL, % 43.6 72.0 B0.0001
Patients with HIV RNA 50 copies/mL, % 50.9 91.5 B0.0001
Prevalent CKD (diagnose or 2 consecutive eGFR B60), % 3.6 18.3 B0.0001
DAD CKD high risk score, % 29.9 50.7 B0.0001
Prevalent fractures (anywhere), % 0.7 7.0 B0.0001
10-year FRAX high risk score group, % 0.3 2.9 B0.0001
Prevalent CVD events (ever), % 3.6 14.0 B0.0001
DAD CVD very high risk score group, % 5.3 19.9 B0.0001
Framingham high risk score group, % 11.6 26.2 B0.0001
Patients on clopidogrel, % 0.8 4.1 B0.0001
Patients on aspirin, % 0.9 8.0 B0.0001
Prevalent hypertension, % 18.8 56.3 B0.0001
On blood-lowering treatment, % 6.0 22.7 B0.0001
Prevalent diabetes, % 8.4 18.5 B0.0001
On antidiabetics, % 2.4 5.8 B0.0001
Prevalent dyslipidaemia, % 14.3 54.5 B0.0001
On treatment with statins, % 9.2 24 B0.0001
CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, glomerular filtration; DAD, Data Collection on Adverse Events of Anti-HIV Drugs;
FRAX, WHO Fracture Risk Assessment tool.
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Introduction: Lipodystrophy is considered to accelerate the process
of aging in HIV-infected persons, but long-term data showing an
impact on morbidity and mortality are lacking. We hypothesized that
lipodystrophy would increase the risk of comorbidities and death.
Methods: Within a previously well-defined cohort [1], including all
consecutive antiretroviral-naive HIV-infected adults who began two
nucleoside reverse transcriptase inhibitors plus at least one protease
inhibitor from October 1996 to September 1999, moderate or severe
body fat changes were clinically assessed and categorized as
lipoatrophy (LA), lipohypertrophy (LH) or both lipodystrophy (LD).
Clinical and laboratory data were periodically registered into a specific
database. Patients were followed until December 2015, death or lost-
to-follow-up, whichever came first. A person-years analysis was used
to calculate the incidence of specific non-AIDS comorbidities (first
diagnosis), AIDS events (new events) or death. Incidences were
compared with Poisson or negative binomial regression models.
Results: Of 494 patients included, 118 (24%) developed LA only, 20
(4%) LH only, and 89 (18%) both; 71 (14%) patients died and 106
(21%) were lost to follow-up. Increasing age, HIV acquisition through
injecting drug use and lack of hepatitis C co-infection were factors
significantly associated with any LA (n207, 42%), any LH (n109,
22%) or any LD (n227, 46%). Both patients with any LA or any LH
had significantly higher total cholesterol and triglycerides at the end
of follow-up relative to patients without any LA or any LH,
respectively. Patients with any LA (but no patients with LH) also
had significantly higher CD4 cell counts (572 vs 492 per mm3,
p0.0025), higher proportion of viral suppression in plasma (87% vs.
69%, pB0.0001) and higher haemoglobin (146 vs. 145 g/dL,
p0.0210) at the end of follow-up compared with patients without
any LA. Incidence rate ratios (IRR) (95% CI) of any LA, any LH or any LD
for non-AIDS comorbidities, AIDS events or death are shown in Table
1 (IRR 1 is the reference for patients without both LA and LH).
Conclusion: Hypertension and diabetes were the only non-AIDS
comorbidities showing a higher risk in patients with any LA, any LH
or any LD. However, contrary to our hypothesis, any LA, any LH or
any LD were associated with a lower risk of death; in addition, any LA
or any LD (but not any LH) were also associated with a lower risk of
AIDS events and hepatic decompensation.
Reference
1. Martinez E, Mocroft A, Garcı´a-Viejo MA, Pe´rez-Cuevas JB, Blanco JL,
Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated
with protease inhibitors: a prospective cohort study. Lancet. 2001;
357:5928. doi: http://dx.doi.org/10.1016/S0140-6736(00)04056-3
O214
Higher rates of neuropsychiatric adverse events leading to
dolutegravir discontinuation in women and older patients
Michael Sabranski1; Christoph Wyen2; Christian Hoffmann1;
Tanya Welz2; Michael Kolb2; Eva Wolf3 and Hans-Juergen Stellbrink1
1Infectious Diseases, ICH Study Center Hamburg, Hamburg, Germany.
2Infectious Diseases, Praxis am Ebertplatz, Cologne, Germany.
3Infectious Diseases, MUC Research, Munich, Germany
Introduction: Dolutegravir (DTG), a second-generation integrase
strand transfer inhibitor (INSTI), is now among the most frequently
used antiretroviral agents. However, recent reports have raised
concerns about potential neurotoxicity.
Methods: We performed a retrospective analysis of a cohort of HIV-
infected patients who had initiated an INSTI in two large German
outpatient clinics between 2007 and 2016. We compared disconti-
nuation rates due to adverse events within 2 years of starting
between DTG, raltegravir (RAL) or elvitegravir (EVG)/cobicistat. We
also evaluated factors associated with DTG discontinuation.
Results: A total of 1950 INSTI-based therapies were initiated amongst
1704 patients eligible for analysis within the observation period. The
estimated rates of any adverse event (AE) and of neuropsychiatric AEs
leading to discontinuation within 12 months were 7.6% and 5.6%
respectively for DTG (n985), 7.6% and 0.7% for EVG (n287) and
3.3% and 1.9% for RAL (n678). Neuropsychiatric AEs leading to DTG
discontinuation were observed more frequently in women (hazard
ratio [HR] 2.64; 95% CI 1.235.65, p0.012), in patients older than
60 years (HR 2.86; 95% CI 1.425.77, p0.003) and in HLA-B*57:01-
negative patients who initiated abacavir at the same time (HR 2.42;
95% CI 1.384.24, p0.002).
Conclusion: In this large cohort, the discontinuation rate of DTG due
to neuropsychiatric AEs was significantly higher than with the other
INSTIs at almost 6% within 12 months. Almost three-fold higher
discontinuation rates observed amongst women and older patients
underscore the need for further investigation, especially in patient
populations usually under-represented in clinical trials.
O215
Cognitive function and depression in HIV-positive
individuals and matched controls
Davide De Francesco1; Jonathan Underwood2; Marta Boffito3;
Frank Post4; Patrick Mallon5; Jaime Vera6; Ian Williams1;
Jane Anderson7; Margaret Johnson8; Caroline Sabin1 and
Alan Winston2
Abstract O213Table 1. Incidence rate ratios (IRR) (95% CI) of any lipoatrophy (LA), any lipohypertrophy (LH) or both lipodystrophy
(LD) for non-AIDS comorbidities, AIDS events or death
Outcomes Any LA (n207) Any LH (n109) Any LD (n227)
Any non-AIDS comorbidity (n379) 1.05 (0.811.36) 1.25 (0.931.68) 1.06 (0.821.38)
Hypertension (n70) 1.77 (1.102.86) 2.41 (1.493.90) 2.00 (1.223.28)
Non-AIDS neoplasia (n65) 1.19 (0.731.93) 1.21 (0.702.11) 1.04 (0.641.70)
Cardiovascular events (n56) 1.30 (0.772.19) 1.38 (0.782.47) 1.53 (0.892.61)
Diabetes mellitus (n42) 2.27 (1.194.31) 2.51 (1.354.65) 2.51 (1.284.90)
Bone fractures (n39) 0.53 (0.271.03) 0.61 (0.261.46) 0.58 (0.311.11)
Chronic kidney disease (n38) 1.09 (0.582.05) 1.05 (0.502.22) 1.06 (0.562.00)
Chronic obstructive pulmonary disease (n34) 0.58 (0.291.17) 1.06 (0.482.34) 0.57 (0.291.15)
Hepatic decompensation (n18) 0.31 (0.100.93)  0.27 (0.090.82)
Neurocognitive impairment (n17) 0.58 (0.221.58) 0.73 (0.212.52) 0.51 (0.191.38)
AIDS events (n104) 0.53 (0.330.86) 0.68 (0.371.24) 0.53 (0.330.85)
Death (n71) 0.41 (0.250.70) 0.48 (0.250.92) 0.43 (0.260.71)
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Introduction: Cognitive disorders and depression remain prevalent in
people living with HIV (PLWH) [1,2]; however, few studies have
investigated the interaction between these comorbidities. We de-
scribe overall cognitive function in a large cohort of PLWH compared
to an appropriate control population and explore factors associated
with cognitive performance, including depression and lifestyle factors.
Methods: One thousand two hundred and sixty-six individuals (643
PLWH aged ]50 years, 343 PLWH B50 years and 280 HIV-negative
controls ]50 years) were enrolled in the Pharmacokinetic and
Clinical Observations in People over Fifty study and completed a
computerised assessment (CogState) of cognitive function covering
six domains. Raw test scores were standardized into Z-scores (mean 0,
SD 1) and averaged to obtain domain and global Z-scores. Depression
was evaluated via the Patient Health Questionnaire (PHQ-9) and
classified as none (score 04), mild (59), moderate (1014) or
severe (1527). Differences between the three groups and the effect
of depression, socio-demographic and lifestyle factors on cognitive
performance were evaluated using median regression. All analyses
accounted for age, gender, ethnicity and level of education.
Results: PLWH aged ]50 and B50 years and HIV-negative controls
aged ]50 were predominantly male (88%, 81% and 65%, respec-
tively), of white ethnicity (87%, 81% and 90%, respectively), with a
median age (IQR) of 56 (5362), 43 (3747) and 58 (5363) years,
respectively. Current alcohol consumption and recreational drugs use
were reported in 80%, 81%and 87% (p0.009) and 26%, 34% and 15%
(pB0.001), respectively, of PLWH aged ]50 and B50 years and HIV-
negative controls. After adjusting for socio-demographics, PLWH aged
]50 and B50 years had reduced global cognitive scores than HIV-
negative controls [adjusted difference between medians (95% CI) was
0.090 (0.149,0.032), p0.003, and0.080 (0.166, 0.007),
p0.07, respectively]. Moderate or severe depression was more pre-
valent in PLWH aged ]50 (27%, pB0.001) and B50 years (22%,
pB0.001) compared to HIV-negative controls (8%). Depression (pB
0.001), years of drinking (p0.003), smoking status (p0.01) and use
of marijuana (p0.02) were associated with cognitive function in
univariate analyses, but only depression (pB0.001) and years of
drinking (p0.008) remained significantly associated in multivariable
analyses. After further adjusting for depression and years of drinking,
differences between groupswere not statistically significant (Figure 1).
Unadjusted (dotted line), adjusted for age, gender, ethnicity and level
of education only (dashed line) and adjusted for age, gender,
ethnicity, level of education, depression and years of drinking.
Conclusion: Reduced cognitive performance in HIV infected indivi-
duals appears to be partially mediated by depressive disorders.
However, this may also indicate that depression and cognitive
impairment in PLWH share a common aetiology and could be related
to similar underlying inflammatory processes.
References
1. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL,
LeBlanc S, et al. HIV-associated neurocognitive disorders before and
during the era of combination antiretroviral therapy: differences in
rates, nature, and predictors. J Neurovirol. 2011;17:316. doi: http://
dx.doi.org/10.1007/s13365-010-0006-1
2. Magidson JF, Skeer MR, Mayer KH, Safren SA. Prevalence of
psychiatric and substance abuse symptomatology among HIV-
infected gay and bisexual men in HIV primary care. Psychosomatics.
2015;56:4708. doi: http://dx.doi.org/10.1016/j.psym.2014.08.004
O22 - Co-infections and Malignancies
O221
Novel HCV therapies: what have we achieved and
remaining challenges?
Andri Rauch
Bern University Hospital, University of Bern, Bern, Switzerland
Abstract O215Figure 1. Differences (with 95% CI) in the median global Z-score across cohorts (]50 PLWH, B50 PLWH and HIV-negative
controls).
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Novel hepatitis C virus (HCV) therapies have revolutionized the
management of hepatitis C in only half a decade. The new direct-
acting antiviral agents (DAAs) inhibit the HCV protease, the NS5A
protein or the NS5B polymerase, and hereby block viral replication,
assembly and release. These drugs have greatly improved treatment
tolerability and efficacy compared with the previous interferon-based
therapies. Fortunately, the promising results of clinical trials hold true
in real-life settings. Even previously difficult-to-treat populations,
including cirrhosis, can now be treated with safe and extremely
effective regimens. However, despite the unprecedented success of
novel HCV treatments, challenges remain: the most urgent priority is
to greatly increase treatment uptake, which is only possible if DAA
costs are lowered substantially. The remarkable success in scaling-up
HCV treatments in Egypt exemplifies how coordinated efforts involving
patients, physicians and public health authorities can impact the
global burden of HCV infection. Another challenge is the emergence of
HCV epidemics among HIV-infected men who have sex with men, and
the surge in HCV infections among people who inject drugs in Eastern
Europe and Southeast Asia. These epidemics can only be controlled if
advances in treatment uptake and efficacy are accompanied by
reductions in high-risk behaviour. Finally, it is important to note that
cure of HCV infection substantially reduces the risk of liver-related
complications, but does not eliminate it, particularly in those with
multiple liver-related risk factors. Despite remaining challenges, the
future of HCV therapy is bright with the potential to eliminate one of
the most common infectious diseases worldwide.
O222
HPV-associated malignancies in HIV
Deborah Konopnicki
Service des Maladies Infectieuses, CHU Saint-Pierre, Brussels,
Belgium
Oncogenic human papillomaviruses (HPV) are responsible for the
development of cancer and pre-cancerous lesions in the anogenital
area (namely in the cervix, vulva and vagina, penis and anus) and in
the oropharyngeal cavity. These lesions are more frequent and more
difficult to treat in HIV-positive patients. In Europe, less than 30% of
HIV-positive men and less than 70% of HIV-positive women have
access to anal and cervical cancer screening, respectively. We will
discuss the different strategies of screening for these cancers, which
have been recently developed or are currently under investigation in
randomized controlled studies and how to implement them.
Preventive vaccines against HPV have been available for almost a
decade, and their use in primary and secondary prophylaxis should
be proposed to HIV-positive patients. Issues on vaccines schedules,
costs and HPV genotypes coverage will be raised. Non-invasive
therapy of HPV-related lesions, such as local administration of
antiviral drugs or the use of therapeutic vaccines, will be presented.
O223
Screening for malignancies: what is new?
Jean-Philippe Spano
Department of Medical Oncology, University Institute of Oncology
(IUC)/University Pierre and Marie CURIE (UPMC), Paris, France
Since the emergence of the HIV pandemic, several viral-induced
cancers were frequently diagnosed: Kaposi’s sarcoma associated with
human herpesvirus 8, non-Hodgkin lymphoma mostly associated
with EpsteinBarr virus and cervical cancer associated with onco-
genic human papillomavirus types. However, in the late 1990s,
several population-based cohort studies, comparing the incidence of
cancers in the HIV population and in the general population, found
higher rates of other cancers (defined as non-AIDS-related malig-
nancies) in people living with HIV (PLWHIV), such as anal cancer,
Hodgkin lymphoma (HL), skin cancers, lip cancer, liver cancer and
lung cancer. In the era of highly active antiretroviral therapy,
additional registry studies and meta-analyses have also shown an
increased rate of cancers in PLWHIV compared with the general
population. Nowadays, the most frequent are HL, cancers of the
lung, anus and liver. Factors implicated in this increased incidence,
such as higher rates of smoking, chronic immunodeficiency and
oncogenic virus, are among the main ones. Strategies to increase
cancer survival in PLWHIV are needed. Beyond the recommendations
in terms of therapeutic strategies likely used in the general
population, screening programme and prevention actions can
provide a positive impact on survival, such as in the general
population. For instance, for lung cancer screening with low-dose
chest computed tomography has shown to be efficient in the general
population at risk, so why not in PLWHIV? The objective of this
presentation is to discuss the main screening for malignancies in
PLWHIV and to present some guidelines, already approved for some
cancer types.
O224
Differences in virological and immunological risk factors
for non-Hodgkin lymphoma (NHL) and Hodgkin (HL):
the D:A:D study
Leah Shepherd1; Lene Ryom2; Matthew Law3; Camilla Hatleberg2;
Stephane de Wit4; Antonella d’Armini Monforte5; Manuel Battegay6;
Andrew Phillips1; Fabrice Bonnet7; Peter Reiss8,9; Christian Pradier10;
Andrew Grulich3; Caroline Sabin1; Jens Lundgren2 and
Amanda Mocroft1
1Department of Infection and Population Health, University College
London, London, UK. 2Department of Infectious Diseases, CHIP,
Section 2100, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark. 3The Kirby Institute, University of New South
Wales, Sydney, Australia. 4Division of Infectious Diseases, Saint Pierre
University Hospital, Universite´ Libre de Bruxelles, Brussels, Belgium.
5Dipartimento di Scienze della Salute, Clinica di Malattie Infectitive e
Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan,
Italy. 6Division of Infectious Diseases & Hospital Epidemiology,
University Hospital Basel, Basel, Switzerland. 7Universite´ de
Bordeaux, CHU de Bordeaux and INSERM U897, Talence, France.
8Division of Infectious Diseases, Academic Medical Centre, University
of Amsterdam, Amsterdam, Netherlands. 9Department of Global
Health, HIV Monitoring Foundation, Amsterdam, Netherlands.
10Department of Public Health, Nice University Hospital, Nice, France
Introduction: Non-Hodgkin (NHL) and Hodgkin lymphomas (HL) are
common in HIV people. Since the introduction of cART, a decline in
NHL but not HL incidence has been observed. Factors affecting risk of
NHL and HL appear to differ in HIV persons.
Materials and methods: D:A:D participants were followed from the
earliest of study entry or January 1, 2004 until first NHL or HL
diagnosis, last visit plus 6 months, death, or February 1, 2015. Crude
incidence rates (IR) of NHL and HL were calculated. Adjusted
incidence rate ratios (aIRR) were calculated using Poisson regression
with generalized estimating equations. Both current and historical
measures of HIV viral load (VL) (current level, area under the curve
[AUC] during follow-up) and CD4 (current and nadir level, AUC) were
considered. Other risk factors investigated are listed in the footnote
to Figure 1.
Results: About 41,583 persons were included contributing 337,020
person-years of follow-up (PYFU) [median of 9 (IQR 611) years per
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person]. Of which, 392 developed NHL (IR 1.2/1000 PYFU, 95% CI
1.11.3) and 149 developed HL (IR 0.4/1000 PYFU, 95% CI 0.40.5).
In age-adjusted analyses, NHL incidence declined by 15% (95% CI
1217)/year from 20042015, whereas IR of HL was stable (change/
year: 3% (95% CI 82%). At diagnosis, persons who developed
HL versus NHL were of similar age (46.2 vs. 46.9 years, p0.25), with
a higher current CD4 (400 vs. 325 cells/mm3, pB0.01), lower current
log10 VL (1.7 vs. 2.3 log10 copies/mL, pB0.01), and lower log10 VL
AUC (4.8 vs. 5.1 log10 copies/mL, pB0.01). After adjustment, the
IR of NHL and HL was over 50% lower in females relative to males
(Figure 1). Persons of older age had higher IR of NHL only. Lower
current CD4 was the strongest predictor of higher NHL IR; however,
higher current VL and VL AUC were also associated. Nadir and CD4
AUC were not associated with NHL after adjustment for current CD4
(both p0.05). The declining trend over time in NHL IR attenuated,
but remained after adjustment (8% (95% CI 4%11%)/year). HL
IR was also associated with lower current CD4, but not with other
markers of VL or CD4 in addition to current CD4. HL IR remained
stable over time (aIRR 1.01; 95% CI 0.951.07).
Conclusion: NHL incidence was associated with lower current
CD4 and both current and historical exposure to viral replication,
suggesting historical exposure to uncontrolled viral replication may
play a part in NHL development in addition to current immuno-
deficiency. Conversely, HL incidence was elevated in those with
current immunodeficiency, but current and historical exposure to
uncontrolled HIV replication were not associated when adjusting for
current CD4.
O23 - Critical issues in Eastern and Central
Europe including MDR TB and Hepatitis
Co-infection
O233
Tackling the HCV epidemic in the EECA region: a physician’s
perspective
Nikoloz Chkhartishvili
Infectious Diseases, AIDS and Clinical Immunology Research Center,
Tbilisi, Georgia
Eastern Europe and Central Asia (EECA) has the largest hepatitis C
virus (HCV) epidemic in the World Health Organization European
region. The epidemic in EECA has been closely linked to economic,
social and public health dislocations in the 1990s that created an
environment supportive of the rapid spread of HCV. It is estimated
that 6 million people are living with chronic hepatitis C infection in
the region, including up to 2.5 million people who inject drugs
(PWID). While EECA is home to a large drug epidemic, the coverage
with prevention interventions, such as needle exchange and opioid
substitution therapy, is very low, and this contributes to sustainment
and further growth of the HCV epidemic. There is a significant burden
of HCV among people living with HIV in EECA, with prevalence
exceeding 80% among HIV-positive PWID. There are differences in
the HCV prevalence between countries, with Georgia having the
Abstract O224Figure 1. Figure adjusted incidence rate ratios (aIRR) for NHL and HL.
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highest adult viraemic prevalence. Access to HCV therapy in the
region is limited and only a small proportion of patients receive
appropriate treatment. Georgia is an exception to this situation,
where the national HCV elimination programme was launched in
April 2015 as a result of support from the US Centers for Disease
Control and Prevention and commitment from Gilead Sciences to
donate direct-acting antiviral agents (DAAs). The goal of the
programme is to eliminate HCV primarily through the test and treat
approach, strengthened by prevention interventions, such as harm
reduction and infection control. While accessibility and affordability
of DAAs in the EECA region is a key issue, effective response to the
HCV epidemic will also require expansion of prevention programmes,
particularly among PWID.
O31 - PrEP in High Income Settings
O311
Update on the evidence for PrEP effectiveness
Sheena McCormack
MRC Clinical Trials Unit, University College London, London, UK
Nine randomized controlled clinical trials have demonstrated a
reduction in HIV incidence when antiretrovirals are offered to HIV-
negative individuals as tenofovir-based oral regimens, tenofovir
vaginal gel or dapivirine released from a vaginal ring. Three trials
failed to show benefit; all three were placebo-controlled, and all three
were conducted in women in low-income settings in sub-Saharan
Africa. The diversity of populations studied in the nine trials, with a
positive result, underscores the breadth of impact that adding
antiretrovirals to the toolkit for HIV-negative individuals could have.
The impact is apparent in some cities in the United States but yet to
be realized elsewhere as other countries have been slow to accept the
evidence and implement models of delivery. The commonest reason
for this delay is the cost of the drug as demand for pre-exposure
prophylaxis (PrEP) is uncertain, although countries that do not
currently fund sexual health services or HIV prevention services
tailored to key populations are also struggling to work out the
feasibility and cost of delivering PrEP. Feasibility and cost of delivery
are not reasons for delay in the UK as a well-established, profession-
ally linked network of sexual health clinics already exists, albeit with
ever-diminishing funding. As well as the cost of the drug, policy
makers cite concerns about an increase in sexually transmitted
infections as a result of PrEP. The evidence from pre-PrEP Europe
demonstrates that syphilis and gonorrhoea have been increasing for a
decade in men who have sex with men, and this mirrors an increase in
new HIV infections. PrEP may contribute further to the increase in
STIs but at least HIV will be curtailed.Whilst policy makers deliberate,
key populations are purchasing PrEP for themselves and services have
already changed practice to support them.
O312
Brief overview of cost-effectiveness of PrEP
Valentina Cambiano
Department of Infection and Population Health, University College
London, London, UK
HIV incidence among men who have sex with men (MSM) remains
high despite the widespread use of antiretroviral therapy (ART) and
high rates of virological suppression. Pre-exposure prophylaxis (PrEP)
has been shown to be highly effective in preventing infections in
MSM. Healthcare systems are facing the decision of whether to
introduce it. The overall goal of the cost-effective analyses is to
maximize the health of the population with the available budget.
Previous modelling studies based around MSM in North America and
Australia found PrEP to be generally not cost-effective. However,
there are issues to consider over appropriate costs, time horizon
considered and groups targeted. We present results from two cost-
effective evaluations of introducing PrEP among MSM in the UK
(which I led) and in The Netherlands (led by Brooke Nichols). The two
evaluations take into account a time horizon long enough to evaluate
the full benefit of PrEP, target similar groups to those in the PROUD
and IPERGAY studies, and consider a realistic uptake.While the UK and
Dutch models differ greatly in structure, the primary conclusions are
the same  PrEP can generally be considered cost-effective (or even
cost-saving) for use among MSM in Europe, when appropriately
considering a long time scale, given that each infection averted is
saving the health service ART costs for many decades to come.
However, if the time horizon under consideration is  we would argue
inappropriately  restricted to the short-medium term, significant
reductions in drug prices are required for PrEP to be considered cost-
effective.
O313
Lessons from implementation in France
Jean-michel Molina
Department of Infectious Diseases, University of Paris Diderot, Paris,
France
In the wake of the striking efficacy results of the PROUD and IPERGAY
trials, France has approved the use of TDF/FTC for PrEP to reduce the
risk of sexual acquisition of HIV among adults in January 2016. In July
2016, more than 1000 patients have been registered on the Gilead
website put in place at the request of the French Drug Agency to
collect information on patients’ characteristics, PrEP efficacy and
safety. PrEP is fully covered by the National Health System. Visits to
doctors and tests for PrEP monitoring are partly reimbursed. PrEP
can only be prescribed in hospitals and Sexual Health Clinics. More
than 90 clinics are currently offering PrEP throughout France. The
vast majority of people requesting PrEP self-select and are MSM
(96.4%), although PrEP is also recommended in other high-risk
individuals but prevention campaigns on the use of PrEP have not
yet started. Interestingly, more than 60% of people receive PrEP on
demand according to the dosing regimen used in the IPERGAY trial,
and so far only two seroconversions have been reported in patients
most likely infected at the time they started PrEP. Also 30% of
patients had experienced STIs before starting PrEP, and the
implementation of PrEP is a clear opportunity for a better preven-
tion, diagnosis and treatment of STIs. Finally, the implementation of
PrEP programmes represents a challenge for hospitals and STI clinics
since no additional resources have been provided, suggesting more
research is needed in defining the best models of care delivery and
monitoring.
O314
Utilization of emtricitabine/tenofovir (FTC/TDF) for
HIV pre-exposure prophylaxis in the United States by
gender (2013-1Q2016)
Staci Bush1; Keith Rawlings1; David Magnuson2; Patty Martin1;
Olga Lugo-Torres1 and Robertino Mera-Giler3
1Medical Affairs, Gilead Sciences, Foster City, CA, USA. 2Drug Safety &
Public Health, Gilead Sciences, Foster City, CA, USA. 3Epidemiology,
Gilead Sciences, Foster City, CA, USA
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Introduction: The availability of FTC/TDF for pre-exposure prophy-
laxis (PrEP) in combination with other strategies to reduce the risk of
sexually acquired HIV-1 in adults at high-risk has altered the HIV
prevention landscape in the United States. While previous analyses
have shown gender differences among individuals started on FTC/
TDF for PrEP, this is the first study to explore the characteristics and
differences in utilization trends by gender and race.
Materials and methods: National electronic patient-level data were
collected from 82% of all US retail pharmacies that dispensed FTC/
TDF between January 1, 2013 and March 31, 2016. A previously
described algorithm identified use of FTC/TDF for PrEP. De-identified
prescription refill data, medical claims and patient demographics
were analyzed through categorical methods. Data were projected to
all retail pharmacies in the United States.
Results: During this time period, a total 67,403 unique individuals
started FTC/TDF for PrEP in the United States. Overall, women
accounted for 9685 (14.4%) of total FTC/TDF for PrEP users. Age
distribution revealed that 9.8% of men and 24.1% of women were
B24 years of age. Between 1Q2013 and 1Q2016 quarter-over-
quarter utilization grew 770%; with growth of 72% for women and
1350% for men. The Northeast was the region with both the largest
percentage of overall FTC/TDF for PrEP starts (29.3%) as well as
unique starts among women (35.2%), while the Western US had the
highest percentage of starts in men (89.9%). Table 1 shows the gender
differences in FTC/TDF for PrEP utilization by race.
For the five quarters ending March 2016, White women were 3.4
and 4.2 times more likely to start PrEP than Black or Hispanic
women, while White men were 8.1 and 6.6 times more likely to start
than their Black or Hispanic counterparts.
Conclusion: The overall population of PrEP user increased steadily
since 2012. The number of starts among males significantly increased
while female uptake remained flat for all racial groups. Despite having
some of the highest lifetime risks of acquiring HIV (1 in 2 for Black
men and 1 in 48 among Black women) PrEP starts have been
disproportionately low. HIV prevention messaging and services need
to be gender and racially focused to decrease new infections in
populations with the most severe burden of HIV in the United States.
O315
InterPrEP: internet-based pre-exposure prophylaxis (PrEP)
with generic tenofovir DF/emtricitabine (TDF/FTC) in
London  analysis of pharmacokinetics, safety and
outcomes
Xinzhu Wang1; Nneka Nwokolo2; Roxanna Korologou-Linden1;
Andrew Hill3; Gary Whitlock2; Isaac Day-Weber1; Myra McClure1 and
Marta Boffito3
1Faculty of Medicine, Imperial College London, London, UK. 2Chelsea
and Westminster Hospital, London, UK. 3St Stephen’s AIDS Trust,
Chelsea and Westminster Hospital, London, UK
Introduction: The UK National Health Service (NHS) does not provide
TDF/FTC for PrEP in the UK. This forces people to purchase generic
versions on the internet (e.g. www.iwantprepnow.co.uk [1]), which is
legal under UK import laws. However, there are concerns about the
authenticity of medicines purchased online. In February 2016, we
established an innovative service offering plasma tenofovir (TFV) and
FTC therapeutic drug monitoring (TDM) for people buying generic
PrEP online, to ensure that drug concentrations were consistent with
previously published data.
Materials and methods: HIV-negative individuals who attended the
GUM clinic (from February to June 2016) who reported purchasing
PrEP on the internet were offered TDM. TFV and FTC plasma
concentrations were measured by ultra-performance liquid chroma-
tography coupled with UV detection, with a linear range of 25 to
10,000 ng/mL. Evaluation of renal function and testing for HIV and
STIs (chlamydia, gonorrhoea, syphilis) were also performed, at
baseline and every 3 months, with risk reduction advice provided.
Results: About 161 individuals presented after purchasing PrEP on
the internet: 74% were White, 94% were taking daily PrEP and 6%
event-driven. The majority of patients received generic TDF/FTC from
Cipla Ltd. There were 118 patients with TDM results: median (range)
TFV concentration was 104 ng/mL (231400 ng/mL); median (range)
FTC concentration was 157 ng/mL (271876 ng/mL). All TFV and FTC
concentrations were above our established median plasma TFV and FTC
cut-offs of 19 ng/mL and 22 ng/mL, respectively, at 24 hours post-dose,
based on previously published data [2,3]. Seven samples were repeated;
six were confirmed to be above cut-off. Baseline eGFR was normal in all
evaluable individuals. Thirty-nine (26%) had an STI at baseline or within
3 months of starting PrEP and 13 had an STI at a follow-up visit. No new
cases of HIV, hepatitis B/C were seen in this cohort.
Conclusions: In a population at high-risk of STI who cannot yet access
PrEP from the UK NHS, concentrations of TFV and FTC in generic
formulations purchased over the internet were similar to those on
the original formulation from Gilead, which have demonstrated high
levels of protection against HIV infection in previous clinical trials.
References
1. I Want PrEP Now. I Want PrEP Now. [cited 2016 July 30] Available
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New approaches and new technologies to improve access
to HIV testing
Teymur Noori
European Centre for Disease Prevention and Control, Stockholm,
Sweden
The epidemiological trends of HIV among men who have sex with
men (MSM) in Europe will be discussed in this presentation. The
speaker, Teymur Noori, who works at the European Centre for
Disease Prevention and Control (ECDC), and is responsible for
monitoring the HIV response in Europe and Central Asia through
the Dublin Declaration monitoring process, will make the case that
additional tools for HIV prevention among MSM are needed in order
to reduce HIV infections. The latest data on the status of pre-
exposure prophylaxis (PrEP) implementation in Europe will also be
discussed. In addition, results from a PrEP survey conducted in
Table 1. Gender differences in FTC/TDF for PrEP utilization by
race
Black White Hispanic Asian
Female 17% 65% 15% 3%
Male 9% 76% 11% 3%
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collaboration with the Hornet Gay Social Network on the informal
use of PrEP among Hornet network users in Europe will be shown.
O317
Implementation from the community perspective
Bruno Spire1,2
1French National Institute for Medical Research (INSERM), Marseilles,
France. 2AIDES, Marseilles, France
In France, over the last decade, AIDES has been strongly involved in
research to support early community access to biomedical preven-
tion tools. As a community-based organization founded in 1984 and
engaged in advocacy as well as in the provision of services to people
living with HIV and most at-risk groups, AIDES has extensively
contributed to major shifts in the French HIV Public Health policy.
Among its achievements are the implementation or rapid HIV and
HCV tests, a drug users’ peer education programme on safe injecting
practices and, more recently, access to HIV pre-exposure prophylaxis
(PrEP). From a community perspective, implementing PrEP in real life
is far more complex than in research. Despite scientific evidence and
a wide consensus among researchers, clinicians and the community,
months of constant advocacy work were necessary to reach a legal
frame around access to PrEP. Scaling-up PrEP was impeded by
existing regional inequalities in access to care, along challenges at
the level of care centres. Also, the implementation of PrEP requires
an increase of human resources and dedicated funding, which
creates new challenges for community-based organizations: how can
we implement a new programme without limiting other pre-existing
ones - in a context of ongoing budget cuts? Finally, it is essential to
overcome hesitations and reluctance among community leaders and
healthcare workers; and to adequately inform those people who
would benefit the most from PrEP, and encourage them to use PrEP.
O32 - The Way Forward
O321
Immunology of HIV persistence: implications for the
development of a cure
Steven G Deeks
Department of Medicine, University of California, San Francisco,
CA, USA
Given the challenge of delivering complex, expensive and potentially
harmful antiretroviral therapy on a global level, there is intense
interest in the development of short-term, well-tolerated regimens
that allow individuals to interrupt therapy indefinitely without
experiencing a rebound in viraemia. Recent heroic interventions,
such as haematopoietic stem cell transplant, suggest that dramatic
reductions in the reservoir size can be achieved, but that complete
eradication will be challenging, if not impossible. Experience with
‘elite’ and post-treatment controllers suggest that disease remission
may be achievable even if replication-competent HIV persists. Achiev-
ing a sustained remission will likely require a low reservoir size and a
potent and durable HIV-specific immune response. Cancer and HIV
persistence share a number of similarities. In each case, a rare
population of cells with the capacity to cause harm becomes
established in difficult to reach tissues. The local environment in
each case is reshaped to prevent immune mechanisms from clearing
the diseased cell. Specifically, a chronic inflammatory environment
stimulates an immunosuppressive response, and therapies that target
these immune pathways have either been very successful (in cancer) or
are now entering the clinic (in HIV disease). These interventions have
the potential to enable successful repurposing of preventative
vaccines into the HIV cure arena, and will be reviewed. It is hoped
that advances in cancer therapy will be translated into the HIV arena,
accelerating our discovery of a potential HIV cure.
O322
Where next for ARVs?
Roy M Gulick
Weill Cornell Medicine, New York, NY, USA
Currently, there are 29 antiretroviral (ARV) drugs approved for the
treatment of HIV infection in six mechanistic classes. ARV therapy
(ART) guidelines worldwide recommend an initial treatment regimen
consisting of a combination of two nucleoside analogue reverse
transcriptase inhibitors (NRTIs) and a third drug, either a non-
nucleoside reverse transcriptase inhibitor (NNRTI), a boosted protease
inhibitor (PI) or an integrase inhibitor (II). Current ART regimens are
highly potent, safe, tolerable and convenient. Current virological sup-
pression rates can exceed 90% in clinical trials and cohort studies, and
one pill, once-daily regimens are widely available. Newer strategies,
formulations and investigational ARV agents continue to move ARVs
forward. Although a three-drug ART regimen is standard, potent two-
drug regimens are under investigation. Long-acting compounds are
under study, including an injectable investigational formulation of the
approvedNNRTI, rilpivirine, and an investigational II, cabotegravir, that
can be dosed together every 1 to 2 months. Other investigational
formulations include implantable devices that provide sustained
release of ARVs, and other newer technologies. The investigational
ARV pipeline contains new agents in existing classes (NRTI, NNRTI, PI,
II) and some of these are associated with either less toxicity [e.g. NRTI,
tenofovir pro-drug TAF (tenofovir alafenamide fumarate); NNRTI,
doravirine] or different resistance profiles (II, bictegravir) than current
drugs. Two new mechanistic ARV classes under investigation are the
CD4 attachment inhibitors and the HIV maturation inhibitors, and
candidate drugs in each class are in clinical development. Currently, we
can control HIV infection long-term with potent, safe and convenient
ART that leads to prolonged healthy survival in our patients.
O33 - Antiretrovial Strategies and New
Drugs
O331
Non-inferiority of dual-therapy (DT) with darunavir/
ritonavir (DRV/r) plus 3TC versus triple-therapy (TT) with
DRV/r plus TDF/FTC or ABC/3TC for maintenance of viral
suppression: 48-week results of the DUAL-GESIDA 8014 trial
Federico Pulido1; Esteban Ribera2; Maria Lagarde1;
Ignacio Pe´rez-Valero3; Jesu´s Santos4; Jose Iribarren5;
Antonio Payeras6; Pere Domingo7; Jose´ Sanz8; Miguel Cervero9;
Adrian Curran2; Francisco Rodriguez10; Marı´a Te´llez11; Pablo Ryan12;
Pilar Barrufet13; Hernando Knobel14; Antonio Rivero15;
Bele´n Alejos16; Marı´a Yllescas16; Jose´ Arribas3 and Study Group
GESIDA-8014-DUAL17
1HIV Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.
2Servicio de Enfermedades Infecciosas, Hospital Vall d’Hebron,
Barcelona, Spain. 3HIV Unit, Hospital La Paz, IdiPAZ, Madrid, Spain.
4Unidad de Enfermedades Infecciosas, Hospital Virgen de la Victoria,
Ma´laga, Spain. 5Servicio de Enfermedades Infecciosas, Hospital
Donostia, San Sebastia´n, Spain. 6Servicio de Medicina Interna,
Hospital Son Llatzer, Palma de Mallorca, Spain. 7Servicio de Medicina
Interna, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
8Servicio de Medicina Interna, Hospital Prı´ncipe de Asturias, Alcala´
de Henares, Spain. 9Servicio de Medicina Interna, Hospital Severo
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Ochoa, Legane´s, Spain. 10Unidad de Enfermedades Infecciosas,
Hospital Infanta Elena, Huelva, Spain. 11Servicio de Medicina Interna,
Hospital Clı´nico San Carlos, Madrid, Spain. 12Servicio de Medicina
Interna, Hospital Infanta Leonor, Madrid, Spain. 13Servicio de
Medicina Interna, Hospital de Mataro´, Mataro´, Spain. 14Servicio de
Enfermedades Infecciosas, Hospital del Mar, Barcelona, Spain.
15Seccio´n de Enfermedades Infecciosas, Hospital Reina Sofia,
Co´rdoba, Spain. 16Fundacio´n de Investigacio´n, SEIMC-GESIDA,
Madrid, Spain. 17GESIDA-8014-DUAL Study Group, Spain
Introduction: DT with DRV/r plus 3TC may be as effective, better
tolerated and substantially less costly than TT with DRV/r plus TDF/
FTC or ABC/3TC for maintenance of viral suppression.
Methods: DUAL is a 48-week multicentre, randomized, open-label,
non-inferiority (margin  12%) clinical trial. HIV-1 infected patients
withB50 copies/mL for]6months on TTwith DRV/r plus TDF/FTC or
ABC/3TC, with no resistance to DRV/r or 3TC/FTC, were randomized
(1:1) to continue TT or switch to DT with DRV/r and 3TC QD. Primary
endpoint: proportion of patients with HIV-1 RNA B50 copies/mL at
week 48 after randomization (FDA snapshot algorithm) in the exposed-
ITT population (e-ITT, excluding never exposed patients). Secondary
endpoints: proportion of patients with persistently suppressed
viraemia, overall tolerability, emerging resistance, changes in CD4
cells, renal function and lipids.
Results: Two hundred and forty-nine patients (75% with TDF/FTC, 25%
with ABC/3TC) were randomized to switch to DT (n126) or to
continue TT (n123). Baseline characteristics were balanced be-
tween arms except a significant shorter duration of virologic
suppression in the DT group (21 vs. 28 months). Proportion of
patients with HIV-1 RNA B50 copies/mL at week 48 (DT vs. TT): in the
e-ITT population 89% (112/126), versus 93% (114/123), difference
3.8 (95% CI 11 to3.4); in the observed population (censoring
discontinuations due to non-virologic reasons) 97% (112/116), versus
98% (114/116), difference 1.7 (95% CI 5.8 to 1.4). The
proportion of patients (e-ITT) maintaining HIV RNA-1 B50 copies/
mL in all determinations was 89% in DT and 87% in TT (difference
1.9%; 95% CI 6.2 to10). Severe adverse events occurred in 5% of
patients in DT and 5% of patients in TT. Study drug discontinuations
due to adverse events in 1% and 2% (pNS). There was no detection
of emergent resistance during the trial and no significant differences
in CD4 cell recovery. Switching to DTwas not associated with significant
changes in e-GFR and TC/HDL ratio relative to continuing TT.
Conclusions: DT with DRV/r plus 3TC was non-inferior and as well
tolerated as DRV/r plus TDF/FTC (or ABC/3TC) for maintenance of
viral suppression. DT has the added benefit of preserving options and
reducing the cost.
O332
French national survey of resistance to integrase inhibitors
shows high differences of resistance selection rate in case of
virological failure in a context of routine hospital care
(ANRS-AC11 virology network)
Anne-Genevieve Marcelin1; Maxime Grude2; Charlotte Charpentier3;
Pantxika Bellcave4; Audrey Rodallec5; Coralie Pallier6;
Stephanie Raymond7; Audrey Mirand8; Laurence Bocket9;
Laurence Morand-Joubert10; Constance Delaugerre11;
Brigitte Montes12; Helene Jeulin13; Thomas Mourez14;
Samira Fafi-Kremer15; Corrine Amiel16; Catherine Roussel17;
Julia Dina18; Marie-Anne Trabaud19; Helene Le Guillou-Guillemette20;
Sophie Valet21; Anne Signori-Schmuck22; Anne Maillard23;
Anne Krivine24; Philippe Flandre2; Diane Descamps3 and
Vincent Calvez1
1Virology, Pitie-Salpetriere Hospital, Paris, France. 2Inserm U1136,
Pitie-Salpeˆtriere Hospital, Paris, France. 3Virology, Bichat Hospital,
Paris, France. 4Virology, Bordeaux Hospital, Bordeaux, France.
5Virology, Nantes Hospital, Nantes, France. 6Virology, Paul Brousse
Hospital, Paris, France. 7Virology, Toulouse Hospital, Paris, France.
8Virology, Clermont-Ferrand Hospital, Clermond-Ferrand, France.
9Virology, Lille Hospital, Lille, France. 10Virology, Saint Antoine, Paris,
France. 11Virology, Saint Louis Hospital, Paris, France. 12Virology,
Montpellier Hospital, Paris, France. 13Virology, Nancy Hospital,
Nancy, France. 14Virology, Rouen Hospital, Rouen, France. 15Virology,
Strasbourg Hospital, Strasbourg, France. 16Virology, Tenon Hospital,
Paris, France. 17Virology, Amiens Hospital, Amiens, France. 18Virology,
Caen Hospital, Caen, France. 19Virology, Lyon Hospital, Lyon, France.
20Virology, Angers, Angers, France. 21Virology, Brest Hospital, Brest,
France. 22Virology, Grenoble Hospital, Grenoble, France. 23Virology,
Rennes Hospital, Rennes, France. 24Virology, Cochin Hospital, Paris,
France
Introduction: Integrase inhibitors (INIs) are now one of the most
important drug classes in clinical practice.With potential for INI cross-
resistance, there is a need to get more resistance related data in
patients failing an INI-containing regimen in a context of routine
hospital care. Doing so with more cases than observed in clinical trials
to date would provide a more precise description about the
robustness to resistance selection of the three INIs used in clinical
practice.
Materials and methods: This national survey of resistance to INIs was
conducted through the ANRS AC11 virology network: patients who
failed to any INI-containing regimens were included to search for
selection of resistance to INI and associated factors. Virological failure
was defined as two consecutive plasma viral load 50 copies/mL. All
the genotypic resistance tests were performed on the second plasma
sample with detectable viral load and interpreted following the ANRS
V25 algorithm. Patients who failed to RAL and EVG did not fail to any
INI before. However, DTG was used either as the first INI or in patients
who failed before to RAL or EVG.
Results: About 489 patients failing to INI (270 to RAL, 111 to EVG and
96 to DTG)-containing regimen were analyzed (median age 48 years,
CD4 398/mm3, viral load 3.13 log copies/mL at time of failure). In
combination with one INI, 250 (51%) patients received two NRTIs,
34 (7%) one NNRTI, 47 (9%) one PI, 76 (16%) one NRTI  one PI,
19 (4%) one NRTI one NNRTI, 22 (4%) one NNRTI one PI and 41
other regimens. Among patients failing to RAL, 32% harboured a virus
resistant to RAL and among patients failing to EVG, 40% harboured a
virus resistant to EVG. Among patients failing to DTG (used as the first
INI or used in patients previously exposed to RAL- or EVG-containing
regimen) 19% harboured a virus resistant to DTG. Among the 96
patients failing to DTG, 49 received DTG as the first INI, neither INI
resistance mutations among the major pathways (92, 118, 121, 140,
143, 148, 155) nor the R263K mutation were present at failure.
Conclusions: In this national survey, RAL and EVG are associated with
32 to 40% resistance at failure. However, in INI-nave patients, failing
to DTG when used as the first INI, no resistance to INI was detected
whatever the antiretroviral associated to DTG.
O333
Switching from cART to dolutegravir (DTG) maintenance
monotherapy in virologically suppressed HIV-1 infected
adults: a randomized multicenter, non-inferiority clinical
trial (DOMONO)
Ingeborg Wijting1; Casper Rokx1; Charles Boucher2; Jeroen Van
Kampen2; Dorine De Vries-Sluijs1; Karin Schurink1; Hannelore Bax1;
Maarten Derksen1; Elrozy Andrinopoulou3; Ineke Van der Ende1;
Eric Van Gorp1; Jan Nouwen1; Annelies Verbon1; Wouter Bierman4
and Bart Rijnders1
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1Infectious DiseasesInternal Medicine, Erasmus MC, Rotterdam,
Netherlands. 2Virology, Erasmus MC, Rotterdam, Netherlands.
3Department of Biostatistics, Erasmus MC, Rotterdam, Netherlands.
4Department of Internal Medicine and Infectious Diseases,
Universitair Medisch Centrum Groningen, Groningen,
The Netherlands
Introduction: DTG-containing cART showed equal or superior viral
suppression when compared with raltegravir-, efavirenz- or
darunavir-containing cART and is one of the preferred regimens in
current treatment guidelines. As short- and long-term side
effects of cART remain a concern, maintenance HIV therapy
with fewer drugs is an attractive goal. Given the high genetic barrier
to resistance, DTG is a potential candidate for maintenance
monotherapy.
Materials/methods: In a randomized, open-label, multicentre study,
we compared DTG maintenance monotherapy (50 mg QDDOLU-
DOLUMONO) with continued cART (con-cART). After 24 weeks, the
con-cART patients switched to DOLUMONO as well (‘delayed switch’).
Eligible patients were on cART and suppressed (B50 c/mL) for 6
months, had a CD4 nadir 200 cells/mL, HIV RNA zenith B100,000
copies/mL, no history of virologic failure and HBV immune. The
primary endpoint was the proportion of patients with virologic
suppression at 24 weeks defined as a viral load (VL) B200 copies/mL
in the on treatment population. With an anticipated viral suppres-
sion of 95% on con-cART, 104 patients were needed to demonstrate
non-inferiority of DOLUMONO (delta 0.12, power 80%, alfa0.025).
Predefined secondary endpoints were (1) proportion with a VL B50
copies/mL after 24 weeks of DOLUMONO versus con-cART and (2)
proportion with a VL B200 copies/mL and B50 copies/mL after 12,
24 and 48 weeks of DOLUMONO in the entire study population
(immediate  delayed switchers combined). The study was
registered as NCT02401828.
Results: The 104 patients included were predominantly male (89%),
had a median age of 45, a HIV RNA zenith of 21,840 copies/mL (IQR
704559,550), CD4 nadir of 345 cells/mL (IQR 270500) and on
cART for 40 months. One patient discontinued DTG at 12 weeks
(with VL B50 copies/mL) for disturbed sleep. Of 103, 102 patients
had a VL B200 copies/mL at week 24: 98% (49/50) on DOLUMONO
and 100% (53/53) on con-cART. DOLUMONO was therefore non-
inferior to con-cART (delta 2% with exact 95% CI 125%). The single
patient on DOLUMONO with virologic failure had a VL at 4 weeks of
70,000 copies/mL despite 100% compliance by pill-count and
therapeutic DTG plasma levels of 1.3 mg/L. Integrase sequencing
on stored pre-cART plasma and at DTG failure did not reveal
resistance-associated mutations. At 24 weeks, more patients on
DOLUMONO had low level viraemia (VL of 50200 copies/mL in 3/49
vs. 0/53, p0.12). Week 24 results of all 104 patients on
DOLUMONO (immediate and delayed switchers combined) will
be presented.
Conclusions: In a carefully selected HIV-1 population on sup-
pressive cART, DTG monotherapy was well tolerated and non-
inferior to cART. Although these results are promising, longer
follow-up is needed as more patients on DOLUMONO had low-level
viraemia.
O334
Subgroup analyses from ONCEMRK, a phase 3 study of
raltegravir (RAL) 1200 mg once daily versus RAL 400 mg
twice daily, in combination with tenofovir/emtricitabine,
in treatment-naive HIV-1 infected subjects
Pedro Cahn1; Richard Kaplan2; Paul Sax3; Kathleen Squires4;
Jean-Michel Molina5; Anchalee Avihingsanon6; Winai Ratanasuwan7;
Evelyn Rojas8; Mohammed Rassool9; Xia Xu10; Anthony Rodgers10;
Sandy Rawlins10; Bach-Yen Nguyen10; Randi Leavitt10 and
Hedy Teppler10
1Fundacion Huesped, Juan A. Fernandez Hospital, Buenos Aires,
Argentina. 2Desmond Tutu HIV Foundation, University of Cape Town,
Cape Town, South Africa. 3Brigham & Women’s Hospital, Harvard
Medical School, Boston, MA, USA. 4Infectious Diseases, Thomas
Jefferson University, Philadelphia, PA, USA. 5Hopital Saint-Louis,
University of Paris Diderot, Paris, France. 6Medical Department,
HIV-NAT Research Collaboration, Bangkok, Thailand. 7Faculty of
Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
8Infectious Diseases, Cericap Multiclinicas, Guatemala City,
Guatemala. 9University of Witwatersrand, Helen Joseph Hospital,
Johannesburg, South Africa. 10Research, Merck & Co., Inc.,
Kenilworth, NJ, USA
Introduction: In HIV-1-infected treatment-naı¨ve subjects receiving
tenofovir/emtricitabine (TDF/FTC), reformulated RAL 1200 mg (two
600-mg tablets) given once daily (QD) demonstrated potent and non-
inferior efficacy at week 48 compared to RAL 400 mg given twice
daily (BID).
Methods: ONCEMRK is a phase 3, multicentre, double-blind,
randomized controlled trial comparing reformulated RAL 1200 mg
QD to RAL 400 mg BID, both given with TDF/FTC, for up to 96 weeks
in treatment-naive HIV-1-infected subjects. Randomization was strati-
fied by screening HIV-1 RNA (vRNA) and chronic hepatitis B/C status.
Results for the primary endpoint (% achieving vRNA B40 copies/mL
at week 48) and secondary endpoint (change from baseline in CD4
count) were summarized within several pre-specified subgroups in
order to further characterize the effect of RAL 1200 mg QD. Summary
statistics were calculated by treatment group within each subgroup
using the observed failure approach for missing data. The difference
between treatment groups and associated 95% CI were also calculated
for each subgroup.
Results: Baseline demographics were balanced across the two
treatment groups. Of 797 treated subjects, 85% were male; racial
origin was 59% white, 17% black and 15% Asian; and the mean age was
35.9 years. At baseline, mean CD4 count was 415/mm3 and mean
plasma vRNA was 4.6 log10 copies/mL; 28% of subjects had baseline
vRNA 100,000 copies/mL, 3% had hepatitis B and/or C co-infection
and 34% had non-B subtype HIV infection. Results for the primary
efficacy endpoint across selected baseline demographic and prognostic
factors are shown below (Table 1). The change in CD4 counts was also
similar across subgroups (results not shown).
Conclusions: Reformulated RAL 1200 mg QD demonstrated potent
and consistent virologic and immunologic efficacy across demographic
and baseline prognostic factors, including baseline plasma vRNA level
100,000 copies/mL, baseline CD4 count 200 cells/mm3, hepatitis
co-infection, gender, viral subtype and geographic region.
O335A
HIV-1 attachment inhibitor prodrug BMS-663068 in
antiretroviral-experienced subjects: week 96 subgroup
analysis
Enrique Rafael Granados-Reyes1; Louis Sloan2; Jerome Ernst3;
Mey Leo´n4; David Stock5; Cyril Llamoso6; Samit Joshi5;
George Hanna7 and Max Lataillade6
1Centro de Investigacio´n Clinica Gramel SC, Mexico City, Mexico.
2Research Department, North Texas Infectious Diseases Consultants,
P.A., Dallas, TX, USA. 3AIDS Community Research Initiative of
America, New York, NY, USA. 4Infectious and Tropical Diseases,
Asociacion Civil Impacta Salud y Educacion, Lima, Peru. 5Research
and Development, Bristol-Myers Squibb, Wallingford, CT, USA.
6Research and Development, ViiV Healthcare, Wallingford, CT, USA.
7Research and Development, Bristol-Myers Squibb, Princeton, NJ, USA
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Introduction: BMS-663068 is a prodrug of BMS-626529, an attach-
ment inhibitor that binds directly to HIV-1 gp120, preventing initial
viral attachment and entry into the host CD4 T-cell. AI438011 is an
ongoing, phase IIb, randomized, active-controlled trial investigating
the safety, efficacy and dose-response of BMS-663068 versus
atazanavir/ritonavir (ATV/r) in treatment-experienced, HIV-1-positive
subjects. Through week 96, BMS-663068 showed generally similar
efficacy to ATV/r. We report a subgroup analysis of viral efficacy and
immunologic response through week 96.
Materials and methods: Treatment-experienced subjects (exposure
to ]1 antiretroviral for ]1 week) with susceptibility to all study
drugs and BMS-626529 IC50 B100 nMwere randomized to four BMS-
663068 arms (400 or 800 mg BID; 600 or 1200 mg QD) or control arm
(ATV/r 300/100 mg QD), with tenofovir disoproxil fumarate 300 mg
(QD)raltegravir 400 mg (BID). Pooled data for BMS-663068 are
presented as BMS-663068 1200mg QDwas selected as the open-label
continuation dose after week 48. Efficacy (observed data) was
evaluated following stratification by age, gender, race, baseline viral
load (VL) and baseline CD4 T-cell count. The study was not powered
to detect statistically significant differences between subgroups.
Results: A total of 251 subjects were treated (BMS-663068: 200; ATV/r:
51). Median age was 39 years, 60% were male and 38% white. Median
baseline VL was 4.85 log10 copies/mL (43% 100,000 copies/mL) and
median CD4 T-cell count 230 cells/mm3 (38% B200 CD4 cells/
mm3). At week 96, response rates (HIV-1 RNA B50 copies/mL) were
generally similar between BMS-663068 and ATV/r arms regardless of
gender, age, race, baseline VL (B100,000 copies/mL vs. ]100,000
copies/mL) and baseline CD4 T-cell count (B200 cells/mm3 vs.
]200 cells/mm3) (Table 1).Mean increases in CD4 T-cell count from
baseline to week 96 were similar among BMS-663068 arms regardless
of age, gender, race and baseline CD4 T-cell count. Increase in CD4
T-cell counts appeared greater for subjects with a baseline VL
]100,000 copies/mL versus B100,000 copies/mL across BMS-
663068 and ATV/r arms (Table 2).
Conclusions: At week 96, virologic response was generally similar for
BMS-663068 and ATV/r in treatment-experienced subjects, regardless
of gender, age, race, baseline VL or baseline CD4 T-cell count. Mean
increases in CD4 T-cell count from baseline to week 96 were similar
for BMS-663068 regardless of age, gender, race and baseline CD4 T-
cell count. These results are mostly consistent with those reported at
Abstract O334Table 1. Proportion of subjects with HIV-1 RNA B40 copies/mL at week 48 by prognostic and demographic factors
(observed failure approach)
Virologic response by subgroup
RAL 1200 mg QD RAL 400 mg BID Difference (QD - BID)
N % B40 c/mL N % B40 c/mL % (95% CI)a
All subjects 501 94.2 251 93.6 0.6 (2.84.7)
Baseline plasma HIV RNA (copies/mL)
5100,000 copies/mL 358 97.2 177 97.7 0.5 (3.23.1)
100,000 copies/mL 143 86.7 74 83.8 2.9 (6.514.1)
Baseline plasma HIV RNA (copies/mL)
5500,000 copies/mL 479 95.2 237 95.8 0.6 (3.63.1)
500,000 copies/mL 22 72.7 14 57.1 15.6 (15.645.9)
Baseline CD4 cell counts (cells/mm3)
5200 cells/mm3 67 85.1 33 87.9 2.8 (16.014.0)
200 cells/mm3 434 95.6 218 94.5 1.1 (2.25.3)
Hepatitis co-infectionb
Hepatitis B or C positive 13 100 7 85.7 14.3 (11.752.2)
Hepatitis B and C negative 488 94.1 244 93.9 0.2 (3.34.3)
Gender
Male 415 94.7 220 93.6 1.1 (2.65.5)
Female 86 91.9 31 93.5 1.7 (11.113.3)
Viral subtype
Clade B 313 94.6 175 93.7 0.9 (3.35.9)
Non-clade B 187 93.6 74 93.2 0.3 (5.78.9)
Geographic region
Africa 41 95.1 12 100 4.9 (16.320.0)
Asia/Pacific 84 94.0 43 93.0 1.0 (7.713.3)
Europe 190 96.3 108 94.4 1.9 (2.98.2)
Latin America 73 94.5 26 100 5.5 (13.37.7)
North America 113 90.3 62 88.7 1.6 (7.512.7)
a95% CIs by Miettinen and Nurminen’s method; bHepatitis B surface antigen and/or HCV RNA by PCR.
Nnumber in subgroup.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Oral Abstracts
19
week 48. A phase III trial is underway to evaluate BMS-663068 for use
in heavily treatment-experienced adults with limited therapeutic
options (NCT02362503).
O335B
HIV-1 attachment inhibitor prodrug BMS-663068 in
antiretroviral-experienced subjects: week 96 safety analysis
Cyril Llamoso1; Johannes Bogner2; Larissa Afonina3; Mey Leo´n4;
Alexey Yakovlev5; David Stock6; Samit Joshi6; George Hanna7 and
Max Lataillade1
1Research and Development, ViiV Healthcare, Wallingford, CT, USA.
2Section for Infectious Diseases, Med. IV, Hospital of the University of
Munich, Munich, Germany. 3Clinical Research and Medical
Information, Republic Hospital of Infectious Diseases, St Petersburg,
Russian Federation. 4Infectious and Tropical Diseases, Asociacion Civil
Abstract O335ATable 1. Response rates (HIV-1 RNA B50 copies/mL) at week 96 by subgroup (observed)
BMS-663068 pooleda (N136)
No. of responders (%)
ATV/r (N30)
No. of responders (%)
Subgroups Subgroups
Age Age
B40 years (n65) 60 (92.3) B40 years (n14) 12 (85.7)
]40 years (n71) 62 (87.3) ]40 years (n16) 15 (93.8)
Gender Gender
Male (n78) 69 (88.5) Male (n17) 16 (94.1)
Female (n58) 53 (91.4) Female (n13) 11 (84.6)
Race Race
Black (n40) 37 (92.5) Black (n8) 7 (87.5)
White (n54) 49 (90.7) White (n12) 11 (91.7)
Other (n42) 36 (85.7) Other (n10) 9 (90.0)
Baseline viral load Baseline viral load
B100,000 copies/mL (n84) 73 (86.9) B100,000 copies/mL (n20) 19 (95.0)
]100,000 copies/mL (n52) 49 (94.2) ]100,000 copies/mL (n10) 8 (80.0)
Baseline CD4 T-cell countsb Baseline CD4 T-cell counts
B200 cells/mm3 (n42) 37 (88.1) B200 cells/mm3 (n13) 12 (92.3)
]200 cells/mm3 (n93) 85 (91.4) ]200 cells/mm3 (n17) 15 (88.2)
aPooled data are presented because BMS-663068 1200 mg QD was selected as the open-label continuation dose after week 48; bOne subject did
not have a baseline CD4 value.
Abstract O335ATable 2. Mean increases in CD4 T-cell count from baseline to week 96 by subgroup (observed)a
BMS-663068 pooledb (N134) cells/mm3 ATV/r (N31) cells/mm3
Subgroups Subgroups
Age Age
B40 years (n64) 215.5 B40 years (n15) 244.0
]40 years (n69) 221.8 ]40 years (n16) 255.8
Gender Gender
Male (n75) 210.1 Male (n18) 151.9
Female (n58) 230.0 Female (n13) 386.0
Race Race
Black (n38) 213.9 Black (n8) 415.4
White (n54) 231.0 White (n13) 259.8
Other (n41) 207.2 Other (n10) 105.2
Baseline viral load Baseline viral load
B100,000 copies/mL (n81) 184.2 B100,000 copies/mL (n21) 208.0
]100,000 copies/mL (n52) 272.6 ]100,000 copies/mL (n10) 338.4
Baseline CD4 T-cell counts Baseline CD4 T-cell counts
B200 cells/mm3 (n42) 202.5 B200 cells/mm3 (n13) 216.4
]200 cells/mm3 (n91) 226.2 ]200 cells/mm3 (n18) 274.4
aOne subject did not have a baseline CD4 value; bPooled data are presented because BMS-663068 1200 mg QD was selected as the open-label
continuation dose after week 48.
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Introduction: BMS-663068 is a prodrug of BMS-626529, an attach-
ment inhibitor that binds directly to HIV-1 gp120, preventing initial
viral attachment and entry into host CD4 T-cells. AI438011 is an
ongoing, phase IIb, randomized, active-controlled trial investigating the
safety, efficacy and dose-response of BMS-663068 versus atazanavir/
ritonavir (ATV/r) in treatment-experienced, HIV-1-positive subjects.
Through week 96, BMS-663068 showed generally similar efficacy to
ATV/r. We report the complete safety profile through week 96.
Materials and methods: Treatment-experienced subjects (exposure
to ]1 antiretroviral for ]1 week) with susceptibility to all study
drugs and BMS-626529 IC50 B100 nMwere randomized to four BMS-
663068 arms (400 or 800 mg BID; 600 or 1200 mg QD) or a control
arm (ATV/r 300/100 mg QD), with tenofovir disoproxil fumarate (TDF)
300 mg (QD)raltegravir (RAL) 400 mg (BID). Pooled safety data for
BMS-663068 are presented because BMS-663068 1200 mg QD was
selected as the open-label continuation dose after week 48.
Results: A total of 251 subjects received treatment (BMS-663068:
200; ATV/r: 51). No BMS-663068-related adverse events (AEs) led to
discontinuation (Table 1). Grade 24 drug-related AEs occurred in
17/200 (8.5%) BMS-663068 treated subjects; these were all single
instances. In the ATV/r arm, grade 24 drug-related AEs occurred in
19/51 (37%) subjects: most were attributable to gastrointestinal and/
or hepatobiliary disorders. Across BMS-663068 arms no trends for
grade 34 laboratory abnormalities were observed. Serious AEs
(SAEs) occurred in 24/200 (12%) and 7/51 (14%) subjects receiving
BMS-663068 and ATV/r, respectively; most were attributable to
infections (BMS-663068: nine [5%]; ATV/r: three [6%]). One unrelated
death occurred (gunshot wound). The most common AE reported for
BMS-663068 was grade 14 transient headache (32/200, 16%),
which was reported in 5/51 (10%) subjects for ATV/r.
Conclusions: BMS-663068 was generally well tolerated, with no
BMS-663068-related AEs leading to discontinuation, and no new
safety signals from the previously described safety profile. No trends
were observed for grade 24 AEs or clinical laboratory abnormalities.
These results support the ongoing phase III trial evaluating BMS-
663068 for use in heavily treatment-experienced adults with limited
therapeutic options (NCT02362503).
O336
Efficacy and safety of long-acting HIV fusion inhibitor
albuvirtide in antiretroviral-experienced adults with HIV-1:
interim 48-week results from the randomized, controlled,
phase 3, non-inferiority TALENT study
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Introduction: Albuvirtide is a once-weekly injectable HIV-1 fusion
inhibitor. We present interim data of the TALENT study (Clinical-
Trials.gov, NCT02369965), that assessed the safety and efficacy of
albuvirtide plus lopinavir-ritonavir in antiretroviral-experienced
adults with HIV-1.
Materials and methods: We carried out the 48-week, phase 3,
randomized, controlled, open-label non-inferiority trial at
12 sites in China. Adults on WHO-recommended first-line treat-
ment for 6 months with plasma viral load 1000 copies/mL were
enrolled and randomly assigned (1:1) to receive albuvirtide (once
weekly) plus ritonavir-boosted lopinavir (albuvirtide) or WHO-recom-
mended second-line treatment (control). The primary endpoint was the
proportion of patients with plasma viral load B50 copies/mL at 48
weeks. Non-inferiority was pre-specified with a margin of 12%.
Results: At the time of analysis, 1185 patients were screened and 372
were enrolled. For the modified intention-to-treat population, 24
weeks data were available for 83 and 92 patients, and 48 weeks for 46
and 50 patients in the albuvirtide and control groups respectively. At
48 weeks, 80.4% patients in the albuvirtide group had HIV-1 RNAB50
copies/mL versus 66.0% in the control group (difference 14.4%, 95% CI
Abstract O335BTable 1. Week 96 pooled safety results
Parameter, n (%)
BMS-663068aTDF (300 mg QD)
RAL (400 mg BID) N200
ATV/r (300/100 mg QD)TDF (300 mg QD)
RAL (400 mg BID) N51
Subjects with ]1 AE (grade 14) 181 (91) 50 (98)
Related grade 14 AEs 64 (32) 28 (55)
Related grade 24 AEs 17 (8.5) 19 (37)
SAEs 24 (12) 7 (14)
AEs leading to discontinuationb 5 (2.5) 5 (10)
Deathsb 1 (0.5) 0
aPooled data are presented because BMS-663068 1200 mg QD was selected as the open-label continuation dose after week 48; bNone were
related to BMS-663068.
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3.0%31.9%), meeting the non-inferiority criteria. For the per-
protocol population, superiority of albuvirtide to control was demon-
strated (94.9% vs. 74.4%, difference 20.5%, 95% CI 5.735.2, p0.01).
Grade 34 adverse event frequencies were similar across groups
(14.0% vs. 11.1%); the most common adverse events for albuvirtide
versus control were diarrhoea (8.6% vs. 14.1%), upper respiratory tract
infection (4.3% vs. 6.1%), grade 3-4 elevated triglycerides (6.5% vs.
4.0%). Renal function impairment was significantly less at 12 weeks in
patients of the albuvirtide group compared with those of the control
group who received TDF (mean change in eGFR 11.47 vs. 1.22
mL/min/1.73 m2, p0.02).
Conclusions: TALENT study is the first phase 3 trial of an injectable
long-acting HIV drug. This interim analysis suggests that once-weekly
albuvirtide in combination with ritonavir-boosted lopinavir is clini-
cally practical, well tolerated and non-inferior to WHO-recommended
second-line regimen in patients failed first-line treatment. Analysis is
scheduled when all enrolled patients complete 48 weeks treatment
to confirm these data.
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ARV-BASED PREVENTION: MOTHER-TO-
CHILD TRANSMISSION
P001
High prevalence of hepatitis C co-infection and adverse
pregnancy outcomes among HIV-infected pregnant women
in Switzerland
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Introduction: Hepatitis C virus (HCV) infection is more prevalent in
HIV-infected compared to HIV-negative women. Limited data on
pregnancy outcomes in HIV/HCV co-infected women are available.
This study aimed to investigate prevalence, immunological para-
meters and pregnancy outcomes associated with HCV-HIV co-
infected pregnant women.
Methods: Prospectively collected data of the Swiss Mother and Child
HIV Cohort Study including pregnancies and deliveries documented
between 2000 and 2015 were analysed. Hepatitis C co-infection
was defined as HCV antibody positivity. Multiple pregnancies were
excluded.
Results: Of 548 women, 75 (13.7%) were HCV seropositive. Compared
with HCV seronegative women those with HIV/HCV co-infection
reported more often a history of injecting drug use (IDU) (65.3% vs.
1.5%, pB0.001), were older at conception (31 years: 74.7% vs.
56.9%, pB0.001) and more were Caucasian (90.7% vs. 30.2%,
pB0.001). More co-infected women were already on antiretroviral
therapy (ART) at time of conception (80.8% vs. 55.3%, pB0.001), had
more ARTswitches during pregnancy, but did not differ in terms of first
CD4 cell count during pregnancy or viral suppression (B400 copies/
mL) at time of delivery (92.6% and 92.9% respectively). Strikingly, HIV/
HCV co-infected women were twice as likely to deliver preterm (B37
weeks) compared to HIV mono-infected women (28% vs. 16.5%, OR
2.0, 95% CI 1.143.50, p0.015). Older age, cigarette smoking and a
history of IDU were associated with preterm delivery in univariable
analysis. After adjustment for those factors and for duration of ART,
HIV/HCV co-infected women still had a higher odds of preterm
delivery, but the result was no longer statistically significant (aOR 1.60,
95% CI 0.594.33, p0.36). We found more newborns of HIV/HCV-
infected mothers with birth weight below 2500 g (63.4% vs. 36.6%,
pB0.001) and any development delay at 6 months of age (aOR 6.07,
95% CI 1.3427.38, p0.019). Regarding vertical transmission, 7/526
(1.3%) babies were HIV infected (none of these from HIV/HCV co-
infected mothers), and 2/71 (2.8%) were HCV infected.
Conclusion: We found a high HCV co-infection rate in HIV-infected
pregnant women in Switzerland. Women with HCV were more likely
to have an adverse pregnancy outcome in terms of preterm delivery
and lower birth weight of the newborn. Treatment of hepatitis C in
HIV co-infected women at childbearing age before pregnancy should
be evaluated to avoid adverse pregnancy outcomes including vertical
transmission of HCV.
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A mother-to-child HIV-1 transmission bottleneck? A new
understanding of the selection biases underlying successful
perinatal infection
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and Philip Goulder1
1Department of Paediatrics, University of Oxford, UK. 2Doris Duke
Medical Research Institute, University of KwaZulu-Natal, Durban,
South Africa
Introduction: Heterosexual HIV-1 transmission has been described as
a severe genetic bottleneck, with a stringent selection bias favouring
the transmission of a high fitness viral variant [1]. Recent work has
also suggested that the selection bottleneck present during transmis-
sion in men who have sex with men (MSM) has notable differences
[2]. There is poorer understanding of the mechanisms underlying
successful mother-to-child transmission, where rates of transmission
are much higher. In this study, we tested the hypothesis that a similar
bottleneck is seen in mother-to-child transmission, and that a viral
variant with high viral replicative capacity (VRC) is responsible for
establishing infection in the child.
Materials and methods: Thirty-eight mother-child HIV transmission
pairs were included in the study (26 children were infected by intra-
uterine [IU] transmission and 12 by intra-partum [IP] transmission).
These pairs were taken from a previously described, treatment-naı¨ve
cohort recruited in Durban, South Africa, between 2003 and 2005
[3]. Samples were taken from the mothers antenatally, within 4
months of delivery, and from the child up to 14 weeks after birth.
Authenticity of the mother-child transmission pairs was validated by
phylogenetic analysis of the viral sequences. Gag-protease chimeric
viruses were generated from mother and child plasma samples and
used in a VRC assay as previously described [4].
Results: The VRC of chimeric viruses derived from the children was
compared with those of their respective mothers. In an unexpected
finding, we show that, overall, the VRC in the children was lower
than in the mothers (mean VRC 0.70. vs 0.80; pB0.0001). Although
this difference was noted for both IU and IP transmission, it was
more notable in the pairs where IU transmission had taken place
(IP: mean VRC difference 0.06, p0.027; IU: mean VRC difference
0.12, p0.0002). Mother and child VRCs were very strongly
correlated (r0.760, pB0.0001). Interestingly, we also observed
that female children tended to have lower VRCs than male children,
although this did not reach significance.
Conclusions: Future treatment interventions will require a detailed
understanding of the mechanisms involved in successful mother-to-
child HIV transmission. Here, we present the new and surprising
finding that, overall, VRC in children is significantly lower than in
their mothers. This finding is the opposite of what is seen during
horizontal HIV transmission. It offers a new understanding of the
selection pressures involved in mother-to-child transmission and will
potentially indicate new therapeutic approaches.
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Introduction: Antiretroviral therapy reduced perinatal transmission
for less than 1% in several countries, but mother-to-child transmis-
sion (MTCT) was not eliminated [1]. Raltegravir (RAL) has demon-
strated good tolerability during pregnancy in previous studies [2] and
could be beneficial to HIV mothers detected in late pregnancy
without prenatal care and demanding rapid viral load control, in
association regimens for HIV mothers failing therapy during preg-
nancy or resistant virus [3]. In developing countries, where HIV late
detection in pregnancy is still a serious problem, associate RAL in
third trimester could be a valid prevention approach to MTCT.
Materials and methods: Seven women were followed in Hospital
Geral de Fortaleza between 2014 and 2016. They received RAL 400 mg
twice daily. Four were HIV late detected in third trimester; two had
previous diagnosis with antiretroviral exposes and viral load higher
than 1000 copies; and one presented viral resistance. Mothers were
followed during pregnancy and children after birth for 6 months.
Results: Mean age was 26.3 years (var 2036). Previous therapy
exposure: naı¨ve (four), TDF/3TC/EFZ (one), TDF/3TC/NVP (one) and
ZDV/3TC/ATV 300 mg/r 100 mg (one). Mean weeks of pregnancy at
RAL initiation 32.3 (var 2137). Associated medications in regimens
with RAL: ZDV/3TC/LPVr (four), TDF/3TC/LPVr (two) and TDF/3TC/
NVP (one). Mean CD4 before RAL 486 cells/mm3, and at birth time
616 cells/mm3. Mean CD8 before RAL 884 cells/mm3, and at birth
time 1015 cells/mm3. Five patients had undetectable viral load at
birth, one had 45 copies/mL and one had 2662 copies/mL. Mean
falling viral load was 3.56 log. One patient documented viral load
falls of 3.8 log in 21 days, another 3.08 log in 7 days and one with 2.2
log in 23 days. Mothers tolerated regimen with RAL without adverse
effects. Six children were not infected, and all seven did not present
malformation. One child was infected, her mother initiated ZDV/3TC/
LPVr/RAL just 5 days prior to birth (viral load 2662). Child presented
viral load after birth of 308,718 (2 months) and 386,152 (3 months),
and genotypic test HIV subtype B, 211K mutation in reverse
transcriptase and 41K, 63P, 71V, 77I, 93L in protease. These results
suggest intrauterine transmission and transmitted resistance muta-
tions in HIV.
Conclusions: We detected rapid viral load falls during pregnancy with
RAL in standard doses, good tolerability in women and safety in
children. Alert for previous transmitted resistance in mother-to-child
prophylaxis, suggesting importance of genotypic test in pregnancy
and early HIV diagnosis.
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from HIV-positive mothers in 2012 to 2015, for the
North-Eastern part of Romania
Carmen Manciuc1; Andrei Vata1; Cristina Nicolau2 and
Alexandra Largu3
1Infectious Diseases, Gr. T. Popa University of Medicine and
Pharmacy, Iasi, Romania. 2HIV/AIDS, Sf. Parascheva Infectious
Diseases Clinical Hospital, Iasi, Romania. 3Behavioral Sciences, Gr. T.
Popa University of Medicine and Pharmacy, Iasi, Romania
Introduction: In the North-Eastern region of Romania most of the
female HIV-positive population is sexually active and at child-bearing
age. In Romania, there is a strict protocol regarding HIV vertical
transmission [1]. We aim to evaluate the efficiency of this protocol
and the degree of appliance, reflected in the HIV status of new-born
infants from HIV-positive mothers for a period of 3 years.
Materials and methods: Of the 1424 patients actively monitored in
the HIV/AIDS Regional Center in Iasi, Romania, 46.5% (663) are
female. We evaluated retrospectively the files of all new-born infants
from HIV-positive mothers for a period of 4 years (January 2012
December 2015).
Results: In the period mentioned above, 127 children were born
(36 in 2012, 38 in 2013, 26 in 2014, 27 in 2015); one death occurred
10 days after birth, due to multiple organ malformations; the
lowest weight at birth was 750 g; three of the children (3%) had a
detectable viral load at birth; in two cases we could not evaluate
the viral load; 125 children (98%) were born through caesarean
section; two were born through natural labour (2%), one of which at
home. Mothers received treatment with lopinavir/ritonavir 
zidovudine/lamivudine through the whole pregnancy in 81 cases,
other antiretroviral regimens in 27 cases, and in nine cases the
mothers did not receive any treatment, being tested for HIV at
birth. For all new-borns prophylaxis was made with zidovudine
lamivudine for 6 weeks. Three children remained positive at 18
months, and therapy for them consisted of zidovudinelamivudine
nevirapine.
Conclusions: Evaluation of pregnant HIV-positive women and pro-
phylaxis for new-born infants in the evaluated period was conducted
according to protocols, which resulted in a small percentage of HIV-
positive children (2.3%) [2,3].
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Determinants and risk of HIV infection among HIV-exposed
infants in western Ethiopia
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Introduction: Ethiopia is one of the sub-Saharan African countries hard-
hit by HIV/AIDS and unfortunately, one of every three children born to
those women gets infected with HIV in the country. Monitoring and
evaluation of the rate and its risk factors for HIV infection among
infants born to HIV-positive mothers are among the major indicators of
the performance of a national HIV control program. However, this is
not well documented in Oromia Regional State of Ethiopia which is the
first largest, most populous and one of the hardest HIV/AIDS-hit regions
in the country. Hence, this institutional-based retrospective study was
conducted in 43 health facilities from November 2014 to January 2015
in selected administrative zones of western Oromia, Ethiopia. The study
participants were HIV-exposed infants enrolled between June 2012 and
October 2014 in the institution.
Method: Medical records of HIV-exposed infants and their mothers
enrolled into the program were reviewed to collect the data.
Results: A total of 492 HIV-exposed infants having HIV DNA/PCR test
result were included in the study. The overall prevalence of HIV
among HIV-exposed infants was 7.70%.
Conclusion: Failure to receive either antiretroviral therapy or pro-
phylaxis for more than 4 months (AOR 4.2, 95% CI 1.412.6), not
receiving co-trimoxazole preventive therapy (AOR 7.8, 95% CI
2.623.7), failure to receive prophylaxis at birth (AOR 18.1, 95% CI
5.263.4) and mixed feeding (AOR 2.302, 95% CI 1.1674.539) were
the factors that increase the risk of mother-to-child transmission of
HIV. In conclusion, the risk of HIV infection among infants born to HIV-
infected mothers is high in the study area. Therefore, education and
promotion for seeking obstetric care and HIV services during their
course of pregnancy, focusing on exclusive breast feeding counselling
and promotion, and early initiation of antiretroviral treatment to HIV-
infected pregnant women are recommended to curb the devastating
consequences of HIV on pregnant women and their newborns.
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Preventing mother-to-child transmission of HIV in a general
hospital: are we following the guidelines?
Funmi Awosusi and Maha Al-Harbi
Pharmacy, Barts Health NHS Trust, London, UK
Introduction: Mother-to-child transmission of HIV has declined to
less than 2% in the UK [1,2]. This decline was a result of the
development in perinatal care and preventive measures offered to
HIV-positive pregnant women [3,4]. In the UK, management of HIV-
infected pregnant women is according to the British HIV Association
(BHIVA) pregnancy guidelines, recently reviewed in 2014. The aim of
the audit was to measure the extent of adherence to the BHIVA
pregnancy guidelines.
Methods: A total of 117 women were identified as HIV-positive preg-
nant women registered to deliver at the hospital, between May 2012
and December 2015. A total of seven maternal and neonatal factors
were evaluated to measure extent of adherence to the guidelines. Data
were collected retrospectively from the hospital database and medical
notes of these women and their neonates. Eleven women had
miscarriages, ten delivered in other different hospitals and one infant
died at birth. These were excluded from analysis, leaving a total of 95
patients. Data were compiled onto a spreadsheet and analyzed.
Results: Adherence to the guidelines varied in all the aspects
examined. Areas where less optimal adherence were observed
included viral load testing at delivery for women taking HAART and
HIV polymerase chain reaction (PCR) testing for neonates at 12 weeks.
Majority of women were undetectable at 36-week gestation (80%),
but only 60% delivered vaginally, even though appropriate mode of
delivery was planned for the patients at 36 weeks. For neonatal
antiretroviral, 55% were documented to have received zidovudine
monotherapy or triple therapy, as appropriate, within 4 hours.
Conclusion: There are variations in adherence of the care provided at
the hospital, to the BHIVA guidelines. Areas for development include
improvement in documentation, maternal viral load testing at
delivery and neonatal HIV PCR testing at 12 weeks.
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Influence of HIV infection in choosing to terminate
pregnancy
Elsa Campoa1; Liliana Pedro1; Filipa Azevedo1; Raquel Pinho1;
Manuela Sima˜o1; Conceic¸a˜o Santos2; Domitilia Faria1; Carlos Santos1
and Luisa Arez1
1Medicine, Algarve Hospital Center, Portima˜o, Portugal. 2Obstetrics
and Gynaecology, Algarve Hospital Center, Portima˜o, Portugal
Introduction: Pregnant HIV patients are often concerned with foetal
development and IU transmission of HIV. Therefore, they frequently
opt for an abortion. Antiretroviral therapy brought new options
to these women due to reduced risk of mother-foetal transmission
[1,2]. We estimated the incidence of abortion in HIV-infected
pregnant women in our clinic, for the last 15 years.
Material and methods: Data were retrospectively collected. The inci-
dence of abortions in women with a known diagnosis of HIV between
2000 and 2015 was compared with the incidence of abortions in
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women who were newly diagnosed with HIV during pregnancy. Sta-
tistical analysis with linear regression was done with SPSS version 23.
Results: Seventy-six women were included, with an average age
at HIV diagnosis of 26.6 (standard deviation 5.5) years. Of 110
pregnancies, 27 (24.5%) ended in a planned abortion (Table 1).
There was a significant relationship between the number of women
with known HIV infection prior to pregnancy and the choice for
abortion (R0.276, p0.004). There was no association between
the prevalence of abortion and the maternal age at the time of HIV
diagnostics.
Conclusion: This study shows that, in our sample, women already
infected with HIV choose to terminate pregnancy more often than
those who are already pregnant at the time of first diagnosis.
Although the use of HAART reduces HIV transmission to the foetus,
the presence of an HIV infection seems to play a role in deciding to
terminate pregnancy. It is necessary to develop more studies about
this and thoroughly inform these patients and help them to make
informed decisions about termination of pregnancy.
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The association between preterm delivery and the risk of
mother-to-child transmission of HIV
Svitlana Posokhova; Sergey Petrovych and Svitlana Shevchenko
Perinatal Center, Odessa Oblast Clinical Hospital, Odessa, Ukraine
Introduction: The prevalence of HIV among Ukrainian women is
estimated to be more than 1%. Increased preterm delivery has
been reported among HIV-infected women in several industrialized
countries. Recent studies have identified HIV as a leading contributor
to preterm delivery. Premature babies born to HIV-positive mothers
are at an increased risk of vertical transmission. The aim of the study
was to evaluate the rate and the risk factors for the mother-to-child
transmission (MTCT) of HIV in women who had preterm delivery
(PTB; B37 weeks of gestation).
Methods: A retrospective study looking at all premature babies born
to HIV-infected mothers between 2010 and 2014 years in Odessa
Regional Perinatal Center. The prematurity risk factors and the rate of
MTCT of HIV were analyzed.
Results: In total, 122 HIV-infected women out of the 1115 eligible for
inclusion into the study had spontaneous preterm delivery (10.9%) of
which 40% were severe preterm (B34 weeks of gestation). The rate
of MTCT in children born prematurely was 21.3%. All women with
preterm birth were divided into two groups. The first group included
26 women whose children were HIV positive and the second group
consisted of 96 women whose children were healthy. Mothers who
gave birth to HIV-infected children more frequently had a combina-
tion of several STDs such as trichomoniasis (38.4%), syphilis (15.4%),
herpes simplex (23.1%), presence of opportunistic infection (6.5%)
and absence of antenatal care (9.8%). The length of time of rupture
of membranes (ROM) in the Group I before delivery 12 hours was
in 69.3% cases. In the Group I viral loads 10,000 copies/mL were
in 23.1%, B1000 copies/mL  15.4% (3.5 times more than in the
second group), unknown  61.5% of women.
Conclusions: Thus, we have found an increased incidence of MTCT
observed in HIV-infected women who gave birth B32 weeks of
Table 1. Frequencies of abortion and the moment of HIV
diagnosis
No abortion Abortion
HIV previous to pregnancy 38 (64.4%) 21 (35.6%)
HIV during pregnancy 45 (88.2%) 6 (11.8%)
Table 1. Maternal baseline characteristics
Maternal baseline
characteristics
Group I
HIV-
positive
babies
(n26)
Group II
HIV-
negative
babies
(n96) p value
Median age, years 25.8 26.5
Intravenous drug users 3 (11.5%) 0 B0.001
Smoking 16 (61.5%) 57 (59.3%) 0.05
Marital status, no. (%)
Single 16 (61.5%) 62 (64.5%)
Gravida including current
pregnancy, no. (%)
1 8 (30.7%) 43 (44.7%)
2 12 (46.2%) 38 (39.5%)
3 4 (15.4%) 8 (8.4%)
4 and more 2 (7.7%) 7 (7.4%)
Gestational age at study
enrolment
2628 weeks 4 (15.4%) 0%
2931 weeks 16 (61.5%) 10 (10.4%) B0.001
3234 weeks 4 (15.4%) 14 (14.6%)
3537 weeks 2 (7.7%) 72 (75%) B0.001
Sexually transmitted diseases
Trichomoniasis 10 (38.4%) 16 (16.6%) B0.01
Chlamydiosis 8 (30.7%) 20 (20.8%)
Syphilis 4 (15.4%) 0% B0.001
Herpes simplex 6 (23.1%) 6 (9.1%) B0.01
Viral load 10,000 copies/mL 6 (23.1%) 20 (20.8%)
B1000 copies/mL 4 (15.4%) 52 (54.1%) B0.001
Unknown 16 (61.5%) 4 (4.1%) B0.001
CD4 cell count 500 cells/mL 4 (15.4%) 68 (70.8%) B0.001
200499 cells/mL 2 (7.7%) 12 (12.5%)
B200 cells/mL 4 (15.4%) 12 (12.5%)
Unknown 16 (61.5%) 4 (4.2%) B0.001
The length of time of rupture
of membranes (ROM)
B12 hours
8 (30.7%) 67 (69.7%) B0.01
12 hours 18 (69.3%) 29 (30.3%) B0.01
Mode of delivery
Vaginal 20 (76.9%) 44 (45.8%) B0.05
Elective caesarean section 0% 36 (37.5%)
Emergency caesarean section 6 (23.1%) 16 (16.7%)
Triple-combined HAART 14 (53.8%) 92 (95.8%)
Untreated 12 (46.2%) 4 (4.2%) B0.001
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
26
gestation (pB0.001), had several STD (RR 1.81; 95% CI 1.202.56), the
vaginal delivery and length of ROM before delivery 12 hours (RR
1.43; 95% CI 1.101.86), a high viral load 10,000 copies/mL (RR 1.62;
95% CI 1.252.23) and who were untreated with HAART (pB0.001).
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Efficacy of prophylactic antiretroviral treatment in
new-born infants from HIV-positive mothers in 20122014,
for the North-Eastern part of Romania
Carmen Doina Manciuc; Liviu Prisacariu; Cristina Nicolau and
Alexandra Largu
HIV/AIDS, Sf. Parascheva Infectious Diseases Clinical Hospital, Iasi,
Romania
Introduction: In the North-Eastern region of Romania most of the
female HIV-positive population is sexually active and at child-bearing
age [1]. In Romania, there is a strict protocol regarding HIV vertical
transmission [2]. We aim to evaluate the efficiency of this protocol
and the degree of appliance, reflected in the HIV status of new-born
infants from HIV-positive mothers for a period of 3 years.
Material and methods: Of the 1424 patients actively monitored in
the HIV/AIDS Regional Center in Iasi, Romania, 46.5% (663) are
female. We evaluated retrospectively the files of all new-born
infants from HIV-positive mothers for a period of 3 years (January
2012December 2014).
Results: In the period mentioned above, 100 children were born (36
in 2012, 38 in 2013, 26 in 2014); one death occurred 10 days after
birth, due to multiple organ malformations; the lowest weight at
birth was 750 g; three of the children (3%) had a detectable viral load
at birth; in one case we could not evaluate the viral load; 98 children
(98%) were born through caesarean section; two were born through
natural labour (2%), one of which at home. Mothers received treat-
ment with lopinavir/ritonavirzidovudine/lamivudine through the
whole pregnancy in 81 cases; in eight cases the mothers did not
receive any treatment, being tested for HIV at birth. For all new-
borns prophylaxis was made with zidovudinelamivudine for 6
weeks. Three children remained positive at 18 months, and therapy
for them consisted of zidovudinelamivudinenevirapine.
Conclusions: Evaluation of pregnant HIV-positive women and prophy-
laxis for new-born infants in the evaluated period was conducted
according to protocols, which resulted in a small percentage of HIV-
positive children (3%).This is one of the aspects thatmake the Romanian
HIV-positive population different from that of other countries [3].
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ARV-BASED PREVENTION: PEP/PREP
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Compliance of fixed-dose single tablet EVG/COBI/FTC/TDF
(Stribild) regimen versus LPV/r /d4T/3TC for PEP in sexual
assault victims: a retrospective sequential period study
Ste´phane De Wit1; Agne`s Libois1; Pierre Mols2 and
Stefano Malinverni2
1Infectious Diseases, Saint-Pierre University Hospital, Brussels,
Belgium. 2Emergency, Saint-Pierre University Hospital, Brussels,
Belgium
Introduction: Post-exposure prophylaxis (PEP) is recommended in
most cases of sexual assaults. Due to many reasons, compliance is
poor in this situation. A single-tablet regimen for PEP showed good
results in terms of adherence and completion [1]. Following a pre-
vious study in our institution indicating a low compliance (40%) to
PEP for sexual assault victims [2], drug regimen has been changed on
1 January 2015 from LPV/r /d4T/3TC to single tablet EVG/COBI/FTC/
TDF aiming to improve compliance. In this study, we evaluate the
impact of this change on compliance.
Materials and methods: We conducted a retrospective sequential
period analysis between January 2011 and December 2015 of persons
consulting at our institution for PEP following sexual assault. Data were
extracted from a prospective PEP registry. Patients receiving 28 days of
treatment were considered compliant. Compliance was extracted from
medical records and calculated from pharmacy records.
Results: A total of 368 cases were included, 283 received PEP. Ninety-
six percent were female with a mean age of 27 years, 50% were
migrant. Exposure was vaginal receptive in 82% of cases, anal
receptive in 21% and oral receptive in 27%. Seventy-one patients
received a single tablet EVG/COBI/FTC/TDF and 212 received a multi-
tablet regimen LPV/r /d4T/3TC twice daily. Baseline characteristics of
the two groups were not statistically significantly different. Compli-
ance was higher in EVG/COBI/FTC/TDF compared with LPV/r /d4T/3TC
(52% vs. 42% respectively, p0.158), but this did not reach statistical
significance.
Conclusion: Switching to a well-tolerated single-pill regimen (EVG/
COBI/FTC/TDF) modestly improves compliance suggesting that in
sexual assault victims other drug regimens and other interventions
should be implemented.
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Increased rate of C. trachomatis infection after being
prescribed PrEP
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Introduction: Increasing use of HIV pre-exposure prophylaxis (PrEP)
using Truvada following clinical trials that have shown nearly 100%
efficacy for high-risk men who have sex with men (MSM) raises con-
cerns that resulting decreased condom use could increase sexually
transmitted infections (STIs). Clinique l’Actuel (CA) is a sexual health
clinic in Montre´al, Que´bec, Canada and the largest provider of health
care for MSM and people living with HIV in the city; in 2015, CA
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treated 60% of N. gonorrhoea (NG) cases in Que´bec province; a
marked increase in NG treatments has been noted at CA since
January 2016. Since August 2015 PrEP has been offered to MSM
coming for STI screening and assessed as high risk by physicians; as
of July 2016, 1059 MSM are receiving PrEP (85% continuous regimen,
15% intermittent regimen) at CA. PrEP may lead to a shift away from
condoms as a prevention strategy, or alternatively offers a new
prevention strategy for those who already engage in condom-less
sex.
Methods: To assess whether PrEP increases condom-preventable
STIs, we enrolled patients with 1 year of follow-up before and
after PrEP prescription. Hundred and thirty-three patients were
included. Patients were seen every 3 months for a physician evalua-
tion, behavioural questionnaire and full STI screen that included PCR
swabs for anal, oral or urethral NG and C. trachomatis (CT). Cases
were ascertained by electronic results with a manual chart review to
confirm positives. The proportion of individuals infected with CT and
NG were compared before and after exposure to PrEP using two-
sided chi squared (x2) test.
Results: The proportion of individuals infected with anal, oral or
urethral CT in the year prior to PrEP were 10%, 2%, 3%, respectively
and in the year post-PrEP were 20%, 2%, 11% in the exposure period
(p-value 0.00, 1.00, 0.01, respectively). The percentage of individuals
infected with CT at any site pre- and post-PrEP were 13% and 26%
(p0.01). The proportion of individuals infected with anal, oral or
urethral NG in the year prior to PrEP were 9%, 8% and 8%, respec-
tively, and in the year after PrEP were 14%, 11%, 6% (p-value 0.24,
0.29, 0.62, respectively). The percentage of individuals infected with
NG pre- and post-PrEP were 17% and 26% (p0.07), respectively.
Conclusion: Increased rates of CT post-PrEP suggest a shift away from
condom use. Increased rates of asymptomatic STIs such as CT but
not NG post-PrEP warrant further study.
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Risk perception in MSM taking PrEP
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Gary Whitlock
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Introduction: There are concerns that those taking pre-exposure pro-
phylaxis (PrEP) may increase their frequency of condomless sexual
intercourse and hence increase their risk of acquiring STIs other than
HIV. We wished to survey the perception of these concerns for those
on PrEP in the UK.
Materials and methods: Between 6 February and 7 June 2016, we
surveyed MSM attending a central London sexual health clinic for
PrEP monitoring. The survey was a self-reported anonymous paper
questionnaire asking about respondents’ PrEP regimen, length of
time on PrEP and how respondents’ sexual activity and partner
selection had changed and how they felt about the risk of acquiring
STIs and HIV since starting PrEP. P-values were computed using
Fisher’s exact test.
Results: Hundred questionnaires were completed: all respondents
were MSM. The majority (77%) were taking daily PrEP, 19% event-
driven and four not-specified. The median time on PrEP was 3
months. Since starting PrEP most respondents indicated they were
more relaxed about their risk of acquiring HIV (83%). With regard to
risk of acquiring other STIs, 20% were less relaxed and most ‘‘felt the
same’’ (78%). Most (63%) indicated that the number of times
they had had condomless sex had not changed since starting PrEP;
30% indicated it had increased. There was a reported increase
in condomless intercourse in those taking PrEP for longer than 4
months compared with those more recently starting (p0.049)
(Table 1).
Conclusions: Our survey suggests that MSM taking PrEP in London,
UK are more relaxed about acquiring HIV but less so about other
STIs. There appears to be an association between length of time on
PrEP and increase of condomless sexual activity. It is important that
PrEP guidelines incorporate regular STI screening and risk reduction
interventions.
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Attitudes towards pre-exposure prophylaxis against HIV
infection among individuals seeking voluntary counselling
and testing for HIV in Taiwan
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Hsin-Yun Sun1; Chien-Ching Hung1 and Shan-Chwen Chang1
1Internal Medicine, National Taiwan University Hospital, Taipei,
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Introduction: Pre-exposure prophylaxis (PrEP) using tenofovir dis-
oproxil fumarate (TDF)/emtricitabine (FTC) against HIV infection have
been shown to be efficacious in clinical trials. Successful implemen-
tation of PrEP in the field settings requires understanding of the
knowledge and opinions of PrEP among the individuals who will
benefit most from the intervention. This survey aimed to understand
the attitudes towards PrEP among individuals in Taiwan who sought
voluntary counselling and testing (VCT) for HIV at a university
hospital, where the HIV incidence rates among men who have sex
with men (MSM) was estimated 5.5 per 100 person-years of follow-
up between 2007 and 2015.
Materials and methods: Between April and June, 2016, a survey was
conducted among VCT clients who completed an anonymous ques-
tionnaire interview with the assistance of a trained counsellor to
inquire about the risks for HIV infection or other sexually transmitted
infections and the knowledge of PrEP against HIV infection. We
collected information on demographics, educational achievement,
occupation, income and risk exposures that prompted the VCT visits.
Tests for anti-HIV antibody and syphilis were performed. Multivariate
logistic regression analysis was performed to identify the associated
factors with consideration to initiate PrEP. All of the variables with
pB0.2 in univariate analysis when comparisons were made between
those who would consider PrEP and those who would not were
entered into multivariate analysis.
Results: During the 3-month study period, all 611 individual clients
with a mean age of 30.1 years (SD 8.3) seeking VCT service agreed to
participate in this survey; 87.6% were male, 68.2% MSM, and 74%
had full-time or part-time jobs, and 20% were students. About one-
third of the clients reported unprotected anal sex with fixed (32.5%)
or unfixed partners (35.0%) within 3 months and use of recreational
drugs (6.4%) or alcohol consumption (18.0%). Less than 40% (37.5%)
knew PrEP while 68.8% knew post-exposure prophylaxis before this
survey. Overall, 309 individuals (50.6%) would consider to initiate
PrEP and 83.5% of them would choose event-driven PrEP strategy. In
Table 1. Since you’ve started PrEP how do you think the
number of times you have had condomless sex has changed?
Length on PrEP Decreased No change Increased Total
4 months or more 3 22 18 43
Less than 4 months 2 41 12 55
Total 5 63 30 98*
*Two respondents did not indicate length on PrEP.
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multivariate analysis, knowledge of PrEP (adjusted odds ratio [AOR]
5.252; 95% CI 1.06625867) and having unprotected anal sex with
unfixed partners (AOR 19.574; 95% CI 2.259169.575) before this
survey was statistically significantly associated with consideration to
initiate PrEP with TDF/FTC.
Conclusions: To facilitate successful implementation of PrEP against
HIV infection, increase of awareness by providing information,
education and communication with respect to PrEP is important to
the population at risk.
P014
‘‘Self-perceived’’ pre-exposure prophylaxis adherence and
its relationship to self-reported ‘‘actual adherence’’ among
Thai men who have sex with men and transgender women
Tarandeep Anand1; Stephen Kerr2; Tanakorn Apornpong2;
Chattiya Nitpolprasert1; Jintanat Ananworanich3;
Praphan Phanuphak4 and Nittaya Phanuphak5
1Adam’s Love, Thai Red Cross AIDS Research Centre, Bangkok,
Thailand. 2Biostatistics, HIV Netherlands Australia Thailand Research
Collaboration, Thai Red Cross AIDS Research Centre, Bangkok,
Thailand. 3Therapeutics Research, US Military HIV Research Program,
Walter Reed Army Institute of Research, Silver Spring, MD, USA.
4Thai Red Cross AIDS Research Centre, Bangkok, Thailand. 5HIV
Prevention, Thai Red Cross AIDS Research Centre, Bangkok
Thailand
Introduction: In Bangkok, one in three Thai men who have sex with
men (MSM) are HIV positive [1] and prevalence among transgender
(TG) women ranges from 10 to 17% [2]. Pre-exposure prophylaxis
(PrEP) is a safe and effective HIV prevention method [3]. Thai MSM
and TG have shown high interest in PrEP uptake, but data on PrEP
adherence and retention remain suboptimal. We sought to under-
stand how self-perceived adherence related to actual adherence, to
inform the development of future PrEP adherence interventions.
Methods: Between January 10 and 11 April 2016, the Thai Red Cross
AIDS Research Centre (TRCARC)’s Adam’s Love (www.adamslove.
org) enrolled MSM and TG into free PrEP services using its real-time
PrEP eCounselling and novel Online-to-Offline (O2O) model at four
sites in Bangkok including TRCARC Anonymous Clinic, Adam’s Love
private clinic and two community-based drop-in centres. Data were
gathered on their self-perceived adherence at PrEP initiation and
compared with self-reported adherence 1 month post PrEP use.
Logistic regression was used to calculate the OR for demographic
and behavioural characteristics associated with 100% self-reported
adherence. Factors significant in univariate analysis at pB0.1 were
adjusted for in a multivariate model. Participants who withdrew or
were lost to follow-up were imputed as non-adherent.
Results: A total of 168 participants were enrolled into the pro-
gramme. Data from 132 participants with available adherence data
after 1 month of PrEP were analyzed. At enrolment, 105 (79.5%)
participants believed they were likely or extremely likely to be
adherent to daily PrEP, but only 13 (9.8%) had reported taking all
seven pills in the week prior to the month 1 visit. After adjusting for
selling sex and cannabis use in a multivariate model, two factors were
independently associated with perfect (100%) self-reported adher-
ence. These were having no income because they were students or
unemployed (OR 5.6, 95% CI 1.323.4; p0.02) and being aware of
sex partners’ HIV status (OR 6.7, 95% CI 1.628.7; p0.01).
Conclusions: Although most Thai MSM and TG believed they would
be highly adherent to PrEP at enrolment, this perception correlated
poorly with actual adherence. Participants without income and those
aware of the HIV status of their sexual partners were significantly
more likely to report 100% adherence. Innovative PrEP adherence
interventions to help overcome daily adherence barriers and promote
consistent high levels of PrEP adherence are urgently needed.
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Polish infectious diseases physicians’ attitudes and beliefs
about pre-exposure prophylaxis for HIV prevention
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Medical University of Warsaw, Warsaw, Poland
Introduction: Pre-exposure prophylaxis (PrEP) for HIV prevention is
rarely implemented in Polish setting. It remains controversial among
infectious diseases specialists, yet no research was undertaken to
identify the concerns. Providing deeper understanding of the exact
nature of physicians’ attitudes about PrEP should help direct further
efforts into resolving the controversies.
Materials and methods: Anonymous questionnaires (150) were
distributed among Polish infectious diseases specialists with ques-
tions addressing their attitudes, beliefs, expectations and experi-
ences related to PrEP. Data were collected in regard to sex, age, years
of practice, city of practice and whether they were members of
academic faculty.
Results: Overall, 62 physicians (41.3%) returned the questionnaires
(mean age 42.5, SD 10.5; 69.4% women). Only nine doctors (14.7%)
had ever prescribed PrEP to patients. Majority considered there were
indications for use of PrEP in seronegative women (70.5%) and
seronegative men (65.6%) planning pregnancy with a serodiscordant
partner and consequently believed PrEP should be funded by the
state in these circumstances (63.94% and 60.7%, respectively). No
other presented situation (such as: men who have sex with men with
a history of unprotected anal intercourse, serodiscordant couples
and intravenous drug users) was considered an indication for PrEP or
a justification for state funding. In the sample, 63.9% of doctors
agreed or strongly agreed with a statement that PrEP was a well-
known issue to them compared to 8.2% who disagreed or strongly
disagreed. Majority (67.7% vs. 11.3%) believed PrEP was efficacious
in preventing new infections and 56.5% (vs. 21%) shared the view it
was a major accomplishment in HIV prevention. Common concerns
included: PrEP leading to abandonment of safer sex practices (64.5%
vs. 16.1%) or serving as an encouragement to risky sexual behaviours
(58.1% vs. 24.2%) and potential drug-resistance emergence (54.1%
vs. 24.6%). Vast majority (77.4% vs. 11.3%) believed that patients
should radically alter their behaviours instead of relying on
pharmacologic interventions.
Conclusions: Polish physicians involved in HIV treatment hold
generally favourable views of PrEP and majority consider themselves
sufficiently educated in this regard. Concerns are raised, however, in
terms of encouragement to risky sexual behaviours, which should be
addressed in research in Central and Eastern European population of
potential PrEP users.
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Pre-exposure prophylaxis awareness in individuals accessing
a non-occupational post-exposure prophylaxis (NPEP)
program
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Wendy Zhang1; Silvia Guillemi1; Marianne Harris1; Troy Grennan2;
Jason Wong2; Val Montessori1; Gina Ogilvie2; Julio Gonzalez
Montaner1 and Mark Hull1
1Providence Health Care, British Columbia Centre for Excellence in
HIV/AIDS, Vancouver, Canada. 2Infectious Disease, BC Centre for
Disease Control, Vancouver, Canada
Introduction: Biomedical prevention strategies are an important
aspect of combination prevention interventions for HIV infection.
Programmes targeting populations at highest HIV risk are likely to
be cost-effective. Individuals who require post-exposure pro-
phylaxis (PrEP) have been shown to be at high risk for subsequent
HIV seroconversion, yet their knowledge of alternate prevention
strategies is unclear. We undertook to assess overall awareness of
PrEP amongst individuals accessing an NPEP program in Vancouver,
Canada.
Methods: Individuals accessing an NPEP pilot program offered at
five sites (four community-based and via an emergency department
of a tertiary care hospital) were sequentially recruited to complete a
self-administered HIV knowledge questionnaire between July 2012
and March 2014. Awareness of PrEP was initially dichotomized as a
yes/no response, and for individuals reporting PrEP awareness, level
of self-reported knowledge was further categorized using a four-
point Likert scale. Factors associated with PrEP awareness were
determined using Fisher’s exact test for categorical values and
Wilcoxon rank sum for continuous variables (pB0.05 considered
significant).
Results: Overall 134 individuals were included, 95% male, 70% white,
with median age of 36 years (interquartile range [IQR] 2842).
Baseline exposure for NPEP included condomless anal sex (CAS) in
84% of individuals (81% MSM) and IDU in 4% of individuals. Overall
n75 (56%) individuals reported being aware of PrEP, with 47 (63%)
reporting moderate/high levels of knowledge, and 51 (68%) were
willing to use PrEP. PrEP awareness was positively associated with
reporting MSM partners (89% vs. 72%, p0.018), being non-IDU
(100% vs. 84%, p0.004) and reporting high levels of knowledge
regarding role of HIV viral load in transmission (29% vs. 8%,
pB0.001). In a multivariate logistic model, high levels of knowledge
regarding HIV viral load in transmission remained the only factor
significantly associated with awareness of PrEP (aOR 3.34, 95% CI
1.129.90, p0.042).
Conclusions: MSM individuals accessing NPEP services report both
high levels of HIV risk and PrEP awareness. Combination NPEP/PrEP
programs should be considered for at-risk individuals.
P017
PrEP use in Lisbon while waiting for a policy
Paula Meireles1; Miguel Rocha2; Maria Jose´ Campos2 and
Henrique Barros3
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Universidade do Porto, Porto, Portugal. 2Grupo de Ativistas em
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Introduction: Pre-exposure prophylaxis (PrEP) with tenofovir/emtri-
citabine (TDF/FTC) has shown to be effective in preventing HIV
among high-risk HIV-negative men who have sex with men (MSM).
These overwhelming results of the trials put pressure on countries to
make PrEP available. Few are already dispensing TDF/FTC as PrEP,
Portugal is not one of those, although we remain one of the most
affected populations in Western Europe. However, some individuals
report the use of PrEP. We aimed to assess the frequency of PrEP use
and the characteristics of users in an HIV-negative MSM cohort [1].
Materials and methods: Using data from the Lisbon Cohort of MSM,
an open prospective cohort of 4243 adult HIV-negative MSM, we
performed a case-cohort analysis; 28 (0.7%) reported to have used
PrEP, and we randomly selected 112 controls. Proportions were
compared using the chi-square or Fisher’s exact test and medians
using the Mann-Whitney.
Results: PrEP users had a significantly higher median number of
visits in the cohort (3 vs. 1, pB0.001), were more frequently born in
countries other than Portugal (39.1% vs. 17.0%, p0.025), reported
more frequently to know and to have used post-exposure prophy-
laxis (PEP) at baseline (34.6% vs. 52.3% did not know about PEP and
11.5% vs. 0.9% used PEP, p0.014). Always using condom with an
occasional partner were more frequently reported among PrEP users
(68% vs. 48%, p0.091). Groups were similar in terms of age,
education and condom use with an HIV-positive steady partner and a
STI diagnosis in the previous 12 months to baseline.
Conclusions: In the absence of an official policy some MSM are
already using TDF/FTC in Portugal, particularly those born abroad
and are concerned with their protection.
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PREVENTION (TASP)
P018
Increasing ART coverage and viral suppression are
associated with a substantial decline in new HIV infections
in the Austrian Tyrol
Gisela Leierer1; Ard van Sighem2; Mario Sarcletti1; Maria Kitchen1;
Martin Gisinger1; Michaela Rappold1; Bruno Ledergerber3 and
Robert Zangerle1
1Department of Dermatology and Venereology, Medical University of
Innsbruck, Innsbruck, Austria. 2Research, Stichting HIV Monitoring,
Amsterdam, Netherlands. 3Division of Infectious Diseases, University
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Introduction: UNAIDS has set the goal that 90% of people living
with HIV (PLHIV) are diagnosed, that 90% of all people diagnosed
receive ART and 90% of all people receiving ART have viral sup-
pression. Apart from being a challenging goal, there is controversy
whether the 909090 UNAIDS targets suffice to curb the HIV
epidemic.
Methods: Patients from the University Hospital Innsbruck (UHI;
covers ]99% patients with ART) who had their last residency in the
Austrian Tyrol. PLHIV estimates were obtained using back-calculation
models [1] to estimate HIV incidence and the undiagnosed fraction
from the patients referred to UHI. The proportion ever diagnosed
and still living in Tyrol who ever initiated ART and the proportion of
them who were virally suppressed (5200 copies/mL) were assessed
for the years 2001 to 2015. Missing HIV RNA was considered as
unsuppressed.
Results: PLHIV were estimated to be 271 in 2001 and 501 in 2015.
The fraction undiagnosed decreased from 18% (95% CI 1224%) in
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2011 to 11% (95% CI 727%) in 2015. The proportion of
diagnosed patients who have ever started ART increased from
64% in 2001 to 91% in 2015 (Figure 1). Among those who started
ART, the proportion of individuals virally suppressed improved from
79 to 97% between 2001 and 2015 (Figure 1). The fraction
of the virally suppressed among PLHIV increased from 39% in 2001
to 79% in 2015, which is well above the 909090 target of 73%.
Estimates of the number of new HIV infections decreased
from 26 (95% CI 1834) in 2009 to eight (95% CI 076) in 2015
(Figure 2).
Conclusions: Although the relationship between the fraction of
virally suppressed and HIV infections does not demonstrate causality
it provides strong supportive evidence that treatment as prevention
can reduce the epidemic. In addition, our data support that in this
setting the 909090 targets may indeed curb the epidemic.
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Introduction: The risk of acquiring tuberculosis (TB) by people living
with HIV (PLHIV) could be drastically reduced through provision of
isoniazid preventive therapy (IPT). In Nigeria, there is paucity of data
on the routine implementation of this intervention and its effec-
tiveness in low-resource settings. The MSH model provides 6 months
of IPT at 2-month intervals for eligible PLHIV. This study assessed
pattern of IPT provision and impact among PLHIV in six USAID-
funded hospitals in Kebbi state, Nigeria.
Methodology: Data were collected in November 2015 by reviewing
a total of 1653 folders of adult and paediatric PLHIV placed on IPT
across six health facilities between January 2013 and October 2015.
Descriptive and inferential statistics were used to analyze findings.
Results: Of the 1653 folders reviewed, 1134 have completed IPTwhile
519 were still on IPT. Only 13 (1.1%) of those who completed IPT
developed TB after average period of 11 months. Only one (0.1%)
developed TB while on IPT. Individuals who completed IPT
without developing TB have the same IPT default rate (31%) as those
who developed TB after IPT completion. Those who completed IPT
without developing TB were found to have lower rate (10%) of ART
default compared with higher rate (60%) in those who developed TB
after IPT completion. IPT default was highest in the first few weeks of
ART initiation.
Conclusion: ART and IPT have combined effect of reducing TB
incidence among PLHIV. Adherence to ART as measured by default
rate has greater impact compared with adherence to IPT in the
reduction of the incidence of TB among PLHIV. Coupled with
enhanced adherence services, pre-packaging IPT and ART as single
prescription will help to overcome integration challenges and reduce
TB burden among PLHIV.
Figure 1. Temporal trends of the proportion on ART of those
diagnosed and the proportion with suppressed HIV-RNA of those
on ART in Tyrol.
Abstract P018Figure 2. Number of new HIV infections in Tyrol over time.
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Cascade of care in TAK project: strong in right side, but
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Introduction: Early cART remains the most effective HIV prevention
strategy, yet poor linkage to care after HIV diagnosis may compro-
mise this benefit [1]. It is important to better understand patient
characteristics and risk for HIV acquisition and association with
response to cART.
Method: The TAK project collects all information on patients
diagnosed with HIV in community-based testing facilities (CBVCTs)
in central Poland, follows their linkage to care and ongoing routine
clinical care [2]. Data collected for persons diagnosed from 2010 to
2013 in CBVCTs were linked with HIV clinic records. Individuals linked
to care were followed from first CBVCTs visit until last visit in the HIV
clinic or 5 December 2015. Cox proportional hazard models were
used to identify factors associated with viral suppression (VS) (first
VS: HIV RNA B50 copies/mL).
Results: Two hundred and thirty-two persons were HIV, 144 (62%)
linked to care, 116 (80% of those linked to care) started cART during
follow-up, of which 113 (97%) achieved VS with median time to VS of
5 (IQR 45) months. Median time from linkage to starting cART was
6 (IQR 39) months. In those who started cART 111 (96%) were men,
98 (84%) homosexual, 26 (22%) had syphilis at baseline, 34 (29%)
had a partner who had never tested for HIV, 33 (28%) had a HIV
partner, 66 (57%) always using condoms with casual partners, 24
(21%) had sex on drugs or alcohol. Median age was 32 (IQR 2837)
years, baseline CD4 count 352 (259415) cells/mL and HIV RNA 4.5
(3.95.1) log copies/mL. After adjustment, factors associated with
higher rate of VS were bisexual orientation, non-PI-based regimen,
HLA B5701() and with lower rate were unknown syphilis status
and higher HIV RNA at cART start (Figure 1).
Conclusions: In this community-based setting, although a low
proportion of persons were linked to care, almost all those linked
to care started cART and achieved rapid VS during follow-up. We
observed high rates of VS, irrespective of prior HIV-associated risk
behaviours. Linkage to care remains the highest priority in preven-
tion strategies in central Poland.
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Durability and tolerability of first-line combination including
two NRTI and RAL or ATV/r or DRV/r in patients enrolled in
the ICONA Foundation cohort
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Table 1. Characteristics of the included patients
ATV/r (N939) DRV (N931) RAL (N202) p
Male gender, n (%) 717 (76.4%) 764 (82.1%) 165 (81.7%) 0.007
Age, years, median (IQR) 39 (3247) 40 (3249) 43 (3551) 0.002
Italians, n (%) 716 (76.2%) 749 (80.4%) 173 (85.6%) 0.004
Mode of HIV transmission, n (%)
Heterosexual 430 (45.8%) 388 (41.7%) 89 (44.1%) B0.001
IVDU 113 (12.0%) 57 (6.1%) 8 (4.0%)
Homosexual 339 (36.1%) 396 (42.5%) 89 (44.1%)
Other/unknown 57 (6.1%) 90 (9.7%) 16 (7.9%)
AIDS, n (%) 81 (8.6%) 148 (15.9%) 21 (10.4%) B0.001
HCV co-infection, n (%)
Positive 120 (12.7%) 74 (7.9%) 11 (5.4%) B0.001
Negative 723 (77.0%) 737 (79.2%) 161 (79.7%)
Not known 96 (10.2%) 120 (12.9%) 30 (14.8%)
HBV co-infection, n (%)
Positive 40 (4.3%) 33 (3.5%) 13 (6.4%) 0.224
Negative 760 (80.9%) 745 (80.0%) 152 (75.2%)
Not known 139 (14.8%) 153 (16.4%) 37 (18.3%)
CD4 cell/mm3, n (%)
0200 98 (10.4%) 11 (1.2%) 13 (6.4%) B0.001
201350 350 (37.3%) 264 (28.4%) 32 (15.8%)
351500 348 (37.1%) 386 (41.5%) 51 (25.2%)
501 143 (15.2%) 270 (29.0%) 106 (52.5%)
Missing 54 (5.7%) 81 (8.7%) 17 (8.4%)
CD4 cell/mm3, median (IQR) 302 (168413) 250 (87393) 351 (206504) B0.001
HIV RNA copies/mL, n (%)
5020,000 235 (25.0%) 176 (18.9%) 54 (26.7%) B0.001
20,000100,000 272 (29.0%) 225 (24.2%) 60 (29.7%)
100,000250,000 145 (15.4%) 164 (17.6%) 29 (14.4%)
250,000 187 (19.9%) 230 (24.7%) 35 (17.3%)
Missing 100 (10.6%) 136 (14.6%) 24 (11.9%)
HIV RNA log10 copies/mL, median (IQR) 4.8 (4.25.3) 5.0 (4.45.5) 4.7 (4.15.3) B0.001
Year of cART start
20082009 98 (10.4%) 11 (1.2%) 13 (6.4%) B0.001
20102011 350 (37.3%) 264 (28.7%) 32 (15.8%)
20122013 348 (37.1%) 386 (41.5%) 51 (25.2%)
20142015 143 (15.2%) 270 (29.0%) 106 (52.5%)
NRTIs combination
FTCTDF 808 (86.1%) 803 (86.2%) 173 (85.6%) 0.973
ABC3TC 131 (13.9%) 128 (13.8%) 29 (14.4%)
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Introduction: Although several randomized studies have shown that
PI/r-including first-line regimens have lower efficacy as compared to
those including integrase inhibitors, they are still used in a number
of conditions, mainly due to their high genetic barrier. We aimed
to reproduce in a real-life setting results of the ACTG 5257 trial,
comparing virologic response, durability and tolerability of first line
raltegravir (RAL)-including regimens to regimens including either
darunavir/ritonavir (DRV/r) or atazanavir/r (ATV/r).
Materials and methods: Patients from the Icona cohort initiating
their first ART regimen from January 2008 (date of availability of RAL
in Italy) with TDF/FTC or ABC/3TC plus ATV/r or DRV/r or RAL with at
least one visit and one CD4 and VL determination in follow-up were
included in the analyses. Primary endpoint: treatment failure (TF):
virologic failure (VF) (HIV RNA 200 copies/mL ]6 months of
therapy) or discontinuation of RAL, ATV/r or DRV/r whatever first
occurs. Secondary endpoints: VF50 (HIV RNA 50 copies/mL ]6
months of therapy); discontinuation (TD) of RAL, ATV/r or DRV/r due
to all causes and discontinuation due to toxicity/tolerability (TDT).
Discontinuation of backbone does not count as endpoint. Survival
analysis with Kaplan-Meier curves and Cox regression model.
Results: A total of 2072 patients were analyzed: 939 (45.3%) started
ATV/r-including regimens, 932 DRV/r (45.0%) and 202 (9.7%) RAL.
Several differences in demographic and clinical characteristics
according to the regimen used were identified (see Table 1). In a
median follow-up of 1.4 years (IQR 0.62.7), TF occurred in 1028
patients, 28.2/100 PYFU (95% CI 25.630), VF50 in 372, 7.9/100
PYFU (95% CI 7.28.8), TD in 978 26.3/100 PYFU (95% CI 24.728),
and TDT in 326 patients, 8.8/100 PYFU (95% CI 7.89.8). In the
multivariable analysis, no differences in TF according to regimens
was found. RAL-including regimens resulted in 46% lower risk of
VF50 compared to ATV/r. Both DRV/r-including and RAL-including
regimens resulted in significantly lower risk of TDT compared to ATV/
r-including regimens (Table 2).
Conclusions: Concerning the risk of discontinuation for toxicity our
results are consistent with those observed in A5257. When
considering virologic failure, only with the threshold of 50 copies/
mL results were somewhat different from those observed in the
randomized comparison, suggesting lower rate of virologic failure for
RAL than ATV/r, although the difference was small and likely due
to methodology discrepancy and residual confounding cannot be
ruled out.
P022
HIV-1 Combinectin GSK3732394: a long-acting inhibitor with
multiple modes of action
Mark Krystal1; David Wensel2; Yongnian Sun3; Jonathan Davis2;
Thomas McDonagh2; Zhufang Li1; Sharon Zhang1; Matt Soars4 and
Mark Cockett1
1Discovery, ViiV Healthcare, Wallingford, CT, USA. 2Bristol-Myers
Squibb, Molecular Discovery Technologies, Waltham, MA,
USA. 3Virology, Bristol-Myers Squibb, Wallingford, CT, USA.
4Preclinical Candidate Optimization, Bristol-Myers Squibb,
Wallingford, CT, USA
Introduction: Long-acting antiretrovirals could provide a useful alter-
native to daily oral therapy for HIV-1 infected individuals. However,
the need for combination therapy and the potential for multiple IV/
IM injections or tolerability issues may create roadblocks to this type
of therapy. Adnectins are small proteins derived from the 10th type
III domain of the human fibronectin protein that possess modifiable
binding loops akin to the complementarity determining region of
an antibody. Using Adnectins, we have developed the Combinectin
inhibitor GSK3732394 (BMS-986197), a long-acting biologic with
three independent and synergistic modes of HIV entry inhibition that
Abstract P021Table 2. Relative hazards of reaching various outcomes from fitting a Cox regression model
Outcomes Unadjusted HR (95% CI) p Adjusted HR (95% CI) p
TF (VF 200 copies/mL or discontinuation)
ATV/r 1.00 1.00
DRV/r 0.99 (0.871.12) 0.821 0.92 (0.801.05) 0.222
RAL 1.01 (0.801.28) 0.930 0.84 (0.661.08) 0.175
VF 50 copies/mL
ATV/r 1.00 1.00
DRV/r 0.92 (0.741.13) 0.431 0.88 (0.701.10) 0.270
RAL 0.51 (0.300.86) 0.011 0.54 (0.320.93) 0.026
All-cause discontinuation
ATV/r 1.00 1.00
DRV/r 1.00 (0.881.15) 0.935 0.93 (0.811.07) 0.296
RAL 1.08 (0.851.38) 0.509 0.88 (0.691.13) 0.321
Discontinuation due to toxicity
ATV/r 1.00 1.00
DRV/r 0.70 (0.560.89) 0.003 0.65 (0.510.82) B0.001
RAL 0.44 (0.260.76) 0.003 0.34 (0.200.60) B0.001
Models were adjusted for gender, age, nation of birth, mode of HIV transmission, hepatitis co-infection status, AIDS diagnosis, nucleoside pair
started, baseline CD4 count and viral load and year of starting cART.
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potentially could be self-administered as a long-acting subcutaneous
injection.
Methods: Adnectins targeting CD4 and a region of gp41 were
isolated and optimized for antiviral potency and biophysical char-
acteristics. The anti-gp41 Adnectin was joined at its amino terminus
to the anti-CD4 Adnectin via a peptide linker. A third inhibitor, an
alpha-helical peptide fusion inhibitor, was linked to the carboxyl end
of the anti-gp41 Adnectin via another linker. Finally, a human serum
albumin (HSA) molecule was attached to amino terminus of the anti-
CD4 Adnectin to optimize in vivo PK.
Results: The EC50s of the isolated anti-CD4 Adnectin, anti-gp41
Adnectin and fusion inhibitor peptide were 8.5, 5.4 and 0.4 nM,
respectively. Various synergies were obtained through linking all
three inhibitors into a single molecule. Optimally combining the two
Adnectins increased potency over 100-fold to 30 pM. Addition of
the fusion inhibitor peptide resulted in an increased resistance
barrier compared to the separate components, as virus resistant to
any one of the three components did not affect the potency of
GSK3732394. Addition of HSA to the amino terminus decreased
potency to 0.27 nM, but improved PK, leading to a projected weekly
human dose. GSK3732394 exhibited broad spectrum activity and was
efficacious in a mouse model of HIV-1 infection.
Conclusions: GSK3732394 is a novel recombinant biologic molecule
containing three independent HIV inhibitors that has been developed
as a potential single long-acting regimen for HIV-1. This molecule
has the biophysical characteristics amenable for a self-administered
subcutaneous weekly injection.
P023
Mono- and dual suppressive antiretroviral regimens in a
real-life setting: the experience of Pitie´-Salpeˆtrire HIV Centre
Fabienne Caby1; Rachid Agher1; Roland Tubiana1; Christine Blanc1;
Marie Jaspard1; Yasmine Dudoit1; Ruxandra Calin1; Vincent Calvez2;
Anne Simon3; Marc-Antoine Valantin1 and Christine Katlama1
1Infectious Diseases, Pitie´-Salpeˆtrie`re, INSERM U1136, Paris, France.
2Virology Laboratory, Pitie´-Salpeˆtrie`re, Paris, France. 3Internal
Medicine, Pitie´-Salpeˆtrie`re, Paris, France
Context: Controlling viral replication with fewer drugs. Identifying
light suppressive ART strategies  one-drug (1-DR) or two-drug (2-
DR) regimen  has become a key issue in the long-term management
of HIV-infected patients for various reasons: cumulative toxicity,
unnecessary drugs and cost saving.
Objectives: To evaluate the ART regimen profile in patients with
suppressed HIV viraemia in a single large HIV care and research
centre in 2015.
Methods: All HIV-infected patients with a suppressed HIV-1 plasma
viral load (pVLB50 copies/mL) in 2015 were included in this
observational study through the NADIS computerised medical data-
base which aims to describe suppressive ART profiles by comp-
aring a 1-DR and a 2-DR to a standard triple-drug regimen (3-DR).
Results: Out of the 4129 HIV-infected patients for whom HIV RNA
was available, 3807 (92%) had HIV RNA B50 copies/mL. The ART
regimen consisted of a 1-DR in 140 patients (4%), a 2-DR in 710
patients (19%), a 3-DR in 2898 patients (77%) and ]4-DR in 59
patients (1.5%). PIs were the most frequent single-drug regimen
(69%). The 2-DR consisted of INSTINNRTI (40%), two NRTIs (13%)
and NRTIPI (11%). When compared to a 3-DR, patients with a 1- or
2-DR were older (pB0.001) with longer ART duration (pB0.0001)
and those on a 2-DR had a lower nadir (p0.006) (Table 1).
Conclusion: Mono- and dual therapies represent, in real life, over
20% of suppressive ART strategies in our centre. These options with
fewer drugs warrant further large-scale investigation.
Abstract P023Table 1. Suppressive ART strategies in Pitie´-Salpeˆtrie`re Hospital in 2015
Median (%) IQR 1-drug regimen 2-drug regimen 3-drug regimen
n140 (4%) n710 (19%) n2898 (77%)
M/F (%) 69% / 21% 68% / 32% 69% / 31%
Age 52 [4659] 53 [4861] 49 [4256]
ART regimen INSTI NNRTI 283 (40%)
RAL/NNRTI 193 (27%)
DTG/NNRTI 90 (13%)
DRV/r 97 (69%) 2 NRTI 94 (13%) 2NRTINNRTI 1240 (43%)
DTG 24 (17%) NRTIPI/r 77 (11%) 2NRTI  INI 831 (29%)
ATV/r 10 (7%) INSTIPI/r 66 (9%) 2NRTIPI/r 630 (22%)
LPV/r 9 (6%) NRTI INI 60 (8%) 2NRTIPI 72 (2.5%)
NRTIPI/r 49 (7%)
Other 81 (11%) Other 125 (4.4%)
ART duration (3 years) 16.8 [920] 18 [821] 10.7 [518]
Current regimen duration (mos) 23 [1054] 15 [739] 28.2 [1261]
CD4/mm3 (IQR) 663 [525824] 627 [474828] 611 [449805]
CD4 nadir/mm3 (IQR) 227 [159319] 196 [93319] 225 [109341]
First line ART 3 (2.1%) 53 (7.5%) 384 (13.3%)
Switch ART 137 (98%) 657 (93%) 2514 (87%)
n3748 patients.
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P024
Safety and antiviral effect of Elpida (VM-1500), a novel
NNRTI (Truvada) in treatment-naı¨ve HIV-1-infected
patients at 24- to 48-week therapy
Alexey Kravchenko1; Elena Orlova-Morozova2; Fiyara Nagimova3;
Oleg Kozirev4; Tatyana Shimonova5; Vadim Bichko6;
Natalya Vostokova7 and Olga Zozulya7
1Russia AIDS Federal Centre, Moscow, Russian Federation. 2Moscow
Region AIDS Center, Moscow, Russian Federation. 3Republic Tatarstan
AIDS Center, Kazan, Russian Federation. 4Volgograd Region AIDS
Center, Volgograd, Russian Federation. 5Moscow City AIDS Center,
Moscow, Russian Federation. 6Viriom, Moscow, Russian Federation.
7IPHARMA, Moscow, Russian Federation
Introduction: In treatment-naı¨ve patients, Elpida 20 and 40 mg QD
(with TDF/FTC) at week 12 demonstrated potent antiviral activity,
comparable to EFV, and favourable safety/tolerability profile. Elpida
20 mg QD was selected for study.
Objective: To evaluate safety and antiviral effect for treatment
regimens with ElpidaTDF/FTC in comparison with EFVTDF/FTC in
treatment-naı¨ve HIV-1 infected patients.
Methodology: A randomized, placebo-controlled, double-blind study
in patients with HIV infection who are antiretroviral therapy-naı¨ve
with median of HIV-1 RNA 4.74.8 log10 copies/mL and CD4-
lymphocytes  349 to 379 cells/mm3. A total of 120 patients were
randomized to Elpida (20 mg, group 1) or EFV (600 mg, group 2) with
1:1 ratio. All patients received TDF/FTC. Hundred percent of patients
completed 24 weeks of treatment and 50% of patients completed 48
weeks of treatment.
Results: After 24 weeks of treatment, the fraction of patients with
B50 HIV-1 RNA copies/mL in 1st gr. was 84.5% and 2nd gr. 66.7%
(p0.031, MTTI-analysis). At 48 weeks therapy - 93.3% and 83.5%,
respectively. The median CD4-lymphocytes increased from 379 to
486 cells/mm3 (gr.1), from 349 to 491 cells/mm3 (gr.2) at 24 weeks
treatment and to 549 cells/mm3 (gr.1) and to 510 cells/mm3 (gr.2) at
48 weeks. AEs (grade 14) were observed in 78.3% and 86.2% of
patients from cohorts 1 and 2, respectively, including drug-related
AEs (36.7% and 77.6%, respectively). For the CNS AEs, those numbers
were 30% and 62.1% (pB0.001), including grade 3 to 4 AEs  1.7%
and 8.6%, respectively.
Conclusions: In treatment-naı¨ve patients, Elpida 20 mg QD (with
TDF/FTC) at 24 to 48 weeks demonstrated potent antiviral activity,
comparable to EFVTDF/FTC, and favourable safety/tolerability
profile. Fewer drug-related AEs were observed for Elpida compared
with EFV. The study will be completed at November 2016.
P025
The integrase strand transfer inhibitor bictegravir has a long
integrase/DNA dissociation half-life
Kirsten White; Anita Majka; Nikolai Novikov; Michael Miller and
Manuel Tsiang
Biology, Gilead, Foster City, CA, USA
Introduction: The HIV integrase strand transfer inhibitor (INSTI)
bictegravir (formerly GS-9883) has a high barrier to resistance
selection in vitro [1]. Bictegravir has an improved in vitro resistance
profile for most HIV isolates with resistance to the other INSTIs
raltegravir, elvitegravir and dolutegravir [1,2]. The apparent dissocia-
tion rate constant of dolutegravir from integrase/DNA complexes was
previously shown to be longer than raltegravir and elvitegravir and
was predicted to correlate with potent antiretroviral activity and a
higher genetic barrier to resistance [3]. Here, the dissociation kinetics
of bictegravir was evaluated.
Methods: The apparent association and dissociation kinetics of 3H-
labelled INSTIs raltegravir, elvitegravir, dolutegravir and bictegravir
were measured using wild-type HIV integrase/DNA complexes and
a scintillation proximity assay as previously described [3]. Single
exponential decay functions were used to analyze both the binding
and competition binding phases yielding apparent association
doubling times (td) and dissociation half-lives (t1/2). However, the
competition binding phases deviated significantly from the single
exponential decay function due to the gradual sedimentation of the
SPA beads, necessitating modelling of the equilibrium binding with
on- and off-rate constants as decreasing functions of time with kon
and koff as initial values of each function, respectively.
Results: The INSTIs bictegravir, dolutegravir, elvitegravir and ralte-
gravir showed rapid association with integrase/DNA complexes with
apparent association doubling times (td) ranging from 14 to 34
minutes: elvitegravir (1494 minutes), raltegravir (22911 minutes),
bictegravir (3194 minutes) and dolutegravir (3491 minutes). The
apparent dissociation half-lives (t1/2) of INSTIs from integrase/DNA
complexes ranged from 3.6 to 122 hours: elvitegravir (3.690.9
hours), raltegravir (1592 hours), dolutegravir (71913 hours) and
bictegravir (122914 hours); p0.0018 for bictegravir versus
dolutegravir. The initial values of the dissociation rate constants
(koff) were determined using the model and converted to a t1/2 which
may be more representative of the actual t1/2: elvitegravir (1.690.2
hours), raltegravir (5.490.4 hours), dolutegravir (1192 hours), and
bictegravir (35919 hours); p0.046 for bictegravir versus dolute-
gravir.
Conclusions: The (t1/2) of bictegravir is the longest reported for any
INSTI that is approved or in development. Long residence times of
INSTIs on the integrase/DNA complex have been correlated with
potent antiretroviral activity against wild-type HIV-1 integrase and a
high barrier to resistance in vitro [3]. The barrier to clinical resistance
for bictegravir is being assessed in ongoing phase 3 studies with the
once-daily, unboosted bictegravir/emtricitabine/tenofovir alafena-
mide single-tablet regimen.
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Durability and prescribing patterns of initial HIV regimens in
treatment-naı¨ve patients
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Introduction: Literature on ARV regimen durability (persistency) in
real-world settings is outdated owing to the introduction of new
drug classes and combinations in recent years. We evaluated the
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composition and durability of contemporary ARV regimens pre-
scribed for treatment-naı¨ve patients in a clinical setting.
Methods: Treatment-naı¨ve HIV-infected patients who initiated ART
between January 2007 and January 2016 at the HIV clinic affiliated
with the University of Alabama, Birmingham, were included. Data on
all initial ARV compositions and durations were extracted from the
electronic medical record with administrative censoring on 8 June
2016. Manual abstraction was performed to confirm ARV regimen
start and stop dates. ARV regimen durability (time to discontinua-
tion) was estimated using Kaplan-Meier survival curves that incor-
porate censoring and its association with various characteristics by
Cox proportional hazard analyses.
Results: Among 589 patients (mean age, 37 years; 79% male; 65%
African American), efavirenz/emtricitabine/tenofovir (193, 33%) was
the most commonly prescribed initial ARV regimen (Table 1). Median
durability of all initial ARV regimens was 45 months (95% CI 4151).
The regimen was discontinued in 332 (56%) patients and a majority
of them (203, 61%) had an undetectable viral load at the time of
discontinuation. A decrease in durability of ARV regimens was found
in more recent years (Table 1, p0.046). After adjusting for various
covariates in multivariable analysis, patients initiating ART from 2010
to 2012 (aHR 1.4, 95% CI 1.11.8; p0.02) and 2013 to 2015 (aHR
1.5, 95% CI 1.12.1; p0.01) were more likely to discontinue ART
than those initiating from 2007 to 2009.
Conclusions: Overall durability of most ARV regimens in our cohort
was almost 4 years. Two multi-tablet regimens and two regimens
recently removed from US first-line treatment guidelines were quite
durable. Decreased durability of ARV regimens occurring in more
recent years appears to be due to patient and provider preferences
for newer regimens and not due to virologic failure.
P027
Integrase inhibitor-based antiretroviral therapy in
vulnerable populations
Brian Conway; Ghazaleh Kiani; Rajvir Shahi; Tyler Raycraft;
Arpreet Singh; Syune Hakobyan and Arshia Alimohammadi
Clinical Research, Vancouver Infectious Diseases Centre, Vancouver,
Canada
Introduction: Current treatment guidelines favour the use of integ-
rase inhibitor (II)-based regimens in the majority of settings where
ART is required, based on the results of clinical trials demonstrating
the superiority of such approaches. Vulnerable inner-city populations
have often been excluded from clinical trials of these agents. There
is a need to generate data to better inform the applicability of
treatment guidelines in these populations.
Methods: We have conducted a retrospective analysis of the database
of a large clinic catering to HIV-infected patients with a high prevalence
of people who inject drugs (PWID). We have abstracted records of
subjects receiving II-based therapy and evaluated response to therapy.
Demographic and clinical correlates of success were evaluated, with a
view to comparing the relative efficacy of raltegravir (RAL), elvitegravir
(ELV) and dolutegravir (DOL)-based regimens.
Results: A total of 247 patients received IIs (141 RAL, 68 ELV, 38
DOL). Baseline characteristics include: 85.8% male, 38.5% intrave-
nous drug users, 5.3% previously treatment naı¨ve, 45.2% HCV co-
infected, and 13.6% on opiate substitution therapy. Median baseline
CD4 count and plasma viral load were 410 (range 301380) cells/mm3
and 43 (range B40300,000) copies/mL. After a median follow up of
44 (3141) months, virologic suppression was achieved in 93.0%/
86.7%/97.3% patients on RAL/ELV/DOL with most current median CD4
count of 555 (range 601700) cells/mm3. No treatment-limiting
toxicity was observed and response rates in PWID (80.7%/66.7%/
90.0%) were equivalent to those observed in non-PWID.
Conclusion: II-based therapies are as effective in ‘‘real life’’ and in
PWID as they have been reported to be in clinical trials, justifying
their selection as regimens of choice for all patients. Medium- and
long-term efficacies of all three agents in this class are comparable,
and the selection of one agent over another should be based on
other criteria than virologic potency and tolerability.
P028
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James Darkwa2 and Debra Meyer4
1Biochemistry, University of Pretoria, Pretoria, South Africa.
2Chemistry, University of Johannesburg, Johannesburg, South Africa.
3DST/NRF Center of Excellence for Biomedical TB Res,Wits University,
Johannesburg, South Africa. 4Dean’s Office, University of
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Abstract P026Table 1. Summary of median durability of ARV regimen by regimen composition and year of initiation in treatment-
naı¨ve HIV patients initiating care at an academically affiliated HIV clinic
ARV regimen composition Treatment share N (%) Median durability, months (95% CI)
Efavirenz/emtricitabine/tenofovir 193 (33) 59 (4763)
Elvitegravir/cobicistat/emtricitabine/tenofovir 115 (20) * (34*)
Rilpivirine/emtricitabine/tenofovir 55 (9) 48 (26*)
Raltegravir/emtricitabine/tenofovir 42 (7) 50 (2866)
Atazanavir/ritonavir/emtricitabine/tenofovir 31 (5) 27 (1976)
Darunavir/ritonavir/emtricitabine/tenofovir 27 (5) 44 (36*)
Dolutegravir/emtricitabine/tenofovir 13 (2) 7 (3*)
Dolutegravir/abacavir/lamivudine 7 (1) 26 ( *)
Other 106 (18) 32 (2636)
Year of ARV regimen initiation Treatment share N (%) Median durability, months (95% CI)
20072009 177 (30) 57 (4566)
20102012 200 (34) 41 (3449)
20132015 212 (36) 38 (32*)
*not estimable.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
37
Introduction: HIV-1 remains a major threat to public health [1]. Sub-
Saharan Africa has the highest prevalence of HIV/AIDS and the overlap
of this infection with other major pandemics that plague the region
has become a major challenge in the treatment of the infection. These
include tuberculosis and malaria [2]. Although HAART has been
successful in the treatment of the virus, these drugs are associated
with a number of adverse effects often resulting in non-compliance by
the patients and increasing an individual’s susceptibility to these
opportunistic infections that are prevalent in the region [3]. It is
therefore crucial to develop novel treatments that are not only
effective against HIV, but opportunistic infections as well. Indeed,
multi-target drugs are becoming increasingly popular with the rise in
syndemic diseases in most parts of the world. Finding novel drugs that
are effective against two or more different infections or diseases,
targeting various pathways within the microorganism / pathology
is where research is heading, and in this study metal modified
chloroquine (Complex 1) was investigated in a type of repurposing
approach for this known malaria drug [4].
Materials and methods: Complex 1 was synthesized and purified
in good yield [5]. The complex was screened for inhibition of the
enzyme HIV-1 protease using a recombinant enzyme (Bachem,
Switzerland) and a fluorescent substrate (Sigma Aldrich, USA). The
complex was also evaluated against the drug-susceptible strain of M.
tuberculosis, H37Rv (ATCC27264) and the 3D7 strain of P. falciparum.
Its effects on cell viability were assessed on TZM-bl cells using a
tetrazolium dye and confirmed by real-time cell analysis (RTCA).
Results: Complex 1 showed HIV-1 protease inhibition values of above
50% at 25 mg/mL. The complex showed remarkable inhibition of M.
tuberculosis with a minimal inhibitory concentration of 5 mM after 14
days of incubation with the bacterium. The IC50 of 1 on P. falciparum
was 0.593 mM, and the CC50 of the complex on TZM-bl cells was
24.3490.68 mg/mL. RTCA showed non-toxicity of the complex at
all tested concentrations, with treatment profiles similar to those
produced by untreated cells.
Conclusion: A complex with inhibitory abilities against HIV-1 replica-
tion, M. tuberculosis and P. falciparum is presented here. Tubercu-
losis and malaria play a major role in the mortality of HIV-infected
patients, and the development of drugs with dual activities that can
control both the viral and opportunistic infections could contribute
to the alleviation of the fatal HIV prognosis.
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Introduction: Since the emergence of new direct-acting agents,
hepatitis C (HCV) treatment has undergone a rapid evolution, bringing
about a radical change in the clinical paradigm. Oral treatment
regimens with high virologic efficacy, great tolerability, favourable
safety profiles, high genetic barriers, and an easy posology are now
available. Despite this, challenges remain to patients who fail the
treatment. This study aims to characterize this group of patients in an
infectious diseases clinic in Lisbon.
Methods: Retrospective observational study of a cohort of HCV
chronically infected patients with or without HIV infection, given new
direct-acting agents (DAAs), from 1 January 2015 to 30 April 2016.
Demographic, epidemiologic, clinical and laboratory data were
collected. Statistical analysis was performed using Microsoft Office†
Excel 2012.
Results: During the analysis period, 426 patients were eligible to
start HCV treatment with DAA regimens (138 HCV mono-infected
and 288 HIV co-infected). Two hundred and nineteen patients have
concluded it (56 HCV mono-infected and 163 HIV co-infected), of
whom 134 patients had their viral load evaluated 12 weeks after
treatment ended: sustained viral response in 126 patients (94%)
and detectable viral load in eight patients (6%). In the latter, all
patients were male with a mean age of 51 years. Mean time of HCV
diagnosis was 12 years. Patients mainly acquired the infection
through parenteric drug use (75%). Seven were HIV co-infected.
Regarding genotype characterization, the most common was geno-
type 1a (50%). Evaluation of IL28B polymorphism revealed CC
predominance (50%). At baseline, mean HCV RNA was 7,103,018
IU/mL. Real-time elastography data, using METAVIR score, revealed a
fibrosis F2 in one patient, F2/F3 in three patients and F3 in four
patients. Concerning previous treatment for HCV, six were treatment
experienced, of whom five were null responders. The most requested
treatment was sofosbuvir/ledipasvir (63%). Five patients were
proposed for 12 weeks and three for 24 weeks of treatment, for
which all had a good adherence. One patient died at the end of
treatment. The others are waiting for retreatment options.
Conclusions: In this preliminary analysis, the eight patients with non-
SVR12 were male and had HIV infection. These factors may be
associated with response and outcome with the new direct-acting
agents. Regarding the efficacy of these drugs, uncertainties and
challenges remain, in addition to continued necessity of identifying
response predictive factors and individual strategies for special
patient groups.
TREATMENT STRATEGIES - TARGET
POPULATIONS: ADOLESCENTS AND
CHILDREN
P031
Genetic variants in CYP2B6 and CYP2A6 explain
interindividual variation in efavirenz plasma concentrations
in routine care of HIV-infected children with diverse ethnic
origin
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Sandra Soeria-Atmadja1; Emma O¨sterberg1; Lars Gustafsson2;
Marja-Liisa Dahl2; Jaran Eriksen2; Johanna Rubin1 and Lars Nave´r1
1Division of Pediatrics, CLINTEC, Karolinska Institutet, Stockholm,
Sweden. 2Division of Clinical Pharmacology, Deparmentt of
Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
Introduction: Approximately 2.6 million children live with HIV globally,
and efavirenz (EFV) is one of themostwidely used antiretroviral agents
for HIV treatment in children and adults. There are concerns about the
appropriateness of current EFV dosing, and it has been discussed
whether EFV dosing should be adapted according to genotype in
children as suggested for adults.The aimof the studywas to investigate
if paediatric EFV dosing should be guided by genetic variation in drug-
metabolizing enzymes rather than by body weight only.
Materials and methods: EFV plasma concentrations measured for
clinical purposes from all children (B18 years old) at Karolinska
University Hospital, Stockholm, Sweden, treated with EFV were
collected retrospectively. They were genotyped for 11 polymorphisms
in genes coding for drug-metabolizing enzymes and P-glycoprotein, of
potential importance for EFV disposition. Data on origin, sex, age,
weight, HIV RNA, viral resistance patterns, CD4 cells, adherence to
treatment, subjective health status and adverse events were collected.
Results: Thirty-six patients and 182 (mean 5 samples/patient) EFV
plasma concentration measurements were included. EFV plasma
concentration varied 21-fold between measurements (n182)
(2.761 mmol/L) and 9-fold measured as mean EFV plasma concen-
tration across the subjects (4.942.4 mmol/L). A multivariate mixed-
effects REML regression model, including multiple gene polymorph-
isms, identified CYP2B6*6 T/T (pB0.0005), CYP2B6*11 G/G
(pB0.0005), CYP2A6*9 A/C (p0.001) genotypes, age at treatment
initiation (p0.002) and time from treatment initiation (pB0.0005)
as independent factors significantly related to loge concentration/
(dose/weight). The contribution of the studied gene polymorphisms
to the intra- and interindividual variation were 6% and 75%,
respectively (Bryk/Raudenbush R-squared level). Asian origin was
significantly related to lower loge mean concentration/ (dose/weight)
compared to African (p0.0085) and Hispanic origin (p0.038).
Conclusions: Genetic polymorphisms in CYP2B6 and CYP2A6 ex-
plained a significant proportion of variability in EFV plasma concen-
tration and Asian origin gave substantially lower plasma concentration
in HIV-infected children in a multi-ethnic outpatient clinic. Knowledge
about individual variants in key drug-metabolizing enzymes could
improve clinical safety and be a way to achieve more predictable EFV
plasma concentrations in HIV-infected children.
P032
Relative bioavailability and food effect of a paediatric
dispersible tablet formulation of the non-nucleoside reverse
transcriptase inhibitor (NNRTI) rilpivirine (RPV)
Herta Crauwels; Nico Goyvaerts; Simon Vanveggel and Rodica Van
Solingen
Janssen Infectious Diseases BVBA, Beerse, Belgium
Introduction: The NNRTI RPV is approved in several countries as a
25 mg once-daily tablet in combination with other antiretrovirals
for treating HIV-1-infected, treatment-naı¨ve patients aged ]12
years with a viral load 5100,000 copies/mL. Further evaluation
of the paediatric use of RPV, including a dose evaluation, is
ongoing in children aged ]6 to B12 years in cohort 2 of the
PAINT study (NCT00799864). The current trial evaluated the relative
bioavailability and food effect of an age-appropriate RPV formulation
for use in children, the RPV dispersible tablet formulation (2.5 mg
RPV).
Methods: Open-label, randomized, crossover study in two panels of
16 healthy adults each (NCT02561936). In panel 1, participants
received a single 25 mg dose of RPV administered as the Edurant†
tablet (reference 1) or as 10 dispersible 2.5 mg tablets (dispersed
in water), in fed conditions (standardised breakfast). In panel 2,
participants received a single 25 mg dose of RPV administered as 10
dispersible 2.5 mg tablets (dispersed in water) in fed conditions
(reference 2) or in fasted conditions, or dispersed in orange juice
in fed conditions. In each panel, there was a 14-day washout in
between treatments. Plasma samples (over 168 hours after dosing)
were analyzed for RPV using a validated LC-MS/MS method (LLOQ
1.00 ng/mL). RPV pharmacokinetic parameters were deter-
mined using non-compartmental analysis. Least square means and
associated 90% confidence intervals of treatment ratios (test/
reference) were calculated based on log-transformed pharmacoki-
netic parameters. Safety and tolerability were assessed throughout
the study.
Results: Table 1 summarizes the statistical results. The RPV
exposure (AUC, Cmax) with the dispersible tablet was 21 to 33%
higher than the reference tablet (Edurant†), in fed conditions.
When taken fasted, the RPV exposure with the dispersible tablet was
28 to 34% lower compared with fed conditions. Dispersion in orange
juice (acidic beverage) compared with water increased the RPV
exposure by 11 to 14%, in fed conditions. One participant
discontinued early before dosing in the last session in panel 1 for
a grade 3 adverse event (bronchitis), considered not related to
RPV. There were no other grade 3 or 4 adverse events and no
serious adverse events. Administration of RPV as the dispersible
tablet formulation was generally well tolerated in fed and fasted
conditions.
Conclusions: A RPV dispersible tablet with good bioavailability was
developed for potential use in the ongoing paediatric trial in HIV-
infected children aged B12 years. Consistent with the Edurant†
tablet formulation, intake of the dispersible tablet with a meal
improved the bioavailability.
Abstract P032Table 1. Statistical analysis summary
Panel Test Reference N/N Cmax AUClast AUCinf
1 Dispersible tablet, fed Edurant†, fed 15/16a 1.28 (1.141.43) 1.21 (1.101.34) 1.33 (1.151.53)
2 Dispersible tablet, fasted Dispersible tablet, fed 16/16b 0.66 (0.560.77) 0.72 (0.630.82) 0.69 (0.570.83)
Dispersible tablet, fed
(dispersed in orange juice)
Dispersible tablet, fed
(dispersed in water)
16/16c 1.11 (0.961.30) 1.14 (1.001.30) 1.12 (0.941.35)
aN/N: 11/9 for AUCinf,
bN/N: 11/11 for AUCinf,
cN/N: 12/11 for AUCinf.
Data was presented as test/reference least square mean ratio (90% CI). N/N: number of participants in the test/reference; one volunteer
discounted before trial completion. Cmaxmaximum plasma concentration; AUClastarea under the plasma concentration-time curve (AUC,
calculated by linear linear trapezoidal summation) from time of administration up to the last timepoint with a measurable concentration post-
dose; AUCinfAUC from time of administration to infinity.
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P033
Predictors of plasma HIV RNA suppression in a cohort of
perinatally HIV-infected individuals
German Contreras1; Gilhen Rodriguez1; Gabriela Del Bianco1;
Norma Perez1; Laura Benjamins2; James Murphy1 and Gloria Heresi1
1Pediatric Infectious Diseases, University of Texas McGovern Medical
School, Houston, TX, USA. 2Adolescence Medicine, University of
Texas McGovern Medical School, Houston, TX, USA
Introduction: Knowledge of factors associated with viral suppression
(VS) among HIV-infected children and adolescents is central to
reduce transmission and improved health outcomes.
Materials and methods: We included individuals attending the UT
Health Paediatric HIV Clinic who were ART naı¨ve and subsequently
started on cART, followed for ]1 year from the start of cART and
maintained on the same cART regimen during this interval. VS was
defined as maintenance of HIV RNA B400 copies/mL for 1 year after
initial VS was achieved. Cumulative HIV RNA was defined as the
overall HIV replication burden in an individual. Median rates of VS
were calculated using KaplanMeir (KM). A Cox regression model
was used to determine predictors of VS.
Results: Thirty perinatally HIV-infected children were included. The
study population was mainly black (76.7%) and male (56.7%); 22
individuals (73.3%) were enrolled into clinical care within the 12
months of birth. The median age at cART initiation was 5.1 months
(IQR 2.727.3). The study population had a CD4 percentage of 33
(2439), a plasma HIV RNA log10 copies/mL of 5.5 (4.85.9) and a
cumulative HIV RNA copy-years/mL of 7.1 (6.87.7) at the time of
cART initiation. The median time from cART initiation to VS was 4.4
months (KM estimate). Time to VS was markedly shorter for those
who did not miss a scheduled clinical appointment compared with
those who missed at least one scheduled clinical appointment (4.4
vs. 22.9 months). Time to VS was shorter for Hispanics compared
with black non-Hispanics (3.7 vs. 10.7 months) and for those
living inside the Houston beltway 610 (2.6 vs. 10.7 months) than
those living outside the beltway 610. The adjusted Cox analysis
showed that there was a lower rate of VS for each log10 of increase
in cumulative HIV RNA (HR 0.11; 95% CI 0.020.81; p0.023)
and for each month of delay in initiating routine HIV care (HR 0.87;
95% CI 0.780.98; p0.01). Individuals born after 2003 had higher
rates of VS per unit of time (HR 158.11; 95% CI 2.888718.54;
p0.013).
Conclusions: Early initiation and sustained enrolment in clinical
care plays a paramount role for successful treatment of perinatally
HIV-infected children and adolescents. Cumulative HIV RNA offers
a robust predictive value for detecting individuals at risk of not
reaching VS.
P034
Characteristics and outcome of HIV-positive children
internationally adopted in France
Olivier Lesens1; Ste´phane Blanche2; Violaine Corbin1 and
Christine Jacomet1
1Infectious Diseases, Centre Hospitalier Universitaire de Clermont-
Ferrand, Clermont-Ferrand, France. 2Unite´ d’Immunologie, AP-HP,
Hoˆpital Necker-Enfants Malades, He´matologie et Rhumatologie p,
Paris, France
Introduction: HIV-positive children comprise a larger percentage of
the children eligible for international adoption [1]. Little is known
about the clinical, immunologic and viral outcomes of these children.
Materials and methods: Twenty-five medical centres agreed to
participate. Children living in France and internationally adopted
between 1 January 2005 and 1 January 2016 were included after
informed consent. Socio-demographic, medical and biologic variables
were collected during the first medical evaluation in France and
6 months later. The yearly percentage of HIV-positive adoptees
was calculated among new adoptees or new HIV-positive children
diagnosed.
Results: Of the 25 medical centres that agreed to participate, 14 gave
care to at least one HIV-positive adoptee. Forty-one HIV-positive
adoptees were included (female: 56%; median age at arrival: 3.91
years). The majority came from East Asia. HIV-positive adoptees
represented about half of newly diagnosed HIV-positive children in
2014 versus less than 20% the preceding years. They represented
also about 5% of new adoptees in 2014 versus about 1% the previous
years. For three children, a new diagnosis of latent chronic hepatitis
B, cured hepatitis B and chronic active hepatitis C was made at
arrival in France. Other clinical diagnoses made at the first consult
were benign diseases, mainly skin diseases. The mean CD4 per-
centage was 32.899% (range 1349%). Only one child had a CD4
percentage below 15%. Forty percent had a detectable viral load (VL)
20 copies/mL at arrival. Among those, resistance to NRTIs was
documented in 10%, resistance to NNRTIs in 12.5% and resistance to
PIs in 2.4%. Thirty-four children received ART in their country of
origin. Among those, 24 continued on the same ARV in France. At 6
months, the mean CD4 percentage was 35.698%, and the VL was
still detectable in 29% children. Of them, one acquired resistance to
NRTI and NNRTI during the 6 months of follow-up.
Conclusions: An increasing number of HIV-infected children have
been internationally adopted in France since 2005. The immune
status was good but detectable VL was frequent at arrival and at
6 months. It can be suspected that adoptive parents will face
difficulties to maintain enough adherence to ART in the long term,
especially during adolescence [2]. Prolonged support from healthcare
providers is needed to face this difficult challenge that combines the
management of adoption and HIV disease [3].
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Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/
3TC) fixed-dose combination (FDC) compared with
ritonavir-boosted atazanavir (ATV/r) plus tenofovir
disoproxil fumarate/emtricitabine (TDF/FTC) in
treatment-naı¨ve women with HIV-1 infection (ARIA study):
subgroup analyses
Margaret Johnson1; Caroline Gatey2; Weeraweet Manosuthi3;
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France. 3Department of Medicine, Bamrasnaradura Institute,
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Introduction: Built around an unboosted integrase-strand transfer
inhibitor (INSTI), the FDC of DTG/ABC/3TC offers a complete regimen
for treatment of HIV-1 infection, with good tolerability and a high
barrier to resistance. To gain additional data for women on this
regimen, we conducted ARIA, an international, randomized, open-
label study to evaluate the safety and efficacy of DTG/ABC/3TC
versus ATV/rFTC/TDF (ClinicalTrials.gov: NCT01910402).
Materials and methods: Treatment-naı¨ve adult women, with HIV-1
RNA ]500 copies/mL, were randomized 1:1 to 48 weeks of treat-
ment with DTG/ABC/3TC or ATV/rFTC/TDF once daily. The primary
endpoint was the proportion of women achieving an HIV-1 RNA B50
copies/mL at week 48 (snapshot algorithm). Women who became
pregnant were withdrawn and were possibly offered entry into a
DTG/ABC/3TC pregnancy study. Additional analyses were performed
to evaluate efficacy based on geographic region and baseline
characteristics.
Results: Four hundred and ninety-five women were randomized and
treated. Subjects were well matched for demographic and baseline
characteristics. Median age was 37 years; 45% of the subjects were
white and 42% African heritage. Overall results showed that DTG/
ABC/3TC was superior to ATV/rFTC/TDF, with 82% and 71%,
respectively, achieving HIV-1 RNA B50 copies/mL at week 48
(adjusted difference 10.5%, 95% CI 3.117.8%, p0.005). Differ-
ences were driven by lower rates of both discontinuations due to
adverse events (AEs) and snapshot virologic non-response in the
DTG/ABC/3TC group. In subgroup analyses conducted based on
region and baseline characteristics, higher response rates were
consistently observed in the DTG/ABC/3TC group compared to ATV/
rTDF/FTC group (Table 1). There were fewer drug-related AEs and
fewer withdrawals due to AEs in the DTG/ABC/3TC group. There were
no treatment-emergent primary INSTI or ABC/3TC resistance muta-
tions in the DTG/ABC/3TC group.
Conclusions: DTG/ABC/3TC demonstrated superior efficacy and a
favourable safety profile compared to ATV/rFTC/TDF in treatment-
naı¨ve women, after 48 weeks of treatment. Subgroup analyses
performed based on baseline characteristics and geographic region
were consistent with overall results.
P036
Sex and gender differences in rilpivirine-based ART: data
from the HIV Center Frankfurt
Gundolf Schu¨ttfort1; Kathrin Philipp1; Hans-Reinhard Brodt1;
Philipp de Leuw1; Siri Go¨pel1; Eva Herrmann2; Pavel Khaykin3;
Christoph Stephan1; Timo Wolf1 and Annette Haberl1
1Infectious Diseases, University Hospital Frankfurt, Frankfurt am
Main, Germany. 2Department for Biostatistics, University Hospital
Frankfurt, Frankfurt am Main, Germany. 3MainFachArzt, Outpatient
Center, Frankfurt am Main, Germany
Introduction: Rilpivirine is a second-generation once-daily non-
nucleoside reverse transcriptase inhibitor (NNRTI), which has shown
high overall response rates in treatment-naı¨ve patients without sex-
and gender-specific differences in clinical trials [13]. Sex- and
gender-specific data in treatment-experienced patients receiving a
rilpivirine-based regimen are still limited. We conducted a 48-week
efficacy and safety analysis in treatment-naı¨ve and treatment-
experienced men and women using retrospective data from the
University Hospital Frankfurt HIV Center.
Materials and methods: Between March 2011 and December
2015, all patients from the HIV Center of the University Hospital
Frankfurt receiving a rilpivirine-based regimen were analyzed in this
retrospective observational study. The primary endpoint was the
proportion of patients with any discontinuation of a rilpivirine-based
therapy at week 48. Furthermore, virologic response rates (FDA
snapshot analysis; HIV-1 RNA B50 copies/mL) were assessed at
week 48.
Results: A total of 188 patients (33% female) were included in the
analysis. Seventy-four percent were treatment experienced and
26% were treatment naı¨ve (Table 1). Regarding sex differences, the
proportion of discontinuations was significantly higher in women
than in men (23% vs. 12%; p0.028; odds ratio 2.24; CI 1.024.91).
There was no significant sex difference regarding discontinuations
between treatment-experienced and treatment-naı¨ve patients (25%
vs. 16% and 23% vs. 12%, respectively). Virologic response rates
(FDA snapshot analysis; HIV-1 RNA B50 copies/mL) were assessed at
week 48 and revealed a higher rate of discontinuations due to
virologic failure in Caucasian women versus non-Caucasian women
(36% vs. 16%; p0.071; odds ratio 1.33; CI 0.208.71).
Conclusions: While overall response rates to rilpivirine-based regi-
mens were high for both treatment-experienced and treatment-
naı¨ve patients, the proportion of discontinuations was significantly
higher in female patients. The total number of patients with virologic
failure was low (16%); race appeared to influence the efficacy of a
rilpivirine-based ART as Caucasian women showed a higher rate of
Table 1. Proportion of subjects with HIV-1 RNA B50 copies/mL
(snapshot)
Subgroup (n)
DTG/ABC/
3TC, N248
(%)
ATV/rTDF/
FTC, N247
(%)
Overall 82 71
Age (years) B50 (424) 80 71
]50 (71) 92 74
CD4cell count
(cells/mm3)
5350 (253) 85 72
350 (242) 78 71
5200 (113) 81 69
200 (382) 82 72
Baseline HIV-1 RNA
(copies/mL)
5100,000
(360)
83 74
100,000
(135)
80 64
HIV-1 subtype B (206) 80 69
Non-B (271) 84 73
Geographic region Western
Europe (131)
83 71
US and
Canada (153)
77 70
Other (211) 85 72
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
41
virologic failure than non-Caucasian women. Therefore, it should be
an interdisciplinary approach to identify and reduce possible barriers
for successful antiretroviral treatment in non-Caucasian female HIV-
positive patients.
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Treatment outcomes and comorbidities in German female
HIV-infected patients in 2015: a comparison to 2008 and to
a male population
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Introduction: We characterized HIV-infected women in Germany,
evaluated ART use and comorbidities, and compared results to 2007/
2008 as well as to a male population in order to further identify
special requirements of women living with HIV.
Materials and methods: Cross-sectional multicentre evaluation of
HIV-positive women and men receiving medical care was performed
in Germany between October 2014 and June 2016. All HIV-specialty
practices and ambulatory care centres in Germany were invited to
participate. Data acquisition was performed using an online ques-
tionnaire. Results were compared to a similar analysis performed in
2007/2008 (n1557).
Results: Seven hundred and eighty-one HIV-positive women (f)
(n447 from 10 centres, n334 from anonymous centres) and 200
HIV-positive men (m) (five centres) were included. Mean age was 45
(f)/44 (m) years, 30.5% (f)/47.7% (m) smoked (pB0.001), 66.7%
(f)/60.8% (m) had a partner (of which 64.6% (f)/53.3% (m) were
HIV-discordant, p0.006) and 60.7% (f)/14.7% (m) had child(ren)
(pB0.001). Half the women had a migration background, the
majority (34%) from Africa, compared to 39% of men (12% from
Africa) (pB0.001). 91.7% (f)/95.0% (m) were currently on ART (77%
in 2008). Half the men and 28.5% of women received INSTIs
(pB0.001); 20.5% (m) versus 38.7% (f) PIs (pB0.001) and 32.6% (m)
versus 41.3% (f) received NNRTIs (p0.03). Sixteen percent of women
started ART due to pregnancy. Toxicity was the primary reason for ART
discontinuation in both women (37% of discontinuations) and men
(36%). 30.7% of women and 16.8% of men reported at least one side
effect on ART (pB0.001), with lipodystrophy being more prevalent in
females (in 16.9% vs. 8.9% of persons on ART, p0.006; 24.5% in
2007/8). HIV-1 RNA was B50 copies/mL in 88.1% (f)/90.5% (m) on
ART (48% in 2008 with 82% B400 copies/mL). Median detectable
viral load in treated individuals was 68 (f)/74 (m) copies/mL (IQR 38
350 (f)/321821 (m)). Median CD4 cell count was 621 (f)/628 (m)
cells/mL (IQR 437828 (f)/419868 (m)).
Conclusions: Though certain disease parameters were comparable
between HIV-infected women and men, we found significant dif-
ferences not only socio-demographically, but also in ART use and
adverse events. We further noted an improvement in the treatment
of HIV-infected women since 2008 as reflected by an increase in both
the number of ART-treated women and, more importantly, in the
number of successfully treated women. We attribute this to an
Abstract P036Table 1. Baseline parameters
Females (n63) Males (n125)
Treatment experienced Treatment naı¨ve Treatment experienced Treatment naı¨ve
Variable (n49) (n14) (n90) (n35)
Age (years: mean9SD) 4199 45911 51911 37911
Range (years) 3446 3555 4158 3046
Race (n Caucasian/non-Caucasian) 18/31 4/10 85/4 24/12
(% Caucasian/non-Caucasian) 36.7/63.3 28.6/71.4 94.4/5.6 68.6/31.4
CD4/ml (mean9SD) 5629290 3869149 6009251 4499188
CD4% (mean9SD) 27.6910.8 21.497.9 28.599 2297
CD4/CD8 ratio (mean9SD) 0.6690.4 0.3790.19 0.7190.40 0.4290.22
Patients with viral load B50 copies/mL (n/%) 32/65.3 (0/0) 74/82.2 (0/0)
Patients with viral load 50 copies/mL (n/%) 17/34.7 (14/100) 16/17.7 (35/100)
Viral load (copies/mL; mean9SD)a  15,082914699  29,501922,597
Viral load range (copies/mL)b 723755,348 87449,500 806235,000 37973,032
aIn treatment-naı¨ve patients; bin treatment-experienced patients with viral-load 50 copies/mL and treatment-naı¨ve patients.
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increasing awareness of women issues, to specific measures taken, to
the updates in treatment guidelines and to novel treatment options.
P039
Discontinuation of first-line ART is associated with female
sex and migration background  data from a German
outpatient clinic
Sylwia Bilinski1; Philipp De Leuw1; Siri Go¨pel1; Pavel Khaykin2;
Gundolf Schu¨ttfort1; Hans-Reinhard Brodt1; Timo Wolf1;
Christoph Stephan1; Eva Herrmann3 and Annette Haberl1
1Department of Infectious Diseases, HIV centre, University Clinic
Frankfurt, Frankfurt, Germany. 2Medical Practice, MainFachArzt,
Frankfurt, Germany. 3Institute for Biostats and Mathematical
Modelling, Goethe University Frankfurt, Frankfurt, Germany
Introduction: Despite individually tailored ART in high-income coun-
tries, some patients still discontinue first-line regimens within the first
year. This study aimed to characterize treatment discontinuations as
well as factors that might be associated with changes in first-line ART.
Methods: Patients who initiated first-line ART between January 2009
and December 2013 at the HIVcenter Frankfurt were enrolled in this
study and analyzed for treatment discontinuations and changes in
ART during the first 60 weeks of therapy. Statistical comparisons
were done with non-parametric tests using a significance level of
alpha5%.
Results: Overall 557 patients, 420 (75.4%) men and 137 (24.6%)
women, were included in this retrospective analysis. Table 1 shows
the baseline characteristics of the study population. One hundred
and thirty-eight (24.8%) patients discontinued ART within the first 60
weeks, 43 (31.4%) out of 137 women and 95 (22.6%) out of 420 men.
ART was interrupted after a mean of 142 days (/124). 81.4% of
women who experienced a discontinuation were migrants, mostly
from African countries. African origin was significantly associated
with discontinuation of first-line ART in men and women (p
0.007). Overall, patients with therapy interruptions had lower CD4
cell counts at baseline and were more likely to be CDC stage C
compared to patients with continuing ART. Most common reasons
for ART discontinuation were adverse events (56.4%), comorbidities
(21%), virological failure (13.5%), adherence issues (12%) and
pregnancies (12%).
Conclusions: Even the potential of individualized ART cannot prevent
treatment changes. In 557 patients starting their first-line ART
between 2009 and 2013, we identified 24.8% treatment discontinua-
tions. Patients with female sex and African origin showed the highest
rate of discontinuations, and despite guideline recommendations,
pregnancy still seems to be an issue for ART modification.
TREATMENT STRATEGIES - TARGET
POPULATIONS: LATE PRESENTERS
P040
Risk factors for late presentation over the last 6 years in
Athens, Greece (20092015)
Angeliki Spanos1; Dimitra Kavatha1; Konstantinos Protopapas1;
Georgios Siakalis1; Maria Argyropoulou2;
Charalampos Moschopoulos1; Emmanouil Antalis1;
Paraskevi Fragkou1; Nikolaos Melachrinopoulos1; Sotirios Tsiodras1;
Anastasia Antoniadou1 and Antonios Papadopoulos1
14th Internal Medicine Unit, Attikon University Hospital, Athens,
Greece. 2Medical School, Kapodistrian University of Athens, Athens,
Greece
Introduction: Late presentation (LP) is a major public health concern
for HIV disease. Higher rate of disease progression and disease
burden are the main reasons for aiming to reduce late presentation.
Although there is an ongoing high interest, the exact parameters for
LP have yet to be fully described. This study aims to identify risk
factors for HIV-infected patients presenting late at an academic
tertiary care centre in Athens, Greece, over the last 6 years in order
to define methods for better controlling the epidemic.
Materials and methods: We conducted a retrospective case-control
study using socio-demographic, behavioural and medical data from
patients’ files that were cross-examined by two medical observers.
We recorded all new HIV diagnoses presenting between the years
2009 and 2015 at our clinic. Patients enrolled were grouped based
on their CD4 cell count that was defined as B350 cells/mm3 or an
HIV-defining disease on presentation for LPs and 350 cells/mm3
for non-LPs. Acute and recent infections with CD4 B350 cells/mm3
Abstract P039Table 1. Baseline characteristics
All patients (n557) Male patients (n420) Female patients (n137)
Age (years) 40.8 (/11.4) 41.5 (/11.2) 38.3 (/11.5)
Migration background 30.2% (including 15% African
origin)
19.3% (including 7% African
origin)
63.5% (including 39% African
origin)
CDC stage
A 61.8% 58.9% 69.6%
B 19.5% 20.7% 16.3%
C 18.6% 20.3% 14.1%
CD4 count 292 (/207) 290 (/213) 298 (/184)
HIV RNA 67.600 73.700 41.450
ART components apart from NRTI
backbone:
Protease inhibitor 55.7% 53.3% 62.8%
NNRTI 27.3% 28.6% 23.4%
Integrase inhibitor 20.5% 22.1% 15.3%
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were reclassified as non-LPs to avoid overestimation of LP due to
transient CD4 cell count [1].
Results: Five hundred and seven patients were enrolled of which
90% were males and 52.3% were LPs. Heterosexuals were more likely
to present late at care versus MSM and IVDUs (pB0.001). Seven out
of ten immigrants presented late at care (pB0.001). A linear relation
is observed between lower education level and late presentation
(pB0.001). There is no significant difference between LPs and non-
LPs for employment, and patients living with their parents were
more likely to present early at care. LPs requiring hospitalization on
diagnosis were 34% versus 12% of non-LPs (pB0.001). Fifty-seven
patients presented an HIV-defining disease on diagnosis representing
23.7% of LPs. Total mortality rate was 4.6% with LPs presenting a two
times higher mortality rate versus non-LPs (0.06% LPs, 0.03% non-
LPs) (pB0.001). Over time, a negative correlation was found for
CD4 cell count from 2009 towards 2015 (Kendall’s tb0.083,
p0.22).
Conclusions: Our data suggest that heterosexuals access medical
care later than MSM and IVDUs, implying a gap in current preventive
approach and that HIV testing should be offered more frequently for
this group. People with lower education and immigrants should be
accessed and orientated towards better prevention control. Our
results demonstrate that the rate of late presentation tends to
increase, a conclusion that demands immediate attention and action
in order to succeed an actual control of the HIV epidemic.
Reference
1. Sasse A, Florence E, Pharris A, De Wit S, Lacor P, Van Beckhoven D,
et al. Belgian Research AIDS & HIV Consortium (BREACH). Late
presentation to HIV testing is overestimated when based on the
consensus definition. HIV Med. 2016;17:2314. doi: http://dx.doi.
org/10.1111/hiv.12292
P041
Late presenters: how do they look after ART nowadays?
Catarina Oliveira Paulo; Frederico Duarte; Eduarda Ruiz Pena;
Ma´rio Guimara˜es; Ricardo Correia Abreu; Sofia Jordao and
Isabel Neves
Infectious Diseases, Hospital Pedro Hispano  Unidade Local de
Sau´de de Matosinhos, Matosinhos, Portugal
Introduction: Currently across Europe, Portugal included, one-third of
patients newly diagnosed with HIV infection are late presenters. In
spite of multiple ART options, there are still no clear differences in
immunogenicity between them, more so in severe immunodeficiency.
Materials and methods: Retrospective study of HIV-infected patients
of the Infectious Diseases Unit of Hospital Pedro Hispano, starting
treatment between January 2010 and January 2016, with European
guidelines advised ART, naı¨ve or more than 6 months since ART
interruption. Exclusion criteria: B18 years old, virologic failure, ART
switch in the first year. Primary outcome: immunologic recovery
in absolute and relative count up to 48 weeks in late presenters
(lymphocytes T CD4 cells (TCD4) B200/mL), relating to back-
bone and third agent. Statistical evaluation was performed with IBM
SPSS version 22 using ANOVA test, excluding drugs with nB3; a
significance of 0.05 was considered as statistically relevant.
Results: Of a total of 75 patients included, 77% male, average age
45913.4 years, 56% (n42) with AIDS, sexual risk in 75% (mostly
heterosexual) and 97% (n73) had type 1 HIV; 23% (n17) HCV
co-infected. At start of treatment TCD4 count average was 84/mL
(1201). At week 4, there was an average increment of 108998
TCD4/mL, week 12 126989/mL, week 24 1569100/mL and 2319
156/mL (n60) at week 48. Final absolute average was 308/mL. All
patients were virologically suppressed since week 24. Concerning
backbone agents used, ABC/3TC showed a higher increment in
absolute TCD4 compared to TDF/FTC at week 12  204 (95% CI
72336) versus 108 (95% CI 55162), p0.034  and week 24 
216 (95% CI 72361) versus 188 (95% CI 102274), p0.031.
Regarding the third agent, an increment in absolute TCD4 count,
DRV/R showed statistical superiority to RAL at week 4  234 (95% CI
56411) versus 58 (95% CI 49164), p0.014. At week 12, DRV/R
was superior to EFV  223 (95% CI 91355) versus 117 (95% CI 25
209), p0.036  while still being superior to RAL  versus 118 (95%
CI 33203), p0.047. No drug showed superiority at week 48 or by
percentage increase in TCD4 at any timing. There was no asso-
ciation between evolution of TCD4 count and initial CDC stage.
Conclusions: In this study, we have concluded that ABC/3TC and
DRV/R may be the best options for a faster increase in TCD4 count,
although the benefit was not sustained and the small sample may
limit the study. Late presenters are at higher risk of considerable
comorbidity and mortality, demanding the most immunogenic option
and these might be favoured. Even with optimized ART, the TCD4
recovery observed was not optimal, stressing the importance of early
diagnosis.
P042
The utility of enfuvirtide revisited
Raquel Pinho; Elsa Campoa; Domitilia Faria; Carlos Santos and
Luisa Arez
Unidade de Portima˜o Servic¸o de Medicina, Centro Hospitalar do
Algarve, Portima˜o, Portugal
Introduction: Cryptosporidiosis’ main symptom is watery diarrhoea.
It is caused by a parasite called cryptosporidium. In persons with
AIDS and in other immunocompromised patients, cryptosporidiosis
can be serious, long lasting and sometimes fatal. If CD4 cell count
is below 200/mm3, cryptosporidiosis is more likely to cause severe
symptoms and complications, including prolonged diarrhoea, dehy-
dration and possibly death. The incidence of cryptosporidiosis in
patients with HIV has decreased since the introduction of highly
active antiretroviral therapy (HAART) [1]. Enfurvitide (T20) is a fusion
inhibitor indicated for use in combination with other antiretroviral
agents for the treatment of HIV-1 infection in treatment-experienced
patients with HIV-1 as part of a salvage regimen. Because of its
subcutaneous administration, in severe cases with cryptosporidiosis
where the absorption of oral therapeutic is doubtful, enfurvitide may
be a therapeutic option.
Materials and methods: We extracted details of three individuals
with a laboratory confirmed IC and HIV diagnosis between January
2013 and December 2014. The diagnosis of cryptosporidiosis was
made by stool sample examination.
Figure 1. CD4 count (cells/uL) at baseline, month 2, 4 and 6 of
treatment with HAART and at June 2016.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
44
Results: A.M., 36-year-old female, L.G., 30-year-old male and A.L.,
59-year-old male were all admitted to the emergency room because
of abdominal pain, nausea, vomiting, weight loss and watery
diarrhoea. The symptoms had been present for more than 2 months
in all cases. On laboratory examination, all patients were low im-
munity HIV positive: A.M. with 86 cells/mL CD4 (17%) and viral load
(VL) 2,010,000 copies/mL; L.G. with 3 cells/mL CD4 (0.3%) and VL of
318,000 copies/mL; and A.L. with 4 cells/uL CD4 and VL 217,000
copies/mL. They started antiretroviral therapy with emtricitabine and
tenofovir/raltegravir but remained symptomatic. This was attributed
to the impaired enteric absorption of these drugs. We then decided
to add subcutaneous enfuvirtide in order to allow for better
bioavailability. After this, all three patients improved their symptoms
and immunologic status (CD4: A.M. 741 cells/mL; L.G. 327 cells/mL;
A.L. 231 cells/mL) (Figure 1). Treatment with subcutaneous enfuvir-
tide was stopped after 8 to 12 weeks, after clinical improvement and
undetectable viremia (Figure 2).
Conclusions: The importance of an immunologic recovery is well
established for the cryptosporidium infection in HIV-positive pa-
tients. We document with this case series the usefulness of
alternative therapies with different routes of administration in order
to improve outcomes, when gastrointestinal absorption is impaired.
Reference
1. O’Connor RM, Shaffie R, Kang G, Ward HD. Cryptosporidiosis in
patients with HIV/AIDS. AIDS. 2011;25:54960. doi: http://dx.doi.
org/10.1097/QAD.0b013e3283437e88
TREATMENT STRATEGIES - TARGET
POPULATIONS: NAIVE PATIENTS
P043
Pre-existing HIV-1 integrase polymorphisms do not
impact treatment response to elvitegravir-containing
fixed-dose combination regimens in treatment-naı¨ve
patients
Michael Abram; Renee Ram; Kirsten White; Michael Miller and
Christian Callebaut
Biology, Gilead Sciences, Inc., Foster City, CA, USA
Introduction: Across 14 phase 2 or 3 clinical studies, analyses of
virologic suppression (HIV-1 RNA B50 copies/mL) of elvitegravir
(EVG)/cobicistat(C)/emtricitabine(F)/tenofovir alafenamide (E/C/F/
TAF; six studies) or E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF;
eight studies) has been evaluated in antiretroviral treatment-naı¨ve,
HIV-infected patients at weeks 48, 96 and/or 144. Here, the pre-
valence of pre-existing integrase (IN) mutations was evaluated
relative to subtype, integrase strand transfer inhibitor (INSTI)
susceptibility and virologic suppression on EVG-containing fixed-
dose combinations.
Methods: HIV-1 IN genotypes were obtained from plasma samples
before initiation of therapy. IN variability (by position and amino acid
change) was compared between patients harbouring B and non-B
subtypes, and to the proportion of patients achieving virologic
suppression on E/C/F/TAF or E/C/F/TDF. INSTI susceptibility of site-
directed mutant viruses was characterized.
Results: Two thousand one hundred and seventy-seven of 3033
treated patients across 14 studies were analyzed by population
sequencing for pre-existing or transmitted drug resistance in
integrase (E/C/F/TAF, n915; E/C/F/TDF, n1262). Most patients
harboured subtype B (85.1%) versus non-B (14.9%). No primary EVG
resistance-associated mutations (RAMs), known to confer reduced
EVG susceptibility (T66I/A/K, E92Q/G, S147G, Q148R/H/K, N155H),
were detected in any treatment-naı¨ve patient. Some secondary INSTI
RAMs were detected as naturally occurring IN polymorphisms,
mostly at very low prevalence (0.11%: H51Y, L68I/V, V72A/T,
L74M, Q95K, T97A, A128T, E138K, S153A, E157K, G163K/R) with
some exceptions (]1%: M50I, L74I, S119G/P/R/T, E157Q); of these,
only V72A conferred low-level reduced EVG susceptibility (5-fold).
Some secondary INSTI RAMs were more prevalent in subtype B
(M50I, S119G/P/R/T, E157Q) or non-B (L74I/M, T97A) subtypes
(pB0.05). Overall, 112 of 288 IN amino acid positions had ]1
variants with a prevalence of ]1%. Most IN variants (585 of 978)
had a prevalence of ]0.1% and were detected more often in non-B
subtypes. Distribution of subtypes and pre-treatment IN variants were
comparable between E/C/F/TAF and E/C/F/TDF treated patients.
Treated patients (with or without pretreatment IN genotype data)
achieved and maintained high rates of virologic suppression. HIV-1
subtype and pre-existing IN polymorphisms at any IN position did not
influence treatment response to E/C/F/TAF or E/C/F/TDF (p0.01).
Conclusions: Pre-existing genotypic INSTI resistance is extremely rare
in treatment-naı¨ve patients, confined only to a select few minor
secondary INSTI RAMs that generally do not confer reduced EVG
susceptibility. Natural IN variability, observed more often in non-B
subtypes, does not influence virologic suppression rates to EVG-
containing fixed-dose combinations. IN genotyping before considera-
tion of EVG-based therapy is currently not warranted unless
transmitted drug resistance with primary EVG RAMs is suspected.
P044
Does ethnic origin influence timing, choice and response to
first-line antiretroviral therapy in France?
Caroline Gatey1; Alexandre Brun2; Isabelle Turpault2; Pierre Sellier3;
Olivier Bouchaud4; Olivier Patey5; Valerie Garrait6; Vincent Jeantils7;
Amelie Chabrol8; Sylvain Diamantis9; Valerie Gregoire-Faucher10;
Eric Froguel11; Olivia Son12; Sylvia Lamy13; Corinne Routier14;
Hocine Ait-Mohand15; Luc Turner16; Gwenn Hamet2;
Constance Delaugerre17; Willy Rozenbaum1; Jean-Michel Molina1
and COREVIH Ile de France
1Infectious Diseases Department, Hopital St Louis, Paris, France.
2Hopital St Louis, COREVIH Ile de France Est, Paris, France. 3Internal
Medicine, Hopital Lariboisiere, Paris, France. 4Infectious Diseases
Department, Hopital Avicennes, Bobigny, France. 5Infectious Diseases
Department, Hopital Intercommunal de Villeneuve St Georges,
Villeneuve St Georges, France. 6Internal Medicine, Hopital
Intercommunal de Cre´teil, Creteil, France. 7Infectious Diseases Unit,
Hopital Jean Verdier, Bondy, France. 8Internal Medicine, Hopital Sud
Francilien, Corbeil Essonne, France. 9Infectious Diseases Department,
Centre Hospitalier Marc Jacquet, Melun, France. 10Infectious
Diseases Unit, Centre Hospitalier de Meaux, Meaux, France.
Figure 2. Viral load (copies/mL) at baseline, month 2, 4 and 6 of
treatment with HAART and at June 2016.
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11Infectious Diseases Department, Centre Hospitalier de Marne la
Valle´e, Jossigny, France. 12Internal Medicine, Hopital de Longjumeau,
Longjumeau, France. 13Internal Medicine, Centre Hospitalier
d’Arpajon, Arpajon, France. 14Internal Medicine, Centre Hospitalier
de Fontainebleau, Fontainebleau, France. 15Medicine Unit, Centre
Medico Chirurgical de Bligny, Bligny, France. 16Internal Medicine,
Centre Hospitalier de Dourdan, Dourdan, France. 17Microbiology
Unit, Hopital St Louis, Paris, France
Introduction: African migrants, originating mostly from West Africa,
represented up to 39% of new HIV diagnosis in France in 2014. We
wished to assess whether timing of ART initiation in naı¨ve patients,
the choice of ART and the response to a first-line ART differed in
African migrants versus European natives.
Materials and methods: We performed a retrospective analysis of
prospectively collected data in the COREVIH Ile de France Est, a large
network of 26 hospitals using the same electronic database (Nadis†).
All naı¨ve patients seen from 1 January to 31 December, 2014, and
who did not participate in clinical trials were enrolled in this study.
We compared baseline characteristics (age, sex, mode of HIV trans-
mission, ethnic origin, centre, CDC stage, CD4 cell counts, plasma HIV
RNA level, HBV/HCV co-infection) among patients starting or
deferring ART in 2014, among those receiving PI- or non-PI-based
ART, and among those experiencing virologic failure over 48 weeks of
follow-up. Univariate and multivariate analyses were performed.
Results: Nine hundred and twelve naı¨ve patients were enrolled in
this study, 446 of whom (49%) were African migrants. Five hundred
and eighty-four patients (64%) initiated ART during the study period,
and ART initiation was significantly and independently associated
with centre, higher baseline viral load, lower baseline CD4 cell
count and ethnic origin. African migrants had an odds ratio (OR) of
1.85 (95% CI 1.222.85, p0.004) to remain ART naı¨ve as compared
to European natives. Among the 584 patients who started ART during
the study period, the majority (45%) received a PI-based ART and the
choice of a PI-based ART was associated significantly and indepen-
dently with centre, higher baseline viral load, lower baseline CD4
cell count and ethnic origin. African migrants had an OR of 0.44 (95%
CI 0.290.66, pB104) to receive a non-PI-based ART as compared
to European natives. Finally, when assessing virologic failure during
follow-up, it was significantly and independently associated with
centre, higher baseline viral load and ethnic origin. African migrants
had an OR of 1.90 (95% CI 1.093.32, p0.02) to develop virologic
failure as compared to European natives.
Conclusion: African migrants who represent a large proportion of
ART-naı¨ve HIV-infected patients in France do not seem to receive the
same ART management as other ethnic groups, and also seem to fail
ART more frequently. Determinants of these differences should be
analyzed in order to provide homogenous care management among
HIV-infected patients regardless of their ethnic origin.
P045
Efficacy and safety of tenofovir alafenamide versus
tenofovir disoproxil fumarate in treatment-naı¨ve Asian
adults
Shinichi Oka1; Ploenchan Chetchotisakd2; Amanda Clarke3;
Khuanchai Supparatpinyo4; Sasisopin Kiertiburanakul5; Julie Ryu6;
David Piontkowsky6; Susan Guo7; Thai Nguyen-Cleary6; Moupali Das8
and Scott McCallister8
1Infectious Diseases, National Center for Global Health and Medicine
Hospital, Tokyo, Japan. 2Infectious Diseases, Khon Kaen University,
Khon Kaen, Thailand. 3Infectious Diseases, Brighton and Sussex
University Hospitals NHS Trust, Brighton, UK. 4Infectious Diseases,
Chiang Mai University, Chiang Mai, Thailand. 5Infectious Diseases,
Ramathibodi Hospital Mahidol University, Bangkok, Thailand.
6Medical Affairs, Gilead Sciences, Foster City, CA, USA. 7Biometrics,
Gilead Sciences, Foster City, CA, USA. 8Clinical Research, Gilead
Sciences, Foster City, CA, USA
Introduction: Tenofovir alafenamide (TAF) is non-inferior in efficacy
to tenofovir disoproxil fumarate (TDF) and has an improved renal and
bone safety profile. In this sub-analysis, we describe the efficacy and
safety of TAF compared to TDF in treatment-naı¨ve Asian adults.
Materials and methods: This analysis consisted of pooled data from
two phase 3, randomized, double blind studies (GS-US-292-0104 and
GS-US-292-0111) of HIV-infected, treatment-naı¨ve adults who in-
itiated a single-tablet regimen (STR) of elvitegravir, cobicistat and
emtricitabine coformulated with tenofovir alafenamide (E/C/F/TAF)
or tenofovir disoproxil fumarate (E/C/F/TDF). Efficacy and safety
endpoints through week 96 by self-identified Asian versus non-Asian
race within and between treatment groups were examined.
Abstract P045Table 1. Week 96 Results
E/C/F/TAF E/C/F/TAF E/C/F/TDF E/C/F/TDF
Week 96 results Asian (N91) Non-Asian (N775) Asian (N89) Non-Asian (N778)
Proportion with HIV-1 RNA B50 copies/mLa,b 97% 85% 93% 84%
Mean change from baseline in CD4 cell count, cells/mL 287 279 250 268
Discontinuations 1% 1% 2% 2%
Discontinuations due to renal adverse events, n 0 0 0 6
Median change from baseline in eGFR, mL/min 7 1 9 7
Median % change from baseline in proteinuria
Urine protein: creatinine ratio (UPCR)b,d 0% 10% 34% 15%
Urine albumin: creatinine ratio (UACR)d B1% 6% 18% 3%
Urine retinol binding protein: creatinine ratio (RBPCR)c,d 12% 14% 72% 74%
Urine beta-2-microglobulin: creatinine ratio (B2MCR)c,d 38% 32% 22% 35%
Mean % change from baseline in spine BMDc,d 0.3% 1.1% 3.2% 2.7%
Mean % change from baseline in hip BMDa,b,c,d 1.5% 0.6% 4.6% 3.1%
pB0.05 for differences between Asian versus non-Asian in the aTAF group or bTDF group; pB0.05 for differences between TAF versus TDF in
the cAsian group or dnon-Asian group.
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Results: One thousand seven hundred and thirty-three adults were
randomized and treated: 10% Asians (91 TAF vs. 89 TDF): ex-US (89%
vs. 83%), median age (30 vs. 31 years), female (45% vs. 36%), median
BMI (22 vs. 22), HIV-1 RNA ]100,000 copies/mL (26% vs. 33%), CD4
count B200 cells/mL (15% vs. 17%), median eGFRCG (109 vs. 105 mL/
min), and proteinuria (8% vs. 8%). At week 96, 97% of Asians on TAF
versus 93% on TDF achieved virologic suppression by FDA snapshot
algorithm, compared to 85% of non-Asians on TAF and 84% on TDF.
Increases in CD4 cell count were numerically higher for Asians on TAF
compared to TDF. Both STRs were well tolerated with 1% disconti-
nuations due to adverse events (AEs) for TAF and 2% for TDF. There
were no discontinuations due to renal AEs in any Asian participants.
There were similar declines in eGFR between TAF and TDF among
Asians, consistent with cobicistat’s reversible inhibition of creatinine
secretion. Changes in other markers of renal safety including urine
RBPCR and B2MCR favoured the TAF group, suggesting less impact
on renal tubular function. There were minimal decreases in spine and
hip bone mineral density (BMD) for the TAF-treated group versus
larger decreases in BMD for Asians treated with TDF. Efficacy and
safety results for non-Asian participants are shown below (Table 1).
Conclusions: TAF and TDF STRs have high and durable efficacy in
treatment-naı¨ve Asian adults, with changes in markers of renal and
bone safety that consistently favoured TAF over TDF. These data
support the use of a TAF-based regimen for the initial treatment of
HIV in Asian adults.
P046
Combining lopinavir/r with new ARV agents in ART-naı¨ve
HIV-infected patients: data from the German multicenter
PROTEKT cohort
Eva Wolf1; Heribert Hillenbrand2; Axel Baumgarten3;
Christoph Stephan4; Thomas Lutz5; Siegfried Koeppe6 and
Johannes Huelsenbeck7
1MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich,
Germany. 2MVZ, PraxisCityOst, Berlin, Germany. 3Zentrum fu¨r
Infektiologie Berlin, Prenzlauer Berg, Berlin, Germany. 4Medical Dept.
No. 2, University Hospital Frankfurt, Goethe University, Frankfurt,
Germany. 5Infektiologikum, Frankfurt-City, Frankfurt, Germany.
6Gemeinschaftspraxis, Drs S. Koeppe/P. Kreckel, Berlin, Germany.
7AbbVie Germany, Medical HIV/HCV, Wiesbaden, Germany
Introduction: With the approval of new ARV agents, innovative
ations are possible in combination with protease inhibitors. PROTEKT,
a non-interventional cohort study initiated in 2008, re-
cruited HIV-1-infected patients receiving cART consisting of lopinavir
(LPV)/r plus a ‘‘novel’’ agent other than NRTI, namely raltegravir
(RAL), maraviroc (MVC) or etravirine (ETR), without restrictions
concerning the use of additional antiretrovirals. Individual choice of
cART was at the treating physician’s discretion. Ethics approval
had been obtained. Observation time was 144 weeks or until
discontinuation of cART.
Methods: Evaluation of 3-year outcomes in the subgroup of ART-
naı¨ve patients of the PROTEKT cohort initiated on cART including LPV/r
plus INI, ETR or MVC. Outcomes of interest were time on cART
(persistence) using Kaplan-Meier (KM) analysis, time to discontinua-
tion due to virologic failure (VF; censoring discontinuations not
related to VF), HIV RNA B50 (400) copies/mL at week 48 using ITT
(snapshot; discontinuationfailure; missing data excluded) and as-
treated (AT) analyses (missings excluded), as well as CD4 cell changes.
Results: Between 2008 and 2014, 501 patients were included in
PROTEKT, 90 of them initiated on first-line cART. Baseline character-
istics of the ART-naı¨ve study population are shown in Table 1: 37%
presented with HIV-related diseases, 7% with hepatitis C, 7% with
renal disease, 68% with HIV RNA 100,000 copies/mL, 32% with
B200 CD4 cells/mL. LPV/r was combined with either RAL (88
patients, 98%), MVC (one patient, 1%) or ETR (one patient, 1%);
63 patients (70%) received dual therapy LPV/rRAL, 18 (20%) LPV/r
RALTDF/FTC. HIV RNA levels B50 (B400) copies/mL at week
48: ITT, 51% (71%) (N40/79 (56/79)); AT, 67% (93%) (N40/60
(56/60)). Median time to discontinuation of cART was 113 weeks;
persistence at weeks 48, 96 and 144 was 73%, 54% and 42%,
respectively; KM estimates regarding discontinuation due to VF were
94%, 87% and 82%. Median CD4 increases at weeks 48, 96 and 144
were 200/mL (IQR 98422), 309 (206449) and 286 (196473),
respectively. Median time to CD4 increase of ]100 cells/mL was 12
weeks. Most common reasons for discontinuation of study drugs
until week 144 were treatment simplification (10/90; 11%), virologic
failure (10/90 patients; 11%; 3/10 with HIV RNA B200 copies/mL)
and adverse events (9/90 patients, 10%).
Conclusion: In the German PROTEKT cohort, LPV/rRAL as dual
therapy or part of cART was used in ART-naı¨ve HIV-infected patients
with advanced HIV disease. Median persistence of 2 years in the
PROTEKT cohort suggests that non-NRTI-based regimens offer an
alternative approach for treatment initiation in specific situations.
P047
Outcome of antiretroviral regimens prescribed by following
the regulations on combination antiretroviral therapy by
Taiwan Centers for Disease Control
Mao-Song Tsai1; Chia-Jui Yang1; Jun-Yu Zhang2; Pei-Ying Wu2;
Shang-Ping Yang2; Yu-Zhen Luo2; His-Yen Chang2; Kuan-Yin Lin3;
Hsin-Yun Sun3 and Chien-Ching Hung3
1Internal Medicine, Far Eastern Memorial Hospital, New Taipei City,
Taiwan. 2Center of Infection Control, National Taiwan University
Table 1. Baseline characteristics of the ART-naı¨ve PROTEKT
study population initiated on LPV/rnew agent9other
antivirals
Baseline characteristics
Total, n 90
Gender, n (%)
Male 82 (91.1%)
Female 8 (8.9%)
Median age, years (IQR) 40 (3147)
Ethnicitya, n (%)
Caucasian 72 (82.8%)
African 10 (11.5%)
Asian 2 (2.3%)
Other 3 (3.4%)
Median HIV RNA level, log copies/mL (IQR) 5.3 (4.76.0)
HIV RNA 100,000 copies/mL, n (%) 61 (67.8%)
Median CD4 cell count, cells/mL (IQR) 302 (162450)
CD4 cell count B200/mL, n (%) 29 (32.2%)
Median rel. CD4 cell count,% (IQR) 15 (1022)
Patients with comorbidities
Renal disease/impairment, n (%) 6 (6.7%)
Liver disease, n (%) 1 (1.1%)
Chronic hepatitis B, n (%) 1 (1.1%)
Chronic hepatitis C, n (%) 6 (6.7%)
CDC B/C 33 (36.7%)
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Hospital, Taipei, Taiwan. 3Department of Internal Medicine, National
Taiwan University Hospital, Taipei, Taiwan
Introduction: To curb the increasing medical cost for HIV care, Taiwan
Centers for Disease Control (CDC) implemented regulations on cART
according to the monthly cost for each regimen on 1 June 2012. By
following the regulations, many individuals commence thymidine
analogue (TA)-based regimens. Prior authorization is needed for
the regimens containing protease inhibitors (PIs), integrase strand
transfer inhibitors (INSTIs) or rilpivirine (RPV) plus non-TA backbones
(abacavir/lamivudine; tenofovir disoproxil fumarate (TDF)/emtricita-
bine; or TDF plus lamivudine). We aimed to describe the outcome of
the regimens prescribed by following the regulations in Taiwan.
Materials and methods: Between June 2012 and June 2016,
antiretroviral-naı¨ve HIV-positive patients who initiated cART were
included. We retrospectively collected information on clinical char-
acteristics, regimens, treatment responses, causes for switch and
genotypic resistance at baseline and follow-up. We investigated the
predictors of treatment modification with Cox proportional hazards
model.
Results: During the 48-month study period, 1390 patients with
baseline median CD4 count of 282 cells/mL and plasma HIV RNA load
(PVL) 4.85 log10 copies/mL initiated cART: 31.1% TA backbones plus
nevirapine, efavirenz or RPV (first category); 59.1% non-TA back-
bones plus nevirapine or efavirenz (second category); 6.3% TA plus
PIs, INSTI or RPV (third category); and 3.7% non-TA plus boosted PI, II
or RPV (fourth category). Overall, 65.6% (n912) had to change the
initial regimens at a median interval of 41 days (range 11140)
because of regimen simplification (33.6%), rash (20.5%), neuropsy-
chiatric adverse effect (14.0%), genotypic resistance/virologic failure
(10.8%), gastrointestinal intolerance (9.3%), anaemia (9.2%) or
hepatitis (4.9%). The rates of regimens modification for drug-related
adverse reactions were 61.4%, 34.1%, 53.6% and 29.4% in patients in
the first, second, third and fourth category of regimens, respectively.
Except for regimen simplification, 6-month modification-free survival
rates were 67.6% (range 64.270.1%) in the patients on regimens
containing non-TA backbones and 48.9% (44.453.1%) in the
patients on regimens containing TA backbone (hazard ratio (HR)
1.82 (95% CI 1.552.14)) (Figure 1). In multivariate analysis, use of
regimens containing TA backbone (HR 1.84; 95% CI 1.572.16) and
higher PVL (HR, per 1-log10 copies/mL increase, 1.15; 95% CI 1.03
1.29) were independent predictors of cART switch.
Conclusions: A significant proportion of patients on cART regimens,
especially the regimens containing TA backbone that were prescribed
by following the regulations of Taiwan CDC, had to be changed due
to toxicities, transmitted drug resistance or unsatisfactory virologic
response.
P048
Prescription pattern and determinants of dolutegravir use
in an antiretroviral-naı¨ve HIV-infected population in Italy:
data from the ICONA Foundation cohort study
Andrea Antinori1; Alessandro Cozzi Lepri2; Antonella Castagna3;
Sergio Lo Caputo4; Cristina Mussini5; Stefano Rusconi6;
Antonio Di Biagio7; Giulia Marchetti8; Silvia Nozza3;
Antonella Cingolani9; Andrea De Luca10; Antonella d’Arminio
Monforte8 and Study Group on behalf of Icona Foundation8
1HIV/AIDS Department, National Institute for Infectious Diseases,
Roma, Italy. 2Infection and Population Health, University College
London, London, UK. 3Infectious Diseases, San Raffaele Hospital,
Milano, Italy. 4Infectious Diseases, University of Bari, Bari, Italy.
5Infectious Diseases, University of Modena, Modena, Italy.
6Infectious Diseases, Luigi Sacco Hospital, University of Milano,
Milano, Italy. 7Infectious Diseases, University of Genova, Genova,
Italy. 8Health Sciences, San Paolo Hospital, University of Milano,
Milano, Italy. 9Infectious Diseases, Catholic University, Roma, Italy.
10Infectious Diseases, University of Siena, Siena, Italy
Introduction: Dolutegravir (DTG), an integrase strand transfer
inhibitor (INSTI), is currently recommended for treatment initiation
in antiretroviral-naı¨ve by most of clinical guidelines. Data from
Abstract P047Figure 1. Time to regimens modification during the first 24 weeks after starting antiretroviral treatment according to the
regimen (TA backbone vs. non-TA backbone).
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randomized trials demonstrated superiority of DTG over NNRTI and
PI/r, supporting its clinical use especially in first-line regimens with
high viral load, regardless of which NRTI pair (TDF/FTC or ABC/3TC)
was initiated. Aim of this analysis was to describe DTG use in a
representative unselected naı¨ve population in Italy and identify its
determinants and patterns of prescription.
Methods: All patients enrolled in ICONA Foundation cohort starting
a DTG-based regimen from ART-naı¨ve, and those concomitantly
starting other third drugs (control group) after 1 January 2014 all
using as NRTI pair TDF/FTC or ABC/3TC were selected. Cross-
sectional analysis was performed, and characteristics at the time of
starting cART compared using chi-square test and univariable and
multivariable logistic regression.
Results: A total of 1944 ARV-naı¨ve individuals starting cART were
included (DTG195; NNRTI715; PI/r576; other INSTI458).
The crude prevalence of DTG use was 10%. Median HIV-1 RNA was
4.7 log10/mL in DTG and 4.6 log10/mL in controls (p0.13); median
CD4 counts were 386 cells/mm3 and 376 cells/mm3, respectively
(p0.78). Proportion of patients with HIV-1 RNA values 100,000
was 36.6% among DTG and 29.3% among controls (p0.06). Fitting
a logistic regression, a significantly increased probability of starting
DTG was found with more recent calendar years and higher baseline
HDL cholesterol values, and a decreased probability in sites located
in central Italy, with a trend towards more frequent use with a pVL
100,000 (Table 1). NRTI pair was TDF/FTC in 65% of DTG and 90%
of controls, and ABC/3TC in 35% of DTG and 10% of controls, with a
significantly higher probability of starting ABC/3TC in the DTG group
(Table 1). Proportion of ABC/3TC combination with DTG was 44% in
pVL 5100,000, but only 24% in pVL 100,000 stratum (interaction
p0.37).
Conclusions: During the first 2 years after its introduction in Italy,
DTG prescriptions in ART-naı¨ves showed an increase over time,
although patterns were not different from those observed for control
regimens, except for a trend for starting DTG at high VL. ABC/3TC
was more frequently prescribed with DTG than in controls, even
though TDF/FTC remains the most prescribed NRTI option combined
with DTG in people with high viral load. Concerns on ABC/3TC
potency, toxicity and lack of rapid HLA results might have affected
clinicians’ choices.
P049
The RESINA data support the individualized therapy based
on primary resistance testing
Elena Knops1; Eugen Schuelter1; Nadine Luebke2;
Maria Neumann-Fraune1; Eva Heger1; Saleta Sierra-Aragon1;
Claudia Mueller1; Mark Oette3; Gerd Faetkenheuer4; Martin Hower5;
Heribert Knechten6; Niels Schuebel7; Stefan Esser8; Stefan Scholten9;
Dieter Haeussinger10; Rolf Kaiser1 and Bjoern Jensen10
1Institute of Virology, University of Cologne, Cologne, Germany.
2Institute for Virology, University of Duesseldorf, Duesseldorf,
Germany. 3Department of Gastroenterology, Krankenhaus der
Augustinerinnen, Cologne, Germany. 4Department of Internal
Medicine, University of Cologne, Cologne, Germany. 5Department of
Internal Medicine, City Hospital Dortmund, Dortmund, Germany.
6Private Practice, Private Practice Dr. Knechten, Aachen, Germany.
7Department of Internal Medicine, Klinikum Osnabrueck,
Osnabrueck, Germany. 8Department of Dermatology, University of
Essen, Essen, Germany. 9Private Practice, Private Practice
Hohenstauffenring, Cologne, Germany. 10Department of
Gastroenterology, Hepatology and Inf, University of Duesseldorf,
Duesseldorf, Germany
Introduction: The RESINA study started in 2001 and was originally
focused on the evaluation of primary resistance in patients at the
time point of first therapy. Additionally, we could follow up these
patients (RESINA cohort) since cART start by collecting the clinical,
virologic and immunologic data.
Materials and methods: The clinical, virologic and immunologic data
were collected from 38 centres since 2001. Genotypic analysis of
resistance-associated mutations (RAMs) was performed from viral
RNA exclusively until 2012, since then additionally from proviral DNA
and/or total NA. Resistance-associated mutations were detected by
Abstract P048Table 1. Odds ratios of starting DTG versus control from fitting a logistic regression
Odds ratios of starting dolutegravir versus control
Characteristics Unadjusted OR (95% CI) p Adjusteda OR (95% CI) p
Viral load, log10 copies/mL
100,000 vs. 5100,000 1.39 (0.981.97) 0.061 2.17 (0.964.93) 0.063
HDL cholesterol, mg/dL
Per 100 higher 2.22 (0.529.49) 0.283 8.02 (1.1356.88) 0.037
Site geographical location
North 1.00
Centre 0.66 (0.440.99) 0.043 0.34 (0.120.99) 0.048
South 1.05 (0.621.76) 0.866 1.18 (0.522.71) 0.693
NRTI pair
ABC/3TC vs. TDF/FTC 5.83 (4.038.43) B0.001 14.30 (6.8130.04) B0.001
Period of initiation
JanuaryDecember 2014 1.00 1.00
JanuaryJune 2015 13.57 (6.9426,55) B0.001 15.49 (5.8341.20) B0.001
July 2015March 2016 24.87 (12.6249.04) B0.001 19.92 (6.6359.84) B0.001
aBesides factors shown in the table, also adjusted for gender, nationality, age, education, employment, mode of HIV transmission, time from HIV
first diagnosis, AIDS diagnosis, HCV status, HBV status, baseline CD4 count, baseline CD8 count, diagnosis of diabetes dyslipidaemia and
psychological disorders, and eGFR.
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Sanger sequencing and recently by next-generation sequencing by
the Illumina MiSeq technology. Additionally, we collect data from any
therapy-experienced patient within the AREVIR project.
Results: Meanwhile the RESINA cohort consists of more than 3800
patients from almost 40 HIV centres in North-Rhine-Westphalia.
Furthermore, we performed a total number of more than 13,000
resistance tests from therapy-naı¨ve and therapy-experienced pa-
tients (RESINA and AREVIR data). During this time, we could observe
a decline in prevalence of resistance-associated mutations in
treatment-experienced patients as documented in the AREVIR
database. In contrast to the decline of RAMs in therapy-experienced
patients, the frequency of primary resistance-associated mutations at
the beginning of cART remains relatively stable. The majority of
the primary RAMs were NRTI resistance mutations throughout the
whole time of observation. NNRTI resistance-associated mutations
did not increase over time although the use of NNRTI increased in
our cohort since 2001. We did not observe an increase in primary PI
resistance-associated mutations and almost no primary INI resistance
mutations.
Conclusions: Despite the declining frequency of resistance-associated
mutations in therapy-experienced patients the frequency of primary
resistance mutations is still high and justifies routine primary
resistance testing. We can further conclude from our data that the
individualized therapies according to the DAIG therapy guidelines
for therapy-naı¨ve patients translate in a low number of NNRTI and
PI resistance-associated mutations in therapy-naı¨ve and therapy-
experienced patients.
TREATMENT STRATEGIES - TARGET
POPULATIONS: PRIMARY INFECTION
P050
The acute/recent HIV infection cohort from Hospital Clinic,
Barcelona: epidemiological trends and evolution from 1997
to 2015
David Nicola´s Ocejo1; Juan Ambrosioni1; Christian Manzardo1;
Fernando Agu¨ero1; Mar Mosquera2; Marta Parera2;
Sonsoles Sanchez-Palomino3; Carmen Ligero1; Emma Fernandez1;
Elisa de Lazzari1; Montserrat Plana3; Jose Gatell1 and Jose Miro´1
1Infectious Diseases, Hospital Clinic Barcelona, Barcelona, Spain.
2Microbiology, Hospital Clinic Barcelona, Barcelona, Spain. 3Institut
d’Investigacions Biome`diques August Pi i Sunyer, Retrovirology and
Viral Immunopathology Laboratory, Barcelona, Spain
Introduction: The epidemiology and clinical management of primary/
recent HIV infection (PHI) has undergone significant changes over the
last 20 years. The epidemiological profile of PHI patients has probably
also varied, although published evidence is scarce.
Methods: Since 1997, data have been collected from every patient
with an acute/recent HIV infection (less than 180 days) visiting our
hospital. The inclusion criteria were a negative antibody assay with a
detectable viral load or a positive p24 antigen, a positive antibody
assay with a negative, indeterminate or incomplete western blot, or
a documented negative test in the preceding 6 months. Patients
were stratified into four time periods (19972001, 20022006,
20072011, 20122015).
Results: In the last 19 years, 337 patients were included with a
median follow-up of 81 months. The main risk factor was men having
sex with men (MSM) with an increasing trend in the most recent
periods (pB0.001). Intravenous drug use (IDU) decreased from 23%
in the earliest period to 1% in the last. Positive HCV serology at
diagnosis was higher in the first period, while syphilis diagnosis
remained stable over time. In the first period, 23% of patients were
immigrants, increasing to 40% in the last period. Non-B subtypes also
increased but not significantly. Nineteen percent of patients
presented with a Fiebig I-III stage at diagnosis and the median
time from infection to diagnosis was 40 days (IQR 2879) with little
change over time (Table 1). Seventy percent of patients presented
with a symptomatic PHI, and 25% of them required hospital
admission. Ninety-three percent of patients started ART. Of them,
27% started during the first 3 months, and 45% during the first
6 months as of the infection date. Median CD4 at ART initiation
Abstract P050Table 1. Epidemiological characteristics of the PHI cohort
Global 19972001 20022006 20072011 20122015 p
Men, n (%) 314 (93.2%) 23 (76.7%) 49 (87.5%) 145 (97.3%) 97 (95.1%) B0.001
Age (years) 33.7 33.3 33.2 34.6 34.4 0.164
Transmission, n (%)  MSM 291 (86.9%) 19 (63.3%) 42 (75%) 138 (93.9%) 92 (90.2%) B0.001
Transmission, n (%)  IDU 17 (5.1%) 7 (23.3%) 5 (8.9%) 4 (2.7%) 1 (1%) 
Origin  Spain 213 (63.4%) 23 (76.7%) 36 (65.5%) 93 (62.4%) 61 (59.8%) 0.391
Origin  immigrants 123 (36.6%) 7 (23.3%) 19 (34.5%) 56 (37.6%) 41 (40.2%) 
Drugs use, n (%)  IV 10 (3.1%) 5 (17.2%) 2 (3.8%) 3 (2.1%) 0 (0%) B0.001
Drugs use, n (%)  inhaled 79 (24.5%) 1 (3.4%) 13 (25%) 38 (27%) 27 (26.7%) 
Drugs use, n (%)  oral 16 (5%) 0 (0%) 2 (3.8%) 6 (4.3%) 8 (7.9%) 
Follow-up (months), median (IQR) 81 (54118) 200 (178217) 134 (120157) 78 (6591) 40 (2748) 
Time from infection to diagnosis (days), median
(IQR)
40 (2879) 31 (2977) 42 (2964) 40 (2686) 39 (2774) B0.001
Fiebig I-III, n (%) 64 (19%) 9 (30%) 14 (25%) 30 (20.1%) 11 (10.8%) 0.004
HCV at diagnosis, n (%) 19 (4.9%) 7 (23.3%) 4 (7.1%) 3 (2.1%) 3 (2.1%) B0.001
VDRL at diagnosis, n (%) 40 (12.8%) 5 (17.2%) 6 (10.9%) 16 (11.2%) 13 (15.3%) 0.684
Time from infection to ART (days), median (IQR) 204 (84523) 99 (63156) 109 (511140) 336 (155646) 122 (80239) B0.001
Time from diagnosis to ART (days), median (IQR) 133 (41472) 56 (2274) 62 (191052) 284 (103622) 79 (36172) B0.001
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remained steady and median time from diagnosis to treatment un-
derwent a temporary increase during the middle periods (pB0.001)
(Figure 1). The chosen ART regimen varied among periods, with a
substitution of PIs with INSTI in the last period (Figure 2).
Conclusions: Our results show significant changes in the profile of
patients with acute/recent HIV infection in Barcelona with an
increase of MSM in the most recent periods. The interval between
diagnosis and ART start increased during the central calendar period
(20022011), reflecting conservative guideline recommendations of
that time. The INSTI-based ART regimens were the preferred starting
option in the last years.
P051
Neurological involvement in patients with acute/recent
HIV-1 infection
Francisca Artigues1; Juan Ambrosioni2; David Nicola´s2;
Judit Pen˜afiel2; Fernando Agu¨ero2; Christian Manzardo2;
Mar Mosquera2; Sonsoles Sa´nchez-Palomino2; Elisa de Lazzari2;
Maria Angeles Marcos2; Montserrat Plana2 and Jose Miro2
1School of Medicine, University of Barcelona, Barcelona, Spain.
2Infectious Diseases, Hospital Clinic, Barcelona, Spain
Introduction: Neurological involvement during primary HIV-1 infec-
tion (PHI) has been poorly studied. Early antiretroviral therapy (ART)
has shown to improve symptoms, to promote a better immunolo-
gical recovery and to reduce the size of viral reservoir [1]. Little is
known, however, about ART in the context of neurological involvement
during PHI [2,3]. The aim of this study was to describe the clinical
characteristics and outcomes of patients presenting neurological
symptoms during PHI and to compare them with a control group
without neurological involvement.
Materials and methods: We described the 14 patients (3.02% of the
whole PHI cohort) with neurological symptoms that were enrolled in
the acute/recent hospital clinic PHI cohort (documented infection
B6 months) between 1997 and 2016. A retrospective case-control
study was developed, matching each case with three controls.
Matching criteria included age (910 years), gender, year of the
diagnosis (94 years) and same Fiebig stage. Statistical analyses were
performed using R software version 3.2.3. The conditional logit
model was used to compare variables between the matched cases
and controls.
Results: Fever and headache with at least one other neurological
symptom were the most frequent manifestations among cases:
28.5% presented as meningitis and 71.5% as meningoencephalitis.
Abstract P050Figure 2. Evolution of the ART chosen as the third drug as starting scheme among periods.
Figure 1. Median and IQR CD4 at ART start during the four study
periods.
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Cerebrospinal fluid showed pleocytosis with lymphocyte predomi-
nance and increased protein levels. Adenosine deaminase was
elevated in 42.8% of cases. No other pathogen was identified in
any case. Case-control comparisons can be seen in Table 1. All cases
required hospitalization, whereas only 19% of the controls did. CD4/
CD8 ratio was significantly lower in the case group (p0.039) and
plasmatic viral load was significantly higher in the case group
(p0.028). There were no differences regarding risk factors, HIV-1
tropism, subtype distribution or prescribed ART regimens. After
6 months on ART, 92% of cases had undetectable HIV-1 viral load,
similar to controls. All cases recovered rapidly with ART and were
discharged without sequels.
Conclusions: Neurological involvement during PHI is an unusual but
serious condition, always requiring hospitalization. Early diagnosis
might be difficult because of the wide range of neurological symp-
toms and similarities with other viral aetiologies. Neurological
manifestations during PHI are associated with a lower CD4/CD8
ratio and with a higher viral load at diagnosis than controls. Im-
mediate initiation of ART to rapidly decrease the viral load is
required in this scenario. Dolutegravir, together with lamivudine and
abacavir, seems a reasonable regimen due to its potency in reducing
viral load and its high CNS penetration.
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P052
Single-tablet regimen with elvitegravir, cobicistat,
emtricitabine and tenofovir for the treatment of early
HIV infection
Ramon Teira1; Maria Galindo2; Marta Montero3; Raquel Portilla4;
Ana Ferrer2 and Elisa Martinez5
1Infectious Diseases, Hospital de Sierrallana, Torrelavega, Spain.
2Infectious Diseases, Hospital Clinico, Valencia, Spain. 3Infectious
Diseases, Hospital La Fe, Valencia, Spain. 4Internal Medicine, Hospital
de Sierrallana, Torrelavega, Spain. 5Hospital de Albacete, Internal
Medicine, Albacete, Spain
Introduction: Treatment of early HIV infection (EHI) (within the
6-month period after the transmission event) has been recommended,
based on pathophysiologic considerations and on surrogate-marker
outcomes. The rationale supporting this recommendation (the
accelerated pace of pathophysiologic events in this early phase of
the infection) argues also for an immediate initiation of treatment.
Stribild†, the single-tablet regimen (STR) including elvitegravir,
Abstract P051Table 1. Comparison between cases and controls
Variable Cases N14 Controls N42 p
PHI symptoms 14 (100%) 35 (83.3%) 
Fever 14 (100%) 29 (69.0%) 
Headache 12 (85.7%) 11 (26.2%) B0.01
Need of hospitalization 14 (100%) 8 (19.0%) 
Days of hospitalization (n20), median (IQR) 6.0 (2.757.75) 7.0 (5.258.0) 0.496
Tropism R5 (n22) 6 (85.7%) 8 (53.3%) 0.229
Subtype B (n38) 10 (100%) 26 (92.9%) 
Days diagnosis  ART (n 53), median (IQR) 11.5 (5.040.8) 140.0 (38.2284.0) 0.041
NNRTI-based ART 4 (28.6%) 10 (23.8%) 0.732
Integrase inhibitor-based ART 2 (14.3%) 9 (21.4%) 0.500
Protease inhibitor-based ART 8 (57.1%) 19 (45.2%) 0.448
Transmitted drug resistance 1 (7.14%) 5 (12.2%) 0.621
Log10 VL diagnosis, median (IQR) 5.99 (5.296.59) 5.24 (4.625.86) 0.019
Log10 VL ART starting (n53), median (IQR) 5.50 (4.806.19) 4.96 (4.375.50) 0.028
Patients with VL B50 copies/mL at 6 months ART (n47) 11 (92%) 23 (66%) 0.133
Patients with VL B50 copies/mL at 12 months ART (n46) 11 (92%) 30 (88%) 0.520
CD4 cells/mm3 diagnosis (n55), median (IQR) 328 (253443) 468 (316568) 0.184
CD4 cells/mm3 ART starting (n51), median (IQR) 368 (263441) 404 (273580) 0.190
CD4 cells/mm3 6 months ART (n48), median (IQR) 581 (493787) 634 (440791) 0.569
CD4 cells/mm3 12 months ART (n46), median (IQR) 804 (642889) 630 (555864) 0.117
CD4/CD8 ratio diagnosis (n55), median (IQR) 0.33 (0.220.44) 0.53 (0.360.80) 0.039
CD4/CD8 ratio ART starting (n51), median (IQR) 0.30 (0.240.45) 0.49 (0.360.67) 0.060
CD4/CD8 ratio 6 months ART (n48), median (IQR) 0.82 (0.650.89) 0.76 (0.530.99) 0.738
CD4/CD8 ratio 12 months ART (n46), median (IQR) 1.00 (0.821.04) 0.88 (0.761.40) 0.780
NNRTI, non-nucleoside reverse-transcriptase inhibitors; VL, viral load. p-value was not calculated in those variables with 100% or 0%.
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cobicistat, emtricitabine and tenofovir, seems particularly well suited
for this indication, due to its not needing additional laboratory data
and the convenience of the STR formulation.
Methods: We reviewed the medical records of those patients
attending the participating clinics with a diagnosis of EHI who started
treatment with Stribild†. We classified them as 1) definite EHI if a)
they had a negative serologic test within the 6 months prior to the
diagnosis and any positive test at presentation or b) they had a
simultaneous negative serologic test and a positive HIV RNA test
or p24 antigen; or 2) probable EHI if they had not a negative
serologic test within the previous 6 months, but they had an
epidemiologic and clinical syndrome suggestive of acute HIV
infection plus an HIV RNA plasma concentration (VL) higher than
100,000 copies/mL.
Results: Stribild† has been available in Spain since January 2014. In
this period, 21 patients attending the participating clinics were
diagnosed with EHI and started treatment with Stribild†, of whom
17 were definite and 4 were probable diagnoses. Nineteen (90.5%)
were male. The median age (95% interquartile range (IQR)) was 34
(3042). HIV infection had been transmitted through sexual contact
in all cases: in two women (100%), in 17 men who had sex with men
(89.5%) and in two men (10.5%) who did not report sex with men.
The median CD4 cell count and VL at the time of diagnosis were 450
(IQR 290567) and 520,000 (153,0001,900,000), respectively. We
have data from 19 patients after 3 months of treatment, and from 12
patients after 1 year. At 3 months, the median VL was 46 copies/mL
(IQR B20254). At 12 months, one patient had withdrawn and had
a VL of 6162, while the remaining 11 were still on treatment, all of
whom, except one, had VL B50 (the other was 106 copies/mL). We
recorded no major or renal adverse effects.
Conclusions: Our results support the hypothesis that Stribild† is
safe and effective for the treatment of EHI. The possible benefit of
immediate initiation warrants further investigation.
P053
Comparison of (TDFFTC) associated with either
darunavir/ritonavirraltegravir or dolutegravir: virological
efficacy of two different treatment strategies for primary
HIV infection (PHI)
Carmela Pinnetti1; Isabella Abbate2; Patrizia Lorenzini1;
Nicoletta Orchi3; Caterina Gori4; Alessandra Amendola2;
Raffaella Libertone1; Gabriella Rozera2; Maria Maddalena Plazzi1;
Gabriele Fabbri1; Maria Rosaria Capobianchi2; Andrea Antinori1 and
Adriana Ammassari1
1Clinical Department, National Institute for Infectious Diseases,
Rome, Italy. 2Laboratory of Virology, National Institute for Infectious
Diseases, Rome, Italy. 3Epidemiology Department, National Institute
for Infectious Diseases, Rome, Italy. 4Antiretroviral Drug Monitoring
Unit, National Institute for Infectious Diseases, Rome, Italy
Introduction: Optimal therapy for PHI is unknown. Although INI
as fourth drug has often been used, RCT failed to demonstrate
virological benefit in respect to conventional cART. Aim was to
compare virological efficacy of (TDFFTC) with darunavir/ritonavir
800/100 mgraltegravir 400 mg BID (DRV/rRAL) BID or dolute-
gravir 50 mg QD (DTG) for PHI therapy.
Methods: SIREA is a monocentre, prospective, observational study.
PHI patients were treated consecutively with TDF/FTC associated
with DRV/rRAL (July 2013 to May 2015) or DTG (May 2015 to April
2016). Follow-up was until first virological response (VR) defined as
HIV RNA 40 copies/mL or death, last observation, whichever came
first. Factors associated with HIV RNA 40 copies/mL during the first
year were evaluated from fitting Cox proportional hazard regression
model retaining significant variables at univariable analysis
(pB0.10).
Results: Eighty-seven patients: males 94.2%, mean age 34 years. HIV
diagnosis was 6 days before (range 410) and acquired by MSM
78.2%, heterosexual 19.5%, IVDU 2.3%. Fiebig: II/III 28.7%, IV 32.5%,
V 15.0%, VI 23.7%. Median baseline (BL): HIV RNA log 5.5 copies/mL
(IQR 4.66.6), HIV DNA x106 PBMC log 4.1 (IQR 3.74.8), CD4 570/
mm3 (IQR 387739). cART contained DRV/rRAL in 63 (72.4%)
cases and DTG in 24 (27.6%). At GRT, no resistance mutations to the
prescribed drugs were found. BL characteristics, particularly HIV RNA
(5.8 (95% CI 5.16.7) log copies/mL for DRV/rRAL vs. 5.1 (4.16.4)
for DTG; p0.12) and HIV DNA (4.2 (3.74.8) log copies/106
PBMC for DRV/rRAL vs. 4.1 (3.84.8) for DTG; p0.90), were not
different between groups. During 296 PYFU 79 patients (90.1%)
achieved VR, response rate for DRV/rRAL 22.5 x100 PYFU (95% CI
17.429.1) and for DTG 57.7 (95% CI 37.289.4) (pB0.001) (Figure 1).
No grade 34 adverse events were seen. In multivariable analysis, BL
Abstract P053Figure 1. Proportion of patients reaching HIV RNA 40 copies/mL at various time points.
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HIV RNA (OR 0.60; 95% CI 0.480.75; pB0.001) and BL CD4 350
500 versus 500/mm3 (OR 0.41; 95% CI 0.220.74; p0.003) were
associated with reduced risk of VR. On the contrary, BL CD4/CD8 1
versus B1 (OR 2.22; 95% CI 1.283.85; p0.004) and DTG versus
DRV/rRAL (OR 3.42; 95% CI 1.836.42; pB0.001) had a higher
chance for VR. Age, gender, transmission mode, Fiebig and days from
diagnosis were not associated.
Conclusions: In PHI, a three-drug cART based on DTG(TDFFTC)
seems to perform better than a four-drug therapy with DRV/r
RAL(TDFFTC) in time to achieve HIV RNA 40 copies/mL in the
first year. Besides potency, also lower pill burden and simpler
schedule may have contributed. Results have to be taken cautiously
because of potential confounder by indication and prescription bias.
TREATMENT STRATEGIES - TARGET
POPULATIONS: EXPERIENCED PATIENTS
P054
Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV)
in treatment-experienced HIV-infected patients: preliminary
results at 24 weeks of the DORIVIR study
Rosario Palacios1; Marisa Mayorga2; Carmen-Marı´a
Gonza´lez-Domenech1; Carmen Hidalgo-Tenorio3; Carmen Ga´lvez4;
Leopoldo Mun˜oz-Medina3; Javier de la Torre5; Ana Lozano6;
Manuel Castan˜o2; Mohamed Omar7 and Jesu´s Santos1
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Universitario Granada, Granada, Spain. 4UGC Enfermedades
Infecciosas, Hospital Torreca´rdenas, Ma´laga, Spain. 5UGC
Enfermedades Infecciosas, Hospital Costa del Sol, Ma´laga
Spain. 6UGC Enfermedades Infecciosas, Hospital de Poniente,
Almerı´a, Spain. 7UGC Enfermedades Infecciosas, Hospital de Jae´n,
Jae´n, Spain
Introduction: DTG/RPV is a two-pill nucleoside reverse trans-
criptase inhibitor (NRTI) and protease inhibitor (PI)-sparing regimen
with very good tolerance. It is currently in phase 3 clinical trials being
developed as two-drug ‘‘maintenance therapy’’. The aim of
this study is to analyze the efficacy and safety of this regimen
in HIV-infected patients who switched from any other ART com-
bination.
Methods: Open-label, multicentre, non-controlled study in seven
hospitals from Andalusia, southern Spain. Patients who switched
from any regimen to DTG/RPV from February 2015 to February 2016
were included. Epidemiological, clinical and antiretroviral data in
addition to immediate reasons for switching were collected. Lipids,
liver and renal tests were measured at baseline and at 24 weeks. The
primary endpoint was the proportion of patients with plasma HIV
RNA B50 copies/mL at 24 weeks (missingfailure), and secondary
endpoints included adverse events and rate of discontinuation
related with adverse events of dual therapy after switching and
metabolic changes at 24 weeks.
Results: Hundred and five patients started DTG/RPV during the
study period: 82 (78.1%) virologically suppressed, 22 (20.9%) non-
virologically suppressed (eight failures and 14 restart of ART) and
one naı¨ve, who was not included for analysis. There were 70.5%
men, mean age was 51.9 years, mean time of HIV infection 214.7
(IQR 140.4288.9) months, and mean time on the prior ART was
37.0 (IQR 7.868.2) months. The most frequent reasons for
switching were toxicity or intolerance (41.9%), convenience (27.6%)
and drugs interactions (17.1%). Prior regimens were based on PI
(56.9%), integrase inhibitors (26.5%) or non-NRTI (16.7%). At this
time 85 patients have completed 24 weeks and all were still taking
the same regimen, 82 (96.5%) of them with undetectable viral
load; the three cases with detectable HIV RNA (532, 316 and 75
copies/mL, respectively) were not considered virological failures.
Mean CD4 cells count increased (622 vs. 552 cells/mL; p0.008),
and a mean decrease in fasting triglycerides (34.6 mg/dL;
p0.005) and glomerular filtration (5.2 mL/min; p0.004)
were observed, with no changes detected in total cholesterol,
HDL-c, LDL-c, creatinine and GPT. No patient stopped DTG/RPV due
to adverse events.
Conclusions: DTG/RPV is effective and safe in a cohort of patients
with long time of HIV infection and prior ART. Most patients changed
from more complex regimens. Toxicity, intolerance, convenience and
interactions were the main reasons for changing. At 24 weeks lipid
profile improved with a decrease in triglycerides.
P055
Efficacy, safety and patient-reported outcomes from
treatment-experienced subjects in routine clinical practice
switching to EVG/COBI/FTC/TAF (GenvoyaAˆ†): the German
TAFNES cohort
Benjamin Schleenvoigt1; Heiko Jessen2; Michael Waizmann3;
Ramona Pauli4; Ansgar Rieke5; Nils Postel6; Thomas Heuchel7;
Christian Schulz8; Markus Mueller9; Arend Moll10;
Christoph Stephan11; Christoph Spinner12; Richard Haubrich13;
Marion Heinzkill14; Carolin Wieszner14 and Hans-Juergen Stellbrink15
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4Gemeinschaftspraxis Becker/Pauli, Munich, Germany.
5Gemeinschaftsklinikum Koblenz-Mayen, Kemperhof, Koblenz,
Germany. 6Prinzmed, Munich, Germany. 7MEDCENTER,
Medizinisches Versorgungszentrum, Chemnitz, Germany. 8Otto-von-
Guericke, Universita¨tsklinikum, Magdeburg, Germany.
9Gemeinschaftspraxis Dres., Ulmer, Frietsch, Mueller, Roll
Stuttgart, Germany. 10Praxiszentrum Kaiserdamm, Berlin
Germany. 11HIV Center, Universita¨tsklinikum Frankfurt, Frankfurt,
Germany. 12University Hospital, Klinikum der Rechts der Isar
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Introduction: Tenofovir alafenamide (TAF), a novel prodrug of TFV
with equal virologic potency of TDF and 91% lower circulating levels
of plasma TFV and fewer off-target effects on renal and bone, was
approved based on large controlled clinical trials of antiretroviral
therapy (ART) naı¨ve and experienced subjects. As no data are
available in patients in routine clinical practice, TAFNES was
developed to evaluate the effectiveness and safety of TAF-based
regimens, starting with Genvoya† (EVG/COBI/FTC/TAF), the first
approved combination including TAF, in treatment-experienced (TE)
and treatment-naı¨ve (TN) HIV-infected patients.
Methods: TAFNES is an ongoing prospective, observational cohort
study, which planned to enrol approximately 150 TN and 150 TE
adult subjects initiated or switched to Genvoya† (EVG/COBI/FTC/
TAF) in routine clinical practice in accordance with the summary of
product characteristics (SmPC). Of clinical outcome variables, only
data assessed during the usual management of patients were
captured in the electronic case report form (eCRF). Self-reported
health-related quality of life (HRQOL) was evaluated using the SF-36,
HIV symptom index (SI) and HIV treatment satisfaction (TS)
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questionnaires. Here we present preliminary results in TE patients
with 3-month follow-up at time of data analysis.
Results: The analysis population consists of 115 TE patients without
documented baseline resistance to any component of EVG/COBI/
FTC/TAF and with available follow-up data at month 3. The
corresponding baseline characteristics, including reasons for treat-
ment switch, are shown in Table 1. The majority of patients (90%)
were switched from TDF-containing ART (55% from EVG/COBI/FTC/
TDF) with 67% exposed to TDF for ]1 year; 64%, 15% and 15% had
been on INI-, NNRTI- or PI-based ART (3% NRTI-sparing, 4% other);
91% of patients (104/114) were switched from suppressed ART (HIV
RNA B50 copies/mL). Estimated GFR (MDRD; mL/min/1.73 m2) and
creatinine clearance (CrCl; Cockroft-Gault; mL/min) were B60 in
8.0% and 9.4%, respectively. At month 3, HIV RNA was B50 copies/
mL in 90% of patients (94/104; as-treated analysis). Median changes
in serum creatinine and CrCl (eGFR) were 0.0 mg/dL and 0.2 mL/
min (0.1 mL/min/1.73 m2) (pn.s.), respectively. Overall, HIV SI
significantly decreased (2.2 (mean), p0.046); mean changes
in SF-36 mental (1.9) and physical scores (0.2) were non-
significant. The mean post-BL TS change of 14.4 (general
satisfaction/clinical subscale 7.5; lifestyle/ease subscale 6.9)
reflected a significant improvement, overall, irrespective of previous
ART (pB0.001).
Conclusion: Of the treatment-experienced patients switching to
Genvoya† (EVG/COBI/FTC/TAF), 55% switched from Stribild† (EVG/
COBI/FTC/TAF) and 45% from other regimens. While eGFR and CrCl
remained stable in this preliminary analysis of 3-month follow-up
data, HIV symptom index and treatment satisfaction improved
significantly.
P056
Frailty improves in both young and old HIV patients
undergoing atazanavir-based regimens
Giovanni Guaraldi; Andrea Malagoli; Giovanni Dolci; Federica Carli;
Marianna Menozzi; Antonella Santoro; Stefano Zona and
Cristina Mussini
Infectious Diseases Unit, University of Modena and Reggio Emilia,
Modena, Italy
Introduction: Biologic ageing is a stochastic process that can be
characterized by the number of health deficits individuals accumu-
late. Probabilities of health transitions with age can be summarized
using a transition model based on the frailty index (FI). Though
health generally worsens with age, the relationship between ageing
and health is dynamic, and periodic improvement and stability in
Abstract P055Table 1. Baseline characteristics in TE experienced patients
Previous ART
EVG/COBI/FTC/TDF
(Stribild†, STB)
TDF-based ART
(not STB) Non-TDF-based ART
N (%) 63 (54.8) 41 (35.7) 11 (9.6)
Male gender, n (%) 60 (95.2) 36 (87.8) 10 (90.9)
White race, n (%) 59 (93.7) 36 (87.8) 11 (100.0)
Median age, years (IQR)a 41 (3452) 46 (3554) 56 (4864)
Age B50 years, n (%)a 44 (69.8) 24 (58.5) 3 (27.3)
Median CD4 count, cells/mL (IQR) 648 (480886) 671 (519892) 678 (609915)
HIV RNA level B50 cp/mL, n (%) 57 (91.9) 37 (90.2) 10 (90.9)
Reasons for switch to E/C/F/TAF, n (%)
(multiple responses allowed)
Simplification of ART 13 (20.6) 22 (53.7) 4 (36.4)
Patients preference 25 (39.7) 18 (43.9) 2 (18.2)
Side effects of current ART 22 (34.9) 21 (51.2) 6 (54.5)
Other 8 (12.7) 3 (7.3) 2 (18.2)
Median serum creatinine, mg/dL (IQR) (range) 1.0 (0.91.1) (0.62.4) 1.0 (0.91.2) (0.51.7) 1.1 (0.81.2) (0.71.5)
Median eGFR (MDRD), mL/min/1.73m2 (IQR)
(range)
87 (76100) (34145) 84 (6992) (45219) 79 (66107) (50123)
eGFR (MDRD)B60 mL/min/1.73m2, n (%) 4 (6.6) 4 (10.0) 1 (9.1)
Median CrCl (Cockroft-Gault), mL/min (IQR) (range) 102 (84122) (38162) 92 (74114) (46179) 99 (62118) (53235)
CrCl (Cockroft-Gault)B60 mL/min, n (%) 4 (7.0) 5 (12.8) 1 (10.0)
Mean SF-36 score mental component (9SD)b 45.4 (12.0) 41.5 (13.9) 44.7 (15.2)
Mean SF-36 score  physical component (9SD)a,b 56.0 (6.9) 51.3 (11.9) 47.0 (11.8)
Mean HIV SIc (9SD) 14.0 (13.7) 18.3 (15.1) 18.7 (12.9)
Mean HIV TS score (9SD) 50.7 (10.5) 49.0 (9.8) 51.9 (5.5)
IQR, interquartile range; SD, standard deviation.
apB0.05 (for 3-group comparison); bnorm-based scoring, higher scores indicate higher HRQOL; crange 080, higher scores indicate more
bothering symptoms; range 060, higher scores indicate greater satisfaction.
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health are common. Useful models of biologic ageing allow for
changes in health that include improvement, maintenance and
deterioration. The objective of this analysis was to describe frailty
index change in HIV patients, below and above the age of 50 years,
undergoing effective atazanavir (ATV)-based regimens.
Materials and methods: Design: Secondary analysis of prospec-
tive cohort data. We analyzed baseline and 4-year follow-up data
from participants in the Modena HIV Metabolic Clinic cohort study,
undergoing boosted or unboosted ATV-based regimens and experien-
cing HIV viral load below 40 copies/mL. Patients were stratified
according to the duration of HIV infection (20, 1020 and B10
years). Frailty was quantified using a 31-item frailty index. The
outcome measure was probability to reduce frailty index score
B0.3 which identify the transition from a frail to a fit health status.
Results: A total of 406 patients were included: 262 (64.53%)
undergoing boosted-ATV and 144 (35.47%) unboosted-ATV regimens.
Table 1 describes the study population, stratified below and above 50
years of age. In Figure 1 panel A depicts the FI change in the follow
up period and panel B shows the logistic regression model to identify
predictors of a frail to fit health status transition.
Discussion: HIV patients on stable ATV-based regimen experience
improvement in health status depicted by a reduction in FI. Longer
duration of HIV infection and baseline frailty index but not age or
boosted versus unboosted ATV regimen were associated with a frail
to fit health status transition. This study underlines the versatility of
ATV-based regimens in both younger and older HIV patients with
different spectrum of health profile.
P057
High-level HIV drug resistance mutations in patients with
unsuppressed viral load from Northern South Africa
Elizabeth Etta1; Cecile Manhaeve2; Keanan McGonigle1;
David Rekosh1; Marie-Louise Hammarskjold1; Denis Tebit3 and
Pascal Bessong4
1Microbiology/ Infectious Diseases, University of Virginia,
Charlottesville, VA, USA. 2Microbiology, Bela-Bela Clinic, HIV/AIDS
Prevention Group, Polokwane, South Africa. 3Microbiology/Infectious
Diseases & Cancer Biology, University of Virginia, Charlottesville, VA,
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Abstract P056Table 1. Study population, stratified below and above 50 years of age
Total B50 years 50 years p
Number of patients (%) 406 262 (64.53%) 144 (35.47%)
Age (SD) 47.91 (7.8) 43.55 (4.58) 55.85 (5.96)
Females (%) 146 (35.96%) 103 (39.31%) 43 (29.86%) 0.073
BMI (SD) 23.84 (3.59) 23.41 (3.29) 24.63 (3.97) 0.001
Pack-years (IQR) 15.81 (0.526.12) 12.75 (022.44) 17.05 (2.8833) 0.003
CD4 nadir (cells/mL) (IQR) 200 (100300) 204 (104300) 189.5 (80292.25) 0.162
Current CD4 (cells/mL) (IQR) 596 (440800) 620 (447812.5) 575.5 (431.75756.25) 0.265
CD4/CD8 (SD) 0.8 (0.43) 0.82 (0.43) 0.77 (0.44) 0.089
ART exposure (months) (IQR) 34.5 (1260) 39.5 (15.2564.75) 21 (949.5) 0.003
CVD (%) 19 (4.68%) 7 (2.67%) 12 (8.33%) 0.001
Hypertension (%) 139 (34.24%) 68 (25.95%) 71 (49.31%) 0.001
Osteoporosis (%) 83 (20.44%) 38 (14.5%) 45 (31.25%) 0.001
Diabetes (%) 48 (11.82%) 15 (5.73%) 33 (22.92%) 0.001
CKD (%) 42 (10.34%) 12 (4.58%) 30 (20.83%) 0.001
Cancers (%) 32 (7.88%) 13 (4.96%) 19 (13.19%) 0.001
Multimorbidity (%) 32 (7.88%) 4 (1.53%) 28 (19.44%) 0.001
Frailty index (SD) 0.34 (0.1) 0.33 (0.1) 0.37 (0.09) 0.001
Abstract P056Figure 1. (a) FI change in the follow-up period; (b) logistic regression model to identify predictors of a frail to fit health status
transition.
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Introduction: Access to cART has significantly improved in the
developing world, with significant reduction in morbidity and
mortality. However, the sustainability of cART may be compromised
by development of drug resistance as evidenced by unsuppressed
viral load. The current study examined drug resistance mutations
(DRMs) in individuals under first-line cART with suspected unsup-
pressed viral load.
Materials and methods: Sixty patients on first-line cART were
recruited between March 2014 and September 2015, from two rural
treatment sites in Limpopo Province, South Africa if they met either
of the following criteria: 1) two consecutive viral loads measure-
ments greater than 1000 copies/mL after a previous suppression or
2) one viral load greater than 1000 copies/mL after 180 days. Nested
PCR gene products from viral RNA (plasma) and proviral DNA
(peripheral blood mononuclear cells (PBMCs)) were directly se-
quenced to determine subtype and examined for protease and
reverse transcriptase inhibitors resistance mutations according to the
Standard HIV Drug Resistance Interpretation Algorithm.
Results: Sequences obtained from 57 patients were examined for
subtype and DRMs. Fifty-two (91.2%) of the 57 were HIV-1 subtype C
in the polymerase gene with one each (1.8%) of subtype B, K/C, C/B
recombinants and unclassified. These 52 (91.2%) patients harboured
at least one major DRM which were distributed as follows: NRTI
(n13; 25.0%), NNRTI (n17; 32.7%) and PI (n3; 5.7%). The most
common mutations were M184V (56%), K103N (50%), V106M
(17.3%), K65R (11.5%), D67N (9.6%). Mutation scores suggest that
the viruses were mostly resistant to 3TC, FTC and NVP, and most
susceptible to d4T, TDF and AZT. Two subjects with viral load of 1000
copies/mL carried DRM in PBMC but not in plasma.
Conclusion: A very high prevalence of drug resistance-associated
mutations was recorded in patients still on first-line cART. The
differences in circulating DRM in plasma and PBMCs in some subjects
suggest the presence of archived drug resistant variants. PBMC is
therefore an interesting compartment for analyzing the dynamics of
drug resistance in a given patient.
P058
Real-life experience of switching to protease inhibitor-based
dual antiretroviral therapy (PIDAT)
Neal Marshall1; Marie McNulty2; Colette Smith3; Leonie Swaden1;
Fiona Burns1 and Chloe Orkin2
1Ian Charleson Centre for HIV Medicine, Royal Free London NHS
Foundation Trust, London, UK. 2Department of HIV Medicine, Bart’s
Health NHS Trust, London, UK. 3Infection and Population Health,
University College London, London, UK
Introduction: PI-based dual antiretroviral therapy (PIDAT) strategies
in suppressed patients have shown variable virological efficacy,
depending partly on accompanying drug class choice. We reviewed
outcomes of PIDAT switches within two metropolitan HIV centres.
Materials and methods: Retrospective evaluation of all patients
switching to a boosted protease inhibitor (bPI) with a drug from
another ARV class from 1 January 2009 till 1 July 2014 with
subsequent follow-up until 1 June 2016. Baseline demographics
and treatment history were identified, with follow-up data at 48 and
96 weeks. Primary analysis included percentage remaining on any
PIDAT strategy (i.e. switch within paradigm allowed), with secondary
analysis considering any change of ART in the PIDAT regimen as a
switch. Data were analyzed using Fisher’s exact test.
Results: Of 255 patients identified, 239 (94%) and 226 (89%)
remained under follow-up at 48 and 96 weeks, respectively. Hundred
and ninety-nine (78%) were male, 171 (67%) white ethnicity, 167
(65%) MSM, with median age and time on ART of 47 and 12.1 years,
respectively. Seventy-seven percent (196) had VL B50 copies/mL at
switch with median (IQR) CD4 count 632 (439839) cells/mm3 and
nadir CD4 125 (32207). Two hundred and twenty-six of 255 (89%)
switched from PI-based ART with 64 (25%) switched or intensified
from another nucleoside-sparing regimen, including 36/255 (14%) PI
monotherapy. NNRTI-based PIDAT was initiated in 103 (40%)
patients, 87/103 (84%) with etravirine. Maraviroc was used for 81/
255 (32%), 50 (20%) a NRTI (30/50 as 3TC or FTC) and 21 (8%) with
raltegravir. Darunavir/r was used in 196 (77%) cases. At 48 and 96
weeks respectively, 177/210 (84%) and 145/184 (79%) remained on
any PIDAT regimen with VL B50 copies/mL respectively (switch from
PIDATfailure, missingexcluded). Using ITT for the initial PIDAT
regimen, 188/210 (90%) and 169/184 (92%) were VL B50 copies/mL
at 48 and 96 weeks. There were statistically significant differences in
VL outcomes by choice of second ARV at both time points (Table 1),
with no differences by CD4 nadir. Nineteen of 239 (8%) and 42/226
(19%) discontinued PIDAT by 48 and 96 weeks, respectively, 9/19
(47%) and 22/42 (52%) with VL 50 copies/mL and 2/226 with
available genotypes demonstrating emergent resistance by 96 weeks
(Y181C on DRV/r/ETR at week 39, and K103N, V106A on LPV/r/NVP
at week 20).
Abstract P058Table 1. Switch and VL outcomes of individuals starting PI/r-based dual therapy regimens
Second ARV
N starting
ARV (%)
48 weeks
(n239)
96 weeks
(n226)
ITT: VL B50
copies/mLa
On PIDAT and VL
B50 copies/
mLb
On specific PIDAT
regimen and VL
B50 copies/mLc
ITT: VL B50
copies/mLa
On PIDAT and VL
B50 copies/
mLb
On specific PIDAT
regimen and VL
B50 copies/mLc
p0.0013 p0.005 p0.02 p0.60 p0.004 p0.03
CCR5 inhibitor 81 62/69 (90%) 58/69 (84%) 57/69 (83%) 56/62 (90%) 45/62 (73%) 43/62 (69%)
INSTI 21 7/13 (54%) 6/13 (46%) 6/13 (46%) 6/7 (86%) 2/7 (29%) 2/7 (29%)
NNRTI 103 89/94 (95%) 84/94 (89%) 80/94 (85%) 77/82 (94%) 71/82 (87%) 65/82 (79%)
NRTI 50 30/34 (88%) 29/34 (85%) 29/34 (85%) 30/33 (91%) 27/33 (82%) 25/33 (76%)
aAmong all with available VL measurement, ignoring ART changes; bnumerator is number with VL B50 copies/mL who remain on PIDAT strategy,
denominator is those under follow-up with available VL measurement at 48/96 weeks; cnumerator is number with VL B50 copies/mL who
remain on original specific PIDAT regimen, denominator is those under follow-up with available VL measurement at 48/96 weeks.
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Conclusions: Real-life outcomes of PI-based dual ARV therapy appear
broadly favourable in clinical practice. The ongoing utility of this
paradigm in the advent of TAF and PI-sparing regimens is unclear.
P059
Long-term virological outcomes of replacing zidovudine or
stavudine with tenofovir in the absence of routine
virological monitoring in Kumasi, Ghana
Giovanni Villa1; Richard Odame Phillips2; Colette Smith3;
Alexander Stockdale1; Apostolos Beloukas1; Lambert Tetteh Appiah4;
David Chadwick5; Alessandra Ruggiero1; Fred Stephen Sarfo2 and
Anna Maria Geretti1
1Institute of Infection and Global Health, University of Liverpool,
Liverpool, UK. 2Department of Medicine, Kwame Nkrumah University
of Science and Technology and Komfo Anokye Teaching Hospital,
Kumasi, Ghana. 3Infection and Population Health, University College
London, London, UK. 4Department of Medicine, Komfo Anokye
Teaching Hospital, Kumasi, Ghana. 5Centre for Clinical Infection,
James Cook University Hospital, Middlesbrough, UK
Introduction: Whilst access to ART is successfully expanding in Africa,
long-term outcomes remain poorly investigated. This study ad-
dressed the outcomes of introducing tenofovir (TDF) in place of
zidovudine (ZDV) or stavudine (d4T) among Ghanaian adults
receiving HIV care in the absence of routine virological monitoring
and determined the associated clinical and psychosocial dimensions.
Methods: The Hepatitis B Infection in Kumasi (HEPIK) study has
prospectively followed HIV/HBV co-infected adults since 2010. This
cross-sectional analysis comprised subjects that had previously
started ZDV or d4T plus lamivudine and efavirenz or nevirapine,
and at the time of HBV diagnosis (T0), replaced ZDV or d4T with TDF
in the absence of virological monitoring. A median of 7.9 (IQR 6.0
9.2) years after starting ART and 4.0 (3.84.1) years after introducing
TDF (T1, November 2015), patients were invited to attend for
assessment, including HIV-1 RNA load, and offered a researcher-
administered questionnaire about adherence (visual analogue scale
and targeted questions); socio-economic, social support and dis-
closure status; and physical and mental health. Plasma viral load at
T0 was determined retrospectively using stored (808C) samples.
Results: A total of 101/180 (56%) invited participants (66% females)
attended the T1 assessment. Of the remaining, 47 (26%) were no
longer contactable (]3 attempts), 17 (9%) declined to attend and 15
(8%) had died. At T1, mean age was 45 (99) years; 90% were still
receiving efavirenz (n87) or nevirapine (n4); 10% were on
lopinavir/ritonavir (LPV/r). CD4 counts were median 572 (383716)
cells/mm3. Suboptimal adherence was reported by 42% of partici-
pants; in univariable analysis, it was more prevalent among men
(pB0.01), those in a relationship (p0.02) and those with higher
socio-economic status (p0.04). Moderate-to-severe depression/
anxiety was reported by 27%; 64% described moderate-to-severe
physical distress. HIV-1 RNA was detectable (40 copies/mL) in
21%, and 1000 copies/mL in 14%, with median levels of 4.2 (2.1
5.1) log10 copies/mL. In univariable analysis, predictors of lack of
virological suppression comprised the CD4 cell count at diagnosis
(p0.03), T0 viral load (p0.05), suboptimal adherence (pB0.01),
lack of partner disclosure (pB0.01) and LPV/r use (p0.03). Lack of
virological suppression was also associated with lower T1 CD4 cell
counts (pB0.01). There was no association with socio-economic/
social support status, or physical/mental health.
Conclusion: One in five subjects receiving long-term ART showed
suboptimal virological suppression with reduced CD4 cell count
recovery. The findings highlight the importance of viral load testing at
key management time points, coupled with targeted interventions to
support adherence and facilitate partner disclosure.
P060
Non-adherence in HIV patients is caused by specific
reasons: results from the German adherence cohort study
Johanna Boretzki1; Carmen Wiese2; Celia Oldenbuettel2;
Ivanka Krznaric3; Anja Meurer4; Alexander Zink5; Christian Lersch1;
Annamaria Balogh6; Eva Wolf6 and Christoph Spinner1
1Department of Medicine II, University Hospital Klinikum rechts der
Isar, Munich, Germany. 2Private Practice, MVZ Karlsplatz, Munich,
Germany. 3Private Practice, Zentrum fu¨r Infektiologie Berlin, Berlin,
Germany. 4Private Practice, Zentrum fuer Innere Medizin und
Infektiologie, Munich, Germany. 5Department of Dermatology and
Allergology, University Hospital Klinikum rechts der Isar, Munich,
Germany. 6MUC Research, Munich, Germany
Introduction: Adherence to antiretroviral treatment (ART) in HIV
patients plays a crucial role for treatment success. Our study aimed
to identify reasons for non-adherence in a large HIV cohort, including
known subjects with difficulties in ART adherence.
Methods: A cross-sectional, non-interventional, multicentre adher-
ence study in treated HIV-infected patients from September 2014 to
April 2015 in Germany was performed after ethic committee’s
approval. Study physicians were asked to recruit patients from all
adherence levels and perform an adherence assessment for each
subject (good, unstable or poor adherence). Questionnaires based on
the SMAQ-MASRI-Hybrid [1] were given to the patient and treating
physician to evaluate factors associated with poor adherence.
Covariables of interest were age, sex, time since HIV diagnosis,
time on ART, current ART regimen, transmission route, comorbidity,
HIV-1 RNA viral loads (VLs) and CD4 cell count. Furthermore, specific
reasons for non-adherence were assessed. For statistical analysis,
extended Fisher’s exact test and KruskalWallis test were used.
Abstract P060Table 1. Overview of questionnaire items and correlation with adherence levels
‘‘Good adherence’’
(n162)
‘‘Unstable
adherence’’ (n36)
‘‘Poor adherence’’
(n17)
p-value (Fisher’s
exact test)
The ART intake reminds me of my disease n7 (4.3%) n4 (11%) n5 (29%) B0.01
I want to go out/I think my medication does not go well
with alcohol/party drugs
n3 (1.9%) n5 (14%) n4 (24%) B0.01
I’m afraid that others see me taking the ARTmedication n4 (2.5%) n4 (11%) n2 (12%) 0.019
I think that the ART dose is too high n3 (1.9%) n4 (11%) n1 (5.9%) 0.037
Sometimes the copayment fee to my ART is too much
for me/other financial reasons
n2 (1.2%) n3 (8.3%) n1 (5.9%) 0.037
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Results: A total of 215 patients were included: 80% male, median
age 47 years (IQR 3754), median time since HIV diagnosis 9 years
(IQR 418) and median CD4 cell count 607 c/L (IQR 410850). HIV
transmission risk was as follows: 50% men having sex with men, 14%
origin of high prevalence countries (HPC), 7% intravenous drug use
(IVDU), 13% other and 19% unknown. Subjects were grouped by
physicians’ adherence assessment: A, ‘‘good adherence’’ n162;
B, ‘‘unstable adherence’’ n36; C, ‘‘poor adherence’’ n17.
Physicians’ assessment of poor adherence correlated in univariate
analyses with lower median age (A: 48 years vs. B: 42 vs. C: 46,
p0.020), origin of HPC (A: 11% vs. B: 19% vs. C: 29%, pB0.01),
IVDU (A: 1.9% vs. B: 22% vs. C: 24%, pB0.01), hepatitis C infection
(A: 3.7% vs. B: 17% vs. C: 5.9%, p0.013), psychiatric disorders (A:
25% vs. B: 42% vs. C: 48%, p0.03), longer time since HIV diagnosis
(A: 9 years vs. B: 10 vs. C: 19, pB0.01), longer time on ART (A: 6
years vs. B: 5 vs. C: 14, p0.022), AIDS-defining events (A: 6.8% vs.
B: 25% vs. C: 24%, pB0.01), prescription of a protease inhibitor (A:
28% vs. B: 47% vs. C: 71%, pB0.01), higher median VL (A: 19 copies/
mL vs. B: 49 vs. C: 4824, pB0.01) and lower median CD4 cell count
(A: 680 c/L vs. B: 503 vs. C: 315, pB0.01). Sex, comedication and pill
burden were not significantly associated. Physicians’ assessment of
poor adherence correlated in univariate analyzes with self-reported,
specific reasons (Table 1).
Conclusion: Adherence evaluation remains challenging. Frequent
self-reported reasons for non-adherence were reminding of disease,
concerns about interaction between ART and alcohol/party drugs
and HIV stigma. A good patientprovider relationship is needed to
face those topics and to remove common barriers to adherence.
Reference
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TREATMENT STRATEGIES - TARGET
POPULATIONS: IDUs
P061
Prevalence of HIV virological failure in a multidisciplinary
centre treating high-risk vulnerable populations
Arshia Alimohammadi; Tyler Raycraft; Ghazaleh Kiani; Rajvir Shahi;
Arpreet Singh; Syune Hakobyan and Brian Conway
Clinical Research, Vancouver Infectious Diseases Centre, Vancouver,
Canada
Introduction: The introduction of new ART has considerably in-
creased the efficacy of HIV regimens and decreased mortality rates
associated with the infection [1,2]. However, adherence to even the
simplest and most effective regimens remains challenging in people
who inject drugs (PWID) [2], and this often limits their access to
treatment as compared to ‘‘lower risk’’ populations [3]. Provision of
care in a dedicated multidisciplinary setting may help increase
success of HIV treatment in this population.
Methods: An observational, retrospective study was conducted
among HIV-infected patients seen at the Vancouver Infectious
Diseases Centre (VIDC), including all PWID who received HIV therapy.
All individuals had access to multidisciplinary care to address
medical, psychiatric, addiction-related and social needs with main-
tenance in long-term follow-up at our centre. Virological failure was
defined as initial suppression of HIV viral load, followed by a
confirmed measure 200 copies/mL, comparing PWID and non-
PWID in this analysis.
Results: Since 2013, 521 HIV patients have initiated treatment at
VIDC, with a mean age of 51.6 years, 11% female. Overall, 179 (32%)
are active PWID or have a history of recent injection drug use, with
HIV/HCV co-infection prevalence of 94% in this subgroup. Within the
PWID population, 63% used heroin, 59% used cocaine, 70% used
other stimulants and 49% were on opiate substitution therapy. In
total, rates of virological suppression were 77% and 84% in PWID and
non-PWID subgroups (pB0.05). Only five (3%) PWID and two non-
PWID (0.6%) experienced true virological failure while on treatment.
All individuals who experienced virological failure were switched to
new regimens and subsequently achieved virological suppression.
Conclusion: When HIV care and treatment are implemented within a
multidisciplinary setting, high-risk populations are highly likely to
achieve HIV RNA suppression, at rates nearly comparable to those
achieved in the general HIV-infected population. Those who did not
were all successfully treated with readily available second-line
regimens. Novel models of care will be needed to allow HIV-infected
PWID to achieve the promise of ‘‘909090’’ within the global
response to the HIV pandemic.
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P062
Methadone maintenance treatment and efficiency of ART in
HIV-positive injecting drug users in Ukraine
Dmytro Zhyvytsia and Vitali Kazeka
Department of Infectious Diseases, SI Zaporizhia Medical Academy of
Post-Graduate Education Ministry of Health of Ukraine, Zaporizhia,
Ukraine
Introduction: The current state of the HIV epidemic process in
Ukraine is characterized by the prevalence of HIV among different
contingents of the population, especially among people who belong
to the high-risk groups and by change in the dominant routes of HIV
transmission. Although the most common way of HIV transmission
is the sexual one, injecting is still the most important in its impact
on the epidemic. The study evaluated the impact of methadone
maintenance treatment (MMT) on efficiency of ART in HIV-infected
injecting drug users (IDUs).
Materials and methods: The study included 65 HIV IDUs who were
divided into two groups. First group included 33 HIV IDUs who were on
MMT. The average time of MMT was 23.7 months (160). The second
group included 32 HIV IDUs who did not receive MMT. The average age
of patients was 37 years (2452). There were 16 (25%) women and 49
(75%) men. The average level of viral load in the studied groups of
patients was not statistically different, and in the first group it was 4.89
(4.15.2) log copies/mL, in the second 5.0 (4.25.6) log copies/mL.
After the enrollment in the study, the ART has been prescribed to all
patients in accordance with the Ukraine clinical protocol.
Results: After 6 months of ART, the proportion of patients with
complete suppression of HIV (HIV RNA1 B50 copies/mL) in the
first group was higher than in the second group; however, this dif-
ference was not significant (75.8% and 61.3%, respectively, p0.21).
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When assessing efficiency of ART after 12 months of observation, the
significantly higher (pB0.01) percentage of patients in the first group
who achieved a complete viral suppression compared with the second
group were 93.9% and 58.1%, respectively. In the second group of
patients within 612 months of treatment, there was a decrease in
the proportion of patients with virologic efficiency of ART  from
61.3% to 58.1% of patients with the full viral suppression.
Conclusions: The study indicates that the use of MMT in HIV-infected
IDUs greatly increases the efficacy of ART, which can be associated
with a significant increase in adherence to the treatment in this
category of patients with mental and behavioural disorders due to
the use of psychoactive substances containing opioids.
P063
Community pharmacy dispensed ART alongside opiate
replacement therapy in Glasgow’s HIV outbreak
Seija Erica Peters1; Kathryn Brown2; Amanda Laird3;
Robert Gillespie4; David Thomson5 and Catriona Milosevic6
1Brownlee Centre, Gartnavel General Hospital, Glasgow, UK.
2Brownlee Centre Pharmacy, Gartnavel General Hospital, Glasgow,
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Introduction: There is currently an outbreak of HIV in people who
inject drugs (PWID) in Glasgow, UK. Improved access to care/ART is
essential for individuals, and for reduction of onward transmission.
Traditionally, ARV medication is prescribed and dispensed via a
hospital-based service. Patients are required to attend a single
hospital in the city for HIV care. Addiction services including opiate
replacement therapy (ORT) are well developed in Glasgow inclusive
of homelessness. We developed a method of delivering ART along-
side opiates using community pharmacies. We describe the devel-
opment process and will present the first 6 months of this project.
Materials and methods: One strategy to manage this outbreak
was to improve access to clinical care and ART. Our hospital HIV
pharmacist led a group to develop pathways for ARV dispensing via
community pharmacies. This was done in consultation with commu-
nity and hospital pharmacies, drug companies, hospital and addiction
healthcare workers. A funding model was agreed. An HIV liaison
nurse from the hospital but working in the community facilitates
patient engagement. An HIV nurse-led clinic has been set up in the
homeless health centre to support monitoring. Prescriptions are
generated from the hospital physician and the patient receives the
medication from the pharmacy. There is no restriction on ARV choice.
ART is dispensed daily with patients receiving supervised consump-
tion if required. Patients requiring a twice-daily regimen are provided
with the second dose to take at home. The patient does not have to
attend the hospital. Checks are in place to inform prescribers of poor
adherence/disengagement in care.
Results: A total of 79 patients’ records have been reviewed to see if
they would potentially benefit from community prescribing. Most
report a history of homelessness and have links with addiction
services. We will present: (1) a description of the model of care
including monitoring and safety checks, (2) evaluation of the first
6 months of patient data from April 2016.
Conclusions: ART has individual and public health benefits. For
PWID, traditional models of hospital-based care can be challenging.
Homelessness limits engagement in care. Addiction services and
involvement of the community pharmacy network with this patient
group are well established in Glasgow. Adapting our ARV prescribing
to fit in with existing community ORT models may improve access to
ART and HIV care.
P064
HIV testing and care in prisoners: the first year results of
opt-out BBV testing in Glasgow, UK
Seija Erica Peters1; Brenda Bissett2; Yvonne Cassells2; Jennifer Paton3
and Celia Aitken4
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Moss, Bishopbriggs, UK. 4Regional Virus Laboratory, Glasgow Royal
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Introduction: In Glasgow, there is an ongoing outbreak of HIV
amongst people who inject drugs (PWIDs). It is well recognized that
the prison population has high numbers of PWIDs. In Scotland, there
is a national plan for identifying and treating prisoners with HCV
[1,2]. As part of increased testing for HCV, an opt-out Blood Borne
Viruses (BBV) testing service (including HIV testing) was developed.
Barlinnie HMP is the largest prison in Scotland and centrally located
in Glasgow. It has 1200 inmates at any one time. We have
evaluated our first year figures of opt-out testing in relation to HIV.
Materials and methods: All prisoners have a medical within 24 hours
of incarceration. From April 2015, a prison nurse and healthcare
assistant saw prisoners at the same time as their medical to offer BBV
testing to them. We record the uptake of this testing monthly. We
reviewed the HIV outbreak data base to identify the number of new
HIV diagnoses from the prison sector.We retrospectively reviewed the
electronic case record for data on attendance and ARV prescribing.
Results: FromApril 2015 toMarch 2016, 1492were BBV tested. Just over
100 refused (data not collected for 3 months). If prisoners had been
tested within the last 6 months, a second test was not offered unless at
particular risk. In total, 11 cases of HIV were identified. Of that, 10
patients with HIV were seen by the BBV consultant during their
incarceration. AllwereHCVco-infectedwithonlyonebeingPCRnegative.
Seven were on prescribed opiates. Six were started on ARV therapy
within the prison. Four failed to attend any OP clinics after liberation.
Only two prisoners have attended all their appointments so far.
Conclusions: BBV testing in the prison setting including HIV testing is
a feasible way to identify infected PWIDs. This may be the first sign of
an HIV outbreak emerging in this population. HIV-positive prisoners
are usually HCV co-infected. Good links to specialist care and therapy
within the prison may encourage prisoners to test. ARV therapy can
be started early and safely. A comprehensive approach to ‘‘through-
care’’ for this population is required to address clinical engagement
after liberation. It is hoped that ARV therapy in this group may stem
the current outbreak. Further review of retention in care is required.
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Correlates of HIV virological non-suppression at a tertiary clinic
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HIV/AIDS and HCV, Vancouver Infectious Diseases Centre, Vancouver,
Canada
Introduction: We wanted to determine which variables and char-
acteristics were associated with HIV virological non-suppression at a
tertiary clinic located in Downtown Vancouver.
Materials and methods: The multidisciplinary programme developed
at the Vancouver Infectious Diseases Centre (VIDC) provides ongoing,
long-term access to specialty medical care and support services in
order to target the clinical and social factors associated with HIV
suppression and maintenance. A retrospective analysis of HIV
treatment responses was conducted to study the factors associated
with virological non-suppression.
Results: We divided the population into four separate cohorts. Group 1
(n241) included individuals who showed HIV RNA suppression and
an increase/no change in CD4 count from baseline. Within this
cohort, there were 222 males with a mean age of 50.9 years (range
2474) and 21 females with a mean age of 51.7 years (range 3363).
Group 2 (n88) included individuals who showed HIV RNA
suppression and a decrease in CD4 count from baseline. Within
this cohort, there were 73 males with a mean age of 54.5 years
(range 2282) and 15 females with a mean age of 50.1 years (range
3164). Group 3 (n9) included individuals who showed HIV RNA
non-suppression and a decrease in CD4 count from baseline. Within
this cohort, there were seven males with a mean age of 51.4 years
(range 3671) and two females with a mean age of 46 years (range
4448). Group 4 (n7) included individuals who showed HIV RNA
non-suppression and an increase/no change in CD4 count from
baseline. Within this cohort, there were seven males with a mean
age of 57.3 years (range 3473). Relevant demographic character-
istics are shown in Table 1.
Conclusions: Virological non-suppression was uncommon, but in-
dividuals in these groups showed higher rates of injection drug use,
homelessness and unemployment. CD4 cell count trajectories were
not associated with any clinical or demographic characteristics
measured in this cohort. Acting on characteristics such as drug use
and homelessness may help reduce the rate of non-response to
antiretroviral therapy in our cohort.
TREATMENT STRATEGIES: ADHERENCE
P066
The effect of relationship status and housing stability on
adherence to combination antiretroviral therapy among
people living with HIV who use illicit drugs in British
Columbia, Canada
Arpreet Singh1; Kate Salters1; Surita Parashar2; Cathy Puskas1;
Lu Wang2; Julio Montaner2; Robert Hogg2 and Hasina Samji3
1Faculty of Health Sciences, Simon Fraser University, Burnaby,
Canada. 2HIV/AIDS, British Columbia Centre for Excellence,
Vancouver, Canada. 3Epidemiology, BC Centre for Disease Control,
Burnaby, Canada
Introduction: High adherence to cART is essential for long-term viral
load suppression among people living with HIV (PLHIV). While a
variety of socio-economic, demographic and clinical characteristics
have been associated with suboptimal adherence to cART, we have
focussed on the previously unexplored association between relation-
ship status and housing stability on adherence among people who
use illicit drugs.
Methods: Sociodemographic survey data collected between July
2007 and January 2010 as part of the Longitudinal Investigation into
Supportive and Ancillary health services (LISA) cohort and clinical
data collected through the provincial Drug Treatment Program (DTP)
were used in this study. Study participants were PLHIV ]19 years of
age who used illicit drugs (heroin, crack, cocaine and/or metham-
phetamine) within 3 months prior to the interview, and currently
accessing cART, with pharmacy refill compliance data in the 6-month
period prior to the interview. Optimal adherence (]95%) was the
main outcome of interest. The main explanatory variables included
housing status (stable vs. unstable housing) and relationship status
(single/separated/divorced/widowed (SSDW) or legally married/
common law/regular partner/non-regular partner (LCRN)). Separate
logistic regression confounder models were used to determine the
effect of relationship status and housing stability on the association
between illicit drug use and adherence to cART. The combined
current crack use and relationship status variable was the main
interest in the first model, while the combined current crack use and
housing status variable was the main interest in the second model.
Confounders were controlled for in both models.
Results: This study included 405 individuals, of whom 115 (28%)
were women and 5 (1%) were transgender. A total of 261 (65%) of
participants achieved optimal adherence, 317 (78%) were currently
using crack, 208 (51%) were unstably housed and 122 (30%) were
LCRN. The first confounder model showed relationship status (LCRN
and SSDW) combined with current crack use, were significantly
associated with suboptimal adherence (aOR 2.88, 95% CI 1.226.79;
and aOR 2.42; 95% CI 1.085.42, respectively), as were current crack
use and unstable housing in the second confounder model (aOR
2.83; 95% CI 1.3326.025).
Conclusion: Relationship status and housing status did not predict
optimal cART adherence independently; however, when combined
with current crack use, they were significantly associated with
suboptimal adherence to cART. Interventions, particularly those
focussed on housing and addictions support services, need to be
targeted towards current crack users in order to remove barriers to
cART adherence.
Table 1. Socio-demographic characteristics dichotomised into
four separate cohorts to present our study population (n345)
Socio-demographic
characteristics
Group
1
Group
2
Group
3
Group
4
Ethnicity Caucasian 34 1 9 1
First Nations 10 2 8 
Other 15  9 
Risk factors Men who have sex
with men
136 4 40 3
People who inject
drugs
74 5 32 5
Cocaine 49 2 14 1
Amphetamines 34 4 7 2
Opioids 33 3 14 
Benzodiazepines 14 1 7 
Homeless 41 3 20 
Not homeless 42 3 20 2
Employed 45 1 15 1
Unemployed 30 4 12 2
Alcohol 67 3 31 1
No alcohol 49 3 14 1
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P067
HIV support group within a multidisciplinary healthcare
delivery model as a treatment strategy for people who
inject drugs
Rajvir Shahi; Ghazaleh Kiani; Arshia Alimohammadi; Tyler Raycraft;
Arpreet Singh; Syune Hakobyan and Brian Conway
Clinical Research, Vancouver Infectious Diseases Centre, Vancouver,
Canada
Introduction: Among the 18,000 residents living on the Downtown
East Side (DTES) of Vancouver, over 20% are infected with HIV. An
innovative approach is needed to engage these individuals in care to
fulfill the goals of the ‘‘909090’’ program endorsed by the World
Health Organization to address the global HIV pandemic.
Materials and methods: In 2013, structured HIV support groups
were designed as an innovative strategy to engage this vulnerable
population in a multidisciplinary program of care. The group is held
once a week for 4 hours, led by medical doctors, nurses and other
community-based workers. Individuals attending the group are given
a presentation on a topic related to HIV/AIDS, such as HIV
transmission, therapy or substance abuse. They are also able to ask
medical questions and voice their health-related concerns in an open
and safe environment. Two meals are provided as well as services to
address medical, psychological, social and addiction-related needs. A
retrospective analysis to assess characteristics of individuals attend-
ing the group regularly (at least once per month) was performed, and
commitment to HIV treatment was evaluated.
Results: A total of 74 HIV-infected patients (mean age 52 years, 12%
females, 14% First Nations) regularly attended the group. Among
these HIV-positive individuals attending the group, 55 (74.3%) were
people who actively inject drugs (PWID), 36 (48.6%) self-identified
as being homeless and 25 (33.8%) had an underlying psychiatric
disease. The majority (73/74, 98.6%) were receiving antiretroviral
therapy and 58/73 (79.4%) of these individuals had a suppressed HIV
plasma viral load (B40 copies/mL). The remaining 15/73 (20.5%) are
on treatment, but have not yet suppressed.
Conclusions: This HIV support group model has shown to be effective
at engaging and retaining HIV-infected patients in care, with the vast
majority having a maximal response to antiretroviral therapy. These
individuals were previously undiagnosed or not receiving care.
Approaches such as the one we have developed will be essential
to reaching the goal of ‘‘909090’’ especially in more vulnerable
populations.
P068
Adherence to cART and low-level viremia in a large
single-centre clinical cohort
Franco Maggiolo1; Elisa Di Filippo1; Annapaola Callegaro2;
Giorgio Colombo3; Sergio Di Matteo4; Daniela Valenti1 and
Marco Rizzi1
1Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
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Introduction: To monitor the use of cART is relevant to evaluate
outcomes, adherence to prescriptions and therapeutic strategies.
Materials and methods: We analyzed the full cohort of a large
reference hospital in Northern Italy. Data on drug use were derived
from pharmacy records and were cross-linked with clinical data from
the outpatient clinic database. The period from 1 October 2012 to 30
September 2014 was considered for a mean individual follow-up of
1.18 years and a total follow-up of 2676 person-years. Adherence
was calculated on the basis of pharmacy refill. We defined virologic
response by categories: always B3 copies/mL (KB3), sometimes
B3 but always B50 copies/mL (VB3), always 3 but always B50
copies/mL (K3) and sometimes 50 copies/mL (V50).
Results: Over the considered 2 years, 2589 HIV subjects were
prescribed ARV drugs. According to univariate analysis, adherence
correlated with several baseline variables: hepatitis co-infection
(p0.002), nationality, risk factor for HIV infection, third drug
included into the regimen, line of therapy, time on cART and age
(pB0.0001 for all). When entered in a multivariate model, only
nationality (p0.002), time on cART (p0.005), age (pB0.0001)
and the third drug into the regimen (pB0.0001) retained statistical
significance. Adherence was higher for NNRTI-based regimens (93.4%;
pB0.0001), when compared with all other regimens, similarly
adherence was lower for PI-based cART (89.3%; pB0.0001) and
entry inhibitors-based cART (85.1%; p0.001), while there was no
difference between regimen with or without INI (90.2% vs. 91.5%;
p0.20). Adherence correlated with the virologic outcome, too. The
mean adherence rate resulted of 91% in the KB3 and VB3 groups
and lowered to 88% in the K3 and V50 groups (pB0.001).When
insufficient (B90%) adherence was considered, a steady adherence
level B90% was more frequently present in K3 patients (26.3% of
them), while sporadic drug holidays were typically observed in V50
patients (17.9%; pB0.0001).
Conclusions: We demonstrated a relationship between virologic
outcomes and adherence even when very low residual levels of HIV
RNA (LLV) are considered. This fact is in favour of an active viral
replication at least in some patients with LLV. However, the virologic
outcome highly depends on forgiveness of modern ARV regimens as
demonstrated by virologic responses in patients with insufficient
adherence. Adherence is influenced by several demographic factors,
but it is significantly linked to the choice of drugs, too. Although we
observed a high standard of actual adherence, adherence rates could
and should be improved.
P069
Developing a patient-reported outcome measure (PRO) for
HIV care on perceived barriers to antiretroviral adherence:
assessing the needs of HIV clinicians though typological
analysis
Isabelle Toupin1; Kim Engler1; David Lessard1; Andra`s Le`na`rt1;
Franc¸ois Raffi2; Bruno Spire3 and Bertrand Lebouche´4
1Department of Family Medicine, McGill University, Montreal,
Canada. 2Infectious Diseases, University Hospital, Nantes, France.
3Universite´ Aix-Marseille, SESSTIM, Marseille, France. 4Chronic Viral
Illness Service, Research Institute of the McGill University Health
Centre (MUHC), Montreal, Canada
Introduction: Today, while many potent antiretroviral treatments
(ART) and strategies are available, their clinical efficacy depends on
patients adhering to them as prescribed. However, obstacles to
adherence are common, multiple, recurrent and can be inadequately
dealt with in clinical care. Tools are needed to address this apparent
gap in HIV care. The use of a new PRO in HIV clinical care, based on
patients’ perceived barriers to ART adherence, could prove helpful. In
creating this PRO (I-Score Study/CTN 283), it is essential to take the
needs of clinicians into consideration from the outset, given the
crucial role these stakeholders play in their successful use in practise.
Objective: To identify HIV-specialized clinicians’ needs in regards to
the clinical use of a new PRO which would be based on patients’ self-
identified barriers to taking their ART.
Materials and methods: Five focus groups were conducted including
32 clinicians from across France. The focus groups were transcribed
verbatim, coded vertically with Atlas.ti and, as the method was
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deemed appropriate, submitted to a typological analysis producing
ideal types.
Results: The typological analysis identified seven patient profiles
(ideal types), each tied to different barriers to adherence and
indicating distinct needs for the PRO’s content and data collection
strategies. For the patient who: (1) is passive, the PRO must collect
information on ART knowledge with closed questions and visual
scales; (2) never forgets a dose, adherence must be verified with
indirect questions; (3) tolerates the intolerable, questions must
target problems experienced by patients with their ART; (4) doesn’t
care, as long as they live life to the fullest, interactive questions must
be integrated on lifestyle and risk taking; (5) is obsessive, quality of
life and life events must be assessed and space provided for textual
responses for qualifying answers; (6) must prioritize, family/domestic
life should be evaluated with Likert scales; (7) lives precariously,
simple questions constructed with basic vocabulary and emoticons
should be used to capture life circumstances and socio-economic
context.
Conclusions: The clinicians’ needs for the new PRO were articulated
in relation to different patient profiles, with multiple implications for
the tool’s content. The challenge will be to respond to both these
needs and those that will be identified by patients in another
component of the I-Score Study.
P070
Patient acceptance of a web-linked smartphone app to
assess treatment compliance in HIV-infected subjects:
a pilot study
Ferran Sala-Pin˜ol1; Angels Andreu-Crespo1; Josep Llibre2; Josep Coll2;
Jordi Grasa3; Angels Calvet4; Bonaventura Clotet2 and
Xavier Bonafont-Pujol1
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Introduction: Lack of adherence to ART increases therapeutic failure,
resistance selection and health system expenditures through more
expensive regimens. It is a public health problem, since uncontrolled
viremia boosts transmission of both the infection and resistance. The
study aim is to evaluate acceptance of a smartphone app, linked to a
web, managed by the healthcare team (Figure 1).
Materials and methods: expertSalud† is a validated free app
including all Spanish registered drugs with predefined and free
clinical controls and intake timetables. Patients confirm drug intakes
on their smartphones. App links to a website where patients and
healthcare practitioners track in real time their compliance without
waiting for the next visit to detect adherence failures. The device
maintains protection of confidential data. Patients were asked to
report about all benefits and difficulties encountered. System
usability was tested through two satisfaction surveys about com-
bined app and web done at first and third months, using two
different 18-question (scored 010) surveys.
Results: It is the first trial of a web-linked app used in real time by
patients and their clinical team. From August 2015 to January 2016,
hospital pharmacists recruited 81 smartphone users among subjects
who started or changed ART, asking them to download and evaluate
app. A total of 50 (62%) patients downloaded expertSalud†. Poor
mobile phone coverage and troublesome registration hindered
downloading. Before leaving the study, some patients noticed app
dysfunctions. In total, 40 subjects answered at least one of the
surveys and 21 both of them. The mean satisfaction score with the
app in the first survey was 8.05/10, and 7.7/10 in the second one.
For the web, the mean scores were 7.37 and 5.73, respectively
(Figure 2). In both surveys, the app received the highest scores for
allowing to include all their treatments (8.458.68) and selecting pill
image and colour avoiding treatment confusion (8.308.33). Patients
appreciated record easiness (8.067.89) and checking visualization
(7.778.06), and they considered the app could be useful to improve
their adherence (NA7.90).
Conclusions: In this pilot study, patient’s acceptance of an app
to monitor ART intakes and adherence by the healthcare team
was high. However, only half of the app users completed all the
evaluation forms. App-linked web could be useful in detecting early
treatment non-compliance and driving the implementation of
targeted strategies. Suggestions received will improve system
friendliness in the app development in new fully powered studies.
P071
The moderating role of treatment engagement on the
relationship between neurocognitive impairment and
antiretroviral treatment (ART) adherence
Roman Shrestha1; Pramila Karki2; Tania Huedo-Medina2 and
Michael Copenhaver2
Figure 1. App screenshot.
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Introduction: Prior research has recognized neurocognitive impair-
ment (NCI) and treatment engagement as important predictors of
ART adherence [14]. No studies to date, however, have explored
the possible ways and the extent to which a similar outcome can
occur when these factors operate together, particularly among
people who use drugs (PWUDs). This study sought to answer
whether treatment engagement moderates the relationship between
NCI and ART adherence.
Methods: A total of 116 HIV-positive opioid-dependent individuals
enrolled in a methadone maintenance treatment (MMT) and
reporting drug- and/or sex-related HIV risk behaviours were recruited
from MMT clinic in New Haven, Connecticut. Participants completed
an audio-computer-assisted self-interview (ACASI) that measured NCI
(Brief Inventory of Neurocognitive Impairment), ART adherence
(Visual Analogue Scale) and treatment engagement. An ordinary
least squares regression-based path analytic framework was used to
test whether treatment engagement (moderator) moderates the
relationship between NCI (predictor) and ART adherence (outcome).
Results: Results showed that NCI (B0.745, p0.004) was
negatively associated with ART adherence. The interactive effect
between NCI and treatment engagement was significantly associated
with ART adherence (B0.086, p0.023), which supports the
moderation effect. Post hoc analyses revealed that at low levels of
treatment engagement, NCI was significantly negatively associated
with ART adherence, while at high levels of treatment engagement,
the relationship was non-significant.
Conclusions: The findings make an important contribution to our
understanding of the applicability of a moderated model, such that
NCI had an increased negative influence on ART adherence for
individuals with lower treatment engagement. This highlights the
need for future interventions to accommodate individuals’ NCI and
improve treatment engagement in order to improve adherence to
ART and thus health-related quality of life among opioid-dependent
individuals living with HIV.
References
1. Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive
impairment and medication adherence in HIV patients with and
without cocaine dependence. J Behav Med. 2011;34:12838. doi:
http://dx.doi.org/10.1007/s10865-010-9293-5
2. Malee K, Williams PL, Montepiedra G, Nichols S, Sirois PA, Storm
D, et al. The role of cognitive functioning in medication adherence of
children and adolescents with HIV infection. J Pediatr Psychol.
2009;34:16475. doi: http://dx.doi.org/10.1093/jpepsy/jsn068
3. Nicholas PK, Willard S, Thompson C, Dawson-Rose C, Corless IB,
Wantland DJ, et al. Engagement with care, substance use, and ad-
herence to therapy in HIV/AIDS. AIDS Res Treat. 2014;2014:675739.
4. Farrell L, Ingersoll K, Ceperich SD. Enhancing patient adherence:
promoting engagement via positive patient-provider relationships in
HIV/AIDS care. Med Encount. 2009;23:6971.
P072
Real-world persistence and outcomes for HIV-1 treatment:
single- versus multiple-tablet regimen comparison
Donna Sweet1; David Budd2 and Josh Cohen3
Abstract P070Figure 2. Survey results.
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Introduction: Advances in ART for HIV treatment have reduced
patient morbidity and mortality [1]. Once-daily single-tablet regi-
mens (STRs) may improve adherence and persistence by reducing pill
burden compared to multi-tablet regimens (MTRs) [1, 2]. Persistence
and adherence have been correlated with improved patient out-
comes [3]. This retrospective study evaluated real-world persistence
among HIV-1 infected patents comparing STRs versus MTRs using the
Truven MarketScan† database.
Materials and methods: Adults (]18 years), diagnosed with HIV-1,
with ]1 prescription for ART during the index period (1 January
2011 through 31 December 2015) were identified. Patients were
required to have continuous enrollment for 6-month baseline and
follow-up periods until the end of enrollment or end of the study
period, whichever came first. Primary outcome was index regimen
persistence, defined as time from index regimen start date to end of
first 90-day gap between fills for any ART in the index regimen, or to
the start date of an ART not in index regimen. KaplanMeier and Cox
proportional hazard models evaluated persistence and risk of
discontinuation or switch across treatments controlling for age,
gender, health-plan type, US region, Charlson comorbidity index (CCI)
and baseline comorbidities.
Results: Index regimens are listed in Table 1. STRs were the index
regimen for two-thirds of patients. A majority of patients were male
(83%). Patients prescribed MTRs were older (mean age: 43.2 vs. 39.8
years, pB0.0001). MTR patients had higher rates of diabetes (7.0%
vs. 5.7%, p0.03), chronic kidney disease (2.4% vs. 1.1%, pB0.0001)
and cardiovascular disease (25.6% vs. 22.2%, p0.001). STRs
demonstrated significantly greater persistence compared to MTRs.
Controlling for baseline differences, MTRs were at twice the risk of
discontinuation/switch (hazard ratio (HR) 1.95) compared to STRs.
Median time to discontinuation/switch was 37.5 months for STRs, com-
pared to 21.4 months among MTRs (pB0.0001). Among STRs, EVG/
COB/FTC/TDF had a greater propensity for persistence compared to
RPV/FTC/TDF (HR 1.14) and ABC/3TC/DTG (HR 1.24). Median time to
switch for FTC/TDF  DTG was 22.1 months (pB0.0001). FTC/TDF
 DTG had a significantly increased risk for discontinuation/switch
compared to EVG/COB/FTC/TDF (HR 1.54), but a comparable risk
compared to ABC/3TC/DTG (HR 0.98).
Conclusions: STRs improve persistence and reduce switching
among HIV patients. EVG/COB/FTC/TDF had the highest persistency
among STRs. STRs are likely to result in better patient outcomes
compared to MTRs due to improved outcomes associated with
persistence.
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Introduction: While the majority of the published literature has
focussed on the role of patients’ attitude regarding adherence, the
healthcare provider (HCP) has a significant role in patient adherence
with ART. This is a great concern to HCPs as a great level of
adherence is needed for most patients to achieve full and sustained
viral suppression. This study was designed to better understand the
factors that impact clinicians’ prescribing patterns for ART that will
optimize patient adherence to HIV therapy in the US.
Methods: In mid-2014, two cross-sectional internet-based surveys
were conducted in the US with 400 patients prescribed with an ARV
and with 200 physicians who treat HIV. The 30-minute online surveys
were pretested with a small group of respondents (n5 patients
and n5 physicians). The patient survey included HIV treatment
experience, medication side effects, adherence behaviours, treat-
ment satisfaction and interaction with HCPs. The physician survey
addressed similar topics to allow for direct comparisons between HIV
patients and physicians.
Results: The patient sample were primarily males (79.3%) with an
average age of 41.1 (SD 13.2) years with 61% homosexual, 28.1%
heterosexual and 11.1% bisexual. A total of 59% of patients were
diagnosed with comorbidities, the most common being depression,
hypertension and hyperlipidemia. The physician sample included
119 primary care physicians (PCPs) and 81 infectious disease (ID)
specialists. The factors most important for IDs and PCPs in ARV
prescribing, were virologic control, followed by adherence and
Abstract P072Table 1. Index regimens
Single-tablet regimens (STRs) n4156 61.3%
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate EVG/COB/FTC/TDF 31.9%
rilpivirine/emtricitabine/tenofovir disoproxil fumarate RPV/FTC/TDF 23.0%
abacavir/lamivudine/dolutegravir ABC/3TC/DTG 6.4%
Multi-tablet regimens (MTRs) n2622 38.7%
emtricitabine/tenofovir disoproxil fumaratedolutegravir FTC/TDFDTG 3.8%
emtricitabine/tenofovir disoproxil fumaratedarunavir/ritonavir FTC/TDFDRV/r 16.8%
emtricitabine/tenofovir disoproxil fumarateatazanavir/ritonavir FTC/TDFATV/r 12.0%
abacavir/lamivudinedolutegravir ABC/3TCDTG 1.9%
abacavir/lamivudinedarunavir/ritonavir ABC/3TCDRV/r 1.4%
abacavir/lamivudineatazanavir/ritonavir ABC/3TCATV/r 2.8%
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side effects. PCPs were more concerned with affordability/insurance
coverage than IDs. Moreover, there were significant differences
between the choices of ARV for patients with comorbidities, for IDs
compared to PCPs. These included kidney and liver diseases;
hyperlipidemia and diabetes most affected HCPs’ treatment deci-
sions (Figure 1).
Conclusion: Adherence challenges persist for both IDs and PCPs in
prescribing ARVs. Understanding the optimal prescribing patterns for
ARVs and ensuring that HCPs consider both the polypharmacy
related to both HIV as well as comorbid conditions is important,
especially as HIV is being treated as a chronic disease.
P075
MATH study: migrants adherence to therapy at an HIV
outpatient clinic
Catarina Rodrigues; Yohana Martins; Umbelina Caixas;
Fatima Lampreia and Isabel Germano
Servic¸o Medicina 1.4, Hospital Sa˜o Jose´, Lisbon, Portugal
Introduction: Strict adherence to ART is essential for HIV suppression 
to reduce the risk of treatment resistance, improve health and
quality of life of those infected, reduce mortality and minimize risk of
transmission. By contrast, poor adherence to therapy is a major
cause of treatment failure. It is essential to identify factors for poor
adherence in order to a customized action. The aim of this study is
to determine adherence differences to HIV therapy between the
migrant and the Portuguese population on follow-up in our HIV
outpatient clinic.
Material and methods: Cross-sectional, descriptive study including
719 patients followed in a Portuguese HIV outpatient clinic since the
year 2000. Of these, 651 patients met the inclusion criteria (over 18
years old, on follow-up since 2000, with one or more appointments
in 2015); 428 Portuguese patients and 223 migrants  143 from
Africa (mostly Angola, Cap Verde and Guinea), 58 from South
America (almost all from Brazil), 13 from Europe and 2 from Asia.
Adherence was defined by undetectable viral load in the last two
evaluations. Results between the two groups were compared using
Chi-squared test.
Results: Total of 651 patients, mean age of 44.8 years (Portuguese
45.6 vs. migrants 43.2), 450 males and 201 females (Portuguese
315 males/113 females vs. migrants 135 males/88 females). Non-
adherence in the Portuguese group was present in 28 patients (6.5%;
n428) and in the migrants group in 13 patients (5.8%; n223).
The reasons for non-adherence in the Portuguese group were mostly
alcohol and drug abuse or depression and other mental disorders;
while in the migrant group were low level of health education and
low social support. We saw that usually the regime prescribed did
not influence adherence  number of doses/tablets, adverse effects
or relation with/without meal.
Conclusions: Even though the adherence in the Portuguese group
was lower in percentage than in the migrant group, the reasons for
this suboptimal adherence might improve with interventions in our
outpatient clinic, such as better social support and reinforcement of
health education with enhanced risk perception and better knowl-
edge of this disease.
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Predictors of retention to care among HIV-infected patients
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Introduction: Retention to care is vital in order to improve HIV
outcomes. Data regarding retention to care of HIV-positive indivi-
duals in Greece are scarce. The objective of this study was to assess
retention to care and identify factors associated with incomplete
retention in a longitudinal cohort of HIV-infected patients in
Northern Greece.
Materials and methods: We conducted a retrospective cohort study
in Thessaloniki, Northern Greece of 1450 newly diagnosed HIV
patients 18 years old who entered care from 1990 to 2015 and
followed until present. Retention to care was defined as having at
least one visit each year of care throughout the entire follow-up
period. Also, we studied predictors of gaps in care and the analysis
was divided into three distinct time periods. A secondary analysis
was done to determine the relationship between demographic and
clinical variables and the number of years out of care.
Abstract P073Figure 1. Differentiating factors influencing HCPs’ choices of ARVs.
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Results: Of the 1450 patients included, 38.41% had at least one gap
in care during the study period. Patients with complete retention to
care were older (37.10910.71 vs. 35.85911.00), fully insured
(71.8% vs. 53.1%, pB0.005), more likely to be registered to care
between 2010 and 2015 (48.5% vs. 23.5%, pB0.005), to have higher
educational level (30.5% vs. 25.1%, p0.029) and were more likely
to receive HAART (81.9% vs. 71.8%, pB0.005) and have viral
suppression (91% vs. 80%, pB0.005), than those displaying gaps
in care. In the adjusted analysis, older age, Greek origin, full
insurance, HAART intake and viral suppression were all associated
with increased likelihood of retention. Clinic registration between
1990 and 2000 (p0.044) and 2000 and 2010 (pB0.005) were also
predicting factors of retention to care. Ten-year survival between
non-retained (63%) and retained patients (92%) was statistically
significant (pB0.005). Retention was associated with decreased
likelihood of death (aHR 0.37, 95% CI 0.260.52; pB0.005). Patients
with high education level and Greek origin presented less years out
of care (p0.002 and pB0.005, respectively). Patients with one or
more hospital admissions had more years out care compared with
those no hospital admission (pB0.05).
Conclusions: Foreign origin, lack of insurance and type of transmis-
sion other than MSM are predictors of incomplete retention to care.
Retention to care is associated with better HIV infection outcomes
and survival. Our results suggest that one-third of newly diagnosed
HIV-infected patients will experience at least one gap in care.
Interventions should focus on prevention of gaps and maintenance
of continuous follow-up of HIV patients.
TREATMENT STRATEGIES: CURE
P077
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The Berlin patient is presumed to be the only person cured from HIV
infection by hematopoietic stem cell transplantation (HSCT) from a
homozygous CCR5-d32 donor. Attempts to reproduce cure by HSCT
have failed because of either viral rebound or death due to the
underlying malignancy. We here report a patient alive, well and
negative for proviral DNA 900 days after HSCT. A 41-year-old HIV-
infected male patient was diagnosed acute myeloid leukaemia (AML,
inv16, CBF-MYH11) in January 2011. Since the diagnosis of HIV
infection in October 2010, he had been treated with TDF/FTCDRV
(January 2011 VL 44 copies/mL; CD4 474 cells/mL). To avoid
interactions with chemotherapy DRV was switched to RAL in March
2011. He achieved CR of the AML after one induction course (ICE)
and received a second induction and three consolidation courses
according to AML-SG 07/04. In September 2012, AML relapsed and
he was treated with A-HAM and a second cycle high-dose cytarabine.
While in second CR, he received unmodified peripheral blood stem
cells from a female 10/10 CCR5-d32 DKMS donor after conditioning
with fludarabine/treosulfan in February 2013. Before transplant, HIV
resistance analysis was performed and viral tropism was determined.
There were no significant resistance mutations, and the coreceptor
usage was predicted as R5-tropic (Sanger sequencing: FPR 44.5%;
NGS: 0.14% X4 at 3.5% FPR; geno2pheno). The proviral DNA load was
1.45 log10 copies/106 PBMCs, and in the western blot, all anticipated
bands could be detected. During transplant and until today, the
patient remained on ART (since June 2014 ABC/3TC/DTG), and the
viral load remained undetectable in plasma and liquor. He had a
second relapse of AML in June 2013 but re-entered molecular
remission after a total of eight courses of 5-azacytidine and four
donor lymphocyte infusions. Concerning HIV, all collected samples
were negative for proviral DNA by conventional and digital droplet
PCR in two different labs, namely PBMCs (20142016), rectal biopsy
(April 2015) and bone marrow (August 2015). Western blots from
2014, 2015 and 2016 showed incomplete patterns with fading bands.
Viral outgrowth assays are in progress. Like in the Berlin patient, all
tests from the Duesseldorf patient so far suggest that HIV may have
been eradicated and that he may be the second individual cured
from HIV by allogeneic CCR5-d32 HSCT. Further investigations will be
performed before considering the discontinuation of ART.
P078
Differential efficacy of ABX464 and its primary metabolite
ABX464-NGlc on HIV replication in human PBMCs and
macrophages: implications for treatment strategies to
eliminate virus reservoirs
Didier Scherrer1; Jean-Marc Steens1; Paul Gineste1; Noelie Campos1;
Aude Garcel1; Erika Schlaefper2; Roberto Speck2; Jamal Tazi3 and
Hartmut Ehrlich1
1ABIVAX, Paris, France. 2Division of Infectious Diseases, University
Hospital of Zurich, Zurich, Switzerland. 3Institute of Molecular
Genetics of Montpellier, Centre National de la Recherche
Scientifique, Montpellier, France
Introduction: We developed a first-in-class small molecule (ABX464)
with a novel mechanism of anti-HIV involving modulation of viral
RNA splicing [1]. ABX464 was demonstrated to be effective in
inhibiting HIV replication in vitro, in vivo and in HIV patients [2].
Studies in humanized mice infected with HIV demonstrated that
ABX464 monotherapy had an antiviral effect, which was sustained
after treatment interruption. Therefore, ABX464 may have an effect
on virus reservoirs. In humans, ABX464 is metabolized to one main
metabolite, ABX464-NGlc. We investigated the differential effects of
parent compound and metabolite on virus replication in vitro in both
stimulated PBMCs and macrophages to investigate potential antiviral
effects in macrophages, the cell population considered to be the key
virus reservoir.
Materials and methods: Human PBMCs and monocytes were
isolated from healthy donors. Cultured cells were treated with
ABX464 or ABX464-NGlc and then infected with virus. Following
612 days of incubation, HIV p24 titration was performed on
supernatants by ELISA with Ingen Innotest kit.
Results: Dose-dependent inhibition of HIV-1 replication by ABX464
was demonstrated in stimulated PBMCs with an IC50 ranging
between 0.1 and 0.5 mM, while the metabolite did not show any
efficacy in inhibiting virus replication in human PBMC in vitro. By
contrast, although the metabolite demonstrated no antiviral effect
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on PBMCs, it blocked virus replication in primary macrophages
reaching inhibition levels of up to 90% at 0.1 mM.
Conclusions: These findings have substantial implications for target-
ing the HIV reservoir with ABX464. Studies in healthy subjects
demonstrated ABX464-NGlc’s Cmax was about 160-fold higher than
those of ABX464 and had a much longer t1/2 (90110 hours) than the
parent compound (23 hours), resulting in a 1000-fold difference
in AUC between the two compounds [3]. The markedly higher plasma
concentrations of ABX464-NGlc, and its ability to inhibit viral
replication in infected macrophage cultures with the same IC50 as
the parent drug, may allow effective targeting of the reservoir in
patients whose viral load is fully controlled by existing ARTs. In this
case, the primary aim of the therapeutic intervention with ABX464 is
to delay/prevent the viral rebound typically originating from the
reservoir. This concept is being explored in an ongoing clinical trial, in
which patients receive ABX464 for 4 weeks in combination with
standard ART, with subsequent cessation of all treatments and
intense viral load monitoring until viral rebound.
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Development of methods for in vitro reactivation of latent
reservoir of HIV-1 infection in patients under suppressive
HAART
Gnaneshwer Jadav
Medical Biotechnologies, University of Siena, Siena, Italy
Introduction: Latent reservoir of HIV-1 infection has a relevant
impact in the management of the treatment and in the evaluation of
the eradication strategies approaches. We have developed in vitro
models by using HDAC inhibitors and PKC agonists to reactivate the
transcription of proviral HIV DNA in cell culture using lymphocytes
collected from HIV-1 infected patients under suppressive ART. The
aims of our study were to evaluate (1) the size of the viral particles
produced by lymphocytes by using a specific qPCR method and (2)
the comparison of the sequences of viral regions involved in drug
resistance obtained from both newly produced viral populations and
proviral DNA.
Materials and methods: Lymphocytes from HIV-1 infected patients
under successful antiretroviral treatment were harvested from whole
blood and both stored as the baseline sample and resuspended in
the appropriate growth medium for the evaluation of HIV RNA
production by using reactivating agents PHA or PMA alone or in
combination with vorinostat (VOR). We calculated the amount of
genomic viral RNA in the cell culture supernatants by a specific qRT-
PCR system targeting the 3’ poly-adenylated tail of HIV RNA genome.
We compared the sequences of the regions involved in drug resis-
tance by the partial amplification of POL and ENV gene from both
baseline HIV DNA and from supernatant viral RNA of successfully
induced lymphocytes.
Results: We have showed that PKC agonists such as PMA or PHA,
when combined with HDAC inhibitors such as VOR, effectively
induced viral transcription in lymphocytes from patients on success-
ful ART at higher levels than those obtained stimulating lymphocytes
with PHA or PMA alone. From the data observed in the comparison
of POL sequences between baseline HIV DNA and supernatant viral
RNA, we found that 7/13 patients showed similar genotypes, among
which 6 had no mutation and 1 case showed the same resistance
mutations in both DNA and RNA. Interestingly, 4/13 patients
had mutations detected in reactivated viral RNA but not found in
the baseline proviral HIV DNA. Similarly, the comparison of the
sequences of the V3 domain of the ENV showed that 2/6 patients
had a different predicted coreceptor usage between proviral HIV
DNA and reactivated viral RNA.
Conclusions: Latent HIV-1 infection of lymphocytes remains the
major barrier to HIV-1 eradication and our data confirmed that could
have a relevant impact in the management of HIV infection
treatment as well.
TREATMENT STRATEGIES: SIMPLIFICATION
P080
Dual regimen with dolutegravir and lamivudine maintains
virologic suppression even in heavily treatment-experienced
HIV-infected patients: 48-week results from a pilot study
(DOLULAM)
Jacques Reynes1; Nadia Meftah2 and Brigitte Montes3
1Infectious Diseases, Montpellier University Hospital, Montpellier,
France. 2COREVIH, Montpellier University Hospital, Montpellier,
France. 3Virology, Montpellier University Hospital, Montpellier,
France
Introduction: Dolutegravir (DTG) is an HIV integrase inhibitor with a
potent antiviral activity and high genetic barrier. However, few viral
rebounds with emergence of integrase resistance mutations during
DTG monotherapy maintenance were observed [1]. M184I/V muta-
tions against lamivudine (3TC) could prevent the emergence of
resistance mutations against DTG [2].
Methods: DOLULAM is a prospective cohort study. Patients on a
stable antiretroviral regimen with HIV RNA B50 copies/mL for 12
months, with problems of tolerability and without resistance to
integrase inhibitors, were given the opportunity to switch to
dolutegravir 50 mg plus lamivudine 300 mg once daily. Visits and
laboratory tests including plasma HIV-1 RNA levels (VL)(Roche Cobas
Ampliprep/Taqman HIV-1 version 2.0; limit of detection, 20 copies/mL)
were scheduled at baseline (BL), 6, 12, 24 (36 optional) and
48 weeks.
Results: We enrolled 27 patients from October 2014 to April 2015
(20 men, 7 women; median age: 59 years; plasma HIV-1 RNA zenith
100,000 copies/mL: 56%; median nadir CD4: 167/mm3; median
baseline CD4: 601/mm3). Before switching to dual therapy, patients
had been taking antiretroviral therapy for a median of 215 (range
22329) months and the last HAART (TDF: 48%; PI/r: 81%; RAL: 26%)
for a median of 51 (13108) months. Ten (37%) patients had a
history of genotypic test prior switch with M184V mutation. During
the first 48 weeks of follow-up, no patient experienced virologic
failure (defined as confirmed VL 50 copies/mL) or severe clinical or
laboratory adverse event, or was lost to follow-up. Three patients
experienced one blip (52, 31 and 66 copies/mL at week 12, 24 and
36). Three patients wanted to discontinue DTG3TC combination
(two at week 16 and week 24 for fatigue, one at week 18 after blip at
week 12 visit). There was a small decrease from baseline in estimated
glomerular filtration rate (eGFR) at first on-treatment assessment
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(median week 6 evolution: 9 mL/min/1.73 m2) but remained
stable over the 48-week follow-up (7).
Conclusions: These results suggest that, in this population of heavily
treatment-experienced patients without or with history of M184I/V
mutation, dolutegravir plus lamivudine dual therapy is an attractive
strategy of maintenance.
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Introduction: In the absence of virologic eradication despite com-
bination of antiretroviral therapy, patients infected by HIV have to
take the treatment throughout their life. Intermittent regimen could
be an alternative for those as evocated in previous studies (FOTO,
BREATHER).
Material and methods: An open-label, multicentre, single-arm
prospective study had been conducted to evaluate the capacity of
a weekly strategy of 4 consecutive days treatment ("period on")
followed by 3 days without treatment ("period off"), in HIV-1
patients with undetectable viral load for at least 12 months. Patients
had no treatment modification in the past 6 months, and were on
two nucleosides analogues and either boosted protease inhibitor
(PI/r) or a NNRTI. Plasma antiretroviral residual concentrations on
"period on" collected at day 0, week 16, week 40 and on "period off"
collected at week 4, week 8, week 12, week 32 and week 48 were
measured using a validated turbulent flow chromatography method
coupled to triple quadrupole mass spectrometry detection with
electrospray ionization interface. The laps between the last medica-
tion intake and the sample collecting time over 48 hours were
considered as off period samples.
Results: Among the 100 patients included, 12 drug combinations were
used: TDFFTC (n89), ABC3TC (10), ABCTDF (1) combined
with a PI/r for 29 (DRV/r: 15; ATV/r: 13; LPV/r: 1) or a NNRTI for 71 (EFV:
40; RPV: 26; ETV: 5). After 48 weeks, 96% (95% CI 90-98, Kaplan-Meier
estimate) were still under intermittent 4/7 days regimen without
failure. In total, 877 samples were analyzed (292 "on" and 585 "off"). A
total of 94.4% of plasma samples are consistent with the timing.
Significant differences had been observed between "on" concentra-
tions and "off" concentrations for DRV (258791393 ng/mL vs. 17918
ng/mL, pB0.0001), ATV (10879644 ng/mL vs. 529146 ng/mL, p
0.0005), LPV (39922 ng/mLvs.B20 ng/mL), EFV (221891046 ng/mL
vs. 6929391 ng/mL, pB0.0001) and RPV (106951 ng/mL vs. 3920
ng/mL, pB0.0001). Many PI were undetectable on "off" period. For
ETV (4479360 ng/mL vs. 2699266 ng/mL, p0.0625) only a ten-
dency was observed, probably because of low number of patients in
this group. All "on" concentrations were in accordance with French
guidelines.
Conclusion: A total of 96% of patients maintained viral load
undetectable despite low or undetectable plasma concentrations
after 3 days of treatment interruption on a 4-days-a-week regimen.
PI plasma samples were almost always undetectable since NNRTI
ones were decreased but above the limit of quantification according
to their longer half-lives.
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Dual therapy with non-boosted atazanavir plus lamivudine
is an effective simplification strategy for virologically stable
patients with HIV
Juan Pasquau; Samantha Elizabeth de Jesu´s; Coral Garcı´a-Vallecillos
and Carmen Hidalgo-Tenorio
Infectious Diseases, Hospital Universitario Virgen de las Nieves 
Complejo Hospitalario de Granada, Granada, Spain
Introduction: The main objective of this simplification therapy is the
reduction of potential toxicity of long-term antiretroviral treatment.
In this regard, the withdrawal of ritonavir has demonstrated
advantages in terms of tolerance and metabolic toxicity. There are
previous studies that establish that non-boosted ATV400 has similar
efficacy and a better toxicity profile than ritonavir-boosted ATV
(ATV/r). But we have scarce information on the efficacy and safety of
the dual regimen with lamivudine (3TC)ATV400.
Methods: This is a retrospective, single-centre, observational study in
which we analyzed the evolution of our virologically stable patients who
received a triple therapy or a dual therapywith 3TCATV/r and switched
to a dual therapy with 3TCATV400 as a simplification strategy.
Results: A total of 46 patients received the non-boosted ATV400 plus
3TC combination. They had previously taken antiretroviral treatment
for an average of 12.1 years and four previous treatment combina-
tions, a mean CD4 nadir of 229 cells/mm3 and a baseline viral load of
95,004 copies/mL. A total of 17.4% of patients were co-infected with
HCV. In all patients, the viral load had been suppressed for over 6
months and they had tolerated their previous treatment well, which in
35/46 cases was a dual therapy with ritonavir. After an observation
period of 44.6 patient-years, only one patient discontinued the study
combination, due to virologic failure. During the study, there were no
adverse events and 157 viral loads were determined. Of these, 94.9%
were B50 copies/mL and 86.6% were B20 copies/mL (61.3% were
completely undetectable). A total of 67.4% of patients maintained a
viral loadB20 copies/mL during the whole study, and 84.8% achieved
a completely undetectable viral load at some point during the study.
There were eight viral loads 50 copies/mL and five of them were
blips. Only one patient had virologic failure (2.2%), with two conse-
cutive detectable viral loads (1132 and 3558 copies/mL), associated
with resistance to ATV (protease mutations: 10F, 20T and 50L). This
virologic failure was associated with confirmed poor treatment
adherence.
Conclusions: Our data, and those of other studies, suggest that the
3TCATV400 dual combination, as a simplification strategy in stable
patients, suppresses HIV replication and is non-inferior to triple
therapy. We believe this attractive strategy can be explored safely
and should be confirmed with further studies.
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P083
Lamivudinedolutegravir as simplification strategy in
patients with suppressed HIV RNA
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Daniela Valenti1 and Diego Ripamonti1
1Infectious Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy.
2Infectious Diseases, Fondazione IRCCS Policlinico San Matteo,
Pavia, Italy. 3Infectious Diseases, University of Modena, Modena,
Italy
Introduction: cART is generally based on a backbone consisting of
two NRTIs and on a third agent of a different class. The availability of
new potent drugs raises the opportunity to change the classical
NRTI-backbone paradigm and to explore less-drug regimens able to
overcome adverse events due to commonly used NRTIs.
Materials and methods: This is a prospective, multi-centre, proof-of-
concept, cohort study in patients on stable cART, with a confirmed
(6 months) viremia B50 copies/mL, absence of M184V mutation
or HBsAg and with intolerance/contra-indications to current cART.
Patients were switched to a dual 3TCDTG regimen and prospec-
tively monitored. ITT analysis results are reported.
Results: A total of 94 patients, mostly males (76.5%) and with a
mean age of 53 years (SD 11) were enrolled. The most common risk
factors for HIV infection were heterosexual (54.3%) and homosexual
(22.3%) relationships. At switch, patients were on ARV drugs for a
mean of 11.3 years (SD 6.8). They had been on the ongoing therapy
for a mean of 50.2 months (SD 40.1) and virologically suppressed for
a mean of 88.8 (SD 74.4) months. They had experienced a mean of
4.1 lines of therapy (range 110) and were currently treated with
a variety of drugs: 91.5% were assuming a NRTI (TDF 51.1% and
ABC 37.2%); 55.3% were on a NNRTI-based regimen, 30.1% were
assuming PIs and 17.0% an integrase inhibitor. At switch, all of them
presented an HIV RNA B50 copies/mL and a CD4 mean count of 742
cells/mL (SD 353), but 91.5% of them presented comorbidities mainly
involving the cardiovascular system (35.1%), the bone (33.0%), the
liver (23.4%), the nervous system (21.3%), the kidney (9.6%), the
metabolic status (17.0%) or the glucose homeostasis (6.4%). During
the 6 months of FU, no patient stopped therapy nor we observed any
virologic failure. CD4 mean increment was of 61 cells/mL (p0.018)
without significant changes of CD8 cells or CD4/CD8 ratio. Total
(5 mg/dL) HDL and LDL cholesterol were stable, while triglycerides
slightly decreased (18 mg/dL, p0.025). Blood creatinine increased
from 0.92 to 1.00 mg/dL (pB0.0001). Finally, the dual switch therapy
reduced the mean daily cost of therapy of 7.00 Euros.
Conclusion: A dual 3TCDTG regimen is a feasible alternative in
virologically controlled patients that may overcome the limits of a
classical NRTI backbone. This alternative regimen is cost-effective.
Our results indicate the opportunity of a larger controlled trial.
P084
In monotherapy, darunavir/cobicistat demonstrates
equivalence to darunavir/ritonavir, and in selected patients
is as effective as bitherapies or triple therapies
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Samantha Elizabeth de Jesus; Georgette Fatoul del Pino;
Carmen Hidalgo-Tenorio; David Vinuesa-Garcı´a; Miguel A´ngel Lo´pez-
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Granada, Spain
Introduction: Various studies have demonstrated the bioequivalence
of darunavir/ritonavir (DRV/r) and darunavir/cobicistat (DRV/c).
However, there are doubts about how the lower plasma trough
concentrations achieved with DRV/c may affect therapeutic efficacy.
Triple therapy is not a good model to test the equivalence of only
one component of the treatment, but monotherapy is. It is for this
reason that the objective for this study was to analyze the virologic
efficacy achieved with DRV/c when used in monotherapy.
Materials and methods: This is an observational, retrospective,
single-centre analysis of all patients in our hospital who received
DRV/c in monotherapy. We analyzed the evolution of HIV viremia,
and we have compared these results with those achieved previously
with DRV/r and lopinavir/ritonavir (LPV/r) in our historic controls. In
addition, we compared these results to those obtained in a recent
three-way comparison (monotherapy vs. bitherapy vs. triple therapy)
of contemporary patients in our centre.
Results: Since July 2015 to May 2016, 181 patients have received
DRV/c in monotherapy (94.5% from monotherapy with DRV/r
(93.6%) or LPV/r (6.4%)). Only four patients discontinued DRV/c:
one due to virologic failure and three due to mild intolerance. The
global exposition time for this cohort was 58.9 patient-years. During
this time, 196 plasma viral loads (VL) have been determined: 91.9%
(180/196) were B50 copies/mL (62.8% (123/196) were undetect-
able, 20.4% (40/196) were detectable but below the level of
detection (B20 copies/mL) and 8.7% (17/196) were between 20
and 50 copies/mL), 6.1% (12/196) were between 50 and 200 and 2%
(4/196) were 200 copies/mL. In a previous analysis of our patients
(n185) who were receiving monotherapy with DRV/r or LPV/r
(20052013), 1003 VL have been determined: 84.1% were B50
copies/mL, 10.7% between 50 and 200, and 5.2% 200 copies/mL.
Moreover, in another comparative study of parallel viral loads
recorded during the same period of time (from March 2014 to April
2015) between the different strategies (monotherapy vs. bitherapy
vs. triple therapy, for 6 months), our patients on monotherapy
Abstract P084Table 1. Stratified viral load distribution between different ARV combinations
Antiretroviral
combination N patients
N VL
tests
%VL
undetectable
%VL detectable
B20
%VL 20
50
%VL
B50
%VL 50
200
%VL
200
DRV/cobicistata 181 196 62.8 20.4 8.7 91.9 6.1 2
DRV/r or LPV/rb 185 1003    84.1 10.7 5.2
Monotherapyc 49 105 55.7 29.2 8.5 93.4 2.8 3.8
Dual therapyc 79 167 56.9 25.1 8.4 90.8 4.2 5.4
Triple therapyc 93 193 51.6 22.9 7.8 82.3 6.2 11.5
VL, HIV plasma viral load (copies/mL).
aCurrent analysis (monotherapy with DRV/c between July 2015 and May 2016); bhistorical data of our patients on monotherapy (20052013);
ccomparative study of our patients (between March 2014 and April 2015).
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(n49, with DRV/r or LPV/r) presented a VL B50 copies/mL in
93.4% of cases, compared with 90.8% with dual therapies (n79)
and 82.3% with triple therapies (n93) (Table 1).
Conclusions: In real life, DRV/c presents an equivalent virologic
efficacy to DRV/r and LPV/r. In addition, in selected patients who it is
prescribed to and maintained in monotherapy, the stratified analysis
of the viremias is similar to that of dual therapy and triple therapy.
P085
Darunavir/cobicistat as antiretroviral treatment simplification
strategy in patients with stable monotherapy with
ritonavir-boosted protease inhibitors in the clinical setting
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Josep Maria Llibre1; Roger Paredes3; Bonaventura Clotet3 and
Jose´ Molto´1
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Pujol, Badalona, Spain. 2Medicine School, Universitat Auto`noma de
Barcelona, Barcelona, Spain. 3HIV Unit, Lluita contra la SIDA
Foundation, IrsiCaixa Foundation, Hospital Germans Trias i Pujol,
Badalona, Spain
Antiretroviral treatment with darunavir/ritonavir monotherapy has
been extensively used as simplification NRTI-sparing strategy in the
last years. Recently, co-formulated darunavir/cobicistat has become
available. In comparison with ritonavir, cobicistat has no intrinsic
antiretroviral activity, it is more selective than ritonavir in terms of
inhibition of different isoenzymes of the cytochrome P450 system,
and it does not induce CYP isoenzymes or glucuronidation. In a
clinical trial, exposure to darunavir following darunavir/ritonavir and
darunavir/cobicistat administration was not significantly different,
although darunavir trough concentrations were 30% lower with
cobicistat than with ritonavir [1]. This difference seems not to be
clinically relevant in patients on triple therapy and without resistance
mutations associated to darunavir. However, there are not clinical
trials evaluating the effectiveness and safety of darunavir/cobicistat
as monotherapy simplification strategy. We retrospectively studied
all HIV-1-infected subjects treated with darunavir/ritonavir or
lopinavir/ritonavir monotherapy who were switched to darunavir/
cobicistat monotherapy while having plasma VL B50 copies/mL, and
had at least one subsequent follow-up visit in our clinic. The primary
endpoint was the percentage of patients who maintained virologic
suppression (HIV-1 VL B50 copies/mL) after switching. Virologic
failure was defined as a VL 50 copies/mL in two consecutive
determinations or as any change in the monotherapy regimen after a
single determination with a pVL 50 copies/mL. We also evaluated
other reasons for treatment discontinuation. Analyses were per-
formed considering all regimens (full data set analysis) as ‘‘treatment
switch equals failure.’’ A total of 124 subjects on stable PI
monotherapy during a median time of 380 (IQR 345425) weeks
were switched to darunavir/cobicistat, 121 (97.6%) with darunavir/
ritonavir and three (2.4%) with lopinavir/ritonavir. The median time
of follow-up on darunavir/cobicistat was of 20 (IQR 1221) weeks.
Two patients discontinued darunavir/cobicistat and 122/124 (98.4%)
subjects maintained virologic suppression. One subject experienced
virologic failure after 23 weeks on darunavir/cobicistat. One addi-
tional patient discontinued because of diarrhoea which was solved
switching again to darunavir/ritonavir. Switching to monotherapy
strategy with darunavir/cobicistat seems to be effective and safe in
the short term in subjects from clinical setting with suppressive and
long-term PI monotherapy. Data from long-term effectiveness and
clinical trials are needed.
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Abstract P086Table 1. Population characteristics
Overall population (N1461) EFV/FTC/TDF (N998) RPV/FTC/TDF (N463) p
Male gender 1083 (74) 762 (77) 321 (69) 0.003
Risk factor
Heterosexual 513 (35) 347 (35) 166 (36) B0.001
Homosexual/bisexual 443 (30) 310 (31) 133 (29)
IDU 167 (11) 97 (8) 70 (15)
Other 232 (16) 186 (19) 46 (10)
HCV 215 (15) 127 (15) 88 (26) B0.001
Prior AIDS events 336 (23) 239 (26) 97 (22) 0.144
Age (years), median (IQR) 44 (3750) 44 (3749) 46 (3852) 0.014
Time from HIV diagnosis (years), median (IQR) 6.9 (2.612.9) 6.0 (2.411.4) 8.9 (3.816.5) B0.001
Time of ARV (years), median (IQR) 4.6 (1.29.9) 3.9 (18.9) 6.0 (2.213.0) B0.001
Baseline CD4(cells/mL), median (IQR) 573 (424773) 546 (400717) 662 (480905) B0.001
Nadir CD4(cells/mL), median (IQR) 224 (102328) 213 (98315) 248 (119391) B0.001
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Objectives: To compare safety, efficacy and durability of simplification
to different STR (efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF)
vs. rilpivirine (RPV)/FTC/TDF) in virologically suppressed patients.
Materials and methods: We retrospectively analyzed HIV patients
with HIV RNA B50 copies/mL on a ]3-drugs non-STR therapy
switching to STR in five Italian centres. Patients were followed from
baseline (time of switch) until STR discontinuation or a 3-year
maximum follow-up. Time to treatment discontinuation (TD) and
virologic failure (VF: HIV RNA 50 copies/mL in two consecutive
determinations or 1000 copies/mL in one) and their predictors
were investigated.
Results: A total of 1461 patients were enrolled of which 998 (68%)
switching to EFV/FTC/TDF and 463 (32%) to RPV/FTC/TDF (character-
istics in Table 1).TD occurred in 223 (22%) patients with an incidence of
8.7 per 100 PYFU in EFV/FTC/TDF and in 50 (11%) patients with an
incidence of 5.3 per 100 PYFU in RPV/FTC/TDF.VF occurred in 34 (3.4%)
patients with an incidence of 1.3 per 100 PYFU in EFV/FTC/TDF and in
24 (5.2%) patients with an incidence of 2.6 per 100 PYFU in RPV/FTC/
TDF. At survival analysis, the estimated 3-year probability of remaining
free from TD was 77.7% in EFV/FTC/TDF versus 89.2% in RPV/FTC/TDF
(p0.001); after excluding patients switching to EFV/FTC/TDF from
EFVTDF/FTC (sub-population 1, n806), TD was 71.7% versus
89.2% (pB0.001), respectively. At multivariate Cox regression analy-
sis, predictors of TDweremale sex (aHR 0.73, p0.020), age (aHR 1.01
per year more, p0.033), switching from NNRTI-based regimen (aHR
0.53, p0.028), STR regimen (RPV/FTC/TDF vs. EFV/FTC/TDF, aHR
0.35, pB0.001), the latter being confirmed also in sub-population 1
(aHR 0.25, pB0.001) together with time on cART (aHR 1.06,
pB0.001). The 3-year probability of remaining free from VF was
96.6% EFV/FTC/TDF versus 94.8% RPV/FTC/TDF (p0.011) in the
overall population, 96.8% versus 94.8% in sub-population 1
(p0.074). At multivariate analysis, time on cART demonstrated a
possible association with VF in the overall population (aHR 1.041,
p0.088), more relevant in sub-population 1 (aHR 1.069, p0.020).
Three years after switch, a statistically significant difference in mean
change of total cholesterol and HDL at 3 years and of creatinine at 2
years was observed between the two groups (Figure 1); these data
were substantially confirmed until 2 years after switch in sub-
population 1 and in those switching from a PI-based regimen.
Conclusion: Both regimens showed good safety and efficacy,
although switch to RPV/FTC/TDF seemed to be better tolerated
and with a better lipid profile while EFV/FTC/TDF seemed to have a
lower probability of VF.
Value expressed as N (%).
P087
Efficacy and safety of switch from DRV/r to DRV/COBI in HIV
monotherapy
A´ngela Gutie´rrez Liarte; Ana Go´mez Berrocal; Rosa De Miguel
Buckley and Jesu´s Sanz Sanz
Infectious Diseases, Hospital La Princesa, Madrid, Spain
Introduction: DRV/r monotherapy is an effective maintenance
strategy endorsed by clinical practise guidelines for selected patients.
Cobicistat (COBI) is a booster that is as an alternative to ritonavir. DRV/
COBI has got equivalent efficacy and safety profile as DRV/r.
Coformulated DRV/COBI 800/150 mg has been recently approved
for commercialization, which can simplify treatment regimens.
Primary endpoint of this study was a combined efficacy endpoint of
coformulated DRV/COBI 800/150 mg monotherapy as a simplification
strategy in patients receiving DRV/r. Efficacy was defined as RNA HIV
B50 copies/mL and the absence of treatment switch or discontinua-
tion. Secondary endpoints were to analyze the drug safety profile and
the development of resistance mutations in case of virologic failure.
Materials and methods: Observational, longitudinal, retrospective
cohort study of 59 patients on previous monotherapy with DRV/r
that were switched to coformulated DRV/COBI 800/150 mg, at the
Infectious Diseases Department at La Princesa Hospital (Madrid,
Spain). Efficacy and safety data from baseline and control point were
collected. Failure was defined as RNA HIV 50 copies/mL in a
unique determination, according to the snapshot algorithm or
treatment switch or discontinuation. For safety evaluation, clinical
events and laboratory data were reviewed. Adverse events were
graded according to the Division of AIDS classification system.
Statistical analysis was performed with IBM SPSS Statistics V22.0.
Results: After 9.85 weeks of median follow-up, the combined
efficacy was 96.6%. There were two cases of virologic failure. Both
patients presented a CD4 nadir count below 200106 cells/L, no
previous history of virologic failure or resistance mutations, and RNA
HIV B50 copies/mL at baseline. One of them (1.7%) acquired the
E138A mutation in the reverse transcriptase, without the appearance
of resistance mutations for protease inhibitors. Adverse events were
described in 10.2% of the patients, all of which were grade 2. There
were no treatment switches or discontinuations. Reduction of 5.38
mL/min/m2 in the GFR was observed. Total cholesterol levels
increased 6.8 mg/dL.
Conclusion: DRV/COBI 800/150 mg is an effective and safe regimen
that allows to simplify boosted DRV monotherapy for the treatment
of HIV.Figure 1. Lipids and creatinine mean changes.
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P088
Efficacy and safety of dual therapy with Rilpivirine and
boosted Darunavir in treatment-experienced HIV patients
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Maria Jose Galindo8; Jose Alberto Terron9 and Miguel Garcia-
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Introduction: Long-term care and prevention of cumulative toxicity
related to antiretroviral therapy (ART) have become main objectives
of HIV patient management. Nuke-sparing regimens offer an
alternative to conventional therapy, with similar efficacy and less
potential toxicity. Dual therapy with rilpivirine and boosted darunavir
(RPVDRVb) is an attractive combination, currently used in clinical
practise but with little data from clinical trials. For this reason, we
have retrospectively analyzed why this combination is being used as
well as its efficacy and safety in real-life patients.
Methods: Here we present preliminary data of an observational,
multi-centre, retrospective study in HIV patients that have received
RPVDRVb for at least 24 weeks to optimize and/or simplify their
previous ART.
Results: Data from 140 patients of 15 hospitals were collected with a
median (m) age of 47 years, 25.7% had previous AIDS stage and
CD4 lymphocyte nadir of 163 cells/mL (m) (IQR 61283). They had
been diagnosed with HIV for 239 months (m) and had received 124
months (m) of ART, with five previous treatment combinations (m).
The reason for switch was simplification/optimization (47.9%), toxi-
city or intolerance (20%), and insufficient efficacy (with VLB1000
copies/mL) of previous ART (7.9%). A total of 23.6% of patients
presented a baseline VL between 50 and 1000 copies/mL. In 82.9%,
the combination was boosted with ritonavir and 43.6% of these
patients switched to cobicistat during the study. In the ‘‘intention-to-
treat’’ analysis at 24 weeks, 92.6% of 122 patients continue on study
treatment without virological failure (VF) criteria. Only 4.1% had VF
and of the remaining 3.3%, 0.8% abandoned treatment and 2.5%
presented toxicity or intolerance. Data from 18/140 patients still
have to be collected. In the analysis of virological efficacy of
‘‘observed data,’’ the last observed viral load of the 140 patients
who received the combination was B50 copies/mL in 87.1% of
cases.
Conclusions: We have observed that dual therapy with RPVDRVb
is being used in clinical practise, and it has proven to be effective in a
group of patients with a different profile from that of those required
to test monotherapy or other dual therapies with lamivudine
(advanced HIV infection, long exposure to ART, low CD4 nadir
and low level viremia).
P089
Simplification to dual protease inhibitor (PI)-, integrase
strand transfer inhibitor (INSTI)- and non-nucleoside
reverse-transcriptase inhibitor (NNRTI)-based less drugs
regimens in treatment-experienced HIV-1-infected patients
Antonio Mastroianni1; Elisabetta Briganti1; Francesco Allegrini1;
Carmela Grosso1; Sandra Brighi1; Gianfranco Ravaglia2;
Fabio Pieraccini2 and Claudio Cancellieri1
1UO Malattie Infettive, Ospedale G.B. Morgagni  L. Pierantoni, Forlı`,
Italy. 2UO Farmacia, Ospedale G.B. Morgagni  L. Pierantoni, Forlı`,
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Introduction: A retrospective analysis was undertaken to assess viro-
immunological and clinical outcomes of ritonavir (Rt)-boosted
protease inhibitor (PI)-based and integrase strand transfer inhibitor
(INSTI)-based regimens versus NRTI-NNRTI-based less drugs regimens
(LDR) in adult patients with a previous history of continuous three-
drugs PI- or NNRTI-based ART, who started dual ART, once both
plasma viral load (PVL) B40 copies/mL and CD4 cell count 200
cells/mL were achieved for at least 48 months.
Materials and methods: This was a monocentric, retrospective study
in a large tertiary care centre in Italy. HIV-infected patients receiving
Rt-boosted PI- and INSTI-based dual therapy (ATV/RtLMV, ATV/
RtLMV, LPV/RtLMV, RALNVP, 3TCRAL) versus NRTI-NNRTI-
based (3TCNVP, 3TCEFV) LDRs were systematically identified.
The primary outcome was the proportion of patients who main-
tained virological suppression at week 12, 24 and 48. Other primary
outcomes included immunological response, treatment failure and
development of drug resistance. The secondary endpoint was safety
(serious adverse effects, AIDS-related events and death). Follow-up
consisted of clinical assessments and routine laboratory monitoring,
and neurocognitive status at baseline and regularly at weeks 4, 8, 12
and every 12 weeks.
Results: Using our electronic medical database (Log80 software), we
exhaustively identified 130 patients that met our inclusion criteria
out of 790 HIV patients followed at the Infectious Diseases Unit of
Forlı` and Cesena Hospitals, searching up to 30 June 2016. Patient
median age was 54 years; 56% were men. All of the patients were
treatment experienced. Median baseline CD4 cell count was
803,065/mL and viral load was B40 copies/mL in all patients,
respectively. At 1218 months, an estimated 100% of patients
maintained undetectable viral load, there were no changes in CD4
cell count from baseline, there were no adverse events or com-
munication of new pathology and/or adherence problems. Dual ART
selection, according to the tolerability profile, the presence of
comorbidities and HIV-1 drug susceptibility testing, included: DRV/
RtLMV (41 patients), ATV/RtLMV (30 patients), 3TCNVP (25
patients), LPV/RtLMV (11 patients), RALNVP (6 patients),
3TCEFV (3 patients) and 3TCRAL (3 patients).The most common
reason for modifying ART was the development of dyslipidaemia and
bone mineral density changes, and less frequently renal toxicity and
hepatotoxicity.
Conclusions: In our experience, both PI-, INSTI- and NNRTI-based
less drugs regimens provided a high proportion of durable viro-
logical suppression and the average CD4 count has remained
above 350.
P090
Dolutegravir and unboosted atazanavir: a dual NRTI- and
booster-free antiretroviral regimen simplification in HIV-1
infected patients with viral suppression
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Anna Maria Cattelan5; Eugenia Quiros Roldan6; Micol Ferrara4;
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Introduction: There are increasing concerns about long-term toxicity
of antiretroviral treatment. NRTIs have the potential for long-term
toxicities and ritonavir has negative metabolic consequences and
drug-drug interactions. The combination of dolutegravir (DTG) with
unboosted atazanavir (uATV) is an intriguing new NRTI- and booster-
free regimen. We report a real-life experience of the simplification of
different antiretroviral regimens to DTGuATV.
Methods: A total of 61 patients were enrolled in our observational
study; 58 subjects with at least one follow-up visit. We evaluated
several laboratory parameters including CD4 T cell, HIV RNA and
metabolic values. We measured ATV and DTG trough concentra-
tions after a minimal 2-week interval from the start of the new
regimen.
Results: Patients enrolled in the study were predominantly males
(63%), CDC stage C was 22%, HCV-Ab positivity was 28% and the
previous regimen included more frequently 3 drugs, mainly PIs
(90%). Patients had a median time since first HIV-positive test of 16.1
years (10.223.6) and a median time of ART exposure of 14.3 years
(9.019.0). The reasons for switching to uATV  DTG were several:
mainly toxicities, comorbidities and simplification (Table 1). As far as
uATV: 55 patients were administered 400 mg QD, two patients 300
mg QD and one patient 200 mg BID; DTG was dosed 50 mg QD, but
one patient received 50 mg BID. Patients had a median follow-up of
4.9 months (IQR 2.37.8). At last visit, all patients on treatment had
undetectable HIV RNA. Two patients presented a viral blip during
follow-up (91 and 98 copies/mL), subsequently HIV RNA returned
negative without treatment modification. There were three treat-
ment discontinuations: one severe hyperbilirubinemia (grade 3), one
G-I intolerance and one patient was lost to follow-up. No differences
were found in laboratory parameters between baseline and the
last follow-up including immuno-virologic variables, except for a
significant decrease in tryglicerides (Table 2). ATV and DTG mean
concentrations were 310 ng/mL (95% CI 116504) and 3216 ng/mL
(95% CI 24363996) respectively. ATV concentration was below 150
ng/mL in 11 out of 28 patients.
Conclusions: ART switch towards this dual-drug regimen NRTI and
booster-sparing, although in a short follow-up, appears to be well
tolerated and safe. Virologic suppression was maintained in all
patients despite long-lasting HIV infection and ART treatment. DTG
concentrations are high in the majority of the patients as
expected from previous pharmacokinetics study. Despite low ATV
concentrations in several patients, no virologic failures were
observed. This NRTI- and RTV-sparing regimen appears an attractive
new strategy in patients with metabolic disorders and NRTI-related
toxicities.
P091
Treatment of HIV-positive patients with lamivudine plus
boosted protease inhibitor in a real-world setting
Chien-Yu Cheng1; Shu-Hsing Cheng1; Shu-Yin Chang2; Mei-Hui Lin2;
Shin-Yen Ku2; Hui-Ting Shieh2 and Na-Lee Sun2
1Department of Internal Medicine, Taoyuan General Hospital,
Ministry of Health and Welfare, Taoyuan City, Taiwan. 2AIDS Care
Center, Taoyuan General Hospital, Ministry of Health and Welfare,
Taoyuan City, Taiwan
Introduction: Some adverse effects of nucleoside reverse transcriptase
inhibitors including renal injury, myocardial injury and osteoporosis
Table 1. Baseline characteristics of the studied population
Characteristic Baseline
(n61)
Age (years) 52.1 (47.058.4)
Years since first HIV-positive test 16.1 (10.223.6)
Years of ARV exposure 14.3 (9.019.0)
CDC stage
A1 7 (11%)
A2 12 (20%)
A3 6 (10%)
B2 13 (21%)
B3 3 (5%)
C2 1 (2%)
C3 12 (20%)
Unknown 7 (11%)
Male gender 37 (61%)
Risk factor
Man who has sex with man 12 (20%)
Heterosexual 24 (39%)
Intravenous drug user 17 (28%)
Other/unknown 8 (13%)
White race 58 (95%)
European origin 58 (95%)
HCV-Ab positivity 17 (28%)
Genotype 1a 6
Genotype 1b 5
Genotype 3 2
Genotype 4 2
Unknown genotype 2
Type of ART regimen
PI/r monotherapy 2 (3%)
Dual therapy 16 (26%)
Three or more drugs 43 (71%)
Type of ART regimen according to the drug class
PI-based 55 (90%)
INSTI-based 3 (5%)
NNRTI-based 3 (5%)
Reasons for switch to ATVDTG regimen
Cardiovascular disease 2 (3%)
Concern of cardiovascular disease 7 (12%)
Dyslipidemia 8 (13%)
Comorbidity 4 (7%)
Immunologic failure  CD4 drop 1 (1.5%)
Non-compliance 1 (1.5%)
Simplified treatment available 15 (25%)
Toxicity  GI tract/abdomen 5 (8%)
Toxicity  liver 3 (5%)
Toxicity  kidney 8 (13%)
Toxicity  not specified 2 (3%)
Treatment failure 1 (1.5%)
Side effects 1 (1.5%)
Other 3 (5%)
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could limit the prescription of antiretroviral therapy in HIV-positive
patients, especially the aging patients with non-communicable dis-
eases. The GARDEL and OLE study of lamivudine plus lopinavir/ritonavir
demonstrated effectiveness and safety of dual therapy [1]. However,
the information of dual therapy in real world remains limited, so we
launch an observational study to monitor effectiveness and safety of
dual therapy of lamivudine plus boosted protease inhibitors.
Materials and methods: This prospective study was launched to
evaluate the effectiveness of virologic response and safety of dual
therapy of lamivudine (300 mg) plus lopinavir/ritonavir and darunavir/
ritonavir, and naı¨ve and treatment-experienced HIV-positive patients
were enrolled since May 2015. Patients with positive hepatitis B
antigen were excluded. In weeks 12, 24 and 48, CD4 lymphocyte cell
counts and plasma HIV RNA were measured, and these data are
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
VF
P = 0.016
P = 0.01
P = 0.97
group 1 & 2 group 3
group 1: naive patients
group 2: switch before suppresed viral loads
group 2: stable switch
TF LTFU
Abstract P091Figure 1. Virologic failure (VF) and treatment failure (TF) of dual therapy in 116 naı¨ve patients, 39 treatment-experienced
patients without suppressed plasma HIV RNA and 86 patients with suppressed plasma HIV RNA.
Abstract P090Table 2. Laboratory parameters at baseline and at last visit
Characteristic Baseline (n61) Last visit (n58) Change from baseline p
CD4 (cells/mL) 733 (578946) 690 (513872) 6 (150;83) 0.395
CD8 (cells/mL) 850 (5831159) 840 (5601169) 40 (165;117) 0.977
CD4 and CD8 ratio 0.90 (0.621.23) 0.90 (0.631.20) 0.07 (0.10;0.15) 0.988
White blood cells (109/L) 6.7 (5.58.4) 6.2 (5.57.4) 0.2 (0.8;0.6) 0.290
ALT (U/L) 26 (2042) 29 (2137) 1 (5;7) 0.829
AST (U/L) 26 (2235) 25 (2032) 0 (4;4) 0.535
Gamma GT (U/L) 27 (1849) 21 (1739) 1 (7;3) 0.262
Total bilirubin (mg/dL) 2.03 (1.083.00) 1.58 (0.992.28) 0.72 (1.58; 0.01) 0.168
Direct bilirubin (mg/dL) 0.72 (0.400.97) 0.57 (0.360.72) 0.07 (0.19;0.08) 0.136
Indirect bilirubin (mg/dL) 1.21 (0.642.00) 0.81 (0.501.58) 0.50 (1.16; 0.42) 0.544
FIB-4 1.18 (0.911.61) 1.23 (0.871.68) 0.04 (0.13;0.10) 0.866
Creatinine (mg/dL) 0.90 (0.801.04) 0.96 (0.811.16) 0.08 (0;0.15) 0.240
EGFR (mL/min/1.73 m2) 89 (76100) 83 (6696) 5 (13;0) 0.300
Total cholesterol (mg/dL) 194 (156219) 184 (165216) 2 (21;15) 0.790
LDL cholesterol (mg/dL) 119 (90149) 108 (85131) 3 (7;13) 0.363
HDL cholesterol (mg/dL) 46 (3957) 50 (4265) 7 (4;12) 0.091
Total and HDL cholesterol ratio 3.93 (3.085.29) 3.58 (2.884.44) 0.25 (0.85;0.29) 0.116
Triglycerides (mg/dL) 139 (86193) 108 (84145) 13 (70;18) 0.049
Glucose (mg/dL) 92 (8498) 91 (84106) 0 (9;5) 0.814
Haemoglobin (109/L) 14.8 (13.915.9) 14.7 (13.915.7) 0.2 (0.6;0.4) 0.616
Platelets (109/L) 223 (174272) 230 (180276) 0 (19;12) 0.828
MannWhitney tests were used to evaluate differences between BL and follow-up; results are reported as median (IQR) or frequencies (%).
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compared with those at baseline before enrolment. All adverse
effects are documented during the study.
Results: Since May 2015 to May 2016, 116 naı¨ve patients (group 1),
39 (group 2) treatment-experienced patients without suppressed
HIV RNA (50 copies/mL) and 82 (group 3) treatment-experienced
patients with suppressed HIV RNA (B50 copies/mL) were enrolled in
the study. The median age was 3499 and 3898 years in group 1 & 2
and group 3 (pB0.001), and 94.2% and 79.3% (pB0.001) were male
patients, respectively. Positive HCV Ab was 36.1% versus 37.3%
(p0.79). Median baseline CD4 cell counts before enrolment were
338 (5908) and 490 (861071) cells/L (pB0.001). However, rate of
virologic failure (plasma HIV RNA 200 copies/mL) was 10.3%
(10/97) and 1.3% (1/76) (p0.016, ORs 8.62, 95% CI 1.0868.91) for
group 1 & 2 and group 3 in week 24. Treatment failure was 20%
versus 7.3% (p0.01, ORs 3.23, 95% CI 1.109.49), respectively.
Thirty-seven patients discontinued dual therapy, 20% patients (29/
145) taking lopinavir/ritonavir had severe GI tract upset or diarrhoea
and 7.3% patients (8/110) taking darunavir/ritonavir had
grade 3 urticaria or diarrhoea (p0.004, ORs 3.19, 95% CI 1.40
7.29) (Figure 1).
Conclusions: Lamivudine plus lopinavir/ritonavir or darunavir/
ritonavir demonstrated comparable effectiveness for patients with
suppressed HIV RNA in our cohort. However, adverse effects of GI
tract upset and diarrhoea could impede application of dual therapy
for naı¨ve patients in real world.
Reference
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Sergio Maria Ferrara1; Alessandra Tartaglia2; Salvatore Sica1 and
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Introduction: Simplification to a dual therapy improves adherence by
reducing pill burden, short- and long-term toxicities and lowers
additional costs for clinical management. ATV/r3TC dual therapy
has recently been approved by Italian and European guidelines as
switching strategies from standard cART in virologically suppressed
patients. The aim of this 48-month observational study in a real-life
setting was to evaluate the efficacy, safety and impact on
cardiovascular event of ATV/r3TC dual therapy.
Methods: We enrolled 55 HIV-positive patients on stable HIV VL
suppression in the last 6 months, without resistance to PI and in
absence of chronic HBV co-infection. Cardiovascular risk was
evaluated using the Framingham risk score (FRS). Carotid intima-
media thickness (c-IMT) was assessed by colour Doppler ultrasono-
graphy and a c-IMT 0.9 mm was considered to be pathological.
Results: Thirty-five patients were males (64.2%), and median age was
49 years (range 2874 years) (Table 1). Thirteen subjects (24.5%) had
AIDS and 15 (27.3%) were HCV co-infected. A total of 32 patients
(58.2%) were smokers. Length of HIV diagnosis was 12.5 years (133
years). Cumulative exposure to HAART was 9 years (120 years).
Median baseline CD4 count was 674 cells/mm3. In previous regimen,
ARV backbone was TDF/FTC (81.8%) and ABC/3TC (18.2%). Reasons
for switching were: 43 simplification (78.2%); 12 TDF-related
toxicities (21.8%) distributed as follows: seven (58.3%) renal toxicity
and five (41.7%) osteoporosis.
After 48 weeks of dual therapy all participants maintained virological
suppression and no severe adverse events or treatment interruptions
were registered; mean CD4 count gain was 58 cells/mm3. A
significant increase in mean lipid concentration was reported for HDL
cholesterol (7.9 mg/dL, pB0.0001), LDL cholesterol (2.2 mg/dL,
pB0.0001) and triglycerides (20.5 mg/dL, pB0.0001) while total
cholesterol decreased (6.5 mg/dL, pB0.0001). However, total
cholesterol/HDL ratio and LDL/HDL ratio did not demonstrate any
significant change (mean changes at 48 months 0.06 and
0.003). No progression of c-IMT was observed at 48 weeks leading
to an improvement of FRS (p0.003). Hyperbilirubinaemia corre-
lated with c-IMT at 48 weeks (p0.0009) suggesting a potential
anti-inflammatory and protective role. Slow c-IMT progression
correlated with CD4/CD8 ratio B0.8 (p0.004) which seems to
be a surrogate predictor of CV risk. A significant increase of eGFR
(CKD-EPI mL/min/1.732) was observed in patients switching for TDF
toxicity (p0.005). Moreover, the use of ATV/r3TC regimen
permitted in our cohort to save of t242,676 per year compared
with conventional therapy. (Table 2)
Table 1. Characteristics of patients (total patients55)
Total N of patients55
Sex, n (%)
Females 20 (36.4%)
Males 35 (63.6%)
Age, years, median (range)
Total 49 (2874)
Males 50.5 (2874)
Females 47 (3270)
Risk factor, n (%)
Heterosexual 28 (50.9%)
MSM 11 (20%)
TD 16 (29.1%)
CDC stage, n (%)
C3 14 (25.4%)
Other 41 (74.5%)
HAART exposure, years, median (range) 9 (120)
Length of HIV infection, years, median (range) 12.5 (18)
Previous HAART regimens
PI (%) 24 (43.6%)
NN (%) 5 (9.1%)
Naive 26 (47.3%)
HCV co-infection, n (%) 15 (27.3%)
Comorbidities
Total 39/55 (70.96%)
Smoking 32/39 (82.1%)
Diabetes 3 (7.7%)
Hypertension 5 (12.8%)
Dyslipidaemia 5 (12.8%)
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Conclusions: Dual ATV/r3TC therapy may optimize cART and
helps clinicians to avoid drawbacks and toxicities due to NRTI
backbone, while maintaining the efficacy and the convenience of a
robust cART.
TREATMENT STRATEGIES: SWITCH STUDIES
P093
Efficacy and safety of emtricitabine/tenofovir alafenamide
(FTC/TAF) versus emtricitabine/tenofovir disoproxil
fumarate (FTC/TDF) as a backbone for treatment of HIV-1
infection in virologically suppressed adults: subgroup
analysis by third agent
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Introduction: The efficacy and safety of TAF has been mostly
evaluated in the context of the coformulation of elvitegravir (E),
cobicistat (C), FTC (F) and TAF (E/C/F/TAF). Multiple clinical trials of
E/C/F/TAF have consistently demonstrated the advantages of TAF
over TDF for markers of renal and bone safety. However, it has not
been shown whether these safety advantages of TAF are seen when
combined with other third agents.
Materials and methods: We conducted a subgroup analysis by the
class of co-administered third agent (boosted protease inhibitors
(PIs) vs. unboosted third agent) for efficacy (prespecified) and safety
Abstract P092Table 2. Costs and saving of dual therapy compared to conventional treatment in our cohort (Foggia, Italy)
cART regimens
Monthly costs
(Ospedali Riuniti
Foggia, Italy)
Monthly saving per patient
(compared with dual ATV/r3TC
therapy)
Monthly saving (compared
with dual ATV/r3TC
therapy)
Saving per year (compared
with dual ATV/r3TC
therapy)
ATV/rTDF/FTC t724.5 n45 patients: t16848.0 n45 patients: t16,848.0 n45 patients: t202,176.0
ATV/rABC/3TC t687.6 t337.5 n10 patients: t3375.0 n10 patients: t40,500.0
ATV/r3TC t350.1   n55 patients: t242,676.0
Abstract P093Table 1. Changes in measures of renal and bone safety by third agent
Boosted PI Boosted PI Unboosted third agent Unboosted third agent
FTC/TAF (n155) FTC/TDF (n151) FTC/TAF (n178) FTC/TDF (n179)
eGFR
Median baseline (mL/min) 102.2 104.5 98.3 97.2
Median changes at week 48* (mL/min) 7.7 3.3 9.3 2.8
Urine protein: creatinine ratio
Median baseline value (mg/g) 57.8 66.7 60.6 59.6
Median % changes at week 48* 11.1 12.8 16.9 2.1
Urine albumin: creatinine ratio
Median baseline value (mg/g) 6.3 6.4 5.8 6.1
Median % changes at week 48* 1.8 21.2 11.6 4.4
Urine beta-2-microglobulin: creatinine ratio
Median baseline value (mg/g) 140.3 186.5 131.9 134.2
Median % changes at week 48* 39.3 36.4 40.2 14.0
Urine retinol binding protein: creatinine ratio
Median baseline value (mg/g) 112.4 117.5 100.9 106.8
Median % changes at week 48* 13.5 24.8 17.3 11.8
Spine BMD
Mean baseline value (g/m2) 1.08 1.07 1.09 1.08
Mean % changes at week 48* 1.48 0.40 1.45 0.13
Hip BMD
Mean baseline (g/m2) 0.98 0.97 0.98 0.98
Mean % changes at week 48* 1.10 0.08 1.00 0.22
*p-values for all between-group differences (FTC/TAF vs. FTC/TDF) were B0.05.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
77
(ad hoc) from a 48-week randomized, double-blind, active-controlled
study in virologically suppressed, HIV-positive participants who
switched to FTC/TAF from FTC/TDF versus continuing FTC/TDF while
remaining on their original third agent. The prespecified non-
inferiority margin for the overall study was 10%.
Results: Among 663 treated (FTC/TAF n333, FTC/TDF n330), 47%
and 46%, respectively, received boosted PIs. Median age (49 years),
median CD4 count (646 cells/mL), renal laboratory parameters and
bone mineral density (BMD) were similar between the subgroups.
Overall, median duration of FTC/TDF use prior to dosing was 5.1
years. At week 48, significant differences in changes of renal
biomarkers and BMD were observed favouring FTC/TAF over FTC/
TDF (pB0.05 for all), with similar improvements within the FTC/TAF
arm in those who received boosted PIs versus unboosted third agents
(Table 1). Few participants discontinued study drug due to adverse
events in either subgroup (boosted PI: FTC/TAF 4%, FTC/TDF 1%;
unboosted third agent: FTC/TAF 1%, FTC/TDF 1%). No cases of Fanconi
syndrome or proximal renal tubulopathy were reported. Switching to
an FTC/TAF-containing regimen was non-inferior to staying on a
baseline FTC/TDF-containing regimen in maintaining HIV-1 RNA less
than 50 copies/mL for participants receiving either a boosted PI (92%
vs. 93%; difference: 1.1%; 95% CI 7.14.9%) or an unboosted
third agent (97% vs. 93%; difference: 3.3%; 95% CI 1.27.9%).
Conclusions: Regardless of third agent (boosted PI or unboosted
third agent), FTC/TAF was non-inferior to FTC/TDF in maintaining
virologic suppression at week 48 and renal and bone parameters
significantly improved in those who switched from TDF to TAF.
Overall safety was similar for FTC/TAF administered with a boosted PI
or an unboosted third agent. FTC/TAF can be an important NRTI
backbone option that can be used in combination with a variety of
third agents.
P094
Population pharmacokinetics (PK) of dolutegravir (DTG)
alone and following treatment switch
Laura Dickinson1; Margherita Bracchi2; Emilie Elliot2; Laura Else1;
Saye Khoo1; David Back1; Mark Nelson2 and Marta Boffito2
1Department of Molecular & Clinical Pharmacology, University of
Liverpool, Liverpool, UK. 2St Stephen’s Centre, Chelsea &
Westminster Foundation Trust, London, UK
Introduction: The integrase inhibitor DTG is a preferred antiretroviral
in many treatment guidelines. Efavirenz (EFV) induces DTG UGT1A1
and CYP3A4-dependent metabolism but dose adjustments are not
recommended following treatment switch with steady-state DTG
reached week 4 post-switch [1,2]. Population PK analysis was
performed to describe DTG PK and investigate changes in DTG after
switching from an EFV-based regimen.
Materials and methods: Model development (NONMEM version 7.3)
combined DTG concentration-time data (50 mg once daily) from two
studies. Study 1 was in healthy volunteers administered DTG for 10
days with serial blood sampling performed for 216 hours following
the final dose [3]. Study 2 was in HIV-infected, virologically
suppressed patients switched from EFV to DTG with random single
samples drawn at week 1, 2, 3 and 4 post-switch (samples between 1
and 25.75 hours post-dose). The impact of residual EFV on DTG
apparent oral clearance (CL/F) after switching compared with DTG
alone was determined. Covariates including weight, age, BMI, sex,
ethnicity, HIV status and food consumption within 3 hours of drug
intake were also assessed and the model evaluated by simulation
and visual predictive check.
Results: Fifty-six individuals were included (n14 female, n35
Caucasian; n17 healthy, n39 HIV). DTG up to 216 hours was
described by a two-compartment model parameterized by CL/F
(estimate (RSE%): 0.85 L/h (5%)), central volume of distribution (Vc/
F: 17 L (7%)), intercompartmental clearance (Q/F: 0.0082 L/h (20%))
and peripheral volume of distribution (Vp/F: 0.73 L (8%)) with
absorption rate constant fixed to 2.24 hours1 [4]. Interindividual
variability was 17% (41%) and 16% (39%) for CL/F and Vc/F,
respectively. Following multivariate analysis weight was the only
significant covariate to remain in the model. DTG CL/F was increased
by 34%, 60%, 13% and 11% at week 1, 2, 3 and 4 following switch,
respectively compared with DTG alone. Based on 100 simulations
DTG AUC024, Cmax and trough (C24) at week 1, 2, 3, 4 post-switch
were significantly lower than DTG alone (Table 1); however, all
simulated C24 were above the protein-adjusted IC90 of 0.064 mg/L
post-switch (median (range) 0.81 mg/L (0.251.75)).
Conclusions: Population PK parameters were comparable with
previous reports [4] with between-study differences attributable to
EFV. Simulated DTG PK parameters were reduced following switch
even at week 3/week 4 (20% for C24), potentially highlighting
important PK differences between healthy and HIV-infected indivi-
duals. However, consistent with recent data [1] concentrations
remained above the protein-adjusted IC90 post-switch, supporting
findings that dose adjustments may not be required in the described
patient population.
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Abstract P094Table 1. Changes in DTG PK parameters following switch from an EFV-based regimen expressed as geometric mean
ratio (GMR; 90% CI) determined from simulations using the final model parameters (n100)
GMR (95% CI; DTG as reference)
Parameter Week 1 Week 2 Week 3 Week 4
AUC0-24 0.73 (0.690.76) 0.61 (0.580.64) 0.87 (0.830.91) 0.88 (0.840.92)
Cmax 0.84 (0.800.88) 0.78 (0.740.82) 0.92 (0.880.96) 0.92 (0.880.97)
C24 0.57 (0.530.61) 0.40 (0.370.42) 0.79 (0.740.84) 0.81 (0.760.86)
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P095
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Introduction: To assess, in a clinical cohort of virologically suppressed
patients, the virologic response after switching ARV treatment to a
dolutegravir (DTG)-based regimen based on the genotypic suscept-
ibility score.
Materials and methods: A prospective, observational, single-centre
cohort enrolling all patients with a plasma viral load (pVL) B50
copies/mL initiating a DTG-based regimen between September and
December 2015. VL were performed using Cobas Taqman HIV-1
version 2.0 assay. The Genotypic Susceptibility Score (GSS) of the
antiretroviral regimen was calculated using the ANRS version 25
(September 2015) algorithm including DTG, translating the inter-
pretations ‘‘susceptible’’, ‘‘possible resistance’’ and ‘‘resistance’’ into
susceptibility scores of 1, 0.5 and 0, respectively.
Results: Among 254 patients who switched to a DTG-based regimen,
209 had historical available genotypes. Among them, taking into
account all historical genotypes, 27 (13%), 61 (29%) and 121 (58%)
had a GSS equal to 1 or 1.5, 2 and 3, respectively. Median time since
last genotype was 9, 9 and 5 years in the 1 or 1.5, 2 and 3 GSS strata,
respectively. Patients’ characteristics at time of DTG-based regimen
initiation were different according to the GSS, as depicted in Table 1.
At week 24, seven patients (3.3%) discontinued DTG-based regimen:
neuro-psychological side effects (n1), cutaneous side effects
(n1), pregnancy (n1), renal toxicity (n1), headaches (n1)
and patients’ decision (n2). At week 12, 95%, 96% and 95% of the
patients had pVL B50 copies/mL in the 1 or 1.5, 2 and 3 GSS strata,
respectively. At week 24, 100%, 96% and 96% of the patients had pVL
B50 copies/mL, in the 1 or 1.5, 2 and 3 GSS strata, respectively.
Among the 12 patients (11.9%) displaying a pVL 50 copies/mL
(median 102 copies/mL, IQR 61417), nine experienced a viral blip,
one a virologic failure (VF) and in the two remaining patients no
further control sample was available. The only one patient (1%)
experiencing VF was highly pre-treated including a previous VF under
a RAL-based regimen with no selection of integrase resistance
mutations and with a GSS3.
Conclusions: In this observational cohort, patients’ characteristics at
time of switching to a DTG-based regimen were different depending
on the GSS strata. However, short-term follow-up showed a high level
of the maintenance of virologic suppression, regardless of the baseline
GSS. These data suggest that DTG remains potentially able to maintain
viral suppression when combined with fully or incompletely active
drugs in these long-term virologically suppressed patients.
P096
Evaluation of virologic efficacy and economic savings in a
Portuguese hospital after splitting the single-tablet regimen
EFV/FTC/TDF (Atripla†) to an equivalent double-tablet
regimen (efavirenz+Truvada†)
Mafalda Guimara˜es; Ineˆs Vaz Pinto; Catarina Santos and Sara Alves
Cascais Hospital, HIV Unit, Cascais, Portugal
Introduction: Single-tablet regimens (STR) of ART are now widely
available. The combination of fixed-dose antiretrovirals in just one
Abstract P095Table 1. Patients’ characteristics
Characteristic GSS1 or 1.5 (n27) GSS2 (n61) GSS3 (n121)
Male sex, n (%) 21 (78) 35 (57) 86 (71)
Age, median years (IQR) 51 (4655) 53 (4259) 51 (4158)
Time since HIV diagnosis, median years (IQR) 21 (1624) 20 (821) 13 (621)
Duration of prior ART, median years (IQR) 17 (1020) 18 (519) 11 (520)
Number of previous ART lines, median (IQR) 8 (510) 6 (27) 4 (27)
Duration of HIV-1 RNA B50 copies/mL before switch, median years (IQR) 3 (27) 4 (25) 3 (15)
Baseline CD4 cell count, median cells/mm3 (IQR) 670 (435863) 645 (535865) 570 (400750)
Nadir CD4 cell count, median cells/mm3 (IQR) 183 (63209) 236 (204386) 221 (85325)
Associated antiretroviral drugs, n (%)
ABC/3TC 19 (70) 4 (7) 75 (62)
TDF/FTC 1 (4) 4 (7) 29 (24)
3TC 0 (0) 7 (11) 0 (0)
RPV 3 (11) 26 (43) 0 (0)
DRV/r 0 (0) 5 (8) 0 (0)
ATV/r 1 (4) 6 (10) 0 (0)
RPVNRTI 0 (0) 3 (5) 10 (8)
Other ARV drugs 3 (11) 6 (10) 7 (6)
Number of NRTI drug resistance mutations, median (IQR) 2 (15) 2 (03) 0 (00)
Number of M184V, n (%) 27 (100) 32 (52) 10 (8)
Number of NNRTI drug resistance mutations, median (IQR) 1 (02) 0 (02) 0 (01)
Number of major PI drug resistance mutations, median (IQR) 0 (02) 0 (00) 0 (00)
Time since last genotypic resistance test, median years (IQR) 9 (412) 9 (514) 5 (312)
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tablet has been shown to improve long-term adherence and
patients’ satisfaction. Also, STR eliminates the possibility of selective
non-adherence. Due to the global economic crisis since 2009 and
subsequent financial restraints observed in health systems world-
wide, the board of Cascais Hospital decided in April 2014 to split the
STR Atripla† for its two constituents, FTC/TDF (Truvada†) and
efavirenz. The switch from STR to a dual-tablet regimen (DTR) was
done by each patient’s doctor, after full explanation and patient
consent. The purpose of our study was to retrospectively evaluate
the impact of splitting a STR into its two separate components on
virologic effectiveness at 24 weeks. We also looked at the direct
economic benefits obtained with this global switch.
Material and methods: The switch from STR to DTR was made
between April 1 and June 30, 2014, at the time of clinic appointment
or pharmacy refill, where patients were referred to the clinic. We
reviewed clinical files and present data on demographic character-
ization by age, sex and route of HIV transmission. Data were
collected on CD4 count and HIV viral load (VL) at the time of switch
and at 24 weeks thereafter.
Results: On 31 March 2014 a total of 1036 patients at our clinic were
on ART; 230 patients were on Atripla† (22.2%). A total of eight
patients did not do the split (three lost to follow-up, three had
virologic failure, one for lactose intolerance and one for lack of
consent). A total of 222 patients were switched from STR to a DTR.
At week 24, 31 (13.9%) patients were no longer taking the
efavirenz+Truvada† regimen, mainly due to perceived adverse effects
of either of the two components of the regimen. Of the 190 patients
still taking efavirenz+Truvada† 24 weeks after the split of Atripla†,
179 (94%) had VL B20 copies/mL at week 24. Two patients were lost
to follow-up, eight had virologic blips (VL 20 but B500 copies/mL)
and one had virologic failure. The direct economic savings obtained by
splitting a STR was _291,000 in a 9-month period.
Conclusions: Our centre’s experience with switching all patients on a
STR to an equivalent DTR proved to be effective and resulted in
significant economic savings that continue to the future.
P097
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Introduction: In patients switching from complex salvage regimens
for simplification or failure, the association of dolutegravir and
darunavir provides high genetic barrier to HIV-1 resistance.
Methods: All HIV-1 infected subjects treated with dolutegravir plus
boosted darunavir between March 2014 and September 2015 were
included in an observational cohort. After ethics committees’
approval, no further enrolment was allowed. Only clinical events,
demographic data, CD4 cell counts, HIV-1 RNA, serum creatinine and
urinary proteins were deemed relevant for this study.
Results: Hundred and fourteen subjects were enrolled. The mean age
was 51, females were 26.5% and non-Caucasians 9.7%. The main risk
factor was being male homosexual (46%), followed by drug abuse
(28.3%) and heterosexual intercourse (23.9%). The main reason for
switching was simplification (46%), followed by viral failure (27.4%),
toxicity (14.9%), persistent low-level viremia (5.3%), lack of adher-
ence (3.5%) and immunologic failure/disease progression (2.6%). RT
mutations were present in 83.2%, 80.5% had protease mutations and
10.5% had INSTI mutations. Between week 24 and 48 one subject
was lost to follow-up, one died of drug abuse and one of cancer-
related sepsis, one dropped out for elevation of liver enzymes, one
for dyslipidaemia and one stopped all drugs for personal decision.
The proportion of viremic subjects at baseline declined steadily by
week 4 from 40.7% to 14.1%, with a 1 log10 decay in all but one,
that had stopped the therapy for 3 weeks, and further by week 24 to
6.2% (range 53805 copies/mL). Measurable viremia B50 copies/
mL declined from 20.4% to 5.3%. Subjects at zero viremia increased
from 38.9% to 59.3% by week 4 and to 73.5% by week 24. Of the 84
subjects who have a 48-week follow-up, five still have 50 copies
HIV-1 RNA/mL (range 5199), 16 have viral load B50 copies and in
63 zero viremia. Eighteen subjects had reduced sensitivity to
darunavir (Stanford median score 15, range 1540), but none failed.
Also, none of the subjects who had baseline INSTI mutations failed
and there was no accumulation of mutations. The median variation
in serum creatinine was 0.01 (range 0.2 to 0.21), and only
one subject had a new onset of mild proteinuria.
Conclusions: This dual regimen yielded excellent results in a complicate
population, providing the simplest and safest salvage regimen ever.
P098
A retrospective analysis to evaluate and compare the
efficacy of switching to Stribild fixed-dose combination in
virologically suppressed HIV-1 infected adults with or
without the archived NRTI resistance mutation M184V/I
Vanessa Silebi
Infectious Diseases, Mercy Hospital, Miami, FL, USA
Introduction: The prevalence of an isolated NRTI M184V/I resistance
mutation in reverse transcriptase (RT) region in HIV-1 infected
patients is as high as 60% [14] with limited switch options in
patients harbouring this mutation, and it is recommended that these
patients be switched to protease inhibitor-containing regimens. The
aim of this retrospective pilot study is to validate the ability of
elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate
Table 1. Results
Time Mutation %VL B50 CD4 X (SD)
Baseline Resistant (n30) 100 483 (199)
Sensitive (n29) 100 628 (253)
12 weeks Resistant (n30) 90 489 (262)
Sensitive (n25) 96 666 (286)
24 weeks Resistant (n28) 96 491 (263)
Sensitive (n27) 89 636 (294)
48 weeks Resistant (n26) 88 502 (224)
Sensitive (n24) 96 675 (269)
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
80
(Stribild) fixed-dose combination (FDC) to maintain virological
suppression in patients harbouring M184V and/or M184I mutations
to NRTIs over a one-year period.
Methods: Using data collected from a single site HIV clinic, we
examined the ability of Stribild to maintain virological suppression in
30 patients harbouring M184V and/or M184I mutations compared
with 29 patients in the M184V/I negative cohort. Eligible patients
had documented VL B50 copies/mL prior to switch, with subse-
quent VL and CD4 counts collected at follow-up visits at 12, 24 and
48-week time points. All patients were randomly selected in both
arms. The primary endpoint measured was the proportion of subjects
in each arm with HIV-1 RNA B50 copies/mL at Week 12.
Results: The Resistant arm saw 90%, 96% and 88% VL suppression
(defined at B50 copies/mL) over the 12, 24 and 48 week time points,
respectively (Table 1). Of note three patients in the M184V/I cohort
(10%) rebounded at week 12, all self-reported non-compliant; two of
the three patients re-suppressed at week 24. For secondary endpoints,
data trended with both cohorts benefiting while on Stribild.
Conclusions: Data indicate Stribild may be a reasonable option in
virologically suppressed (HIV-1 RNA B50 copies/mL) HIV-1 infected
adults harbouring an archived isolated M184V and/or M184I
mutation. Future analysis and correlation with previous regimens
and included mutations prior to switch will be analyzed. A
prospective, multi-centre study to determine the variables that
affect switch therapy is currently being planned.
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Dolutegravir plus rilpivirine in cART-experienced subjects:
an observational cohort
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Cossu1; Giuseppe Vittorio De Socio3; Simona Di Giambenedetto4;
Benedetto Maurizio Celesia5; Barbara Argenteri1; Antonio Di Biagio6;
GianCarlo Orofino7; Giorgio Barbarini8 and Giuliano Rizzardini1
11st Division of Infectious Diseases, Luigi Sacco University Hospital,
Milano, Italy. 2Division of Infectious Diseases, Careggi Hospital,
Firenze, Italy. 3Infectious Diseases Clinic, Azienda Ospedaliero-
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Introduction: Little is known on the efficacy and safety of the dual
combination of rilpivirine and dolutegravir and randomized trials are
ongoing. Our purpose is to describe an experience with this regimen
in clinical practice.
Methods: All HIV-1 infected subjects treated with dolutegravir plus
rilpivirine between October 2014 and September 2015 were included
in an observational cohort. After ethics committees’ approval, no
further enrolment was allowed. Only clinical events, demographic
data, CD4 cell counts, HIV-1 RNA, serum creatinine and urinary
proteins were deemed relevant for this study.
Results: We enrolled 135 subjects, mean age 52, 31.5% females and
10% non-Caucasians. Risk factors were balanced (32.4% drug abuse,
33.3% heterosexual and 34.2% male homosexual intercourse). Fifty-
six (50.5%) had failed at least one regimen. The main reason for
switch was simplification (50.5%), followed by toxicity (33.3%), need
for anti-HCV therapy (n6), persistent low-level viremia (n4),
non-adherence (n3) and viral failure (n1). Between week 24 and
48 one subject discontinued study drug for headache, two for drug
interactions and two died, one of sepsis and one of illicit drug abuse.
Sixty-two had reverse transcriptase mutations, 69 had protease
mutations and one had full INSTI resistance. Seventeen had baseline
viral replication (median 1932 copies/mL, range 55971,654), 28 had
B50 copies/mL and in 90 (67%) HIV-1 RNA could not be detected. At
week 4, in 116 (86%) HIV-1 RNA was not detected, 16 had viral load
below 50 copies/mL and three had 50 to 57 copies/mL. At week 24
one subject had viral rebound without mutations due to missed drug
refill (11,030 copies/mL), 19 had B50 copies/mL and 115 had
undetectable viremia. CD4 T-cells increased by week 24 from 718
to 751/mmc. Of the 54 who have a 48-week follow-up, the
abovementioned subject still had a treatment interruption, with
14,770 copies/mL, five had B50 copies/mL and 48 undetectable
viremia. One subject had low-level resistance to rilpivirine, one
intermediate and four high-level resistance (Stanford median score
50, range 1570): none of them was failing at the 48-week follow-up.
The median variation in serum creatinine was0.1 (range0.47 to
0.31); none developed proteinuria. The dual regimen was very
well tolerated in this population.
Conclusions: A dual regimen of dolutegravir plus rilpivirine proved
safe and effective in this cohort of non-naı¨ve HIV-1-infected subjects.
P100
Switching to elvitegravir/cobicistat/emtricitabine/tenofovir
disoproxil fumarate single-tablet regimen (Stribild†):
effects on T-cell compartment and HIV reservoirs
Esther Merlini1; Federico Cazzaniga1; Anna Casabianca2;
Chiara Orlandi2; Giuseppe Ancona1; Viola Cogliandro1;
Camilla Tincati1; Teresa Bini1; Mauro Magnani2; Antonella d’Arminio
Monforte1 and Giulia Marchetti1
1Health Sciences, University of Milan, Milan, Italy. 2Department of
Biomolecular Sciences, University of Urbino ‘‘Carlo Bo’’, Urbino, Italy
Introduction: EVG/c/FTC/TDF (Stribild) is non-inferior to PI/r-based
regimens in cART switching patients. However, the effects of EVG/c/
FTC/TDF on immune system and HIV reservoirs have not been fully
investigated.We investigated the impact of 24 weeks EVG/c/FTC/TDF
on T-cell compartment and HIV reservoirs in HIV-infected patients,
switching from a suppressive PI-based regimen.
Methods: Thirty HIV patients on effective PI-based regimens (HIV
RNA B40 copies/mL) were followed for 24 weeks after switching to
EVG/c/FTC/TDF. At baseline (W0), after 12 (W12) and 24 (W24)
weeks we analyzed: HLA-DR/CD38/Ki67/CCR7/CD45RA/CD127/PD1
on CD4/CD8, IFNg/IL2 production after HIV/SEB exposure (flow
cytometry), total HIV DNA (THIV-DNA), low levels HIV residual
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Abstract P100Table 1. Immune phenotypes and HIV reservoir in a cohort of HIV-infected patients switching to Stribild
Week 0 Week 12 Week 24 p Week 0 Week 12 Week 24 p
T-cell activation T-cell proliferation
HLA-DRCD38CD4, %
(IQR)
2.28 (1.443.78) 1.46 (13.18) 1.26 (0.82.63) 0.016 Ki67CD4, % (IQR) 2.12 (1.593.74) 2.44 (1.844.65) 3.34 (0.875.21) 0.846
HLA-DRCD38CD8, %
(IQR)
5.32 (3.2311.36) 4.54 (2.356.63) 4.64 (2.986.85) 0.048 Ki67CD8, % (IQR) 1.83 (1.222.22) 1.91 (1.172.98) 1.81 (0.774.65) 0.747
HLA-DRCD4, % (IQR) 9.4 (7.4717.22) 9 (6.2214.62) 8.15 (5.311.9) 0.006 SEB stimulation responses
CD38CD8, % (IQR) 24.02 (15.334.05) 16.73 (11.731.2) 14.9 (11.222.8) 0.018 CD4 IFNg, % (IQR) 0.18 (01.46) 0.34 (00.87) 0.46 (0.070.86) 0.497
T-cell exhaustion CD4 IFNg IL-2, % (IQR) 0.21 (0.020.64) 0.14 (0.010.79) 0.03 (00.07) 0.024
PD-1CD4, % (IQR) 3.84 (2.255.35) 2.84 (1.476.01) 2.79 (2.043.68) 0.289 CD4 IL-2, % (IQR) 1.55 (0.503.22) 0.26 (02.03) 0.2 (00.47) 0.0001
PD-1CD8, % (IQR) 4.15 (1.486.36) 3.16 (1.65.76) 3.29 (1.623.64) 0.339 CD8 IFNg, % (IQR) 2.01 (0.484.39) 2.79 (0.953.98) 1.15 (03.45) 0.024
T-cell homeostasis CD8 IFNg IL-2, % (IQR) 0.13 (0.040.26) 0.09 (0.010.45) 0 (00.05) 0.003
CD127CD4, % (IQR) 26.2 (20.535.9) 21.4 (10.233.1) 28.6 (20.134.5) 0.129
CD127CD8, % (IQR) 18.6 (15.625.3) 21.8 (11.327.1) 23.3 (17.927.9) 0.072 HIV stimulation responses
NAIVECD4, % (IQR) 5.43 (2.37.28) 4.52 (1.496.49) 1.72 (0.536.92) 0.256 CD4 IFNg, % (IQR) 0 (00.06) 0 (00.06) 0.03 (00.09) 0.001
CMCD4, % (IQR) 3.26 (2.256.40) 3.21 (2.095.08) 2.09 (0.326.65) 0.030 CD4 IFNg IL-2, % (IQR) 0 (00.001) 0 (00.02) 0 (00.06) 0.062
EMCD4, % (IQR) 53.5 (44.267.7) 53.5 (4163) 54.7 (45.261.1) 0.482 CD4 IL-2, % (IQR) 0 (00.11) 0 (00) 0 (00.03) 0.089
TDCD4, % (IQR) 32.2 (15.440) 34.75 (24.444.4) 39.6 (24.349.2) 0.405 CD8 IFNg, % (IQR) 0 (00.39) 0 (00.26) 0 (00.04) 0.828
NAIVECD8, % (IQR) 32.2 (15.440) 13.2 (3.0321.4) 7.98 (4.5418.9) 0.657 CD8 IFNg IL-2, % (IQR) 0 (00.1) 0 (00) 0 (00.01) 0.267
CMCD8, % (IQR) 0.84 (0.313.01) 2.01 (0.644.41) 1.47 (0.542.64) 0.482
EMCD8, % (IQR) 33.2 (22.343.8) 33.4 (25.647.2) 37.1 (27.543.5) 0.857 HIV reservoir
TDCD8, % (IQR) 52.6 (34.760.3) 46.2 (29.461.0) 47.4 (35.358.6) 0.962 tot HIV DNA, copies/10*4 CD4
(IQR)
3 (213) 5 (312) 4 (27) 0.223
CM, central memory CCR7CD45RA-; EM, effector memory CCR7-CD45RA-; IQR, interquartile range; SEB, Staphylococcal enterotoxin B; TD, terminally differentiated CCR7-CD45RA.
Note: Data are presented as median (IQR). Statistical analyses: Friedman test with Dunn’s multiple comparison test.
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viremia (LL-RV) (qPCR). Statistical analyses: Friedman, Wilcoxon
signed rank and Spearman correlation tests.
Results: Patients were predominantly male (70%); median agewas
44; median HIV infection duration was 8 years; median time of HIV
RNA suppression and cART duration was 5 and 6 years, respectively.
At baseline, all patients were receiving TDFFTC (for a median of 5
years) in association with either DVR/r (47%) or ATV/r (53%). No
HCV/HBV co-infections were found. Upon EVG/c/FTC/TDF introduc-
tion no changes in CD4 (634 cells/mm3 vs. 614 cells/mm3 vs. 582
cells/mm3; p0.465) and in LL-RV (0 copies/mL vs. 0 copies/mL vs. 0
copies/mL; p0.081) were shown. Table 1 lists viro-immunologic
results. Following EVG/c/FTC/TDF switch, we observed a significant
reduction in HLA-DRCD38CD4 (p0.016) and HLA-DR
CD38CD8 (p0.048). Interestingly, SEB exposure resulted in a
significant reduction of IFN-g/IL-2-producing CD4 (p0.024) and
CD8 (p0.003), IFNg-producing CD8 (p0.024) and IL-2-
producing CD4 (p0.0001). No major differences were found
after HIV stimulation. We failed to find any differences in T-cell
exhaustion, proliferation and maturation, with the exception of a
decrease in central memory CD4 (p0.030). Similarly, no changes
in THIV-DNA were found. At T0, LL-RV positively correlates with THIV-
DNA (r0.60, p0.005) and HLA-DRCD38CD4 (r0.45,
p0.022). Besides, THIV-DNA positively correlates with IFNgIL2
CD4 and inversely with IFNgCD8 (r0.51, p0.019;
r0.45, p0.039, respectively) after SEB challenge. Interestingly,
at W24 only the positive correlation between LL-RV and THIV-DNA
(r0.58, p0.030) persists.
Conclusions: In HIV virologically suppressed patients, 24 weeks
of EVG/c/FTC/TDF resulted in substantial reduction of activated
T-lymphocytes and ex-vivo T-lymphocyte susceptibility to exogenous
super-stimulation. Despite failing to detect changes in HIV reservoirs
following EVG/c/FTC/TDF, we capture an association between HIV
DNA and both residual viremia and IFNg/IL2-producing T cells,
suggesting poly-functional T-cell recruitment as a response to
ongoing viral challenge. Altogether, these data would propose a
favourable effect of EVG/c/FTC/TDF to preserve immune-activation-
driven damage to T-cell homeostasis, in turn possibly containing cell-
associated HIV viral burden in already virologically suppressed
patients.
P101
Reducing pill burden is more durable than reducing drug
burden as strategy of HIV treatment simplification
Mauro Zaccarelli1; Patrizia Lorenzini1; Nicola Gianotti2;
Stefano Rusconi3; Pierluigi Viale4; Antonio Chirianni5;
Laura Sighinolfi6; Giustino Parruti7; Antonella D’Arminio Monforte8;
Andrea Antinori1 and Study Group on behalf of Icona Foundation8
1Clinical Department, National Institute for Infectious Diseases
Lazzaro Spallanzani, Rome, Italy. 2Department of Infectious Diseases,
San Raffaele Scientific Institute, Universita` Vita-Salute San Raffaele,
Milan, Italy. 3Dipartimento di Scienze Biomediche e Cliniche ‘Luigi
Sacco’, Division of Infectious and Tropical Diseases, University of
Milan, Milan, Italy. 4Infectious Diseases Unit, Department of Medical
and Surgical Sciences, Sant’Orsola Hospital, University of Bologna,
Bologna, Italy. 53rd Department of Infectious Diseases, D. Cotugno
Hospital-AORN dei Colli, Naples, Italy. 6Department of Infectious
Diseases, S. Anna Hospital, Ferrara, Italy. 7Infectious Diseases Unit,
Pescara General Hospital, Pescara, Italy. 8Clinic of Infectious Diseases,
Department of Health Sciences, ASST Santi Paolo e Carlo, University
of Milan, Milan, Italy
Introduction: Reducing antiretroviral toxicity and improving adher-
ence involves different switching strategies as reducing pill burden by
single-tablet regimen (STR) or drug burden by regimens with two or
one drug (less drug regimen, LDR). We aimed to compare the two
approaches in patients who switched with suppressed viremia.
Materials and methods: From the Italian ICONA cohort, patients
with undetectable HIV RNA switching to STR or LDR from any triple
regimen were selected. Drug discontinuation by any cause (DAC) was
the end-point of the analysis assessed by incidence rates and Poisson
regression.
Results: Overall, 842 patients (525 STR, 317 LDR) were analyzed. STR
included TDF/FTC/EFV (36.8%), TDF/FTC/RPV (48.4%) and EVG/COBI/
FTC/TDF (14.9%). LDR included dual regimens: LPV/r, ATV/r, DRV/r
plus 3TC (29.7%) or any MVC, RAL, ETV (15.7%) and PI/r mono-
therapy (54.6%). Patients switching to STR were more frequently
receiving NNRTI, changed from first line of therapy and from NNRTI
or INSTI, changed without failure or toxicity, had higher haemoglobin
and transaminase. In contrast, patients switching to LDR were more
often on PI/r, changed for toxicity, were older, had longer history
of HIV infection and regimens, higher triglycerides and creatinine
(Table 1). Overall, 240 patients (107/525 STR, 133/317 LDR)
discontinued therapy in 1525 patient-years of follow-up (PYFU).
The crude IR of DAC was 15.7/100 PYFU (95% CI 13.917.9): 10.8/
100 PYFU (95% CI 8.913.0) in STR and 24.9 (95% CI 21.029.6) in
LDR (pB0.001). Among causes of discontinuation, toxicity was
significantly higher in STR patients (57.0% vs. 28.6%, pB0.001),
while in LDR discontinuation was associated with different situations:
physician decision, switch to other regimen and intensification. No
difference was found for discontinuation by viral failure (STR 4.7% vs.
LDR 3.0%). By multivariable Poisson regression (Table 2), HCV
co-infection, higher creatinine and switching from PI/r were
associated with higher risk of DAC; longer duration of HIV, MSM,
being at second switch versus first and change without failure or
toxicity were associated with lower risk. Switching to STR was
associated with significant 50% reduction of DAC (IRR 0.53; 95% CI
0.390.71) as compared with switching to LDR. Risk of DAC did not
differ among the three STR, while, among LDR, probability of DAC
was higher in mono than dual regimens (IRR 1.89; 95% CI 1.332.69).
Excluding monotherapy, rates of DAC remained significantly lower in
STR.
Conclusions: Switching to STR was associated with greater stability
of the regimen and consequently lower treatment discontinuation.
LDR can be useful in limited settings in order to reduce NRTI
toxicity.
P102
Efficacy and safety of switch to DRV/cobicistat in patients
who are virologically suppressed with treatment regimens
containing DRV/r
Sara de la Fuente Moral1; Alberto Diaz de Santiago1;
Carlos Folguera2; Carmen De Mendoza Fernandez1 and
Alfonso Angel-Moreno Maroto1
1Internal Medicine, Hospital Puerta de Hierro Majadahonda-Madrid,
Madrid, Spain. 2Pharmacy Service, Hospital Puerta de Hierro
Majadahonda-Madrid, Madrid, Spain
Introduction: DRV boosted with ritonavir (r) is part of preferred
antiretroviral therapies. Boosting DRV with cobicistat (cobi), a new
selective inhibitor of cytochrome P450, allows coformulation in a
single tablet, recently approved based on favourable bioequivalence
data [1]. Cobicistat inhibits the tubular secretion of creatinine,
leading to mild increase of serum creatinine levels, with no effect on
actual glomerular filtration rate [2]. However, safety and efficacy
data about DRV/r in clinical practice are still scarce. The aim of this
study was to evaluate the efficacy, safety and tolerability of switching
to DRV/cobi in HIV-infected patients who are virologically suppressed
on a stable regimen containing ritonavir-boosted DRV.
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Materials and methods: Retrospective study of patients following the
switch from DRV/r to DRV/cobi. Other components of the regimen
remained unchanged. Eligibility criteria included HIV-1 RNA below 100
copies/mL at time of treatment switch. Patients with detectable
viraemia on ART, naı¨ve patients and patients who started treatment
with DRV/cobi from treatment schemes not containing DRV/r were
excluded. The primary endpoint was to determine percentage of
patients who remained virologically suppressed after switch. Secondary
outcomes included changes in renal function and lipid profile. Clinical
data were collected from patients’ medical records.
Results: We analyzed 150 virologically suppressed patients switching
from DRV/r to DRV/cobi from July 2015 to May 2016. Baseline
features are shown in Table 1. Out of 150 patients, 15 (10%) did not
continue on care, so data from 135 patients were analyzed. Mean
time to control analysis was 4.16 months (0.26.5). Most patients
remained suppressed after changing treatment. There were four (3%)
patients with virological failure; three of them due to poor treatment
compliance, and one in the setting of chemotherapy treatment for
lymphoma. Creatinine levels were slightly higher after switching to
DRV/cobi, with no statistically significant differences neither in
patients with or without concomitant treatment with tenofovir
(Table 2 and Figure 1). Total cholesterol, LDL and HDL cholesterol
remained unchanged, while a statistically significant decrease of 14
mg/dL was observed in the triglyceride level (Figure 2).
Abstract P101Table 1. Characteristics and differences of patients switching to STR and LDR
LDR STR p
N 317 525
Male gender, n (%) 246 (77.6) 418 (79.6) 0.487
Age, years, median (IQR) 46 (3952) 43 (3650) B0.001
Years from HIV test and first visit, median (IQR) 5.8 (2.815.3) 4.8 (2.49.8) 0.002
Mode of HIV transmission, n (%)
Heterosexual 119 (37.5) 201 (38.3) 0.064
IVDU 51 (16.1) 54 (10.3) 0.114
MSM 134 (42.3) 238 (45.3) 0.391
Other/unknown 13 (4.1) 32 (6.1) 0.341
HCV co-infection, n (%)
Positive 61 (19.2) 74 (14.1) 0.106
Negative 240 (75.7) 429 (81.7) 0.486
Not known 16 (5.1) 22 (4.2) 0.609
HBV co-infection, n (%)
Positive 10 (3.1) 17 (3.2) 0.970
Negative 282 (89.0) 469 (89.3) 0.909
Not known 25 (7.9) 39 (7.4) 0.894
Number of regimens at switch, n (%)
1 139 (43.8) 315 (60.0) B0.001
2 71 (22.4) 100 (19.1) 0.797
3 or more 107 (33.7) 110 (20.9) B0.001
Months of undetectable HIV RNA pre-switch, median (IQR) 25.4 (1252) 23.2 (854) 0.130
Overall years of cART, median (IQR) 3 (28) 3 (16) 0.145
Laboratory data at switch, median (IQR)
Haemoglobin, mg/dL 14.6 (13.515.5) 14.8 (13.815.6) 0.026
White blood cells/mm3 6300 (51007680) 5990 (50007300) 0.088
Triglicerides, mg/dL 133 (94198) 121 (85169) 0.004
Cholesterol, mg/dL 193 (165221) 188 (161217) 0.255
Creatinine, mg/dL 0.95 (0.801.13) 0.89 (0.781.00) B0.001
ALT, mg/dL 23 (1633) 28 (2040) B0.001
CD4, cells/mm3 598 (464807) 606 (463805) 0.734
Type of pre-switch regimen, n (%)
NRTI/NNRTI 44 (13.9) 197 (37.5) B0.001
NRTI/PI/r 265 (83.6) 296 (56.4) B0.001
NRTI/INSTI 8 (2.5) 32 (6.1) 0.019
Reason for switching, n (%)
Toxicity 106 (33.4) 104 (19.8) B0.001
Adherence/patient’s decision 8 (2.5) 15 (2.9) 0.831
Neither failure nor toxicity 191 (60.2) 384 (73.1) 0.005
Other/unknown 12 (3.8) 22 (4.2) 0.896
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Conclusions: In HIV-1-infected patients, who are virologically
suppressed, switching from RTV to cobicistat, cobi-boosting DRV
was effective maintaining virological suppression and well tolerated.
Mild and non-progressive increase in serum creatinine was con-
firmed. Cobicistat does not have clinically relevant effect on lipid
profile.
Reference
1. Kakuda TN, Opsomer M, Timmers M, Iterbeke K, Van De Casteele T,
Hillewaert V, et al. Pharmacokinetics of darunavir in fixed-dose
combination with cobicistat compared with coadministration of
darunavir and ritonavir as single agents in healthy volunteers. J Clin
Pharmacol. 2014;54:94957. doi: http://dxdoi.org/10.1002/jcph.290
2. Temesgen Z. Cobicistat, a pharmacoenhancer for HIV treatments.
Drugs Today (Barc). 2013;49:2337. doi: http://dxdoi.org/10.1358/
dot.2013.49.4.1947288
Abstract P101Table 2. Rate ratio of DAC from fitting a
Poisson regression
RR
95% CI
low
95% CI
high p
Age (per 10 years older) 1.12 1.12 0.98 0.105
Years from first HIV test and
visit (each)
0.97 0.94 0.99 0.007
Mode of HIV transmission
Heterosexual 1.00
IVDU 0.77 0.46 1.29 0.321
MSM 0.71 0.53 0.96 0.026
Other/unknown 0.81 0.45 1.45 0.468
HCV co-infection
Negative 1.00
Positive 1.99 1.27 3.13 0.003
Unknown 0.81 0.56 1.87 0.947
Number of regimens at switch
1 1.00
2 0.59 0.41 0.85 0.005
3 or more 0.81 0.64 1.29 0.586
Laboratory tests
Triglycerides (per 10 mg/dL) 1.00 0.99 1.01 0.823
Creatinine (per 10 mg/dL) 1.30 1.01 1.67 0.041
ALT (per 10 UI/mL more) 1.01 0.99 1.03 0.168
Type of pre-switch regimen
NRTI/NNRTI 1.00
NRTI/PI/r 1.60 1.14 2.23 0.006
NRTI/INSTI 2.09 0.98 4.45 0.055
Reason for switching
Toxicity 1.00
Adherence/patient’s
decision
1.11 0.50 2.47 0.801
Neither failure nor toxicity 0.65 0.48 0.87 0.005
Other/unknown 1.81 0.99 3.31 0.053
STR versus LDR 0.53 0.39 0.71 B0.001
Abstract P102Table 1. Patient characteristics
Patients (n135) (lost 15, 10%)
Male gender, n (%) 107 (71.3)
Age, year, mean 9 SD 51.199.5
ART regimen, n (%)
Triple therapy 73 (54.1)
Dual therapy 43 (31.8)
Monotherapy 19 (14.1)
Risk group, n (%)
HSH 56 (41.5)
HTX 31 (22.9)
IDU 45 (33.4)
Transfusional 3 (2.2)
TDF, n (%) 31 (23)
Abstract P102Table 2. Serum creatinine levels and lipid
profile before and after switch to DRV/c
DRV/r DRV/c p
Creatinine (all) 0.9390.05 1.0190.05 1
On TDF 0.8990.02 0.9890.03 1
Not TDF 0.9490.06 1.0290.07 1
Total cholesterol 195.493.8 196.793.9 0.6
LDL cholesterol 109.293.2 115.793.4 0.9
HDL cholesterol 51.191.3 50.591.25 0.3
Triglycerides 177.1911.6 162.8913.9 0.03
Abstract P102Figure 1. Serum creatinine levels before and after
switch to DRV/c.
Abstract P102Figure 2. Lipid profile before and after switch to
DRV/c.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
85
P103
Confirmed efficacy and safety of dual therapy based in
lamivudine plus a ritonavir-boosted protease inhibitor in
the clinical setting
Marı´a Fontecha-Ortega1; Vanessa Mun˜oz-Mendoza2;
Cristina Go´mez3; Matilde Sa´nchez-Conde3; Miguel Angel Rodrı´guez3;
Maria Jesu´s Vivancos3 and Jose Luis Casado3
1Internal Medicine, Hospital de Getafe, Getafe, Spain. 2Internal
Medicine, Hospital Obispo Polanco, Teruel, Spain. 3Infectious
Diseases, Hospital Ramo´n y Cajal, Madrid, Spain
Introduction: The aim of this study was to evaluate the efficacy, safety
and additional benefits of a dual regimen with lamivudine (3TC) 
protease inhibitor (PI) boosted with ritonavir in the clinical setting.
Materials and methods: Prospective study of 99 HIV-infected
patients, HBV negative, without resistance to lamivudine or PI,
who switched to this dual therapy because toxicity or intolerance.
Routine laboratory tests, including estimated glomerular filtration
rate (eGFR CKD-EPI equation), lipid parameters, immunovirological
evaluation and a complete urinary determination were performed at
inclusion and during follow-up.
Results: The mean age was 49.8 years (3574), and 66% were male.
The median time of HIV infection was 20.6 years (15.824.4), nadir
CD4 count was 193 cells/mm3 (IQR 90306) and 42% had a previous
AIDS diagnosis. Overall, patients were pre-treated with a mean of 6
regimens (110) for a median of 40.5 months. At the time of switch,
92% had an HIV RNA level B50 copies/L and the median CD4 count
was 555 cells/microL (IQR 394799). Causes of switch were toxicity/
intolerance in 71%, simplification in 24% and lack of adherence leading
to detectable HIV load in 4%. Renal toxicity was observed in 50% of
cases, followed by lipodystrophy in 10%. The main combination used
was 3TCdarunavir/r (n70) and 3TClopinavir/r in 21 cases. At 48
weeks, the efficacy by intention to treat was 97% (96/99), with three
virological failures attributed to non-adherence. The median increase
in CD4 count was35 and80 cells/mL at 6 and 12 months. After
switching, a significant increase in total cholesterol (TC), LDL choles-
terol and triglycerides was observed during the first 6 months (p
0.001, p0.05 and p0.07, respectively), with partial recovery at
12months, and it wasmoremarked in 64 patients previously receiving
tenofovir disoproxil fumarate (TDF). On the contrary, there was a
significant improvement in the eGFR at 6 and 12months (p0.03 and
p0.01), and urinary parameters improved significantly.
Conclusions: In this study, in the clinical setting, we demonstrate the
efficacy and safety of dual therapy with 3TC associated with a
boosted PI, with 97% remaining free of virological failure after 48
weeks and improvement in renal involvement. By contrast, it is
expected a significant increase in total cholesterol and LDL
cholesterol initially, with partial recovery at 48 weeks.
P104
Preferred regimens and reasons for switches in HIV-positive
individuals in the German HIV-HEART cohort study over 30
years of antiretroviral treatment evolution
Volker Holzendorf1; Stefan Esser2 and on behalf of the HIVHEART
Study Group2
1Clinical Trial Centre Leipzig  KKS, University of Leipzig, Leipzig,
Germany. 2Clinic of Dermatology and Venerology, University Hospital
Essen, Essen, Germany
Introduction: ART changes over the time and yields benefits in terms
of virological suppression, tolerability and regimen simplification also
in the contexts of ageing and polypharmacy. Compared with
other countries all ART regimens are assumed by German health
insurance coverage because German guidelines recommend perso-
nalized ART. We analyze the non-restrictive treatment choices and
reasons for switches of the German clinicians in the HIV-HEART
cohort.
Methods: The HIV-HEART study is an ongoing, prospective and
observational cohort study in the German Ruhr area to assess the
frequency and clinical course of cardiac disorders in 1538 HIV-positive
individuals (HIV). From the first diagnosis of HIV infection until 31
December 2015 ART, medical history and reasons for switches of ART
were collected based on the health records, medication plans and the
anamnesis. ART history was divided into five chronologic 5-year time
periods (1995, 19962000, 20012005, 20052010, 20112015),
which were compared with each other
Results: One thousand five hundred and thirty-eight HIV (mean age:
49.9911.0 years; male: 84.4%; Caucasian: 88.3%; MSM: 52.2%) were
included at their last study visit. Sixteen thousand eight hundred and
eighty patient-years since the first HIV diagnosis of the HIV were
reviewed. According to the CDC classification of the HIV infection,
HIV were distributed over the clinical categories (A: 32.3%; B: 29.2%;
C: 30.5%; n.k.: 6.2%) while almost the half had an advanced
immunodeficiency (I: 7.8%; II: 39.2%; III: 46.6%; n.k.: 6.2%). HIV
were treated with ART on average for 10.295.8 years with mean
3.893.2 different regimens over the time. 90.9% of the living HIV
had an HIV RNA below the level of detection at their last visit. Since
the beginning of the HAART era the number of switches including the
initiation of the ART in naı¨ve HIV per 5-year time period decreased
from 2.7 to 1.4. The catched main reasons (n20) for ART
switch changed: 1996 to 2001: adverse events 44.1%, virological
failure 24.9% and compliance 21.1%; 2011 to 2015: adverse events
55.6%, patients request 19.3%, virological failure 9.1% and
drug interactions 7.6%. In 1995, 87% of HIV were treated only
with NRTIs; in 2001, 53% with a PI-containing regimen; in 2010, 36%
with an NNRTI regimen; and in 2015, 36% take an INSTI-containing
regimen.
Conclusions: Using new treatment options clinicians try to optimize
the ART regimens over the time. More than 90% of the HIV
achieved a viral load below the level of detection. Tolerability was
still the most important reason for ART switches. Currently INSTI-
containing regimens were preferred.
P105
Drug concentrations, adherence, patient-reported
symptoms and health-related quality of life in HIV-infected,
virologically controlled patients switching to
maravirocdarunavir/ritonavir or continuing the previous
triple therapy: sub-studies from the randomized GUSTA trial
Barbara Rossetti1; Roberta Gagliardini2; Lucia Lisi3; Melissa Masini1;
Silvia Lamonica2; Francesca Vignale4; Gaetana Sterrantino5;
Giancarlo Orofino6; Manuela Colafigli7; Alessandra Latini7;
Andrea Tosti8; Stefano Rusconi9; Michele Trezzi10;
Alessandro D’Avino2; Pierfrancesco Grima11; Ivano Mezzaroma12;
Antonio Di Biagio13; Pierluigi Navarra3; Simona Di Giambenedetto2
and Andrea De Luca1
1Infectious Diseases Clinic, Azienda Ospedaliera Universitaria Senese,
Siena, Italy. 2Infectious Diseases Clinic, Catholic University of Sacred
Heart, Rome, Italy. 3Pharmacology, Catholic University of Sacred
Heart, Rome, Italy. 4Infectious Diseases Clinic, University G.
D’Annunzio, Chieti, Italy. 5Tropical and Infectious Diseases Clinic,
Azienda Ospedaliero Universitaria Careggi, Florence, Italy. 6Infectious
Diseases Unit, Amedeo di Savoia Hospital, Turin, Italy. 7Infectious
Dermatology and Allergology, IFO San Gallicano, Rome, Italy.
8Infectious Diseases Clinic, University of Perugia, Perugia, Italy.
9Infectious Diseases Clinic, DIBIC Luigi Sacco, University of Milan,
Milan, Italy. 10Infectious Diseases Unit, San Jacopo Hospital, Pistoia,
Italy. 11Infectious Diseases Unit, Santa Caterina Hospital, Galatina,
Italy. 12Infectious Diseases Clinic, Sapienza University, Rome, Italy.
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13Infectious Diseases Clinic, IRCCS Azienda Ospedaliera Universitaria
San Martino-IST, Genova, Italy
Introduction: The randomized GUSTA trial, comparing switch to
maraviroc (MVC) 300 mg  darunavir/ritonavir (DRV/RTV) 800/100
mg OAD (switch arm, S) versus continuation of the previous three-
drug, virologically suppressive regimen (continuation arm, C) in patients
carrying R5 virus was prematurely discontinued due to an excess of
virologic failures (VF) in arm S. Aims of the sub-studies were to analyze
drug levels in arm S, compare adherence, patient-reported symptoms
and health-related quality of life (QoL) between arms and analyze the
correlation between these parameters and treatment outcome.
Materials and methods: Plasma drug concentrations were measured
between week 4 and 96 by a validated UPLC-MS/MS and Ctrough
was calculated. In both arms, self-reported adherence (VAS 0100%
weeks 0, 4, 24 and 48), patient-reported symptoms and physical/
mental QoL scores (VAS 0100% weeks 0 and 48) were collected
using validated questionnaires.
Results: Hundred and fourteen patients were analyzed (62 S, 52 C):
23% females, 40% heterosexuals, median age 49 years, baseline CD4
711 cells/mL, on ART since 10 years. Median Ctrough for DRV (n292
samples) was 1333 ng/mL (IQR 7771686), MVC (n257) 55 ng/mL
(41106), RTV (n285) 37 ng/mL (2156). In nine patients with VF
drug Ctrough at VF were significantly lower as compared with those
during treatment success: DRV 1251ng/mL (01864) versus 1328 ng/mL
(7871678), p0.004, MVC 39 ng/mL (5207) versus 55 ng/mL
(45104), p0.001, and RTV 4 ng/mL (0143) versus 42 ng/mL
(2156), pB0.001. By linear regression, DRV Ctrough associated
negativelywith anti-HCV status (mean586 ng/mL; p0.041) and
eGFR (10 mL/min: 8 ng/mL; p0.011), and positively with age
(10 years: 249 ng/mL; p0.003). Adherence, patient-reported
symptoms, physical health ormental health-relatedQoL scores did not
differ between arms (Table 1). Physical health declined significantly
from baseline at 48 weeks in arm C but not in S (Table 1). Adherence
was significantly lower in patients with VF (arm S) and treatment
failure (arm C) (Table 1). At time points with self-reported adherence
580% 6/51 (11.8%) in arm S versus 0/35 (0%) in arm C showed VF (x2
p0.07). Values indicate means (standard deviations). The symptoms
score reports the sum of the values of the intensity of the symptom
(between 1 (absent) and 5 (very much)) divided by the number of
evaluable symptoms per patient (max 30 total symptoms; ISS QoL
adapted). p-value of between-arm comparisons (week 48 vs. baseline;
success vs. failure); in arm S all failures were virologic; in arm C all
failures were due to treatment discontinuation.
Conclusions: Switch to MVCDRV/RTV OAD as compared with
continuing a previous triple ART does not determine modifications in
adherence, patient-reported symptoms and QoL. The excess of VF
with this regimen seems associated with a lower forgiveness, not
allowing to maintain virologic suppression during periods of
suboptimal adherence with reduced drug exposure. Candidates to
this regimen need to be carefully selected and instructed.
P106
A comparison between tenofovir/emtricitabine/
elvitegravir/cobicistat and dolutegravir-based three-drug
regimens as switch strategies for virologically controlled,
HIV-infected patients
Gianmaria Baldin1; Alberto Borghetti1; Amedeo Capetti2;
Gaetana Sterrantino3; Stefano Rusconi4; Alessandra Latini5;
Andrea Giacometti6; Maria Vittoria Cossu7; Manuela Colafigli5;
Mariangela Micale2; Sara Veloci2; Francesca Lombardi1;
Ramona De Marco1; Arianna Emiliozzi1; Andrea De Luca8;
Simona Di Giambenedetto1 and Giordano Madeddu9A
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Introduction: In cART, dolutegravir and elvitegravir are recom-
mended first-line drugs for naı¨ve, HIV-infected patients. Concerning
their use in treatment-experienced, virologically controlled patients,
a comparison of the efficacy and safety of dolutegravir- and
elvitegravir-based cART is lacking.
Materials and methods: The primary study endpoint was to evaluate
rates of virologic failure (VF, one HIV RNA 1000 copies/mL or two
consecutive HIV RNA 50 copies/mL) and treatment failure (TF,
discontinuation of elvitegravir or dolutegravir for any cause) in a
multi-centre cohort of virologically controlled, HIV-infected patients
switching to dolutegravir (plus either tenofovir/emtricitabine or
abacavir/lamivudine) or to tenofovir/emtricitabine/elvitegravir/
cobicistat. Predictors of TF were analyzed by Cox regression. Changes
in metabolic, liver and renal functions at week 24 and 48 in each
group were also evaluated.
Results: Two hundred and forty patients were eligible: 67 and 173
started elvitegravir and dolutegravir, respectively. Study arms did not
differ for baseline characteristics except for nadir CD4 count, previous
AIDS events, reasons for switching to the new regimen (see Table 1). In
the tenofovir/emtricitabine/elvitegravir/cobicistat arm, VF was de-
tected in one case over 54.5 patient-years follow-up (PYFU), whereas
in the dolutegravir study arm no VF was documented over 90.8 PYFU.
Conversely, 16 TF (17.6 per 100 PYFU) occurred in the dolutegravir arm,
whereas four TF (7.3 per 100 PYFU) occurred with elvitegravir. Survival
analysis revealed a 81.0% and a 96.4% probability of remaining with
dolutegravir and elvitegravir at week 48, respectively (log-rank: 0.014).
Causes of TF in the tenofovir/emtricitabine/elvitegravir/cobicistat arm
were: neurologic events (two), renal toxicity (one) and unspecified
reason (one). Causes of TF in the dolutegravir arm were: hypersensi-
tivity reactions (two), gastro-intestinal (one), liver (three), renal (one)
and neurologic (six) toxicities, drug interaction (one) and unspecified
reasons (two). In a multivariate model, anti-HCV positive serostatus
was predictive of TF (aHR 2.76, 95% CI 1.067.19; p0.038), after
Abstract P106Table 1. Characteristics of study population at baseline
Variables Overall n240 Elvitegravir n67 Dolutegravir n173 p
Agea 51 (456) 50 (4054) 51 (4657) 0.082
Male sex 178 (74.2) 54 (80.6) 124 (71.7) 0.157
Risk factor for HIV
Heterosexual 98 (40.8) 26 (38.8) 72 (41.6) 0.074
MSM 67 (27.9) 25 (37.3) 42 (24.3)
IDU 59 (24.6) 15 (22.4) 44 (25.4)
Other/unknown 16 (6.7) 1 (1.5) 15 (8.7)
Italian nationality 227 (94.6) 65 (97.0) 162 (93.6) 0.582
CDC stage C 69 (28.7) 12 (17.9) 57 (32.9) 0.021
Anti-HCV 61 (25.4) 18 (26.9) 43 (24.9) 0.748
HBsAg 18 (7.5) 6 (9.0) 12 (6.9) 0.594
Time from HIV diagnosisa 14 (523) 12 (421) 15 (623) 0.273
Time on ARV therapya 10 (418) 12 (317) 10 (418) 0.293
Nadir CD4 counta 213 (68326) 308 (202413) 175 (43286) B0.001
Zenith HIV RNAa (log10 copies/mL) 5.06 (4.665.45) 5.06 (4.525.26) 5.06 (4.715.50) 0.322
Baseline CD4 counta 586 (445869) 662 (494908) 568 (421817) 0.082
Previous virologic failure 104 (43.7) 30 (46.2) 74 (42.8) 0.640
Years of virologic suppressiona 4 (18) 1 (05) 5 (19) B0.001
Therapies before switch
2 NRTIINI 57 (23.8) 14 (20.9) 43 (24.9) 0.518
2 NRTINNRTI 56 (23.3) 18 (26.9) 38 (22.0) 0.421
2 NRTIPI 92 (38.3) 27 (40.3) 65 (37.6) 0.697
Mono/dual therapy 24 (10.0) 3 (4.5) 21 (12.1) 0.076
Other 12 (5.0) 6 (9.0) 6 (3.5) 0.075
Reasons for previous treatment discontinuation
Toxicity 54 (22.5) 8 (11.9) 46 (26.6) B0.001
Simplification 90 (37.5) 45 (67.2) 45 (26.0)
DDI 54 (22.5) 0 54 (21.2)
Other 42 (17.5) 14 (20.9) 28 (16.2)
DDI, drug-drug interactions; IDU, intravenous drug users; INI, integrase inhibitor; MSM, men who have sex with men; (N)NRTI, (non-) nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor. aValues within brackets are expressed in percentage except for median values (interquartile range).
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adjusting for cART (aHR dolutegravir vs. elvitegravir 4.37, 95% CI 0.97
19.66; p0.055), male sex (aHR vs. female 0.40, 0.161.01; p0.052)
and years of antiretroviral therapy (pns). A change in total
cholesterol levels (22 mg/dL; p0.023) was evident in the
dolutegravir but not in the elvitegravir arm (19 mg/dL; p0.069)
at week 48. Triglycerides decreased significantly in both study arms at
week 48. As expected, a decrease in eGFR was seen with tenofovir/
emtricitabine/elvitegravir/cobicistat (15 mL/min; pB0.001).
Conclusions: High virologic efficacy of elvitegravir and dolutegravir-
based cART was confirmed in our cohort. Despite a better metabolic
profile, more TFs were detected with dolutegravir than with
elvitegravir, which prompts the need for further investigation.
P107
Durability, metabolic impact and efficacy of switching from
a PI/r- to an INI-containing regimen in a monocentric cohort
of drug-experienced HIV-positive subjects
Stefano Rusconi; Letizia Oreni; Tiziana Formenti; Andrea Giacomelli;
Valentina Di Cristo; Angelica Lupo; Elisa Colella; Marco Franzetti;
Anna Lisa Ridolfo and Massimo Galli
Infectious Diseases Unit, DIBIC Luigi Sacco, Universita’ degli Studi di
Milano, Milan, Italy
Introduction: Boosted protease inhibitors (PI/r) have been the
cornerstone of antiretroviral therapy for many years. Patients and
physicians are increasingly worried about long-term safety of anti-HIV
drugs. With this aim, we analyzed our cohort of drug-experienced
patients previously treated with a PI/r who were switched to an
integrase inhibitor (INI).
Methods: Hundred and thirty-one patients were studied over time.
We evaluated several parameters involved in the persistence of
treatment, such as CD4 lymphocytes, HIV RNA, previous PI/r
exposure glucose, creatinine, AST, ALT, amylase, triglycerides, total
and HDL cholesterol and HCV/HBV status. The probability of remaining
on an INI-containing regimen was estimated using Kaplan-Meier
curves, paired samples were examined with Friedman test or Cochran
Q test, if the variables were quantitative or dichotomous, respectively.
Baseline clinical predictors of the INI-containing regimen survival were
assessed by a multivariable Cox proportional hazard regression model.
We also evaluated dual-energy X-ray absorptiometry (DXA) during INI
treatment.
Results: Reasons for interrupting PI/r were: drug interactions 8.4%,
immuno-virological failure 13.7%, side effects 26.7% and simplification
51.1%. The median observation time of the cohort was 17.8 months
(IQR 5.240.1). Among the 131 patients, 26 interrupted the INI-
containing regimen and 105 continued at the last observation. The
probability of maintaining an INI-containing regimen was 0.91 (95% CI
0.860.96) at 6 months, 0.86 (0.800.93) at 12 months and 0.82
(0.740.89) at 18 months. The treatment survival differed at the last
observation according to the PI/r included in the previous regimen,
with a significant difference among atazanavir (ATV)/r, lopinavir (LPV)/r,
fosamprenavir (FPV)/r and darunavir (DRV)/r (pB0.0001) (Figure 1).
PI/r included in the previous regimen was confirmed to be
independently associated to the INI-containing regimen durability
by multivariable analysis. No change in treatment survival was
observed after stratifying for the three INI used in clinical practice,
although there was a significant difference (p0.014) in the switch
to RAL various PI/r (FPV/rLPV/rATV/rDRV/r). Among the
parameters that we followed over time, HIV RNA B37 copies/mL
increased between baseline and month 12 (67% vs. 89%;
pB0.0001), median triglycerides decreased (155 vs. 121 mg/dL;
pB0.0001) and median total cholesterol decreased (185 vs. 174 mg/
dL; p0.013). DXA was assessed in 15 patients on both lumbar spine
and bilateral hips, being normal, osteopenia or osteoporosis in 47%,
40% and 13%, and 54%, 46% and 0%, respectively.
Conclusions: Regimen switch to INI demonstrated an optimal
durability, together with virologic efficacy and maintenance of
steady-state immunologic profile. Moreover, a favourable effect on
lipids as far as triglycerides and total cholesterol was seen. Of note, a
longer duration of the INI-containing regimen was observed after
being treated with ATV/r and LPV/r in the previous drug combination.
P108
Switch to dolutegravir in HIV patients responding to a first-
line antiretroviral treatment: 48 weeks results
Luba Tau1; Tomer Ziv-Baran2; Ronit Cohen-Poradosu1; Ari Leshno1;
Danny Alon1; David Shasha1; Steven Rapaport1; Asaf Wasserman1;
Talya Finn1; Eugene Katchman1; David Hassin1; Israel Yust1;
Tamar Brofman1; Boaz Avidor1 and Dan Turner1
1Crusaid Kobler AIDS Center Tel Aviv, Tel Aviv Sourasky Medical
Center, Tel Aviv, Israel. 2School of Public Health, Sackler Faculty of
Medicine, Tel Aviv University, Tel Aviv, Israel
Abstract P107Figure 1. Treatment survival at the last observation according to the PI/r included in the previous regimen (atazanavir (ATV)/r,
lopinavir (LPV)/r, fosamprenavir (FPV)/r and darunavir (DRV)/r[s1]).
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Objectives: Dolutegravir (DTG) has shown a potent antiviral effect
and favourable safety profile. This study compares retrospectively
efficacy and safety between patients who had responded to an ARV
regimen which was continued and prospectively those who were
switched to DTG. Results at 48 weeks are presented.
Methods: This cohort study was performed on all patients followed
in Tel Aviv who had responded to a non-DTG first-line ARV regimen
(HIV-1 viral load B200 copies/mL) for at least 6 months. The
prospective study group (group A) was switched to a DTG-containing
regimen while the retrospective group (group B) continued their
non-DTG ARV regimen. Laboratory parameters analyzed within 48
weeks include HIV viral load (VL), CD4 cell count, CD4/CD8 ratio,
plasma fasting glucose, total cholesterol, HDL cholesterol, LDL
cholesterol, ALT, creatinine level, WBC, haemoglobin and platelet
count. Adverse clinical events were recorded after reviewing the
medical records.
Results: Analysis included 157 patients (73 in group A; 84 in group
B). Before switching to DTG 24 patients in group A were treated with
raltegravir, 36 with PI and 13 with NNRTI. Amongst group B, 31
patients were treated with raltegravir, 39 with PI and 14 with NNRTI.
At 48 weeks, 70 patients (96%) in group A and 76 (90.5%) in group B
had VL B40 copies/mLl (p0.183), VL 200 copies/mL was
detected in one patient from group B. Median CD4 cell count in
group A at baseline was 660 and 661 in group B (p0.338). At 48
weeks, median CD4 count in group A was 707 and 734 in group B
(p0.275). Changes from baseline creatinine were higher in group B
(p0.015) but this difference was not clinically relevant. Glucose,
total cholesterol, LDL and HDL cholesterol, and ALT levels were
similar in both groups. Also, there was no difference in complete
blood count parameters (WBC, HGB, PLT) or CD4/CD8 ratio between
the groups. In group A adverse clinical events were noted in 19% of
patients. DTG was stopped in two patients (2.7%) due to adverse
effects. In group B adverse effects were noted in 31% of patients.
Fifty percent of patients on NNRTI treatment experienced side
effects, 38% of patients in PI group and 6% in the raltegravir group.
Conclusions: Switching treatment-responding patients to DTG was
effective and safe at 48 weeks.
P109
Antiretroviral treatment received by patients in the Spanish
VACH cohort: change over time
Bernardino Roca
Infectious Diseases and Medicine, VACH Cohort of Spanish Hospitals,
Castellon, Spain
Introduction: Antiretroviral treatment has had a dramatic impact on
HIV infection control, but continued changes in recommended
treatments have occurred throughout the history of the disease. In
this study, we aim to achieve knowledge on changes that have taken
place over the last 20 years on antiretroviral therapy prescription.
Materials and methods: This study is based on the Spanish VACH
cohort of HIV-infected patients. The cohort was established in 2000,
and is participated by 23 hospitals, belonging to most regions of the
country. Data from all patients are included in a common software,
Advanced HIV, specifically developed for the follow-up of HIV-
infected patients. For this study we obtain from that application
sociodemographic and clinical data from all patients, and analyze
treatment that patients have taken in four separate time periods. We
use descriptive and basic bivariate statistics.
Results: On 31 January 2016 the VACH cohort was formed by a total of
33,729 patients; 25,986 (77.04%) are men. According to data from the
last registered visit, mean and standard deviation of age of all patients
is 45.29912.53 years; 80.10% of patients are receiving antiretroviral
treatment; mean and standard deviation of CD4 lymphocyte count is
5419348 cells/mm3 and 75% have HIV RNA below 200 copies/mL.
Table 1 and Figure 1 show the number of patients that are taking each
modality of antiretroviral treatment at each one of four time periods,
according to data from the last registered visit from every patient.
There is a strong association between taking treatment and survival in
all four time periods (pB0.0001).
Conclusions: Modalities of antiretroviral treatment received by
patients in the Spanish VACH cohort has substantially varied a long
time. Almost all HIV-infected patients receive antiretroviral treat-
ment now. Combination treatment with two nucleoside/tide analo-
gue and one integrase strand transfer inhibitor is the modality of
treatment most commonly used now.
P110
The RAL-AGE study: benefits of switching to raltegravir-
containing regimens in the older population
Paolo Pavone1; Noemi Giustini1; Gabriella d’Ettorre2; Sara Serafino1;
Ivan Schietroma1; Giuseppe Corano Scheri1; Ivano Mezzaroma1;
Mauro Andreotti3; Andrea Mastrangelo1; Claudio Maria Mastroianni1
and Vincenzo Vullo1
1Public Health and Infectious Diseases, Sapienza University, Rome,
Italy. 2Public Health and Infectious Diseases, Policlinico Umberto I,
Rome, Italy. 3Department of Therapeutic Research and Medicines
Evaluation, Istituto Superiore di Sanita`, Rome, Italy
Introduction: Raltegravir (RAL) is considered one of the better-
tolerated antiretroviral medications, due to limited side effects and
few long-term safety concerns. Furthermore RAL displays minimal
drugdrug interactions, making it a good option for ageing patients
Table 1. Main results of the study
2NAII 2NAPI 2NANN
Other
treatment
No
treatment
19962005 0 1623 1511 1214 2858
20062010 81 2240 3394 1033 1043
20112013 325 1552 2921 1324 466
20142015 3018 1575 2470 1965 230
II, integrase strand transfer inhibitor; NA, nucleoside/tide analogue;
NN, non-nucleoside analogue; PI, protease inhibitor.
Figure 1. Main results of the study.
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on multiple medications but the use of bid regimens in the elderly is
sometime avoided due to poor adherence concerns.
Materials and methods: We retrospectively evaluated 20 HIV,
over 60-years-old, experienced patients, who had switched from
any antiretroviral drug to raltegravir-based nuc-sparing/protease
inhibitors(PI)-containing regimens (n10) or standard nucleoside-
backbone regimens (n10) because of toxicity, convenience or
other reasons. Data were collected from medical records. The time
horizon for patient follow-up was at least 12 months. The following
information was extracted from the database of the department:
age, sex, race, smoking, risk factors, AIDS history, hepatitis,
comorbidities, BMI, blood count, HIV RNA, CD4, CD8, previous
ART regimens, creatinine, cholesterol and triglycerides, and choles-
tasis index. SPSS software was used.
Results: The median age of the patients was 64.5 years (15 males, 5
females) with a median of HIV diagnosis years of 13. HIV RNA at
baseline was undetectable in most of the patients except two.
Median CD4 count was 450.5 cells/mm3 (IQR 353717). Twelve
patients had AIDS history. Reasons to switch were renal insufficiency,
dyslipidaemia, HIV drug resistance and drugdrug interactions. No
adverse effect related to the use of raltegravir was reported. Only
one patient presented virologic failure, whereas viremic blips were
observed in four patients. After switching to RAL-containing regi-
mens triglycerides values showed a statistically significant reduction
from a median value of 165 mg/dL to 111.5 mg/dL (p0.016).
Comparing patients who switched to a standard nucleoside-backbone
containing regimen (NRTI-R) versus those who switched to PI-based
nuc-sparing regimens (PI-R) we found that only NRTI-R patients
presented a statistically significant reduction of triglycerides (155 mg/
dL at T0 vs. 95 mg/dL at T2, median values, p0.047). Furthermore,
the NRTI-R patients compared with PI-R patients presented reduced
values of creatinine (0.9 mg/dL vs. 1.1 mg/dL, p0.043), reduced
values of alkaline phosphatase (47 UI/L vs. 85 UI/L, p0.046) and
higher levels of CD4 count (635 cells/mm3 vs. 453 cells/mm3,
p0.035).
Conclusions: RAL-containing regimens are safe and highly effective in
the older population. Reduction of trigliceryde levels is more
pronounced when RAL is used with nucleoside-backbone than in
PI-containing regimens. When using RAL, switching to a standard
nucleoside-backbone regimen appears to be less toxic than nuc-
sparing/PI-containing regimens in older patients.
P111
Characteristics and satisfaction survey in patients switching
to darunavir/cobicistat (DRV/c)
Maria Vivancos-Gallego; Ana Moreno; Carmen Quereda; Jose
Luis Casado; Cristina Gomez Ayerbe; Matilde Sanchez-Conde;
Santos Del Campo; Santiago Moreno and Maria Perez Elias
Infectious Diseases, Instituto Ramo´n y Cajal de Investigacio´n
Sanitaria, Madrid, Spain
Introduction: Coformulated ARV in a single pill, as DRV/c could
improve adherence and satisfaction to ARVs. No studies had explored
this outcome with new boosted PI, DRV/c [1,2]. A satisfaction
questionnaire was conducted to know how patients feel with the
new treatment.
Methods: From July 2015 to January 2016, we retrospectively
reviewed all patients switching to a DRV/c regimen. After switching
to DRV/c a short satisfaction questionnaire was filled out by
participants. All questions referred to the changes with respect to
the prior regimen. Overall satisfaction and convenience were
categorized as: better, equal or worse. All symptoms were evaluated
and could be categorized as getting better or worse and scored 110.
Results: Hundred and sixty-nine patients started a DRV/c regimen:
76.9% men, with a median age of 52.3 years, 59.5% IDU as route of
HIV transmission, AIDS stage 50.6%, HCV co-infection 56.6%, baseline
CD4 count 694 and a median exposure to ARTof 17 (127) years. Main
reasons for switching were simplification 80% and toxicity 9%. Previous
treatment was PI monotherapy (31%), PI2 NRTIs and PI3TC
(15.6%). Mean reduction in the number of tablets was significant (3 to
1.8; pB0.001). After switching, boosted PI distribution was: DRV/c
34%, DRV/c3TC 18% and DRV/cDTG 15%. Fifty-four out of 169
patients were surveyed. Majority, 92.5% answered that they felt better
than before or equal, while 7.5% felt worse. Convenience was scored,
81.1% better, 15.1% equal or 3.8% worse. Asking about specific
symptoms, 26.4% referred some symptom that improved (with a
scored 2.13 vs. 1.47; p0.002), while 28.3% referred at least one
worsening symptom (1.13 vs. 1.94; pB0.001). There was a statistically
significant improvement in frequency of stools (1.69 vs. 1.19;
p0.002). A higher improvement was found when patients came
from DRV/r compared with those who came from non-DRV/r (97.6%
vs. 72.7%; p0.005). Patients with prior non-DRV/r compared with
DRV/r regimens had a higher frequency of stools score before changing
to DRV/c (2.64 vs. 1.45; p0.043), while turned to similar frequency
of stools score after switching (1.14 vs. 1.36; p0.56).
Conclusions: DRV/c was prescribed mostly in HIV-infected patients
with longer time of exposure to ART, previous AIDS and HIV/HCV co-
infection. Simplification was the main reason for switching to DRV/c.
Patients switching to DRV/c valued the new treatment as better or
equal and more convenient. Patients taking DRV/r before the switch
referred more satisfaction comparing with those who were taking
non-DRV/r.
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Short-term safety and tolerability of switch of
backbone antiretroviral agents to coformulated tenofovir
disoproxil fumarate/emtricitabine in HIV-positive
Taiwanese patients
Hsi-Yen Chang1; Pei-Ying Wu1; Jun-Yu Zhang1; Shang-Ping Yang1;
Yu-Zhen Luo1; Wen-Chun Liu2; Hsin-Yun Sun2; Chien-Ching Hung2 and
Shan-Chwen Chang2
1Center of Infection Control, National Taiwan University Hospital,
Taipei, Taiwan. 2Department of Internal Medicine, National Taiwan
University Hospital, Taipei, Taiwan
Introduction: Coformulated tenofovir disoproxil fumarate (TDF)/
emtricitabine (FTC) has become the recommended backbone anti-
retrovirals in combination with other non-nucleoside reverse
transcriptase inhibitors (non-NRTIs), protease inhibitors or integrase
strand transfer inhibitors. Access to this coformulation is limited,
however, in many countries in Asia-Pacific regions. We aimed to
assess the safety and tolerability of switch of two NRTIs backbone
to TDF/FTC in treatment of HIV infection in Taiwan, where access to
TDF/FTC was not available until May 2015.
Materials and methods: All HIV-positive patients with a mean age of
40.5 years and 88.5% being homosexual males whose backbone
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antiretrovirals were switched to TDF/FTC between May 2015 and
May 2016 were included in this analysis. We collected information on
the demographic and clinical characteristics before switch and CD4,
plasma HIV RNA load (PVL), lipids, serum creatinine, glycosuria,
proteinuria and beta-2 microglobulin at baseline and during follow-
up. Adverse effects and causes of discontinuation were also
recorded.
Results: During the 12-month observation period, 1164 patients
switched from TDF and lamivudine (n818), coformulated abacavir/
lamivudine (n229) and coformulated zidovudine/lamivudine
(n117) to TDF/FTC, without changes made to the third agents,
after a mean exposure duration of 60 (SD, 47), 91 (SD, 32) and 40
(SD, 40) weeks, respectively. CD4 and PVL before switch were 613
cells/mm3 (SD, 284) and 1.50 log10 copies/mL (SD, 0.70). After an
interval of 240 days (SD, 68), the mean CD4 and PVL remained stable
(610 cells/mm3 and 1.38 log10 copies/mL, respectively), so was
mean serum creatinine for TDF and lamivudine group (0.93 vs. 0.92
mg/dL) and zidovudine/lamivudine group (0.94 vs. 0.96 mg/dL), but
it increased from 0.94 to 1.12 mg/dL for abacavir/lamivudine group.
Mean total cholesterol, triglyceride and low-density lipoprotein-
cholesterol decreased from 178.0 to 167.2, 178.1 to 134.9, and 105.0
to 99.4 mg/dL for abacavir/lamivudine group, respectively, and 161.4
to 152.3, 150 to 135.1 and 97.1 to 94.3 mg/dL for zidovudine/
lamivudine group, respectively. Urine beta-2 microglubulin increased
from 1.24 to 1.44, 0.68 to 1.62 and 1.37 to 2.9 mg/L, for TDF and
lamivudine, abacavir/lamivudine, and zidovudine/lamivudine group,
respectively. TDF/FTC was discontinued in 46 patients (4.0%), due to
diarrhoea (n5), nausea (n6), allergy (n5), paresthesias (n5),
increased serum creatinine (n5), increased PVL and emergence of
resistance (n6) and other miscellaneous causes (n16).
Conclusions: Coformulated TDF/FTC was generally well tolerated and
safe in HIV-positive Taiwanese, with additional lipid-lowering effects
in those who had been on abacavir/lamivudine- or zidovudine/
lamivudine-containing regimens. Periodic renal monitoring for renal
tubular dysfunction is warranted.
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Optimizing viral load testing to improve quality of care and
client retention for PLHIVs in HIV clinic in Northern Nigeria:
impact and experiences
Emmanuel Nwabueze1; Nwokedi Ndulue1; Ginika Egesimba1;
Med Makumbi1; Zipporah Kpamor1; Emeka Okechukwu2 and
Joy Kolin1
1Management Sciences for Health, ProACT, Abuja, Nigeria. 2USAID,
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Introduction: PLHIVs on antiretroviral (ARV) regimen with plasma
viral load above 1000 copies/mL based on two consecutive viral load
measurements after 3 months, with adherence support, are said to
be in virology failure. Virology failure leads to easy HIV transmission,
evitable morbidity and mortality especially if antiretroviral therapy
(ART) drugs are switched without initial VL testing. Unfortunately, VL
testing is so costly. The few available PCR laboratories and point-of-
care (POC) VL machines that are used for the testing are not evenly
distributed in the country. Currently over 70% of PLHIVs have not
done any VL test in the last one year since enrolled into care. In
2014, MSH ProACT, a USAID-funded programme in Nigeria, launched
a PCR laboratory in Usman Danfodiyo University Teaching Hospital
Sokoto to provide free VL testing. This is in alignment with PEPFAR
and UNAID 90:90:90 strategies. This study was to find out the impact
of the PCR laboratory on PLHIVs’ quality of care.
Methods: Retrospective study was done one year after the PCR
launch. Clinical audit of the VL register and chart review of 268
folders of clients with detectable VL results 20 VL copies were
conducted. Analysis of client retention data was also done. Update
training was conducted for clinicians and other healthcare workers
(HCWs) working in the ART clinic to optimize VL testing.
Results: The analysis of the VL register showed that 268 out of 583
recorded results (46%) had detectable VL of which 141 (53%) are
1000 copies/mL. Chart review of the 268 folders revealed that 162
were not switched and 106 were switched: 22 (21%) were rightly
switched and 84 (79%) were wrongly switched (considering the
retrogressive outcome documented). 66 (78%) of these wrong ART
switches had 1000 copies of which 28 (42%) were in World Health
Organization stages 3 and 4. These wrong switches were made prior
to the launch of the PCR laboratory.
Discussion: After the launch, seven (100%) of the subsequent
switches were done well. Currently most clients do better without
requiring switching post VL testing and adherence counselling.
Within a year, client retention improved to 77% as compared with
59% in the previous year. Quality of care and clients’ adherence
improved.
Conclusions: VL testing improves quality of care for all PLHIVs. If PCR
laboratories or POC VL machines are suitably deployed, health
system will be strengthened, there will be reduction in wrong
switches and, subsequently, reduction in mortality and morbidity
among PLHIVs.
TREATMENT STRATEGIES: OTHER
P114
Knowing the epidemic is the best way to define diagnosis
and treatment strategies to reach the 909090 goals: the
experience of Portugal in using the ECDC HIV modelling tool
Antonio Diniz1; Jose Loff2 and Helena Cortes-Martins3
1Immunodeficiency Unit, Directorate General of Health and CHLN,
Lisboa, Portugal. 2Department of Epidemiology and Surveillance,
Directorate General of Health, Lisboa, Portugal. 3Infectious Diseases,
National Health Institute, Lisboa, Portugal
Introduction: In Portugal, data from the continuous of care show
that in 2014 approximately 34,000 persons living with HIV (PLHIV)
were in care, 82.8% of which on antiretroviral treatment and 78.4%
virologically suppressed. However, updated estimates for HIV
prevalence, incidence and PLHIV diagnosed are still missing, making
difficult defining appropriate diagnosis and treatment strategies to
reach the 909090 goals.
Material and methods: Annual estimates (19832014) for the
number of PLHIV, undiagnosed fraction, new infections and time to
diagnosis were produced using the new software application ‘‘ECDC
HIV modelling tool,’’ and the data from the national HIV surveillance
system. The model was constructed based on the ‘‘Incidence
Method’’ [1]. Several cut points were considered to fit the model
to the Portuguese HIV epidemic.
Results: Estimates were produced for total HIV-infected population
and for main transmission categories: heterosexual, men who have
sex with men (MSM), intravenous drug users (IVDU) (Table 1). At the
end of 2014, an estimated number of 44,176 individuals were living
with HIV in Portugal (prevalence: 0.43%). Of those, 4298 (9.7%) were
not aware of their infection.
Conclusions: Current estimates indicate a lower prevalence than
previous assessments. Estimated undiagnosed fraction and time to
diagnosis vary for different transmission modes reflecting past
interventions and current trends of the epidemic. Portugal has now
updated data that will allow building the ‘‘treatment cascade.’’
According to these results, Portugal has reached the cascade first
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goal (90% of the PLHIV already diagnosed) with time to diagnosis
becoming progressively shorter. In order to reach all 909090 goals,
wemust now address our efforts to define and apply new and stronger
strategies related to linkage/retention in care and to treatment.
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Introduction: As HIV infection requires lifelong treatment, studying
drug retention times and factors influencing treatment durability is
essential. The Swedish database InfCareHIV includes high-quality
data from more than 99% of all patients diagnosed with HIV infection
in Sweden and provides a unique opportunity to examine outcomes
in a nationwide real-world cohort.
Methods: Adult patients who started a new therapy defined as a
new third agent (all ARVs that are not NRTIs) 2009 to 2014 with more
than 100 observations in treatment-naı¨ve or treatment-experienced
patients were included. Dolutegravir was excluded due to short
follow-up period. Multivariate Cox proportional hazards models were
used to estimate hazard ratios for treatment discontinuation.
Results: Two thousand five hundred and forty-one treatment-naı¨ve
patients started 2583 episodes of treatmentswith a third agent. Efavirenz
was most commonly used (n1096) followed by darunavir (n504),
atazanavir (n386), lopinavir (n292), rilpivirine (n156) and
raltegravir (n149). In comparison with efavirenz, patients on rilpivirine
were least likely to discontinue treatment (adjusted HR 0.33; 95% CI
0.200.54, pB0.001), while patients on lopinavir were most likely to
discontinue treatment (adjusted HR 2.80; 95% CI 2.303.40, pB0.001).
Two thousand nine hundred and ninety-one treatment-experienced
patients started 4552 episodes of treatments with a third agent.
Darunavir was most commonly used (n1285), followed by
atazanavir (n806), efavirenz (n694), raltegravir (n622), rilpi-
virine (n592), lopinavir (n291) and etravirine (n262). Com-
pared to darunavir all other drugs except for rilpivirine had higher
risk for discontinuation in the multivariate adjusted analyses:
rilpivirine (HR 0.66; 95% CI 0.520.83, pB0.001), atazanavir (HR
1.71; 95% CI 1.481.97, pB0.001), efavirenz (HR 1.86; 95% CI 1.59
2.17, pB0.001), raltegravir (HR 1.35; 95% CI 1.151.58, pB0.001),
lopinavir (HR 3.58; 95% CI 3.024.25, pB0.001) and etravirine (HR
1.61; 95% CI 1.311.98, pB0.001).
Besides the ARV treatment, certain baseline characteristics of
patients were independently associated with differences in drug
retention time. In naı¨ve patients, the use of other backbone than
TDF/FTC or ABC/3TC increased the risk for early treatment
discontinuation. In treatment-experienced patients, detectable plas-
ma viral load at the time of switch or being highly treatment
experienced increased the risk for early treatment discontinuation.
Conclusions: Treatment durability is dependent on several factors,
among others patient characteristics and ART guidelines. The choice
of third agent has a strong impact, with significant differences found
between drugs.
P116
Discontinuation of dolutegravir (DTG)-based regimens in
clinical practice
Maria J Vivancos-Gallego; Ana Moreno; Maria J Perez-Elias;
Cristina Gomez Ayerbe; Jose Luis Casado; Carmen Quereda;
Matilde Sanchez-Conde; Sergio Serrano Villar; Fernando Dronda;
Enrique Navas; Miguel Angel Rodriguez and Santiago Moreno
Infectious Diseases, Instituto Ramon y Cajal de Investigacio´n
Sanitaria, Hospital Ramon y Cajal, Madrid, Spain
Introduction: Real-life data have shown a higher rate of side effects
with dolutegravir (DTG)-based regimens than previously described in
clinical trials. In order to confirm these observations, we have
reviewed our experience in patients who discontinued DTG for any
reason.
Materials and methods: Retrospective analysis of all patients who
discontinued DTG in our hospital cohort. Pre-treated and treatment-
naı¨ve patients were included. Baseline characteristics at the time of
DTG initiation and antiretroviral therapy before and after DTG were
recorded. We describe any reason for dolutegravir discontinuation.
Results: Among 2470 HIV-infected patients, 827 (33.5%) patients
received DTG (69.4% STR of ABC/3TC/DTG) from September 2014 to
May 2016 for a median period of 156.8 days (41199). A total of 104
(12.6%) patients discontinued DTG for any reason and were switched
to other ARV regimens. Of these 104 patients (60.6% STR of ABC/
3TC/DTG), mean age was 49.6910.5 years, 74 (71.2%) were men,
baseline CD4 count was 5749324 cells/mm3, viral load was
detectable before starting DTG in 17 (16.3%) and 30 (29%) had
previous AIDS. Only seven (6.7%) patients were naı¨ve. There were 41
Abstract P114Table 1. Estimates of PLHIV, PLHIV diagnosed and undiagnosed, undiagnosed fraction, new infections and time to
diagnosis, global and by transmission categories (2014)
Global Heterosexual MSM IVDU
PLHIV 44,176 (43,17545,154) 22,109 (21,41623,236) 7930 (75328440) 13,353 (13,11913,900)
PLHIV diagnosed 39,877 (39,47640,295) 19,239 (18,98719,574) 7071 (68967288) 13,193 (13,00813,513)
PLHIV undiagnosed 4298 (35085274) 2870 (22003783) 859 (5701292) 161 (95665)
Undiagnosed fraction (%) 9.7 (8.011.8) 13 (10.316.3) 10.8 (7.415.5) 1.2 (0.74.8)
New infections 528 (361088) 414 (47953) 106 (58414) 5 (0281)
Time to diagnosis (years) 4.1 (3.74.4) 4.5 (4.05.1) 2.8 (2.23.4) 3.4 (1.75.8)
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patients (39.4%) who were lost to follow-up. Main reasons for
stopping DTG-based regimen were toxicity in 36 patients (4.3% of all
patients who initiated DTG, 33.9% of all discontinuations), and
physician’s decision in 11 patients (1.3% and 10.6%, respectively).
Most frequent toxicities leading to drug interruption included
headache (nine patients), high cholesterol (eight patients), insomnia
(seven patients) and dizziness (six patients). One patient developed
serious mood disorders with early recovery after discontinuation.
Conclusions: In our real-life cohort, we did find a high proportion of
DTG discontinuation attributable not only to toxicity. CNS adverse
events are the most frequent cause of discontinuation. Ongoing
pharmacovigilance is important to identify events that might be
associated with the drug.
P117
Dolutegravir (DTG) monotherapy treatment de-escalation in
virological controlled, pre-treated HIV patients: results from
the DoluMono cohort study
Celia Oldenbu¨ttel1; Eva Wolf1; Ayla Ritter2; Sebastian Noe1;
Silke Heldwein1; Rita Pascucci1; Carmen Wiese1; Ariane von Krosigk1;
Eva Ja¨gel-Guedes1; Hans Ja¨ger1; Annamaria Balogh1; Christine Ko¨gl1
and Christoph Spinner2
1MVZ Karlsplatz, Munich, Germany. 2Department of Medicine II,
University Hospital Klinikum rechts der Isar, Munich, Germany
Introduction: Long-term antiretroviral treatment (ART) with (poten-
tial) toxicity in HIV-infected patients requires ongoing investigation of
novel strategies. Besides ‘‘nuke-free’’‘ concepts and protease in-
hibitor monotherapy, integrase inhibitor (INSTI) monotherapy may
offer a favourable safety profile. The high resistance barrier of
dolutegravir (DTG) might be crucial for successful maintenance of
virological control, but published data are sparse.
Methods: Retrospective, mono-centric cohort study. Patients on
suppressive ART switched to DTG monotherapy in clinical routine
practice fulfilling inclusion criteria (HIV RNA level B50 copies/mL for
]6 months at time of switch [one accepted blip B200 copies/mL
with re-suppression], no known INSTI resistance or prior INSTI failure,
no replicative HBV infection and no history of AIDS) were enrolled.
Results: We identified 31 patients with week 24 follow-up data.
Median time on previous ART was 26 months (2428) including an
NNRTI in 32%, a boosted PI in 6% and an INSTI in 61% of cases. At
week 24, HIV RNA remained B50 copies/mL in 94% of all patients.
One patient discontinued DTG monotherapy on his own wish (3%),
and in another patient confirmed virological failure (3%) with HIV
RNA 538 copies/mL and evolution of INSTI mutations Q148H/G140S
was documented. Changes in immune, renal and metabolic status/
function showed no statistically significant changes, except a
significant decrease of gGT (Table 1).
Conclusion: Switching to DTGmonotherapy in selected patients might
be safe and effective. However, in one case evolution of INSTI resis-
tance was observed. Further studies should assess risk factors for DTG
monotherapy failure. Meanwhile, caution should be warranted.
P118
Outcomes of cabotegravir (CAB) treatment in HIV-1 ART-
naive patients with chronic or acute hepatitis C virus (HCV)
co-infection: data from the phase IIb programme
Shanker Thiagarajah1; David Dorey2; Jenny Huang2; Gilly Roberts1;
Britt Stancil3 and David Margolis4
1Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline,
London, UK. 2Clinical Statistics, GlaxoSmithKline, Mississauga,
Canada. 3Biostatistics, PAREXEL International, Durham, NC, USA.
4Global Medical Strategy, ViiV Healthcare, Durham, NC, USA
Introduction: HCV co-infection is prevalent in the HIV-1 population,
and acute HCV infection has been reported. CAB is a long-acting (LA)
intramuscular integrase inhibitor (INI) in clinical development for the
treatment of HIV in combination with LA rilpivirine. Acute reversible
transaminitis has been reported with INI treatment. This report
describes the safety and efficacy outcomes of CAB treatment for HIV-
1 infected ART-naı¨ve subjects with acute and chronic HCV co-
infection during two ongoing phase IIb studies (LATTE and LATTE-2).
Materials and methods: Subjects with HCV co-infection were
identified using HCV antibody results at baseline. Subjects with acute
HCV infection were identified using polymerase chain reaction assay,
once subjects had met prespecified criteria for liver aminotransami-
nase elevations (ATE). The following were assessed: protocol defined
HIV virological failure (PDVF), withdrawals, emergent grade 2 or higher
ATE on CAB, meeting predefined liver stopping criteria (LSC).
Results: In the intent-to-treat-exposed (ITT-E) population receiving
CAB treatment, 22 of 490 (4.5%) subjects were HCV antibody reactive
at baseline (Table 1). Of these 22 co-infected subjects, one subject
developed PDVF through week 144 (LATTE, n9), and no subject
developed PDVF through week 48 (LATTE-2, n13). Two co-infected
subjects were withdrawn due to drug-related adverse events:
suspected drug-induced liver injury (DILI) meeting LSC (n1) and
nausea (n1). Three co-infected subjects had emergent grade 2 or
higher ATE, two of which were withdrawn: DILI (n1), withdrawal of
consent-subject homeless with difficulty travelling (n1). Ten of 490
(2%) subjects on LATTE and LATTE-2 developed acute HCV infections
Abstract P117Table 1. Overview of selected study parameters at baseline and week 24 with delta and p-value
Parameter Week 0 (n31) Week 24 (n30) Delta (week 24-0) p
HIV RNA B50 copies/mL (patients), ITT snapshot 31 (100%) 29 (94%) 2 (6%) 0.500
CD4 absolute (/mL) 752 (581970) 747 (573913) 21.5 (9885) 0.959
ALT (U/L) 33 (2644) 32 (2642) 1.5 (913) 0.758
AST (U/L) 21 (1926) 23 (1929) 0.5 (55) 0.910
gGT (U/L) 36 (2864) 30 (2351) 4.5 (221) 0.014
HDL cholesterol (mg/dL) 56 (4568) 51.5 (4362) 2.5 (83) 0.174
LDL cholesterol (mg/dL) 115 (92142) 122 (95138) 0.5 (926) 0.300
Total cholesterol (mg/dL) 182 (160214) 194 (178221) 4 (2833) 0.524
Triglycerides (mg/dL) 146 (96187) 130 (98196) 3 (3845) 0.681
Serum creatinine (mg/dL) 1.1 (11.4) 1.15 (1.031.43) 0.02 (0.060.15) 0.225
eGFR (mL/min) 95 (81114) 109.05 (83120) 6 (414) 0.077
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while on CAB, characterized by ATE. Five subjects were withdrawn
after meeting LSC and transitioned to alternative ART. Five remaining
subjects on LATTE-2 who met LSC had transaminase decline indicating
stable disease or spontaneous clearance of HCV and were permitted
per protocol to continue on CAB LA. All five acute HCV subjects
continuing on CAB LA maintained HIV-1 viral suppression (B50
copies/mL at week 48). One (1/5) remaining acute HCV subject later
discontinued CAB LA due to rebound ATE considered related to the
underlying evolving HCV infection. Triumeq was started with con-
tinued HIV-1 viral suppression (B50 copies/mL at week 48).
Conclusions: Data from the phase IIb studies, albeit in small numbers
of subjects, support the conclusion that chronic HCV co-infection
does not adversely impact treatment outcomes in most subjects and
uncomplicated acute HCV infection may not be a barrier to CAB LA as
a treatment option.
P119
Antiretroviral treatment patterns in the US: an analysis of
real-world data
Abstract P118Table 1. Summary of PDVF and safety results by HCV infection status for LATTE and LATTE-2 subjects* exposed to
cabotegravir
Hepatitis C
infection status,
ITT-E (N490)
Number of subjects with
protocol defined
virological failure, n (%)
Number of subjects with grade 2
or higher transaminitis, maximum
post baseline emergent ALT or
AST, n (%)
Number of subjects with
drug-related adverse events
leading to withdrawal, n (%)
Number of subjects who
met protocol defined liver
stopping criteria, n (%)
HCV co-infection
(N22)
1/22 (4.5%) 3/22 (14%) 2/22 (9%) 1/22 (4.5%)
Acute HCV
infection
(N10)
0/10 10/10 (100%) 0/10 10/10 (100%)%
Non-infected
(N458)
12/458 (2.6%)$ 45/458 (9.8%) 11/458 (2.4%) 3/458 (B1%)§
*LATTE (N181) used week 144 data cut and LATTE-2 (N309) used week 48 data cut; $Nine subjects were ineligible to enter the
maintenance period (HIV-1 RNA 50 copies/mL just prior) and did not meet the confirmed PDVF criteria at time of withdrawal; %Five subjects
with acute HCV infection met protocol defined liver stopping criteria but were permitted by protocol to continue on CAB LA; §One additional
subject who met liver stopping criteria based on local laboratory tests is not counted in the numerator.
Abstract P119Figure 1. The proportion of patients who initiated different third agents.
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and Felix Cao2
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USA. 2Health Economics and Outcomes Research, Optum, Eden
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Introduction: Recommended initial treatment regimens for HIV-
infected individuals include a ‘‘backbone’’ of two nucleoside reverse
transcriptase inhibitors (NRTIs) in combination with a ‘‘third agent’’
from another class such as integrase strand transfer inhibitor (INSTI),
protease inhibitor (PI) or non-nucleoside reverse transcriptase
inhibitor (NNRTI). Recent treatment guidelines have moved from
recommending PI- and NNRTI-based regimens to more INSTI-based
regimens. In treatment-experienced patients who fail therapy, it is
recommended that the new regimen should include at least two fully
active agents. This study describes the changes in third agents in the
real-world setting over time.
Methods: This is descriptive analysis using a US insurance claims
database. Patients with HIV and newly initiating a different third
agent class (INSTI, PI or NNRTI) were identified from 1 July 2011 to
30 September 2015. Patients were excluded if they were not
continuously enrolled in the health plan for a year.
Results: In total, 9525 patients with HIV started a new third agent
regimen. A majority of patients were new initiators of third agents
(77.0%) with the remainder of patients adding on or switching to a
new third agent. Most were male (82.3%), had commercial type
insurance (89.3%) and had a mean age of 45.2 (SD911.9). In
patients who newly initiated a third agent, 31.9% started on an INSTI,
24.8% on a PI and 43.3% on a NNRTI. However, the proportion of
patients starting INSTI increased from 19.3% in 2012 to 50.3% in
2015, while the proportions of patients starting other third agents
decreased over time (Figure 1). In third agent-experienced patients,
10.8% were on an INSTI, 59.3% on a PI and 37.5% on a NNRTI at
baseline. Less than 2% of patients were on a fusion inhibitor or entry
inhibitor, and 7.5% of patients were on multiple third agents at
baseline. Among patients already on a third agent, 66.3% of patients
added or switched to an INSTI, 10.6% to a PI and 23.1% to a NNRTI.
The proportion of patients who added or switched to an INSTI
increased from 49.4% in 2012 to 80.6% in 2015, while proportions of
patients starting other third agents decreased over time.
Conclusion: There is an increase in new initiators and treatment-
experienced patients starting INSTI compared to other third agents.
Future studies are needed to examine the tolerability and outcomes
related to these changes in third agents.
P120
Selected antiretroviral treatment option is associated with
virological success: multicentre data from Poland
Milosz Parczewski1; Magdalena Leszczyszyn-Pynka1; Adam Witor2;
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Elzbieta Jablonowska6; Kamila Wo´jcik-Cichy6; Juliusz Kamerys6;
Dariusz Bielec7; Justyna Stempkowska7; Aleksandra Kocbach8 and
Wieslawa Bludzin9
1Department of Infectious, Tropical Diseases and Immune Deficiency,
Pomeranian Medical University, Szczecin, Poland. 2Outpatients Clinic
for Immune Deficiency, Regional Hospital, Chorzo´w, Poland.
3Department of Infectious Diseases, Hepatology, Wroclaw Medical
University, Wroclaw, Poland. 4Department of Infectious Diseases,
Jagiellonian University Medical College, Krako´w, Poland.
5Department of Infectious Diseases and Hepatology, Medical
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Introduction: Modern antiretroviral therapies allow to effectively
suppress HIV-1 viral load in majority of treated cases; however, due
to differences in clinical practice, virological success rates may vary
significantly across the treatment centres. The aim of this study was
to analyze treatment efficacy in real-life Polish cohorts and identify
variables associated with undetectable HIV-1 viral load.
Materials and methods: Cross-sectional data on the antiretroviral
treatment efficacy were collected for the 2249 (25.3% of total
countrywide treated cases) patients followed up in 9/17 Polish HIV
treatment centres. Data of patients on stable cART treated 6
months with at least one follow-up visit and HIV RNA measurement
in 2016 were analyzed. Treatment options included nucleos(t)ide
backbone (NRTI) plus protease inhibitor (PI) in 942 cases (37.7%),
NRTI plus non-nucleoside reverse transcriptase inhibitor (NNRTI) in
768 (30.73%), NRTI plus integrase inhibitor (INI) in 632 (25.29%),
NRTI-sparing regimen of PIINI in 68 (2.72%) and other combina-
tions in 89 (3.56%) individuals. Virological success was defined as HIV
RNA B50 copies/mL in the last measurement taken in 2016. For
statistics chi-squared test, Mann-Whitney U test and multivariate
logistic regression models adjusted for gender, AIDS history, HIV viral
load at baseline, lymphocyte CD4 nadir B200 cells/mL, transmission
route and age were used.
Results: Undetectable viral load (B50 copies/mL) was observed in
2256 (90.28%) individuals. Virological success rate differed consider-
ably across the regimens (835/942 [88.64%] for NRTIPI, 732/768
[95.31%] for NRTINNRTI, 563/632 [89.08%] for NRTIINI and 54/
68 [79.41%] for PIINI, pB0.0001). NRTINNRTI regimens were
associated with higher adjusted odds ratio (aOR) of virological
success compared to NRTIPI [aOR 2.68 (95% CI 1.415.13),
p0.003], NRTIINI [aOR 4.04 (95% CI 2.137.78), pB0.0001] or
PIINI [aOR 7.92 (95% CI 2.7322.99), pB0.0001] (Figure 1). It
should be noted, however, that patients receiving NRTINNRTI
presented with lower baseline HIV viral load [median 4.64 (IQR
4.165.07) log copies/mL] and higher CD4 nadir [median 283
(IQR 175403) cells/mL] compared to NRTIPI-treated [median 4.9
Figure 1. Antiretroviral regimen-associated differences in the
frequency of HIV-1 viral load B50 copies/mL.
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(IQR 4.345.41) log copies/mL, pB0.001 and 190 (IQR 76311)
cells/mL, pB0.0001, respectively], NRTIINI-treated [median 4.9
(IQR 4.415.44) log copies/mL, pB0.001 and 228 (IQR 90393)
cells/mL, pB0.0001, respectively] or PIINI-treated cases [median
5.42 (IQR 4.795.94) log copies/mL, pB0.0001 and 155 (IQR
59246) cells/mL, pB0.0001, respectively]. Additionally, patients
on NRTI-sparing PIINI regimen were notably older at diagnosis
[median 38 (IQR 2948) years] and treatment initiation [median
37 (IQR 3146) years] compared to the remaining treated groups
[median 31 (IQR 2538) years, pB0.0001 and 33 (IQR 2840) years,
pB0.0001, respectively].
Conclusions: While NNRTI-based therapy is associated with higher
virological efficacy, it may be explained by the preselection of
patients with more favourable virological and immunological char-
acteristics. Challenging-to-treat and older populations often receive
PIINI-based, NRTI-sparing regimens despite poorer efficacy in the
clinical setting.
P121
Much less treatment modification with recently approved
drugs: the Austrian HIV Cohort Study
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Introduction: Adverse effects and to a lesser degree viral failure of
combination ART commonly result in treatment modification.
Patients and methods: Patients were analyzed for factors associated
with treatment modification, defined as stop or as change of drugs.
Dolutegravir (DGV), elvitegravir (EVG), raltegravir (RAL), darunavir
(DRV) and rilpivirine (RPV) were separately analyzed. RPV and EVG
were included only when taken as single-tablet regimen, and DRV
only as 800 mg daily dose. All patients were limited to standard
regimen, and the pre-treated patients were only included if they
received the particular drug for the first time (first-use regimens).
Observation period lasted from 1 July 2013 to 1 January 2016. Cox
regression models were performed to identify predictors of mod-
ification and Kaplan-Meier estimates were used to calculate
probabilities of modification.
Results: We analyzed 787 naı¨ve patients and 1790 first-use regimens
among 1590 pre-treated patients. Overall, ART was modified among
181 (23.0%) naı¨ve patients and 330 (18.4%) individuals with first-use
Figure 1. Time to treatment modification by drugs.
Figure 2. Time to treatment modification by drugs.
Abstract P121Table 1. Factors associated with treatment modification: multivariable Cox regression
Drug-naı¨ve patients
Multivariable Cox
regression
First use of drug in
pre-treated patients
Multivariable Cox
regression
Number of patients with
modification/all HR [95% CI]
Number of patients with
modification/all HR [95% CI]
Drugs
Dolutegravir 14/235 0.98 [0.432.23] 90/928 0.60 [0.430.84]
Elvitegravir 8/89 0.89 [0.352.26] 38/191 1.09 [0.731.65]
Raltegravir 36/83 5.71 [2.7911.71] 63/154 2.07 [1.432.98]
Darunavir 60/152 4.50 [2.298.86] 77/224 1.63 [1.152.30]
Other 53/124 5.29 [2.6810.44]
Rilpivirine 10/104 1.00 [1.001.00] 62/293 1.00 [1.001.00]
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regimens, most of them in the first year. The overall probability of
modification among the naı¨ve patients rose from 20.0% at 1 and 30.8%
at 2 years and from 17.8 to 30.2% among the pre-treated patients,
respectively. Modifications of individual drugs are given in Figure 1 and
Figure 2. Among the naı¨ve patients taking RAL, DRV or other drugs
showed a higher risk for modification compared to RPV, whereas in
pre-treated patients, DGV showed a lower risk of modification (Table 1).
Demographic and HIV-related factors were not associated with treat-
ment modification with the exception of drug users, who had a
higher risk of modification among pre-treated patients. Availability
of more convenient treatment (37.0%) was the main reason for
discontinuation within the naı¨ve patients and, patients wish (19.4%)
was the most cited reason for the pre-treated ones.
Conclusion: Much less treatment modification in individuals initiat-
ing ART with recently approved drugs which support a better
tolerability and a more convenient profile also in a non-trial setting.
However, there seems to be a difference between recently approved
drugs in pre-treated patients, since we observed the lowest rate of
modification in patients who received DGV. The low rate found for
RPV may be attributed to strict selection of patients according to
guidelines in regard to viral load.
P122
Integrase strand transfer inhibitors in the treatment of
HIV-2 infection: report of 39 patients
Filipa Sequeira1; Sara Grazina2; Joa˜o Alves2; Susana Peres2;
Fernando Borges2; Ana Cla´udia Miranda2; Isabel Aldir2 and
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Introduction: Few data are available on integrase strand transfer inhi-
bitors (ISTI)-based regimens response among HIV-2 infected patients.
Materials and methods: Retrospective longitudinal study. Data on
patients’ demographic characteristics and ISTI response (clinical,
immunological or virological) among HIV-2 infected patients were
collected.
Results: Thirty-nine patients with HIV-2 infection were on ISTI-based
regimens. Sixty-two percent were female. Seventeen patients were
from Portugal, 15 from Guinea-Bissau, five from Cape Verde, one
from Sao Tome and one from Spain. The median age at diagnosis was
46.5 years. The time between diagnosis of HIV-2 infection and ART
initiation ranged from 1 week to 23 years (median of 5 years). The
median CD4 count at diagnosis was 362.8 cells/mm3 (22.1%), and at
ISTI initiation was 315.9 cells/mm3 (21.9%). The median follow-up
after ISTI initiation was 2.7 years (min: 12 weeks, max: 8 years).
Fourteen patients were naı¨ve and 28 patients switched to ISTI. The
reasons for switch were immune failure (n13), cardiovascular risk
(n6), osteoporosis (n2), nephropathy (n4), intolerance (n2)
and HIV-1/2 infection (n1). Thirty-one patients received RAL, and
eight received DTG. Optimized background ARV regimens included
DRV/r (n10), LPV/r (n8), SQV/r (n5) and ATV/r (n2) as-
sociated with two nucleoside reverse transcriptase inhibitors (NRTI).
At week 12, 24 and 36 plasma HIV-2 RNA was undetectable in 92.3%,
97.2% and 94.8%, respectively, and median CD4 cell count was
362/mm3 (77733), 506/mm3 (132992) and 516/mm3 (25989).
One patient had to stop ISTI at week 36 because of immune failure
due to ISTI resistance and died after 3 years.
Conclusions: Our series confirm the clinical effectiveness of ISTI in
treatment-experienced and -naı¨ve patients with HIV-2 infection
when given with other ARVs to which the virus is susceptible. ISTI
appears to perform well in treatment of HIV-2 patients as first
regimen or after switch as therapy for a large proportion of patients
when the first-line regimens may not have been sufficiently potent.
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Effect of probiotics on inflammation in the gut in HIV-
infected individuals evaluated using PET/MR
Caroline Arnbjerg1; Karin Pedersen1; Sofie Jespersen1;
Barbara Fischer2; Helle Johannesen2; Eva Fallentin2; Adam Hansen2;
Andreas Kjær2; Marius Trøseid3 and Susanne Dam Nielsen1
1Department of Infectious Diseases, Rigshospitalet, University
Hospital of Copenhagen, Copenhagen, Denmark. 2Department of
Clinical Physiology, Nuclear Medicine, Rigshospitalet, University
Hospital of Copenhagen, Copenhagen, Denmark. 3Department of
Infectious Diseases, Oslo University Hospital, Oslo, Norway
Introduction: Microbial translocation in HIV-infected individuals has
been associated with increased risk of non-AIDS comorbidity in-
cluding cardiovascular complications. Initiation of cART often results
in immune reconstruction in peripheral blood but does not lead to
normalization of the gut-associated lymphoid tissue (GALT). The aim
of this study was to investigate the effect of the probiotic strain
Lactobacillus rhamnosus GG on microbial translocation both on local
inflammation in the gut and on systemic inflammation.
Methods: The study was a prospective, clinical intervention trial and
included 15 cART-naı¨ve, and 30 cART-treated HIV-infected participants.
All participants ingested probiotics (Dicoflor60†, Pharmaforce ApS,
Denmark) in dose of 6  109 colony-forming units twice a day for a
period of 8 weeks. Local inflammation was measured using fluoro-D-
glucose positron emission tomography/magnetic resonance (FDG PET/
MR) scans. Local inflammation in the bowel was assessed in five regions:
terminal ileum, ascending, transverse, descending and sigmoid colon and
rectum. Furthermore, fasting blood samples were obtained both at
baseline and after 8weeks of probiotics. Lipopolysaccharide (LPS), soluble
inflammation markers of inflammation IL-6, IL-2, TNF-alfa and hsCRP as
well as the CD4+ T-cell count were determined.
Results: Forty-five participants completed the study, 15 cART-naı¨ve
and 30 cART-treated participants, of which 15 participants were scanned
using PET/MR before and after probiotics. On PET/MR, two out of five
cART-naı¨ve participants and 4 out of 10 cART-treated participants had
evidence of decreasing inflammation on a global score. In terminal
ileum, 4 out of 5 cART-naı¨ve and 4 out of 10 cART-treated participants
had decreasing inflammation (p=0.07). Among the cART-treated
participants, concentration of LPS was found to increase (0.450.49
EU/mL, p=0.033). In contrast, no effect of LGG on markers of systemic
inflammation in either cART-treated or cART-naı¨ve HIV-infected
participants was found. Finally, an increase in CD4+ T-cell count was
found in the cART-treated group (659697 cells/mL, p=0.029).
Conclusion: Using PET/MR to evaluate gut inflammation is feasible.
The probiotic strain Lactobacillus rhamnosus GG did not have any
beneficial effect on microbial translocation or systemic inflammation
in HIV-infected individuals. However, PET/MR scans indicated a
possible reduction of local inflammation. Future studies evaluating
PET/MR scans as a method to assess the gut inflammation in HIV-
infected individuals are warranted.
P124
Starting antiretroviral therapy for HIV at the first visit and
early after inclusion into care: an observational study
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1Department of Infectious Diseases, University of Zagreb School of
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Introduction: Croatia has a centralized system of care and all HIV-
infected persons are treated at the University Hospital of Infectious
Diseases (UHID) in Zagreb. All patients collect antiretroviral drugs
from the hospital pharmacy at UHID. The centre at UHID is also the
only centre in Croatia that provides psychosocial and adherence
support to people living with HIV. Data on ART initiation at first clinic
visit are limited [1,2]. We describe the characteristics of patients who
start ART immediately and early after inclusion into care at UHID,
and examine whether starting ART on the first visit (same-day
starters) is equally successful as starting ART within the next 30 days
(early starters).
Materials and methods: We included ART-naı¨ve individuals aged 18
years or older, who entered care between January 2005 and
December 2014 and started ART within 30 days of inclusion into
care. Excluded were pregnant women and persons who were in HIV
care elsewhere before entering care at UHID. We abstracted data
from the electronic database. When ART was prescribed at the
physician-patient visit the exact date of when ART was taken was
recorded on the first follow-up visit. The primary outcome of the
study was time to HIV1 RNA viral load B50 copies/mL, which was
assessed by survival analysis. We also examined factors related to
first visit ART initiation by logistic regression analysis.
Results: We studied 378 patients whomet the eligibility criteria of whom
123 (32.5%) received ART at the first visit at UHID (Table 1).
The median time of initiation of ART in the group of early starters was 5
(Q1Q3, 214) days. By 12 months, the probability of achieving an HIV1
RNA viral load B50 copies/mL was 87.7% (95% CI 81.092.9%) and
89.3% (95%CI, 85.092.8%) in the same-day starters versus early starters,
respectively (Figure 1).
On multivariable analysis, the following factors were related to
starting ART at the first visit: not having clinical AIDS (OR 2.96; 95% CI
1.774.94), a CD4 cell count 5350/mm3 (OR 4.28; 95% CI 1.88
Abstract P124Table 1. Main characteristics of 378 patients who started antiretroviral therapy within one month after inclusion
into care in the period 2005 to 2014
ART initiation at first
physician-patient visit
ART initiation within 30 days
after the first visit Total
Variables N123 N255 N378 p
Age, years 39.2 (31.848.0) 36.4 (30.343.6) 38.2 (31.446.8) 0.043
Male gender 115 (93.5) 225 (88.2) 340 (89.9) 0.111
Residence outside Zagreb 81 (65.9) 156 (61.2) 237 (62.7) 0.378
Mode of transmission
Men who have sex with men (MSM) 98 (79.7) 173 (67.8) 271 (71.7) 0.017*
Male to female or female to male 22 (17.9) 64 (25.1) 86 (22.8)
Persons who inject drugs 1 (0.8) 7 (2.7) 8 (2.1)
Unknown 2 (1.6) 11 (4.3) 13 (3.4)
Integrated into care within 30 days$ 97 (78.9) 233 (91.4) 330 (87.3) B0.001
Period 0.194
20052009 37 (30.1) 94 (36.9) 131 (34.7)
20102014 86 (69.9) 161 (63.1) 247 (65.3)
Had clinical AIDS 34 (27.6) 117 (45.9) 151 (39.9) B0.001
CD4 cell count per mm3 93 (30255) 125 (47260) 102 (33255) 0.193
Categories of CD4 cell count, per mm3 0.006
B100 54 (43.9) 133 (52.2) 187 (49.5)
100350 59 (48.0) 82 (32.2) 141 (37.3)
350 10 (8.1) 40 (15.7) 50 (13.2)
Log HIV1 RNA, copies/mL 5.5 (4.95.9) 5.2 (4.85.8) 5.4 (4.95.9) 0.051
HIV RNA 200,000 copies/mL 54 (43.9) 148 (58.0) 202 (53.4) 0.010
Initial ART type
2NRTNNRT 69 (56.1) 170 (66.7) 239 (63.2) 0.018%
2NRTPI 50 (40.7) 71 (27.8) 121 (32.0)
2NRT II 3 (2.4) 7 (2.7) 10 (2.6)
Other 1 (0.8) 7 (2.7) 8 (2.1)
Had hepatitis C antibody 3 (2.4) 8 (3.1) 11 (2.9) 0.761
Had hepatitis B surface antigen 5 (4.1) 13 (5.1) 18 (4.8) 0.659
Causes of failure 0.966
Virological failure§ 14 (11.4) 25 (9.8) 39 (10.3)
Died 4 (3.3) 8 (3.1) 12 (3.2)
Lost to follow-up 1 (0.8) 2 (0.8) 3 (0.8)
Stopped ART 0 (0.0) 2 (0.8) 2 (0.5)
Values on the table are frequencies or medians with Q1Q3. *MSM versus non-MSM; $time from HIV test to first CD4 count measurement;
%comparison of NNRT versus PI; §at 12 months.
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9.72), being MSM (OR 2.65; 95% CI 1.514.67), receiving 2NRT1PI
(OR 1.92; 95% CI 1.173.14) and being integrated into care after 30
days (OR 2.63; 95% CI 1.375.08).
Conclusions: In this HIV-infected patient population with predomi-
nantly advanced immunosuppression at entry into care, same-day
ART was as successful as therapy given within 1 month after the first
physician-patient visit.
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Introduction: Given recent developments in HIV treatment it is
important that, in addition to health status and symptoms, a more
holistic view of the impact of HIV on quality of life (QoL) is obtained.
The HIV Dependent Quality of Life (HIVDQoL) questionnaire is an
individualized condition-specific QoL questionnaire based on a
template developed by CB for the ADDQoL [1] (Audit of Diabetes-
Dependent QoL) and DQoL measures for other conditions [2].
Qualitative work to design the item content of the HIVDQoL is
reported elsewhere [3]. This abstract reports the psychometric
evaluation of the HIVDQoL.
Methods: The study employed a survey design with participants
(N255) recruited from the UK (N128) and the US (N127), via
the internet, by Opinion Health. Mean age of participants was 49
years (SD 10.64), mean time since diagnosis was 15 years (SD 9.43),
203 participants were male and 49 were female. Participants chose
to complete and return the questionnaire individually (via post) or
with a researcher (via phone). The HIVDQoL included two overview
items which measure generic ‘‘present QoL’’ and ‘‘HIV-specific QoL’’
and 26 items that measure the impact of having HIV on specific aspects
of life (e.g. family, physical appearance) and measures the importance
of these aspects of life for QoL. ‘‘Not applicable’’ options are provided
for items that do not apply to everyone (e.g. work). Exploratory factor
analysis (EFA) was used to examine scale structure and reliability using
Cronbach’s alpha coefficient of internal consistency.
Results: EFA was conducted in two stages. Principal components
analysis, eigenvalues 1, scree plot and parallel analysis guided
the number of factors to extract, and principal axis factoring was
used to determine the underlying structure. The analysis revealed a
one-factor structure which included 24 of the 26 items. Two items
were dropped (religious/spiritual life; having children) due to low
communality and low loadings. The 24 items explained 40% of the
variance. The factor matrix revealed the lowest loading item
loaded at 0.442 and included seven excellent items (loading
0.71), five very good items (0.63), six good items (0.55)
and five fair items (0.45). Reliability was strong: alpha0.939 for
the 24 items.
Conclusions: The HIVDQoL is here shown to have sound psycho-
metric properties including excellent reliability. It is suitable for use
in clinical trials, other research and in routine clinical practice to
evaluate the impact of HIV and its treatment on QoL with a view to
identifying treatments that optimize QoL.
Abstract P124Figure 1. Kaplan-Meier estimates of proportion of patients with HIV RNA B 50 copies/ml according to time of initiation
antiretroviral therapy.
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Individualized NRTI-sparing antiretroviral regimens in a
real-world clinical setting maintain virologic efficacy with
significant cost reduction
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Introduction: NRTI-sparing regimens have been proposed as a
strategy to avoid toxicities associated with these drugs. These
therapies may have an additional financial benefit. Some clinical trials
have explored these NRTI-sparing mono- and dual therapies, and
there is growing evidence from real-world practice in this issue.
Materials and methods: We retrospectively reviewed the medical
records of the HIV patients treated with a mono- or dual therapy
in our hospital. Treatment changes and simplifications were made by
the responsible clinician according to patients’ clinical characteristics,
antiretroviral therapy (ART) history and toxicities. Clinical, virologic
and immunologic data were collected, as well as lipid profile and
renal function. Additionally the cost of each regimen and the saving
associated with the new therapy were calculated.
Results: Twenty-nine patients (51.7% women) were analyzed (14% of
all patients with ART in our hospital). The median age was 48 years
(IQR 2772). The median duration of infection was 17 years (IQR
525.5), with a median duration from the start of their first ART of
9 years (IQR 3.716.6). The median time of undetectability was
8.2 years (IQR 3.416.2). All patients were undetectable at the time
of initial analysis. 27.6% had clinical category C. Initially 19 (65.5%)
patients were receiving as NRTI backbone TDFFTC, 6 (20.7%)
ABC3TC, 1 patient TDF and 4 patients had a previous NRTI-sparing
regimen. The therapy was changed in 25 patients: eight (27.2%)
received ritonavir- or cobicistat-boosted DRV with 3TC, 10 (34.4%)
patients received ATV/r with 3TC and four patients were treated with
a DRV/r monotherapy. Other therapies were DLG3TC (one),
ETRDRV (three), RALDRV (one) and RALETR (two). At 6 months
of follow-up, there were no virologic failures. The reason for the
change was renal toxicity in 12 patients (41.4%), bone disease in
6 (20.7%) and unknown in 5 cases (17.2%). There were no significant
changes in the number of CD4, total cholesterol, HDL, LDL, TG and
renal function. There was a significant improvement in CD4% (2% at
6 months, 95% CI 0.023.83). An average monthly saving of t200
(29%) per patient was achieved.
Conclusions: In a real-world clinical setting, individualized NRTI-
sparing antiretroviral regimens, even in patients with a long
evolution of HIV infection, maintained virologic efficacy. Additionally,
these strategies reduced the cost of treatment.
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in HIV-1 patients enrolled in the Mater Misericordiae
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Introduction: Fixed Dose Combinations (FDCs) are popular HIV treat-
ment options due to simpler dosing regimens and improved patient
adherence leading to better health outcomes. Emerging evidence
suggests integrase inhibitors (INSTI) such as dolutegravir (DTG) and
elvitegravir (EVG) may be able to achieve non-detectable (ND) viral
loads (VL) more rapidly than established treatments, and benefit
certain patient groups such as pregnant women. The study investi-
gated if Triumeq and Stribild, two FDCs containing DTG and EVG
respectively, induce viral suppression more rapidly than other FDCs
not containing integrase inhibitors.
Materials and methods: The MMUH-ID cohort collects retrospective
and prospective follow up information on demographics, diagnostics,
HIV acquisition risks, clinical assessments and medications (history,
regimens, drug class, dose, frequency, start and stop dates). HIV
RNA results are obtained weekly from the National Virus Reference
Laboratory (NVRL) and are manually captured into the cohort database.
Patients commenced on FDC ART of either Atripla (efavirenz/
tenofovir/emtricitabine), Eviplera (emtricitabine/rilpivirine/tenofovir),
Stribild (cobicistat/EVG/emtricitabine/tenofovir) or Triumeq (DTG/
abacavir/lamivudine) from July 2008 to April 2016 were re-
viewed to determine when they reached the primary end-point of
ND VL - two consecutive VL B50 copies/mL. Time to ND VL was
measured from initiation of an FDC. Kaplan-Meier curves and the log-
rank test were used to compare time to ND VL between FDC groups.
Results: A total of 124 patients were included in the analysis (84.7%
male, median age 38 years). Seventy-three patients (58.9%) were
commenced on Atripla, with 56 reaching ND VL with a median time
to ND VL of 5.7 (4.38.0) months after treatment initiation. 33
patients (26.6%) were commenced on Eviplera with 29 reaching ND
VL with a median time of 7.34 (6.016.1) months. Thirteen patients
(10.5%) were commenced on Stribild with eight reaching ND VL with
a median time of 3.41 (1.84.6) months. Five were commenced on
Triumeq (4%) with four reaching ND VL with a median time of 3.67
(2.52-Na) months. Attaining ND VL was significantly different
between the FDC ART groups (log-rank11.2, p0.003), with
lesser time to ND VL attainment in subjects initiated on Stribild and
Triumeq.
Conclusions: FDCs containing INSTIs offer a promising approach to
rapidly reducing VL in HIV-1 infected patients. INSTIs are becoming
the standard of care in many clinical settings and should especially be
prioritized in situations in which there is a clinical need for rapid viral
suppression.
P128
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hepatitis C with direct-acting antivirals in co-infected
patients
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Introduction: Since the advent of new direct-acting antivirals (DAAs)
for the treatment of hepatitis C virus (HCV), this has become a priority
for many of our patients. The disadvantages are the numerous
interactions between DAAs and antiretrovirals used by our co-infected
patients that force clinicians to make changes in the ART.
Material and methods: The Basque Health System (Osakidetza) has
adopted guidelines to treat HCV that prioritize the use of Abbvie
drugs (ombitasvirparitaprevirritonavir with or without dasabuvir).
Since then, we have performed 219 treatments in co-infected patients.
We have analyzed changes in ART in patients during treatment with
DAAs.
Results: Two hundred and nineteen treatments with DAAs have been
started in co-infected patients (123 completed, 96 still ongoing).
Seventy-nine of the 219 patients who started HCV treatment have
not changed their ART, while 140 required changes to avoid
interactions. The most frequent changes according to antiretroviral
family have been efavirenz (EFV) to raltegravir (RAL) (37) and
rilpivirine (RPV) (20) and lopinavir (LPV) to darunavir (DRV) (17)
and RAL (9). Changes between NRTI have been rare (five).
After analyzing the 123 episodes that have completed treatment,
we have observed that 45 (36.5%) have returned to prior ART, 35
(28.4%) have continued with the modified ART (of which 17 were
based on EFV and 15 LPVr), in 10 (8.1%) adjustments have been
made to avoid toxicities (seven) or simplify the ART (three) and in 33
cases (26.8%) there has been no need to make any changes.
Regarding patients in PI-monotherapy (24) during treatment with
DAAs, 17 have been changed (11 to triple therapy and six to other
PI). Nineteen patients in PI-monotherapy (14 LPVr and five DRVr)
have finished HCV treatment and 17 have returned to their previous
regimen.
Conclusions: Treatment of co-infected patients with DAAs involves in
many cases, changes in ART regimen to avoid interactions (in our
case 64%). Most changes occur to new antiretrovirals with better
tolerance profile and less interactions (RAL and RPV). Once treat-
ment with DAAs is completed, most of the patients return to their
initial ART although a significant percentage (near 30% in our series)
prefers the modified ART, and in some patients adjustments in ART
are made to improve the profile toxicity or simplify the regimen
(8%). Virtually, all patients in PI-monotherapy return to it although
many require changes during treatment with DAAs.
P129
The use of protease inhibitors in patients with blips
is associated with virologic failure
Eduardo Sanchez-Brown and Luis Enrique Soto-Ramirez
Infectious Diseases, Instituto Nacional de Ciencias Medicas y
Nutricio´n Salvador Zubiran, Mexico City, Mexico
Introduction: There is conflicting evidence whether blips are as-
sociated with virologic failure or rebound, and it has not been
determined if some demographic, virologic and treatment factors in
patients with blips are associated with these adverse outcomes. The
main objective of this study was to determine which factors are
associated with virologic failure in patients with blips.
Materials and methods: Retrospective, observational cohort study of
patients enrolled in the HIV clinic of a hospital in Mexico City who
presented with at least one blip episode between 2004 and 2012.
Blip was defined as a single detectable viral load above the limit of
quantitation but below 1000 copies/mL. Patients with blips were
classified in two groups: failure group and suppressed group. We
excluded all cases who failed to a treatment regime different from
the one used at the time of the blip in the failure group. Relative
risks for predictors of virologic failure were calculated, survival curves
were generated to compare the rates of virologic failure according to
drug history and differences were tested for statistical significance
using the generalized Wilcoxon test.
Results: Of a total 1876 patients, 414 (22.06%) presented with at
least one blip episode. Three hundred and nineteen were randomly
selected for this study. Sixty-nine (21.6%) of the 319 met the defi-
nition of virologic failure (two consecutive viral loads 50 copies/mL
at least 30 days apart). For statistical analysis, we used 51 cases with
virologic failure and 229 with no failure (21 excluded due to a follow-
up shorter than the mean time to failure in the Failure Group). The
three factors associated with virologic failure were being under 20
years of age at the time of HIV diagnosis (RR 2.31 [1.224.38],
p0.01), overall use of protease inhibitors (RR 5.84 [2.1715.72],
pB0.0001) and use of protease inhibitor, at the moment of blip/
failure (RR 2.95 [1.725.08], pB0.0001). Those who were on PI-
based regimes at the moment of failure were more likely to achieve
virologic failure earlier on than those who were not taking a PI-based
regime (p0.027).
Conclusions: Use of protease inhibitors and being under 20 years of
age at the time of diagnosis were associated with virologic failure in
patients with blips. The presence of blips may be used as a predictor
of virologic rebound in those cases. While adherence can be an
important determinant of failure, the forgiveness of the PI would be
against that.
P130
Baseline characteristics of the TRIUMPH and DOL-ART
cohorts: use of Triumeq† (DTG/ABC/3TC) or other
DTG-based ART in routine clinical care in Germany
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Germany. 6Universita¨tsklinikum, Magdeburg, Germany. 7HIV-Center,
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10Praxis Prenzlauer Berg, Berlin, Germany. 11IFI-Institute, Hamburg,
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Introduction: TRIUMPH and DOL-ART are two consecutive, prospec-
tive and observational German cohort studies in HIV-1 infected
patients initiated on integrase inhibitor-based ART with dolutegravir.
DOL-ART included patients already receiving Tivicay† (DTG) in
combination ART. Recruitment of TRIUMPH started after DOL-ART
recruitment was completed and included patients receiving Triumeq†,
a one-pill regimen consisting of DTG/ABC/3TC.
Methods: In both cohorts, patients are followed in routine clinical
care for 3 years with respect to monitoring measures, efficacy and
safety parameters. Here, we compare the baseline characteristics of
the cohorts in terms of demographics, HIV-related variables,
comorbidities and comedication.
Results: TRIUMPH included 398 patients (32 centres), DOL-ART
included 411 patients (37 centres). Characteristics of the two study
populations are shown in Table 1. Patients of the TRIUMPH cohort
were less frequently and less intensively pre-treated than patients in
DOL-ART. In pre-treated patients, the reasons for switch (multiple
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responses permitted) to DTG-based ART were as follows (TRIUMPH vs
DOL-ART): treatment simplification (57.0% vs. 30.1%), side effects on
previous ART (24.3% vs. 31.7%), patient wish (30.6% vs. 24.7%),
comorbidities or concomitant medication (11.1% vs. 12.2%) or
virologic failure (1.3% vs. 9.6%). In DOL-ART, the majority of patients
(84.9%) received standard triple therapy including either Kivexa† or
Truvada†. The prevalence of comorbidities was lower in TRIUMPH
than in DOL-ART (2 comorbidities 3.5% vs. 10.5%) with differences
seen in both ART-naı¨ve and pre-treated patients. In ART-naı¨ve patients,
most common comorbidity (]10%) was depression (14.7% vs. 16.2%).
In pre-treated patients, most common comorbidities (]10%) were
depression (23.4% vs. 33.3%), hypertension (11.5% vs. 18.6%) and
cardiovascular diseases (6.4% vs. 11.2%). In TRIUMPH (DOL-ART), 18.4%
(24.2%) of ART-naı¨ve patients and 34.5% (36.2%) of pre-treated patients
received concomitant medication other than ART. In ART-naı¨ve
patients, most common concomitant medication (]10%) included
prophylaxis/treatment of opportunistic infections 3.7% (10.1%).
In pre-treated patients, most common concomitant medication
included antihypertensives 14.9% (19.2%) and antidepressants
11.1% (11.9%).
Conclusion: The TRIUMPH and DOL-ARTcohorts showed that standard
triple therapy consisting of DTG plus two NRTI as single- or as multi-
tablet regimen are used for both ART-naı¨ve and pre-treated patients.
‘‘Simplification of ART’’ and ‘‘side effects on previous ART’’ were the
main reasons for switch to Triumeq† or DTGX, respectively. Based
on CDC classification and comorbidities, the burden of disease was
somewhat lower in TRIUMPH than in DOL-ART.Themajority of patients
were switched from suppressive ART demonstrating an obvious need
for treatment optimization in clinical practice.
P131
Long-term use of darunavir/r QD containing regimens
in daily practice in Belgium: retrospective observational
cohort data of 1701 HIV patients
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Bernard Vandercam4; Jean-Christophe Goffard5; Eric Van
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Objectives: To describe the use of darunavir/ritonavir (DRV/r) QD in
daily practice in Belgium.
Abstract P130Table 1. Patient characteristics before introduction of DTG-containing ART
TRIUMPH (N398) DOL-ART (N411)
ART naı¨ve
(N163)
Pre-treated
(N235)
ART-naı¨ve
(N99)
Pre-treated
(N312)
Sex, male, N (%) 155 (95.1) 203 (86.4) 89 (89.9) 268 (85.9)
Age, years, median (range) 39 (2948) 45 (3552) 39 (3248) 46 (3853)
CDC stage C, N (%) 9 (5.5) 54 (23.0) 10 (10.1) 86 (27.6)
BL HIV RNA, log copies/mL, median (IQR) 4.4 (3.94.9) 1.7 (1.71.7) 4.7 (4.15.1) 1.7 (1.71.8)
BL HIV-1 RNA ]100,000 copies/mL, N (%) 30 (18.4)  29 (29.3) 
BL HIV-1 RNA ]500,000 copies/mL, N (%) 6 (3.7) 8 (8.1)
BL HIV-1 RNA 50 copies/mL, N (%)  198 (84.3)  224 (71.8)
BL CD4 cell count, cells/mL, median (IQR) 450 (282597) 602 (434834) 377 (245549) 584 (422800)
BL CD4 cell count, 200/mL, N (%) 22 (13.5) 8 (3.4) 18 (18.2) 23 (7.4)
2 previous regimens, N (%)  48 (20.4)  135 (43.3)
Comorbidities, N (%) 49 (30.1) 123 (52.3) 35 (35.4) 193 (61.9)
Depression, N (%) 24 (14.7) 55 (23.4) 16 (16.2) 104 (33.3)
Hypertension, N (%) 12 (7.4) 27 (11.5) 6 (6.1) 58 (18.6)
Cardiovascular diseases, N (%) 2 (1.2) 15 (6.4) 3 (3.0) 35 (11.2)
Chronic HCV infection, N (%) 6 (3.7) 20 (8.5) 5 (5.1) 20 (6.4)
Pulmonary disease, N (%) 4 (2.5) 17 (7.2) 6 (6.1) 22 (7.1)
Dyslipidaemia (requiring treatment), N (%) 0 (0.0) 10 (4.3) 0 (0.0) 30 (9.6)
Diabetes mellitus, N (%) 4 (2.5) 13 (5.5) 4 (4.0) 13 (4.2)
Concomitant medication, N (%) 30 (18.4) 81 (34.5) 24 (24.2) 113 (36.2)
Antihypertensives, N (%) 13 (8.0) 35 (14.9) 6 (6.1) 60 (19.2)
Antidepressants, N (%) 6 (3.7) 26 (11.1) 5 (5.1) 37 (11.9)
Ca2 /Fe2 -containing supplements/multivitamin, N (%) 2 (1.2) 12 (5.1) 3 (3.0) 10 (3.2)
Prophylaxis/treatment of opportunistic infection, N (%) 6 (3.7) 7 (3.0) 10 (10.1) 13 (4.2)
Metformin, N (%) 0 (0.0) 4 (1.7) 1 (1.0) 5 (1.6)
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Methods: Design: Observational, non-interventional, non-comparative,
retrospective, multicentre cohort study. Data were collected from
existing databases from eight AIDS reference centres in Belgium.
Inclusion: HIV-1 infected adults (treatment-naı¨ve or experienced
patients), who received at least one dose of DRV/r 800 mg/100 mg
QD in various combinations from 1 January 2010 on, with a minimum
follow-up of 6 months. Primary endpoints: time to treatment dis-
continuation (using Kaplan-Meier estimates), rate and reasons for
discontinuation of DRV/r QD containing regimen. Secondary end-
points: virologic suppression, change from baseline in CD4 count,
effect of DRV/r on kidney function.
Results: Data from 1701 HIV-infected patients were collected and
analyzed. Baseline characteristics: overall, 66.5%weremale, mean age
of 42.9 years (911.1), mean CD4 count 441.8 cells/mm3 (9287.1) and
mean CD4 nadir 248.9 cells/mm3 (9177.3); 33.1% of patients were
treatment naı¨ve (44.2% with baseline viral load (BL VL) ]100,000
copies/mL) and 66.9% were ART-experienced patients (48.5% with BL
VL B50 copies/mL). Tenofovir-emtricitabine was used as backbone in
72.6% of naı¨ve patients and 52.2% of experienced patients. Overall,
median follow-up period (Q1Q3) on DRV/r QD was 2.45 (1.503.34)
years. The probability to remain on treatment (95% CI) was 87.0%
(85.288.5%) for the first year and 78.9% (76.780.9%) for the second
year and 69.1% (66.371.7%) for the third year (Figure 1).
Four hundred and fifty-nine patients (27.0%) discontinued treatment
with DRV/r QD. The main reasons were simplification (6.7%), adverse
events (6.9%, of which 4.0% for GI problems), patient’s or physician’s
decision, drug-drug interactions or inclusion in a clinical trial. Reason
for discontinuation was missing in 3.1%. Discontinuation for lack of
efficacy was noted in only 0.8%. CD4 count increased by 164.4
cells/mm3 from baseline to end of follow-up. Lipids (TG, TChol,
LDL-C, HDL-C) and renal (eGFR) parameters remained stable
throughout the period. At the end of the follow-up period 81% of
patients had HIV RNA B50 copies/mL.
Conclusion: This retrospective cohort analysis of patients on
darunavir/r QD in Belgium confirms the long-term efficacy and good
tolerability of DRV/r QD in real-life setting. The rate of discontinuation
of DRV/r QD in daily practice is low and rarely due to lack of efficacy.
No unexpected adverse events were reported.
P132
Assessment of the results at 96 weeks of a multicentric
Portuguese cohort of patients treated with emtricitabine/
tenofovir/rilpivirine
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Margarida Mota4; Rosa´rio Serra˜o1; Mari Mesquita2; Ana Teresa
Goes5; Tiago Teixeira4 and Carmela Pin˜eiro1
1Infectious Diseases, Centro Hospitalar Sa˜o Joa˜o, Porto, Portugal.
2Internal Medicine, Centro Hospitalar Taˆmega e Sousa, Penafiel,
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Portugal. 4Internal Medicine, Centro Hospitalar Vila Nova de Gaia/
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Introduction: Rilpivirine is a second-generation non-nucleoside re-
verse transcriptase inhibitor (NNRTI), included in Eviplera†. Clinical
trials have demonstrated its effectiveness and relatively favourable
profile of adverse effects compared to first-generation NNRTIs.
Objective: To assess the evolution of different indicators in naı¨ve and
experienced patients on ART who were started on FTC/TDF/RPV.
Methods: Retrospective cohort study of patients treated with FTC/
TDF/RPV for more than 2 years in four Portuguese hospitals. We
evaluated demographic characteristics, reasons for FTC/TDF/RPV use,
adverse events and analytical parameters. In patients who switched to
this regimen due to adverse effects, resolution of symptoms was
evaluated.
Results: Two hundred and ninety-eight patients were included. Two
hundred and twenty-six (76%) were male with a mean age of 46.6
years. Forty-five patients (15%) were previously ART naı¨ve, 69
patients were under PI-containing regimens (27.2%), 183 patients
under NNRTI-containing regimens (72.3%) and one under an INSTI-
Abstract P131Figure 1. Time to treatment discontinuation (Kaplan-Meier) for all patients initiated on DRV/r QD.
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containing regimen (0.3%). Reasons for switching to FTC/TDF/RPV
were dyslipidaemia in 66 patients (26.1%), central nervous system
toxicity in 71 (28.1%), other toxicities in 12 (4.7%), therapeutic
simplification in 62 (24.5%) and other reasons in 42 (16.6%). At 96
weeks, median CD4 lymphocyte count increased (525 vs. 633 cells/
mm3, pB0.001). Viral load was detectable in 43 patients (17%) at
baseline and in seven patients (2.7%) after 96 weeks (pB0.001), of
which only one had confirmed virological failure. Liver profile was
unchanged during follow-up in the global sample, but the 67 patients
(22.5%) who had chronic hepatitis B or C had a statistically significant
improvement of both median alanine aminotransferase (ALT) (38 vs.
25.5 UI/L, p0.001) and aspartate aminotransferase (AST) (33 vs.
28 UI/L, p0.009). In the global sample, there was a statistically
significant (pB0.001) decrease of median total cholesterol (185 vs.
175 mg/dL), LDL (111 vs. 107 mg/dL) and tryglicerides (115 vs.
98 mg/dL). This effect was mostly evident in patients who switched to
FTC/TDF/RPV due to dyslipidaemia. There was a slight but statistically
significant increase in creatinine values during the follow-up
(pB0.0001), without clinical relevance. All patients who switched
due to neuropsychiatric toxicity reported improvement of symptoms.
During this time, nine patients (3%) stopped FTC/TDF/RPV due to
virological failure (nine), NNRTI-related toxicity (one), other toxicity
(four) or undisclosed reasons (one).
Conclusions: In this cohort, FTC/TDF/RPV showed good tolerability, a
low rate of adverse effects and favourable lipid and hepatic profiles,
mostly in patients with chronic hepatitis or previous dyslipidaemia.
Immunological and virological efficacy was maintained during 96
weeks follow-up.
P133
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care in Germany
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Introduction: DOL-ART is a prospective, 3-year, German non-
interventional study (NIS) initiated 2 months after EMA approval of
dolutegravir (DTG, Tivicay†), to understand how the real-world
experience with the drug compares with that from clinical trials.
Methods: HIV-infected patients enrolled into the study had to be on
a DTG-based ART for ]4 weeks. Primary and secondary objectives of
DOL-ART comprise the evaluation of monitoring measures in routine
clinical care of these patients, effectiveness and safety of DTG-based
ART: frequency and type of monitoring measures (including labora-
tory tests and referrals to specialists), virologic effectiveness and the
incidence of adverse drug reactions (ADRs).
Results: N411 patients were included in DOL-ART between March
andMay 2014: 87%males, median age 45 years (IQR 3652), 23%with
history of AIDS; 76% pre-treated. Of ART-naı¨ve patients, 18% had
B200 CD4/mL, 29% 100,000 HIV RNA copies/mL; of pre-treated
patients, 72% had B50 HIV RNA copies/mL; 85% of the study
population received triple therapy consisting of DTG plus either TDF/
FTC (45%) or ABC/3TC (40%); relevant comorbidities and concomitant
medication were documented in 55% and 33% of patients, respec-
tively. Median observation time until data cut was 15.8 months (IQR
15.216.8), with 86.4% of patients remaining under follow-up. Serum
chemistry, blood count and HIV RNA/CD4 cell controls represented the
overall majority of the measures (75.9%). Median number of
monitoring measures per patient-year was 13.7 (IQR 10.517.4), in
particular 14.9 (10.618.5) in ART-naı¨ves and 13.6 (10.317.2) in pre-
treated, 13.6 (10.717.4) in patients aged 550 years and 13.8 (10.2
17.2) in patients 50 years of age. Urine and microbiology tests
accounted for 10.2% and 6.9% of the other measures, respectively;
referrals to specialists (7.0%) were documented in 57.2% of patients
(53.5% of ART-naı¨ves, 58.3% of pre-treated). Reasons for study
discontinuation (multiple responses permitted) were stopping of
DTG (7.8%, incl. one virologic failure), patient wish (3.2%), loss to
follow-up (2.2%), death (0.2%) and other (2.4%). During the first
year, 10.7% of patients experienced ADRs; 4.4% discontinued DTG for
this, including 1.2% for depression and 1% for gastrointestinal
symptoms.
Conclusion: During a median observation time of 15.8 months,
monitoring measures were mainly related to routine quarterly con-
trols of HIV disease, consistent with recommendations of national
guidelines. Discontinuation rates due to ADRs and virologic failure
were 4.4% and 0.2%, respectively. These preliminary NIS data in a real-
world cohort replicate the good effectiveness and tolerability of DTG
shown in registration studies.
P134
First Canadian HIV/HIV kidney transplantation and
first results of the prospective cohort of solid organ
transplantation for HIV individuals of Centre Hospitalier
de l’Universite´ de Montre´al
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Claude Fortin1; Marie-Chantal Fortin2; Jacques Malaise4;
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Introduction: Due to careful selection of potential candidates, patients
and grafts survival among HIV-infected patients is similar to non-
infected patients with solid organ transplantation (SOT). Management
of drug interactions is a challenge in HIV-infected patients. Protease
inhibitors (PI) interact with tacrolimus, making dosage adjustments
more difficult to handle, thus increasing the risk of rejection.
Prospective cohorts of HIV-infected kidney and liver recipients are
mostly from Europe and the USA. The aim of this study is to describe a
Canadian single-centre experience with SOT of HIV-infected patients,
including the first Canadian HIV/HIV kidney transplantation.
Materials and methods: This is a prospective cohort study con-
ducted at the Centre Hospitalier de l’Universite´ de Montre´al (CHUM).
The study consists of a chart review of HIV-infected patients
evaluated, listed or who received a SOT. Eligibility criteria include
CD4 T-cell count above 200 cells/mL, undetectable HIV viral load,
stable ART for at least 3 months and no untreatable opportunistic
infections (OIs). Data were collected from clinical charts and include
demographic characteristics, medical history including detailed HIV,
hepatic and renal disease status and both pre- and post-transplant
assessment laboratory. Study endpoints are HIV virologic escape post-
transplantation, OIs, rejection and mortality during the solid organ
transplant process.
Results: A total of 11 HIV-infected patients were recruited and five
among them received a kidney transplantation and one a liver
transplantation (Table 1). Medial follow-up is 6 months (range 249).
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All patients received basiliximab induction, and immunosuppressive
agents consisted of tacrolimus (n6), prednisone (n6), mycophe-
nolate mofetil (n2), azathioprine (n1) and leflunomide (n1).
Most patients were on an integrase inhibitor (II)-based regimen
(n4) while some were on a PI-based regimen (n2). HIV viral load
remained steadily undetectable post-transplantation in all patients
and no HIV-associated OI was reported. One kidney recipient on
darunavir/ritonavir/etravirine/raltegravir developed post-transplan-
tation chronic rejection. All kidney recipients remain dialysis-free at
this time with a post-transplant mean eGFR of 55.5 mL/min/1.73 m2.
One patient received a kidney graft from an HIV-infected donor. Both
the donor and the recipient were on a similar II-based regimen
before, during and after the transplantation.
Conclusions: Our preliminary results demonstrate that SOT is a viable
option for HIV-infected patients with terminal organ failure. ART free
of drug interaction should be promoted when possible to prevent
rejection. With careful selection, HIV/HIV kidney transplantation
can be performed without loss of virologic control.
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Why do HIV/AIDS patients fail? Incidence, causes,
demographic, immunologic and clinical characteristics of HIV
patients who fail to achieve complete virologic suppression
Daniel Elbirt; Yanina Inberg; Keren Mahlab-Guri; Ilan Asher;
Shira Bezalel-Rosenberg; Michael Burke and Zev Sthoeger
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Introduction: Patients treated with HAART are expected to reach
complete viral suppression. Still, in ‘‘real life’’ about 20% of patients do
not achieve this goal. The ‘‘failing’’ patients demand a significant part
of the HIV clinic efforts and resources. We believe that characteriza-
tion of these failing patients could help targeting them in a more
effective way.
Methods: We conducted a retrospective ‘‘snap shot’’ analysis,
seeking for failing patients. Data were obtained from charts of HIV
patients in a major Israeli HIV/AIDS centre during 2015. We included
adults on HIV treatment for at least 1 year. All patients had at least
two viral load tests during the year prior to enrolment. Virologically
suppressed patients were defined as having two consecutive
undetectable viral loads (B20 copies/mL).
Results: Seven hundred and sixty-six patients were included. Fifty-
four percent were men, mean age 47.06911.48 years (37%, 50
years old), the mean follow-up was 11.896.4 years. Risk groups: 65%
of patients were from endemic area (Ethiopia), 13% were men who
have sex with men (MSM) and 7% intravenous drug users (IVDU). In
our analysis, 85 (11%) of the patients did not achieve complete viral
suppression. African patients were more prone to fail compared to
other risk groups (77% of the failing patients vs. 6% [MSM] and 12%
[IVDU]; pB0.05). Age, sex, follow-up, matrimonial status, working
status and AIDS at diagnosis were not associated with failing, while a
serodiscordant spouse was associated with a lower rate of virologic
failure (7% vs. 14%; p0.03). The failing patients had more com-
plications (48% vs 32%; p0.005). Patients treated with protease
inhibitor (PI)-based regimen did not have higher failing rates, NNRTI-
based regimen predicted a lower chance of virologic failure (31% vs.
7%; pB0.05), and an integrase-based regimen predicted higher rates
of failing (46% vs 33%; pB0.05).
Conclusions: We found that a target of 90% (89% in our cohort) viral
suppression is achieved in ‘‘real life.’’ HIV patients originating from
Africa were more prone to fail treatment. We found no correlation
between other demographic and socioeconomic factors and the
chances to fail therapy. Interestingly, living with a serodiscordant
couple was associated with lower rates of virologic failure. We also
found a correlation between HAART regimens and virologic failure
rates. While PI-based regimen had no influence, NNRTI-based
treatment was associated with lower chance to fail and integrase-
based treatment was associated with higher rate of failing.
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Abstract P134Table 1. Clinical characteristics of solid organ recipient and post-transplant follow-up
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Pre-transplant assessment
Age 57 52 40 50 56 45
Gender M M M F F M
Organ Kidney Kidney Kidney Liver Kidney Kidney
Time on dialysis (months) 40 132 83 N/A 70 54
CD4 T-cell count (cells/ml) 500 390 620 300 200 410
Post-transplant follow-up
ART ABC, 3TC, DTG ABC, 3TC, RAL DRV/r, ETR, RAL FTC, 3TC, RAL ABC, 3TC, RPV, DTG DRV/r, EFV, RAL
Immunosuppressive regimen TAC, MMF,
prednisone
TAC,
prednisone
TAC, LEF,
prednisone
TAC, AZA,
prednisone
TAC, MMF,
prednisone
TAC, MMF,
prednisone
CD4 T-cell count (cells/ml) 330 410 510 350 270 540
HIV viral load (copies/ml) B40 B40 B40 B40 B40 B40
eGFR (ml/min/1,73m2) 53 28 39 54 98 61
Rejection (n) 0 0 1 0 0 0
Follow-up (months) 6 49 19 5 2 6
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Introduction: TMC114-HIV4042 is a non-interventional study evalu-
ating virologic response and safety of darunavir/ritonavir (DRV/r)
administered with other ARV agents in clinical practice. Here, we
show the effects on liver function and safety in all HIV1-infected
DRV-naı¨ve patients.
Methods: Two hundred and thirty-three DRV-naı¨ve patients, 117 ARV
naı¨ve and 116 ARV experienced, received a DRV/r-based regimen in
routine practice, together with other active ARVs, and were observed
for 1240 months up to end 2012 or earlier discontinuation. Serum
biochemistry including aspartate aminotransferase (AST), alanine
aminotransferase (ALT), gamma-glutamyl-transferase (GGT) and
bilirubin was obtained before entry and at about 3-month intervals.
Reported hepato-biliary adverse events (AEs) were examined. Time
trends were analyzed using repeated-measures mixed models, with
values imputed after study end for hepatic AEs.
Results: Fifty-two patients (22.3%) had viral hepatitis (26 HCV, 16
HBV, nine both, one unspecified) active at entry (Table 1).
Background ARV therapy at entry included a fixed tenofovir-
emtricitabine combination in 107 (91.5%) ARV-naı¨ve patients and
66 (56.9%) ARV-experienced patients. Hepatic AEs (non-serious
except one fatal) were reported in seven patients (3.0%), four ARV
naı¨ve and three ARV experienced: 5/52 (9.6%) in patients co-infected
(three HCV, two HBV), 1/23 (4.3%) with past HBV/HCV infection
not active, 1/158 (0.6%) not co-infected with HBV/HCV. An HCV
co-infected ARV-experienced patient died of liver failure assessed as
unrelated with ARVs, one HCV co-infected ARV-naı¨ve withdrew
for hypertransaminasemia probably DRV-related, and one HBV co-
infected ARV-naı¨ve withdrew for increased GGT possibly DRV-related.
In four patients, hepatic AEs unrelated with DRV (raised ASTand ALT in
two patients; raised AST, ALT and GGT in one patient; cholestasis with
raised GGT in one patient) withdrew without changing the DRV-based
Table 1. Demographic characteristics, CDC clinical stage and
concomitant liver diseases at entry
ARV-naı¨ve
(N117)
ARV-
experienced
(N116)
Age, years
mean9SD 42.0911.0 44.399.5
Gender at birth, N (%)
Male 99 (84.6) 91 (78.4)
Race, N (%)
Black 5 (4.3) 3 (2.6)
Caucasian/other 112 (95.7) 113 (97.4)
CDC clinical stage C, N (%) 38 (32.5) 41 (35.3)
History of HBV-HCV hepatitis, N (%)
No 88 (75.2) 70 (60.3)
Not active (b) 9 (7.7) 14 (12.1)
HBV 6 5
HCV 2 5
HBV/HCV 1 3
Unspecified 0 1
Active (a) 20 (17.1) 32 (27.6)
HBV 12 4
HCV 6 20
HBV/HCV 2 7
Unspecified 0 1
aHCV RNA quantitation within 6 months before entry, or positive
HBV and HCV serology within 6 months before entry, or reported as
an active concomitant disease at entry.
bHCV RNA quantitation more than 6 months before entry, or positive
HBV and HCV serology more than 6 months before entry, or reported
as a previous (not active) disease at entry.
CDC, Center for Disease Control and Prevention; HBV, hepatitis B
virus; HCV, hepatitis C virus; SD: standard deviation.
Abstract P136Figure 1. Time trend of serum ALT levels (geometric mean) during the study.
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ARV therapy. Mean ASTand ALT levels decreased by about 10 U/L until
68 months remaining constant thereafter in ARV-naı¨ve patients and
were stable throughout in ARV-experienced patients (Figure 1). Mean
GGT levels in both groups decreased until 610 months and changed
slightly thereafter. Total bilirubin levels quickly reverted to normal in
14 patients with baseline hyperbilirubinemia who switched from
atazanavir at entry; mean values in the other patients, although
slightly increasing, were always B0.6 mg/dL (Figure 2).
Conclusions: In HIV-infected patients given a DRV/r-based regimen
for a mean duration 20 months, liver AEs were few and mostly
related to the underlying viral hepatitis, and mean serum liver
enzymes and total bilirubin levels did not worsen.
P137
Long-term use of darunavir/r QD monotherapy in daily
practice: retrospective observational cohort data of
111 HIV patients in Belgium
Ste´phane De Wit1; Eric Florence2; Linos Vandekerckhove3;
Bernard Vandercam4; Jean-Christophe Goffard5; Eric Van
Wijngaerden6; Michel Moutschen7; Remy Demeester8;
Hilde Piryns9 and Pushpike Thilakarathne10
1Infectious Diseases, Saint-Pierre University Hospital, Brussels,
Belgium. 2Infectious Diseases, Institute of Tropical Medicine,
Antwerp, Belgium. 3Infectious Diseases, Ghent University Hospital,
Abstract P137Figure 1. Time to treatment discontinuation (Kaplan-Meier) for patients on DRV/r QD monotherapy.
Abstract P136Figure 2. Time trend of total bilirubinemia (geometric mean) during the study.
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Brussels, Belgium. 6Infectious Diseases, University Hospital Leuven,
Leuven, Belgium. 7Infectious Diseases, Lie`ge University Hospital,
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Objectives: To describe the use of darunavir/ritonavir monotherapy
(DRV/r) in daily practice in Belgium.
Methods: Design: Observational, non-interventional, non-compara-
tive, retrospective, multicentre cohort study. Datawere collected from
existing databases from eight AIDS reference centres in Belgium.
A subgroup on darunavir/r QD monotherapy was analyzed. Inclusion:
HIV-1 infected adults, on DRV/r 800 mg/100 mg QD monotherapy
(received at least one dose of DRV/r from January 1, 2010 on, with
a minimum follow-up of 6 months). Primary endpoints: Time to
treatment discontinuation (using Kaplan-Meier estimates), rate and
reason for discontinuation of DRV/r QD monotherapy.
Results: Hundred and eleven patients (9.8%), all treatment experi-
enced, received DRV/r QD monotherapy, out of a group of 1701
patients exposed to DRV/r. Baseline characteristics of the mono-
therapy subgroup: 65.8% were male, mean age of 49.4 years (911.0),
65.8% Caucasian, mean CD4 count 648.1 cells/ mm3 (9347.3) and
18% had CD4 counts B350 cells/mm3. Mean CD4 nadir was 223.0
cells/mm3 (9157.5); 21.6% had a CD4 nadir B100 cells/mm3, and in
51.4% of patients the CD4 nadir was ]200 cells/mm
3. 84.7% of
patients had HIV RNA B50 copies/mL at baseline. Median follow-up
period (Q1Q3) was 2.55 (1.273.34) years. The probability to remain
on treatment (95% CI) was 81.3% (72.587.5%) for the first year, also
81.3% (72.587.5%) for the second year and 74.2% (63.182.4%) for
the third year (Figure 1).
The probability to remain on monotherapy did not differ significantly
from the overall cohort on DRV/r QD containing combination
regimen (log rank test p-values: 0.4496). Twenty-eight of 111
patients (25.2%) discontinued treatment with DRV/r QD monother-
apy. Main reasons were adverse events such as GI toxicity (4.5%),
liver toxicity (0.9%), other toxicities (1.8%), hypersensitivity reaction
(1.8%), patient’s decision (5.4%) or death (5.4%). Non-compliance
was mentioned in 1.8% and lack of efficacy in 1.8%. At the end of
follow-up period, 77% of patients had HIV RNA B50 copies/mL.
Conclusions: In this real-life, long-term, retrospective Belgian cohort,
around 9.8% of treatment-experienced patients on DRV/r QD were
on monotherapy. The results confirm the efficacy and good tolerability
of DRV/r QD monotherapy. The rates of discontinuation in the DRV/r
QD monotherapy group are not very different from those in the
overall cohort containing DRV/r QD in combination regimen. DRV/r
monotherapy is not registered and is only recommended to a selected
group of patients according to the European guidelines.
P138
Development of a contemporary symptom diary
for patients with HIV
Jessica Markowitz1; Naomi Knoble1; Benoit Arnould2 and Albert Wu3
1Patient-Centered Outcomes, Mapi, Boston, MA, USA. 2Patient-
Centered Outcomes, Mapi, Lyon, France. 3Health Policy and
Management, Johns Hopkins School of Public Health, Baltimore,
MD, USA
Introduction: The widespread adoption of modern ART has changed
the landscape of HIV treatment. The most widely used patient
reported outcomes (PRO) questionnaires were developed over a
decade ago and may not adequately capture the experience of HIV
patients today. In addition, best practices in patient symptom
measurement have changed substantially, and there is growing
interest in using daily symptom diaries, which may capture the
patient experience more accurately. The goal of this project was to
identify the HIV symptoms experienced by patients as a result of
both their disease and treatment and, using that information,
develop a web-based symptom diary for patients with HIV to
capture the presence and impact of symptoms on a daily basis.
Materials and methods: A narrative review of the literature was
conducted to identify PRO symptom measures in HIV and evaluate
their validity in the current environment of HIV treatment. A web-
based survey regarding important HIV symptoms was completed by
20 US clinicians specializing in HIV/infectious disease. Results from
the literature review and clinician survey were used as the basis for
diary development. Patients were recruited from four geographically
diverse treatment centres in the US (CA, NM, DC, MA). Concept
elicitation interviews and cognitive debriefing on the initial diary
were completed with 26 patients who guided diary refinement.
Next, 48 patients (inclusive of the 26) used the web-based diary daily
for 1 week and completed a cognitive debriefing interview to finalize
the content/format of the diary. The diary asks patients to report on
symptoms (using checklists/pictures) and symptom impact.
Results: Participants (77% male) were White (62%) or Black/African
American (34%) and Hispanic (15%). Mean participant age was 52
(range 2769). Educational level of at least some college was 69%;
63% were employed. HIV transmission mode was primarily MSM
(70%); patients reported a variety of HIV treatment regimens. The
diary took 510 minutes to complete each day, and the majority of
the feedback on the diary was positive. Patients accessed the diary
by computer (42%), smartphone (33%), tablet (10%) and combina-
tion (14%). The diary enabled comprehensive and organized capture
of symptoms that patients viewed as relevant, with impact measured
at the individual symptom level.
Conclusions: This daily HIV symptom diary is brief, easy to com-
plete and well received by patients. It provides patients of diverse
background, education and treatments, and the opportunity to voice
their symptom experience. Validity studies are ongoing.
P139
A moderated mediation model of HIV-related stigma,
depression and social support on health-related quality
of life among incarcerated Malaysian men with HIV and
opioid dependence
Roman Shrestha1; Michael Copenhaver2 and Frederick Altice3
1Community Medicine and Health Care, University of Connecticut
Health Center, Farmington, CT, USA. 2Allied Health Sciences,
University of Connecticut, Storrs, CT, USA. 3Internal Medicine, Yale
University, New Haven, CT, USA
Introduction: Although it is well established that HIV-related stigma,
depression and lack of social support are negatively associated
with health-related quality of life (HRQoL) among people living with
HIV (PLHIV) [13], no studies to date have examined how these
psychosocial factors interact with each other and affect HRQoL
among incarcerated PLHIV. This paper incorporated a moderated
mediationmodel to explorewhether depressionmediates the effect of
HIV-related stigma on HRQoL as a function of the underlying level of
social support.
Methods: Incarcerated HIV-infected men with opioid dependence
(N301) were recruited from Malaysia’s largest prison, located in
Greater Kuala Lumpur. Participants were assessed using the Berger
HIV Stigma Scale (40160), the Center for Epidemiological Studies
Depression (CES-D) Scale (060), the Medical Outcomes Study Social
Support Survey (0100) and the RAND 36-ItemHealth Survey (0100).
An ordinary least squares regression-based path analytic framework
was used to test the moderated mediation model.
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Results: Results showed that the effect of HIV-related stigma on
HRQoL was mediated via depression (a1: b0.1463, pB0.001;
b: b0.8392, pB0.001), as demonstrated by the two-tailed
significance test (Sobel z3.8762, pB0.001). Furthermore,
the association between social support and HRQoL was positive
(b0.4352, p0.0433), whereas the interaction between HIV-
related stigma and depression was negatively associated with HRQoL
(b0.0317, p0.0133).This indicated that the predicted influence
of HIV-related stigma on HRQoL via depression had negative effect on
HRQoL for individuals with low social support.
Conclusions: Findings provide evidence of the moderated effect of
social support on the translation of HIV-related stigma into HRQoL
via depression. The results suggest that social support can buffer the
negative impact of depression on HRQoL and highlights the need for
future interventions to target these psychosocial factors in order to
improve HRQoL among incarcerated PLHIV.
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The DRIVER study: asymptomatic STI systematic screening
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in a cohort of outpatients HIV-infected MSM seen in
France  phase 1 results
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Introduction: HIV-infected men who have sex with men (MSM) are
frequently affected by symptomatic sexually transmitted infections
(STI). Most of those who are stabilized on treatment benefit from
semestrial follow-up visits which may provide an opportunity to
screen them for asymptomatic STI (ASTI). The DRIVER study seeks to
determine whether this should be done on a systematic basis or
oriented by risk factors (RF). Phase 1 explored the ASTI prevalence
and evaluated the relevance of a series of RF for STI which could be
used eventually to build a decisional score.
Material and methods: Patients were prospectively included at 13
hospital-based HIV clinics of the Paris (France) region. During any one
of their semestrial follow-up visits, clinical data were recorded, a self-
administered sociodemographic and behavioural questionnaire was
filled in and patients were screened for syphilis antibodies and PCR
for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
(pharynx, anus and first-void urine). Statistical correlation between
recorded items and the presence of STI was measured by the chi-
square law.
Results: Four hundred and eighty-fiveasymptomaticMSMHIV-positive
patients (median age 47 years, average time living with HIV 13 years,
undetectable viral load in 94%, average CD4 679/mm3) were
included. More than 80% had at least graduated from high school,
and 72% had a stable professional situation. Nearly 63% had a history
of STI (genital warts in 39%, syphilis in 45%), within the previous 12
months in 18%. An ongoing ASTI was found in 13.6% (syphilis 5.6%, CT
or NG infection 8%). RF significantly associated with recent syphilis
were not being engaged in a stable relationship (p0.013), to have
receptive anal sex (p0.03) and to have a history of previous syphilis
(p0.005). Those associated with CT or NG infection were having
a stable professional occupation (pB0.001) and to use illicit drugs
during sex (p0.05).
Discussion and conclusion: The DRIVER study shown the high
frequency of past and recent STI history and confirm the relevance
of our study. Out of a long and thorough list of possible RF, only a few
were found to be positively correlated with ASTI, some of them
counter intuitive, i.e. stable occupation and CT/NG infection. These
results were comparable from the scientific literature, and they
confirm the frequency of ASTI in the HIV-positive MSM population.
The predictive value of an STI-screening RF-based decisional score
will be tested during phase 2 of the DRIVER study.
P141
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Introduction: TMC114-HIV4042 is a non-interventional study evalu-
ating the virologic response and safety of darunavir/ritonavir (DRV/r)
administered with other ARV agents in clinical practice. Here, we
show the effects on lipid and glucose metabolism in all HIV1-infected
DRV-naı¨ve patients.
Methods: Two hundred and thirty-three DRV-naı¨ve patients, 117 ARV
naı¨ve and 116 ARV experienced, received a DRV/r-based regimen in
routine practice, together with other active ARVs, and were observed
for 1240 months up to end 2012 or earlier discontinuation. Serum
biochemistry including lipids and glucose was obtained before entry
and at about 3-month intervals, or longer when allowed by stable
patient conditions. Reported adverse events (AEs) related to lipid
and glucose metabolism were examined.
Results: Patients were mostly men (99 ARV naı¨ve and 91 ARV
experienced); 38 and 41, respectively, were in Centers for Disease
Control and Prevention clinical stage C at entry; mean age was 42
and 44 years, respectively. At baseline, eight patients (seven ARV
experienced) were reportedly hyperlipidaemic and five (four ARV
experienced) diabetic. Background ARV therapy at entry included a
fixed tenofovir-emtricitabine combination in 107 (91.5%) ARV-naı¨ve
patients and 66 (56.9%) ARV-experienced patients. During the study,
hyperlipidaemia was reported as AE in 14 patients (6.0%), eight ARV
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naı¨ve and six ARV experienced, none serious; nine (3.9%) were
assessed by the clinician as at least possibly related to DRV; one
caused study discontinuation. Two patients had diabetes reactivation
(one with weight increase and hyperlipaemia), one lipodystrophy
causing withdrawal and one weight decrease requiring hospitalization
(Table 1). Over the first 4 months, levels of triglycerides, total, low-
density lipoprotein and high-density lipoprotein cholesterol increased
in ARV-naı¨ve patients then they were approximately constant; median
baseline and final values were 117147, 147183, 91118 and 3540
mg/dL, respectively. In ARV-experienced patients lipid parameters
remained stable; median baseline and final values were 137134,
176193, 114121 and 4242 mg/dL, respectively. Median serum-
glucose levels remained stable in both groups.
Conclusions: In HIV-infected patients given a DRV/r-based regimen
for a mean duration of 20 months, serum-glucose levels did not
change. In ARV-naı¨ve patients, lipid parameters increased during the
first months of the study although remaining in the normal range
except for triglycerides (20 mg/dL). Study discontinuations due to
lipid dysmetabolism were rare.
O P P O R T U N I S T I C I N F E C T I O N S :
TUBERCULOSIS
P142
Low rifampicin and isoniazid concentrations are associated
with delayed sputum conversion in HIV-positive patients
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Introduction: HIV-positive patients co-infected with tuberculosis (TB)
have anti-TB drug concentrations lower than reference ranges;
however, the relationship between concentrations of anti-TB drugs
and treatment response remains controversial.We sought to evaluate
if there is an association between low concentrations of first-line anti-
TB drugs and delayed sputum conversion in a cohort of HIV/TB co-
infected Ugandan adults.
Materials and methods: We enrolled HIV-infected Ugandan adults
diagnosed with a first episode of pulmonary TB. Patients underwent
pharmacokinetic sampling 1, 2 and 4 hours after drug intake to
estimate the maximum drug concentrations (eCmax) at 2, 8 and
24 weeks of TB treatment using high-performance liquid chromato-
graphy. Low concentrations were defined as an eCmax below the
previously described cut-offs for rifampicin B8 mg/L and isoniazid
B3 mg/L. Sputum conversion was defined as conversion of sputum
culture or smear from positive to persistently negative results during
follow-up. Cox regression and Kaplan-Meier curves were used to
determine the association between sputum conversion dynamics and
anti-TB drug concentrations.
Results: From April 2013 to May 2015, we included 226 HIV-infected
patients with positive sputum cultures or smears at baseline. The
median age was 34 years (interquartile range [IQR] 2940), 58%
(133) were male, the median CD4 cell count was 191 cells/mm3 (IQR
70333), and the median BMI was 19.1 kg/m2 (IQR 17.621.6). The
majority (177, 78%) of all patients was ART naı¨ve at time of TB
diagnosis. Patients with low isoniazid and rifampicin concentrations
were less likely to undergo sputum conversion before the end of
follow-up compared to those with normal concentrations (HR 0.51;
95% CI 0.350.72; pB0.001 and HR 0.61; 95% CI 0.440.84;
p0.003 respectively). In addition, patients with ]1 drugs below
the cut-off had a higher probability of remaining culture/smear
positive over time compared to those with no drug below the cut-
off (Figure 1). These associations remained unchanged in models
adjusted for age, sex and BMI.
Abstract P141Table 1. Metabolic AEs reported during the study, N (%) of patients
ARV naı¨ve
(N117)
ARV naı¨ve
(N117)
ARV experienced
(N116)
ARV experienced
(N116)
Type of metabolic AE  WHO-ART preferred term AEs ADRs AEs ADRs
Hyperlipidaemias 8 (6.8%) 5 (4.3%) 6 (5.2%) 4 (3.4%)
- Hypercholesterolemia 2 2 1 1
- Hypercholesterolemia 0 0 1 (e) 1
- Hypertriglyceridemia 1 0 3 2
- Hyperlipaemia (l) 4 2 1 0
- Hyperlipaemia (l) 1 (a) 1 0 0
Other metabolic AEs
- Diabetes mellitus reactivated 1 (a) 0 1 0
- Weight increase 1 (a) 0 0 0
- Weight decrease 1 (s) 0 0 0
- Lipodystrophy 1 (e) 1 0 0
(l) hypercholesterolemiahypertriglyceridemia; (a) AEs occurring in the same patient; (s) serious AE (caused hospitalization); (e) study
discontinued because of AE. ADR, adverse drug reaction (AE possibly or probably related to DRV according to the clinician); WHO-ART, World
Health Organization adverse reactions terminology.
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Conclusions: Low isoniazid or rifampicin concentrations in HIV/TB
co-infected patients resulted in delayed sputum conversion. This has
potential implications on TB transmission.
P143
Isoniazid preventive therapy is highly cost-effective
among TB/HIV co-infected patients in Uganda
Christine Sekaggya Wiltshire1; Andreas Kuznik2 and
Mohammed Lamorde1
1Research, Infectious Diseases Institute, Kampala, Uganda.
2Pharmaceuticals, Regeneron Pharmaceuticals, New York, NY, USA
Introduction: Isoniazid preventive therapy (IPT) for at least 6 months
is recommended by the WHO for the treatment of latent tuberculosis
(TB) in patients infected with HIV. This study aimed to determine the
cost-effectiveness of IPT versus no treatment for latent TB among
HIV-infected patients in an urban outpatient clinic in Kampala,
Uganda.
Methods: The analysis was conducted from the perspective of the
national health system. Using decision analysis, we modelled the
impact of IPT versus no IPT on costs and patient outcomes, using
a probability of developing TB of 2.5% in the IPT arm and 7.5% in
the no-IPT arm, based on published sources [1]. We estimated the
median daily price of isoniazid at $0.048 over the course of
6 months, based on international drug price lists. We also included
the cost of first- and second-line TB treatment at $12.90 and $110.7,
respectively [2]. The TB associated mortality rate (10.5%) and failure/
relapse rate (12.4%) associated with TB treatment was obtained from
a systematic review of first-line treatment of TB in HIV-infected
patients [3]. We used a life expectancy of 35.1 years estimate from a
study on patients on combined antiretroviral therapy in Uganda [4].
Study results were expressed in cost per disability-adjusted life years
(DALY) averted and compared against WHO cost-effectiveness
thresholds.
Results: The full course of IPT is associated with a cost of $8.64, but
approximately $1.33 of which are offset due to reduced need for
first- and second-line TB therapy, yielding a net cost of $7.31. IPT is
also associated with a reduction in DALYs by 0.118, yielding a cost/
DALY averted of $62, which is well below Ugandan per capita GDP.
Conclusion: Use of IPT is highly cost-effective in TB/HIV co-infected
patients. National programmes should consider IPT a priority in
Uganda and health providers should be encouraged to increase
compliance with WHO guidelines on treatment of latent TB.
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Introduction: Mortality in tuberculous meningitis (TBM) varies from
around 20% in HIV-negative patients to more than 50% in HIV-
positive patients. A prediction score for unfavourable outcome
including altered consciousness, neurologic deficit, hydrocephalus,
vasculitis, immunosuppression and diabetes mellitus has been
recently published. The aim of our study was to assess if this score is
better associated with mortality than neurologic staging in HIV-
infected versus HIV-non-infected patients.
Materials and methods: We retrospectively analyzed patients ad-
mitted to a tertiary care facility between 2005 and 2015 with TBM.
Patients were diagnosed as definite, probable and possible TBM
according to a consensus definition [1]. Neurologic stages were
classified according to the Medical Research Council (MRC) definitions
[2]. Hamsi scoring [3] was calculated for all patients for further dis-
tribution of mortality.
Results: We identified 115 patients of which 55 (48%) had definite, 33
(29%) probable and 27 (23%) possible TBM. Thirty-two (28%) patients
Abstract P142Figure 1. Kaplan-Meier showing probability of remaining smear or culture positive over time among those with 0/1/2 drugs
below the cut-off.
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were in MRC stage 1, 58 (50%) were in stage 2 and 25 (22%) in stage 3.
Fifty-two (45%) patients were immunosuppressed, of which 41 (36%)
patients were HIV infected. Fifteen (37%) HIV-infected patients versus
six (8%) non-HIV patients died during hospitalization (pB0.001, OR
6.5, 95% CI 2.218.6). In the non-HIV patients who were immuno-
suppressed the mortality was 25%. The median CD4 cell count in HIV-
infected patients who died versus those who survived was 67 (IQR 19
145) versus 86 (IQR 45192), respectively.Mortality rateswere 9.4% in
patients diagnosed in MRC stage 1, 10.3% for patients in stage 2 and
48% for those in stage 3. Mortality rates in HIV-infected patients were
one (2%) for MRC stage 1, four (10%) for stage 2 and 10 (24%) for stage
3 (p0.007). In non-HIV patients mortality was 3% in all three stages.
The distribution of mortality for the Hamsi scores 1 to 6 was 0%, 5.3%,
14.8%, 25.9%, 33% and 40%, respectively.Themedian Hamsi scorewas
4, both in patients who survived (IQR 25) and in those who died (IQR
45) in the HIV-positive group. In the HIV-negative group, the median
Hamsi score was 3 (IQR 24) in patients who died versus 3 (IQR 35) in
those who survived. Area under ROC curve for Hamsi score versus
clinical staging was 0.775 versus 0.721, respectively (Figure 1).
Conclusions: Immunosuppression, particularly HIV infection, is
associated with higher mortality in TBM. Higher Hamsi score was
associated with higher mortality. Hamsi score was similar with
clinical staging in predicting in-hospital mortality. In advanced HIV
disease the mortality was not associated with CD4 cell count.
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Tuberculosis infection in HIV patients in a
Portuguese population
Anto´nio Maio; Daniel Coutinho; Sofia Nunes; Jorge Velez;
Filomena Freitas and Ce´lia Oliveira
Infectious Diseases Department, Centro Hospitalar do Baixo Vouga,
Aveiro, Portugal
Introduction: Tuberculosis (TB) is the most common opportunistic
infection affecting HIV patients and remains the most common
cause of death in patients with AIDS. HIV increases the risk of disease
from TB and leads to more frequent extrapulmonary involvement,
atypical manifestations and paucibacillary disease, which can delay
diagnosis.
Material and methods: Retrospective analysis of files pertaining
inpatients with TB and concurrent HIV infection admitted between
January 2005 and December 2014. Data were analyzed using x2 or
Fisher’s exact test (pB0.005statistically significant) and odds ratio
was calculated.
Results: From 222 patients diagnosed with TB during the study, 48
had concurrent HIV infection. Of these 15 had a pulmonary form of TB
(PTB) and 36 an extrapulmonary form (ETB) (p0.052). There was an
increased risk of ETB in HIV patients (OR 5.156). In both groups men
were the most common gender (PTB 80.0%; ETB 80.6%) with a
median age of 39.5 years (PTB 34 years (31.543); ETB 43 years (32
50)). CD4 count and viral load was obtained in 40 patients, with a
median CD4 count of 74.50 cells/mL (13136) and viral load of
211,006 copies/mL (14304,430,000). In HIV patients, most TB
diagnosis were done in the context of new HIV diagnosis (n34,
70.8%). The others were diagnosed in non-adherence patients. The
most common forms of TB were pulmonary (n15), disseminated
(n11), ganglionar (n10), meningeal and pleural (n8). The HIV
infection was associated with the presence of disseminated
(p0.000, OR 12.64), pleural (p0.000, OR 8.5), meningeal
(p0.000, OR 2.96) and ganglionar forms of TB (p0.000, OR
2.38). Its absence is associated with pulmonary (p0.000, OR 4.08)
and osteoarticular forms (p0.000, OR 5.4231). TB case was
confirmed by culture or PCR test plus smear in 17 cases, was
probable (PCR or smear or histology) in 16 cases and possible (only
clinical) in 15 cases. Six patients died because of TB infection (12.5%,
PTB n2 vs. ETB n5) with no prevalence of any particular form
of TB.
Conclusion: Risk of ETB in HIV patients seems to be higher than PTB.
We found an association of HIV infection with disseminated, pleural,
meningeal and ganglionar forms. Definitive diagnosis is very
difficult in these patients because of paucibacillary disease, requiring
sometimes the use of clinical criteria and empiric therapy. Diagnosis in
time and appropriate treatments can change the prognosis of these
patients.
Abstract P144Figure 1. ROC curve.
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P147
Use of dolutegravir in combination with rifampicin-based TB
therapy in HIV/TB co-infected patients: real-world
experience from Leeds, UK
Muge Cevik1; Rachel Vincent2 and Hugh McGann2
1Infectious Diseases, Western General Hospital, Edinburgh, UK.
2Infectious Diseases, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Introduction: Co-administration of TB and HIV treatment is now
the standard of care. Rifampicin-based therapy is the first-line
TB treatment; however, there are significant drug interactions
as rifampicin is a potent inducer of cytochrome P450 and UGT.
Dolutegravir is substrate of UGT1A1 and CYP34 both are induced by
rifampicin therefore co-administration of rifampicin decreases dolute-
gravir plasma concentrations. It is recommended to use dolutegravir
50 mg twice daily when given together with rifampicin. Our HIV MDT
has approved the use of dolutegravir in TB/HIV co-infected patients
who had adverse reactions with efavirenz or where efavirenz was
contraindicated.We aim to present real-world experience of our HIV/
TB co-infected patients who were on rifampicin-based TB therapy in
combination with dolutegravir-based regimen.
Methods: All HIV/TB co-infected patients who were on dolutegravir-
based ART and were receiving rifampicin-based TB therapy were
identified. Data were retrospectively collated through electronic
patient records and case note review. Descriptive statistics were
performed to examine demographics, baseline characteristics, CD4
count and HIV viral load. In this cohort, dolutegravir was used 50 mg
BID in combination with rifampicin 600 mg OD in all patients.
Results: We identified seven patients (one male) who were on
dolutegravir-based regimen in combination with rifampicin. Median
age was 41 years (2748) and all were black African in origin. Five
patients were naı¨ve to ART whereas two were ART experienced.
There was no baseline integrase resistance mutations identified. At
baseline median CD4 count was 90 cells/mL (3365), five patients
had CD4 B100 cells/mL and only one patient had undetectable viral
load. At 6 months after HIV treatment median CD4 count improved
to 230 cells/mL (104625) and all except one patient had
undetectable HIV viral load. This patient was not suppressed due
to well-documented poor adherence and repeat resistance test
revealed new M184V mutation with no integrase resistance. In our
cohort all patients tolerated the treatment well without significant
adverse events. Four patients successfully completed TB therapy and
three are on ongoing treatment. Two patients have subsequently
switched from dolutegravir due to MSK symptoms after TB treat-
ment was completed.
Conclusion: In this small cohort of HIV/TB co-infected patients co-
administration of twice-daily dolutegravir in combination with
rifampicin was well tolerated with good virological outcome both
in naı¨ve and treatment-experienced patients.
P148
The practice and value of interferon gamma release assay
testing for latent tuberculosis infection in people living with
HIV: a retrospective review of patients at Leeds Teaching
Hospitals Trust
Amy Baggott1; Muge Cevik2 and Hugh McGann1
1Infectious Diseases and Travel Medicine, St James’s University
Hospital, Leeds, UK. 2Infectious Diseases, Western General Hospital,
Edinburgh, UK
Introduction: Both NICE and BHIVA guidelines recommend interferon
gamma release assay (IGRA) testing for diagnosing latent tuberculosis
(TB) infection in people living with HIV with exposure risk for TB
[1,2]. However, ‘‘indeterminate’’ IGRA results are more common in
HIV-infected subjects and the possibility of false negative results
in those patients with very advanced immunocompromise is a
concern [3,4].
Methods: As such, a retrospective review was conducted
of all patients diagnosed with both TB and HIV in the Leeds Teaching
Hospitals Trust during the past 5 years. Records were checked to see
if those patients with risk factors for TB exposure had been
correctly screened for latent TB with an IGRA test at the time of
HIV diagnosis and, if so, how the result had influenced treatment.
Demographic data were collected about the patients and their
laboratory results, treatment histories and outcomes were analyzed.
Results: Of 31 patients, only two had ever had IGRA testing. One had
been tested 7 years after being diagnosed with HIV and just 2 weeks
before being diagnosed with active TB, with a positive result. The
other was tested within 2 weeks of being diagnosed with very
advanced HIV and had a false negative result. He was started on
treatment for active TB 2 months later and died during treatment.
Nine patients were diagnosed with HIV at the same time as TB, but
22 patients were diagnosed with HIV more than a month before
being diagnosed with HIV, with an average interval of 4.7 years
between diagnoses. Twenty of these 22 patients had exposure risk
for TB and should have been screened for latent TB. Two
of the patients had MDRTB which would not have been effectively
prevented by chemoprophylaxis, even if they had been screened
for latent infection. Two deaths occurred, but neither would
have been prevented by IGRA testing. Over half of the cohort may
have potentially benefited from IGRA testing to screen for latent
TB as part of their routine HIV care. However, as the one case
who did have an IGRA test at the time of HIV diagnosis demonstrates,
IGRA testing can be unreliable in those who present with advanced
HIV.
Conclusion: From these data, there are missed opportunities to
diagnose and treat latent TB, but it is difficult to know how useful
IGRA testing would truly have been, if the results had been
indeterminate or falsely negative in those who presented with very
low CD4 counts.
References
1. National Institute for Health and Care Excellence (NICE). NICE
guideline (NG33): tuberculosis. NICE; 2016.
2. Pozniak AL, Coyne KM, Miller RF, Lipman MCI, Freedman AR,
Ormerod LP, et al. BHIVA guidelines for the treatment of TB/HIV
coinfection 2011. British HIV Association; 2011.
3. Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X,
Marais BJ, et al. High level of discordant IGRA results in HIV-infected
adults and children. Int J Tuberc Lung Dis. 2008;12:41723.
4. Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM,
Dilektasli AG, et al. Risk assessment of tuberculosis in immuno-
compromised patients. A TBNET study. Am J Respir Crit Care Med.
2014;190:116876. doi: http://dx.doi.org/10.1164/rccm.201405-
0967OC
P149
Abstract Withdrawn
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
114
OPPORTUNISTIC INFECTIONS: OTHERS
P150
Incidence and survival in HIV-infected patients with central
nervous system opportunistic infections in the cART era:
a 10-year Romanian single-centre experience
Cristiana Oprea1; Irina Ianache2; Ionut Popa2; Luminita Ene2;
Roxana Radoi2; Gratiela Tardei3; Eugenia Ungureanu2;
Simona Erscoiu1; Emanoil Ceausu2 and Petre Calistru1
1Infectious Diseases, Carol Davila University of Medicine and
Pharmacy, Bucharest, Romania. 2Infectious Diseases, Victor Babes
Clinical Hospital for Infectious and Tropical Diseases, Bucharest,
Romania. 3Laboratory of Virology and Immunology, Victor Babes
Clinical Hospital for Infectious and Tropical Diseases, Bucharest,
Romania
Introduction: Despite the global decline in the cART era, HIV-
associated neurologic opportunistic infections (CNS-OIs) remain an
important cause of morbidity and mortality especially in resource-
limited settings. The aim of our study was to evaluate the incidence
of CNS-OIs (including brain tumors) and the factors related to
survival in HIV-infected patients admitted in a tertiary health care
facility.
Methods: Retrospective study on HIV-infected patients diagnosed
with CNS-OIs at Victor Babes Hospital Bucharest between January
2006 and December 2015. We evaluated demographic, immunologic,
virologic variables and treatment characteristics in patients with
CNS-OIs. Survival distribution was estimated using Kaplan-Meier
methods.
Results: A total of 215 patients, 56.2%males, were diagnosedwith 220
CNS-OIs (incidence 12.9/1000 PY). The median age at CNS-OIs
diagnosis was 29 years (IQR 2340).Themain routes of HIVacquisition
were: heterosexual contact (HSX) 52.7%, parenteral in early childhood
(PI) 38.5% and injecting drug use (IDU) in 6.8%. The median CD4 cell
count and HIV viral load (VL) at CNS-OIs diagnosis were 35/mL (IQR 13
86) and 5.24 log10 copies/mL (IQR 4.15.7), respectively. The most
common CNS-OIs were: cerebral toxoplasmosis 64 (29.0%), progres-
sive multifocal leukoencephalopathy (PML) 62 (28.1%), tuberculous
meningitis (TBM) 41 (18.6%), cryptococcal meningitis (CM) 37 (16.8%),
primary cerebral lymphoma (PCNSL) 10 (4.5%) and CMV encephalitis
Abstract P150Table 1. Immuno-virologic characteristics, mortality and survival in HIV-infected patients with CNS-OIs
PML
n62
TBM
n41
CM
n37
PCNSL
n10
CMVE
n6
Toxo
n64 p
CD4 cell count/mm3,
median (IQR)
39 (16103) 65 (23122) 21 (1156) 40 (1678) 23 (1148) 29 (1163) 0.08
Nadir CD4 cell count/mm3,
median (IQR)
33 (1277) 37 (1965) 13 (828) 32 (1141) 13 (821) 23 (1154) 0.06
HIV RNA log10 copies/mL,
median (IQR)
4.76 (2.855.39) 5.32 (4.465.84) 5.37 (4.615.76) 5.71 (5.145.87) 5.89 (5.585.92) 5.33 (4.975.80) 0.007
Survival in months,
median (IQR)
22.1 (3.155.12) 14.9 (4.027.6) 16.2 (2.344.3) 2.3 (1.24.1) 38 (11.878.9) 17.8 (2.743.1) 0.08
Mortality, n (%) 23 (37.0) 20 (48.7) 18 (48.6) 7 (70.0) 2 (33.3) 24 (37.5) 0.31
Early mortality, n (%) 16 (25.8) 8 (19.5) 12 (32.4) 7 (70.0) 1 (16.6) 19 (29.6) 0.05
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(CMVE) 6 (2.7%). Ninety patients (41.8%) with therapeutic failure on
cART, mainly due to non-adherence, developed CNS-OIs. In 74 (33.6%)
cases, HIV and CNS-OIs were diagnosed simultaneously. PI patients
were younger at both HIV and CNS-OIs diagnosis compared with HSX
and IDUs (11, 22 vs. 35, 38 vs. 31, 31 years), respectively (pB0.001),
and developedmore often PML (43.5% vs. 20.6% vs. 0.0%, pB0.0001).
Patients diagnosed with CM and CMVE had the lowest nadir and
median CD4 cell count and higher VL at diagnosis (Table 1). The overall
mortality rate was 42.7%. Compared to HSX and IDUs, PI had a lower
mortality rate (29.4% vs. 51.7%, 46.6%, p0.006) and a longer survival
time (months) (35.3 vs. 7.4, 16.2 respectively, p0.001). IDU and HSX
mode of HIV transmission, low CD4 cell count (B100/mL), low nadir
CD4 cell count (B35/mL) and high VL (5 log10 copies/mL) were
associatedwith shortermedian survival time and highermortality in all
cases.
Conclusions: The incidence and mortality rate of CNS-OIs in
Romanian HIV-infected patients were high. HIV-related mortality
and morbidity in patients with CNS-OIs was increased due to late
presentation and/or non-adherence to cART.
P151
In spite of international guidelines, vaccine coverage
of HIV-infected patients remains low
Amandine Gagneux-Brunon; Anne Fre´sard; Maelle Detoc;
Elena Charrie`re; Ve´ronique Ronat; Fre´de´ric Lucht and
Elisabeth Botelho-Nevers
Infectious and Tropical Diseases, University Hospital of Saint-Etienne,
Saint-Etienne, France
Introduction: HIV-infected patients are at risk of vaccine-preventable
diseases. HIV care is an opportunity to improve vaccine coverage. EACS
[1], BHIVA [2] and French [3] guidelines recommend immunization as
in general population (tetanus (T), diphtheria (D), poliomyelitis (P),
pertussis, and measles, mumps and rubella (MMR)) associated with
specific vaccinations (influenza, pneumococcal infections, viral hepa-
titis B (HBV) and A, human papilloma virus).The aimof our studywas to
assess the status of immunization of HIV-infected patients for specific
and non-specific vaccinations.
Materials and methods: Single-centre study, status of immunization
was collected in patients’ charts and vaccination booklets. All
patients were includable in the study.
Results: Five hundred and sixty-nine patients were included, mean
age was 49.4911.5 years, sex ratio was 2.67, 527 (92.6%) patients
had an undetectable viral load, median CD4 positive cells count was
660/mm3 (532146), 217 (38.1%) patients had at least one
significant comorbidity (liver disease in 21.2%, diabetes in 12.9%,
chronic obstructive pulmonary disease in 7.3%, renal insufficiency in
5.1%, chronic cardiopathy in 4.6%, neoplasm in 1.4%). Two hundred
and sixty-one patients of 425 (61.4%) were correctly immunized
against D, T and P, 96/356 (27%) against pertussis, 26/279 (9.3%)
against MMR. Only 17 patients of 279 with available information
were correctly immunized against D, T, P, pertussis and MMR. Of 474
patients with available information about immunization against HBV,
282 (59.5%) were correctly immunized (after immunization or with
natural immunity). Concerning immunization against Streptococcus
pneumoniae, 107 patients (26.5%) (of 403 with available data)
received a conjugate vaccine before the non-conjugate polysacchar-
ide vaccine. Two hundred and twenty-nine (52.5% of the patients
with data) were immunized against influenza during last winter.
Patients with comorbidities were more often correctly immunized
against Streptococcus pneumoniae and influenza than patients
without a comorbidity (51/147 vs. 56/256, p0.005, and 89/151
vs. 140/284, p0.036, respectively).
Conclusion: Our data suggest that vaccine coverage in HIV-infected
patients remains low (and comparable to previously published
studies, and lower than in the general population), patients with
a comorbidity were more likely correctly immunized against Strep-
tococcus pneumoniae and influenza than patients without comorbid-
ity. With the improvement of the condition of HIV-infected patients,
physicians involved in HIV care may pay more attention to prevention.
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Does syphilis impact on HIV infection when both
diagnoses are concomitant?
Rosario Palacios; Carmen Marı´a Gonza´lez-Domenech;
Isabel Antequera; Josefa Ruiz-Morales; Enrique Nun˜o;
Encarnacio´n Clavijo; Manuel Ma´rquez and Jesu´s Santos
UGC Enfermedades Infecciosas, Hospital Virgen de la Victoria,
Ma´laga, Spain
Introduction: Syphilis causes viral load blips in virologically sup-
pressed patients on antiretroviral therapy, as well as a reduction in
the CD4 lymphocyte count [1,2]. The importance of this interaction is
that co-infection increases the risk of HIV transmission [3]. The aim of
this study was to examine whether syphilis impacts on HIV infection
when both infections are diagnosed at the same time in men who
have sex with men (MSM).
Materials and methods: All cases of HIV-MSM diagnosed at our
centre in 2009 to 2015 were reviewed. Patients were excluded from
this study if they had a prior diagnosis of syphilis in order to avoid
confounding factors in the serological tests. We examined epidemio-
logical, clinical, immunological and virological variables among the
patients with and without syphilis at the time of diagnosis of HIV
infection. Diagnostic criteria for syphilis are: treponemal and rapid
plasma reagin (RPR) both positive, except for patients with primary
syphilis, who only require a positive RPR.
Results: During the study period, 566 patients were diagnosed
with HIV infection (446 MSM); 37 patients were excluded, so the
final sample included 409 MSM. Of these, 72 (17.6%) were diagnosed
with syphilis at the same time as their diagnosis of HIV infection.
Syphilis was asymptomatic in 34 (47.2%) cases. The epidemiological
and clinical characteristics were similar in patients with or without
syphilis, and no differences were found in basal viral load (4.67 vs.
4.66 log copies/mL; p0.3) or CD4 cell count (431 vs. 428 cell/mL;
p0.7). Nor were there differences between the patients with
symptomatic syphilis and the patients without syphilis.
Conclusions: Syphilis does not impact on the clinical presentation
nor on the immunovirological parameters when the diagnoses of
both syphilis and HIV are coincident. The specific weight that
Treponema pallidum infection may have on HIV-infected patients
not on antiretroviral therapy is minimum.
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CO-MORBIDITIES AND COMPLICATIONS OF
DISEASE AND/OR TREATMENT: AGEING
P153
Health-related costs in chronic HIV infection: a case-control
study versus general population using a claims-based
approach in Germany
Eva Wolf1 and Stefan Christensen2
1Clinical Research, MUC Research, Munich, Germany. 2Infectious
Diseases, Center for Interdisciplinary Medicine (CIM), Munich,
Germany
Introduction: Due to very effective ART available for HIV treatment,
people living with HIV (PLHIV) are now older but also suffering from
age-related comorbidities, transforming HIV management into
chronic care. However, data on excess comorbidity burden in PLHIV
are limited. This study characterizes the cost to the health system, of
managing comorbidities of HIV patients, compared with a matched,
HIV-negative control cohort in Germany.
Materials and methods: This is a retrospective health insurance
claims database analysis, comparing the healthcare costs of an HIV
cohort (HIV) to a matched cohort from the general population
(non-HIV). Inclusion criteria for HIV cohort were ]1 HIV ICD-10-
GM code in 2014, age 21 years at index date, and continuous
documentation for the previous 3 years. Index date was the last
available HIV diagnosis code. A control cohort was selected from
general, non-HIV population, and paired (2:1 control-to-case ratio)
based on age, gender, residence district, health insurance status and
educational level, at index date. Level of significance was aB0.05.
Results: One thousand nine hundred and sixty-nine HIV patients
were included and paired with 3938 non-HIV individuals. Mean age
was 48 years and 83.5% were males. Cardiovascular disease, chronic
renal disease, osteoporotic bone fractures and HBV and HCV co-
infection were more prevalent in HIV patients. The total average
per patient per year (PPPY) costs (9SD, standard deviation)
excluding costs exclusively related with HIV (ART) were significantly
higher (pB0.05) in HIV compared wiht non-HIV (8039t942,586t
vs. 3664t920,961t, respectively). When looking at individual
categories in Figure 1, the main driver of this significant difference
is the PPPY pharmaceutical cost excluding ART (3942t), which
accounts for nearly 49% of total costs for HIV, but only 32% for
non-HIV (1201t). Outpatient costs and inpatient costs were also
statistically higher for HIV compared with non-HIV. There was no
difference for sick leave payments, and devices costs for HIV
compared with non-HIV cohort.
Conclusions: Higher inpatient, outpatient and drug-related costs not
associated with ART were observed in a German HIV cohort com-
pared with a matched non-HIV cohort using health insurance claims
data. With effective ART, PLHIV are ageing and developing chronic
comorbidities, potentially requiring a holistic, long-term, multidisci-
plinary approach, including not only careful consideration of
ART choice, but also screening, monitoring and treatment of
comorbidities and aspects of lifestyle, potentially leading to improved
outcomes.
P154
Ageing and the evolution of comorbidities among
HIV patients in the EuroSIDA cohort
Sara Lopes1; Ole Kirk2; Jens Lundgren2; Kamilla Laut2;
Simon Edwards3; Claudine Duvivier4; Christoph Stephan5;
Helen Sambatakou6; Katarzyna Maciejewska7; Filipa Araga˜o1 and
Amanda Mocroft8
1Health Economics and Outcomes Research, Gilead Sciences, London,
UK. 2Department of Infectious Diseases, Centre for Health and
Infectious Disease Research, Copenhagen, Denmark. 3Academic
Department of Genitourinary Medicine, Mortimer Market Centre,
London, UK. 4Service de Maladies Infectieuses et Tropicales, Hoˆpital
Necker-Enfants Madales, Centre d’Infectiologie Necker-Pasteur,
Universite´ Paris Descartes, Paris, France. 5Zentrum der Inneren
Medizin II, JW Goethe University Hospital, HIV Haus 68, Frankfurt am
Main, Germany. 62nd Department of Internal Medicine, Hippokration
General Hospital, Athens, Greece. 7Clinic of Infectious, Tropical
Diseases and Immune Deficiencies, Pomeranian Medical University,
Szczecin, Poland. 8HIV Epidemiology and Biostatistics Unit,
Department of Infection and Population Health, University College
London, London, UK
Introduction: The prevalence of age-related comorbidities is likely to
increase as HIV patients prolong survival due to availability of
effective ART. We aimed to characterize the common comorbidities’
prevalence and their risk and factors, such as renal impairment, bone
fractures and cardiovascular (CV) events over time after standardiza-
tion for age.
Abstract P153Figure 1. Mean per person per year (PPPY) individual categories cost per cohort.
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Materials and methods: Two cross-sectional analyses (2006 and
2014) were conducted in patients within EuroSIDA cohort. Adult
patients were selected if they had ]1 clinical visit in the year of
analysis. Analyzed outcomes included prevalence of comorbidities:
CV events, renal impairment (chronic kidney disease (CKD); defined
as a confirmed (3 months apart) eGFR B60, nadir eGFR B60 mL/
min using CKD-EPI formula) and bone fractures. Risk factors
considered included diagnosis of hypertension (systolic blood
pressure (BP) ]140 mm Hg and/or diastolic BP ]90 mmHg and/
or on hypertensive drugs), dyslipidaemia (total cholesterol ]6.2
mmol/L, HDL 50.9 mmol/L or triglycerides ]2.3 mmol/L) and
diabetes (clinical diagnosis and/or antidiabetics/insulin use); and the
risk score for CV and CKD development using Data Collection on
Adverse Events of Anti-HIV Drugs (DAD) CKD risk score, DAD CVD
5-year risk score and Framingham 10-year CVD risk score.
Results: Nine thousand five hundred and fifty-four patients were
under follow-up in 2006 and 11,504 in 2014. 73.6% and 71.9% of
patients were male in 2006 and 2014, respectively. Figure 1
summarizes the prevalence of comorbidities and risk factors for
all, and patients]50 years in 2006 and 2014, who represent 44.0% of
the 2014 cohort. Overall, the prevalence of CKD increased over time
(2.0% vs. 5.1%), as did for any bone fractures (2.0% vs. 5.3%),
hypertension (25.8% vs. 40.6%), diabetes (5.9% vs. 6.8%) and
dyslipidaemia (69.4% vs. 72.3%). Similarly, the proportion of patients
in DAD CKD high-risk group (score ]5) increased from 50.5% to
55.6%, in Framingham high-risk group (score 20%) increased from
18.3% to 24.9% and in DAD CVD high- and very high-risk groups
(scores 510% and 10%, respectively) increased from 9.5% to
15.3%, respectively. The increase in the prevalence of CKD, hyperten-
sion and fractures over time was notable amongst those ]50 years.
Conclusions: As persons with HIV age, there is an increasing pre-
valence of common underlying comorbidities. Careful consideration
of modifiable factors, including lifestyle and antiretroviral therapy as
well as a multidisciplinary approach to managing HIV patients with
different comorbidities, may help improve patient outcomes.
P155
Future challenges for clinical care of an ageing population
infected with HIV: a ‘‘geriatric HIV’’ modelling study
Davide De Francesco1; Andrea Malagoli2; Olga Theou3;
Stefano Zona2; Federica Carli2; Giovanni Dolci2; Cristina Mussini2;
Susan Kirkland4; Chiara Mussi5; Matteo Cesari6; Kenneth Rockwood3
and Giovanni Guaraldi2
1Department of Infection & Population Health, University College
London, London, UK. 2Department of Medical and Surgical Sciences,
University of Modena and Reggio Emilia, Modena, Italy. 3Geriatric
Medicine Research, Dalhousie University, Halifax, Canada.
4Department of Community Health & Epidemiology, Dalhousie
University, Halifax, Canada. 5Geriatrics Division, University of
Modena and Reggio Emilia, Modena, Italy. 6Centre Hospitalier
Universitaire de Toulouse, Ge´rontopoˆle, Toulouse, France
Introduction: According to a modelling study, in 15 years’ time
multimorbidity in HIV patients will be the norm [1]. In this context
frailty, geriatric syndromes and disability will be relevant clinical
outcomes. We aimed at quantifying the scale of change in frailty and
its implications for HIV care in Italy in the year 2030.
Materials and methods: An individual-based model of the ageing
population of the Modena HIV Metabolic Clinic (MHMC) was
constructed using data collected between 2009 and 2015 from
3086 patients. The model follows patients enrolled to the clinic up to
2015 and generates new entries on a yearly basis up to 2030. Number,
age and gender of new entries were modelled using trends observed
in the period 2009 to 2015. Patients were followed as they age and
accumulate deficits, resulting in the Frailty Index (FI, quantified as the
proportion of deficits present out of a total of 37). FI at enrolment
was generated from a gamma distribution with age- and gender-
specific parameters estimated using the MHMC 2009 to 2015 data.
Patients were classified as non-frail (FI 00.3), frail (0.30.4) and
most-frail (FI0.4). Changes in the FI over a 1-year period and death
rates were modelled following a validated mathematical model
developed in a large Canadian ageing population [2], with parameters
adjusted to best represent the changes observed in the MHMC 2009
to 2015 population. Geriatric syndrome was defined as of one or
more self-reported falls in the past 12 months. Disability was assessed
in eight categories of activities of daily function and defined as
impairment in ]1 categories. The relationship between age, gender,
geriatric syndrome and disability, observed in 2014 to 2015 at MHMC,
was postulated to constant over time.
Results: Our model suggests that the median age of HIV-positive
patients on combination antiretroviral therapy will increase from 49
years in 2015 to 59 in 2030, with the proportion of HIV-positive
patients aged ]50 years increasing from 42% in 2015 to 95% in
2030 (Figure 1). In the same period, the proportion of frail and most-
frail patients will increase from 26% to 28% and from 24% to 48%,
respectively. In 2030, we predict that 30% of HIV-positive patients
will have geriatric syndrome and 34% will be disabled (Figure 2).
Abstract P154Figure 1. Prevalence of comorbidities and risk factors in 2006 and 2014 for all patients and ]50 years.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
118
Conclusion: The increasing numbers of older patients with frailty,
geriatric syndromes and disability depict a ‘‘geriatric HIV’’ scenario.
This model suggests evidence-based screening and monitoring
protocols to ensure high-quality care.
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Quantifying the future clinical burden of an ageing HIV-
positive population in Italy: a mathematical modelling study
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Introduction: Effective HIV treatment is extending life expectancy of
HIV-positive people, putting them at risk of suffering from age-
related non-communicable diseases (NCDs). Health systems must
prepare for the changes and forecasts are needed. As HIV epidemics
across countries vary in terms of at-risk populations and lifestyle
factors, it is important to develop country-specific estimates of
future morbidity and disease burden. We developed a model of an
ageing HIV-positive population for Italy, to provide the first ever
national forecasts.
Materials and methods: An individual-based model of the ageing
HIV-positive population was adapted to the Italian setting. The model
follows patients on HIV treatment as they age, and develop NCDs,
including cardiovascular disease (CVD; hypertension, hypercholester-
olaemia, strokes and myocardial infractions), diabetes mellitus,
chronic kidney disease and non-AIDS malignancies. The model also
simulates how certain NCDs can increase the risk of developing other
NCDs (e.g. how hypertension can increase the risk of CVD). The
model was parameterized using data from 2774 HIV-positive patients
seen for HIV care between 1997 and 2010 from the ICONA
Foundation study, a large cohort encompassing 42 infectious disease
centres across Italy. Extensive model validation was carried out on
this dataset. National level forecasts were developed by scaling the
results to national HIV surveillance and programme data. The model
was used to make demographic and epidemiological forecasts from
2015 to 2030.
Results: The model estimates that the mean age for HIV-positive
patients on treatment in Italy will increase from 45.8 years in 2015 to
Abstract P155Figure 1. Observed (red box) and predicted distribution of disability (a) and geriatric syndromes (b) in HIV-positive patients
between 2014 and 2030.
Abstract P155Figure 2. Observed (red box) and predicted age distribution (a) and burden of frailty (b) in HIV-positive patients between
2009 and 2030.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
119
48.8 years in 2020 and 54.5 by 2030, with the proportion of HIV-
positive patients aged ]50 increasing from 35% to 41% to 62%,
respectively. The model predicts that, by 2030, 47% of HIV-positive
patients will suffer from ]3 NCDs (compared with 27% in 2020 and
16% in 2015) and 92% from ]1 NCDs. This will be driven by a steep
increase in the burden of CVD (Figure 1). The demographic
predictions suggest faster ageing and higher predicted NCD burden
for 2030 than the Netherlands.
Conclusions: The age of HIV-positive patients on treatment in Italy is
rising and will be accompanied by a rapid increase in NCD-related
multimorbidity, assuming current demographic and epidemiological
trends remain constant. These changes will have important and far-
reaching consequences for HIV-positive patient care, requiring future
HIV care to be able to respond to rising complexity of individualized
patient needs.
P157
Quantifying the future clinical burden of an ageing HIV-
positive population in the USA: a mathematical modelling
study
Mikaela Smit; Rachel Cassidy and Timothy Hallett
Department of Infectious Disease Epidemiology, Imperial College
London, London, UK
Introduction: Effective HIV treatment is extending life expectancy of
HIV-positive people, putting them at risk of suffering from age-
related non-communicable diseases (NCDs). Health systems must
prepare for the changes and forecasts are needed. As HIV epidemics
across countries vary in terms of at-risk populations and lifestyle
factors, it is important to develop country-specific estimates of
future morbidity and disease burden. We developed a model of an
ageing HIV-positive population for the United States, to provide the
first ever national forecasts.
Materials and methods: An individual-based model of the ageing
HIV-positive population was adapted to the US setting. The model
follows patients on HIV treatment as they age, and develop NCDs,
including cardiovascular disease (CVD; hypertension, hypercholester-
olaemia, strokes and myocardial infarctions), diabetes mellitus,
chronic kidney disease, and non-AIDS malignancies. The model also
simulates how certain NCDs can increase the risk of developing other
NCDs (e.g. how hypertension can increase the risk of CVD).
The model was parameterized using data from 3087 HIV-positive
patients between 2005 and 2010 from a retrospective analysis of a
cohort of commercially insured HIV-positive patients in the United
States drawn from a geographically representative national sample.
Extensive model validation was carried out on this dataset. National
level forecasts were developed by scaling the results to
national HIV surveillance and programme data. The model was
used to make demographic and epidemiological forecasts from 2015
to 2030.
Results: The model estimates that the mean age for HIV-positive
patients on treatment in the United States will increase from
49.0 years in 2015 to 51.6 years in 2020 and 56.3 by 2030, with
the proportion of HIV-positive patients aged ]50 increasing from
42% to 52% to 71%, respectively. The model predicts that, by 2030,
41% of HIV-positive patients will suffer from ]3 NCDs (compared
with 23% in 2020 and 12% in 2015) and 89% from ]1 NCDs. This will
be driven by a steep increase in the burden of CVD (Figure 1).
The demographic predictions suggest faster ageing and higher
predicted NCD burden for 2030 than the Netherlands.
Conclusions: The age of HIV-positive patients on treatment in the
United States is rising and will be accompanied by a rapid increase in
NCD-related multimorbidity, assuming current demographic and
epidemiological trends remain constant. These changes will have
important and far-reaching consequences for HIV-positive patient
care, requiring future HIV care to be able to respond to rising
complexity of individualized patient needs.
Abstract P156Figure 1. Predicted burden of NCDs amongst HIV-positive patients on treatment in Italy, as simulated by the model.
The bar graph shows the number of people living with HIV (PLHIV) on HIV treatment with 0, 1, 2 or ]3 comorbidities between 2010 and 2030,
while the Venn diagram represents the relative number of HIV-positive patients with the three most prevalent comorbidities and their overlap
in 2030
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Introduction: GEPPO is a new Italian HIV geriatric cohort which aims
to describe health transition over time in HIV-positive patients above
65 years as compared with HIV-negative subjects. The objective of
this analysis was to describe multimorbidity, polypharmacy and
antiretrovirals’ use in the subset of people between 65 and 75 and
above 75 years of age.
Materials and methods: Cross-sectional study comparing HIV
patients and HIV individuals referred to a cardiovascular screening
clinic in a geriatric centre. They were matched for age (94 years)
and sex. Multimorbidity (MM) was classified as the presence of three
or more of non-infectious comorbidities, polypharmacy (PP) as the
use of five or more medications (excluding ART). Patients were
stratified according to the duration of HIV infection (20, 1020
and B10 years).
Results: A total of 1652 patients were included (1276 HIV and 376
HIV). Table 1 describes the study population between 65 and 75
years of age, whereas Table 2 describes the study population above 75
years of age.
Logistic regression analyses were performed to identify predictors of
MM and PP comparing HIV patients versus controls (Figure 1).
Discussion: This study takes advantage of the survival bias unavoid-
able in any ageing cohort to describe the clinical and HIV
characteristic of HIV ageing champions. In this extreme age group
HIV duration 20 years is a major driver for polypharmacy.
P159
Comorbidity in chronic HIV infection: a case-control study in
Germany using health insurance claims data
Stefan Christensen1 and Eva Wolf2
1Infectious Diseases, Center for Interdisciplinary Medicine (CIM),
Munich, Germany. 2Clinical Research, MUC Research, Munich,
Germany
Introduction: ART has increased life expectancy of people living with
HIV (PLHIV), transforming HIV management into chronic care. In
ageing PLHIV the prevalence of comorbidities is increasing. However,
data on excess comorbidity burden in PLHIV are inconclusive. This
study characterizes the prevalence of comorbidities in an HIV
population, compared with a matched, non-HIV control cohort
from the general population in Germany.
Abstract P157Figure 1. Predicted burden of NCDs amongst HIV-positive patients on treatment in the United States, as simulated by the model.
The bar graph shows the number of people living with HIV (PLHIV) on HIV treatment with 0, 1, 2 or ]3 comorbidities between 2010 and 2030, while
the Venn diagram represents the relative number of HIV-positive patients with the three most prevalent comorbidities and their overlap in 2030.
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Abstract P158Table 1. Baseline characteristics of the study population between 65 and 75 years of age
Total
(n1111)
HIV
(n153)
HIV
(n958)
HIV vs.
HIV
HIV B10 years
(n211)
HIV 1020 years
(n436)
HIV 20 years
(n311)
HIV
duration
HIV vs.
HIV duration
Variable Mean (SD or%) Mean (SD or%) Mean (SD or%) p Mean (SD or%) Mean (SD or%) Mean (SD or%) p p
Age 69.11 (2.62) 68.95 (2.73) 69.12 (2.6) 0.47 69.32 (2.56) 69.13 (2.57) 68.98 (2.67) 0.26 0.37
Females 177 (15.71%) 24 (15.69%) 150 (15.66%) 1 34 (16.11%) 67 (15.37%) 49 (15.76%) 0.97 0.99
BMI 26.52 (9.83) 28.72 (3.92) 26.07 (10.63) B0.01 28.06 (21.1) 25.83 (4.25) 25.06 (4.18) B0.01 B0.01
Current smokers 261 (27.19%) 28 (19.18%) 230 (28.5%) 0.02 45 (25.71%) 96 (26.37%) 89 (33.21%) 0.11 0.02
Hypertension 502 (61.9%) 102 (66.67%) 399 (61.2%) 0.24 84 (54.9%) 192 (60.19%) 123 (68.33%) 0.04 0.04
T2DM 216 (27.07%) 37 (24.18%) 178 (27.86%) 0.41 32 (21.19%) 80 (25.72%) 66 (37.29%) B0.01 B0.01
CVD 143 (18.17%) 33 (21.57%) 110 (17.52%) 0.29 17 (11.56%) 50 (16.34%) 43 (24.57%) B0.01 B0.01
CKD 121 (16.24%) 5 (7.94%) 115 (17.01%) 0.09 25 (15.15%) 52 (15.76%) 38 (20.99%) 0.24 0.09
COPD 59 (7.63%) 17 (11.41%) 41 (6.63%) 0.07 11 (7.59%) 13 (4.38%) 17 (9.66%) 0.07 0.03
Dyslipidaemia 502 (68.67%) 37 (56.92%) 463 (70.15%) 0.04 98 (61.64%) 230 (71.43%) 135 (75.42%) 0.02 B0.01
Multimorbidity 412 (61.31%) 40 (63.49%) 370 (61.36%) 0.84 72 (51.06%) 174 (59.79%) 124 (72.51%) B0.01 B0.01
Polypharmacy 194 (30.27%) 23 (15.03%) 170 (34.98%) B0.01 28 (29.47%) 80 (34.48%) 62 (38.99%) 0.3 B0.01
Abstract P158Table 2. Baseline characteristics of the study population above 75 years of age
Total
(n1111)
HIV
(n153)
HIV
(n958)
HIV vs.
HIV
HIV B10 years
(n211)
HIV 1020 years
(n436)
HIV 20 years
(n311)
HIV
duration
HIV vs.
HIV duration
Variable Mean (SD or%) Mean (SD or%) Mean (SD or%) p Mean (SD or%) Mean (SD or%) Mean (SD or%) p p
Age 78.66 (3.43) 78.97 (3.49) 78.44 (3.37) 0.06 78.25 (3) 78.65 (3.7) 78.25 (3.06) 0.99 0.28
Females 124 (22.7%) 61 (27.34%) 61 (19.18%) 0.03 11 (15.9%) 31 (19.8%) 19 (20.43%) 0.74 0.13
BMI 26.22 (4.68) 27.39 (5.12) 25.24 (4.01) B0.01 26.25 (4.18) 24.97 (4.03) 24.93 (3.78) 0.11 B0.01
Current smokers 57 (12.18%) 18 (9%) 39 (14.72%) 0.08 5 (9.09%) 23 (17.97%) 11 (13.41) 0.27 0.09
Hypertension 328 (70.54%) 153 (69.23%) 173 (71.78%) 0.61 41 (70.69%) 88 (73.95%) 44 (68.75%) 0.74 0.81
T2DM 122 (26.87%) 49 (22.27%) 70 (30.3%) 0.07 10 (17.86%) 37 (33.04%) 23 (36.51%) 0.06 0.02
CVD 130 (29.28%) 68 (30.91%) 61 (27.48%) 0.49 17 (31.48%) 25 (23.58%) 19 (30.65%) 0.46 0.54
CKD 83 (23.92%) 11 (10.28%) 72 (30.38%) B0.01 15 (25.42%) 34 (29.57%) 23 (36.51%) 0.40 B0.01
COPD 66 (15%) 45 (20.55%) 20 (9.13%) B0.01 4 (7.69%) 9 (8.49%) 7 (11.48%) 0.75 B0.01
Dyslipidaemia 223 (65.01%) 50 (46.73%) 172 (73.5%) B0.01 28 (49.12%) 97 (84.35%) 47 (75.81%) B0.01 B0.01
Multimorbidity 228 (71.03%) 70 (65.42%) 156 (73.58%) 0.17 32 (62.75%) 77 (75.49%) 47 (79.66%) 0.11 0.09
Polypharmacy 168 (41.18%) 84 (37.67%) 84 (45.65%) 0.13 23 (54.76%) 33 (36.26%) 28 (54.9%) 0.04 0.02
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Materials and methods: This is a retrospective health insurance
claims database analysis, comparing the prevalence of comorbidities
in an HIV cohort (HIV) to a matched cohort from the general
population (non-HIV). Inclusion criteria for HIV cohort were ]1
HIV ICD-10-GM code in 2014, age 21 years at index date and
continuous documentation for the previous 3 years. Index date was
the last available HIV diagnosis code. A control cohort was selected
from a general, non-HIV population, and paired (using a 2:1 control-
to-case ratio) based on age, gender, residence district, health
insurance status and educational level, at index date.
Results: One thousand nine hundred and sixty-nine patients were
included in the HIV cohort and paired with 3938 individuals of the
non-HIV cohort. Mean age was 48 years (SD912.2) and 83.5% were
males. Approximately 21.6% were retired and 49.5% had an educa-
tional level equivalent to technician or master craftsman certificate.
When looking at specific comorbidities over the previous 12 months,
there was a statistically significantly higher prevalence in the HIV
cohort compared with the non-HIV cohort (12.8% vs. 10.4% respec-
tively; p0.0056) of cardiovascular disease (CVD), chronic renal
disease (CKD; 4.3% vs. 2.4%; pB0.001) and osteoporotic bone frac-
tures (OBF; 6.4% vs. 2.1%; pB0.0001). HBVand HCVco-infection were
significantly more prevalent in the HIV cohort (pB0.0001). No
significant differences were found regarding the prevalence of type II
diabetes, dyslipidaemia or alcohol abuse. Hypertension was significantly
more prevalent in the non-HIV cohort (29.3% for HIV vs. 32.6% non-
HIV; p0.0095). Major depressive disorders were doubled in the HIV
cohort (recurrent single episodes) 25.0% (8.4%) versus 12.7% (4.5%).
Conclusions: As PLHIV age, and are treated for longer periods, more
age-related comorbidities develop, some of which have been
associated with ART. This requires a shift in HIV management
including regular monitoring and screening for comorbidities, and
optimal selection of ART. We show this is of particular relevance as
CVD, CKD and OBF are more prevalent in PLHIV versus non-HIV
population. Understanding the nature of these differences may
optimize treatment and improve patient outcomes.
P160
Burden and determinants of frailty in a cohort of
asymptomatic HIV ART-suppressed subjects without known
comorbidities
Serena Vita1; Miriam Lichtner2; Raffaella Rossi1; Irene Pozzetto2;
Cecilia Tosato1; Raffaella Marocco2; Paola Zuccala`1; Claudia Mascia1;
Michela Campagna1; Gabriella d’Ettorre1; Ombretta Turriziani1;
Francesca Falasca1; Camilla Ajassa1; Claudio Maria Mastroianni2 and
Vullo Vincenzo1
1Public Health and Infectious Diseases, Sapienza University, Rome,
Italy. 2Public Health and Infectious Diseases, Sapienza University, Polo
Pontino, Latina, Italy
Introduction: HIV-infected persons are living longer. Survival gains
have been accompanied by an incipient burden of key geriatric
syndromes, such as frailty, which lead to increased hospitalization
and premature death. Frailty is not yet well understood in the
context of patients undergoing cART, without known comorbidities.
We performed a pilot study to tentatively investigate the determi-
nants of frailty in aviraemic, asymptomatic HIV patients.
Materials and methods: We enrolled 80 patients with 1 year of
successful cART. We excluded patients with active organ disease in
the previous 2 years, diabetes mellitus, renal failure, B18 years old
and pregnant women.We collected clinical data and measured frailty
with the SHARE-FI test, degrees of depression with patient health
questionnaire (PHQ)-2 following by PHQ-9 in case of a score 3,
cognitive abilities with the Montreal Cognitive Assessment (MoCA).
Based on frailty phenotype, three groups were constituted: prefrails,
frails and robusts. In these groups plus a group of 20 healthy donors
(HD) we determined the inflammatory background, detecting
Abstract P158Figure 1. Predictors of multimorbidity and polypharmacy.
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plasmatic soluble (s) CD163, sCD14, IL-6 using ELISA tests. HCV, CMV
serology and CMV-DNA-PCR in urine were tested. Non-parametric
tests were used for statistical analysis.
Results: The study population included 41 males and 39 females, with
a median age of 49.5 years, 82.5% Italians, 50% employed, 53.7%
smokers, 78.7% heterosexuals. 12.5% presented a frail and 28.8% a
prefrail phenotype, 32.5% presented a mood variation and 51.2% a
cognitive impairment. The frailty phenotype was associated with male
gender (p0.05), smoker status (pB0.001), HCV serostatus
(p0.03), PI-based therapy (p0.002) and cognitive impairment
(pB0.001); no differences were found in age, CD4 nadir, actual CD4
and year living with HIV, CMV serostatus and CMV-DNA in urine.
Moreover, 100% of frails were affected by mood variation, compared
with 39% of prefrails and 21% of robust (pB0.001). Frails have shown
abnormalities ofMoCA in 33%of frails, in 77%of prefrails and in 27%of
robusts (pB0.0001). Regarding the plasma levels of sCD163 and
sCD14 we observed an increased level compare with HD only in frail
and prefrail subjects (pB0.01 and p0.001, respectively).
Conclusions: Although our study population was asymptomatic and
without known organ diseases, we found a high prevalence of
prefrail and frail patients with cognitive impairment and depression.
Factors associated with frailty were smokers status, HCV co-infection,
depression, cognitive impairment, PI-based therapy and an increased
inflammatory milieu in terms of sCD163 and sCD14. Multivariate
analysis with a larger sample is needed to confirm these results.
P161
Current models of care for the management of HIV patients
with comorbidities in England: a survey
Elaney Youssef1; Vanessa Cooper2; Eileen Nixon2; Jaime Vera3;
Martin Fisher2 and Juliet Wright1
1Medical Education, Brighton and Sussex Medical School, Brighton,
UK. 2HIV Research, Brighton and Sussex University Hospital NHS
Trust, Brighton, UK. 3Global Health & Infectious Disease, Brighton
and Sussex Medical School, Brighton, UK
Introduction: The number of people aged ]50 living with HIV
in the UK is rapidly increasing. Effective treatmentmeans HIV is usually
well controlled; however, there has been an increase in individuals
experiencing comorbid conditions associated with ‘‘normal’’ ageing.
This aim of this study was to find out what models of care are currently
in place for the management of patients with comorbidities.
Materials and methods: A link to an online questionnaire was sent
via the British HIV Association (BHIVA) Audit Committee to one HIV
clinician in each HIV unit in England.
Results: Forty-four units responded. Only 11 units (25%) provided
specialized clinics for the management of comorbidities. These
included: 1) Specialist clinics for the management of a non-infectious
comorbidity (any age) e.g. a liver or renal clinic (n10). These clinics
utilized in-person appointments (n3), or a combination of virtual
and in-person appointments (n7). They were managed by an HIV
clinician and non-HIV clinician together (n8), HIV clinician with an
interest in the specialist area (n4) or specialist with an interest in
HIV (n4). 2) Services for HIV patients with multiple comorbidities
(any age) (n2). 3) Dedicated clinics for older people (n5) with
eligibility determined by age (]50 years) or the presence of a
comorbidity. Additionally, two HIV units employed a GP on site and
two had set up a locally enhanced service providing enhanced
primary care for HIV-positive patients. Six HIV units ran nurse-led
clinics for patients with comorbid conditions. Co-ordination of care
for patients with comorbid conditions was conducted by an HIV
specialist doctor (n27), the patient’s GP (n18), HIV specialist
nurse (n11) or the patient themselves (n9). Eleven clinics
reported using case management for patients with multiple
comorbid conditions. Self-management support (e.g. nurse-led or
as part of an expert patient programme) for patients with comorbid
conditions was provided at 18 HIV units.
Conclusions: Only a quarter of the clinics surveyed had set up clinics
for the management of comorbidities in people living with HIV.While
a variety of different approaches were used, services were usually
focused on the management of one comorbidity, and few provided
services for multiple comorbidities. This is an increasing priority in
the context of an ageing population.
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Introduction: ART has improved life expectancy and significantly
reduced AIDS-related morbidity/mortality. As people living with HIV
(PLHIV) age, prevalence of chronic comorbidities including cardio-
vascular disease (CVD) and chronic kidney disease (CKD) increase.
The aim of this study is to describe the demographics and evolution
of HIV disease markers and comorbidities prevalence in PLHIV in
Greece in 2003 versus 2013.
Materials and methods: Data were derived from AMACS (Athens
Multicenter AIDS Cohort Study), a population-based cohort, that
prospectively collects anonymized epidemiologic, clinical, laboratory
and treatment data for PLHIV in Greece. Two cross-sectional analyses
(2003 and 2013) were performed focusing on patient demographics,
HIV disease markers, ART, comorbidities prevalence, including
CKD, CVD, diabetes, dyslipidaemia and hypertension. CVD risk was
estimated by Framingham 10-year Event Risk calculation (FRS); eGFR
calculation was based on CKD-EPI formula. Comparisons were based
on population average models excluding missing values.
Results: Two thousand four hundred and three PLHIV were identified
in 2003 and 4910 in 2013 (1730 contributing for both cross-sections).
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Table 1 details demographics, disease markers and comorbidities for
both study years. Individuals in 2013 were on average older, and
diagnosed/treated for HIV for longer, compared with those in 2003.
In 2013, PLHIV were also more likely to be on ART (particularly on
triple regimen), virologically suppressed and with a higher median
CD4 count. CKD and dyslipidemia prevalence increased over time.
There was an increase in prescription of lipid-lowering treatment
(3.5% in 2003 vs. 7.7% in 2013, pB0.001), accompanied by an
improvement in LDL, triglycerides and total cholesterol. Among 220
and 879 individuals eligible for FRS calculation, the median score
numerically decreased (9.7% in 2003 vs. 8.2% in 2013, p0.096) but
the proportion of patients in the high-risk group (20%) increased
from 18.2% to 22.2%.
Conclusions: The availability of new ART and the increased treatment
uptake led to significant improvements, within the 2003 to 2013
decade, in the Greek AMACS cohort patients’ immunologic status
and viral suppression rates. PLHIV aged alongside an increase in
prevalence of comorbidities during these 10 years. The proportion of
PLHIV with high FRS increased over time, but the median CVD risk of
the cohort slightly declined, which might be partially attributed to
the effective lipid control measures. The shift in HIV epidemic
paradigm should be addressed with appropriate monitoring and
holistic management of HIV care, in terms of optimal ART selection
and long-term management and prevention of comorbidities.
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Introduction: HIV-infected patients above 65 years of age have
higher prevalence of comorbidities and polypharmacy. The aim of the
study is to describe ARVs’ use in elderly patients living with HIV.
Materials and methods: Cross-sectional study analyzing HIV
patients aged ]65 years, recruited from 11 HIV outpatients clinics
in Italy. Multimorbidity (MM) was classified as the presence of three
or more of non-infectious comorbidities in the same individual,
including cardiovascular disease, chronic kidney disease, dyslipidae-
mia, hypertension, type 2 diabetes mellitus and chronic obstructive
Abstract P162Table 1. Patient demographics, HIV markers and comorbidities in 2003 and 2013
2003 (n2403) 2013 (n4910) p
Mean age, years (SD) 41.1 (10.6) 43.8 (11.4) B0.001
Age ]50 18.2% 26.9% B0.001
Median CD4, count/mL (IQR) 493/mL (299717) 610/mL (425828) B0.001
AIDS diagnosis 16.2% 13.0% B0.001
Median time since diagnosis, years (IQR) 6.0 (2.99.0) 6.7 (2.813.1) B0.001
HIV RNA B50 copies/mL 34.1% 72.4% B0.001
Patients on ART 76.5% 84.4% B0.001
Median time on ART, years (IQR) 3.8 (0.56.4) 4.5 (1.111.0) B0.001
Triple therapy (2 NRTI3rd agent) 63.5% 76.9% B0.001
eGFR B60 mL/min/1.73 m2 2.4% 3.4% 0.006
Overall cardiovascular events (ever) 1.8% 2.1% B0.001
Myocardial infarction (ever) 1.3% 1.7% 0.001
Stroke (ever) 0.3% 0.4% 0.102
Median Framingham risk score (IQR) 9.7% (4.317.0) 8.2% (3.918.1) 0.096
Patients with high (FRS 20%) 10-year CVD risk 18.2% 22.2% 0.002
Dyslipidemia 64.9% 70.3% B0.001
Patients on lipid-lowering treatment 3.5% 7.5% B0.001
Median total cholesterol, mg/dL (IQR) 202 (169239) 189 (161220) B0.001
Median HDL, mg/dL (IQR) 46 (3755) 43 (3653) B0.001
Median LDL, mg/dL (IQR) 122 (97154) 114 (91140) B0.001
Median triglycerides, mg/dL (IQR) 144 (96237) 123 (86183) B0.001
Hypertension 27.0% 27.5% 0.819
Diabetes 6.2% 5.6% 0.028
Percentages calculated after exclusion of missing values. eGFR, estimated glomerular filtration rate; IQR, interquartile range; NRTI, nucleotide
reverse transcriptase inhibitor; SD, standard deviation.
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pulmonary disease. Polypharmacy (PP) was defined as the use of five
or more medications. Patients were stratified according to the
duration of HIV infection (20, 1020 and B10 years). Separate
multivariate logistic regression were built to identify predictors of
‘‘not conventional’’ ARV strategies, including unboosted PI, mono/
dual, NRTI-spearing and TDF-free.
Results: We enrolled 1297 HIV-positive patients: 83.35% males;
12.47% HCV co-infected, 9.6% HBV co-infected; mean age 71.4 years
(4.91 SD); mean HIV duration 16.83 years (7.6 SD); mean CD4 nadir
220.28 cells/mm3 (177.38 SD); mean current CD4 count 641.96 cells/
mm3; mean CD4/CD8 ratio 0.98 (1.43 SD); 94.3% out of patients had
HIV RNA B40 copies/mL. HIV duration was 280 (21.94%) less than 10
years, 592 (46.39%) between 10 and 20 years, and 404 (31.66%) more
than 20 years. ARV prescription: 66.3% triple therapy (third drug:
45.76% NNRTI, 28.35% PI, 15.53% INSTI, 1.41% NRTI, 8.94% other),
while 1.64% took more than three drugs. Prevalence of not conven-
tional ARV strategies was: 25.98% dual therapy, 6.08% PI monother-
apy, NRTI-sparing regimen 56.9%, unboosted PI 22.61%, TDF-free
70.2%. Total multimorbidity frequency was 49.17%, whereas poly-
pharmacy frequency was 37.89%. Figure 1 shows multivariate logistic
regression for use of not conventional ARV strategies. The presence of
MM, PP and male gender were predictive for mono/dual and NRTI-
sparing regimens. Furthermore, PP was significantly associated with
TDF-sparing regimens.
Conclusions: Geriatric HIV patients have high prevalence of multi-
morbidity and polypharmacy. A significant proportion of these patients
are treated with non-conventional ARV regimens: the selection of ARVs
seems to be driven by several factors including MM and PP.
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Introduction: Currently, about 50% of HIV-infected persons in high-
income countries are older than 50, with increased risk of developing
age-related diseases [1]. CD4/CD8 ratio inversion has been asso-
ciated with non-communicable diseases and frailty phenotype [2,3].
The study objective was to describe associations between CD4/CD8
ratio and meaningful endpoints of ageing with HIV (multimorbidity,
frailty and disability).
Material and methods: Cross-sectional study. Inclusion criteria: HIV-
infected adults, effective antiretroviral treatment (HIV VL B40
copies/mL), access in the Modena HIV Metabolic Clinic within
2008 and 2016. CD4/CD8 ratio cutoff was set at 0.8, multimorbidity
(MM) was defined as presence of 2 comorbidities among:
cardiovascular events (CVD), chronic kidney disease, hypertension
(HTN), chronic obstructive pulmonary disease (COPD), cancer and
diabetes mellitus (DM). Frailty was defined as frailty index 0.31 [4].
Disability was defined as presence of ]1 deficit at IADL questionnaire
or SPPB score B9 or falls within the last year. Statistical considerations:
after descriptive analysis according to CD4/CD8 ratio, univariate and
multivariable logistic regression models adjusted for sex and age were
created to assess relation between CD4/CD8 ratio and MM, frailty and
disability.
Results: 2945 patients were included. Table 1 shows descriptive
analysis. Figure 1 depicts logistic regression models to assess CD4/
CD8 association with study outcomes: a protective role of CD4/CD8
ratio was confirmed regarding CVD (OR 0.69, 95% CI 0.450.94,
p0.038), MM (OR 0.60, 95% CI 0.410.88, p0.009) and frailty
(OR 0.65, 95% CI 0.550.77, pB0.001). Other factors with positive
Abstract P163Figure 1. Multivariate logistic regression for four not conventional ARV therapy.
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association were male sex and age. No association was found
between CD4/CD8 ratio and disability. At further logistic regression
models, higher CD4 cells nadir was positively associated with high
CD4/CD8 ratio, while male sex, MM and frailty had a negative
significant association.
Conclusion: Age-related health outcomes result from concomitant
processes of ageing, inflammation, HIV infection, comorbidities and
lifestyle. We found independent associations between routinely
performed markers of immune reconstitution and important clinical
features of ageing HIV-infected patients: low CD4/CD8 ratio was
associated with comorbidities alone or aggregated in MM and frailty.
This is a novelty presented by our study: previous studies found
associations with isolated comorbidities and frailty phenotype. It also
confirmed the reverse association between MM, frailty and low
Abstract P164Table 1. Anthropometrical and clinical characteristics of patients
Characteristics
CD4/CD8 ratio B0.8 - N (%) or median
(IQR)
CD4/CD8 ratio 0.8 - N (%) or median
(IQR) p
Total number of patients 1470 (49) 1475 (51)
Female sex 391 (27) 550 (37) B0.001
Age 49 (4554) 50 (4554) 0.900
Smokers 775 (53) 854 (58) 0.004
Packyear (if smoker) 20.8 (1032) 17.9 (9.330) 0.004
No physical activity 717 (51) 665 (48) 0.051
Intense alcohol intake (3/week) 14 (0.9) 16 (1.1) 0.923
BMI 23.8 (2126) 23.3 (2125.7) 0.001
HIV duration (months) 241 (158299) 239 (156299) 0.427
Risk factor for HIV B0.001
Intravenous drug users 409 (28) 357 (24)
Men who have sex with men 453 (31) 407 (27.5)
Heterosexual 431 (29) 557 (37.8)
Other 177 (12) 154 (10)
CDC C stage 375 (25.5) 305 (20.7) 0.005
Age at ARV initiation 36 (3143) 34 (3142) 0.005
ARV initiation period 0.106
B1996 437 (30.4) 397 (27.4)
19962005 637 (44) 696 (48)
]2006 363 (25) 358 (24.7)
CD4 cells nadir cells/mm3 163 (60260) 221 (109330) B0.001
CD8/CD38 cells count cells/mm3 84 (51152) 58.5 (3894) B0.001
LDL cholesterol mg/dL 113 (3757) 112 (92136) 0.791
HDL cholesterol mg/dL 45 (3557) 51 (4162) B0.001
Total cholesterol mg/dL 188 (161226) 189 (165217) 0.352
Glucose 94 (86103) 93 (87102) 0.451
GOT 24 (2034) 22 (1931) B0.001
HOMA index 2 (1.23) 1.7 (1.12.8) B0.001
C reactive protein 0.2 (0.130.3) 0.2 (0.180.22) 0.262
Cardiovascular disease 100 (6.8) 63 (4.3) 0.003
Hypertension 563 (38) 509 (34.5) 0.033
Diabetes mellitus 231 (15.7) 193 (13.1) 0.042
Chronic kidney disease 148 (10.1) 145 (9.8) 0.830
Cancer 39 (3.9) 36 (2.4) 0.026
Chronic obstructive pulmonary
disease
57 (3.9) 36 (2.44) 0.026
Multimorbidity 90 (6.1) 55 (3.7) 0.003
Frailty (2643 patients) 722 (54.8) 577 (43.5) B0.001
IADL deficit (830 patients) 94 (25.3) 118 (25.7) 0.903
SPPB B9 (459 patients) 13 (6.28) 15 (5.95) 0.884
FALLS (665 patients) 57 (19.6) 76 (20.3) 0.815
Comorbidities (CVD, HTN, DM and COPD), MM and frailty prevalence were significantly higher in the low CD4/CD8 ratio group. No differences
were found in disability items prevalence.
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CD4/CD8 ratio. Further studies could be important to integrate
clinical geriatric syndromes and immunologic elements in the ageing
HIV-infected population.
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Introduction: Success of ART has changed the distribution of causes
of death among HIV-positive patients and new causes of death have
emerged, such as liver-related or non-AIDS-defining malignancies
(NADM). We describe and compare the mortality rates and excess
mortality rates according to age in HIV-positive persons in the Cohort
of the Spanish AIDS Research Network (CoRIS) from 2004 till 2014.
Methods: CoRIS is a multicentre, open, prospective cohort of
HIV-infected patients naı¨ve to ART at entry. We calculated: mortality
rates (per 1000 py) for overall and cause-specific death comparing aged
B/]50 years and excess mortality rates (per 1000 py) comparing
overall and cause-specificmortalitywith that of the general population
of similar age and sex. Agewasmodelled as a time-dependent variable.
Death was classified by modified CoDE procedures [1].
Results: Overall, 347 deaths were recorded in 9569 (34,385 py of
follow-up) persons, leading to a mortality rate of 10.09 per 1000 py
(95% CI 9.0811.21). The proportion of total py aged ]50 years
increased from 8.8 to 21.2%, from 2004 to 2014. The mortality rate
ratio was 2.70 (95% CI 2.153.38) higher for patients aged ]50.
Forty-three percent of the total deaths were attributable to AIDS,
followed by 14% due to NADM, 9% liver-related, 7% other infectious
diseases, 3% cardiovascular and 12% for other causes and unknown.
For cause-specific deaths, the mortality rate was 4.33 (3.695.09) for
AIDS-related, 1.40 (1.051.85) for NADM, 0.93 (0.661.32) for liver-
related, 0.67 (0.441.01) for other infectious diseases and 0.26 (0.14
0.50) for cardiovascular. Mortality rate ratio was higher for patients
]50 years for all causes and for cause-specific death. The overall
excess mortality rate was 8.81 (per 1000 py) (95% CI 7.879.87), being
7.37 (6.448.44) for subjects B50 years and 16.65 (13.5120.53) for
]50 years. For NADM, excess mortality rate was 0.46 (0.270.79) for
B50 years and 2.79 (1.674.65) for ]50 years. For liver-related, it
was 0.84 (0.561.25) for B50 years and 1.13 (0.502.52) for ]50
years. And finally, for other infectious diseases, it was 0.64 (0.430.98)
for B50 years and 0.54 (0.330.89) for ]50 years.
Conclusion: High overall mortality rate and excess mortality rate
were observed in HIV-positive subjects, especially among older
patients. By cause-specific, higher NADM mortality and excess
mortality was observed in patients aged ]50. However no
significant differences by age were detected by liver diseases,
although it represents an important cause of death in these patients.
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Abstract P164Figure 1. Logistic regressions for age-related health outcomes.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
128
Hospital Clinico de San Carlos, Madrid, Spain. 14Infectious Diseases,
Hospital de Basurto, Bilbao, Spain. 15AM-VACH, AM-VACH, Cartaya,
Spain
Introduction: In 2012, in Central and Western Europe, it was
estimated that 33% of HIV patients were 50 years old or older. This
will bring new challenges in the management of HIV population:
patients are living longer and chronologically ageing; HIV itself has
been associated with accelerated ageing and development of
comorbidities; certain antiretrovirals are associated with age-related,
organ-specific toxicities. Therefore, it is important to characterize the
evolution of the prevalence of risk factors and comorbidities to inform
management of HIV care in general, and choice of ART in particular.
Methods: The VACH cohort is a multicentre Spanish cohort. To be
included in the cohort, a patient is required to have confirmed HIV
infection, age over 16, and 1 follow-up visit in the cohort’s
hospitals. All patients receiving ART with at least one visit in 2010
and at least one visit in 2014 were included in this analysis. Two
cross-sectional analyses (2010 and 2014) were conducted on this set
of patients. Analyzed outcomes included prevalence of: 1) comor-
bidities: a) cardiovascular events, b) renal impairment, c) bone
fractures (any location); 2) risk factors: a) hypertension, b) dyslipi-
demia, c) diabetes, d) secondary osteoporosis, e) alcohol abuse
(exceeding 3 units/day (42g/day)). Descriptive analysis consisted of
number of patients/events and its respective percentage over the
available information (missing data were not considered).
Results: Nine thousand nine hundred and sixty patients met the
inclusion criteria and were included in the analysis. Forty-three
percent of patients were at least 50 years old in 2014. 73.3% were
male and 39% were ever-intravenous drug users. Among ART-
experienced, the proportion of patients virologically suppressed
increased by 7% and the proportion with CD4 cells count 500
cells/mm3 increased by 8% from 2010 to 2014. Figure 1 shows the
changes in the prevalence of comorbidities and risk factors between
2010 and 2014.
Conclusions: The proportion of patients older than 50 in the VACH
cohort has increased significantly, as it has happened with the
prevalences of age-related comorbidities in recent years.
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Introduction: In most of Western Europe, HIV is considered a chronic
disease associated with reasonable life expectancy. Eleven AIDS
reference centers and seven reference laboratories have been
established across Belgium to handle HIV diagnosis, care and patient
tracking. Although Belgium is at the forefront of HIV care, to date,
country-wide analysis of data collected at those centers has not been
conducted. The purpose of this analysis is to 1) provide an
epidemiologic ‘‘snapshot’’ of the HIV-positive population in Belgium,
and 2) determine the prevalence of key non-infectious comorbidities
(NICMs) that may affect the quality and length of HIV-positive
individuals’ lives.
Materials and methods: Data were analyzed from four of the largest
reference centres in Belgium (St Pierre University Hospital, University
of Liege  Sart Tilman, University of Ghent Hospital and Erasme
Hospital). In total, 5787 patients met the inclusion criteria of
receiving follow-up care at least once between 1 June 2014 and 1
July 2016.
Results: Out of 5787 follow-up cases in these four centers in 2014 to
2016, 95% have initiated treatment. The mean age of patients under
follow-up was 46.6. The prevalence rates of diabetes mellitus,
Abstract P166Figure 1. Changes in the prevalence of cardivascular, renal and bone comorbidities and related risk factors between 2010
and 2014 in the VACH cohort.
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viraemic hepatitis C and renal disease were 5.9%, 3.1% and 7.7%,
respectively. Cardiovascular disease, defined as the occurrence of
myocardial infarction, stroke or an invasive coronary procedure,
occurred in 3.3% of the patients. The combined prevalence of non-
AIDS-defining cancers (defined as anal cancer, liver cancer, Hodgkin’s
lymphoma and lung cancer) was 0.8% among the cohort population.
Specific risk factors were also relatively common among patients:
38% were former or current cigarette smokers and one-third had
been diagnosed with hypertension.
Conclusions: NICMs in the HIV-positive population such as cardiovas-
cular disease and renal disease are of increasing importance as AIDS-
related deaths are delayed through careful patient management. A
country-wide analysis of available data, including data on the
prevalence of common NICMs, is critical to planning for the healthcare
needs of the ageing HIV-positive population in Belgium.
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Introduction: The proportion of new HIV diagnoses in later life is
increasing. Older adults have clinical features that difference them
from younger individuals, constituting a vulnerable population.
However, data describing the steps of the care continuum for this
age group are scarce.
Materials and methods: We conducted a retrospective analysis
including all older adults (]50 years) with a new HIV diagnosis over
a 13-year period in a large public hospital in Buenos Aires. We
calculated the proportion of patients presenting with advanced stage
HIV disease (WHO clinical stage IV or CD4 cell count B200 cells/mL),
the proportion of patients who were linked and retained in care,
initiated ART according to the WHO recommendations for each year
analyzed and were virally suppressed. We also determined the
factors associated with loss to follow-up (LTFU) in this age group
using multivariate logistic regression.
Results: From January 2002 to December 2014, 1239 patients were
tested positive for HIV, of whom 218 (17.5%) were older adults. Fifty-
three percent of these individuals had advanced HIV disease and 32%
were hospitalized at diagnosis. Most patients (93.1%) were linked to
care, 11 patients (5%) died before 1 year of follow-up (all of them
because of AIDS-related events) and 65.5% were retained into care.
Of the 123 patients who started ART, 94 (76.4%) achieved viral
suppression. 30.4% of patients were LTFU. The odds of being LTFU
were higher for MSM (OR 2.65 (IQR 1.215.77)) than for heterosexual
patients. Conversely, those who were diagnosed at AIDS events (OR
0.39 (IQR 0.200.76)) and patients on antiretroviral therapy (OR 0.21
(IQR 0.060.72)) were less likely to be LTFU. Age, gender and
educational level were not associated with LTFU in this cohort.
Conclusions: This study highlights the need for newer strategies
aimed to timely diagnosis in older adults and to develop interven-
tions to prevent LTFU focused on this age group.
CO-MORBIDITIES AND COMPLICATIONS
OF DISEASE AND/OR TREATMENT: BONE
P169
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Objectives: Trabecular bone score (TBS) is a novel, non-invasive
measure of bone microarchitecture that can detect differences in
bone quality in individuals with similar bone mineral density (BMD).
We have previously shown that lower TBS in HIV-positive subjects is
influenced by the high-smoking rates in this population. We now aim
to investigate HIV-specific factors associated with TBS.
Methods: BMD was measured by dual X-ray absorptiometry (DXA) in
HIV-positive subjects from the HIV UPBEAT study; TBS was derived
from baseline lumbar spine (LS) DXA images using TBS Insight
software (version 2.2.1). Significant between-group differences were
assessed using Wilcoxon tests. Univariate linear regression explored
the impact of HIV-specific factors including: nadir CD4, current CD4
and CD8 T-cell counts, HIV RNA B40 copies, time from HIV diagnosis
and being on ART, on TBS; factors associated with a lower TBS in
these models were added to a multivariable model adjusted for LS
BMD, demographics, body mass index (BMI) and current smoking.
Results: The 201 HIV-positive subjects (40% male, 39% African,
median (inter-quartile range (IQR)) age 39 (3346) years) had HIV
diagnosed for a median (IQR) of 4.5 (28) years, a median nadir CD4
of 311 (108306) cells/mm3, exposure to ART, protease inhibitors
(PI) and tenofovir disproxil fumarate (TDF) was 2.7 (0.55), 0.3 (02.4)
and 1.3 (03) years, respectively. ART-naı¨ve patients had higher TBS
than those on ART (1.438 (1.306, 1.481) vs. 1.343 (1.258, 1.421),
p0.005). While TDF exposure was not significantly associated with
TBS (1.347 (1.270, 1.422) vs. 1.380 (1.265, 1.471), p0.314), those
exposed to PIs had lower TBS (1.323 (1.248, 1.382)) compared with
no PI exposure (1.386 (1.289, 1.452), p0.005). In unadjusted
analysis lower TBS was associated with duration of diagnosed HIV,
intravenous drug use, nadir CD4, being on ART (specifically PIs) and
cumulative PI exposure (all pB0.05). HIV viraemia was not
significantly associated with TBS (0.008 (0.031, 0.048), p0.69).
In adjusted analyses, smoking status, nadir CD4 and receipt of PI-
containing ART were independent predictors of lower TBS (Table 1).
Conclusion: While smoking remains an independent predictor of TBS
in HIV-positive subjects, our results, although derived from an
observational study and therefore limited in determining causality,
highlight the potential impact of ART on bone quality with PIs, but
not TDF, being significantly associated with lower TBS. Baseline
Table 1. Results from multivariable linear regression analysisa
of associations between smoking status, nadir CD4 count and
receipt of PI therapy with TBS
Variable
Effect on
TBS
95% confidence
intervals p
Current smoker 0.047 0.085, 0.008 0.01
Nadir CD4 T-cell count (per
50 cells/mm3 higher)
0.005 0.003, 0.011 0.04
PI-containing ART 0.045 0.079, 0.011 0.009
aModel also adjusted for LS BMD, age, gender, ethnicity and BMI.
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immune status was also an independent predictor of TBS suggesting
a possible effect of immune activation on bone quality. Further
studies should focus on the clinical utility of TBS to monitor bone
quality and in fracture risk prediction in HIV-positive persons.
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Introduction: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
is a mainstay backbone in ART for treatment-naı¨ve patients.
Although potent and well tolerated, TDF may cause bone toxicity.
The magnitude of off-target side effects is proposed to be related to
tenofovir (TFV) plasma concentrations, which may be affected by
drugfood and drugdrug interactions with concomitant antiretro-
virals. We compared bone outcomes (osteoporosis and osteoporotic
fractures) with efavirenz (EFV)TDF/FTC versus non-EFV-based TDF/
FTC regimens associated with higher TFV plasma concentrations in
treatment-naı¨ve HIV-infected veterans.
Methods: This historical cohort study used national Veterans Health
Administration (VHA) datasets to identify veterans newly initiating
ART in 2003 to 2015. We controlled for selection bias and
confounding with inverse-probability treatment weighting. Covari-
ates included baseline demographics, clinical characteristics, HIV
laboratory measures, bone measures and other key diagnoses/
medication exposures. We used weighted regression models to
compare rates of bone adverse events between new users of TDF/
FTC with EFV compared to TDF/FTC with non-EFV regimens (i.e.
rilpivirine (RPV), elvitegravir/cobicistat (EVG/c) and boosted protease
inhibitors (PIs)).
Results: Of 33,048 HIV veterans, 13,366 received an ART regimen of
interest, and 7236were treatment naı¨ve (4178 EFVand 3058 non-EFV).
The median age was 51, 96% were male, and 59% and 30% were Black
and Caucasian, respectively. Standardized differences between groups
were less than 0.1 for all baseline characteristics following weighting,
indicating no significant differences between groups. Crude rates of
bone outcomes and adjusted hazard ratios (aHRs) for comparisons
with at least five events per treatment group are summarized in Table
1 and Table 2. Unadjusted rates of osteoporosis and osteoporotic
fractures were lower in patients who received EFVTDF/FTC versus
each other treatment group. In adjusted analyses, risks were
significantly lower for vertebral, upper arm and wrist/forearm
fractures for EFV versus all non-EFV regimens combined and versus
PIs. For EFV versus EVG/c and RPV, too few events were observed to
make stable estimates for the individual outcomes, and no significant
differences were observed for the composite bone outcome.
Conclusions: EFVTDF/FTC was associated with a significantly lower
risk for bone toxicity and fractures compared to other TDF-containing
regimens in the VHA. The third agent in ART regimens can have a
significant effect on the risk of bone adverse events associated with
TDF.
P171
Prevalence and risk factors of vertebral fractures in patients
on antiretroviral treatment
Abstract P170Table 1. Crude incidence of bone adverse events by treatment group (per 1000 PY)
Outcomes EFV (n4178) All non-EFV (n3059) EVG/c (n234) RPV (n173) PI (n2651)
Any bone outcome 28.4 37.4 49.8 36.0 36.7
Osteoporosis 8.7 12.0 20.6 14.1 11.4
Any osteoporotic fracture 9.9 18.5 13.6 28.6 18.1
Vertebral fracture 2.1 4.2 6.8 7.1 3.9
Hip fracture 3.7 3.1 0.0 14.0 2.6
Upper arm fracture 1.4 3.5 0.0 0.0 3.9
Wrist/forearm fracture 3.3 8.2 6.8 7.1 8.3
Abstract P170Table 2. Risk of bone adverse events by treatment group
Outcomes EFV vs. non-EFV: aHR (95% CI) EFV vs. EVG/c: aHR (95% CI) EFV vs. RPV: aHR (95% CI) EFV vs. PI: aHR (95% CI)
Any bone outcome 0.78 (0.650.94) 0.94 (0.701.25) 0.85 (0.661.08) 0.78 (0.650.94)
Osteoporosis 0.75 (0.551.04)   0.77 (0.551.07)
Any osteoporotic fracture 0.57 (0.430.76)   0.57 (0.430.77)
Vertebral fracture 0.45 (0.250.81)   0.47 (0.260.85)
Hip fracture 1.24 (0.692.21)   1.50 (0.802.83)
Upper arm fracture 0.48 (0.230.98)   0.43 (0.210.88)
Wrist/forearm fracture 0.47 (0.290.75)   0.45 (0.280.72)
, Fewer than five events.
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Introduction: Low bone mineral density (BMD) and fragility fractures
are common in patients infected with HIV and antiretrovirals use. In
low- and middle-income countries, we don’t have DEXA scan to
evaluate osteopenia or osteoporosis in HIV-infected patients. The aim
of this study was to determine the prevalence and associated risk
factors for vertebral fractures in HIV-infected patients in a tertiary
care hospital in Mexico.
Materials and methods: We conducted a cross-sectional study from
August 2014 to February 2015 at the Hospital de Infectologı´a, ‘‘La
Raza’’ National Medical Center. Outpatients 40 years who were
receiving ART and attending at the clinic were included. Vertebral
deformities were detected with lateral spine X-ray using a semi-
quantitative morphometric analysis of centrally digitized images:
anterior, middle and posterior vertebral heights were measured, and
height ratios were calculated. Each vertebral body fractures were
defined as mild, moderate and severe on basis of height ratio
decreases of 20 to 25%, 26 to 40% and 40%, respectively. The
‘‘spine deformity index’’ (SDI) was calculated by summing the grade
of vertebral deformities, according to the semiquantitative method
by Genant [1,2]: SDI 1 is indicative of vertebral fracture according
to its definition.
Results: We included 104 patients, 87% were men. Median age was
49 years old (IQR 42.052.75). The most common centers for disease
control (CDC) stage was B2 in 40.56 (39%), 47 (45%) had or have had
protease inhibitors (PIs) in regimen and 100 (96%) had or were under
treatment with nucleosides antiretroviral transcriptase inhibitors.
The median years on ART was 6.5 (1.69.0). At the moment of the
study, 83 (80%) had undetectable HIV-1 RNA viral load, 32 (31%) had
a previous fracture, 4 (4%) had hepatitis C virus (HCV) co-infection,
and 57 (55%) had a history of corticosteroids treatment. The
prevalence of vertebral fractures was 25% (95% CI 1734%). Risk
factors associated to fractures were: female gender OR 0.50 (95% CI
0.102.45), p0.39; HCV co-infection OR 3.1 (95% CI 0.4223.7),
p0.23; previous corticosteroids use OR 0.51 (95% CI 0.201.25),
p0.13; AIDS OR 0.53 (95% CI 0.211.34), p0.18; HIV-1 RNA viral
load 100,000 copies/mL OR 1.64 (95% CI 0.299.12), p0.56; and
current or previous PIs OR 0.85 (95% CI 0.342.09), p0.73.
Conclusions: The prevalence of vertebral fractures was high among
HIV-infected patients. A screening for bone disease should be done
in patients at risk of fragility fractures. Spine X-ray may be considered
in patients at increased risk, irrespective of BMD; that is, in elderly
patients majorly in low- and middle-income countries.
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Introduction: Guidelines for bone disease in HIV recommend a
screening/risk evaluation process guided by age and classical risk
factors, followed by implementation of bone mineral density (BMD)
and/or FRAX algorithm accordingly [13]. Risk-mitigating interven-
tions should take into account country-specific risk thresholds [2].
This study assessed the fracture risk in a cohort of HIV individuals
and described factors associated with increased fracture risk.
Materials and methods: Cross-sectional fracture risk evaluation was
performed by BMD (osteoporosis vs. osteopenia/normal values [3])
and by Greece-specific FRAX algorithm for those ]40 years [4]
through three sequential steps: (A) HIV not added, (B) HIV
added as a ‘‘secondary cause’’ and (C)(B)inclusion of femoral
neck T-score value. Greece-specific FRAX intervention thresholds
were used (major osteoporotic fracture and hip fracture risk ]10%
and ]2.5%, respectively for those ]40 and B75 years) [4].
Analysis was performed for factors associated with increased fracture
risk (defined as osteoporosis, prevalent fragility fractures and/or
FRAX score).
Results: Hundred and forty-three PLWH with available BMD were
included: age 45 years, female 26%, stage C 10.5%, BMI 25.5 kg/m2,
HIV duration 5.4 years, CD4 current/nadir 604/285 cells/mL, 117 on
ART, ART duration 5.1 years, VL B50 copies/mL 74%, estimated
Glomerular Filtration Rate calculated by CKD-EPI formula (Chronic
Kidney Disease Epidemiology Collaboration formula) (eGFR-CKD-EPI)
102.7 mL/min/1.73 m2 (median values where applicable). Osteo-
porosis and osteopenia were diagnosed in 11.9% and 43.4%,
respectively. Osteoporosis was associated with ART exposure (naı¨ve
Abstract P172Table 1. Median 10-year FRAX calculated fracture probability (A) excluding or (B) including HIV infection as a
secondary cause of osteoporosis or (C) including HIV infection plus the available femoral neck T-score
10-year FRAX-calculated
fracture probability
(A) Median
(IQR 13)
(B) Median
(IQR 13)
(C) Median
(IQR 13)
Hip fracture 0.2% (0.10.7) 0.3% (0.11.1) 0.4% (0.11.42) A vs. B, pB0.001, A vs. C, pB0.001, B vs. C, p0.073
Major osteoporotic fracture 1.9% (1.43.6) 2.6% (1.94.9) 2.5% (2.54.5) A vs. B, pB0.001, A vs. C, pB0.001, B vs. C, p0.064
Above intervention thresholds 3/98 (3.1%) 8/98 (8.2%) 14/98 (14.3%) p for trend 0.007
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0/26 vs. 17/117, p0.042) and CD4 nadir (182 vs. 301, p0.05)
(age and years of HIV adjusted). Median FRAX fracture risks for the
98 aged ]40 years are shown in Table 1.
Increased FRAX score (C) was associated with age (63 vs. 50 years,
p0.002) and eGFR (91 vs. 99 mL/min, p0.031). For those 40 to
49 years, FRAX calculation without BMD missed all four cases for
intervention (4/44, 9.1%). For those ]50 years, BMD measurement
identified nine osteoporotic individuals and FRAX with BMD another
nine at risk (in total 18/54, 33.3%). Treatment for osteoporosis
should have been considered in 22/98 ]40 years (22.5%) (age ]50
years, p0.009 and menopause, p0.015).
Conclusions: HIV infection increases significantly the calculated
fracture risk. About 22.5% of PLWH ]40 years were at increased
fracture risk independently of ART and labs. If BMD was not
available, 13/22 (59%) cases for intervention would have been
missed. A combined approach of FRAX with BMD values for everyone
]40 years (vs. ]50 years [2]) seems plausible for increasing the
yield of fracture risk identification and allowing appropriate inter-
vention strategies.
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Introduction: Migrants and refugees from countries with a high
incidence of HIV and other co-infections such as hepatitis C virus
(HCV) and/or hepatitis B virus represent an emerging challenge for
the healthcare system. We used dual-energy X-ray absorptiometry
(DEXA) to detect osteoporosis (OP) in HIV/HCV co-infected and HIV
mono-infected groups in order to determine OP prevalence by age,
gender and geographic origin.
Materials and methods: We conducted a cross-sectional study on
211 HIV mono-infected and 81 HIV/HCV co-infected patients
attending the AIDS Centre of the Infectious Diseases Department
of Palermo University Hospital, Italy, between January 2010 and May
2015. All patients underwent a DEXA scan.
Results: HIV mono-infection was prevalent among non-Europen
Union (nEU) women. HIV/HCV co-infection was higher in nEU males
than females. Comparing the groups split according to age, it turned
out that there was a significant difference among them with respect
to HIV in nEU and European Union (EU) patients (pB0.000). These
differences, identified by residual analysis, were greater in nEU
patients aged between 28 and 47. Stratifying by age, prevalence of
OP was significantly higher in patients ]49 years with HIV/HCV co-
infection. OP prevalence was higher among HIV/HCV co-infected EU
and nEU female patients than among those with HIV mono-infection
(p0.011). Comparing the groups split according to age and
geographical origin, we found that there was a significant difference
among them with respect to HIV/HCV and OP in nEU and EU patients
(respectively, p0.017 and pB0.000). These differences, identified
by residual analysis, showed a higher prevalence of OP among nEU
patients aged 28 to 47 years (pB0.000).
Conclusions: Our study provides evidence for the usefulness of early
screening for OP in HIV/HCV co-infected patients, especially in nEU
women. Significant and sustained improvements in mortality and
morbidity, and control of the current HCV epidemic in HIV-infected
subgroups such as migrants could then become a feasible goal.
CO-MORBIDITIES AND COMPLICATIONS
OF DISEASE AND/OR TREATMENT:
CARDIOVASCULAR
P174
Cardiovascular events  a thing of the past? A real-life
assessment in an inner-city Toronto clinic
Fred Crouzat1; Brenda Varriano2; Ina Sandler3; Graham Smith1;
Samantha Steinberg4; Colin Kovacs1; David Fletcher1; David Knox1;
Barry Merkley1; Benny Chang1; David Tilley1; Megan Ascai1;
Malika Sharma1 and Mona Loutfy1
1Infectious Disease, Maple Leaf Medical Clinic, Toronto, Canada.
2Institute of Medical Sciences, University of Toronto, Toronto,
Canada. 3Maple Leaf Medical Clinic, Toronto, Canada. 4Faculty of
Science, University of Guelph, Guelph, Canada
Introduction: Following co-morbid cardiovascular events (CVE)
amongst HIV-positive patients is essential. Abacavir’s impact on
CVE is unclear and challenges clinicians. We characterized CVE at the
largest Canadian HIV clinic stratified three-fold: 1) patients being
antiretroviral-naı¨ve or -experienced; 2) taking abacavir or tenofovir-
disoproxil-fumerate (TDF) or switching between the two and 3) time-
era (before and after 2009).
Materials and methods: This is a retrospective study using electronic
medical records (EMRs) of all HIV-positive patients treated at Maple
Leaf Medical Clinic, who started a combination ART (cART) regimen
(3 to 7 drugs) with abacavir or TDF (one-switch between the two
permitted). Patients were excluded if a pre-cART CVE or a second-
switch between abacavir and TDF occurred. Patients were assessed
as those starting cART (antiretroviral-naı¨ve) and overall (antiretrovir-
al-naı¨ve and  experienced). The outcome was CVE (cardiovascular
(CAE) or cerebralvascular (CEE)). There were four exposures-of-
interest: always-abacavir-, always-TDF-, first-abacavir-switched-to-
TDF- and first-TDF-switched-to-abacavir cART regimens. The analysis
was stratified into being on cART: (1) before or (2) after 1 January
2009. Evaluation started at cART-initiation and ended at: CVE date,
second switch between abacavir and TDF or last data-cut date (16
July 2015). Descriptive statistics and bivariate analyses were done
using standard statistical methods. Multivariable Cox regression was
carried out with time-to-CVE as the outcome and time-on-abacavir
or -TDF as the exposure-of-interest. Confounders corrected for
included: Framingham-score and time-on-PI.
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Results: Of 2851 patients, 1439 were antiretroviral-naı¨ve. Of the
total, median age40 (IQR3446), 92% male, 65% Caucasian,
median HIV duration5.2 years (IQR1.510.6), baseline
log10VL4.02 (IQR1.704.91) and CD4-count330cells/uL
(IQR210500); 658-on-an-abacavir-regimen, 1186-on-a-TDF-regimen,
736 switched from abacavir-to-TDF and 271-switched-from-
TDF-to-abacavir. Seventy-six CVE occurred [15-in antiretroviral-naı¨ve
and 61-in antiretroviral-experienced (pB0.0001)]. 61/76 of the
events were CAE and 15/76 were CEE (pB0.0001). 69/76 CVE
were before 2009 and 8/76 after (pB0.0001). 40/76 CVE were on-
abacavir, 15/76 on-TDF, 19/76-switched from abacavir to TDF and 2/
76-switched from TDF to abacavir (pB0.0001). 21/21 switches
occurred prior to 2009 and 38/40 on-abacavir remained on it after
2009. The multivariable Cox regression revealed that Framingham
score and time-on-a-PI increased the CVE risk [aHR1.10-per-1-
point (95%CI1.041.18) and aHR1.11-per-year (95%CI0.94
1.31), respectively]; time-on-abacavir (aHR0.17-per-year (95%CI
0.090.34) and time-on-TDF (aHR0.13-per-year (95%CI0.06
0.25), both decreased the chance of a CVE.
Conclusions: 91% CVE occurred before 2009 and 80% in antiretrovir-
al-experienced patients. Abacavir was associated with CVE before
2009 and in our overall-population and in univariate but not
multivariable analyses. Our multivariable model showed that the
Framingham score predicted CVE but the longer duration on TDF or
abacavir decreased CVE risk. Abacavir’s impact on CVE is still unclear
but this analysis is helpful to understand CVE in our clinic.
P175
Risk of cardiovascular disease events with atazanavir-based
antiretroviral treatment regimens among HIV-infected
veterans: a US national study
Joanne LaFleur1; Adam Bress2; Lisa Rosenblatt3; Jacob Crook4;
Paul Sax5; Joel Myers6 and Corey Ritchings6
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Outcomes Research, Bristol-Myers Squibb, Princeton, NJ, USA.
4Division of Epidemiology, University of Utah and Salt Lake City VA
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Introduction: Cardiovascular disease (CVD) is a leading cause of
death in HIV-infected patients. Atazanavir (ATV) has been associated
with slower progression of atherosclerosis in several studies, but
there is limited information on the relative impact of ATV on the risk
of CVD events compared to other regimens. We examined CVD
events with ATV-based regimens versus those based on other
protease inhibitors (PIs), non-nucleoside reverse transcriptase in-
hibitors (NNRTIs) and integrase inhibitors (INSTIs) in treatment-naı¨ve
HIV-infected veterans.
Methods: This historical cohort study used national United States
Veterans Health Administration (VHA) datasets to identify HIV
veterans newly initiating ART in 2003 to 2015. We controlled for
selection bias and confounding by indication with inverse probability
of treatment weights. Covariates included baseline demographics,
HIV laboratory measures, comorbidities and key concomitant
medications. We used Cox proportional hazards regression models
to calculate hazard ratios for incident CVD events (myocardial
infarction (MI) and stroke) associated with new users of ATV
compared to each non-ATV regimen.
Results: Of 33,048 HIV veterans, 21,289 received an ART regimen
of interest during the study period, and 10,385 were treatment naı¨ve
including 1530 with ATV and 2459, 5785 and 611 with other PIs,
NNRTIs and INSTIs, respectively. The mean (standard deviation) age
was 50.0 (10.1), 93% were male, and 56% and 30% were Black and
Caucasian, respectively. After weighting, standardized mean differ-
ences between groups were less than 0.1 for all baseline character-
istics, indicating no significant differences between groups. Risks
were significantly lower with ATV compared to other PIs for MI and
for ATV compared to INSTI-based regimens for the MI/stroke
composite outcome (Table 1).
Conclusions: In the VHA, ATV-based regimens were generally
associated with a lower risk for CVD events compared to
other antiretrovirals. Further research to elucidate the mechanism
for a potential reduced risk of CVD events with atazanavir is
warranted.
P176
A reappraisal with meta-analysis of abacavir use and
cardiovascular disease events
Mario Cruciani1 and Saverio Parisi2
1Infectious Diseases Service, San Bonifacio Hospital, Verona, Italy.
2Department of Histology, Microbiology and Biotechnology,
University of Padua, Padua, Italy
Introduction: Nucleoside reverse transcriptase inhibitors (NRTIs)
continue to be a cornerstone of antiretroviral therapy (ART), and
currently recommended regimens include the NRTIs combination of
abacavir (ABC)/3TC or tenofovir (TDF)/emtricitabine. Whether the
exposure to ABC contributes to cardiovascular risk remains unclear.
Results from several cohort studies have identified an increase
Abstract P175Table 1. Risk of CVD events with ATV versus non-ATV-based regimens
Outcome
ATV crude incidence
(per 1000 patient-years)
ATV vs. other PIs: HR
(95% CI)
ATV vs. NNRTIs: HR
(95% CI)
ATV vs. INSTIs: HR
(95% CI)
MI 5.16 0.46 (0.260.81)* 0.72 (0.481.09) 0.71 (0.311.61)
Overall stroke 18.31 0.89 (0.661.22) 1.01 (0.811.27) 0.71 (0.471.07)
Ischemic stroke 17.65 0.90 (0.661.25) 1.03 (0.811.29) 0.74 (0.481.12)
Haemorrhagic stroke 0.64 0.50 (0.181.42) 0.50 (0.161.52) 0.18 (0.021.36)
MI/stroke 23.04 0.80 (0.611.05) 0.94 (0.771.15) 0.69 (0.471.00)*
MI/stroke/death 38.83 0.90 (0.731.12) 0.98 (0.841.15) 0.81 (0.601.10)
All-cause death$ 16.02 1.01 (0.731.39) 0.91 (0.721.15) 1.11 (0.661.90)
*PB0.05.
$Based on VA vital status files.
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cardiovascular risk after ABC exposure, but the results of other
cohort studies, of randomized clinical trials (RCTs) and of meta-
analyses of RCTs did not find this association. In this study we have
updated the results of a previous meta-analysis [1], focusing on trials
with a head-to-head comparison of ABC and TDF.
Methods: A systematic review and meta-analysis was performed
using Cochrane methodologies. Data extracted included: myocardial
infarction (MI), any cardiovascular events and overall mortality. We
used a conventional Mantel-Haenszel method, with risk ratio and
95% confidence intervals (CIs).
Results: We obtained data from 11 RCTs conducted from 2006
to 2015, comparing ART with ABC to TDF, both in combination with
the same third agent. Risk of bias assessment showed an overall good
methodological quality of included studies; however, since overall
cardiovascular event andMIwere not predefined outcomes inmanyof
the included studies, we judged the quality of the evidence
‘‘moderate’’ for these outcomes. Data on overall cardiovascular
events were available from nine RCTs (4847 patients), data on MI
from nine RCTs (5130 patients) and data on mortality from
six RCTs (3646 patients). Compared to the TDF, ABC use did not
increase the occurrence of overall cardiovascular events (RR 1.32;
95% CI 0.672.59 (Figure 1)), the occurrence of MI (RR 0.74;
95% CI 0.262.12) and the overall mortality (RR 1.05; 95% CI 0.38
2.91).
Conclusions: Our meta-analysis of RCTs did not show an increase in
the occurrence of overall cardiovascular events, MI and overall
mortality in ABC compared to TDF recipients.
Reference
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Introduction: In recent years, effective ART resulted in increasing
survival of HIV-infected individuals and in the emergence of
comorbid non-communicable diseases (NCDs) as a global burden.
We characterized the prevalence, awareness and management of
elevated blood pressure (BP) among individuals engaged in ART
programmes in urban Zambia to provide a foundation for future
public health strategies.
Materials and methods: We analyzed recorded data about cardio-
vascular (CV) risk factors (elevated BP, overweight (body mass index
]25 kg/m2), smoking, hazardous drinking) from all HIV-infected
adults enroled in a prospective cohort in Lusaka, Zambia. We used
Chi-squared and Mann-Whitney tests to evaluate associations
between individual patient characteristics and elevated BP, defined
as one or more values of systolic BP ]140 mmHg or diastolic BP
]90 mmHg. In patients with elevated BP, we explored patient
awareness and management of elevated BP as well as history of CV
events (diabetes, stroke and heart condition) and family history of
hypertension using mobile phone follow-ups.
Results: Among 895 individuals, 92 (10.3%) individuals had elevated
BP and 57 (6.4%) had at least two elevated measurements. Patients
with elevated BP were older (median age 37 vs. 34 years, pB0.001),
more likely to be men (61% vs. 46%, p0.01) and to be overweight
(26% vs. 12%, pB0.001) compared to other participants. Pre-ART
CD4 cell count as well as proportion of patients with hepatitis B
infection and alcohol/tobacco consumption were similar in both
groups. Among the group with elevated BP, 66 (72%) were
contactable telephonically and 35 (53%) of them were aware of
their condition (Figure 1). For those aware of their condition, the
information about elevated BP had been communicated primarily by
a nurse (60%) and at ART clinics at scheduled study visits (63%).
Fourteen (21%) reported having ever taken BP-lowering drugs;
however, only one (3%) was currently taking a BP-lowering drug
prescribed following a CV event in a university teaching hospital. Of
the 66 patients contacted, 24 (36%) had ]2 related CV risk factors,
and nine (14%) reported prior history of CV events.
Conclusions: Despite routine screening for arterial hypertension,
awareness of elevated BP is low and prescription of BP-lowering
drugs is rare even in individuals with reported CV events, and regular
follow-ups. This suggests that integrated NCD screening and manage-
ment in a population linked to care through ART programmes has not
yet been realized.
Abstract P176Figure 1. Forest plot: outcome: overall cardiovascular events. Comparison: abacavir versus tenofovir.
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Introduction: Pitavastatin is a new statin highly effective in lowering
cholesterol, but its effect on the immune system in HIV-infected
patients is unknown. The aim of this study was to evaluate the
effects of pitavastatin on immune activation in HIV patients receiving
antiretroviral treatment.
Materials and methods: Clinical trial was carried out to compare in
HIV-infected patients with hypercholesterolemia on antiretroviral
treatment, dietpitavastatin versus diet at 24 weeks. Student’s t-
test for paired data was used to compare changes of the parameters
analyzed.
Results: Fifty-one patients were included, 30 started with pitavastatin
and 21 with diet. Three patients were withdrawn in the pitavastatin
group and five in the diet group. There were 21 males, 51911 years
receiving treatment with NNRTIs (14 patients), PI (11 patients) and
integrase inhibitors (one patient) in pitavastatin group. There were
14 males, 4799 years receiving treatment with NNRTIs (seven
patients), PI (seven patients) and integrase inhibitors (two patients).
After 24 weeks, there was a significant decrease in total cholesterol
(237.6943.24 mg/dL to 191.6926.7 mg/dL; pB0.001), cholesterol-LDL
(158.5935.8 mg/dL to 114.79927.4 mg/dL; pB0.001), triglycerides
(205.899103.9 mg/dL to 169.05988.7 mg/dL; p0.027), CD38-
mean fluorescence intensity (MFI) in NKs (9007.0593692.2 to
7640.5394720.66; p0.034) and CD38-MFI in CD4CD28 T
lymphocytes (1415.679509.87 to 1253.399592.39; p0.049) and
increased of Apo A1 (127.3396.42 mg/dL to 150.6799.71 mg/dL;
p0.007) in pitavastatin group. However the levels of total
cholesterol, cholesterol-LDL and Apo A1 were not affected in the
diet group. There was a significant increase of CD38-MFI in CD4
CD28- T lymphocytes (423091021.2 to 3106.7191171.3; p0.012)
in diet group. Pitavastatin was well tolerated and there were no
serious side effects.
Conclusions: Pitavastatin is safe and significantly reduces the levels
of total cholesterol and LDL in HIV-infec ted patients on antiretroviral
therapy. Additionally, pitavastatin decreases immune activation and
therefore might reduce non-AIDS events.
P179
Extensive vascular phenotyping  for the detection of
subclinical atheromatosis, arteriosclerosis and arterial
hypertrophy  and its association with international
cardiovascular prediction scores in HIV-infected individuals:
a single-centre study
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Abstract P177Figure 1. Level of awareness and use of blood pressure-lowering drugs among contacted patients with elevated blood
pressure (N66).
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Introduction: Accelerated subclinical arterial damage has been
widely identified in HIV-infected individuals and has arterial site-
specific predilection [1]. The increased incidence of cardiovascular
disease (CVD) in HIV-infected individuals is mediated [2] and
predicted [3] by the presence of subclinical arterial damage. Various
CVD risk prediction scores  derived mostly from general popula-
tions  are used for CVD prevention in HIV-infected individuals. All
scores underestimate the presence of subclinical arterial damage in
these populations and exhibit low agreement [4]. No mortality-based
comparison studies and no consensus exist regarding the best
available CVD risk prediction score for HIV-infected individuals. We
performed (i) extensive vascular phenotyping to detect subclinical
arterial damage of all types of arterial pathology at different arterial
beds and (ii) tested/compared the association of the four most
widely applied CVD risk prediction scores with the presence of
subclinical arterial pathology.
Materials and methods: Consecutive HIV-infected individuals, free of
CVD, underwent by the same technician vascular tests for the
detection of (i) atheromatosis (common/internal carotid and femoral
bed plaque, ankle-brachial index), (ii) arteriosclerosis (common
carotid elasticity, aortic pulse wave velocity) and (iii) arterial
hypertrophy (common carotid intimal-medial thickness). The Eur-
opean Society of Cardiology (ESC), Framingham (FR), American Heart
Association/American College of Cardiology (AHA/ACC) and the Data
collection on Adverse effects of Anti-HIV Drugs study (DAD) scores
were assessed. Logistic regression and ROC analysis and c-statistics
were applied.
Results: Out of 134 participants (92.5% males; age 40.891.5 years),
76.1% had at least one type of subclinical arterial pathology, 60%
arteriosclerosis, 35.3% arterial hypertrophy, 31.6% atheromatosis.
The ESC, FR and DAD scores presented statistically significant and
consistent association with combined as well as with almost each
type of arterial pathology in separate. On the contrary, the AHA/ACC
score failed to associate with any type of arterial pathology. The ESC,
FR and DAD scores, but not the AHA/ACC score, detected the
presence of combined arterial pathology. The FR-10 year-CHD score
had higher area under the curve than all other scores (AUC: 0.756,
pB0.001; c-statistics pB0.05 versus all other scores).
Conclusions: This single-center, single-operator vascular pheno-
typing study in HIV-infected individuals suggests that: (i) extensive
subclinical arterial pathology of all types is present in this population;
(ii) the ESC, DAD and FR scores, but not the AHA/ACC score, associate
with and detect all types of subclinical arterial pathology.
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Introduction: Initiation of antiretroviral therapy reduces hyperactiv-
ity of the immune system; however, the effect on endothelial cell
function seems to be contradictory [1].
Abstract P180Figure 1. Immunologic responses to initiation of cART.
Immune activation levels measured by the frequency of CD38HLA-DR CD8 T (left panel). Levels of the exhaustion marker PD-1 in the CD8 T
(right panel).
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Design: We performed a 24-week prospective, case-control and
comparative pilot study of antiretroviral-naı¨ve HIV-infected patients
who started a darunavir (DRV)- or rilpivirine (RPV)-based regimen and
age/sex-matched non-HIV-infected volunteers to compare changes at
week 24 from baseline in levels of circulating endothelial cells (CECs),
endothelial progenitor cells (EPCs) and circulating angiogenic cells
(CACs), as well as changes in immune activation markers and their
association with virologic, immunologic and clinical parameters.
Results: The study population comprised 48 participants (24 HIV-
infected patients and 24 non-infected volunteers). Both HIV groups
completely suppressed viremia and had significantly increased CD4 T-
cell counts after 24 weeks of treatment. HIV-infected patients had
higher levels of activation markers than the control group in CD8 T-
cell populations at baseline; these decreased after 24 weeks of
treatment but without reaching the levels of the control group. No
statistical differences in immune activation were seen between the
DRV and RPV groups (Figure 1.). Levels of CECs were higher and
levels of EPCs and CACs were lower in HIV-infected patients than in
the control group, although all these parameters were similar
between the DRV group and the control group but not the RPV
group at week 24 (Figure 2). An unfavourable association was
observed between RPV, age and increased number of CECs.
Conclusions: Restoration of circulating levels of EPCs and CECs in
DRV-treated patients was greater than in those treated with RPV,
suggesting ongoing endothelial repair mechanisms.
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Introduction: Patients with HIV have high cardiovascular risk [1].
Cardiovascular disease (CVD) is a common cause of death amongst
people with HIV [2]. We aimed to review contributors to cardiovas-
cular risk in patients with HIV at high risk of CVD and the
management of lipids with reference to NICE guidelines 2008 [3].
Materials and methods: Patients with estimated 10-year CVD risk
greater than 20% (QRISK2 score) in 2014 were selected from the
clinic database. Data recorded included demographic details, CD4
count, viral load, antiretroviral treatment, contributors to QRISK2
score and lipid management.
Results: We identified 39 patients with QRISK2 greater than 20%. The
viral load was undetectable (B40 copies/mL) in 89% of these
patients indicating well-controlled HIV. Median CD4 count was 612
cells/mm3, four patients had CD4 less than 350 cells/mm3. Modifi-
able risks were identified in 86.5% of patients; 40.5% were current
smokers, 43.2% had a systolic blood pressure 140 mmHg or
diastolic 90 mmHg, 54.1% had non-HDL cholesterol greater than
3 mmol/L, 32.4% had a BMI 30 kg/m2. NICE guidelines 2008
(CG67) recommended statin be offered if 10-year risk 20% [3].
Only 26 out of 37 patients (70.3%) were on statin prior to risk
assessment (included two patients on fenofibrate due to intolerance
of statin). A statin was subsequently commenced in 4 of the
remaining 11 patients (36.4%). None achieved the recently adopted
target of 40% reduction in non-HDL cholesterol after 8 months [4].
Conclusions: Modifiable CVD factors (smoking, hypertension, lipids
and weight) contributed to a significant number of patients with high
CVD in our cohort. Lifestyle changes should be promoted and
supported better in HIV clinics. This would include better commu-
nication with the GPs. Our clinic is developing a standard letter for
GPs requesting assistance with addressing modifiable risk factors, to
be sent when a patient with high cardiovascular risk is identified.
Once statin is commenced lipids should be monitored and reviewed
to ensure target reduction in non-HDL cholesterol is achieved.
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Abstract P180Figure 2. Endothelial response to cART initiation.
Frequencies of CEC (right), EPC (middle) and CAC (right) are shown at baseline and the end of the study (week 24). Data uninfected volunteers
represented by empty dots. Light grey dots correspond to RPV and dark grey to DRV group.
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Introduction: Non-communicable diseases (NCDs) are emerging as
an important concern related to the improvement of life expectancy
of HIV-infected patients, to antiretroviral drug toxicity and also to the
chronic inflammation associated with persistent viral replication [1].
Few studies have been conducted in low-income countries, particu-
larly in West Africa [2,3]. We are interested in severe morbidity of
cardiovascular diseases (CVD) in HIV-positive patients on antiretro-
viral therapy. Therefore, we assessed the prevalence of severe CVD in
HIV-infected patients followed up in the Tropical and Infectious
Diseases Unit (TIDU) and looked for factors associated with them.
Materials and methods: A cross-sectional study was conducted at
the TIDU in Abidjan, from April to July 2015, in patients aged over 18
years, HIV positive and on antiretroviral therapy for at least 12
months. Data were collected using a structured questionnaire.
Clinical assessment, laboratory tests, transthoracic echocardiography
and electrocardiogram were performed for all the patients. All the
subjects underwent ultrasonography of the carotid and femoral
vessels to evaluate intima-media thickness. The primary endpoint
was proportion of patients with severe CVD. Analysis of factors
associated was conducted by logistic regression.
Results: Two hundred and seventy eight patients (mean age 46
years, female 74.5%) were included. The proportion of patients with
clinical stage C of the CDC classification was 119 (42.8%) and 229
(82.4%) were with virologic suppression (undetectable viral load).
The prevalence of severe CVD was 7.6% [95% CI 4.7411.32]; the
majority was represented by pulmonary arterial hypertension (5%).
In multivariate analysis, running time below 30 min, high blood
pressure, high ALT rate, high glycaemia rate and low nadir CD4 count
were significantly associated with the prevalence of CVD.
Conclusion: The prevalence of life-threatening CVD was significant.
Therefore, standardized screening and risk reduction interventions
should be routinely undertaken among HIV-infected patients on
HAART [4] and discussion of the current approach to primary
prevention of CVD in HIV-positive patients is crucial.
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Introduction: Premature atherosclerosis has been linked to HIV
infection and/or to antiretroviral treatment [1]. Carotid intima-media
thickness (CIMT) and pulsatility index (PI) accessed by carotid duplex
ultrasonography (CDU) and transcranial Doppler (TCD) may be useful
markers [24].
Materials and methods: Carotid and cerebral circulation were
evaluated by CDU and TCD in 40 HIV-infected Caucasian men (mean
age 49.495.9 years). CD4 T-cell current and nadir counts, current
and zenith viral load and HIV drug classes with duration of ART were
registered; cardiovascular risk scores were also assessed. Multivariate
regression analysis and Pearson’s correlation coefficient were used.
Results: All men received ART and presented mean CD4 count of
8179369 cells/mm3 (mean nadir 242.89158.2 cells/mm3) at the
time of the study, 95% had non-detectable viral load (mean zenith
381,4169858,881 copies/mL), 35% had history of high blood
pressure, 35% dyslipidaemia, 7.5% diabetes and 80% tobacco
consumption. Cardiovascular risk by Framingham Risk Score, SCORE
and ASCVD score were low at 10 years and lifetime. More than half
(67.5%) had increased CIMT (mean 0.9290.13 mm), but none
presented increased PI. No correlation was found between duration
of infection, ART classes or cardiovascular risk scores with CDU or
TCD data. However, a significantly positive association between a
CD4 nadir count B400 cells/mm3 and an increase of 0.12 in PI
was confirmed by regression analysis where CD4 categories showed
significant effect over PI (p0.04).
Conclusions: In this series, HIV infection showed an association with
premature cerebral atherosclerosis, even at low cardiovascular risk
scores, and independently of therapies employed and treatment
time. PI may be an early marker of atherosclerosis in HIV-infected
people with CD4 nadir B400 cells/mm3. There is a need to
evaluate these parameters in a larger number of HIV-infected people,
including elite controllers.
References
1. Calza L, Manfredi R, Pocaterra D, Chiodo F. Risk of premature
atherosclerosis and ischemic heart disease associated with HIV
infection and antiretroviral therapy. J Infect. 2008;57:1632. doi:
http://dx.doi.org/10.1016/j.jinf.2008.02.006
2. Hsue P, Lo J, Franklin A, Bolger A, Martin J, Deeks S, et al.
Progression of atherosclerosis as assessed by carotid intima-media
thickness in patients with HIV infection. Circulation. 2004;109:1603
8. doi: http://dx.doi.org/10.1161/01.CIR.0000124480.32233.8A
3. Longenecker C, Hoit B. Imaging atherosclerosis in HIV: carotid
intima-media thickness and beyond. Transl Res. 2012;159:12739.
doi: http://dx.doi.org/10.1016/j.trsl.2011.10.007
4. Stein J, Currier J, Hsue P. Arterial disease in patients with human
immunodeficiency virus infection: what has imaging taught us? JACC
Cardiovasc Imaging. 2014;7:51525. doi: http://dx.doi.org/10.1016/
j.jcmg.2013.08.019
P184
CVD risk assessment using various tools in an HIV cohort in
Greece
Efmorfili Zouzia1; Eleni Kakalou2; Vasileios Papastamopoulos2;
Theodoros Kakkavas2; Dionysios Dimas1; Theophilos Rosenberg1 and
Athanasios Skoutelis2
1Medical School, MSc International Medicine-Health Crises
Management, School of Medicine, National and Kapodistrian
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
139
University of Athens, Greece. 2Infectious Diseases Department,
Evangelismos General Hospital, Athens, Greece
Introduction: ART has led to improvements in life expectancy but
chronic diseases, including cardiovascular disease (CVD), have
emerged as a major factor of morbidity and mortality among the
HIV infected. Traditional CVD risk prediction tools have questionable
accuracy in this population. Only the D:A:D algorithm has been
specifically developed for HIV patients. This study aims: a) to describe
the prevalence of CVD risk factors in an HIV-infected population
using various CVD risk prediction tools; b) to compare the results
calculated by standard CVD risk assessment tools with those of the
D:A:D risk equation.
Materials and methods: A cross-sectional study was conducted in
Evangelismos General Hospital in Athens, Greece. Patients attending
the outpatient HIV clinic during the period of 1 to 31 March 2016
were included. A total of 120 patients were included and
their data were analyzed. Electronic medical records were used to
collect data. Seven cardiovascular risk assessment tools were used
(Framingham CVD, Framingham Hard CHD, SCORE, PROCAM
Health Check, CUORE, QRISK2 and D:A:D Risk Score). Agreement
among results was assessed using Cohen’s weighted kappa
coefficient.
Results: 81.5% (95% CI 73.687.5) of participants were male and
76.3% (95% CI 67.883.0) were born in Greece. The mean age was
41.9 (SD 10.47) and transmission mode was sexual in 62.2% (95% CI
53.270.4) and intravenous drug use in 30.3% (95% CI 22.739) of
cases; 67.8% were current smokers. D:A:D risk equation classified
8.9% as of low (L), 83% as of medium (M) and 8% as of high risk (H)
for CVD. Respectively, other equations’ estimated results were:
Framingham CVD (L:72%  M:20.6%  H:7.5%), Framingham Hard
CHD (L:73.7%  M:18.4%  H:7.9%), CUORE (L:61.5%  M:37.4% 
H:1.1%), SCORE (L:65.8%  M:30.8%  H:3.4%), PROCAM (L:90.4% 
M:6.1%  H:3.5%) and QRISK2 (L:90.4%  M:4.4%  H:5.3%).
Calculating weighted Cohen’s kappa using three categories, ‘‘low-
risk,’’ ‘‘medium-risk’’ and ‘‘high-risk,’’ coefficient values were very low
(B0.2), indicating poor agreement between different tools. How-
ever, when categories ‘‘low-risk’’ and ‘‘medium-risk’’ were merged
into one (‘‘non-high risk’’), Cohen’s kappa resulted in significantly
better agreement between the results of the various algorithms (in
some cases k0.7) (Table 1).
Conclusions: General population CVD risk assessment tools
underestimate CVD risk of HIV patients, especially in the ‘‘medium-
risk’’ strata. D:A:D risk equation might be the tool of choice
for this population [1,2]. Smoking prevalence is high in the
present cohort and efforts should focus on assisting patients to
quit smoking.
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Introduction: The effect of immune restoration with ART on HIV-
related cardiac inflammation is unknown. We investigated the
presence of myocarditis before and after ART initiation in patients
with HIV advanced disease.
Materials and methods: Myocardial inflammatory changes were
studied with MRI, using Lake Louise Consensus Criteria [1] in ART-
naı¨ve, HIV-infected adults with CD4 T cell counts B200 cells/mL, at
ART initiation and 6 weeks later. Myocardial function was assessed
with transthoracic echocardiogram. Troponin I, proBNP (heart-injury
biomarkers) and serum antibodies and plasma PCR for cardiotropic
pathogens were measured. Immune activation and lymphocyte
differentiation were analyzed by flow cytometry.
Results: Seventeen patients were enroled, 15 (88%) were men. At
baseline, median age was 34 years and CD4 count 46 cells/mL. No
patients had cardiovascular-related symptoms at enrolment. We
summarized in Table 1 the frequency of myocardial inflammation,
myocardial dysfunction and pulmonary hypertension, and the
presence of HHV-6, HHV-8 and parvovirus B19 at baseline and 6
weeks after ART in all subjects. Among those with baseline
myocardial inflammation (n6), three (50%) had systolic dysfunc-
tion and one had diastolic dysfunction. None had cardiovascular-
related symptoms. Among the five (29%) patients with myocardial
inflammation at week 6, two (40%) had systolic dysfunction, two
(40%) diastolic and one more had both. One patient progressed to
symptomatic heart failure after ART initiation. He had the most
severe baseline systolic dysfunction (LVEF 41%), which resolved with
medical treatment after 1 year of follow-up (LVEF 61%). No
myocardial inflammation at baseline and at 6 weeks was observed
in eight (47%) subjects; four (23%) had baseline inflammation that
spontaneously resolved after 6 weeks; inflammation persisted after
6 weeks of ART in 2/6 patients, and three more developed new
inflammation after ART. Baseline and 6-week IgG for T. gondii, CMV
Abstract P184Table 1. Agreement between D:A:D and other CVD calculation tools (high, non-high risk)
Framingham CVD Framingham Hard CHD Score PROCAM QRISK2 CUORE
D:A:D
K 0.729 0.191 0.434 0.595 0.266 0.206
95% CI 0.475, 0.982 0.104, 0.485 0.092, 0.775 0.278, 0.912 0.070, 0.602 0.137, 0.548
p-value B0.001 0.047 B0.001 B0.001 0.004 0.002
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and EBV were frequent and not associated with myocardial
inflammation. No evidence of past or present T. cruzi or Coxsackie
virus was found. No association was found between myocardial
inflammation and HPVB19, HHV-6 or -8, or with immune activation
markers.
Conclusions: Subclinical myocarditis was common in this group of
patients with HIV-associated advanced disease; and resolved spon-
taneously after ART initiation in most patients. Three patients
developed myocarditis after ART initiation with no apparent
associated infectious cause, suggesting a possible role of immune
restoration disease. In one of them, myocardial inflammation caused
heart failure requiring clinical management for 1 year. Awareness of
this condition may improve management of those patients.
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Introduction: Comorbidities are relevant in the management of HIV
infection; however, few studies have considered the choice of ARV
regimen based on non-HIV-dependent comorbidities.
Materials and methods: In this uncontrolled pilot study, we enroled
patients with cardiovascular disease or diabetes. All were on an
effective cART (HIV RNA B50 copies/mL for 6 months). Patients
were switched to TDF/FTC/RPV STR and all received a 40 mg dose of
atorvastatin. According to the American Heart Association indica-
tions [1], the reduction of LDL-cholesterol levels at 3 and 6 months
were used as primary goal of the study.
Results: Twenty patients, half diabetics and half with a previous
cardiovascular accident (e.g. stroke, MI, stent positioning), were
enroled. Nineteen were males, with a mean age of 55 years (range
4069). One-third were smokers. They had been on cART for a mean
of 11 years (range 222) and on current cART for 4.8 years (range
0.613). At enrolment, all had HIV RNA B50 copies/mL with a mean
CD4 count of 693 cells/mcL. Their copharmacy included aspirin and
beta-blockers (40% each), antidiabetics, statins (35% each) ramipril,
anti-lipid drugs (30% each) and a sartan (20%). Other medications
were taken by 35% of subjects. All patients maintained viral
suppression over time, a single virologic blip (60 copies/mL) was
observed in one patient at 6 months. CD4 counts increased by 57
cells/mcL. Total cholesterol decreased from 206 (SD 33) to 144 mg/dL
(SD 35), HDL from 46 (SD 19) to 39 mg/dL (SD 14) and LDL from 123
(SD 19) to 79 mg/dL (SD 24) (for all pB0.001); HDL/LDL ratio was
normalized in all patients. D-dimer levels were studied to explore
the anti-inflammatory, non-lipidic lowering effects of atorvastatin.
They varied from 391 ng/mL (SD 263) at baseline to 311 ng/mL (SD
260) (p0.010) at 3 months, to 319 ng/mL (SD 251) after 6 months
(p0.012). Therapy was well tolerated and CPK levels did not
modify.
Conclusions: The management of comorbidities is paramount in HIV
patients. Cardiovascular diseases are recognized as a major
contributor to morbidity and mortality in HIV-infected subjects.
TDF/FTC/RPV has a neutral lipid effect and no interactions with
statins allowing for the use of these drugs at full dose. We
demonstrated that the concomitant use of TDF/FTC/RPV and
atorvastatin reduces the cardiovascular risk of HIV patients by
significantly lowering both LDL and d-dimer blood levels while
maintaining virologic suppression.
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Lipid profile in HIV patients with long-term ART: darunavir
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Abstract P185Table 1. Frequency of abnormal findings in heart assessment, cardiotropic pathogens and CD4 counts and HIV
RNA measurements at baseline and 6 weeks after ART initiation in 17 patients starting treatment with advanced HIV disease (B200
CD4 cells/mm3)
Variable Basal n (%) 6 weeks n (%)
Myocardial inflammation 6 (35) 5 (29)
Systolic dysfunction (LVEF B60%) 5 3
Diastolic dysfunction (slow relaxation pattern) 2 3
Systolicdiastolic dysfunction 1 0
Pulmonary hypertension (TTE) 1 1
Plasma PCR for HHV6 0 1
Plasma PCR for HHV8 1 2
Plasma PCR for parvovirus B19 2 0
CD4 cells/mm3 46 (1881) 208 (90.5205)
CD4 /CD8 ratio 0.063 (0.0480.092) 0.25 (0.1310.326)
HIV RNA copies/mm3 449,967 (227,367740,959) 143 (87502)
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Introduction: The long-standing use of ART in association with
dyslipidaemia and cardiovascular events has previously been thor-
oughly studied. Protease inhibitors (PIs) have been linked to an
increased risk of dyslipidaemia when compared with other ART
groups such as integrase inhibitors (INIs) or non-nucleoside reverse
transcriptase inhibitors (NNRTIs), namely, rilpivirine. Our aim was to
describe the lipid profile outcome of three different drugs (darunavir,
raltegravir and rilpivirine) in a real-life situation.
Materials and methods: We conducted an observational study in our
Infectious Diseases Department. Eligible subjects included HIV-1
infected adults, with virologic suppression, under an ART regimen
consisting of a backbone of two nucleoside reverse transcriptase
inhibitors (NRTIs) plus a third agent: darunavir (group 1), raltegravir
(group 2) and rilpivirine (group 3), for at least 1 year (2015). We
evaluated the changes in the lipid profile in these groups, comparing
the differences in total cholesterol (TC), high-density lipoprotein
(HDL), low-density lipoprotein (LDL), triglycerides (TG), at baseline
(without ART, under PIs, NNRTIs or INIs) and at current time.
Results: A total of 192 patients were included, 72.4% males with a
mean age of 47.2 years. In group 1 (N101), we observed a
medium increase of 4 mg/dL in TC, with a major increase in LDL
(17 mg/dL). However, medium TG value decreased 11 mg/dL. In
subgroup analysis, 22 patients naı¨ve at baseline had an increase of
34 mg/dL in TC (LDL: 25 mg/dL), with decrease in TG. Sixty-three
patients initially under other PIs showed the same pattern. In group
2 (N37), TC and TG decreased, but LDL increased 2 mg/dL. Six
patients were naı¨ve, and showed a TC increase of 25 mg/dL, and
TG decrease 1 mg/dL; 21 patients on PIs had TC and LDL decreased
(7 mg/dL, 5 mg/dL), with 62 mg/dL decline in TG. However, the
10 patients with NNRTIs at baseline presented with TC increase:
5 mg/dL; HDL decrease: 7 mg/dL, LDL increase: 11 mg/dL; and TG
decrease: 5 mg/dL. In group 3 (N54), all parameters of lipid profile
showed a substantial decrease. In patients initially under PIs
(N13) TC decreased: 18 mg/dL; LDL: 11 mg/dL; TG: 28 mg/dL.
Seventeen patients under NNRTIs showed 19 mg/dL decline in TC,
12 mg/dL in LDL and 25 mg/dL in TG. Even the naı¨ve subgroup
(N22) showed a TC decrease 2 mg/dL and TG decrease 13 mg/dL.
Adversely two patients under INIs showed an increase in all
parameters.
Conclusions: Rilpivirine showed a better evolution in lipid profile,
both in naı¨ve and experienced patients, in comparison to darunavir
and raltegravir. As this study considered real-life data, the informa-
tion could be very useful in clinical practice and future ART
decision making.
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Introduction: Increased rates of non-AIDS mortality, including cardi-
ovascular diseases (CVD), emerged as an important issue in HIV-
infected patients [1,2]. Thus, we aimed to estimate cardiovascular risk
in HIV-infected patients using four cardiovascular risk scores recom-
mended by different international guidelines: Framingham Risk Score
(FRS), Systematic Coronary Risk Evaluation (SCORE), American Heart
Association Atherosclerotic Cardiovascular Disease risk score (ASCVD)
and one designed particularly for HIV-infected patients, Data Collec-
tion on Adverse Events of Anti-HIV Drugs (D:A:D) model. Furthermore,
we also aimed to analyze the agreement of the high D:A:D CVD score
with other high CVD scores and to calculate discriminative power for
each of used scores in Serbian patient population.
Materials and methods: We included 202 patients in cross-sectional
study conducted at HIV/AIDS Center at Clinic for Infectious and
Tropical Diseases, Belgrade, Serbia from January 2014 to January
2015.We collected data on risk factors for CVD including age, gender,
race, total cholesterol, systolic blood pressure, smoking status and
also HIV-specific parameters such as duration and current use of
lopinavir or abacavir, as well as family history. Inclusion criteria were
at least 12 months on antiretroviral therapy and age range of 40 to
79 years. We calculated agreement between D:A:D score and three
other scores using Cohen’s kappa coefficient (k). We also described
discriminative power of each of the scores using receiver operating
characteristic (ROC curves).
Results: All patients were Caucasians with median age of 49 years,
151 (74.8%) were males. As for traditional risk factors, 100 (49.5%)
patients are current smokers, 64 (31%) had hypertension, while
hypercholesterolemia was found in 72 (35.4%). Fifty-one (25.2%)
persons were overweight (BMI 25), 15 (7.4%) were obese (BMI
30), 45 (22.3%) had metabolic syndrome and seven diabetes
(3.5%). The prevalence of high CVD scores were 8%, 13%, 35% and
40% for SCORE, FRS, D:A:D and ASCVD score, respectively. The
agreement between high D:A:D score and high ASCVD score was
higher (k0.73) than between the D:A:D score and FRS (k0.59) or
SCORE (k0.60) algorithms. We also found that D:A:D score and
ASCVD score had a highly significant predictive value for outcome in
comparison with two other scores (Figure 1).
Among four estimated CVD risks, D:A:D score and ASCVD score had a
highly significant predictive value for outcome. D:A:D score had the
area under the receiver operator, ROC curve, AUC of 0.691
(p0.004), while the ASCVD had the area under the ROC curve of
0.624 (p0.05).
Abstract P188Figure 1. Evaluation of discriminative power
(D:A:D ROC0.691, ASCVD ROC 0.624).
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Conclusion: We found a high number of HIV-infected patients in our
population who are in need of CVD risk reduction. We also found
substantial agreement of D:A:D and ASCVD risk score in order to
estimate CVD risk in Serbian patient population.
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Introduction: B-cell dysfunction and activation is thought to con-
tribute to lymphoma development in HIV people; however, the
mechanisms are complex and not well understood. We investigated
markers of B-cell dysfunction prior to lymphoma diagnosis.
Abstract P189Figure 1. Odds ratios of lymphoma in those with a marker level of greater than the upper limit of the normal (ULN) relative
to a level in the normal range, B2 and 2 years prior to diagnosis.
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Materials and methods: A nested case control study of 73 HIV
people with lymphoma (52 non-Hodgkin lymphoma and 21 Hodgkin
lymphoma) and 142 matched controls within EuroSIDA was con-
ducted. Cases and controls were matched on date of first and
last sample preceding lymphoma, age and CD4 cell count at first
sample, gender and region of Europe. Prospectively stored plasma
samples before lymphoma (or matched date in controls) were
measured for markers of B-cell dysfunction and activation: free
light chain [FLC]-kappa, FLC-lambda, immunoglobulin [Ig]G, IgA, IgM
and IgD. Conditional logistic regression investigated associations
between markers and lymphoma B2 and 2 years prior to
diagnosis.
Results: A total of 215 HIV people were included with a median of
2.0 (IQR 0.44.3) years between first sample and end of follow-up.
Considering cases and controls together, all markers were correlated
with lower CD4 level (FLC-lambda: Spearman’s r0.27, pB0.01;
FLC-kappa: r0.24, pB0.01; IgG: r0.27, pB0.01; IgA:
r0.13, pB0.01; IgM: r0.17, pB0.01; IgD: r0.09,
pB0.01). FLC-lambda (r0.32, pB0.01), FLC-kappa (r0.28,
pB0.01), IgG (r0.40, pB0.01) and IgM (r0.40, pB0.01)
were also positively correlated with HIV-VL. In the years prior to
diagnosis, levels of FLC-kappa were stable in cases but increasing in
controls by 4% (95% CI 18%) per year (p-value for difference
0.10). Levels of IgG and IgM were declining in cases by 4% (95% CI
16%) and 9% (95% CI 414%) per year, respectively, but stable in
controls (p: for different in slopes in cases and controls: 0.10 and
pB0.01 respectively). Levels of FLC-lambda, IgA and IgD were similar
in cases and controls over time (all p0.05). Elevated FLC-lambda
(OR 3.28, 95% CI 1.477.7), FLC-kappa (OR 3.40, 95% CI 1.0514.50)
and IgG (OR 2.67, 95% CI 1.206.28) were associated with higher
odds of lymphoma 2 years prior to diagnosis; however, levels were
not predictive within 2 years prior to diagnosis (Figure 1). A similar
trend was observed for IgM; however, significance was borderline
with high uncertainty (2 years OR 9.10, 95% CI 1.00433.52; B2
years OR 7.12, 95% CI 0.69354.54). IgA and IgD were not associated
with lymphoma.
139 (cases46, controls93) people had samples B2 years prior
to diagnosis and 156 (cases53, controls103) people had
samples 2 years prior to diagnosis.
Conclusions: FLC-lambda, FLC-kappa and IgG were higher than 2
years before lymphoma diagnosis, but the difference diminished
nearer diagnosis. B-cell dysfunction, as demonstrated by poly-
clonal hyperglobulinemia, occurs many years prior to lymphoma
development.
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Introduction: There are limited data on comparison of clinical
outcome of lymphoma in HIV-positive (HIV-L) versus HIV-negative
individuals (nHIV-L). Objectives of our analysis were to estimate
overall survival (OS) after a diagnosis of lymphoma, comparing HIV-L
versus nHIV-L and to identify predictors of death.
Materials and methods: All HIV-infected patients with a diagnosis
of HIV-L (non-Hodgkin lymphoma, NHL; Hodgkin disease, HD)
between 1 January 2000 and 31 December 2013 in ICONA or in
three collaborating hospital databases were included. As controls,
patients with nHIV-L seen for care in one of these centres over the
same time period were included. Survival estimates by kaplan
meier (KM) and predictors of OS by multivariable Cox regression
after adjusting for main potential confounders (calendar year, age,
gender, international prognostic index (IPI), treatment) were
performed.
Abstract P190Table 1. Unadjusted and adjusted HR of death in all NHL, in DLBCL and in HD from fitting three separate
multivariable Cox regression hazard models
Unadjusted HR
(95% CI) p
Adjusteda HR
(95% CI) p
Adjustedb HR
(95% CI) p
Adjustedc HR
(95% CI) p
All NHL
HIV- 1.00 1.00 1.00 1.00
HIV 1.63 (1.292.06) B0.001 2.08 (1.562.76) B0.001 1.35 (1.031.78) 0.03 1.52 (1.092.12) 0.01
DLBCL
HIV- 1.00 1.00 1.00 1.00
HIV 1.44 (1.091.91) 0.01 1.83 (1.332.53) B0.001 1.32 (0.961.81) 0.08 1.37 (0.951.99) 0.09
Adjusteda RH (95% CI) Adjustedd RH (95% CI) Adjustede RH (95% CI)
HD
HIV- 1.00 1.00 1.00 1.00
HIV 2.36 (1.503.70) B0.001 2.26 (1.373.74) 0.001 2.15 (1.134.09) 0.006 2.10 (1.084.06) 0.007
aAdjusted for age gender and calendar year; badjusted for rituximab and IPI; cadjusted for factors in a and b; dadjusted for ABVD regimen and
staging; eadjusted for factors in a and d.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
144
Results: A total of 1355 patients were included: 488 HIV-L (343 NHL
and 145 HD) and 867 nHIV-L (589 NHL and 278 HD). Median age 49
years (IQR 3864), 522 female (38%) and 423 (32%) had HD; of NHL,
765 (84%) were diffuse large B-cell lymphoma (DLBCL); among HIV-L,
91 (22%) were intravenous drug user (IVDU), median CD4 count at
lymphoma diagnosis 235 cells/mm3 (IQR 134428) and 443 (91%)
were on cART. HIV-L was more aggressive than nHIV-L (worse IPI
score). The 3-year cumulative probability of death was 34% for HIV-L
(95% CI 3038) and 18% (15.520.8) for nHIV-L (log rank p0.001).
In univariable analysis, a significantly increased 3-year cumulative
probability of death for HIV-L compared to nHIV-L was reported for
all NHL (38.9% vs. 22.1%; pB0.001), for DLBCL (36.9% vs. 22.5%;
p0.008), for HD (22.3% vs. 10.1%; pB0.001). Unadjusted and
adjusted hazard ratio (HR) of death according to HIV status in all NHL,
in DLBCL and in HD from fitting separate Cox regression models are
shown in Table 1. Results were mostly consistent when we
performed a matched-cohort analysis using propensity scores, and
restricting analysis, among HIV-L, to cART-treated only. Considering
only NHL in HIV, older age (HR 1.45 (1.261.66)) and higher IPI (1.39
(0.872.23)) were independently associated with increased risk of
death, whereas female gender (0.64 (0.450.90)) were associated
with a decreased risk.
Conclusions: Comparing a large population of HIV-L and nHIV-L,
we found an increased risk of death associated with HIV. The
excess of risk independently attributable to HIV status ranged
between 37% for DLBCL and 2-fold higher for HD, after controlling
for unbalanced aggressive presentation and advanced stage at
diagnosis. We cannot rule out bias due to other unmeasured
confounding.
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Introduction: Research suggests significant gaps exist in cancer
screening practices for women living with HIV (WLWH); however,
there is limited research from regions where screening is universally
available. Annual Pap tests are considered best practice for WLWH, in
response to the higher rates of cervical cancer. Current mammo-
graphy recommendations suggest once every 24 months for women
aged 40 to 74, with no specification for WLWH or immune-
suppressed women.
Materials and methods: The comparison of outcomes and service
utilization trends (COAST) study provides a retrospective, population-
based cohort of HIV-positive individuals between 1996 and 2013 in
British Columbia, Canada. The primary outcome variables (mammo-
graphy for breast cancer and pelvic exams and/or Pap tests for
cervical cancer screening) were identified by physician billing codes.
Screening was identified between HIV diagnosis date and December
2013 as well as within the previous 12 and 24 months for cervical
and breast cancer, respectively. Multivariate logistic model identified
factors associated with receipt of breast and cervical cancer screen-
ing since HIV diagnosis.
Results: Of the 1070 WLWH between ages 40 and 74 in our study,
198 (18.5%) received at least one mammogram since being
diagnosed with HIV, and only 61 (5.7%) in the previous 24 months.
Additionally, among 1683 WLWH between ages 25 and 69, 628
(37.3%) received at least one Pap test since being diagnosed with HIV
and only 97 (5.8%) in the previous 12 months. Receipt of Pap test
since known HIV diagnosis date was less likely for individuals who
have used injection drugs (AOR 0.62, 95% CI 0.500.77), are of
Indigenous ancestry (AOR 0.66, 95% CI 0.500.87) and urban
dwellers (AOR 0.50, 95% CI 0.340.74), but more likely for older
individuals (AOR 1.16, 95% CI 1.051.28) and those with higher
baseline CD4 cell count (AOR 1.11, 95% CI 1.051.16). Receiving a
mammogram since HIV diagnosis was less likely for WLWH who were
diagnosed with HIV after the year 2000 (compared to 1996 to 2000)
(AOR 0.59, 95% CI 0.430.81) and those of Indigenous ancestry (AOR
0.59, 95% CI 0.400.87), but more likely for older individuals (AOR
1.96, 95% CI 1.702.26).
Conclusions: An alarmingly small proportion of WLWH in our sample
received a mammogram and Pap test since being diagnosed with HIV
despite current recommendations. This is notably low, even when
accounting for completeness of administrative data such as physician
billing codes. Of note, theremay be significant barriers to screening for
Indigenous WLWH and those with advanced HIV infection.
CO-MORBIDITIES AND COMPLICATIONS
OF DISEASE AND/OR TREATMENT -
MALIGNANCIES: NON-AIDS-DEFINING
P192
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Introduction: The elevated risk of AIDS-defining malignancies (ADM)
among people living with HIV has been largely and directly attributed
to cell-mediated immune suppression, characterized by low CD4
counts. Since the advent of modern cART, rates of ADM have
subsequently declined; however, the potential protective effect of
early cART therapy initiation on cancer incidence, particularly non-
ADM, remains largely unknown.
Materials and methods: The comparison of outcomes and service
utilization trends (COAST) study provides a retrospective, population-
based cohort of HIV-positive individuals between 1996 and 2013 in
British Columbia, Canada. For this study, we included women with a
confirmed HIV diagnosis. Incident cancer cases were identified by
International Classification of Diseases for Oncology (ICD-O)codes.
We conducted a Poisson regression to determine correlates of all-
type cancer, ADM and non-ADM, and an adjusted model to
determine incidence rate (per 1000 PY) by baseline CD4 cell count
(B200, 200350 and 350 cells/mm3) among women living with
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HIV (WLWH). We also calculated the attributable fraction (AF) of
malignancies associated with CD4 count at cART initiation.
Results: Among 1660 WLWH included in this study, 50 WLWH were
diagnosed with cancer between 1996 and 2013 (31 ADM and 19
non-ADM). Compared to WLWH without cancer,WLWH with a cancer
diagnosis were more likely to have lower baseline CD4 (median 135
(IQR 60260) cells/mm3 vs. 260 (IQR 140390) cells/mm3), nadir
CD4 (median 45.0 (10101) cells/mm3 vs. 133 (43250) cells/mm3)
and a higher proportion of AIDS-defining illness at baseline (26.0%
vs. 10.3%). Initiating cART with higher baseline CD4 cell count (350
cells/mm3) is associated with lower all-type cancer diagnosis (RR
0.33 (95% CI 0.160.70)) and non-ADM diagnosis (RR 0.15 (95% CI
0.030.64)) compared to those to initiate cART with CD4 of B200
cells/mm3. No significant association was found between baseline
CD4 and incidence of ADM diagnosis. After adjusting for age at HIV
diagnosis, the incidence rate of all-type cancer is 5.55 (95% CI 3.89
7.91) cases per 1000 PY with AF of 63.66% and non-ADM incidence is
2.50 (95% CI 1.474.27) cases per 1000 PY with AF of 82.06% for
those with a CD4 of B200 cells/mm3, compared to those with CD4
of 350 cells/mm3 at cART baseline.
Conclusions: Early initiation of cART may be protective against all-
type cancer and non-ADM diagnosis. In the context of ‘‘Treatment as
Prevention,’’ this study suggests there may be significant oncologic
health benefits of early treatment initiation for some WLWH.
P193
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Introduction: Anal squamous cell carcinoma (ASCC) is one of the
most frequent non-AIDS-defining malignancies in HIV-infected MSM
[1]. A protocol of early diagnosis of ASCC has been considered cost-
effective.
Materials and methods: This is a single-centre study conducted
between May 2010 and June 2015. The patients were included in a
screening, therapeutic and prophylaxis (implement use of condom,
and qHPV vaccine (n64 patients)) programme of HPV and ASCC.
Baseline visit (V0) enclosed HPV PCR genotyping (GeneAmp PCR
System 9700, Applied Biosystems), cytology and high-resolution
anoscopy (HRA). In V0 and each visit, we collected medical history,
sexual habits, CD4 and HIV viral load. Patients diagnosed with LSIL
were subjected to an annual check-up that included HPV testing and
HRA; patients diagnosed with HSIL were sent to the general surgery
service where they underwent a mucosectomy; or they received
intra-anal imiquimod three times/week for 16 weeks. When ASCC
was diagnosed, the patient was sent to the Oncology Service;
patients with normal HRA were evaluated every year with anal
cytology and HPV PCR, in cases of anal squamous intraepithelial
lesions and/or oncogenic HPV, a HRA was carried out. The cytologic
and histologic classification was Bethesda’s and LASTS Project for
HPV-Associated Lesions, respectively.
Results: Two hundred and seventy-seven patients were included,
with an average age of 36.8 years, and follow-up during 18.1
months/patient (IQR 034). In V0, 277 HRA were carried out:
40.8% were normal, 44.4% LSIL, 14.4% HSIL and 0.4% ASCC. IR of
HSIL was 78.41000 person-years, and IR of ACSS 242100,000
person-years. 16.1% and 1.6% of patients with normal HRA
progressed to HSIL and ASCC, respectively. 19.1% of patients with
LSIL progressed to HSIL. In the multiple logistic regression analysis,
we observed, as a predictive factor of a new case of HSIL, previous
LSIL in HRA, OR 5 (95% CI 1.615.9). The rest of variables
analyzed (history of AIDS-defining illnesses, median time of HIV
duration, antiretroviral therapy, education, employment, smoking,
alcohol, STDs, genotypes or number of HPV, viral load, CD4
cells/uL, qHPV vaccine, imiquimod and mucosectomy) were not
related.
Conclusions: One in every five of patients with LSIL progressed to
premalignant lesions in 18 months. The only risk factor associated
with the high IR of HSIL was preliminary diagnosis of low squamous
intraepithelial lesions.
Reference
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Introduction: The management of HIV-associated multicentric Cas-
tleman’s disease (MCD) was revolutionized by the introduction of
rituximab-based immunochemotherapy in 2003. However, relapses
may occur following treatment and the clinicopathological features
and outcomes after relapse of MCD have not been described.
Materials and methods: A retrospective review of prospectively
collected data on 83 patients treated with rituximab-based therapy
at the National Centre for HIV Malignancy.
Results: Eighty-four patients (72 male, mean age 42 years) were
treated with rituximab-based immunotherapy for MCD (median
plasma HHV8 viral load at MCD diagnosis 375,000 copies/mL). Four
died from refractory or progressive MCD within the first month of
treatment and 80 achieved clinical remission. The median follow-up
for these 80 patients is 4.2 years, the 5-year overall survival is 92%
(95% CI 8499%) (Figure 1) and seven patients have died (three from
HHV8-related lymphomas, one pulmonary Kaposi Sarcoma (KS), two
suicides and one MCD (at fourth relapse).
Fifteen of 80 who achieved remission have relapsed at least once
with biopsy-confirmed relapsed MCD (including three patients with
concurrent lymphoma). The median time to first relapse is 22 months
(range 894). At first relapse all 15 had symptoms of median
duration 2 months (compared to 4 months at first diagnosis) and
detectable plasma HHV8 viraemia. The median CD19 (B-cell) count at
relapse was 474/mL (16%) suggesting that this had recovered
following rituximab first-line therapy. The 5-year relapse-free survival
for patients achieving remission is 78% (95% CI 6789%) (Figure 2).
The risk of relapse was not influenced by gender (p0.7), age
(p0.1), time since HIV diagnosis (p0.3), prior AIDS diagnosis
(p0.2), plasma HIV viraemia (p0.9), use of antiretroviral therapy
(p0.1), CD4 (p0.9), CD8 (p0.1), CD19 (B cell) (p0.4) and
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CD16/56 (Natural Killer (NK) cell) (p0.5) counts. The plasma HHV8
at MCD diagnosis (p0.4) and the addition of chemotherapy to
rituximab for high-risk patients (p0.2) similarly did not affect the
relapse risk. All 12 patients with no lymphoma at relapse were
retreated with rituximab-based immunotherapy and all achieved a
second clinical remission. Five have had second relapses also
successfully treated and three have had third relapses including
one patient who died from progressive MCD at fourth relapse 9.4
years after first MCD diagnosis.
Conclusions: Relapse following rituximab-based treatment for MCD
is not infrequent and may occur after recovery of CD19 (B cell)
counts. Clinical, virological and immunological predictors of relapse
have not been identified. Relapses are usually sensitive to rechallen-
ging with rituximab-based immunochemotherapy.
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Introduction: With advent of antiretroviral therapy, non-communic-
able diseases, including malignancies, are increasingly contributing to
morbidity and mortality among HIV-infected patients. Data on
incidence of cancer (AIDS-defining and non-AIDS-defining malignan-
cies) in patients on virologically suppressive ART from resource-
limited settings like India are rare.
Materials and methods: HIV-infected patients following up
at a private HIV clinic from February 2009 to 2016 and on
virologically suppressive ART (plasma viral load B1000 copies/mL)
were included. Patients presenting with incident cancer were
recorded. Histopathology examination, immunohistochemistry
testing, bone marrow and cerebrospinal fluid examination and
positron emission tomography scan were done for diagnosis,
staging and prognostication of cancer. Cox proportional hazard
model was developed to assess relationship between time to cancer
and covariates namely age, gender, baseline CD4, hepatitis B co-
infection, baseline addictions and duration of virologically suppres-
sive ART.
Results: A total of 1431 HIV-infected individuals (36% females) with
median follow-up on suppressive ART of 40 months were included.
Median age was 40 years and median baseline CD4 count 161 cells/
mm
3. Of these, 39 patients had diagnosis of incident cancer
with an incidence of 7.29 (95% CI 5.329.97) episodes per 1000
person-years. Non-Hodgkin’s lymphoma (15/39), Hodgkin’s lympho-
ma (4/39) and hepatocellular carcinoma (3/39) were the commonly
diagnosed incident cancers in our cohort. Overall 18/39 (46.15%)
patients had AIDS-defining cancers while 21/39 (53.85%) had non-
AIDS-defining cancers. Eight of 21 (38.1%) patients had infection-
related non-AIDS-defining cancers (i.e. hepatocellular carcinoma,
anal cancer and Hodgkin’s lymphoma) and 13/21 (61.9%) patients
had infection-unrelated non-AIDS-defining cancer (i.e. lung cancer,
ovarian cancer, cancer of oral cavity). Median time to development
of cancer was 24 months. Male patients (p0.039) and those with
HIV/hepatitis B co-infection (p0.018) were significantly associated
with incident cancer (Table 1). Forty-one percent of patients died
during treatment of incident cancer.
Conclusion: Spectrum of incident cancers in our cohort of virologi-
cally suppressed HIV patients is evenly distributed between AIDS-
defining and non-AIDS-defining malignancies. Regular screening for
cancer amongst elderly HIV-infected males and HIV/hepatitis B co-
infected patients is warranted. Emphasis on tobacco de-addiction
can further reduce cancer incidence.
P196
Self-administered treatment with imiquimod 5% cream for
intra-anal HSIL (AIN2/3) in HIV-positive patients: efficacy,
safety and a comfortable option
Abstract P194Figure 1. Five-year overall survival of 84 patients
treated with rituximab-based immunotherapy for HIV-associated
MCD: 92% (95% CI 8499%).
Abstract P194Figure 2. Five-year relapse-free survival for pa-
tients achieving remission from HIV-associated MCD following
rituximab first-line therapy: 78% (95% CI 6789%).
Abstract P195Table 1. Risk factors associated with incident
cancer in Pune cohort
Factors
Hazard rates
ratio (RR)
p
value
95% CI for hazard
rates ratio
Age 40 years 1.886 0.056 0.9833.620
Male:female 2.515 0.039 1.0466.046
Baseline hepatitis B 3.835 0.005 1.4908.974
Baseline CD4
count 550
1.881 0.086 0.9143.868
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Introduction: Anal squamous cell carcinoma (ASCC) is one of the
most frequent non-AIDS-defining malignancies in HIV-infected
patients; it is closely related to the infection by oncogenic HPV
genotypes (HR-HPV). Currently there are diverse treatments for
premalignant lesions with disappointing results. Imiquimod is a
drug with anticarcinogenic and antiviral activity, and it is recom-
mended for treatment of genital/perianal condylomas. It is not
suggested for the treatment of anal HSIL; nevertheless, the results
of two research studies about imiquimod in premalignant anal
lesions in HIV-positive patients have been published with a cure
rate of 45 to 61% [1,2]. The aim of this prospective study was to
analyze the efficacy of 3 consecutive days a week for 4 months of
self-administered treatment with imiquimod 5% cream for anal
HSIL, and to assess safety, and antiviral activity against HPV, in
seropositive patients.
Methods: Between May 2013 and May 2016, 20 HIV-positive patients
with HSIL were enroled to self-apply imiquimod cream into the anal
canal. Baseline visit (V0) and each visit enclosed cytology, HPV PCR
genotyping (GeneAmp PCR System 9700, Applied Biosystems) and
high-resolution anoscopy (HRA) (Zeiss 150 fc#), medical history,
sexual habits, CD4 and HIV viral load. Response was assessed by
cytology, HRA and biopsy 1 month after therapy, and annually. If HSIL
persisted, the treatment with imiquimod was extended 6 weeks more.
The cytologic and histologic classification was Bethesda’s, and LASTS
Project for HPV-Associated Lesions, respectively.
Results: The average age was 36.5 years, 95% MSM and 5% WSM,
50% had history of AIDS-defining illnesses, CD4 nadir 295 cells/mL
and current CD4 577 cells/mL. Ninety percent antiretroviral therapy,
and 94.7% viral load B50 copies/mL. Fifty percent were smokers,
20% had syphilis and 35% genital/perianal warts. Sixty-three percent
of them used condoms in 100% of intimate relationships. Ninety-five
percent had HR-HPV genotypes, and the most frequent was HPV16
(65%). The median of quadrants of anal canal affected with HSIL was
2 (IQR 12). Complete response was observed 90% of the patients
(88% (16/18) received imiquimod 4 months, and 11.1% (2/18)
required prolonged the treatment), the median disease-free time
was 21 months (IQR 11.327.5). Ten percent dropped out due to
intolerance. After imiquimod, the clearance rate of HR-HPV was
higher than the acquisition rate, 28.6% versus 21.4%, respectively,
p0.014.
Conclusions: Imiquimod could be an effective, safe and comfor-
table option for the treatment of anal HSIL in HIV-positive patients; and
it could exercise control over the infection of HR-HPV in anal mucosa.
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Introduction: The prevalence of non-AIDS-defining cancers (non-
ADCs) is increasing among people living with HIV. Conversely,
some non-ADCs are associated with HIV prevalence figures higher
than those of the general population. After observing HIV testing
rates below 5% in our oncology centre, we performed a study
Investigating Barriers In HIV-Testing Oncology Patients (IBITOP I)
among oncology physicians and patients at Lausanne University
Hospital (LUH) [1]. We found that 18% of cancer patients were
offered HIV testing although patient acceptance of testing was
high (91%). After this study, the Swiss Federal Office of Public Health
HIV testing recommendations were updated to include cancer
patients undergoing chemotherapy in the lists of HIV testing
indications. The study presented here, IBITOP II, examined HIV
testing practices and physician barriers to testing following these
recommendations.
Methods: Between 1 January and 31 October 2015, patients of
unknown HIV status newly diagnosed with solid-organ non-ADCs
referred to LUH Oncology Service, Lausanne, Switzerland, were
offered free HIV testing as part of their oncology work-up. The
primary endpoints were 1) physician proposition rates for HIV testing
and 2) physician reasons for not offering testing.
Results: Of 438 patients of unknown HIV status with a new non-ADC
diagnosis, 255 (58%) were offered HIV testing, of whom 42 declined
(acceptance rate 213/255, 84%). Excluding 37 patients tested prior to
their oncology consultation, 146 patients (of 438, 33%) were not
offered testing. The most frequent physician reasons for not testing
were: forgetting (35 patients, 24%); patient follow-up elsewhere (25
patients, 17%); no planned chemotherapy (25 patients, 17%);
excessive burden of information for the patient (23 patients, 16%)
and no time (21 patients, 14%).
Conclusion: This is the first study exploring physician reasons
for not HIV-testing cancer patients despite current national HIV
testing recommendations. Given the physician barriers we observe,
testing will not be practised universally among cancer patients.
Further, it is possible the testing rate of 58% will be lower outside
the context of a study on testing. As HIV-positive status impacts
on the medical management of cancer patients, knowledge
of HIV status is important. We conclude that opt-out testing
in this setting, conducted as part of the baseline oncology
work-up, would circumvent physician barriers and optimize testing
rates.
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Introduction: HIV-infected patients are at increased risk of develop-
ing certain cancers, especially those related to viral infections [1,2].
Patients and methods: We conducted a retrospective cohort study
on 4994 HIV-infected patients that were followed up in our hospital
between 1986 and 2016. We evaluated the incidence of types of
cancer occurring in this cohort.
Results: We detected 416 patients with at least one malignancy.
Epidemiological data appears in Table 1 and Table 2.
HIV infection and cancer were simultaneously diagnosed in 111
patients (26.6%) and in the other 304 patients after a median of 7
years (IQR 115) of follow-up. The malignancy was diagnosed as
clinically advanced in 35 patients (8.4%). The most frequent cancers
were Kaposi’s sarcoma (110, 26.4%; disseminated 40/110, 36.7%),
cervix carcinoma (85, 20.4%), lymphoma (78, 18.7%; non-Hodgkin
lymphoma 43/78, 55.84%), anal carcinoma (26, 6.25%), hepatocel-
lular carcinoma (20, 4.8%), lung carcinoma (13, 3.1%) and head
and neck tumours (11, 2.6%). Hundred and fifteen (27%) cancers
were related to human papillomavirus (HPV) and 20 hepato-
cellular carcinoma (100%) had chronic HBV and/or HCV infection,
19/20 chronic HCV co-infection. After 15 years (IQR 821) of follow-
up, 73 patients developed a second malignancy (mainly lymphoma
and cervix carcinoma) and afterwards, 8 patients developed a third
cancer. Non-AIDS-defining cancers (lung carcinoma, hepatocellular
carcinoma and head and neck cancers) were significantly more
frequent in late ART period (pB0.001 for all). No differences
were found in the incidence of anal carcinoma. On the other hand,
AIDS-defining cancers trended to decrease with the ART improve-
ment. During follow-up, 62 patients died mainly due to progression
of their malignancies (87.1%). Higher mortality was observed in
patients with lung carcinoma (100%) and hepatocellular carcinoma
(65%).
Conclusions: A malignancy was, in a substantial number of cases,
the first manifestation of HIV infection. As expected, a significant
proportion of cancers were related to other viral infections;
especially HPV and hepatitis virus. Non-AIDS-defining cancers
were more frequent during the late ART period and have high
mortality.
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Introduction: In recent years in Russia, the number of cases of HIV
infection transmitted heterosexually increased. This led to an
increase in the number of women of reproductive age among
patients with HIV infection. HIV-infected women have a higher risk of
papillomavirus infection than HIV-negative women, as well as a
higher risk of malignancy and persistence.
Objective: To study the prevalence of human papilloma virus (HPV)
in HIV-infected women.
Materials and methods: We examined 561 people (155 (27.6%) HIV-
positive patients and 406 (72.4%) HIV-negative women) from January
2014 to March 2016. For all women, HPV PAP test was performed.
Results: In the study group, young women up to 40 years (62.4%)
were predominant. For 60 (38.7%) patients, HIV infection was
diagnosed with HPV. In 92% of these patients, HPV concentration
was greater than log circ;3. In the control group, HPV was found to
be 14.8%. HPV concentration in the control group was observed log
circ;3 more in 75% of cases. Analyzing the distribution of ASC-US and
CIN, we discovered in the group with HIV infection that CIN1 and
CIN2 substantially prevailed. The study showed a difference in the
frequency of detection of certain genotypes in the study groups
(Table 1).
Table 1. Baseline characteristics
N (%)
Total 416
Male 279 (67%)
Median age at cancer diagnosis 42 (IQR 3550)
Caucasian 367 (89.2%)
Risk behaviour
- Sexual 239 (57.4%)
- Parenteral 130 (31.2%)
- Unknown 47 (11.3%)
Chronic HBV 17 (4%)
Chronic HCV 87 (20.9%)
AIDS 280 (67.3%)
CD4 nadir (cells/mL) 132 (IQR 47224)
Receiving ART on diagnosis 277 (69%)
Abstract P198Table 2. Type of malignancy related to ART use and diagnosis time
Pre-ART (before 1996) Early ART (19962006) Late ART (after 2006) p
Total malignancies 46 148 222
Lymphoma 3 (6.5%) 35 (23.6%) 40 (18%) 0.031
Kaposi’s sarcoma 18 (39.1%) 56 (37.8%) 36 (16.2%) B0.001
Cervix cancer 17 (36.9%) 38 (25.6%) 30 (13.5%) B0.001
Anal cancer 4 (8.7%) 4 (2.7%) 18 (8.1%) 0.084
Hepatocellular carcinoma 0 2 (1.35%) 18 (8.1%) B0.001
Lung carcinoma 0 0 13 (5.8%) B0.001
Head and neck cancer 0 0 11 (4.9%) B0.001
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In both groups, we found no combination of 16 and 18 genotypes.
The most common changes in the results of cytogram PAP test were
correlated with genotype 16. The group of HIV-infected women
shared the leading position 16, 31 and 18 genotypes. The high
oncogenic HPV types were more often detected in HIV-infected
women.
Conclusions: In the group of HIV-infected women significant abnorm-
alities associated with HPV were observed more than the control
group. We must look for ways to solve this problem by advising HIV-
positive women and their partners, conducting educational seminars,
providing information on the need for screening for HPV among
women living with HIV and the general population.
CO-MORBIDITIES AND COMPLICATIONS
OF DISEASE AND/OR TREATMENT:
METABOLIC
P200
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Introduction: Millions of HIV-infected Africans are living longer due to
long-term antiretroviral therapy (ART), yet little is known about
glucose metabolism disorders in this group.We aimed to compare the
prevalence of glucose metabolism disorders among HIV-infected
adults on long-term ART to ART-naı¨ve adults and HIV-negative
controls, hypothesizing that the odds of glucose metabolism dis-
orders would be two-fold greater even after adjusting for possible
confounders.
Methods: In this cross-sectional study conducted between October
2012 and April 2013, consecutive adults (18 years) attending an
HIV clinic in Tanzania were enroled in three groups: 153 HIV-negative
controls, 151 HIV-infected, ART-naı¨ve and 150 HIV-infected on ART
for ]2 years. The primary outcome was the prevalence of glucose
metabolism disorders as determined by oral glucose tolerance
testing. We compared glucose metabolism disorder prevalence
between each HIV group versus the control group by Fisher’s exact
test and used multivariable logistic regression to determine factors
associated with glucose metabolism disorders.
Results: HIV-infected adults on ART had a higher prevalence of
glucose metabolism disorders (49/150 (32.7%) vs. 11/153 (7.2%),
pB0.001) and frank diabetes mellitus (27/150 (18.0%) vs. 8/153
(5.2%), p0.001) than HIV-negative adults, which remained highly
significant even after adjusting for age, gender, adiposity and
socioeconomic status (OR 5.72 (2.7811.77), pB0.001). Glucose
metabolism disorders were significantly associated with higher
CD4 T-cell counts. Awareness of diabetes mellitus was B25%.
Conclusions: HIV-infected adults on long-term ART had five-fold
greater odds of glucose metabolism disorders than HIV-negative
controls but were rarely aware of their diagnosis. Intensive glucose
metabolism disorder screening and education are needed in HIV
clinics in sub-Saharan Africa. Further research should determine
how glucose metabolism disorders might be related to immune
reconstitution.
Abstract P199Table 1. The distribution of HPV genotypes in the studied groups
Groups HPV (%) HPV concentration logˆ 3 Mixed HPV genotypes Leading genotypes
HIV infection 38.7% 92% 48.3% 18, 16, 1, 45
Control group 14.8% 75% 23.3% 16, 33, 45
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Introduction: The widespread use of combination antiretroviral
treatment (cART) has led to a decrease of mortality and morbidity
and improvement of survival in HIV-positive patients. However,
increasing trends of metabolic complications including type 2
diabetes mellitus (DM) have threatened the long-term successful
management of HIV infection. Our study aimed to evaluate the
incidence of DM in ART-naı¨ve HIV-positive Taiwanese adults who
initiated ART in 2004 to 2013.
Materials and methods: Between 2004 and 2013, 1432 ART-naı¨ve
HIV-positive patients without DM initiated cART at the National
Taiwan University Hospital. All patients were followed until the date
when DM was diagnosed, 31 December 2015, loss to follow-up or
death, whichever occurred first. Incident DM was defined as fasting
glucose ]126 mg/dL or HbA1C ]6.5%. The trends of DM were
compared between patients initiating cART in 2004 to 2008 (n564
patients) and those in 2009 to 2013 (n886).
Results: Over a total observation of 7632 person-years of follow-up
(PYFU), DM was diagnosed in 28 patients, with an overall incidence
rate of 3.7 per 1000 PYFU. While the rate increased with cumulative
exposure to cART, from 0 per 1000 PYFU in patients with cumulative
exposure to cART of B12 months to 3.9 per 1000 PYFU in those with
cumulative exposure of ]36 months, the overall rate decreased
from 4.8 per 1000 PYFU in 20042008 to 1.2 per 1000 PYFU
(p0.02). The occurrence of DM was associated with an older age
(adjusted hazard ratio (aHR) 1.049; 95% CI 1.0131.085), exposure to
boosted darunavir (aHR 3.287; 95% CI 1.1689.254) and exposure
to tenofovir/emtricitabine (aHR 0.194; 95% CI 0.0720.522). The
incident rate of DM increased with cumulative exposure to
zidovudine/lamivudine duration: B12 months, 2.6 per 1000 PYFU;
12 to 24 months, 2.0 per 1000 PYFU; 24 to 36 months, 4.3 per 1000
PYFU; and ]36 months, 4.8 per 1000 PYFU. In contrast, the rate
remained stable with cumulative exposure to tenofovir/emtricita-
bine: B12 months, 0.9 per 1000 PYFU; 12 to 24 months, 1.2 per
1000 PYFU; 24 to 36 months, 1.3 per 1000 PYFU; and ]36 months,
1.2 per 1000 PYFU. The rates were higher in patients with exposure
to stavudine and/or didanosine, ranging from 7.7 to 10 per 1000
PYFU.
Conclusions: The incidence of DM in HIV-positive Taiwanese patients
initiating cART decreased from 4.8 per 1000 PYFU in 20042008 to
1.2 per 1000 PYFU in 20092013. The trends of DM incidence varied
with the cumulative exposure to different combination of nu-
cleos(t)ide reverse transcriptase inhibitors.
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Introduction: Type 2 diabetes (T2D) is more common in people living
with HIV (PLHIV) than general populations, thought to be driven by
HIV-specific and general factors. Early detection of risk is key to limit
disease progression. Several clinical risk tools are available but do not
account for the consequences of HIV infection.We aimed to compare
the sensitivity and specificity of diabetes risk tools in PLHIV.
Materials and methods: A wide range of clinical factors was
measured and recorded in a representative HIV-positive patient
sample attending three London outpatient clinics. Glycaemic status
was classified as: normal, prediabetes or T2D by fasting glucose
(B6.0, 6.06.9 and ]7.0 mmol/L respectively) or by previous
diagnosis. T2D risk was calculated using three risk tools: the Finnish
(FINDRISC), Q-Diabetes and the Data Collection on Adverse Events of
Anti-HIV Drugs (D:A:D) risk scores. Percentage calculations were used
to evaluate dysglycaemia prevalence against published national
averages. Receiver operator characteristic (ROC) curves were used
to calculate tool sensitivity and specificity.
Results: Of 338 patients sampled, 17.2% had prediabetes and 15.1%
had T2D. In the general London population, the rates of prediabetes
and T2D are 10.8% and 7.6% respectively (data collected elsewhere).
The Q-Diabetes tool calculates T2D relative risk; the mean for this
cohort was 2.4. ROC analysis suggested that D:A:D is the most
sensitive and specific of the three tools for prediabetes, correctly
identifying 100% of those affected (area under curve [AUC] 0.879;
95% CI 0.8430.914; pB0.001), compared to FINDRISC and
QDiabetes with 0.804 (95% CI 0.7510.858; pB0.001) and 0.611
(95% CI 0.5330.688; pB0.001) respectively. For T2D detection,
D:A:D had the greatest specificity, followed by the FINDRISC score,
identifying 96% and 90%, respectively (AUC 0.888; 95% CI 0.851
0.924; pB0.001 for D:A:D; for FINDRISC, AUC 0.825; 95% CI 0.775
0.875; pB0.001). Q-Diabetes had a comparable specificity of 84% for
T2D (AUC 0.676; 95% CI 0.6050.747; pB0.001) but the poorest
sensitivity of the three tools tested (42%, 65% and 68% for Q-
Diabetes, FINDRISC and D:A:D, respectively).
Conclusion: The D:A:D tool appears to be the most statistically
sensitive and specific method for predicting both prediabetes and
T2D in this HIV-positive cohort, with the FINDRISC tool also
performing well. The Q-Diabetes tool, developed for use in the UK,
has the lowest sensitivity of three tools. Pending development of an
HIV-specific diabetes risk tool, the D:A:D tool should be used to
estimate risk of T2D in PLHIV.
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Lipodystrophy as cause of metabolic syndrome:
a contribution of antiretroviral drugs to increased
cardiovascular risk
Vanessa Mun˜oz-Mendoza1; Maria Fontecha-Ortega2; Cristina Go´mez
Ayerbe3; Maria Jesu´s Vivancos Gallego3; Matilde Sa´nchez Conde3 and
Jose Luis Casado Osorio3
1Internal Medicine, Hospital Obispo Polanco, Teruel, Spain. 2Internal
Medicine, Hospital de Getafe, Madrid, Spain. 3Infectious Diseases,
Hospital Ramo´n y Cajal, Madrid, Spain
Introduction: Lipodystrophy syndrome (LS) is characterized by
abnormal fat distribution with visceral fat accumulation and
peripheral lipoatrophy. The aim of this study was to evaluate the
development of cardiovascular risk factors and the progression to
metabolic syndrome in patients with previous lipodystrophy accord-
ing to the severity of fat accumulation.
Materials and methods: Cross-sectional study of 276 HIV patients
previously evaluated for the presence of lipodystrophy and its
severity (absence, mild, moderate or severe) through HOPS ques-
tionnaire during 20042011. Patients were evaluated for fat
accumulation by dual X-ray absorptiometry (DXA) and the presence
of hypertension (HTA), diabetes mellitus (DM), waist circumference,
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
151
insulin resistance and lipid alterations. Metabolic syndrome (MS) was
defined according to ATP-III, IDF and AHA criteria.
Results: Mean age was 45.1 years (2080), 80% were males, and
prior fat accumulation was classified as absent in 37%, mild in 21%,
moderate in 19% and severe in 23%. Mean BMI was 24.2 (16.134.5)
and 6% had a BMI 30. The median time of HIV infection was 15
years (721). All patients with lipodystrophy had a history of prior
therapy with thymidine analogues, and at the inclusion, 47% were
receiving a PI and 53% an NNRTI. Median time from questionnaire to
evaluation was 9.5 years. DXA scan showed a close correlation with
severity of lipodystrophy by questionnaire. A systolic blood pressure
140 mmgHG was observed in 30%, serum glucose 110 mg/dL in
13%, insulin resistance in 23%, total cholesterol 200 mg/dL in 30%,
LDL cholesterol 130 mg/dL in 31%, HDL cholesterol B35 mg/dL in
29% and triglycerides (TG) 200 mg/dL in 22%. Patients having
moderate or severe fat accumulation showed increased values of
these parameters. Thus, overall, 40% fulfilled the ATP III criteria for
metabolic syndrome (ranging from 23% in absence of LD, 32% mild,
46% moderate to 71% in case of previous severe LD), a similar
presentation to that observed with the IDF definition (36% of MS;
ranging from 20% in absence to 69% in severe) and higher than that
of AHA (overall, 19%; ranging from 8%, 5%, 21% to 45%).
Conclusions: The presence of fat accumulation and its severity is
associated with increased incidence of different cardiovascular risk
factors and progressive appearance of ‘‘iatrogenic’’ secondary
metabolic syndrome.
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HAART is not associated with future diabetes risk
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Introduction: HAART and HIV infection have been implicated in
impairing glucose and lipid metabolism in people living with HIV.
Increases in body mass index (BMI) following HAART initiation have
been well documented in the literature. We aimed to investigate the
association between BMI status at HAART initiation and future risk of
developing type 2 diabetes.
Methods and materials: A wide range of clinical factors were
measured and recorded in a representative HIV-positive patient
sample attending three London outpatient clinics. BMI was calcu-
lated prior to commencing HAART and 1 year after initiating therapy
and were classified according to World Health Organization interna-
tional criteria (underweight 518.5 kg/m2, normal 18.524.9 and
overweight 25.029.9, obese ]30.0). Glycaemic status was classi-
fied by fasting glucose as normal or dysglycaemia (B6.0 and ]6.0
mmol/L respectively). Univariate statistical analysis and binary
logistic regression were used to estimate contributions to risk of
dysglycaemia.
Results: Binary logistic regression suggests that BMI percentage
change in the first year post-HAART was a significant predictor of
dysglycaemia with relative risk (RR) of 6.6% for each percentage
increase in BMI (RR 1.066; 95% CI 1.0311.101; pB0.001) (Table 1).
Dysglycaemia risk increased by 13% for each percentage increase in
BMI (RR 1.131; 95% CI 1.0681.198; pB0.001) for normal weight
subjects and by 41% for obese patients (RR 1.408; 95% CI 1.069
1.853; p0.015). Weight gain in those patients with a BMI below
18.5 kg/m2 was not associated with future diabetes risk. The type of
HAART used in the first year of treatment was not significantly
associated with future dysglycaemia.
Conclusion: Normalisation of undernutrition in the year
following initiation of HAART is not associated with future diabetes
risk. Prevention of excessive weight gain following initiation
of HAART should be a priority in those with a BMI greater than
18.5 kg/m2.
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associated with diabetes risk
Jonathan Mok1; Louise Goff2; Barry Peters3 and Alastair Duncan2
1School of Medical Education, King’s College London, London, UK.
2Division of Diabetes and Nutritional Sciences, King’s College London,
London, UK. 3Harrison Wing, Guy’s and St Thomas’ Hospital NHS
Foundation Trust, London, UK
Introduction: HIV infection and antiretroviral therapy have been
implicated in mediating metabolic derangement. Hepatic steatosis
has been associated with the development of dysglycaemia in HIV-
negative cohorts; however, the impact of HIV and concordant factors
has been relatively understudied. We aimed to investigate the
prevalence of hepatic steatosis in an urban HIV cohort and assess its
association with other factors.
Methods and materials: As part of the NIHR-funded STOP Diabetes
in HIV cross-sectional study, a range of clinical information was
collected from a sample structured to statistically represent HIV-
positive patients attending large South London clinics. Hepatic
steatosis was diagnosed by biopsy or FibroScan. Glycaemic status
was classified by fasting glucose as normal or dysglycaemia (B6.0
and ]6.0 mmol/L, respectively). Univariate statistical analysis and
binary logistic regression were used to estimate risk factors for
hepatic steatosis, and contributions to risk of dysglycaemia.
Results: Hepatic steatosis was present in 21% (n71) of the total
cohort (n339). There was a significant correlation between hepatic
steatosis and dysglycaemia (Pearson’s Chi-squared pB0.001). For
those with hepatic steatosis, the odds ratio (OR) of developing the
condition is 10.08 (95% CI 5.5318.40; pB0.001). Significant ORs
were found for nucleoside reverse transcriptase inhibitors tradition-
ally associated with metabolic dysfunction: zidovudine, stavudine,
didanosine and zalcitabine (OR 20.339; 95% CI 1.144361.611;
p0.040). Other significant factors included statin therapy (OR
3.313; 95% CI 1.7676.211; pB0.001), overweight (OR 0.320; 95%
CI 0.1340.767; p0.011) and obesity (OR 0.073; 95% CI 0.031
0.174; pB0.001).
Conclusion: Hepatic steatosis is significantly correlated with diabetes
risk in people living with HIV. Factors that are implicated in mediating
this metabolic derangement include the use of nucleoside reverse
transcriptase inhibitors and statin therapies, and BMI. The diagnosis
and subsequent treatment of hepatic steatosis in HIV patients
is key.
Table 1. Percentage change in BMI after 1 year of HAART,
stratified by pre-HAART BMI status
BMI status
pre-HAART
n
(cohort%)
BMI change 1
year post-
HAART
initiation (%) 95% CI p
Underweight 19 (6) 19.2 9.3, 31.3 B0.001
Normal weight 171 (56) 4.7 3.6, 5.8 B0.001
Overweight 80 (26) 3.3 1.5, 5.1 B0.001
Obese 36 (12) 1.6 1.2, 4.1 0.221
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P206
HIV-positive inflammatory activity monitoring correlated to
insulin resistance: HIRE study
Melissa Soares Medeiros1; Henrique Pires Moreira2; Debora Veras Da
Ponte2; Ana Carolina dos Santos Araujo2; Andre Pereira de Brito
Neves2; Rebecca Santos Souza1; Huylmer Lucena Chaves2;
Morgana Feitosa de Queiroga2; Vinicius Ximenes Paula2 and
Erico Antonio Gomes Arruda3
1Infectious Diseases, Unichristus University/Hospital Sao Jose,
Fortaleza, Brazil. 2Infectious Diseases, Unichristus University,
Fortaleza, Brazil. 3Infectious Diseases, UECE University/Hospital Sao
Jose, Fortaleza, Brazil
Introduction: Insulin resistance and diabetes mellitus are important
metabolic complications of HIV-infected patients’ therapy, since an
increased survival occurred after HAART [1,2]. HIV-infected patients
have an increased risk of hyperglycaemia associated with inflamma-
tory activity and medications, and this can implicate directly in
survival and life quality [3]. Inflammatory status related to these
patients can also be responsible for increases risk of hospitalization
and bad prognosis [4].
Materials and methods: This study was a retrospective analysis of a
multicentre cohort proposed to evaluate impact and risk factors for
insulin resistance in HIV outpatients of Unichristus Center University
and Hospital Geral de Fortaleza, including sociodemographic issues,
hospitalization data, comorbidities and laboratory data.
Results: A total of 218 patients were included, 73.9% male, median
age of 37 years, median HIV diagnosis of 24 months and median
follow-up period of 21 months. CD4/CD8 rate before ART 0.3890.29
and final 0.6290.4, initial CD4 count mean 400 cells/mm3 and final
570 cells/mm3, 97.3% had suppressed viral load in final visit. Only
2.8% of patients had diabetes mellitus before HIV diagnosis. There
was a significant increase in glucose levels after HAART initiation
(18.5% vs. 36.7%, p0.0025). Fasting glucose elevation was
detected as a risk factor to develop symptoms during follow-up
(RR 1.35; 95% CI 1.011.80; p0.002). A higher monocyte/
lymphocyte ratio was associated with hospitalization during the
follow-up before (p0.011) and after (p0.033) introduction of
ART. After introduction of HAART, there was an increase in Castelli
index for hyperglycaemic patients, but significant difference did not
remain during follow-up. Castelli index was 4.591.2 before ART,
4.891.4 after 12 months, 5.491.8 after 24 months and 5.391.8
after 36 months.
Conclusion: Antiretroviral therapy is an important factor associated
with higher glucose levels, and causes insulin resistance associated
with uncontrolled lipid levels. Perhaps, HIV treatment is essential
to control chronic inflammation and its consequences. Mono-
cyte/lymphocyte ratio can be an easy marker for inflammation
activation monitoring and could be associated with higher risk for
hospitalization.
References
1. Galescu O, Bhangoo A, Ten S. Insulin resistance, lipodystrophy and
cardiometabolic syndrome in HIV/AIDS. Rev Endocr Metab Disord.
2013;14:13340. doi: http://dx.doi.org/10.1007/s11154-013-9247-7
2. Kagaruki GB, Kimaro GD, Mweya CN, Kilale AM, Mrisho RM, Shao
AF, et al. Prevalence and risk factors of metabolic syndrome among
individuals living with HIV and receiving antiretroviral treatment in
Tanzania. Br J Med Med Res. 2015;5:131727. doi: http://dx.doi.org/
10.9734/BJMMR/2015/14455
3. Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA.
Association between systemic inflammation and incident diabetes in
HIV-infected patients after initiation of antiretroviral therapy.
Diabetes Care. 2010;33:22449. doi: http://dx.doi.org/10.2337/
dc10-0633
4. Shen Y, Wang Z, Liu L, Zhang R, Zheng Y, Lu H. Prevalence of
hyperglycaemia among adults with newly diagnosed HIV/AIDS in
China. BMC Infect Dis. 2013;13:79. doi: http://dx.doi.org/10.1186/
1471-2334-13-79
P207
A cross-sectional study of comorbidities in HIV-infected
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Introduction: HIV-infected individuals may be at increased risks of
age-associated non-communicable comorbidities during use of cART.
We conducted a nationwide surveillance for the prevalence of non-
communicable comorbidities among HIV-infected patients receiving
cART.
Materials and methods: Comorbidity data from 2010 to 2013 were
obtained from the Taiwan National Health Insurance Research
Database while 20,726 HIV-infected patients were identified. Non-
communicable comorbidities are defined as type II diabetes mellitus
(DM), hypertension, dyslipidaemia, acute coronary syndrome (ACS)
and cholelithiasis or nephrolithiasis.
Results: Among 20,726 HIV-infected patients in Taiwan, 13,142 of
them receiving antiretroviral therapy were included in the analysis.
Mean age of the 13,142 patients was 36.6 while 34.1% of them are
older than 40 years and most are male (93.6%). The annual number
of subjects newly on cART increased from 1819 to 3418 during study
period. In the newly on cART population, around 70% were aged
between 20 and 39 years and the majority were male (93%). The
prevalences of comorbidities in the total study population were type
II DM 7.3%, hypertension 33.6%, dyslipidaemia 24.0%, major
depressive disorder 21.2%, use of sedative drug 39.5%, ACS 0.5%
and cholelithiasis or nephrolithiasis 5.5%. In addition, the prevalence
increased sharply after age 40, especially for metabolic comorbidities
(type II DM: 15.0% vs. 3.3%; hypertension: 46.7% vs. 26.8%;
dyslipidaemia: 34.9% vs. 18.4%; ACS: 1.2% vs. 0.2%; cholelithiasis
or nephrolithiasis: 7.3% vs. 4.6%). In the study population, 13.2% of
patients had more than two concomitant comorbidities and that
prevalence also increased sharply after 40 years old (24.8% vs. 7.2%).
Conclusion: According to our nation-wide surveillance between 2010
and 2013, comorbidities among HIV-infected patients receiving cART
in Taiwan demonstrated high prevalence in patients aged 40 years or
older.
CO-MORBIDITIES AND COMPLICATIONS
OF DISEASE AND/OR TREATMENT:
NEUROLOGICAL
P208
Tryptophan metabolism and its relationship with central
nervous system toxicity in subjects switching from efavirenz
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Introduction: The pathogenesis of central nervous system (CNS)
toxicities observed in antiretroviral treated (ART) persons living with
HIV (PLWH) remains elusive. We investigated the associations
between indoleamine 2,3-dioxygenase-1 (IDO-1) activity, via kynur-
enine/tryptophan (KYN/TRP) ratios, and measurements of CNS
toxicity in PLWH switching from efavirenz (EFV) to dolutegravir
(DTG).
Materials and Methods: In a prospective, randomised, open-label,
multi-centre study, virologically-suppressed PLWH receiving an EFV-
containing regimen for 12 weeks with ongoing CNS toxicity were
switched to DTG and followed-up for 12 weeks. Plasma neopterin,
TRP and KYN concentrations were measured and the KYN/TRP ratio
calculated. Rates of CNS toxicities were measured using a ques-
tionnaire based on the EFV label and graded according to the ACTG
adverse events scale. They included dizziness, depression, insomnia,
anxiety, confusion, impaired concentration, headache, somnolence,
aggression and abnormal dreams. Scores ranged from 0 (none) to
3 (severe) and were summed, giving a total score ranging from 0 to 30.
CNS toxicity measurements also included assessment using the
Instrumental Activities of Daily Living (IADL) and Hospital Anxiety &
Depression (HAD) scales. Univariate (paired-samples t-tests) and
linear mixed model analyses were conducted.
Results: The majority of subjects were male (95%) and White (95%).
Mean age was 47.8 years. The mean plasma concentration of KYN sig-
nificantly increased from baseline to week 12 (2.12 to 2.49 mmol/L,
p0.002). A non-significant increase was observed for the KYN/TRP
ratio (39.7 to 44.8 mmol/mmol, p0.012). Significant reductions
in mean CNS toxicity score (10.1 to 4.5, pB0.001) and HAD score
(14.1 to 8.4, pB0.001) were observed from baseline to week 12.
Mean IADL scores did not change significantly (7.8 to 7.90,
pB0.570). In the linear mixed model analyses, plasma KYN
concentrations and KYN/TRP ratios were found to be statistically,
significantly, negatively correlated with CNS toxicity scores. For every
1 mmol/L increase observed in KYN concentration, a 1.7 point
decrease was observed in the CNS toxicity score (Table 1). Likewise,
for every 1 mmol/mmol increase observed in the KYN/TRP ratio,
a 0.1 point decrease was observed in the CNS toxicity score. No
significant relationship was observed for KYN or KYN/TRP ratios and
HAD scores.
Conclusions: Switching from EFV to DTG was associated with
improvements in CNS toxicity and HAD scores, and increases in
plasma KYN concentrations. Increases in plasma KYN concentrations
and the KYN/TRP ratio correlated with decreases in CNS toxicity.
Underlying mechanisms need to be established and may include EFV-
induced changes in concentrations of hepatic reactive oxygen species
and CNS inflammatory processes.
P209
Multicentre open-label pilot study of switching from
efavirenz to dolutegravir for central nervous system (CNS)
toxicity
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Laura Dickinson5; Marta Boffito1 and Mark Nelson6
1Chelsea and Westminster Hospital, St Stephen’s AIDS Trust, London,
UK. 2HIV/GUM, Royal Sussex County Hospital, Brighton, UK. 3HIV/
GUM, Mortimer Market Centre, London, UK. 4HIV/GUM, St Mary’s
Hospital, London, UK. 5Molecular & Clinical Pharmacology, University
of Liverpool, Liverpool, UK. 6HIV/GUM, Chelsea and Westminster
Hospital, London, UK
Introduction: Efavirenz (EFV) remains a widely used third agent with
increasing numbers of patients switching due to CNS toxicities. Data
on improvement of CNS toxicities after switch to dolutegravir (DTG)
are scarce. We investigated substitution of EFV for DTG, in
combination with two NRTIs, in patients with ongoing EFV-associated
CNS side effects.
Methods: A randomized open-label multicentre study of virologically
suppressed patients receiving an EFV-containing regimen for at least
12 weeks. Randomization was to immediate (IS) versus delayed
switch (DS) (after 4 weeks) to DTG, without backbone change.
Primary endpoint was rate of CNS toxicity (CNS score) at 4 weeks in
the IS versus DS arms, measured by a questionnaire based on EFV
SPC and graded according to ACTG adverse event scale. Secondary
endpoints were: rate of CNS toxicity at 12 weeks post-switch, change
in sleep, quality of life, neurocognitive function, CD4 count, fasting
lipids, maintenance of virological suppression post-switch and DTG
PK post-switch.
Results: Forty patients (38 males), mean age 48 years (range 2767)
were enrolled: 19 IS and 21 DS arms. Median CD4 was 544/601 cells/m
in IS/DS, respectively. Baseline CNS score was similar in both arms
(IS 33, DS 40). There was a significant improvement in CNS score at
week 4 in the IS arm versus DS arm (pB0.001). Combined (both
arms) improvement in total CNS score, 4 weeks post-switch was
significant (pB0.001) and maintained during the study period
(pB0.001). Reduction in abnormal dreams (pB0.001), dizziness
and depression (p0.008) at weeks 4 and 12 post-switch were
observed (Table 1). Significant improvement in hospital anxiety and
depression scale (HADS), quality of life (EQ-5D) and quality of sleep
(Pittsburgh Sleep Score) was found at weeks 4 and 12 post-switch. All
subjects completed the study and maintained virological suppression
without changes in CD4 cell count/% or adherence. Better lipid
profile with changes (mmol/L) in total cholesterol, LDL and
triglycerides at weeks 4 and 12 post-switch was observed (mean
change at week 12: cholesterol 0.8, pB0.001; LDL 0.38,
pB0.001; triglycerides 0.24, pB0.001). Geometric mean (95% CI)
Abstract P208Table 1. Linear mixed model results for KYN and KYN/TRP ratio and CNS toxicity from baseline to week 12
Parameter Estimate (95% CI) t(df) P 2 Log Likelihood for Model
Model 1: CNS Toxicity and KYN
Mean CNS Toxicity Score 10.4 (7.0 to 13.9) 6.0 (104) B0.001 685.2
KYN, mmol/L 1.7 (3.1 to 0.3) 2.4 (111) 0.019
Model 2: CNS Toxicity and KYN/TRP Ratio
Mean CNS Toxicity Score 10.4 (6.8 to 14.1) 5.7 (83) B0.001 690.4
KYN/TRP Ratio, mmol/mmol 0.1 (0.2 to 0.0) 2.3 (89) 0.027
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of DTG plasma concentrations 24 hours post-dose (predicted by
population PK modelling) was 862.8 ng/mL (848.9962.2 ng/mL).
Concentrations increased over the 4 weeks post-switch and all
remained above DTG IC90 for WT virus (64 ng/mL).
Conclusions: Switching EFV to DTG was associated with significant
improvement in CNS toxicity, with a reduction in overall CNS score
and improvement in depression, dizziness and quality of sleep,
without affecting antiretroviral efficacy.
P210
Psychiatric adverse events from the DTG ART-naı¨ve phase 3
clinical trials
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Nassrin Payvandy5; Justin Koteff6 and Michael Aboud3
1Research and Development, ViiV Healthcare, Brentford, UK.
2Statistics, ViiV Healthcare, Mississauga, Canada. 3Medical Affairs,
ViiV Healthcare, Brentford, UK. 4Pharmacovigilance, GlaxoSmithKline,
Stockley Park, UK. 5Pharmacovigilance, ViiV Healthcare, Brentford,
UK. 6Medical Affairs, ViiV Healthcare, Research Triangle Park,
North Carolina, USA
Introduction: To provide characterization of select psychiatric
adverse events (pAEs), including anxiety, depression (including:
depression, bipolar, suicidal ideations and hypomania), insomnia
and nightmares/abnormal dreams reported in the dolutegravir (DTG)
phase 3/3b treatment-naı¨ve clinical trials.
Materials and Methods: Safety data of pAEs from phase 3/3b trials
in ART-naı¨ve adults were analysed. Data at 96 weeks for SPRING-2,
SINGLE, FLAMINGO and at 48 weeks for the all-women study, ARIA,
Table 1. Abstract P209Table 1. Overall CNS score at week 4 (IS vs. DS) and CNS grade 3/4 side effects (S/E) at 4 and 12 weeks post-
switch in IS and DS arms
IS (N19) DS (N21) IS (N19) DS (N21) IS (N21) DS (N19) IS (N21) DS (N19)
BL W4 p
W4 post-
switch
W12 post-
switch
Overall CNS
score (0100),
median (IQR)
33 (2053) 40 (2753) 10 (720) 33 (2043) B0.001 10 (720) 10 (323) 10 (317) 10 (323)
% of
improvement:
16% (436) 13%
(1026)
17% (433) 16% (1033)
pB0.001 pB0.001 pB0.001 pB0.001
Proportion (%)
of patients
with:
Proportion
(%) of
patients with
grade 3/4 S/E:
Overall grade 3/4
toxicity
100 95.2 26.3 95.2 B0.001 26.3
(pB0.001)
47.6
(pB0.001)
26.3
(pB0.001)
42.9 (pB0.001)
Insomnia 47.4 61.9 21.1 42.9 0.258 21.1
(p0.025)
28.6
(p0.317)
15.8
(p0.014)
19.1 (p0.317)
Abnormal
dreams
84.2 85.7 5.3 81 B0.001 5.3
(pB0.001)
14.3
(pB0.001)
0
(pB0.001)
19.1 (pB0.001)
Dizziness 21.1 28.6 0 28.6 0.037 0 () 0 () 0 () 0 ()
Depression 42.1 38.1 5.3 38.1 0.035 5.3
(p0.008)
4.8
(p0.008)
5.3
(p0.008)
19.1 (p0.046)
Anxiety 36.8 52.4 10.5 19.1 0.756 10.5
(p0.059)
4.8
(p0.180)
5.3
(p0.014)
14.3 (p0.564)
Confusion 15.8 0 0 0  0 () 0 () 5.3
(p0.157)
4.8 ()
Impaired
concentration
26.3 28.6 10.5 19.1 0.756 10.5
(p0.180)
14.3
(p0.564)
5.3
(p0.046)
9.5 (p0.317)
Headache 0 19.1 0 19.1 0.140 0 () 0 () 0 () 4.8 (p0.083)
Somnolence 21.1 38.1 5.3 28.6 0.128 5.3
(p0.180)
14.3
(p0.083)
10.5
(p0.317)
14.3 (p0.083)
Aggressive
behaviour
10.5 23.8 5.3 19.1 0.402 5.3
(p0.564)
4.8
(p0.083)
5.3
(p0.317)
4.8 (p0.083)
BL, baseline; DS, delayed switch; IQR, inter-quartile range; IS, immediate switch; S/E, side effect; W4, week 4; W12, week 12.
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were analysed. Frequencies of pAEs were summarized for DTG and
the comparator drug by study.
Results: There were 2634 subjects analysed in the four clinical
studies including 1315 patients treated with DTG. Safety summaries
showed a low number of pAEs across all study treatment arms, with
the majority of these being low grade (12). The rates of pAEs
leading to withdrawals were low across all trials (B5% for each
individual analysis). Anxiety led to four discontinuations with EFV in
SINGLE. Depression led to one discontinuation with DTG in SINGLE,
two with RAL in SPRING-2 and seven patients on EFV in SINGLE.
Insomnia led to two DTG discontinuations, one each in SINGLE and
ARIA respectively, and three EFV patients in SINGLE. Additionally in
SINGLE, two DTG and seven EFV patients discontinued because of
nightmares/abnormal dreams. There was higher pAE reporting within
SINGLE that was inconsistent with the other studies. The rates of
anxiety, insomnia, depression and nightmares/abnormal dreams, in
the DTG and comparators arms across the four phase 3/3b clinical
trials, are outlined in Figure 1.
Conclusions: In the four treatment-naı¨ve clinical trials, DTG once
daily was well tolerated with a low rate of pAEs. The inconsistency
seen in the SINGLE study may be partially explained by study design
bias; a double-blind study versus efavirenz and the use of the HIV
Symptom Index Distress Module. The majority of all pAE cases were
low grade, and few led to discontinuations.
P211
Prevalence of undiagnosed neurocognitive impairment in
HIV-infected adults taking efavirenz on a long-term basis
with undetectable or low HIV RNA compared with protease
inhibitors
Nuno Marques1; Catarina Fernandes2; Sandra Tejo2; Ana Cristina
Rosa3; Maria Emı´lia Nogueira3; So´nia Rocha2; Joa˜o Treˆpa2 and
Jose´ Saraiva da Cunha2
1Infectious Diseases, Hospital Garcia de Orta, EPE, Almada, Portugal.
2Infectious Diseases, Centro Hospitalar e Universita´rio de Coimbra,
EPE, Coimbra, Portugal. 3Department of Mathematics, Faculty of
Sciences and Technology, University of Coimbra, Coimbra, Portugal
Introduction: Neurocognitive impairment remains a major issue in
HIV infection. The main objective was to assess the prevalence of
HIV-associated neurocognitive disorders (HAND) according to the
Frascati criteria in asymptomatic HIV-infected adults on stable and
long-term cART regimen containing EFV versus a protease inhibitor
(PI) regimen.
Materials and methods: Cross-sectional comparative study of HIV-
infected adults on cART containing EFV or a PI (DRV/r; ATV/r or LPV/r)
with undetectable or low (B400 copies/mL) viral load for over
6 months and on the same regimen for at least the past 12 months.
Exclusion criteria were pregnancy; previous diagnosis of: dementia of
any cause; major opportunistic infection of the brain in the past 3
years before study entry; history of ischemic or haemorrhagic stroke;
history of untreated and/or symptomatic syphilis; current major
psychiatric/neurologic disorders according to the opinion of the
investigators; current illicit drug-use disorder and/or alcohol abuse.
Patients were clinical evaluated with neurologic exam, CD4 count,
HIV viral load, urine drug screen and syphilis serology. Psychological
testing included International HIV Dementia Scale (IHDS), Beck
Depression Inventory, The Lawton Instrumental Activities of Daily
Living and an adaption of the questionnaire to assess adherence to
antiretroviral treatment  HIV (CEAT-VIH). Additional testing was
performed in case of IHDS score B10. Statistical analysis was
performed using SPSS version 22 and SAS-JMP version 12 for Firth
bias-adjustment in logistic regression.
Results: A total of 314 patients (sample size with power of 80% and
level of significance of 5%), 157 on EFV and 157 on PI were included.
HAND was not associated with EFV or PI regimens (p0.359). Its
prevalence was 18.5% (n29) on EFV and 14% (n22) on PI group.
Baseline characteristics are shown in Table 1. In the univariate
analysis, the variables associated with HAND were: mental status
abnormalities such as memory (pB0.001), abstraction, judgment and
mood (pB0.001) and calculation abilities (p0.015); abnormalities
in the casual gait (p0.032), heel-to-toe gait (pB0.001) and toes
walking (p0.007); dysdiadochokinesis (p0.002); diabetes (p
0.025); dyslipidaemia (p0.043); hypertension (p0.048); anaemia
(p0.028), report of adverse events on CEAT-VIH (p0.05); educa-
tional level, such as illiteracy (pB0.001) and primary education
(pB0.01) and older age (pB0.001).
Conclusions: Abnormalities in the neurologic exam, metabolic
comorbidities, anaemia, older age and education level were asso-
ciated with HAND.
Acknowledgements: This work has been supported by an unrest-
ricted grant from Gilead Sciences Europe Ltd.
P212
Adverse events and discontinuation of dolutegravir-based
therapy in naı¨ve and experienced HIV patients: tertiary HIV
centre experience
Abstract P210Figure 1. Psychiatric Adverse Events rates from the DTG ART-Naı¨ve Phase III Clinical Trials.
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Introduction: Dolutegravir was first available for use on a compas-
sionate basis in the UK in 2013 for the treatment of HIV and was then
licensed in 2014. It is now recommended as one of the preferred
third agents in the national British HIV Association guidelines [1].
Abstract P211Table 1. Baseline characteristics
Baseline characteristics EFV group (n157) PI group (n157) [DRV/r: 66; ATV/r: 63; LPV/r: 28] p
Age (mean9SD) 48.82 (912.12) 48.74 (911.35) 0.95
Gender 0.892
Male 121 (77.1%) 123 (78.3%)
Female 36 (22.9%) 34 (21.7%)
Body mass index (mean9SD) 24.47 (94.27) 25.51 (94.33) 0.112
Educational level 0.446
Illiteracy 4 (2.5%) 4 (2.5%)
Basic 1st cycle 33 (21%) 49 (31.2%)
Basic 2nd cycle 24 (15.3%) 19 (12.1%)
Basic 3rd cycle 45 (28.7%) 42 (26.8%)
Secondary 36 (22.9%) 28 (17.8%)
Higher education 15 (9.6%) 15 (9.6%)
HIV transmission categories 0.999
Heterosexual 89 (56.7%) 88 (56%)
Men who have sex with men 33 (21%) 34 (21.7%)
Blood transfusion 1 (0.6%) 0 (0%)
Injection drug use 34 (21.7%) 35 (22.3%)
Years of HIV infection (mean9SD) 10.73 (95.37) 9.95 (96.01) 0.224
Years on current cART (mean9SD) 5.36 (92.4) 4.27 (92.34) B0.001
Years on antiretroviral therapy (mean9SD) 7.98 (94.59) 7.18 (94.75) 0.098
Years of HIV viral suppression (mean9SD) 7.21 (94.21) 5.34 (93.56) B0.001
AIDS B0.001
History of AIDS 21 (13.4%) 49 (31.2%)
No history of AIDS 136 (86.6%) 108 (68.8%)
Nadir CD4 243.85 (9136.56) 177.24 (9150.58) B0.001
CD4 count at the time of study entry 690.27 (9285.89) 589.77 (9287.32) 0.002
CPE, antiretroviral CSF penetration-effectiveness B0.001
CPE of 6 0 (0%) 47 (29.9%)
CPE of 7 135 (86%) 84 (53.5%)
CPE of 8 21 (13.4%) 23 (14.7%)
CPE of 9 1 (0.6%) 3 (1.9%)
Syphilis 0.019
History of syphilis 37 (23.6%) 57 (36.3%)
No history of syphilis 120 (76.4%) 100 (63.7%)
Erectile dysfunction 0.036
Presence of erectile dysfunction 1 (0.6%) 8 (5.1%)
No erectile dysfunction 156 (99.4%) 149 (94.9%)
Antidepressant use 0.1
No antidepressant use 141 (89.8%) 130 (82.8%)
Antidepressant use 16 (10.2%) 27 (17.2%)
HCV co-infection 0.599
No HCV co-infection 112 (73.2%) 115 (76.2%)
HCV co-infection 41 (26.8%) 36 (23.8%)
ABC/3TC backbone 21 (13.4%) 25 (15.9%)
AZT/3TC backbone 1 (0.6%) 9 (5.7%)
FTC/TDF backbone 135 (86%) 121 (77.1%)
AZTTDF backbone 0 (0%) 2 (1.3%)
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Despite dolutegravir’s perception as a well-tolerated antiretroviral,
its SPC describes psychiatric side effects including insomnia,
abnormal dreams and depression as common (incidence 110%)
and headaches as very common (incidence 10%) [2]. This study
looked at real-world data of dolutegravir tolerability and switch in
our UK tertiary centre that manages over 1500 HIV-positive patients.
Materials and methods: A retrospective case review of all patients
who received dolutegravir-containing antiretroviral regimens was
conducted, both as fixed-dose combination (Triumeq) and dolute-
gravir single tablet. Data were collected from when dolutegravir was
first prescribed in our centre (June 2013) until June 2016. Informa-
tion regarding patient demographics, previous experience to ART,
documented side effects and switch was collected from HIV patient
records.
Results: Hundred and seventy-eight patients have received dolute-
gravir-containing regimens in our centre, 126/178 (71%) were
treatment-experienced patients and 52/178 (29%) naı¨ve patients.
Table 1 shows patient demographics; they are predominantly
Caucasian males, with ART-naı¨ve patients being on average 10 years
younger than their ART-experienced counterparts. More ART-naı¨ve
patients commenced a fixed-dose combination tablet containing
dolutegravir (Triumeq) compared to ART-experienced patients, 90%
(47/52) compared to 69% (87/126).
In total, 59/178 (33%) patients starting a regimen containing
dolutegravir experienced adverse events. Of these, 68% (40/59)
were experienced patients. Table 2 shows the adverse events
experienced. Despite 35 (20%) of all patients suffering severe CNS
side effects (anxiety, depression, paranoia and personality change)
only one patient suffered severe CNS disturbance with new suicidal
ideation and self-harm. Only 10 patients (6%) had to stop their
dolutegravir-containing regimen with eight (4%) of these stopping
due to side effects.
Conclusion: In our cohort, the majority of patients starting
dolutegravir-containing regimens were treatment experienced. ART-
experienced patients also suffered the most adverse events, with
CNS problems being the most common. Whilst up to one-third of
patients experienced adverse events from their dolutegravir-containing
regimen, very few patients have needed to stop their treatment. From
our real-world data the incidence of CNS side effects is significantly
greater than in its licensing studies and has an implication on the use
of dolutegravir in the clinical setting.
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Introduction: Biomarkers able to differentiate patients with HIV-
associated neurocognitive disorders (HAND) are urgently needed for
diagnosing and managing HIV-positive patients. Specifically infected
astrocytes may be involved in the process since they are key
elements in the neurovascular unit and blood brain barrier (BBB).
Materials and methods: Naı¨ve and treated patients complaining of
cognitive disturbances and undergoing complete cognitive tests
(eight areas, diagnosis according to the Frascati criteria) and lumbar
puncture (less than 6 months apart) were included; patients with
opportunistic infections or neoplasms affecting the central nervous
system were excluded. Immunovirological and therapeutic data as
well as plasma S100Beta and CSF (tau, ptau, BAmil, neopterin,
S100Beta, CSAR) biomarkers were recorded. Variables are described
as medians (interquartile ranges) and analysed through non-
parametric tests.
Results: Seventy-nine patients were included: 58 (73.4%) were male
and 38 (48.1%) were on treatment. Median age, plasma and CSF HIV
RNA and CD4 T cell count were 47 years (4356), 74,912 copies/mL
(55342,216), 1614 copies/mL (6812,662) and 102 cells/mm3
(48408). Thirty-six patients (45.5%) were diagnosed with HAND:
25 asymptomatic (31.6%), eight mild neurocognitive impairment
(10.1%) and three dementias (3.8%). CSF tau, p-tau, BAmil,
neopterin, S100Beta, plasma S100Beta and CSAR were 105 pg/mL
(38251), 33 pg/mL (2144), 839.8 pg/mL (6511156), 1.6 ng/mL
(15.2), 150.5 pg/mL (88.6275), 34 pg/mL (3452.5) and 6 (4.1
7.68). CSF tau (234 pg/mL (87.9357) vs. 62 pg/mL (37.5206.4),
pB0.001) and CSF S100Beta (227.3 pg/mL (111.7299.6) vs. 129 pg/mL
(76.8220), p0.025) were significantly higher in patients with
HAND; CSF neopterin was borderline higher in patients with HAND
Table 1. Patient demographics
Demographics Naı¨ve Experienced Total
Gender
Male 47/52 (90%) 81/126 (64%) 128/178 (72%)
Female 5/52 (10%) 45/126 (36%) 50/178 (28%)
Ethnicity
Caucasian 46/52 (88%) 92/126 (73%) 138/178 (78%)
African/Afro
Caribbean
4/52 (8%) 32/126 (25%) 36/178 (20%)
Asian/other 2/52 (4%) 2/126 (2%) 4/178 (2%)
Age
Median 34 years 43 years 40 years
Range 2064 years 1876 years 1876 years
Table 2. Incidence of adverse events of patients in dolute-
gravir-containing regimens
Adverse event Naı¨ve (/52) Experienced (/126) Total (/178)
Central nervous
system (CNS)
10 (19%) 25 (20%) 35 (20%)
Gastrointestinal 6 (12%) 11 (9%) 17 (10%)
Neurological 7 (13%) 5 (4%) 12 (7%)
Musculoskeletal 0 (0%) 6 (5%) 6 (3%)
Lethargy 1 (2%) 5 (5%) 6 (3%)
Dermatological 1 (2%) 3 (2%) 4 (2%)
Urogenital 0 (0%) 2 (2%) 2 (1%)
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(2.9 ng/mL (1.258.95) vs. 1.45 ng/mL (0.753.18), p0.051).
Plasma S100Beta was found to be mildly associated with CSAR
(p0.042, r0.272). Furthermore, we observed significant correla-
tions between CSF S100Beta, CSF neopterin and tau and specific
neurocognitive tests (mostly in the areas of attention, verbal flu-
ency, concentration and short-term memory), as shown in Table 1
underneath.
Conclusions: CSF tau and S100beta were significantly higher in
patients with HAND. The former represents a marker of neuronal
damage while the latter is produced by activated astrocytes, thus
highlighting the potential role of these cells in the pathogenesis of
HIV-associated neurological damage. Higher CSF markers were
associated with worse performances in selected test in memory,
attention and verbal fluency domains. Plasma S100Beta was asso-
ciated with CSAR but this observation needs to be further confirmed
in order to validate a peripheral marker of BBB impairment.
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Introduction: Incidence of neurosymptomatic CSF HIV escape in
patients on suppressive protease inhibitor (PI)-based ART is inade-
quately studied in resource-limited settings (RLS) like India. Data on
emergence of multidrug-resistant HIV in CNS are also rare.
Methods: HIV patients enrolled in cohort from February 2009 to
2016 and currently taking PI-based ART (two nucleoside reverse
transcriptase inhibitors (NRTI) plus boosted PI or raltegravir plus
boosted PI) for minimum 6 months with plasma viral load B1000
copies/mL were included. Those presenting with incident neurode-
terioration were recorded as cases. Magnetic resonance imaging
(MRI) and CSF study was done to establish diagnosis. Paired plasma
and CSF viral load was done to diagnose CSF HIV escape. CSF escape
was defined as CSF viral load 50 copies/mL while plasma load
B50 copies/mL or CSF viral load 1 log higher than plasma viral load.
CSF genotypic resistance testing (GRT) was performed in a subset of
patients.
Results: Out of 1427 ART-experienced individuals (36% females), 322
were on PI-based suppressive ART. Median age was 40 years, median
baseline CD4 count 161 cells/mm3 and median duration of
suppressive ART 39 months. Seventeen patients developed CSF HIV
escape and incident encephalopathy (incidence rate: 14.73 (95% CI
8.1626.59) episodes per 1000 person-years). Median plasma and
CSF viral load in patients were 170 and 2300 copies/mL. Median time
to development of CSF escape was 33 months. CSF GRT was
performed in 7/17 patients. Resistance mutations to lamivudine
(M184V) and NNRTI were seen in all seven patients. Thymidine
analogue mutations (TAMs) conferring NRTI cross resistance and
major PI mutations (I50L, V82A) were seen in 5/7 patients each. In
10/17 therapy was changed only on basis of cerebral penetration
effectiveness score (CPE) of ART. Eleven of 17 patients with CSF
escape had plasma and CSF HIV viral load B50 copies/mL after
change to neuroactive ART. There was one death due to CSF HIV
escape. Use of tenofovir and atazanavir/ritonavir was associated with
CSF escape while zidovudine protected against it. History of smoking
(p0.034) and CPE score B6 (p0.031) were strongly associated
with CSF escape.
Conclusions: Association of CSF escape with CPE score B6 further
strengthens the case for using ART with better CNS penetration. CSF
GRT shows emergence of multidrug-resistant CNS HIV requiring use
of newer ARVs like darunavir, raltegravir and maraviroc which are
sparsely available in RLS like India.
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Introduction: The major efavirenz metabolite, 8-hydroxy-efavirenz,
has been reported as plausibly responsible for efavirenz-induced
neurotoxic effects [13]. Notably, up to 35% of patients on
efavirenz suffer from mood changes [4]. This work aimed to
investigate 8-hydroxy-efavirenz as a determinant of mood changes
and to evaluate the suitability of 8-hydroxy-efavirenz biomonitoring
for the management of these manifestations.
Materials and methods: A case control study comparing the plasma
concentrations of efavirenz, 8-hydroxy-efavirenz and 8-hydroxy-
efavirenz-glucuronide was performed in two age-matched groups
of HIV-infected male patients, one without adverse central nervous
Abstract P213Table 1. Correlations between CSF biomarkers and specific neurocognitive tests among HIV-positive patients
Stroop test
Trail Making test
AB Corsi test
Serial Repetition
of Disyllabic
Words Verbal Fluency
Free and Cue Selective
Reminding test
CSF tau p 0.05 rho 0.39 NS p B0.01 rho 0.47 p 0.01 rho 0.35 p 0.03 rho 0.30 NS
CSF S100 b NS p 0.03 rho 0.29 p B0.01 rho 0.37 p 0.04 rho 0.24 NS Delayed: p 0.04 rho
0.40 Immediate: p 0.03
rho 0.41
CSF
neopterin
p 0.03 rho 0.36 NS p 0.01 rho 0.31 NS p 0.05 rho 0.26 NS
NS, non-significant. Spearman correlation test was used to make statistical analysis.
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system complaints (control group, 28 patients) and the other
presenting mood changes (study group, 14 patients). The following
anthropometric and clinical data were gathered for each patient:
age, time on efavirenz, antiretroviral comedication, time between
blood sampling and last efavirenz dose intake, viral load, CD4 cell
count, alanine aminotransferase levels and self-reported symptoms
of mood changes (anxiety, agitation, euphoria, mental confusion,
paranoia, hallucinations and depression). The study protocol received
prior approval from the Ethics Committee of Centro Hospitalar de
Lisboa Central, EPE (115/2013). Patients gave their written informed
consent in accordance with the Declaration of Helsinki and
compliance was controlled by the clinician.
Results: There were no differences between the two groups regarding
the recorded clinical and anthropometric parameters. The most noticed
mood change was anxiety, in 71% of the patients. Non-conjugated 8-
hydroxy-efavirenz plasma levels were higher in the study group, when
compared to the control group (p0.020). No differences were found
for efavirenz or 8-hydroxy-efavirenz-glucuronide levels among groups.
Efavirenz was directly associated with 8-hydroxy-efavirenz-glucuronide
(Spearman r0.414, pB0.010) within therapeutic efavirenz concen-
trations. However, for toxic plasma concentrations of the parent drug
(4 mg/L), this correlation was lost.
Conclusion: The biotransformation of efavirenz into 8-hydroxy-
efavirenz has a role in efavirenz-related mood changes. The plasma
concentration of this metabolite is a suitable parameter for
therapeutic drug monitoring and mood changes management.
Moreover, these data suggest that 8-hydroxy-efavirenz crosses
the blood-brain barrier and that toxic concentrations of efavirenz
might inhibit peripheral detoxification of 8-hydroxy-efavirenz via
glucuronidation.
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Portugal), through research grants UID/QUI/00100/2013, RECI/QEQ-
MED/0330/2012, SFRH/BD/80690/2011; SFRH/BD/86791/2012; IF/
01091/2013, and the LRI Innovative Science Award.
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Introduction: The diagnosis of HAND relies on neuropsychological
assessment (NPA), often confounded by other conditions affecting
cognitive performance. Moreover, these methods do not distinguish
static and residual impairment from active and ongoing brain injury.
For a more accurate clinical diagnosis, plasma and CSF biomarkers
analysis was performed.
Materials and methods: Single-centre, cross-sectional analysis of
immune activation (neopterin, sCD14) or neuronal injury (neurofila-
ment light-chain protein, NFL) biomarkers by ELISA assay in CSF/
plasma paired samples from HIV-positive patients well characterized
for neurocognitive impairment (NCI) and HAND classification. All
patients underwent lumbar puncture (LP) and received NPA in a
period of 6 months before or after LP. A comprehensive tests battery
(14 tests/five domains) was used to diagnose NCI. HAND were
classified according to Frascati’s criteria. Wilcoxon matched-pairs test
was used.
Results: Fifty-four CSF/plasma pairs from as many patients included:
74% male, median age 47 years (IQR 4051), heterosexual 31%,
MSM 9%, IVDU 33%; 79% CDC C. Neurological signs/symptoms in
76%. Median current and nadir CD4 cells/mm3 was 251 (IQR 105
384) and 68 (IQR 24118), respectively; 41 patients (76%) were on
ARV, median plasma log10 HIV RNA was 2.5 (IQR 1.64.5) and CSF
2.2 (IQR 1.63.8). Undetectable HIV RNA in 30% of plasma and 32%
of CSF sample. According to Frascati’s criteria, eight patients (14.8%)
resulted unimpaired, 30 patients had NCI (nine ANI 30%; 13 MND
43.3%; eight HAD 26.7%), and 16 patients (29.6%) showed a major
confounder and were excluded from the analysis. CSF neopterin
Abstract P216Figure 1. Concentration of CSF NFL (log pg/mL), CSF neopterin (log ng/mL) and plasma NFL (log pg/mL) according to
unimpaired results by neuropsychological assessment and HAND classification.
ANI, asymptomatic neurocognitive impairment; HAD, HIV-associated dementia; MND, mild neurocognitive disorders.
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concentration increased with NCI worsening (unimpaired 164 ng/mL,
ANI 124, MND 191, HAD 350, p for linear trend test0.002) (Figure 1).
Both NFL concentration in CSF (median in unimpaired 677 pg/mL,
ANI 762, MND 814, HAD 1164, p at test for linear trend0.025) and
in plasma (unimpaired 1676 pg/mL, ANI 1719, MND 1830, HAD 2795,
p for linear trend0.033) increased by HAND occurrence and
severity, and a significant difference was observed both for NFL
concentration in CSF (p0.036) and plasma (p0.027) in pairwise
comparison between unimpaired and HAD (Figure 1). No differences
were found in plasma and CSF sCD14 by HAND.
Conclusions: NFL concentration both in CSF and in plasma seems to
better discriminate patients with active neuronal injury with a good
correlation with HAD stage. Instead, CSF neopterin was less sensitive
to predict HAND. Mild NCI, remarkably ANI, was not sufficiently
characterized by all biomarkers, due to presumably sub-clinical active
CNS disease even in cognitively unimpaired individuals.
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Introduction: Neuro3 is a pilot open-label study of ARV intensi-
fication in virologically controlled patients presenting HAND (HIV-
associated neurocognitive disorders): ARV was changed for a new
combination with CNS penetration effectiveness (CPE or CHARTER)
score improved ]3 points and total CPE ]9. The major endpoint
is the evaluation of neurocognitive disorders after 48 and 96 weeks.
Materials and methods: Sixty-three patients were screened with
BREF 515/18 or mHIVDS 510/12 in eight investigational centres.
Thirty-one patients were included with at least two ability domains
altered (1 SD) for the following tests, after Beck Depression
Inventory BDI II: Grooved Pegboard (d and nd), Verbal Fluency, CVLT,
Digit span, PASAT, Digit symbol, Wisconsin Card Sorting Test (six
domains). Raw test scores were converted to obtain a global deficit
score (GDS) and each patient was classified into HAND levels (ANI,
MND, HAD) using Cognitive Complaint Questionnaire (CCQ) score.
Ultrasensitive HIV RNA and ARV drugs concentrations were per-
formed at baseline and follow-up in plasma and CSF. Exclusion
criteria were drug or alcohol abuse, positivity for HBsAg or HCV,
hypothyroidism, vitamin B deficiency and psychiatric troubles. For
CPE score, we considered only drugs without genotypic resistance.
Results: Median range characteristics of the 31 enrolled patients
were: 26 men, 54 years (3364), educational level of 11 years (517),
HIV duration 20 years (229), undetectable plasma HIV RNA duration
7 years, baseline plasma HIV RNA 2 copies/mL (2 patients 20:26
and 40 copies/mL), baseline CSF HIV RNA B1 copy/mL (nine
patients between 7 and 78 copies/mL), 29% of undetectable drugs
in CSF, baseline CPE of 6 (38) with current ARV therapy, CPE after
new combination of 10 (all score ]9 except two patients).
Treatment intensification was obtained with INSTI (64.5%), CCR5
inhibitor (32.3%) or NNRTI (19.4%). Median GDS was significatively
reduced from 1.4 at baseline to 0.8 at week 48 and 1.0 at week 96,
number of altered domains from four to three at week 48 and week
96, CCQ score from 4 to 2 at week 48 and 1 at week 96, BDI score
from 14 to 8 at week 48 and 10 at week 96. At baseline, there were
seven ANI, eight MND, and 16 HAD. At weeks 48 and 96, 16/31
patients (52%) and 19/31 (61%) were classified in an improving
category of HAND. The evolution of CSF HIV RNA and drug
concentrations are consistent with the drug combination used.
Conclusions: Treatment intensification by NNRTI, INSTI and/or R5
inhibitor was associated with a statistically significant improvement
in cognitive tests at week 48 and week 96.
CO-MORBIDITIES AND COMPLICATIONS
OF DISEASE AND/OR TREATMENT: RENAL
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Introduction: Atazanavir (ATV) and lopinavir (LPV) have been asso-
ciated with kidney disease progression in HIV-positive individuals, with
no data reported for darunavir (DRV). We examined kidney function in
patients who switched their protease inhibitor from ATV or LPV to DRV.
Materials and methods: The UK CHIC study is an ongoing cohort of
HIV-positive individuals accessing HIV care in the UK since 1996.
Individuals who switched from either ATV or LPV to DRV with at least
6 months exposure and two estimated glomerular filtration rate
(eGFR) measurements both pre- and post-switch were included in
this study. Mixed effects linear regression models were used to
compare pre- and post-switch eGFR slopes in all switchers, those
with rapid eGFR decline (5 mL/min/1.73 m2/year) on ATV or LPV,
those with eGFR B60 mL/min/1.73 m2 prior to switch and according
to tenofovir (TDF) use. Models were adjusted for age, gender,
ethnicity and time-updated CD4 cell count, HIV RNA and TDF use.
Mean (95% CI) eGFR slopes are reported in mL/min/1.73 m2/year.
Results: Data from 1691 patients were included. At the time of
switching, median age was 45 years, 79% were male, 77% had an
undetectable viral load, and the median eGFR was 93 mL/min/1.73 m2.
Mean (95% CI) pre- and post-switch eGFR slopes were 0.97
(1.35, 0.59) and 1.06 (0.69, 1.44) for ATV, and 0.51 (0.90,
0.12) and 0.43 (0.14, 0.71) for LPV, showing a significant increase
in eGFR after switching to DRV. Amongst those with rapid eGFR
decline on ATV or LPV, stable or improved kidney function was
observed following the switch to DRV (Table 1). Improved kidney
function after switching was also observed in those with an eGFR
B60 mL/min/1.73 m2 prior to switch (Table 1). When split by TDF
use prior to switch, we observed steeper eGFR declines pre-switch
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and more rapid eGFR increases post-switch amongst those exposed
to TDF, compared to those unexposed. Further, there was no
significant difference in pre- and post-switch eGFR slopes amongst
those not receiving TDF. Significant changes in eGFR slopes were still
observed following switch to DRV in those who did not also
discontinue TDF at the time of the switch (Table 1).
Conclusions: Improved kidney function was observed in patients
who switched from ATV or LPV to DRV, particularly amongst those
with renal dysfunction and those exposed to TDF prior to switching,
suggesting that DRV may have a more favourable renal safety profile.
P219
Renal health after long-term exposure to tenofovir
disoproxil fumarate (TDF) in HIV/HBV co-infected individuals
in Sub-Saharan Africa: results from the HEPIK cohort
Giovanni Villa1; Richard Odame Phillips2; Colette Smith3;
Alexander Stockdale1; Apostolos Beloukas1; Lambert Tetteh Appiah2;
David Chadwick4; Alessandra Ruggiero1; Fred Stephen Sarfo2;
Frank Post5 and Anna Maria Geretti1
1Institute of Infection and Global Health, University of Liverpool,
Liverpool, UK. 2Department of Medicine, Kwame Nkrumah University
of Science and Technology and Komfo Anokye Teaching Hospital,
Kumasi, Ghana. 3Infection and Population Health, University College
London, London, UK. 4Centre for Clinical Infection, James Cook
University Hospital, Middlesbrough, UK. 5King’s Centre for Global
Health, King’s College London, London, UK
Introduction: Tenofovir is recommended for the antiretroviral
treatment of HIV-positive adults in Sub-Saharan Africa, including
individuals co-infected with HBV. Use of TDF is gradually expanding in
the region, where evidence indicates a high burden of pre-existing
renal disease. This cross-sectional analysis evaluated the renal profile
of HIV/HBV co-infected subjects receiving long-term TDF as part of
ART in Kumasi, Ghana.
Methods: Patients underwent a comprehensive clinical and labora-
tory assessment, including serum biochemistry with creatinine and
eGFR (CKD-EPI), urinary protein-to-creatinine ratio (uPCR), albumin-
to-protein ratio (uAPR; if uPCR 520 mg/mmol), glycated haemoglo-
bin (HbA1c), urinary schistosoma antigen, full blood count and CD4
cell count, and HIV-1 RNA and HBV DNA load. Tubular proteinuria
(TP) was defined as a uPCR 20 mg/mmol in the absence of
significance albuminuria (uAPR B0.4 mg/mmol).
Results: The study comprised 101 subjects (66% women; mean age
45 years) that had received ART for median 7.9 years (IQR 6.09.2)
and TDF for median 4.1 years (3.94.3), 90% were on efavirenz
(n87) or nevirapine (n4) and 10% were on lopinavir/ritonavir
(LPV/r). CD4 counts were median 572 (383716) cells/mm3. Overall
21% had detectable HIV-1 RNA (40 copies/mL), with median levels
of 4.2 (2.15.1) log10 copies/mL; 17% had detectable HBV DNA
(15 IU/mL), with median levels of 2.4 (1.73.4) log10 IU/mL.
Blood pressure was raised in 35% of subjects and 10% had grade 3
elevations; 6% had diabetes (HbA1c ]48 mmol/mol and/or specific
treatment); 17% had a positive schistosoma test. Median uPCR was
13 (1320) mg/mmol; 28% had uPCR ]20 and 13% 50 mg/mmol.
TP was detected in 16% of participants and was independently
predicted by female gender (adjOR 10.5; 95% CI 1.388; p0.03)
and hypertension (adjOR 2.1 per grade increment; 95% CI 1.33.5;
pB0.01). Five of 13 patients with uPCR 50 mg/mmol had
uAPR B0.4, and this was associated with diabetes (OR 27; 95% CI
2.81265; pB0.01). Median eGFR was 103 (91115) and B60 mL/
min/1.73 m2 in 4%. When comparing the eGFR measured after
1 year of TDF with the current one, the mean eGFR change was
2.6 mL/min/1.73 m2/year (SD94.3), and independently pre-
dicted by LPV/r use (p0.05) and a suppressed HBV DNA load
(p0.01).
Conclusions: Subjects on stable ART in Ghana have a substantial
prevalence of comorbidities that can impact on renal function.
The findings point to an urgent need to define ascertainment and
management strategies for renal health in these populations.
Abstract P218Table 1. Pre- and post-switch eGFR slopes amongst individuals who switch from either atazanavir or lopinavir to
darunavir
Mean change in eGFR per year (95% CI)
N Pre-switch Post-switch p
All switchers
Atazanavir 676 0.97 (1.35, 0.59) 1.06 (0.69, 1.44) B0.001
Lopinavir 1015 0.51 (0.90, 0.12) 0.43 (0.14, 0.71) B0.001
Rapid eGFR decline (5 mL/min/1.73 m2)
Atazanavir 49 14.74 (18.79, 10.69) 2.55 (0.50, 4.61) B0.001
Lopinavir 42 12.99 (15.68, 12.30) 0.63 (0.85, 2.11) B0.001
eGFR B60 mL/min/1.73 m2
Atazanavir 87 6.59 (8.69, 4.48) 2.68 (1.23, 4.13) B0.001
Lopinavir 66 2.77 (4.08, 1.46) 2.13 (0.28, 3.99) B0.001
Received TDF prior to switch
Atazanavir 478 1.08 (1.52, 0.64) 1.47 (1.01, 1.93) B0.001
Lopinavir 605 0.90 (1.09, 0.52) 0.48 (0.13, 0.82) B0.001
Did not receive TDF prior to switch
Atazanavir 198 0.27 (0.93, 0.40) 0.69 (0.04, 1.34) 0.051
Lopinavir 410 0.35 (0.87, 1.57) 0.55 (0.05, 1.05) 0.777
Did not discontinue TDF at the time of switch
Atazanavir 530 0.42 (0.86, 0.02) 0.38 (0.07, 0.69) 0.006
Lopinavir 901 0.44 (0.74, 0.14) 0.52 (0.27, 0.77) B0.001
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Factors associated with decreased estimated glomerular
filtration rate (eGFR) among HIV-1 positive persons in
methadone programme: data from Warsaw HIV Outpatient
Clinic
Bartłomiej Matłosz1; Ewa Pietraszkiewicz1; Ewa Firlag-Burkacka1;
Ewa Grycner1; Andrzej Horban2 and Justyna Kowalska2
1HIV Outpatient Clinic, Hospital for Infectious Diseases, Warsaw,
Poland. 2Department for Adults Infectious Diseases, Medical
University of Warsaw, Warsaw, Poland
Introduction: Intravenous drug use is listed as one of the risk factors
for impaired renal function; however, this group is rarely assessed for
specific renal-related risks. Here we analyze the group of patients in
methadone programme due to opiate and/or mixed addiction.
Materials and methods: Patients attending methadone programme
from 1994 to 2015 were included in the study. Electronic medical
records (available since 1994) included demographic data, laboratory
tests, antiretroviral treatment history, methadone dosing and drug
abstinence. Methadone was provided in oral solution (0.1% con-
centration before and 0.5% after 2 January 2014). Patients’ drug
abstinence was routinely checked monthly on personnel demand
(BioMaxima urine tests) for amphetamine, opiates, benzodiazepines
and THC. We have evaluated two study outcomes: (i) having at least
one (1eGFR) or (ii) three (3eGFR) eGFR B60 mL/min (MDRD
formula). Logistic regression models investigated factors related to
study outcomes (multivariate included all pB0.1 in univariate).
Results: In total, 267 persons with 2593 person-years of follow-up
were included into analyses, 83 (31.1%) women, 218 (81.6%)
infected through injecting drugs. Median age at entering HIV care
was 30.2 (IQR 25.935.5) years, weight 69 (6177) kg, HIV RNA 4.2
(3.24.8) log copies/mL, CD4 count 440 (255619) cells/mL, serum
creatinine 71 (5688) mmol/L. At the time of analyses 251 (94%)
were on ARV, 204 (81%) on PIs, 123 (46%) were anti-HBc total and
97 (36%) anti-HCV. Median methadone dose was 80 (6090) mg.
Fifty-two (19.5%) patients had 1eGFR and 20 (7.5%) 3eGFR B60. In
total, 57 (21%) patients broke abstinence with no effect on study
outcomes (univariate OR 1.09 (0.353.41; p0.88) for 1eGFR; OR
1.62 [0.723.68; p0.25] for 3eGFR B60). Multivariate model
results are presented in Table 1.
Conclusions: We have demonstrated high rate of kidney function
impairment among HIV-1 positive patients in methadone pro-
gramme. All risk factors for decreased eGFR in this subpopulation
of patients were similar to those described for general HIV
population [1]. Breaking abstinence and methadone dose had no
effect on study outcomes. These findings imply the need for frequent
but standard kidney function monitoring in this subgroup of patients.
Reference
1. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, et al.
Development and validation of a risk score for chronic kidney disease
in HIV infection using prospective cohort data from the D:A:D study.
PLoS Med. 2015;12:e1001809. doi: http://dx.doi.org/10.1371/jour-
nal.pmed.1001809
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Kidney tubular dysfunction and decline in renal function in
HIV-infected Chinese receiving tenofovir disoproxil fumarate
Chung Yan Grace Lui1; Pui Chung Denise Chan2; CY Simon Cheung3;
Man Po Lee3; Claire Naftalin2; Ka Lun Chan3; Ngai Sze Wong2 and
Shui Shan Lee2
1Department of Medicine and Therapeutics, Prince of Wales
Hospital, Hong Kong, Hong Kong. 2Stanley Ho Centre for Emerging A
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Infectious Diseases, The Chinese University of Hong Kong, Hong
Kong, Hong Kong. 3Department of Medicine, Queen Elizabeth
Hospital, Hong Kong, Hong Kong
Introduction: The prevalence of kidney tubular dysfunction (KTD) in
Chinese HIV-infected individuals taking tenofovir disoproxil fumarate
(TDF) and its impact on renal function over time are not known.
Materials and methods: A cross-sectional study was performed in a
cohort of Chinese HIV-infected individuals in Hong Kong who had
received ]3 months of TDF. Blood and urine tests were taken to
measure creatinine clearance (by Cockcroft Gault equation), and
markers of KTD (fractional tubular resorption of phosphate and
excretion of uric acid, b2-microglobulin, a1-microglobulin, N-acetyl-
b-D-glucosaminidase and retinol-binding-protein). KTD was defined
as the presence of at least three abnormal markers. Serial creatinine
clearance from prior to initiation of TDF until up to 96 months post-
treatment were collected from patients’ records. Variables associated
with KTD were evaluated using binary logistic regression. Association
between KTD and serial creatinine clearance was evaluated by
generalized estimating equations (GEE).
Results: Hundred and forty-one HIV-infected individuals were
recruited from June 2014 to January 2015: mean (9SD) age
46910 years, 88% male, median (IQR) duration of HIV diagnosis
84 (40155) months, 51% with history of AIDS, 8% with diabetes,
15% with hypertension, median duration of TDF 40 (1761) months,
55% on protease inhibitors (PI). KTD was present in 21% of
individuals, and was associated with older age, lower body weight,
higher prevalence of diabetes, history of AIDS, lower nadir CD4
count, duration of TDF, use of PI and lower baseline creatinine
clearance prior to initiation of TDF (all pB0.05). Multivariable
analysis showed that KTD was independently associated with
diabetes (adjusted odds ratio (OR) 11.5, 95% CI 2.161.8,
p0.005), current use of PI (OR 3.1, 95% CI 1.09.6, p0.048),
duration of TDF (OR 1.02, 95% CI 1.001.03, p0.048) and baseline
creatinine clearance (OR 0.97, 95% CI 0.951.00, p0.022), after
adjustment for the above variables. KTD was a significant variable for
creatinine clearance across time in GEE model, and remained
significant after adjustment for comorbidities, class of antiretroviral
drugs, duration of HIV diagnosis, duration of TDF therapy and
baseline creatinine clearance in GEE models. Creatinine clearance
decreased over time after initiation of TDF (B0.14, p0.01), and
negatively correlated with KTD (B16.9, p0.002). Annual
rate of change of creatinine clearance was 2.14 mL/min and
1.57 mL/min in those with and without KTD (Figure 1).
Conclusions: KTD was present in 21% of HIV-infected Chinese
individuals taking TDF, and was associated with more rapid decline
in creatinine clearance over time.
P222
TDF, ATV/r and other ARV: renal safety in a resource-
limiting country
Francisco Beraldi de Magalhaes1; Suelem Silva Penteado2;
Mariana Collodetto Soares3; Daniel Claro Amaral3; Melissa Mello
Mazepa3; Paulo Kato3 and Monica Gomes da Silva1
1Infectious Diseases, Federal University of Parana, Curitiba, Brazil.
2Pharmacy, Federal University of Parana, Curitiba, Brazil. 3School of
Medicine, Federal University of Parana, Curitiba, Brazil
Introduction: With increased options of ARV and the need for long-
term intake, tolerance and safety are important characteristics of
ARV combinations. In resource-limited settings, economic restrains
may guide ARV choices [1]. In Brazil, a frequent combination is the
association of TDF/3TC with ATV/r, mostly because its low pill burden
compared to other local options. Concerning the nephrotoxicity of
these ARVs [2,3], alone or in combination, we design this study to
evaluate the eGFR in HIV patients taking ARVs, and compare the
effect of different ARV combinations.
Materials and methods: This is a retrospective cohort to evaluate
renal impairment in HIV-infected patients followed at the infectious
disease out-clinic in a Brazilian hospital. During the study period, 777
patients were seen at the clinic and withdrawn their ARV at hospital’s
pharmacy. Patients were analyzed in four groups: group 1: patients
taking TDF with any ARV except ATV/r; group 2: patients taking TDF
associated with ATV/r; group 3: patients taking ATV/r with any ARV
except TDF; group 4: patients taking any ARV but never ATV/r and
TDF. All patients had their eGFR by using the CKD-EPI formula,
calculated on their 6-month visits, until 4 years [4]. Proteinuria,
crystalluria, diabetes, hepatitis B and C and viral load suppression
were also evaluated.
Results: A total of 639 patients were enrolled. Comparing groups 1, 2
and 3 with group 4, we observed different decline in eGFR. In up to
Abstract P221Figure 1. Change in creatinine clearance over time in those with (red line) and without (blue line) kidney tubular dysfunction.
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4 years of follow-up, group 3 presents a reduction of 4.82 mL/min/
1.73 m2 (p0.0003), group 1 reduces in 4.25 mL/min/1.73 m2
(pB0.00001). However, group 2 exhibited a more pronounced
reduction compared with other groups, declining 7.51 mL/min/
1.73 m2 (pB0.00001) of eGFR after 4 years of use, compared to
other strategies. Group 2 eGFR decline was 76% higher than in
patients who took TDF without ATV/r and 56% higher than ATV/r
without TDF. Group 4 expressed a lower eGFR reduction during
study period. The presence of HCV co-infection was also associated
with eGFR reduction of 13.89 mL/min/1.73 m2 (p0.00026) as
proteinuria and diabetes, eGFR decline of 6.01 mL/min/1.73 m2
(pB0.00001) and 3.40 mL/min/1.73 m2 (p0.0628), respectively.
Interestingly, eGFR was higher when patients maintain partially
suppressed VL compared to those with undetectable VL.
Conclusion: In summary, combinations including TDF, ATV/r or both
lead to a significant reduction in eGFR compared to strategies without
these medications. This reduction is more pronounced with the
association of TDF and boosted ATV. More convenient ARV options
with safer kidney profile are needed in resource-limiting countries.
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Kidney transplant in HIV-positive population: outcomes and
therapeutic perspectives in a 10-year experience
Claudia Chirico1; Ilaria Izzo1; Salvatore Casari1; Nicola Bossini2;
Nigritella Brianese1; Maria Antonia Forleo1; Emanuele Foca`1;
Silvio Sandrini2 and Francesco Castelli1
1Infectious Diseases, ASST Spedali Civili, Brescia, Italy. 2Kidney
Transplantation Unit, ASST Spedali Civili, Brescia, Italy
Introduction: The introduction of HAART made solid organ trans-
plantation a concrete option for HIV-infected patients with end-stage
organ disease, due to a prolonged life expectancy. Data about
patients and grafts survival are encouraging, but there are still
uncertainties about the prognosis in this category of patients and
about PK interactions between HAART and immunosuppressive
therapy, often with necessity of HAART modification. The aim of
our study was to investigate the outcome of HIV-infected patients
after kidney transplantation, focusing on the grafts survival, on the
control of HIV disease and on HAART options.
Materials and methods: We performed a retrospective, single-centre
study on kidney transplantation in HIV-positive patients, evaluated
between 2005 and February 2016 in the Department of Infectious
Diseases of Brescia, Northern Italy. We included HIV-positive patients
with end-stage renal disease, sustained virologic suppression (if
appropriate) and CD4 T-cell count 200 cells/mm3.
Results: We evaluated 60 patients; 32 (53%) met the eligibility
criteria (all in HAART except one patient) and entered the waiting list
for kidney transplantation; 24 (40%) patients underwent transplanta-
tion, while 22 (37%) were excluded (three died, nine lost to follow-
up, three transplanted in other centres, seven for personal reasons).
In a median follow-up time of 51 months, we observed a cumulative
number of 19 rejections in 15 patients (62.5%) and a general graft
survival proportion of 67% (N16 patients). Three patients (12.5%)
experienced AIDS-defining events (one oesophageal candidiasis, two
cutaneous Kaposi’s sarcoma). We observed a mortality of 21% (five
patients), for: invasive sinusal mucormycosis (one), sepsis in
pancolitis (one), West Nile virus encephalitis (one), acute myocardial
infarction (one) and colorectal cancer (one). To avoid PK interactions,
we changed the regimen from a PI/NRTI-based to a INI-based
regimen in 12 patients (50%).
Conclusions: Our study confirms the safety and effectiveness of
kidney transplantation in HIV-infected patients. In our experience,
we observed a high incidence of acute rejection, as reported by
other studies. We expect that the recent implementation of the
immunosuppressive protocol at transplant will allow a better
immunologic control. The recent introduction of INI allows a better
strategy of HAART, with lower incidence of PK interactions with
immunosuppressive drugs.
P224
Renal function and chronic kidney disease prognosis
through the lens of comorbidities in people living with HIV
infection: an association hard to escape
Ioanna Kalkounou1; Theodoros Retsas1; Sofia Kourkounti1;
Ioannis Katsarolis2 and Vasileios Paparizos1
1HIV Unit, Andreas Syggros’ Hospital of Cutaneous & Venereal
Diseases, Athens, Greece. 2Medical Affairs, Gilead Sciences Hellas,
Hellinikon, Greece
Introduction: Chronic kidney disease (CKD) is prevalent among
people living with HIV infection (PLHIV). HIV care guidelines stress
the importance of preserving renal function [1]. The aim of this study
was to describe the parameters that affect renal function status in a
cohort of PLHIV and the risk of progression to CKD.
Materials and methods: Cross-sectional, single-centre, retrospective
study in a random sample of clinically stable PLHIV on routine follow-
up during the last quarter of 2015. Creatinine clearance (eGFR) was
calculated by Cockroft-Gault equation with the most recent serum
creatinine and height/weight available within 6 months (grouped by
]90, 7089, 5069, B50 mL/min). D:A:D algorithm for CKD risk
progression was applied (low-medium-high risk) [2]. Demographics,
HIV-relevant data and comorbidities were collected from file.
Multimorbidity was defined as ]2 prevalent chronic conditions
per individual.
Results: Four hundred and forty-nine PLHIV were included in the
analysis sample: 84.2% men, stage C 16.3%, age 47 years, time of HIV
diagnosis 11 years, current CD4 607 cells/mL, CD4/CD8 0.69 (median
values). Approximately 94% were on ART (median ART duration 4.7
years, VL B50 90%). The distribution of eGFR levels was as follows:
]90 mL/min 39.9%, 7089 mL/min 42%, 5069 mL/min 16.1%, and
B50 mL/min 2%. Classification in D:A:D risk groups was available for
438/449: low 31.7%  medium 27.2%  high 41.1%. For 282/449
(62.8%) a comorbidity was prevalent (associated with age pB0.001,
time of HIV diagnosis pB0.001, eGFR pB0.001). Lipid disorders
were the most prevalent (30.7%) followed by neuropsychiatric
conditions (16.5%), viral hepatitis (8.9%), hypertension (6.9%),
diabetes (5.1%) and cardiovascular disease (4.7%). In approximately
18%, ]2 comorbidities were prevalent. Comorbidities’ prevalence
differed per eGFR group: ]90 mL/min 54%, 7089 mL/min 62.2%,
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5069 mL/min 84.5% and B50 mL/min 88.9% (pB0.001). A similar
pattern was identified for multimorbidity prevalence (pB0.001):
]70 mL/min 14.1%, 5069 mL/min 32.4% and B50 mL/min 44.4%.
Multimorbidity followed the same pattern per D:A:D risk group: low
5%  medium 17.6%  high 27.8%. Of interest, 46/173 (26.6%) with
eGFR ]90 mL/min were at medium and high risk for CKD
progression (26% and 0.6% respectively). For those 46 with normal
eGFR and medium or high D:A:D risk score, 28 had at least one
comorbidity (pB0.001).
Conclusions: Approximately 40% of the cohort displayed normal
eGFR levels (]90 mL/min), while 41% were at high risk for CKD
progression. eGRF and D:A:D risk group were closely associated with
the co-existence of comorbidities. Special consideration should be
paid to PLHIV with normal eGFR levels and their treatment
management, given the identified medium/high risk for CKD
progression. Given the rising prevalence of ageing HIV population,
implementation of the D:A:D CKD prediction algorithm, along with
eGFR, may optimize HIV treatment decisions.
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Introduction: Chronic kidney disease (CKD) is more prevalent in
HIV-infected patients than in general population. EACS [1], IDSA [2]
published guidelines for CKD diagnosis with classifications integrating
estimated glomerular filtration rate (GFR) and urinary protein to
creatinine ratio (uPCR) or urinary albumin creatinine ratio (uACR).
These guidelines differ and may have an impact for the estimation of
the prevalence of CKD in HIV-infected patients.
Materials and methods: We compared in a single centre population
of HIV-infected patients the prevalence of CKD using French [3], EACS
and IDSA guidelines for CKD diagnosis. GFR was estimated with
MDRD (for French guidelines) and CKD-EPI (for EACS and IDSA
guidelines). uACR and uPCR were measured in spot urine at the same
time of estimates of GFR. EACS and IDSA classifications combined
uPCR and/or uACR to eGFR. French classification uses only eGFR
(except in patients with eGFR greater than 90 mL/min/1.73 m2, CKD
is defined if uPCR 200 mg/g). We also estimated in this population
the prevalence of eGFR under 60 and 70 mL/min/1.73 m2.
Results: We included 236 participants (mean age 48.9910 years, sex
ratio 4.64/1), 219 (92.4%) received combined antiretroviral thera-
pies, and 201 (91.7%) of them had an undetectable viral load.
Median of CD4 positive cells count was 552/mm3 (551840). Median
uPCR and uACR respectively were 116 mg/g (08934) and 11 mg/g
(05914). uPCR exceeded 150 mg/g in 86 (36.3%) patients and uACR
exceeded 30 mg/g in 51 (21.5%) patients. Mean MDRD and CKD-EPI
respectively were 93.4921.2 and 97.7917.3 mL/min/1.73 m2.
EACS, IDSA with uACR, IDSA with uPCR, and French classifications
respectively identify 21 (8.9%), 54 (22.9%), 87 (36.9%) and 126
(47.4%) patients at risk for poorer kidney outcomes (pB0.001 for
EACS vs. IDSA, IDSA uACR vs. IDSA uPCR, French vs. EACS and IDSA
guidelines). Eighteen and 26 patients were respectively identified
with a GFR under 70 mL/min/1.73 m2 using CKD-EPI or MDRD
(pB0.001). Nine and 18 patients were respectively identified with a
GFR under 60 mL/min/1.73 m2 using respectively CKD-EPI and MDRD
(pB0.001).
Conclusion: A standardized definition of CKD in HIV-infected patients
based on both markers is needed. EACS and IDSA guidelines for CKD
diagnosis should be more evaluated in HIV-infected patients.
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Introduction: The continuous exposition to antiretrovirals has been
pointed out as important risk factor for earlier kidney dysfunction in
HIV individuals [1]. This nephrotoxic effect is mainly focused at
kidney tubular level. Screening for newly selective and non-invasive
markers reflecting a pathophysiological mechanism is paramount for
early diagnosis in order to prevent kidney disease progression. The
mercapturic acid pathway is a metabolic route for processing drugs
and toxins. The last step of this pathway is catalysed by N-
acetyltransferase enzyme type 8 (NAT8) allowing the transfer of an
acetyl group from acetyl-CoA to the cysteine amino group, producing
a mercapturic acid, which is excreted in the urine [2]. This proximal
tubular enzyme has recently been pointed out as a regulator of
kidney function and nephrotoxic response [3]. The aim of the present
work was to evaluate N-acetylated cysteine-disulphides conjugates,
namely N-acetyl-cysteine (uNAC) and coenzyme A (ucoA) on kidney
disease progression.
Methods: A 1-year prospective nested case-control analysis was
performed in a cohort of HIV patients under cART, with visits at time
0 of study admission (T0), 6 (T6) and 12 (T12) months. Glomerular
filtration rate (eGFR) was estimated by CKD-EPI equation, expressed
in mL/min/1.73 m2. Patients were stratified according their eGFR
evolution: group A  no decline in eGFR; group B  declined eGFR
]10% at T12. uNAC and ucoA were quantified by HPLC-FD. Data are
presented as percentage relative to T0.
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Results: A total of 23 HIV-infected patients were included (70% men,
30% Black, 53 [IQR 4663] years old at month 0, 88% with
undetectable viral load at month 0; cART scheme: 96% NRTI; 83%
NNRTI; 29% PI; 8% II). The percentage of patients on tenofovir and
the time of exposure to antiretrovirals between group A (69%, 894
years) and group B (70%; 996 years) was similar. The eGFR and
analytes levels remained unchanged in group A through study time
(n13). Patients of group B (n10) at month 12 showed decreased
eGFR (8397% of T0 paired t-test, p0.010), corresponding to
significant decreased uNAC (60940% Wilcoxon signed rank test,
p0.006) and ucoA (449SD27% paired t-test, p0.032).
Conclusions: Kidney disease progression was associated with a
significant decline in both acetylated cysteine-disulphides conjugates
and coenzyme A. The present results might suggest the NAT8 role in
the pathophysiological mechanism of underlying kidney dysfunction.
This functional tool seems to be suitable to study kidney disease
progression in HIV patients and to assess the contribution of
antiretroviral drugs in this context.
Financial support: EXPL/DTP-FTO/1792/2013; PD/BD/105892/2014
(CGD).
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Nephrotic range proteinuria in a patient with HIV infection
and a history of intravenous drug abuse: case report and
review of the literature
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Introduction: Nephrotic range proteinuria in patients infected with
HIV and a history of intravenous drug abuse may occur in the context
of several underlying conditions such as HIV nephropathy, HCV or
HBV nephropathy in co-infected cases, heroin-associated nephro-
pathy or AA amyloidosis complicating chronic infections or lympho-
mas.We describe the case of nephrotic range proteinuria in a patient
with HIV infection and active intravenous heroin abuse.
Material and methods: A 37-year-old Caucasian male with HIV and
HCV co-infection was admitted to our department for epistaxis and
anaemia. He had been successfully suppressed with HAART, with a
CD4 cell count of 308/L. His medical history was also remarkable for
active intravenous heroin abuse, chronic skin and soft tissue
infection of the lower extremities and deep venous thrombosis for
which he received acenocoumarol. Initial laboratory work-up
revealed acute renal failure and significant hypoalbuminemia
(creatinine: 3.2 mg/dL, urea: 68.9 mg/dL, ALB: 1.6 g/dL). Urine
analysis was positive for excessive protein loss (16.489 g/24h),
whereas his ultrasound imaging revealed enlarged kidneys with
increased echogenicity. Further diagnostic work-up included renal
biopsy, which was positive for AA amyloidosis.
Results: Recurrent chronic infections associated with intravenous
drug abuse in HIV patients may be complicated with renal AA
amyloidosis. Overt proteinuria with normal sized or enlarged kidneys
may help diagnostic guidance; however, clinical features between
HIVAN and AA amyloidosis are often indistinguishable thus making
diagnostic accuracy quite daunting. Unless patients remain abstinent
from drug abuse, prognosis is poor with rapid progression to end
stage renal disease.
Conclusions: Treating physicians should be aware of the association
between renal AA amyloidosis and intravenous drug abuse in HIV-
infected patients, and its indistinguishable clinical and laboratory
findings when compared to HIVAN. High-risk groups with chronic skin
and soft tissue infections in the context of intravenous substance
abuse should be periodically assessed for proteinuria. In suspicious
cases, renal biopsy remains the gold standard for establishing
accurate diagnosis and guiding therapeutic approach.
Co-morbidities and complications of
disease and/or treatment: Other
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Introduction: Integrase inhibitors are preferentially recommended in
guidelines because they have shown better tolerability than other
drugs in clinical trials. We aimed to compare the rates and reasons
for discontinuation of raltegravir (RAL), elvitegravir (EVG) and
dolutegravir (DTG) in a large cohort of HIV-infected patients.
Methods: Retrospective study of all antiretroviral-naı¨ve and
antiretroviral-experienced with undetectable plasma HIV RNA who
were prescribed a first regimen containing RAL, EVG or DTG and had
at least one follow-up visit. We predefined the following major
outcomes: early (51 year) discontinuation, and early discontinua-
tion due to toxicity. Specific toxicities were grouped by organs/
systems according to the description in the clinical history database.
We also planned sensitivity analyses regarding any discontinuation
irrespective of follow-up, and discontinuation restricted to the period
20142015 (when all three integrase inhibitors were available).
Incidence was calculated as the number of episodes per 1000
person-years. Risk factors for discontinuation were assessed by
multivariate Cox models.
Results: Patients on EVG were younger, more commonly men who
had sex with men, and with higher baseline CD4 cell count, and
patients on RAL were less frequently males. Incidence of early
discontinuation was 271 (n71, 12.7% of the patients on RAL,
n557), 168 (n26, 8.1% of the patients on EVG, n322) and 264
(n26, 12.3% of the patients on DTG, n322) per 1000 patient-
years (p0.0821). Early discontinuations due to toxicity were more
common with EVG (n16, 5.0%) (61.5% of EVG discontinuations)
than with RAL (n20, 3.6%) (28.2% of RAL discontinuations) or DTG
(n8, 3.8%) (38.8% of DTG discontinuations) (p0.0083). Specific
reasons for early discontinuations due to toxicity were digestive
(n7, 35%), neuropsychiatric (n7, 35%), skin/mucoses (n4,
20%), muscular (n3, 15%), respiratory (n1, 5%) and systemic
(n2, 10%) for RAL; muscular (n6, 38%), digestive (n4, 25%),
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
167
neuropsychiatric (n3, 19%), skin/mucoses (n2, 13%), and kidney
(n1, 6%) for EVG; and neuropsychiatric (n7, 88%), muscular
(n3, 38%), and systemic (n3, 38%) for DTG. Some specific
toxicities such as neuropsychiatric (p0.0046) or systemic
(p0.0224) were more common with dolutegravir. Age (HR 1.04,
95% CI 1.021.07, p0.0007) was the only independent risk factor
for early discontinuation due to toxicity. Planned sensitivity analyses
confirmed previous results.
Conclusions: EVG tended to be less discontinued in general, but
discontinuations due to toxicity were more common with EVG than
with RAL or DTG. Neuropsychiatric toxicity leading to drug dis-
continuation was more frequently associated with DTG than with
RAL or EVG.
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antiretroviral treatment for HIV
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Introduction: Predicting whether adverse events (AEs) will occur in
combination antiretroviral therapy (cART) for patients infected with
HIV would be a valuable tool in the choice of cART regimens. A
biomarker predicting AEs in other diseases is the enzyme inosine 5’-
triphosphate pyrophosphohydrolase (ITPase). A decreased ITPase
activity is associated with a reduced risk of anaemia in patients
treated for hepatitis C, but with an increased risk of AEs in patients
treated with thiopurines. The purine analogues abacavir, tenofovir
and didanosine that are part of the backbone in most cART regimens
are a potential substrate for ITPase. Here, we determined whether
ITPase activity may be used as biomarker for occurrence of AEs
during tenofovir, abacavir or didanosine use.
Materials and methods: In 393 adult HIV-seropositive patients (1464
cART regimens), AEs were defined as events that led to stop or
change of cART regimen. Clinical and demographic data were
retrieved from the Dutch HIV monitoring foundation and the medical
records. ITPase activity in erythrocytes was measured. ITPase activity
]4 mmol IMP/mmol Hb/hour was considered as normal. Logistic
regression analysis with repeated statement and weighted by total
duration of cART therapy and cumulative duration of purine
analogue therapy was used to determine odds ratios (ORs) for
developing AEs.
Results: Two hundred and five patients (52.2%) had an ITPase activity
B4 mmol IMP/mmol Hb/hour. In cART regimens containing tenofovir
a decreased ITPase activity was associated with a reduction in AEs
(p0.01; OR 0.65), a longer mean regimen duration (p0.001) and
significantly less often switching of medication secondary to AEs
(p0.02) compared to normal ITPase activity. Moreover, of all the
renal AEs that occurred in patients using tenofovir 63.6% occurred in
the patients with normal ITPase activity (p0.04). In contrast, in cART
regimens containing abacavir, a decreased ITPase activity was
associated with increased switching of medication due to AEs
(p0.03) and significantly more AEs occurred compared to regimens
prescribed in normal ITPase activity (crude p0.02; after logistic
regression p0.08; OR 1.69). No association was found for ITPase
activity and occurrence of AEs in didanosine-containing regimens.
Conclusions: Here, we show that ITPase activity is a potential
biomarker for AEs in patients using tenofovir and abacavir in their
cART regimen. ITPase enzyme activity B4 mmol IMP/mmol Hb/hour
seems to be protective against occurrence of AEs in cART regimens
containing tenofovir, while it leads to an increase in AEs in cART
regimens containing abacavir.
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Introduction: In clinical trials dolutegravir (DTG) proved efficacious
and safe in naı¨ve and experienced patients. However, a recent
study in a real-life setting reported an unexpectedly high rate of
discontinuation mainly due to central nervous system (CNS) events.
Materials and methods: The SCOLTA project is a prospective,
observational, multicentre study created to assess the incidence of
adverse events in patients receiving new antiretroviral drugs. We
aimed to further investigate the tolerability of DTG in a cohort of
HIV-infected patients in clinical practice.
Results: A total of 358 HIV-infected patients were included, 266
(74.3%) males and 113 (31.6%) were heterosexuals. CDC stage was A
in 156 (43.6%) patients. Mean age at enrolment was 46.9911.4
years, mean CD4 cell count 5209383 cells/mL and mean HIV RNA
2.091.9 log10 copies/mL. Eighty-three (23.2%) patients were HCV
Ab and 60 (16.7%) were naı¨ve. After a median follow-up of 7 (IQR
611) months, 20 (4.5%) therapy interruptions were reported. These
were caused by virologic failure in four (1.1%), death in three (0.8%),
therapy simplification in two (0.5%), adverse events in eight (2.2%),
lost to follow-up and other reason in one case each. Among adverse
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events-related interruptions two were grade ]3 reactions, one
acute renal failure and one rash, and six grade 12, one creatinine
increase, one myalgiarhabdomyolysis, one transaminase increase,
two CNS events (one somnolence and one headache) and one
gastrointestinal (vomiting). Among patients with available follow-up
data at week 24 and 48, we found a significant reduction in eGFR at
both follow-up times (11.7 mL/min/1.73 m2, pB0.0001 and 9.1
mL/min/1.73 m2, p0.001, respectively). Regarding lipid profile, we
observed a non-significant reduction in total cholesterol at week 24
and 48 and a slight increase in HDL cholesterol. Triglycerides level
showed a significant reduction at week 24 (22.0 mg/dL, p0.015)
and a further decrease at 48 (9.4 mg/dL, pn.s.). Finally, both
AST and ALT levels decreased during follow-up.
Conclusions: Dolutegravir was well tolerated during follow-up as
confirmed by the low rate of both total DTG-based regimen
discontinuations (4.5%) and adverse events-related interruptions
(2.2%). eGFR showed an initial reduction but a stabilization during
follow-up as already shown in clinical trials, possibly attributable to
the inhibition of the OCT-2 creatinine transporter in the proximal
tubular cells. Dolutegravir was also associated with an improvement
of the lipid profile with significant reduction of triglycerides.
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Introduction: Chronic liver disease (CLD) is a leading cause of
morbidity amongst HIV-infected individuals. An increasing burden is
due to non-viral causes, including non-alcoholic fatty liver disease
(NAFLD) and potentially hepatotoxic ARVs [1]. Exposure to the
antiretroviral didanosine (DDI) can result in non-cirrhotic portal
hypertension (NCPH) [2,3]. Our aim was to assess the spectrum of
CLD associated with DDI use.
Methods: This prospective study (December 2014April 2016)
included HIV-infected individuals exposed to DDI for ]6 months.
Those without liver imaging (ultrasound Scan (USS), computed
tomography (CT) or magnetic resonance imaging (MRI)) within 1 year
underwent liver USS. Hepatic fibrosis was determined by assessment of
liver stiffnessmeasurement (LSM) using FibroScan†. Prior liver biopsy,
laboratory and endoscopy results were reviewed and likely aetiology
identified. Clinically significant CLD was defined by one or more of the
following: portal hypertension (PHT), ]F2 fibrosis (liver biopsy/
FibroScan†), LSM ]9.5 kPa (in HIV mono-infected without NALFD
or alcohol excess), moderatesevere steatohepatitis on liver biopsy.
Results: Amongst our cohort of 2300 patients, 271 (11.8%) had ]6
months DDI exposure. Complete data were available in 162.
Individuals were a mean of 55 years old (range 2783), predominately
male (92.6%) and Caucasian (93.8%), HIV infected (mean 267, range
33381 months) and taking ARVs (mean 237, range 21544 months)
for a prolonged period and most were virologically suppressed
(85.2%). Current hepatitis C and B infection was present in 5.5%
and 9.3%, respectively. PHT was present in 9.1%, with overall NCPH
prevalence 3.1%. All individuals with NCPH had been previously
identified by biopsy. Amongst individuals with NCPH, with LSM, 50%
were abnormal, median 8.2 kPa (IQR 6.713.2). Individuals with NCPH
had almost three times the median exposure to DDI (92 months vs. 34
months, p0.067) and significantly lower current mean CD4 count
(421 cells/mm3 vs. 676 cells/mm3, p0.03), despite no difference in
CD4 nadir (187 cells/mm3 vs. 193 cells/mm3, p0.54) or virological
suppression (B40 copies/mL; 80% vs. 85%, p0.75). The prevalence
of clinically significant CLD was 29.6%, with over half due to NAFLD.
Conclusions: Approximately 30% of HIV-infected individuals with DDI
exposure have clinically significant CLD related to NAFLD (16.7%) and
NCPH (3.1%). Fifty percent of those with NCPH had abnormal LSM
and hence FibroScan† lacked utility in either predicting NCPH or
excluding fibrosis/cirrhosis in individuals with NCPH. Our preliminary
results support screening for CLD in DDI-exposed individuals and
emphasize the under-recognized burden from NAFLD.
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improve in HIV-positive patients switching from an
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Introduction: Neurocognitive impairment (NCI) is an important issue
in the HIV setting, even though cART has reduced prevalence in
recent years. Treatment with EFV may cause well-recognized
neuropsychiatric side effects, but association with NCI remains
controversial. Aim was to assess neurocognitive performance and
psychological symptoms in patients switching from EFV to RPV.
Materials and methods: Single-centre prospective evaluation of
patients switching from EFV to RPV in 2015. All patients underwent
neuropsychological assessment (NPA), before (T1) and after (T2) the
switch. NPA was carried out through a standardized and compre-
hensive battery of 14 tests (five different domains). Furthermore, the
Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI) and
Sleep Disorders Questionnaire were administered. Patients were
classified as having NCI if they scored 1 standard deviation (SD)
below the normal mean in at least two tests, or 2 SD in one test.
HIV-associated neurocognitive disorders (HAND) were classified
according to Frascati’s criteria. Paired Wilcoxon and McNeamar tests
were used for statistical comparisons.
Results: Forty-two patients were evaluated: 83.3% male; median age
46 years; 52.4% MSM; median education 13 years; 14% HCV-Ab
positive; CD4/mm3 nadir was B200 in 35.7%; median CD4 were 555
and 621 cells/mm3 at T1 and T2, respectively; HIV RNA was B40
copies/mL in 95.2% and 97.6% of patients at T1 and T2. At T1, all
patients were receiving an EFV-based cART (92.8% with FTCTDF and
7.2% with ABC3TC). After switch, all patients received coformulated
TDFFTCRPV. Median time between the two tests was 6.6 months
(IQR 4.210.9). At T1, 11 patients (26.2%) had NCI (mild neurocog-
nitive disorder (MND) 2.4%; asymptomatic neurocognitive impair-
ment (ANI) 16.7%; not HIV-related cognitive disorder 7.1%), whereas
at T2, only seven patients (16.7%) presented NCI (ANI 11.9%; cognitive
disorder not HIV-related 4.8%). NPA improved in five patients (11.9%),
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worsened in one (2.4%) and remained stable in 36 (85.7%).
In particular, NPZ8 score significantly increased after switch (0.05 IQR
0.330.42 vs. 0.20 IQR 0.080.51; p0.002) (Figure 1). Also
self-reported questionnaires (BAI and BDI-II) revealed an improve-
ment at T2: the patients proportion with symptoms related to anxiety
were 42.1% at T1 and 18.4% at T2 (p0.013); depression was found
in 37.8% at T1 and 18.9% at T2 (p0.020).
Conclusions: Our results suggest that switch from EFV- to RPV-based
cART may improve NPA as well as psychological symptoms in a
relatively short period of time. EFV-treated patients, despite long-
term therapy, should undergo systematic neurocognitive screening in
order to identify subjects that may benefit from change of treatment.
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Introduction: The aim of this study was to describe ARV treatment
patterns in previously naı¨ve US-based HIV patients with and without
comorbidities.
Materials and methods: A retrospective study was conducted using
Truven Health MarketScan Commercial Claims and Encounters, and
Medicare Supplemental and Coordination of Benefits database.
Index date was the earliest date of any ARV medications between
1 July 2011 and 30 June 2014. HIV patients ]18 years old on index
date, and with continuous health plan enrolment of at least 12
months prior to and 15 days after index date, were included. Patients
who received ARV drugs during 12 months prior to index date or had
only one class of ARV drugs during observation period were
excluded. Comorbidities in 12 months prior to index date were
identified using ICD-9 diagnosis codes. ARV regimen was defined
based on class of third agent used in combination with two NRTIs.
Results: A total of 9960 HIV patients were analyzed. Average age was
40 years (SD 12 years). Majority were men (79%), resided in South
(46%) and had PPO/EPO health plan (58%). Lipid disorder (18%) was
the most common comorbidity detected followed by hypertension
(20%) and depression (12%). Patients with comorbidities were noted
to be older except for patients with depression and tuberculosis (no
difference in age), and anxiety and bipolar disorder (patients with
comorbidity were younger). Presence of comorbidity was observed to
be more common in men with exception of osteoporosis. A total of
9319 (94%) patients received ARV regimen containing two NRTIs with
a NNRTI (44%), INSTI (27%) or a PI (23%). A total of 641 (6%) received
other combinations of ARV drugs. NNRTI-based regimens were
observed to be more commonly utilized when compared to INSTI-
and PI-based regimens, respectively, among patients with lipid
disorder (47% vs. 25% vs. 21%), cardiovascular disease (48% vs. 22%
vs. 20%), cerebrovascular disease (36% vs. 24% vs. 31%), renal disease
(39% vs. 21% vs. 26%), hepatic impairment (44% vs. 28% vs. 19%),
diabetes mellitus/abnormal glucose control (50% vs. 23% vs. 19%),
depression (39% vs. 31% vs. 25%), anxiety (40% vs. 35% vs. 21%) and
bipolar disorder (37% vs. 36% vs. 23%).
Conclusion: DHHS guidelines recommend consideration of individual
comorbidities when selecting initial ARV regimen. The study findings
suggest the need for clinicians to consider comorbidities when
selecting ARV therapy in order to minimize drugdrug interactions,
adverse events and thereby optimize treatment outcomes.
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Introduction: Most studies evaluating safety of EVG/COBI/FTC/TDF
described a significant increase of creatinine in the first 2 weeks of
treatment and only few changes through 48 weeks and no significant
elevation in ALT and AST [1,2]. Our aim was to evaluate the impact of
this regimen on patients experienced (E) or naı¨ve (N) to cART on liver
and kidney toxicity.
Materials and methods: Patients initiating EVG/COBI/FTC/TDF were
enrolled in SCOLTA project, a multicentre observational study
reporting all adverse events (AEs). Patients were evaluated at T0
(baseline), T1 (6 months) and T2 (12 months). Groups were
compared using chi-square for categorical variables and univariate
and multivariate analysis of variance for continuous variables.
Repeated measures were analyzed as change from baseline.
Results: Three hundred and twenty-nine patients were enrolled and
280 (85.1%) had at least one follow-up visit. Patients’ characteristics
are depicted in Table 1: 202 (72.1%) were E and 78 (27.9%) were N.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI,
body mass index; eGFR, estimated glomerular filtration rate; HDL,
high-density lipoprotein-cholesterol; IQR, interquartile range; IVDU,
intravenous drug user; SD, standard deviation.
Figure 1. Comparison of NPZ8 score in patients on EFV-based
cART and after switch to RPV-based regimen.
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The median observation time was 11 months (IQR 715.5). Fifty-four
(19.3%) patients withdrew treatment: 11 were virologic failures, six
switched for significant drug interactions, nine were lost to follow-up,
11 chose to interrupt. One patient died for hepatic cancer and one for
accidental drug overdose. Fifteen patients (4.5%) interrupted their
treatment because of AE (nine grade 12, six grade 34). At T1, we
observed a significant decline in eGFR both in E and N patients (mean
change from T0: E 7.0914.1 mL/min, N 14.7920.2 mL/min,
pB0.001) that was confirmed at T2 (mean change from T0: E7.19
17.7 mL/min, N 16.0922.9 mL/min, pB0.001). After adjusting
for HCV co-infection, CDC stage, BMI, CD4 and eGFR at T0, change
from baseline was statistically significant both in N and E patients
at T1 and T2 versus T0. Both for naı¨ve and experienced subjects,
change from T1 to T2 was negligible (respectively, 1.2912.2 and
0.9915.7 mL/min). No significant differences were observed in AST
and ALT (grade 12 AE) during the observation between N and E and
between HCVAb-positive and HCVAb-negative patients. Four patients
(two E, one of which HCV co-infected and two N) interrupted because
of kidney-related events (impaired creatinine clearance), two for liver-
related events (one liver decompensation in a N HCV co-infected and
one transaminase increase in a N HCV negative).
Conclusions: A close monitoring of renal function is required in
patients initiating EVG/COBI/FTC/TDF especially in first 6 months. No
significant liver toxicity was observed.
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Introduction: Tobacco use is a leading cause of preventable illness
and death for all individuals, but it is even more of a concern for
people living with HIV, who tend to smoke more than the general
population. Well-treated HIV-infected individuals may lose more life
years through smoking than through HIV [1].
Objective: We aimed to investigate in HIV patients, prevalence of
smoking, the nicotine dependence and the propensity to stop
according to the stages of change by a standardized questionnaire.
Abstract P234Table 1. Patients’ characteristics
Experienced Naive
Variables N202 (72.1%) N78 (27.9%) p
Males 147 (72.8) 65 (83.3) 0.06
Risk factor (IVDU) 50 (24.8) 2 (2.6) B0.0001
CDC stage C 52 (25.7) 14 (18.0) 0.05
HCV co-infection (14 missing) 58 (30.0) 2 (2.7) B0.0001
eGFR BL B90.0 99 (50.8) 23 (30.3) 0.002
Mean (SD) or median (IQR) Mean (SD) or median (IQR)
Age (years) 45.6 (9.9) 39.2 (12.0) B0.0001
BMI (kg/m2) 24.1 (3.4) 22.9 (2.7) 0.0009
CD4 (cells/mL) 579 (356) 382 (278) B0.0001
HIV RNA (copies/mL) 24 (1967) 50,042 (8040117,171) B0.0001
ART duration (years) 8.1 (3.416.8) 0
Total cholesterol (mg/dL) 191.0 (45.2) 159.5 (37.2) B0.0001
HDL cholesterol (mg/dL) 43.3 (12.8) 40.1 (13.7) 0.09
Triglycerides (mg/dL) 140 (91.5194.5) 92.5 (71121) B0.0001
Glucose (mg/dL) 94.2 (29.6) 89.9 (17.2) 0.25
AST (IU/L) 24.5 (2035) 24.0 (19.532.0) 0.75
ALT (IU/L) 28 (1846) 27 (16.537.5) 0.27
Creatinine (mg/dL) 0.94 (0.47) 0.99 (1.16) 0.61
Alcaline phosphatase (IU/L) 119.1 (77.4) 88.2 (42.4) 0.005
Phosphate (mg/dL) 3.19 (0.68) 3.10 (0.68) 0.46
eGFR 94.7 (25.3) 106.9 (28.4) 0.0007
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Methods: Multicentre nationwide Italian study, consecutive HIV
patients were included. We evaluated the nicotine dependence by
Fagerstro¨m Test for Nicotine Dependence (FTND), and the propensity
to stop according to the stages of change by a standardized
questionnaire. Smokers and not smokers were compared using chi-
square for categorical variables and univariate and multivariate
analysis of variance for continuous variables.
Results: A total of 899 patients (age 48911, male 71%, Caucasian
ethnicity 88%) were included. Prevalence of current smokers was
52.6%, ex-smokers 16.9% and never smokers 30.4%. Among current
smokers, the mean pack years was 23.9919.6. According the stages
of change, 65.2% of the smokers were in the precontemplation,
14.8% in contemplation, 15.8% in preparation and 4.2% in the action.
The median of FTND was 4 (IQR 26). The dependence degree was
low (point 04), moderatehigh (point 56), very high (point 710)
in 55.5%, 22.2% and 22.4%, respectively. The main study population
characteristics are reported in Table 1.
In multivariable regression model including age, gender, risk factor
for HIV acquisition and ethnicity, CD4 cells count and athero-
sclerotic cardiovascular diseases risk prediction were confirmed as
associated with current but not former smoking. Similarly, in a
logistic multivariate model, current smoking remained associated
with psychiatric comorbidity and alcohol use.
Conclusion: Prevalence rates for smoking in HIV subjects (around
50%) is higher than expected in the Italian general population
(approximately 20%) [2], smoking screening and cessation support
should be offered at HIV clinics. Our findings underscore the value of
smoking cessation strategies targeting HIV persons.
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Introduction: Depression is a well-known predictor of health-related
quality of life (HRQL), specifically in HIV and ageing populations. Little
is known, however, on how precariousness is related to both
depression and HRQL status. A structural equation model relying
on partial least squares (SEM-PLS) was used to analyze the relation
between anxiety/depression, harm avoidance and quality of life
among HIV patients in an online survey.
Methods: Data were collected on 517 HIV patients (70% males,
mean age 48 years) using validated self-reported measures. A
structural model was posited a priori to link various domains:
HRQL (PROOQL-HIV, three dimensions: physical, cognitive and social
health, on a 0100-points scale), personality traits (TCI-56, two
dimensions: harm avoidance and novelty seeking) and anxiety/
depression (HADS, two dimensions). Participants were classified into
a precarious (52%) and a non-precarious (48%) group based on the
French EPICES score. Two-group comparisons were performed using
two-tailed Student’s t and Pearson chi-squared tests. The links
between the various dimensions were assessed using SEM-PLS on
the whole sample and on the two subgroups separately.
Results: Adherence was high (97%) and few patients reported using
drug or having excessive drinking habits. HRQL was higher in men
(pB0.001), non-smokers and soft users of alcohol or drugs (pB0.01).
Univariate analysis suggest that average scores were lower (pB0.001)
in the precarious group for all dimensions of PROQOL-HIV (14% up
to20%) and HADS (10% and14%) but not for harm avoidance.
The SEM-PLS analysis indicates that all prespecified path coefficients
were positive and significant at the 5% level. Depression was
strongly associated with the cognitive (pB0.001) and the physical
(pB0.001) dimensions of PROQOL-HIV while anxiety was strongly
related to harm avoidance (pB0.001) as expected. However, no
significant differences were observed between the two groups at the
level of the structural models despite interesting variations in
regression weights between the two subgroups (lower impact of
depression of social and sexual relationships in the precarious group).
Conclusion: Depression is a strong predictor of lower physical,
cognitive and social health but anxiety and personality traits are also
potential moderators of HRQL, independent of the level of
precariousness.
Abstract P235Table 1. Characteristics of 899 HIV patients at enrolment: 474 (52.7%) current smokers; 273 (30.4%) never smokers;
152 (16.9%) ex-smokers
All HIV patients
N899
Current smokers N474
(52.7%)
Ex-smokers N152
(16.9%)
Never smokers N273
(30.4) p
Age (years) 48.0911 46.9910 53.5912 46.5912 B0.0001
Men (%) 71.2 73.2 80.3 62.3 0.002
Body mass index (kg/m2) 24.894 24.194 26.094 25.394 B0.0001
Caucasian ethnicity (%) 87.8 93.5 93.4 74.7 B0.0001
CDC C3 (%) 27.1 26.0 31.6 26.6 0.95
CD4 lymphocytes (mm3) 6499327 6969365 6319272 5769265 B0.0001
Psychiatric comorbidity (%) 9.5 13.5 5.9 4.4 B0.0001
ASCVD risk (%), median (IQR) 5.5 (2.610.1) 6.9 (4.212.0) 5.5 (2.610.9) 2.6 (1.16.1)
Values are mean9SD.
ASCVD, atherosclerotic cardiovascular diseases risk prediction; p, unadjusted.
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Introduction: HIV-infected men carry an increased risk of HPV-
associated infection, and information for appropriate allocation of
cancer screening as well as vaccination programmes is needed.
Purpose was to describe prevalence of HPV infection at the oral
cavity of HIV-positive men, to identify predictors and to assess
concordance with anal site.
Methods: Paired oral rinse and anal samples were collected from
HIV-positive males within a large cross-sectional programme for anal
cancer screening. Samples were tested with two sets of primers
(MY09/MY11; FAP59/64) and HPV-positive samples typed by CLART2
HPV assay (Genomica) or direct sequencing. Cytologic examination
and immunohistochemical analysis by using a monoclonal antibody
against p16 (INK4a) were done in HPV-positive cases.
Results: Two hundred and forty-two HIV-positive males through
homo-/bisexual contact in 85.5% and heterosexual in 10.3%. Median
age 44.7 years. At testing, cART was prescribed in 93.9%, HIV RNA
B40 copies/mL in 88% and median CD4 699/mm3. Prevalence of
HPV in the oral cavity was significantly lower compared with anal
site: 22.7% (n55) versus 88.8% (n207) (pB0.001). Multiple HPV
types were found in 13 (23.6%) oral and in 157 (75.8%) anal samples
(pB0.001). Risk factors for oral infection were: CD4 B200/mm3
(p0.009), more than 10 partners in previous 12 months (p0.01),
more than 100 lifetime sexual partners (p0.04). Infection at both
sites was found in 51 (21.7%) cases and oral infection was more
frequent in patients with HPV at anal site in respect to those without,
but association was only slightly significant (24.6% vs. 11.4%;
p0.08). In Figure 1, frequency of HPV types by anatomic site,
HR/LR groups and multiplicity are shown. Among the 51 patients
with typed HPV infection at both sites, 44 (86.3%) had completely
different HPV types at oral rinses from those found in anal swabs.
Patients with theoretical benefit from 9-valent vaccination were: 17
(30.9%) with oral and 153 (73.9%) with anal infection. Cytologic
examination of oral rinses showed ASCUS in 37 cases (49%) and HG-
SIL in one.
Conclusions: In HIV-positive patients, prevalence of HPV infection in
the oral cavity was significantly lower than that observed at anal site.
Severe immune depression and sexual history, but not anal infection,
are crucial to identify persons at highest risk of oral HPV infection
and in need of screening. The absence of significant concordance
between oral and anal sites may suggest different infection routes or
timing.
P238
Prevalence and presentation of syphilitic hepatitis in HIV-
infected patients
Tyler Raycraft; Arshia Alimohammadi; Arpreet Singh; Ghazaleh Kiani;
Rajvir Shahi; Syune Hakobyan and Brian Conway
Clinical Research, Vancouver ID Research and Care Centre Society,
Vancouver, Canada
Introduction: Rates of syphilis have been increasing in recent years,
particularly in HIV-infected populations [1]. The reciprocal interaction
between Treponema pallidum and HIV has been well established, but
progression to liver inflammation, termed syphilitic hepatitis (pre-
sent in up to 38% of cases in some studies [2]), is understudied in
this setting. Liver enzyme abnormalities are well documented in HIV
patients, often attributed to co-infection with viral hepatitis, alcohol
use or direct hepatotoxicity of HAART [3]. However, previous studies
have failed to sufficiently examine syphilis as a potential cause of
hepatic inflammation. The aim of this analysis is to determine the
prevalence of syphilitic hepatitis among HIV-infected individuals
diagnosed with acute syphilis.
Methods: We performed a retrospective analysis of all HIV-infected
individuals regularly attending a tertiary clinic in Vancouver, Canada.
We identified cases of acute syphilis resulting in syphilitic hepatitis
according to the following criteria: (1) RPR-confirmed T. pallidum
infection occurring after HIV infection; (2) elevated liver enzyme
laboratory tests, including alkaline phosphatase (ALP), alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) that
normalized after penicillin treatment; and (3) no clearly identifiable
cause of liver inflammation beyond syphilis (such as viral hepatitis
or alcohol use). Any patient exhibiting ongoing risk factors for
T. pallidum acquisition received routine syphilis screening every 6
months. In addition to laboratory data, demographic and clinical
information were collected for each patient. The cases included in
this study occurred between April 2011 and December 2015.
Abstract P237Figure 1. Frequency and multiplicity of HPV infection at the oral (a) and at the anal site (b).
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Results: Among 567 HIV-infected patients, 35 (6.2%) were diagnosed
with acute syphilis based on RPR results. According to our definition,
3/35 (8.6%) cases of early syphilis resulted in syphilitic hepatitis.
Within the cohort demonstrating syphilitic hepatitis, the age range
was 2863, the median RPR titre was 1:256 and all three self-
identified as men who have sex with men (MSM). The common
presenting symptoms are listed in Table 1. However, as demon-
strated in Table 2, no symptoms demonstrated a statistically
significant difference in prevalence between the syphilitic hepatitis
and syphilis without hepatitis groups.
Conclusions: Syphilitic hepatitis is not uncommon in HIV-infected
patients and should be considered as an etiologic agent in this
setting. Active case finding and prompt initiation of treatment may
contribute to the lower prevalence observed in our cohort as
compared to previous reports in the literature.
References
1. Chesson HW, Heffelfinger JD, Voigt RF, Collins D. Estimates of
primary and secondary syphilis rates in persons with HIV in the
United States, 2002. Sex Transm Dis. 2005;32:2659. doi: http://dx.
doi.org/10.1097/01.olq.0000162359.75509.9c
2. Crum-Cianflone N, Weekes J, Bavaro M. Syphilitic hepatitis among
HIV-infected patients. Int J STD AIDS. 2009;20:27884. doi: http://dx.
doi.org/10.1258/ijsa.2008.008324
3. Pol S, Lebra P, Vallet-Pichard A. HIV infection and hepatic enzyme
abnormalities: intricacies of the pathogenic mechanisms. Clin Infect
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Abstract P238Table 2. Comparison of patients with acute/
early syphilis with and without syphilitic hepatitis
Characteristic
Syphilitic
hepatitis
(N3)
Syphilis without
hepatitis (N32)
Abdominal pain 1 1
Pharyngitis 1 0
Rash 2 17
Fever 1 1
Arthralgia 1 6
Skin lesion 2 7
Median RPR titre 1:256 1:10
Median CD4 count (cells/mL) 423 754
Median HIV viral load
(copies/mL)
B40 B40
Receiving ARVs 3 28
Virologic suppression
(VL B40 copies/mL)
2 24
Male 3 30
Mean age (range) 44 (2863) 46 (2563)
African American 1 1
Caucasian 2 27
Hispanic 0 1
Asian 0 3
VL, HIV viral load.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
174
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University of Bristol, Bristol, UK
Introduction: Poor retention in care is associated with higher rates of
mortality. However, the impact of poor engagement in care (EIC) on
life expectancy is not known.
Materials and methods: The UK CHIC study is a cohort of HIV-
positive individuals who have accessed HIV care in the UK since 1996.
Individuals who initiated ART aged ]20 years between 2000 and
2011 with ]1 year of follow-up were included. Pregnant women
and injecting drug users were excluded. EIC rates at 1, 2, 3, 4 and 5
years on ART were calculated as the proportion of months since ART
start that an individual was considered to be in care based on the
REACH algorithm [1] and classified as high (]80%) or low (B80%).
Age-specific mortality rates from each time point on ART (1, 2, 3, 4
and 5 years) for those with high and low EIC were used to construct
abridged life tables for the estimation of life expectancy. Life
expectancy is the average number of additional years an individual
can expect to live at a given age. Expected age at death at ages 35
and 50 are reported by adding the corresponding life expectancy.
Results: Amongst 18,046 individuals, median age at ART initiation was
38 years, 74.5% were male, 54.1% white, 53.5% acquired HIV through
sex between men. Median (IQR) CD4 count was 230 (135333) cells/
mm3 and 66.5% started a non-nucleoside based regimen. EIC was
good at 1, 2, 3, 4 and 5 years of ART duration, with 83.9%, 81.4%,
82.7%, 81.1% and 81.7% having high EIC, respectively. Expected age at
death was lower for those with low EIC (Figure 1). Expected age at
death increased with longer duration of high EIC on ART. At 1 year on
ART, expected age at death (standard error) for a 35- and 50-year-old
with high EIC was 72 (0.3) and 74 (0.2), and after 5 years on ART was
74 (0.4) and 76 (0.4). Life expectancy decreased with a longer
duration of low EIC on ART. Expected age at death for those aged 35
and 50 years with low EIC was 68 (0.6) and 71 (0.6) at 1 year on ART,
but decreased to 65 (0.8) and 68 (0.8) at 5 years on ART.
Conclusions: Poor EIC is associated with decreased life expectancy,
especially if maintained over a long duration on ART. Whilst ART
adherence is vital, high EIC may also contribute to good outcomes in
people living with HIV.
Reference
1. Howarth AR, Burns FM, Apea V, Jose S, Hill T, Delpech VC, et al.
Development and application of a new measure of engagement in
outpatient HIV care. HIV Med. 2016. doi: http://dx.doi.org/10.1111/
hiv.12427. [Epub ahead of print]
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Long sleep and longer naps are associated with severity of
HIV disease
Brice Faraut1; Alexandre Malmartel2; Jade Ghosn3;
Martin Duracinsky4; Damien Le´ger1; Sophie Grabar5 and
Jean-Paul Viard6
1Centre du Sommeil et de la Vigilance, Hotel Dieu Hospital,
Universite´ Paris-Descartes, Paris, France. 2Family Medicine,
Biostatistics and Epidemiology, Hotel Dieu Hospital, Universite´ Paris-
Descartes, Paris, France. 3Immuno-infectiology Unit, Hotel Dieu
Hospital, Universite´ Paris-Descartes, Paris, France. 4Department of
Clinical Research (PRO Unit), Hoˆpital Fernand-Widal, Paris, France.
5Biostatistics and Epidemiology Unit, Hotel Dieu Hospital, Paris,
France. 6Immuno-infectiology Unit, Hotel Dieu Hospital, Paris, France
Introduction: Total sleep time is usually linked to health status with
short sleep B6 hours and long sleep 8 hours both associated with
inflammation and a higher morbidity risk. In HIV infection, little is
known on the association between sleep duration and quality, and
disease severity.
Methods: Self-administered questionnaires were systematically
proposed to HIV-infected patients in a single-centre study to assess
insomnia (ICSD-3 criteria), poor sleep quality (PSQI 5) and total
sleep time. Actigraphy over a 10-day period was also performed in a
sub-sample of voluntary patients. SF-12 (38) and PROQOL-HIV (39)
evaluated quality of life.
Results: Six hundred and forty patients were enrolled, including 97
with actigraphy recordings. PSQI 5 (68%) and insomnia (50%)
reached high prevalence. A CD4 count B500 cells/mm3 was
inversely associated with both insomnia (OR 0.73; pB0.01) and
short sleep (OR 0.73; pB0.01) but positively associated with long
sleep (OR 1.49; pB0.01). Long sleep according to actigraphy was
Abstract P239Figure 1. Life expectancy at exact ages 35 and 50 according to engagement in care rates at 1, 2, 3, 4 and 5 years on ART.
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also associated with a low CD4 nadir (OR 0.2; p0.05) and AIDS
status (OR 3.99; p0.04). Seventy-six percent of long sleepers took
long naps (]1 hour) during weekdays, and napping ]1 hour was
associated with lower CD4 nadir and AIDS status when compared to
napping less than B1 hour (OR 0.52; p0.02 and OR 17.26;
p0.03, respectively). Self-reported napping ]1 hour was also
associated with a CD4/CD8 ratio B1 (OR 2.08; p0.03 vs. non-
napper status). The prevalence of PSQI 5 and insomnia were
associated with the physical component of PROQOL-HIV (respec-
tively: 64.5 vs. 85.5; pB0.01 and 66.3 vs. 81.5; pB0.01), SF-12 MCS
(39.6 vs. 48.2; pB0.01 and 39.6 vs. 47.9; pB0.01) and PCS (48.0 vs.
53.7; p0.03 and 48.8 vs. 52.3; pB0.01).
Conclusions: A high prevalence of insomnia and impaired sleep
quality was found in HIV patients. Severity of the infection was not
associated with short sleep but with long sleep and long naps,
possibly in relation with T-cell activation.
P241
High rates of alcohol and illicit drug consumption among
HIV-infected patients attended in Spain
Alicia Gonzalez-Baeza1; Victor Hontan˜on-Anton˜ana2; Gema Caceres1;
Jesus Montes1 and Ignacio Perez-Valero1
1HIV Unit, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.
2Medicina Interna, Hospital Universitario La Paz (IdiPAZ), Madrid,
Spain
Introduction: The prevalence of risky alcohol and illicit drug
consumption and its associated factors is not well established among
HIV patients attended in Spain.
Materials and methods: All the participants completed self-adminis-
tered questionnaires to screen for risky alcohol consumption (AUDIT
8) and drug use (DUDIT 5 in men; DUDIT 1 in women), and
emotional distress (HADS 12). Type of illicit drugs used and
adherence rates were also reported. We calculated the association
between clinical/demographic and consumption variables. Multiple
logistic regressions were conducted including risky alcohol intake,
risky drug use, use of drugs and polydrug use in the last year as
dependent variables. Covariates included those clinical/demographic
that showed association (pB0.10) with each dependent variable in
the univariate analysis. Moreover, rates of consumption were
compared among participants with different sexual orientation.
Results: Two hundred and forty-six participants were included. The
majority were middle age (mean: 46.4 years), male (82%), high
school or college educated (71.6%) and Spanish born (75.2%). The
96.7% received ART. Of all the participants, 32% reported consump-
tion of any illicit drug during the last year: marijuana/cannabis
(21.6%), cocaine (11.4%), poppers (6.5%), amphetamine derivatives
(6.1%), opioids (2.9%), ketamine (2%), GHB (1.6%) and pentadone
(1.5%). The prevalence of risky alcohol intake was 14% and 15.6% of
the participants had risky drug consumption. Of the total of drug
consumers, 21.5% received boosted ART agents. Patients out of ART
(OR (95% CI) 5.22 (1.1623.49), p0.031) and those with poorer
ART adherence (4.97 (1.8813.30), p0.001) had higher rates of
risky alcohol intake. The use of any drug in the last year was
independently associated with lower age (0.97 (0.940.99),
p0.016) and viral rebound in the last year (5.27 (2.1113.14),
p0.001), whereas risky drug use was only associated with some
viral rebound in the last year (3.09 (1.158.27), p0.025). More-
over, homo- and bisexual participants (2.50 (0.986.38), p0.055)
and those younger (0.5 (0.910.97), p0.008) had higher rates of
polydrug use during the last year. Comparison between homo-/
bisexual and heterosexual patients are included in Table 1.
Homo- and bisexual participants had higher rates of polydrug use,
and amphetamine derivates, mephedrone, cocaine and popper use
in the last year. Heterosexual participants had a trend towards higher
cannabis and opiates use (Table 1).
Conclusion: We found a substantially high prevalence of risky alcohol
intake and drug use. Measures of consumption were associated with
poorer ART adherence, viral rebounds, age or sexual orientation.
Homo- and bisexual participants had higher polydrug use and higher
intakes of particular drugs  amphetamine derivates, cocaine,
popper  that can be used as sexual enhancer. We show updated
data of drugs and alcohol consumption in a HIV sample routinely
attended in Spain.
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Common comorbidities found in a population of
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antiretroviral therapy in five ambulatory clinics in
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1Infectious Diseases/HIV Clinic, Almenara Hospital/Via Libre, Lima,
Peru. 2Infectious Diseases, Grau Hospital, Lima, Peru. 3Infectious
Diseases, Sabogal Hospital, Lima, Peru. 4Infectious Diseases, Loayza
Hospital, Lima, Peru. 5Medical Affairs, Merck Sharp & Dohme Peru,
Lima, Peru. 6HIV Clinic, Via Libre, Lima, Peru
Introduction: As earlier and more regular access to HAART increases
globally, the proportion of chronically treated, clinically stable HIV
patients will increase. The incidence of non-AIDS-defining comorbid-
ities in these patients is not well defined in Peru. The aim of this
study is to characterize this population and to describe most
commonly found comorbidities to help design future policies of
HIV care in the country.
Materials and methods: Review of HIV patients’ records selected
from five HIV clinics in Lima-Callao attending regular appointments
for follow-up visits in JanuaryFebruary 2016. Patients were adults
(21 years), ambulatory, on HIV therapy for 6 months and with
no current or recent AIDS-defining condition (6 months). Records
Table 1. Comparison between homo/bisexual and heterosex-
ual patients
Homosexual/
bisexual
patients
Heterosexual
patients p
Age, mean (SD) 43.3 (10.9) 49.9 (7.8) 0.001
Years since HIV diagnosis,
mean (SD)
10.6 (8.1) 20.3 (8.5) 0.001
Months on ART, mean (SD) 106.8 (86.2) 187.8 (90.2) 0.001
Non-Spanish born, N (%) 45 (34.4) 16 (13.9) 0.002
Risky alcohol intake, N (%) 14 (10.9) 18 (18.2) 0.127
Risky drug use, N (%) 19 (17.4) 18 (14.1) 0.724
Polydrug use, N (%) 25 (19.2) 7 (6.1) 0.002
Cannabis/marijuana, N (%) 22 (16.9) 31 (27) 0.063
Cocaine use, N (%) 22 (16.9) 6 (5.2) 0.004
Amphetamine derivates
use, N (%)
15 (11.5) 0 (0) 0.001
Mephedrone use, N (%) 6 (4.6) 0 (0) 0.031
Poppers, N (%) 16 (12.3) 0 (0) 0.001
Opiates, N (%) 1 (0.77) 6 (5.2) 0.053
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were reviewed to collect information regarding epidemiologic,
clinical and laboratory characteristics. Data obtained were processed
statistically to describe frequencies observed.
Results: Three hundred and three patients were found eligible for
review. A majority of patients were male (73.3%, n222), with a
median age of 46.1 years (range 2179 years). Older individuals
(]60 years) were 15.2% (n46) of the group. Patients had a
diagnosis of HIV infection for an average time of 9.41 years, and were
on HAART for an average of 7.78 years. Most patients were on an
NNRTI-based first-line regimen (76.2%, n231), followed by rescue
regimens (12.2%, n37), PI-based first-line regimens (9.3%, n28)
and other combinations for first-line therapy (2.3%, n7). Median
CD4 count was 614.2 cells/mL and proportion of patients with
undetectable viral load (B40 copies/mL) was 91.1% (n276).
Seventeen patients (5.6%) had viral loads between 41 and 400,
and only 10 patients (3.3%) higher than that. The most frequently
observed metabolic diagnoses were dyslipidaemia, found in 40.6%
patients (n123), and obesity (BMI ]30) in 11.9% (n36).
Diabetes mellitus was diagnosed in 21 patients (6.9%). Hypertension
has been diagnosed in 23 patients (7.6%). Other recorded diagnoses
of cardiovascular disease (coronary disease, CHF, cerebrovascular
disease) were nine (3.0%), one myocardial infarction was reported in
the group. Record of regular medical treatment for dyslipidaemia
was 27.6%. Diabetes and hypertension were regularly treated in
91.3%.
Conclusions: A population of stable, ambulatory HIV patients on
long-term HAART showed a high proportion of metabolic comorbid-
ities, with dyslipidaemia the most frequent condition, followed by
obesity. Prevalence of diabetes was similar to reported elsewhere.
Relatively infrequent was cardiovascular disease. Medical treatment
of dyslipidaemia was low. Care needs to consider proper treatment
of chronic comorbidities in HIV.
P243
Quality of life in an Italian cohort of women living with HIV:
preliminary results from IANUA study (Investigation on
Antiretroviral Therapy)
Alberto Venturini1; Giovanni Cenderello1; Barbara Giannini2;
Marcello Montefiori3; Antonio Di Biagio4; Giovanni Penco1;
Giovanni Mazzarello4; Patrizia Orcamo5; Caterina Merlano5;
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Introduction: The introduction of cART has reduced HIV-associated
morbidity and mortality and changed the patients’ perspective of life.
As a result, health-related quality of life (HRQoL) has become a crucial
clinical issue. It has been suggested that factors influencing HRQoL in
women may differ from those in men. Main objectives are as follows:
assessment of HRQoL in a sample of Italian women from IANUA study;
investigate correlation primarily between CD4 cells count, viral
load, co-infection HIVHCV and changes in HRQoL.
Materials and methods: EQ-5D-3L self-reported questionnaire has
been used in the evaluation of HRQoL. It assesses five dimensions:
‘‘mobility,’’ ‘‘self care,’’ ‘‘usual activities,’’ ‘‘pain/discomfort’’ and
‘‘anxiety/depression.’’ Each dimension has three levels: no problems,
some problems and extreme problems. In addition, it includes a
visual analogue scale (VAS) where one’s own health ‘‘today’’ is rated
from 0 ‘‘worst imaginable health’’ to 100 ‘‘best imaginable health.’’
The respondents provide information on marital status, education,
employment/unemployment, other treatments used in addition to
HAART (one, two, three, four, five or more) and number of
hospitalizations due to HIV/AIDS.
Results: Three hundred and twenty patients completed the ques-
tionnaire. The mean age of the sample was 49 years (range 2186).
The mean VAS score was 74.1. It was lower than the mean VAS score
of the sample of men (n620) of 76.1 (p0.01). Table 1 provides
information about five dimensions of the EQ-5D-3L questionnaire.
Positive correlations were found between HRQoL and CD4 cells
count at last available visit (R 0.14, p0.05) and nadir CD4 cells
count (R 0.17, p0.01). Negative correlations were found between
HRQoL and co-infection HIVHCV (R 0.16, p0.01) and anxiety/
depression (R 0.49, p0.01).
Conclusions: The analysis of self-reported questionnaires indicates
that HRQoL in our sample group is not deeply affected by HIV/AIDS.
The dimensions that are affected in the least are ‘‘mobility’’ and ‘‘self
care’’ while the major problem is ‘‘anxiety/depression’’ with more
than half of the sample reporting moderate or high level.
P244
Seasonal variations in vitamin D levels in HIV-infected
patients: when to test for hypovitaminosis?
Sebastian Noe1; Silke Heldwein1; Rita Pascucci1; Celia Oldenbuettel1;
Ariane von Krosigk1; Carmen Wiese1; Eva Jaegel-Guedes1;
Hans Ja¨ger1; Wolfgang Mayer2; Eva Wolf3 and Christoph Spinner4
1Private Practice, MVZ Karlsplatz, Munich, Germany. 2Private
Laboratory, MVZ Bavariahaus, Munich, Germany. 3MUC Research,
Munich, Germany. 4Department of Medicine II, University Hospital
Klinikum rechts der Isar, Munich, Germany
Introduction: The best time for accurate testing for vitamin D
deficiency in HIV-infected patients remains unclear. We aimed to
study the seasonal changes in serum 25OH-cholecalciferol (vitamin D),
serum calcium and other markers of bone metabolism in an unselected
European population of HIV-infected patients, most of whom were
treated with antiretroviral drugs.
Methods: Retrospective single-centre study. Patients’ medical re-
cords were screened for serum vitamin D levels, b-crosslaps and
surrogate values of bone turnover (serum calcium, phosphate and
alkaline phosphatase (AP)).
Results: A total of 1011 data sets (625 patients) were evaluated.
Overall, the median vitamin D level was 19.6 mg/L (95% confidence
interval 18.820.6). In 207 (16.4%) data sets, patients were receiving
oral cholecalciferol supplementation. Seasonal changes in serum
vitamin D levels were reflected by minimum levels (median 13.5 mg/L)
in March and maximum levels (median 23.7 mg/L) in July (pB0.001).
Seasonal changes in vitamin D levels are shown in Figure 1. In
contrast, serum calcium levels were lowest in September and October
(2.23 mmol/L) and highest in May (2.32 mmol/L).
Table 1. Subjects frequencies in the EQ-5D dimensions
No problems
(%)
Some
problems (%)
Extreme
problems (%)
Mobility 257 (79.8) 61(18.9) 2 (0.6)
Self-care 298 (92.5) 22 (6.8) 1 (0.3)
Usual activities 271 (84.2) 45 (14) 4 (1.2)
Pain/discomfort 186 (57.8) 112 (34.8) 22 (6.8)
Anxiety/depression 127 (39.4) 158 (49.1) 35 (10.9)
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The dotted line shows a polynomic trend line, the x-axis indicates
serum vitamin D levels (mg/L) and the y-axis indicates months
(1January, 12December).
Conclusions: Significant variation in seasonal serum vitamin D levels
was found in an unselected population of HIV-infected patients. This
finding is in line with results from HIV-negative populations.
Accordingly, the time point of vitamin D testing might be crucial
for appropriate diagnosis of hypovitaminosis. We recommend
vitamin D testing between December and May. However, given the
seasonal variation, varying thresholds for vitamin D insufficiency and
deficiency may be needed. As serum calcium levels did not
demonstrate the same pattern, the meaning of this finding is unclear
and warrants further investigation.
P245
Utilizing US prescription and claims data to better
understand treatment dynamics of HIV/HCV co-infection
patients in the second generation DAA era
Michel Denarie1; Steven Gubernick2; Nirmala Panchatcharam3;
Shiwei Gao4; Sean O’Neil4 and Jacob Arluck2
1Real World Evidence Solutions, IMS Health, Plymouth Meeting, PA,
USA. 2IMS Consulting Group, IMS Health, Plymouth Meeting, PA,
USA. 3Advanced Analytics, IMS Health, Plymouth Meeting, PA, USA.
4Managed Services, IMS Health, Plymouth Meeting, PA, USA
Introduction and aims: Since the introduction of the second
generation DAAs, many HIV/HCV co-infection patients previously
warehoused for HCV, but in treatment for HIV, started undergoing
HCV therapy. The intent of this study is to better understand the
treatment dynamics of HIV/HCV co-infection patients in the second
generation DAA era. Key parameters include gender and age
distribution across HIV third agents, proportion of patients receiving
DAA therapies, proportion of HIV third agents pre- and post-HCV
diagnosis and dynamics of patients who switched HIV third agents
post-HCV diagnosis.
Design and methods: This retrospective study utilized IMS long-
itudinal prescription (LRx) and medical claims data (Dx). LRx covers
88% of all retail scripts. The linked Dx data cover 1.1 billion office
claims annually. Patients were selected if they received an HIV
diagnosis or HIV treatment between May 2014 and October 2015.
Patients were identified as HCV if they received either a diagnosis or
a treatment for HCV during the same period. Stability and eligibility
rules were applied to the LRx to minimize the risk of anomalous
results due to variability. We then observed the HIV treatment
regimens pre- and post-HCV co-infection diagnosis.
Results: This retrospective study assesses IMS APLD and claims data
from 30,061 patients having both HIV and HCV diagnoses. Sixty-eight
percent of patients are male and 72% over the age of 50. Thirteen
thousand three hundred and fifty-nine patients have both HIV and
HCV diagnoses and an HIV index regimen. Of these patients, 69% are
male and 73% are over the age of 50 with both age and gender
similar across HIV third agents. Twelve percent received a DAA
regimen for HCV. Greater than 88% of these patients were placed on
a sofosbuvir-based regimen (Harvoni or Sovaldi), and this was similar
across HIV third agents. One thousand five hundred and thirty-three
patients have both HIV and HCV diagnoses and an identifiable HIV
regimen pre- and post-HCV diagnosis. In these patients (which
include those on standard triple therapy and nuc-sparing regimens),
integrase inhibitors are the most frequently used HIV third agent pre-
(51%) and post- (53%) HCV diagnosis followed by NNRTIs (33% pre
and 32% post) and protease inhibitors (32% pre and 26% post).
Hundred and seventy-three patients switched their HIV third agent
post-HCV diagnosis with most (87%) switching to include an
integrase inhibitor as part of their regimen. Of these 149 patients,
50% switched to Tivicay/Triumeq, 45% to Isentress and 5% to
Stribild.
Conclusions: Only 11% of patients having both HIV and HCV
diagnoses and an identifiable HIV regimen pre and post-HCV
diagnosis switched their HIV regimens prior to initiating DAA therapy.
Of those who switched their HIV regimens, 87% switched to include
an integrase inhibitor. In addition, 95% of all switches to integrase
inhibitors were to integrases not requiring a booster (Tivicay/
Triumeq and Isentress).
P246
Comparison of early serologic response of early syphilis to
treatment with a single-dose benzathine penicillin G
between HIV-positive and HIV-negative patients: a cohort
study
Yi-Ching Su1; Lan-Hsin Chang1; Wen-Chun Liu1; Cheng-Hsin Wu1;
Chia-Jui Yang2 and Chien-Ching Hung1
1Internal Medicine, National Taiwan University Hospital, Taipei,
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Introduction: Serologic response of early syphilis to treatment has
been reportedly poorer in HIV-positive patients compared with HIV-
negative patients; however, the interpretation of the published data
is limited by the differences in study design, subjects with different
stages of syphilis included, definition used for serologic response,
treatment administered and follow-up frequency and duration. We
aimed to compare the early serologic response of early syphilis to
benzathine penicillin G (BPG) during the monthly follow-up for 3
consecutive months between HIV-positive and HIV-negative patients.
Materials and methods: Since January 2015, adult patients aged 20
years or older who presented with early syphilis (primary, secondary
and early latent syphilis) with baseline rapid plasma regain (RPR)
titres of 4 or greater were included in this prospective observational
study after the patients received a single dose of BPG for early
syphilis according to the STD Treatment Guidelines 2015 of US CDC
[1]. RPR titres were determined at baseline and thereafter every 4
weeks for 12 weeks, followed by every 12 weeks. Serologic response
was defined as decline of RPR titre by fourfold or greater at each
time point compared with baseline. Serologic failure was defined as
an increase of RPR titre by fourfold or greater during follow-up after
ever achieving a decline of the titre.
Results: Between January 2015 and May 2016, 111 HIV-positive and
24 HIV-negative patients were included; all were men who have sex
Figure 1. Monthly distribution of serum vitamin D levels showing
seasonal changes in non-African patients not taking cholecalciferol
(pB0.001).
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with men. Compared with HIV-positive patients, HIV-uninfected
patients had more cases of secondary syphilis (66.7% vs. 30.6%,
p0.002), less early latent syphilis (25.0% vs. 60.4%, p0.003), less
prior syphilis (8.3% vs. 70.3%, pB0.001). HIV-negative patients had
faster serologic response than HIV-positive patients: 58.3% versus
31.8% (p0.02), 100% versus 60.2%, (pB0.001), 100% versus 77.7%
(p0.02) and 93.8% versus 80.4% (p0.3) at week 4, week 8,
week 12 and week 24, respectively. In multivariate analysis to
examine the factors associated with 12-week serologic response, we
found that the response was associated with early latent syphilis
(adjusted odds ratio (AOR) 0.17; 95% confidence interval (CI) 0.05
0.61) and per 1log2 increase of RPR titre at baseline (AOR 1.01;
95% CI 1.001.01, p0.029).
Conclusions: HIV-negative patients had better early serologic
response of early syphilis to BPG than HIV-positive patients during
the first 12 weeks of follow-up. Early latent syphilis was associated
with a poorer response while a higher RPR titre was associated with
a better response to BPG.
Reference
1. Workowski KA, Bolan GA, Centers for Disease Control and
Prevention. Sexually transmitted diseases treatment guidelines,
2015. MMWR Recomm Rep. 2015;64(RR-3):1137.
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Introduction: There is growing evidence that despite effective cART,
cognitive and emotional impairments have been still observed in
HIV-infected individuals, which depends on multiple factors. One of
the most important predictors of neurocognitive changes is the nadir
CD4 cells count. The aim of the current report is to determine the
neurocognitive and emotional differences between HIV-infected
MSM with undetectable viral load and non-infected controls and
to examine the significance of ARV regimens and nadir CD4 count in
HIV() group.
Materials and methods: In this study, there were 95 HIV() MSM
and 95 HIV-uninfected controls matched on socio-demographic
variables. The characteristics of HIV() group were as follows:
duration of HIV infection M6.5 years (SD5.8); CD4 nadir
M265.2 cells/mL (SD147.5); current CD4 M586.1 cells/mL
(SD217); duration of cART M5.1 years (SD4.9); 56% were
treated with 2NRTIPI/r, 23% 2NRTINNRTI, 21% other regimen.
HIV() subjects were divided into two groups with nadir CD4
count B350 cells/mL (n69) and 350 cells/mL (n26). The partici-
pants performed a battery of standard neuropsychological tests and
psychological questionnaires. In the analyses were used Student’s,
non-parametric tests (KolmogrowSmirnov) and correlations.
Results: HIV() and HIV() groups did not differ in terms of age
and years of education. HIV() individuals achieved lower outcomes
in attention (pB0.05), executive function (pB0.05) and language
(pB0.01) tasks when compared to HIV() controls. Moreover, the
HIV() group demonstrated higher levels of anxiety (pB0.05) and
depression (pB0.05). There were no differences between cART
regimens as well as cognitive and emotional domains. HIV-infected
participants with CD4 nadir B350 cells/mL obtained lower results
in attention (pB0.05) than HIV-infected participants with CD4
nadir 350 cells/mL.
Conclusions: Despite effective cART, the HIV() MSM showed lower
functioning in neurocognitive domains and frail emotional condition
as compared to the control group. We found differences in
neurocognitive functioning in relation to nadir CD4 count. However,
ARV regimen was not an important factor of cognitive decline in
patients with undetectable viral load.
Viral Hepatitis
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TURQUOISE-I part 2: safety and efficacy of
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Introduction: Ombitasvir, paritaprevir co-administered with ritonavir,
and dasabuvir (OBV/PTV/rDSV) comprise the 3 direct-acting
Table 1. Baseline demographics and disease characteristics
GT1
N199
GT4
N28
Male, n (%) 156 (78) 26 (93)
White race, n (%) 172 (86) 25 (89)
Age, median (range), years 50 (2669) 47 (3063)
BMI, median (range), kg/m2 25 (1741)* 24 (1538)
HCV genotype 1a, n (%) 147 (74) 
Cirrhosis, n (%) 22 (11) 0
Treatment-experienced, n (%) 64 (33)$ 11 (39)
HCV RNA, median (range), log10
IU/mL
6.5 (1.87.6) 6.0 (4.77.0)
CD4 cell count, median
(range), /mL%
612 (1332351) 731 (2621533)
BMI, body mass index.
*N198; $N193; %N197 GT1, N27 GT4.
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antiviral (DAA; 3D) regimen9ribavirin (RBV) approved for HCV
genotype (GT) 1 infection. Here we investigate the safety and
efficacy of 3D9RBV for GT1, and the 2 DAA (2D) regimen of
OBVPTV/rRBV approved for GT4, in HIV-1 co-infected patients
with or without compensated cirrhosis.
Methods: TURQUOISE-I, part 2 is a phase 3 multicentre study.
Eligible patients were HCV treatment-naı¨ve or RBV/interferon-
experienced, on an HIV-1 antiretroviral regimen containing atazana-
vir, raltegravir, dolutegravir or darunavir (for GT4 only) and had
plasma HIV-1 RNA B40 copies/mL at screening. Patients received
OBV/PTV/r (25/150/100 mg)9DSV (250 mg)9weight-based RBV for
12 or 24 weeks per label guidelines. Interim safety and efficacy data
are presented.
Results: Table 1 presents baseline demographics on 227 treated
patients as of 21 April 2016. Of the 194 GT1- and 26 GT4-infected
patients with available data, 98% and 100% achieved sustained virologic
response (SVR) at post-treatment week (PTW) 4 (SVR4), respectively.
Three patients experienced virologic failure: one GT1a, treatment-
naı¨ve patient without cirrhosis relapsed at PTW4, a second GT1a,
treatment-naı¨ve patient without cirrhosis relapsed at PTW12 and
one GT1b, treatment-experienced patient with cirrhosis experienced
breakthrough at week 10. No patients discontinued treatment due to
adverse events (AEs). Most AEs were mild to moderate in severity,
and key lab abnormalities were rare (Table 2).
Conclusions: The 2D and 3D regimens were well tolerated and
yielded high SVR4 rates in patients with HCV GT1 or GT4/HIV-1 co-
infection. OBVPTV/r9DSV9RBV is a potent HCV treatment option
for patients with HIV-1 co-infection, regardless of treatment
experience or presence of compensated cirrhosis.
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Introduction: HCV affects 185 million people worldwide and leads to
death and morbidities. HCV has a high genetic diversity and is
classified into seven genotypes and 67 subtypes. Novel anti-HCV
drugs (direct-acting antivirals) eligibility, resistance and cure rates
depend on HCV geno/subtype (GT).
Materials and methods: Anonymized GT and epidemiological
information gained in 20112015 was analyzed retrospectively.
Data were obtained from 52 centres in Austria, Belgium, Germany,
Israel, Italy, Luxembourg, Portugal, Russia, Spain and the UK.
Table 2. Safety and post-baseline laboratory abnormalities
Event, n (%)
GT1
N199
GT4
N28
Any AE 167 (84) 24 (86)
Serious AEs 9 (5) 1 (4)
RBV dose modifications due to
haemoglobin decline
25 (13) 3 (11)
ALT grade ]3 (5ULN) 1 (1) 0
Total bilirubin grade ]3 (3ULN) 26 (13) 2 (7)
Patients on ATV-containing ART, n/N (%) 23/26 (88) 2/2 (100)
Haemoglobin grade 2 (B10 g/dL) 15 (8) 0
Haemoglobin grade 3 (B8 g/dL) 0 0
AE, adverse event; ALT, alanine aminotransferase; ATV, atazanavir;
RBV, ribavirin; ULN, upper limit of normal.
Abstract P249Figure 1. HCV GT distribution patterns.
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Results: Thirty-seven thousand eight hundred and thirty-nine
samples were included in the study. The most prevalent was GT1
(64.9%), followed by GT3 (20.9%) and GT4 (9.0%). Three samples
classified as the recombinant genotype-P were identified in Munich
(Germany). We show that the GT distribution is similar throughout
Western European countries, with some local differences. Here, GTs
1b and 2 prevalences are lower and of GT 1a and 4 higher than in all
previous reports. Israel has a unique GT pattern with only GT1b, 1a
and 4 (78.6%, 20.2% and 1.2%, respectively). In South Russia, the GT
proportions are more similar to Asia, with prevalent GTs 1, 3 and 2
(50.8%, 37.9% and 11.2%, respectively). GTs 5 and 6 were detected in
very low proportions. Three cases of the recombinant genotype P
were reported in Munich (Germany). In addition, we observed that
GT proportion was dependant on patients’ gender, age and
transmission route (Figure 1): GTs 1b and 2 were significantly more
common in female, older, nosocomially-infected patients, while GTs
1a, 3 and 4 were more frequent in male, younger patients infected
by tattooing, drug consume and/or sexual practises. In infections
acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed.
In infections related to sexual practises, lower proportion of GT3
(14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly
abundant in MSM (29.6%). HIV co-infection was significantly
associated with higher proportions GTs 1a and 4 (42.5% and
19.3%, respectively).
Conclusions: Genotype prevalence evolves and correlates to epide-
miological factors. Continuous surveillance is necessary to better
assess hepatitis C infection in Europe and to take appropriate health
actions.
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Introduction: Liver fibrosis progression is faster in HIV/HCV co-
infected than in HCV mono-infected patients. We aimed at assessing
the rate of progression to advanced liver fibrosis among HIV-infected
patients on suppressive ART, with or without HCV co-infection, and
identifying its predictors.
Methods: Patients from the ICONA cohort with known HCV-antibody
(HCVAb) status and a FIB-4 53.25 were studied from baseline (the
first of two consecutive HIV RNA B50 copies/mL under ART), up to
the last available FIB-4, HIV RNA rebound or anti-HCV treatment
introduction, whichever occurred first. Time to development of
advanced fibrosis (the first of two consecutive FIB-4 3.25) was
assessed using multivariable Cox analyses, separately conducted
among HCVAb-positive and HCVAb-negative patients. The tested
covariates were as follows: gender, country of birth, injecting drug
use as HIV risk factor, CD4 nadir, baseline CD4, HDL cholesterol,
diabetes, duration of HIV infection, HCV RNA, HCV genotype,
baseline FIB-4 and first-line ART drugs.
Results: Five thousand seven hundred and seventeen patients with a
median follow-up of 4 (IQR 2.27.4) years, contributing to 30,299
patient-years of follow-up (PYFU) were included. The median number of
FIB-4 measurements was 7 per patient (IQR 414). Patients were pre-
dominantly males (75%), their median age was 40 years (IQR 3446);
20% were HCVAb-positive. Median baseline FIB-4 was 1.09 (IQR
0.811.58) and 0.81 (IQR 0.591.12) among HCVAb-positive and
HCVAb-negative patients, respectively (Table 1). During follow-up,
272 patients progressed to advanced fibrosis. Incidence (0.9 per 100
PYFU (95% CI 0.81.0)) was higher among HCVAb-positive patients
with positive or unknown HCV RNA (2.94 (95% CI 2.433.55) or 3.10
(95% CI 2.513.83) per 100 PYFU) than among HCVAb-negative or
HCVAb-positive HCV RNA-negative patients (0.33 (95% CI 0.260.41)
and 0.49 (95% CI 0.191.32) per 100 PYFU, respectively). At
multivariable analysis, in HCVAb-negative patients, higher baseline
FIB-4 (per unit increase, HR 3.88, 95% CI 2.865.26, pB0.001) and
first-line ART containing didanosine or stavudine (HR 1.65, 95% CI
Abstract P250Table 1. Baseline characteristics of HIV-infected patients under suppressive antiretroviral therapy, with or without
HCV co-infection
Characteristics at baseline HCVAb-negative HCVAb-positive p
Male gender, n (%) 3449 (75.4) 832 (72.7) 0.060
Age (years), median (IQR) 39 (3347) 40 (3645) 0.005
Migrants, n (%) 674 (14.7) 53 (4.6) B0.001
IDU as mode of HIV transmission 108 (2.4%) 806 (70.4%) B0.001
Time since HIV infection, sum (IQR) 1.9 (0.74.9) 9.0 (3.714.8) B0.001
CD4 at baseline cell/mm3, n (%) 276 (152378) 243 (120343) 0.016
Nadir CD4, cell/mm3, n (%) 463 (321619) 442 (285630) B0.001
Calendar year of baseline, median (IQR) 2010 (20042012) 2004 (20012008) B0.001
Diabetes at baseline 176 (3.8%) 53 (4.6%) 0.226
HDL cholesterol, mg/dL 44 (3753) 44 (3655) 0.502
NVP-based first line 217 (4.7%) 79 (6.9%) 0.030
PI/r-based first line 1831 (40.0%) 267 (23.3%) B0.001
ddI/d4t-containing first line 509 (11.1%) 261 (22.8%) B0.001
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0.992.75, p0.054) were associated with higher risk of progres-
sion. In HCVAb-positive patients, adjusting for HCV RNA status,
baseline FIB-4 (per unit increase, HR 3.81, 95% CI 3.154.60,
pB0.001) and first-line didanosine or stavudine (HR 1.38, 95% CI
1.011.89, p0.040) were associated with higher risk of progression
to advanced fibrosis, while HDL cholesterol (35 mg/dL vs. 535
mg/dL, HR 0.65, 95% CI 0.470.89, p0.008) was protective.
Conclusions: In our cohort, progression to more advanced liver
fibrosis was associated with HCV co-infection and, independently of
HCV, to having received d-drugs-containing ART. Although these
regimens are now abandoned, past exposure independently con-
tributed to faster fibrosis progression, suggesting irreversible iatro-
genic damage whose mechanism warrants further investigation. In
HCV co-infected patients, HDL cholesterol had a protective role on
fibrosis progression.
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Introduction: Novel direct-acting antivirals (DAAs) for chronic
hepatitis C virus (HCV) achieve sustained virologic response (SVR)
rates of 90%. Current high prices limit global access to DAAs.
While Gilead (originator company of sofosbuvir) offers voluntary
licences to generic producers in a limited number of countries, these
countries represent only 50% of the worldwide epidemic. Costs of
production can be estimated by tracking the average cost-per-
kilogram of the active pharmaceutical ingredient (API) exported
internationally from India, and combining the estimated per-pill API
expenditure with other components of production cost (e.g.
formulation, packaging). The per-kilogram price of API and steady,
high demand volumes are key determinants of the total production
cost of any medicine.
Materials and methods: Data were extracted from an online
database of Indian export ledgers for per-kilogram prices and
volumes of DAA APIs exported from India over January to June
2016. Average API costs were calculated for June 1, using linear
regression models, weighted by individual export size. For velpatas-
vir, which is the newest DAA in this study and lacks export data, per-
kilogram API cost was estimated from analysis of chemical synthesis
processes described in originator patents. Costs of per-pill API
requirements were combined with estimated costs for formulation
and excipients ($0.04/pill), packaging ($0.35/month). Finally, a profit
margin of 50% was added to estimate a price at which generic
producers could profitably enter the market. Current US and Indian
prices were collected, for comparison, from multiple databases.
Results: Export volumes from India in JanuaryJune 2016 were as
follows: sofosbuvir 10,200 kg, (equivalent to 303,000 12-week
treatment courses), daclatasvir 5443 kg (1,080,000 courses), ledi-
pasvir 240 kg (32,000 courses). API prices decreased throughout the
time frame. Mean API prices on 1 June 2016 were: sofosbuvir $1094/
kg, daclatasvir $998/kg, ledipasvir $2441/kg. API cost for velpatasvir
was estimated at $890011,700/kg. US prices were 1355 times
higher than the target price for sofosbuvir, 4500 times higher for
daclatasvir, 984 times higher for sofosbuvirledipasvir and 346413
times higher for sofosbuvirvelpatasvir (Table 1).
Conclusions: HCV DAAs production costs are falling rapidly. Twelve-
week treatments of sofosbuvir can be manufactured for $62,
sofosbuvirledipasvir $96, daclatasvir $14, sofosbuvirvelpatasvir
$181216. These target prices all include a 50% profit margin for
generic suppliers. These estimated generic prices for DAAs are
comparable to those that have allowed massive treatment scale-up
in HIV/AIDS.
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Introduction: Clinical outcome of HCV therapy of direct-acting
antivirals (DAAs) depends on host and viral factors. This observational,
retrospective and non-interventional study collects data from viral
geno/subtypes (GTs), DAA-resistance-associated mutations (RAMs) in
the NS3/protease, NS5A and NS5B genes, to predict clinical outcome
Abstract P251–Table 1. Calculated target prices and current prices for 12-week DAA treatment courses
Drug
June 2016 API
cost/kg (USD)
Target price per 12-week
treatment
Current global lowest price per
12-week treatment
Current US price per 12-week
treatment
Sofosbuvir (SOF) $1094 $62 $324 $49,86084,000
Daclatasvir $998 $14 $153 $50,65363,000
Ledipasvir (LDV) $2441 $34 unknown unknown
SOFLDV N/A $96 $507 $56,70094,500
Velpatasvir (VEL) $890011,700 $119154 unknown unknown
SOFVEL N/A $181216 unknown $74,760
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using the geno2pheno (HCV) tool. The current geno2pheno version
interprets resistance according to viral GT background.
Materials and methods: Baseline NS3/protease, NS5A and NS5B
sequences were obtained. Subtyping and presence of RAMs against
asunaprevir (ASV), boceprevir (BOC), grazoprevir (GZV), paritaprevir
(PTV), simeprevir (SMV), telaprevir (TVR), daclatasvir (DCV), elbasvir
(EBR), ledipasvir (LDV), ombitasvir (OBV), dasabuvir (DSV) and
sofosbuvir (SOF) were determined by sequencing (either Sanger or
NGS) and subsequent interpretation with geno2pheno (HCV) (www.
hcv.bioinf.mpi-inf.mpg.de/).
Results: One thousand five hundred and seventy HCV-infected
patients from the PEPSI project have been enrolled until June 2016.
We obtained 1024 NS5B sequences, which were used for genotyping.
The most prevalent GTs were as follows: GT1a39.1%; GT1b
34.2%; GT3a16.6%; GT4d4.6%. Baseline treatment susceptibility
was analysed. 595 NS3/protease sequences were obtained and used
for protease-inhibitors resistance prediction (Figure 1). Baseline
resistance was found: ASV2.8%; BOC3.4%; GZV16.5%; PTV
2.0%; SMV21.8%; TVR3.4%. For ASV, 22.0% of the samples were
predicted as possibly resistant. NS5A: the susceptibility of 402
sequences was analyzed. The percentage of resistant samples was
similar for all four NS5A inhibitors, 10.212.0%. NS5B: the sequence
sets used for the analysis of each of the NS5B inhibitors varied, since
the described RAM patterns for each drug comprise different amino
acid residues. While 14.2% of the 502 sequences used for DSV
screening were reported as resistant, none of the 912 samples
screened for SOF were predicted as resistant. Baseline RAM analysis:
the prevalence of the mutations NS3 80K and 170I (18.2% and 14.8%,
respectively) leads to baseline resistance to SMV and GZV (21.8% and
16.5%, respectively). In addition, substitutions on other five amino
acid positions were found in lower proportions. In the NS5A, amino
acids exchanges at positions 28, 30, 31 and 93 were found, leading to
NS5A baseline resistance of 10%. In the NS5B, the mutations 556GNR
were found in 13.0% of the cases.
Conclusions: DAA susceptibility may be compromised at baseline.
Baseline sequencing of target genes is cost-effective procedure to
assess viral genotype in the DAA target genes and to determine
resistance. These two parameters can help the physician to determine
the best treatment and avoid misclassification of viral recombinant GTs.
P253
Are HIV/HCV co-infected patients more likely to experience
multiple lines of ART than HIV mono-infected patients?
Results from the Icona Foundation study
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Introduction: Despite a common perception that ART leads to more
drug discontinuations in HIV/HCV co-infected patients, especially for
certain compounds, as compared to HIV mono-infected, it remains
unclear whether co-infection leads to higher frequency of treatment
changes for a given time in care.
Methods: We performed a cross-sectional analysis within the Icona
Foundation study cohort including all patients who started cART and
were tested for HCVAb at least once over follow-up. People were
defined HCVAb if they were ever tested positive. Individuals who
seroconverted for HCV, spontaneously reverted to HCV negative,
cured or HBV co-infected patients were excluded. Exposure factors
were calculated at the date of starting cART apart from the number
of ART lines ever used which was calculated at the date of last visit.
Total ART lines used were calculated first counting all switches and,
in three other analyses, counting only switches that occurred for a
specific reason as reported by the physician: (1) treatment failure
(virological/immunological failure); (2) change due to toxicity/intol-
erance; and (3) change due to ART simplification. Univariable and
multivariable analyses logistic regression models were performed.
Potential confounders used in the multivariable model are listed in
the footnote of Table 1.
Results: We enrolled 8188 patients: 1626 HCVAb, 6562 HCVAb.
At the date of starting cART, HCVAb patients were younger
(median (IQR) 37 (3342) vs. 38 (3146); pB0.001); more
frequently Italian (95.5% vs. 83%; pB0.001), IDU (79.4% vs. 2.4%;
pB0.001), smokers (32% vs. 29%; pB0.001) and alcohol abusers
(7% vs. 6%; pB0.001); they had lower CD4 nadir (HCVAb with
B350 CD4/mL, 69% vs. 62%; pB0.001). Overall, in HCVAb
subjects, a significantly higher proportion of HCVAb patients had a
history of 3 ART lines (31% vs. 19%; pB0.001). Results were
similar when counting only changes due to failure (4% vs. 3%,
Abstract P252–Figure 1. Proportion of samples resistant, partially resistant and susceptible to the licenced DAAs as predicted by
geno2pheno(HCV).
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pB0.001) and toxicity/intolerance (8% vs. 5%, pB0.001). After
controlling for potential confounders, especially after adding lifestyle
factors, these differences were attenuated and, for the analysis
counting switches due to simplification, there was an inverted trend
(Table 1).
Conclusions: Overall, HCVAb individuals were more likely to be
exposed to multiple lines than HIV mono-infected while in care,
especially when comparing people who used at least three ART lines.
This difference was most likely driven by toxicity and treatment failure.
In contrast, HCVAb showed a cumulative lower risk to change
ART because of simplification, reflecting the tendency of clinicians
to maintain an already suppressive regimen in this population.
P254
Rapid decline of anti-HCV antibodies following treatment of
incident HCV infection in HIV-infected MSM in the Swiss HIV
Cohort Study (SHCS)
Karoline Aebi-Popp1; Gilles Wandeler1; Luisa Salazar-Vizcaya1;
Jan Fehr2; Marcel Stoeckle3; Matthias Hoffmann4; Franziska Suter-
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Introduction: Following clearance of hepatitis C virus (HCV) infection,
HCV antibody titres (anti-HCV) may decline resulting in serorever-
sion. However, it is unclear whether changes in antibody levels differ
between patients with spontaneous HCV clearance and those treated
during early or chronic HCV infection.
Material and methods: We compared anti-HCV dynamics following
an incident HCV infection after HIV diagnosis in 67 HIV-seropositive
men who have sex with men (MSM) grouped by different clinical
outcomes: 22 patients not treated for HCV infection (untreated), 12
with spontaneous HCV clearance and 33 with treatment-induced
sustained virological response (SVR) (median time from diagnosis to
treatment 3.2 months). Anti-HCV antibody levels were measured at
baseline and annually for 3 years thereafter using a commercial ELISA
kit (ARCHITEKT, Abbott Laboratories). Results were compared to 12
SHCS participants with chronic HCV infection acquired before HIV
diagnosis and subsequent SVR (chronic HCV infection). We compared
the relative change (%) in antibody levels between patient groups by
Abstract P253–Table 1. Odds ratios from fitting a logistic regression model
n1626 n6562 All switches (n8188)
No. of ARV lines previously
used
HCVAb n
(%)
HCVAb n
(%) Unadjusted OR (95% CI) p
Adjusteda OR
(95% CI) p
Per additional 1.07 (1.031.12) B0.001 1.01 (0.931.10) 0.82
01 566 (35%) 2745 (42%) 1.00 1.0
23 560 (34%) 2541 (39%) 1.07 (0.941.21) 0.31 1.23 (0.961.69) 0.09
3 500 (31%) 1276 (19%) 1.90 (1.652.18) B0.001 1.72 (1.102.68) 0.02
Only switches due to treatment failure
(n755)
Per additional 204 551 1.07 (1.031.12) B0.001 0.95 (0.871.04) 0.27
None 1422 (87%) 6011 (92%) 1.00 1.0
1 ARV 59 (4%) 141 (2%) 1.77 (1.302.41) B0.001 0.94 (0.531.66) 0.82
23 ARV 75 (5%) 228 (3%) 1.39 (1.061.82) 0.02 0.79 (0.471.33) 0.38
3 ARV 70 (4%) 182 (3%) 1.62 (1.232.16) B0.001 0.81 (0.461.45) 0.49
Only switches due to toxicity/intolerance
(n1471)
Per additional 391 1080 1.10 (1.061.13) B0.001 1.01 (0.951.08) 0.80
None 1235 (76%) 5482 (84%) 1.00 1.0
1 ARV 91 (6%) 213 (3%) 1.90 (1.472.44) B0.001 1.28 (0.782.08) 0.33
23 ARV 165 (10%) 550 (8%) 1.33 (1.111.60) 0.002 1.38 (0.991.93) 0.06
3 ARV 135 (8%) 317 (5%) 1.89 (1.532.33) B0.001 0.98 (0.621.57) 0.96
Only switches due to simplification
(n1292)
Per additional 0.89 (0.840.93) B0.001 0.86 (0.800.94) 0.001
None 1474 (90%) 5422 (83%) 1.0 1.0
1 ARV 9 (0.5%) 126 (2%) 0.26 (0.130.52) B0.001 0.21 (0.070.59) 0.003
23 ARV 84 (5%) 728 (11%) 0.42 (0.340.54) B0.001 0.74 (0.491.12) 0.16
3 ARV 59 (4%) 286 (4%) 0.76 (0.571.01) 0.06 0.48 (0.270.82) 0.007
aAdjusted for age, CD4, HIV RNA, mode of HIV transmission, gender, nationality, smoking, alcohol consumption, calendar year, follow-up
duration and previous use of individual drugs.
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estimating: (1) the maximum drop over the study period and (2)
rates of decline per year over time. Re-infections were assessed by
repeated HCV RNA measurements in all participants.
Results: MSM with SVR following treatment of incident HCV infections
showed a more pronounced decrease in anti-HCV levels within the first
3 years after treatment (median decline 71%) compared to patients
with spontaneous clearance (median decline 37.6%, pB0.001, Figure
1a). Antibody titres remained stable in untreated patients and in those
treated during chronic HCV infection. There was no association between
antibody decline and HCV genotype, IL28B, CD4 T cell count and HIV
viral load. Five of 33 (15%) with SVR and 1/12 (8%) subjects with
spontaneous clearance seroreverted during follow-up. Nine (20%)
subjects experienced a re-infection during follow-up; anti-HCV levels
increased above the level of primary infection at time of re-infection.
Figure 1b shows the estimated trajectories for the relative change in
antibody levels. Patients with an SVR following an incident HCV
infection experienced the fastest decline (rate (IQR)0.47 (0.18
to 0.85)), followed by spontaneous clearers (0.15 (0.06 to
0.27)) and patients with an SVR due to HCV treatment during chronic
HCV infection (0.05 (0.05 to 0.13)).
The origin was diagnosis of incident HCV infection for patients in
the ‘‘untreated’’ and ‘‘spontaneous clearance’’ categories and HCV
Figure 1. Maximum and relative change in antibody titre (%) by clinical outcome category.
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treatment start for patients in the ‘‘treated with SVR’’ and ‘‘treated
during chronic infection’’ categories. The light grey dots indicate
seroreversions
Conclusions: Treatment-induced HCV clearance of incident infection
was associated with the greatest decline in anti-HCV antibody
levels and with highest rates of seroreversions among HIV-
seropositive MSM. These results suggest that fast clearance of HCV
RNA following treatment of incident HCV infection might lead to a
limited viral antigen stimulation required for a persistent antibody
response.
P255
Effectiveness of hepatitis A vaccination in HIV-positive men
who have sex with men during an ongoing hepatitis A
outbreak in Taiwan
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Chun Lo1; Szu-Min Hsieh1; Wang-Huei Sheng1; Yu-Chung Chuang1;
Guan-Jhou Chen1; Chien-Ching Hung1 and Shan-Chwen Chang1
1Department of Internal Medicine, National Taiwan University
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Introduction: An ongoing outbreak of acute hepatitis A virus (HAV)
infection has been occurring among men who have sex with men
(MSM) in Taiwan since June 2015, with more than 400 cases
reported to the Taiwan CDC as of June 2016. This study aimed to
evaluate the effectiveness of HAV vaccination in HIV-positive patients
in an outbreak setting.
Materials and methods: In light of an ongoing outbreak of acute
HAV infection among MSM, we prospectively performed a seroepi-
demiologic survey of HAV in HIV-positive patients during June
2015 to June 2016. The HAV-seronegative patients were offered
HAV vaccine. The serologic outcomes were assessed after the first
and last doses of HAV vaccine. The clinical outcome was acute HAV
infection.
Results: During the 1-year study period, 1237 HAV-seronegative
patients with 94.7% being MSM and a median CD4 count of 567
cells/mm3 (range 42342 cells/mm3) were included for analysis.
Before 30 June 2016, 728 patients (58.9%) had received at least one
dose of HAV vaccine, and 100 (8.1%) had completed the two-dose
vaccine series. Compared with non-vaccinated patients, the vacci-
nated patients were older (mean age, 35.5 years vs. 34.0 years), less
likely to be anti-hepatitis C-positive (5.5% vs. 10.8%) and more likely
to have received antiretroviral therapy (97.0% vs. 93.9%) and have
had HAV vaccination previously (8.9% vs. 4.5%). The overall
seroconversion rate before the administration of the second dose
of HAV vaccine was 27.8%. The seroconversion rates within 4 weeks,
at weeks 48, weeks 816 and weeks 1624 were 18.1%, 20.6%,
48.4% and 51.9%, respectively. One month after the last dose, the
seroconversion rate increased to 95.5%. The factors associated with
seroconversion between the first and last doses of HAV vaccination
were time to anti-HAV IgG testing (adjusted odds ratio (AOR), per 1-
week increase, 1.16; 95% CI 1.091.22) and previous HAV vaccina-
tion (AOR 47.72; 95% CI 7.16317.97). The incidence rate of acute
HAV infection in patients with and without HAV vaccination was 0.13
and 6.45 per 100 person-years, respectively, resulting in a vaccine
effectiveness of 98.0%. The predicting factors of acute HAV infection
included having had not receiving HAV vaccine (adjusted hazard ratio
(AHR) 45.45; 95% CI 5.95333.33) and recent syphilis (AHR 6.11; 95%
CI 3.0212.39).
Conclusions: Despite the impaired immunity from HIV infection and
delayed serologic response to HAV vaccination in HIV-positive MSM,
the risk of acute HAV infection was significantly reduced among the
vaccinated patients during the HAV outbreak setting.
P256
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Introduction: High prices of direct-acting antivirals (DAAs) can
prevent access to treatment. Generic versions of sofosbuvir (SOF)
are being mass produced for prices under 1% of the current U.S.
retail price. Under UK and Australian law, individual patients have the
legal right to import 3 months of treatment for hepatitis C virus
(HCV), for their personal use. This analysis assessed the efficacy and
safety of generic DAAs legally imported into countries where
treatment access is limited.
Methods: SOF, ledipasvir (LDV) and daclatasvir (DCV) were
imported from generic companies into Europe, Australia and North
America. Selection of DAAs and treatment duration depended on
baseline HCV genotype and fibrosis stage. Initial generic supplies
were evaluated using high precision liquid chromatography (HPLC)
and nuclear magnetic resonance (NMR) to evaluate presence of
active drug. Patients taking generic DAAs were evaluated pretreat-
ment, and at weeks 2, 4, 12 and then for SVR4 and 12. Adverse
events were recorded. This analysis includes data from 448 patients,
whose imported treatment was organized from the FixHepC
website.
Results: Of the 448 patients treated, 237 received SOF/LDV, 208 SOF/
DCV and 3 SOF/RBV. By HPLC and NMR, all imported drugs passed
quality control standards for active DAA drugs. Overall, the patients
were 57% male with a mean age of 55 years; 66% were genotype 1,
25% genotype 3 and mean baseline HCV RNA was 6.5 log10 IU/mL.
Based on currently available data, the percentage with HCV RNA
BLLOQ was 196/223 (98.9%) at end of treatment (EOT), 192/211
(91%) at SVR4 and 130/144 (90%) at SVR12. Summary baseline and
outcome data from the patients given SOF/LDV or SOF/DCV are
shown in Table 1.
Conclusions: In this analysis, treatment with legally imported generic
DAAs achieved SVR4 rates of 93% on SOF/LDV and 89% on SOF/DCV.
These SVR rates are comparable to those seen in phase III trials of
the same, but more expensive, branded treatments. Mass treatment
with legally imported generic DAAs is a feasible, low-cost option
where high prices prevent access to branded treatment.
Table 1. HCV RNA undetectability rates for generic DAAs
SOF/LDV SOF/DCV
HCV RNA N237 N208
Treatment naı¨ve (%) 123/237 (52) 130/208 (63)
Cirrhosis (%) 52/237 (23) 79/208 (39]
Genotype 1 (%) 215/237 (91) 80/208 (39)
HCV RNA B25 IU/mL
Week 12/EOT (%) 180/182 (99) 171/173 (99)
SVR4 (%) 104/112 (93) 85/96 (89)
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Introduction: Tenofovir disoproxil fumarate (TDF) combined with
lamivudine (LAM) or emtricitabine are the recommended nucleos(t)-
ide reverse-transcriptase inhibitors backbone for patients co-infected
with HIV and hepatitis B virus (HBV). TDF leads to rapid decline of HBV
DNA. However, data regarding the durability of HBV suppression of
TDF-containing cART in HIV/HBV co-infected patients are scarce in
hyperendemic area of chronic HBV infection. This study aimed to
assess the long-term virologic response of HBV to TDF-containing
cART in HIV-positive patients in Taiwan where the prevalence of
chronic HBV infection was estimated 1520% in persons born before
nationwide neonatal HBV vaccination programme was implemented
in 1986.
Methods: Between 2004 and 2016, 186 HIV/HBV co-infected patients
with baseline HBV DNA 1000 copies/mL were included and
followed for 5 years or longer. Serial blood samples were collected
for determinations of plasma HBV DNA load, HBV serologic markers
(HBsAg, anti-HBs, HBeAg, and anti-HBe) and liver and renal functions
after initiation of cART with or without TDF. Factors associated with
undetectable HBV DNA at 5 years of treatment were explored by
logistic regression.
Results: Of 186 HIV/HBV co-infected patients included, 53 received
cARTwhich contained LAM as the only therapy for HBV, 58 switched to
TDF-containing cART after detection of resistance-associated muta-
tions of HBV to LAM (n40) or an elevation of HBV DNA load (n18)
and 75 received TDF-containing cART as initial anti-HBV therapy. The
percentages of HBV viral suppression at year 1 and year 5 were 64%
and 73.7%, respectively, in patients receiving LAM monotherapy for
HBV, 76.4% and 89.7%, respectively, in patients switching to TDF-
containing cART, and 86.1% and 100%, respectively, in patients
receiving TDF-containing regimens as their first cART. In multivariate
analysis, the only factor associated with failure to achieve viral
suppression at 5 years was higher HBV DNA load at baseline (adjusted
odds ratio (AOR), per 1log10 copies/mL increase, 1.722; 95% CI
1.0942.711, p0.019). TDF exposure was of borderline statistical
significance (AOR 0.183; 95% CI 0.0281.193, p0.076) in the
analysis. During study period, 10 of 46 patients (21.7%) with baseline
HBeAg positivity had HBeAg seroconversion and loss of HBsAg was
observed in four patients (2.2%).
Conclusions: TDF-containing cART achieved durable HBV viral
suppression in HIV/HBV co-infected patients. A higher HBV DNA
load at baseline was associated with failure to achieve HBV viral
suppression after long-term TDF-containing cART.
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Liam Sutcliffe1 and Emma Thomson2
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Introduction: Since 2000, there have been numerous reported cases
of acute hepatitis C virus (HCV) in HIV-positive men who have sex
with men (MSM) in developed countries [1]. The majority of these
men deny any history of injecting drug use (IDU), making sexual
transmission the most likely route of transmission. HCV genotype 4 is
increasing in prevalence amongst MSM populations [2], but is
subject to less research than other HCV genotypes. This study aims
to use a variety of phylogenetic approaches and evolutionary analysis
to determine the origins, spread and changing epidemiology of HCV
genotype 4d (HCV-4d).
Methods: NS5B region sequences were obtained for patients with
HCV-4d using the Los Alamos HCV Sequence Database and NCBI
GenBank. Most of these patients were also co-infected with HIV. For
each sequence, the sample collection date, country and most likely
route of HCV infection were recorded. Sequences were aligned and
maximum likelihood phylogenetic trees created with 1000 bootstrap
replicates. Molecular clock analysis was performed using the
Bayesian Markov chain Monte Carlo (MCMC) approach.
Results: The records of 193 individuals (n193) were reviewed (See
Figure 1 on page 259). In the maximum likelihood tree, a distinct
cluster of 70 sequences from MSM from four European countries was
noted. An MSM cluster was noted containing 12 sequences from the
UK, with a 4.8% pairwise distance from the nearest other sequence. A
strongly supported homologous pair of genetically similar Dutch
sequences was also noted, one from an injecting drug user (IDU) and
one from an MSM who reports IDU. Molecular clock analysis
identified six HCV-4d clusters comprising mostly IDU sequences, and
two MSM-specific clusters. The estimated year of origin of the IDU
clusters ranged from 1982 to 1994, whilst the MSM clusters were
estimated to have originated in 1995 and 1999. In the IDU clusters, 65%
of lineage splits occurred before 1996. In the MSM clusters, 83% of
lineage splits occurred after 2000. The UK-specific MSM cluster appears
to originate following a lineage split from a strain of HCV-4d circulating
in IDUs in Southern Europe in the late 1980s to early 1990s.
Conclusion: Incidental transfer of HCV-4d strains from IDUs and
rising viral transmission in highly connected MSM populations has
led to the formation of international MSM-specific transmission
networks. Increased investment in public health interventions is
required to slow this expanding epidemic.
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Introduction: Twelve-week therapy with the single-tablet regimen
(STR) of sofosbuvir/velpatasvir (SOF/VEL) has demonstrated high
efficacy in genotypes 1 to 6 HCV-infected patients. Astral-5 clinical
trial completed the phase 3 program with the analysis of 12-week
SOF/VEL regimen in HIV/HCV co-infected patients. Previous SOF-
based combinations showed a comparable safety and efficacy profile
in both HCV mono-infected and HCV/HIV co-infected individuals. In
order to confirm these data also for SOF/VEL, we compared data
obtained in Astral-5 trial with safety and efficacy results of HCV
mono-infected individuals produced by Astral 1, 2 and 3.
Methods: Astral-5 study enrolled treatment-naı¨ve and -experienced
HCV/HIV co-infected patients of all HCV genotypes, with or without
cirrhosis. Patients who were on stable ARV regimens with fully
suppressed HIV RNA received SOF/VEL (400 mg/100 mg daily) for 12
weeks. Patients were on a wide range of ARV regimens including
emtricitabine/tenofovir disoproxil fumarate or abacavir/lamivudine
with a backbone of raltegravir, cobicistat/elvitegravir, rilpivirine,
ritonavir-boosted atazanavir, darunavir or lopinavir. Astral 1, 2 and
3 phase 3 trials enrolled treatment-naı¨ve and treatment-experienced
genotype 1 to 6 HCV-infected patients, with and without cirrhosis, no
limit of BMI and no limit of age. Patients received SOF/VEL for 12
weeks.
Results: A total of 106 HIV/HCV co-infected patients were enrolled
and treated with SOF/VEL for 12 weeks. Overall 86% were male, 45%
were black, 77% had IL28B non-CC genotypes, 29% had prior
treatment failure (primarily pegIFN/RBV) and 16% had compensated
cirrhosis. The genotype distribution in HIV/HCV patients was 62%
GT1a, 11% GT1b, 10% GT2, 11% GT3 and 5% GT4. The median
baseline CD4 count was 548 cells/mL (range 1831513 cells/mL) with
a median estimated glomerular filtration rate of 97 mL/min (range
57198 mL/min). Boosted protease inhibitor regimens were the
most commonly used regimen (47%). No patient experienced
confirmed HIV virologic rebound (HIV-1 RNA ]400 copies/mL). A
total of 1035 HCV mono-infected individuals were treated with a 12-
week SOF/VEL regimen in Astral 1, 2 and 3 trials. Cirrhotic patients
represented the 21% (n220) of the total population, and 291
patients (28%) failed a previous anti-HCV treatment. The genotype
distribution was 20% GT1a, 12% GT1b, 23% GT2, 27% GT3, 11% GT4,
3% GT5 and 4% GT6. IL28B non-CC genotype was present in 77% of
the patients. Efficacy and safety outcomes of mono- and co-infected
patients, including complete SVR12, HIV parameters and the impact
of HCV resistance variants on outcome will be presented.
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HIV/hepatitis C co-infected patients are significantly more
complex to manage than HIV mono-infected patients
in a large cohort of treatment-naı¨ve, HIV-positive
individuals
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Ronald D’Amico3; Kathy Schulman4; Susan Zelt5 and Philip Lackey6
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Introduction: HCV co-infection is common in HIV populations due to
shared modes of transmission. Evaluating differences between HIV
only and HIV/HCV populations may lead to earlier identification,
more effective management and better clinical outcomes.
Materials and methods: Using the OPERA database, a collaboration
of caregivers at 79 clinics in 15 states, HIV individuals initiating HIV
antiretroviral therapy for the first time between 1 January 2007 and
31 March 2015 were identified. Patients were followed from HIV
treatment initiation to discontinuation of regimen, loss to follow-up,
death or study end (31 March 2016). Demographics and clinical
characteristics were compared between HIV/HCV co-infected and
HIV-only patients using Pearson chi-square or Wilcoxon rank-sum
tests. Differences in time to HIV viral load (VL) suppression (B50
copies/mL) with and without HCV were assessed using multivariable
Cox proportional hazards regression.
Results: Of 9190 HIV treatment-naı¨ve patients, 7837 (85.3%) were
HCV Ab- and 472 (5.1%) were HCV by diagnosis, VL or treatment.
Additionally, 881 (9.6%) had a history of HCV clearing or no testing
prior to baseline and were excluded. Comparing HCV/HIV co-infected
patients with HIV-only patients, co-infected patients were signifi-
cantly (pB0.0001) older (median age: 46.7 vs. 34.0 years), had a
lower proportion of males (76.9% vs. 86.6%) and were less likely to
be Hispanic (16.9% vs. 25.5%) or men who have sex with men (39.8%
vs. 59.8%). HIV/HCV patients had more comorbidities (CVD, cancer,
endocrine, renal, neuropathy and hypertension) and higher pill
burden for their HIV and non-HIV medications. Co-infected patients
were twice as likely to present with mental illness (25.6% vs. 13.4%),
and a third had documented substance addiction (32.0% vs. 13.7%).
Baseline CD4 counts were lower for HIV/HCV patients (279 vs. 330
cells/mL) with no difference between groups in baseline HIV VL. HIV
treatment was less successful in the HIV/HCV patients, both in
achieving suppression (HIV/HCV: 55.5% vs. HIV: 65.4%, pB0.0001)
and avoiding rebound (HIV/HCV: 12.3% vs. HIV: 9.4%, p0.0376)
during initial treatment. In crude and adjusted models, those with
HCV co-infection were significantly less likely to suppress their HIV VL
to undetectable during their first regimen (Chr 0.784 (95% CI 0.693
0.888), Ahr 0.825 (0.7260.938)).
Conclusions: HIV/HCV co-infected patients differ significantly from
HIV-only patients. They tend to be older, have more comorbidities
and have more complex lifestyles. Strategies to simplify their HIV
care (lower pill burden) and avoid complications (reduce drugdrug
interactions) in order to incorporate HCV treatment and continue
treatment of comorbid conditions will be especially important in this
population.
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Efficacy of generic direct-acting antiviral treatment for
hepatitis C, imported into Russia and Eastern Europe
Andrew Hill1; Julia Dragunova2; Roxanna Korologou-Linden3 and
Sergey Golovin2
1St Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London,
UK. 2International Treatment Preparedness Coalition, St Petersburg,
Russian Federation. 3Faculty of Medicine, Imperial College London,
London, UK
Introduction: Russia and Eastern Europe are not included in
voluntary licence agreements, and prices of direct-acting antivirals
(DAAs) in Eastern Europe are very high. An increasing number of
individuals in Russia/Eastern Europe are treating their hepatitis C
virus (HCV) infection with generic drugs produced in India or Egypt. It
is legal to import DAAs for personal use. This analysis assessed the
efficacy of generic DAAs legally imported into Russia/Eastern Europe.
Methods: Generic versions of sofosbuvir (SOF), ledipasvir (LDV) and
daclatasvir (DCV) were sourced from generic suppliers in India and
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Egypt. The choice of DAAs and the length of treatment were
determined based on baseline HCV genotype and stage of fibrosis.
Patients taking generic DAAs were evaluated pretreatment, and at
week 4 (rapid virological response  RVR), Week 12 or end of
treatment (EOT), and then for sustained virologic response (SVR) 4,
12 and 24. This analysis includes available data from 179 patients
being monitored in infectious disease and state university hospitals
throughout Russia, Belarus, Ukraine, Spain, Colombia, Israel and
Estonia. Patients are monitored by state university hospitals, private
doctors, infectious disease hospitals, local AIDS centres and online
patient Facebook groups such as the Gepatitka group.
Results: Of the 179 patients treated, 42 received SOF/LDV, 136 SOF/
DCV and 1 patient received SOF/RBV. The backbone of their generic
DAA treatment, SOF, was mainly from Indian generic companies:
Hetero (54%), Natco (13%), Mylan (8%) and Zydus (7%). Overall, the
patients were 57% male with a mean age of 36.5 years; 40% were
genotype 1, and mean baseline HCV RNA was 6.34 log10 IU/mL. A
RVR was observed in 70% (26/37) of the patients treated with SOF/
DCV, 82% (9/11) of the patients treated with SOF/LDV. Based on
currently available data, the percentage with HCV RNA BLLOQ was
93% (37/40) at EOT and 16/16 (100%) at SVR 4. EOT responses were
similar for patients treated with SOF/LDV (92%) and SOF/DCV (93%).
Conclusions: In this analysis, treatment with legally imported generic
DAAs achieved high rates of HCV RNA undetectability at EOT, and
SVR in all 16 patients evaluated so far. Mass treatment with the
current generic DAAs is a feasible and economical alternative route
of accessing curative DAAs, where the high prices for branded DAAs
prevent access to treatment.
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High sustained virologic response rates using generic direct-
acting antiviral treatment for hepatitis C, imported into
Southeast Asia
Roxanna Korologou-Linden1; Andrew Hill2; Aditya Wardhana3 and
Giten Khwairakpam4
1Faculty of Medicine, Imperial College London, London, UK. 2St
Stephen’s AIDS Trust, Chelsea and Westminster Hospital, London, UK.
3Indonesian, AIDS Coalition, Jakarta, Indonesia. 4amfAR, The
Foundation for AIDS Research, Treat Asia, Bangkok, Thailand
Introduction: Global elimination of hepatitis C virus (HCV) would be
feasible only if prices of direct-acting antivirals (DAAs) are affordable
for mass treatment programs. Several countries in Southeast Asia are
not included in voluntary license agreements, and prices of DAAs in
Southeast Asia are high. An increasing number of individuals in
Southeast Asia are treating their HCV infection with generic drugs
produced in India. This analysis assessed the efficacy of generic DAAs
imported into Southeast Asia.
Methods: Generic versions of sofosbuvir (SOF), ledipasvir (LDV) and
daclatasvir (DCV) were sourced from generic suppliers in India. The
choice of DAAs and the length of treatment were determined based
on baseline HCV genotype and stage of fibrosis. Patients taking
generic DAAs were evaluated pre-treatment, and at weeks 4 and 12
during treatment and then for sustained virologic response (SVR) 4,
12 and 24. This analysis includes available data from 62 patients
being monitored in regional medical institutes and national uni-
versity hospitals throughout Singapore, Vietnam, Thailand, Indonesia
and India.
Results: Of the 62 patients treated, 22 received SOF/LDV, 15 SOF/
DCV and 25 SOF/RBV. The backbone of combination DAA therapy,
SOF, was predominantly from Indian generic companies: Cipla (40%),
Zydus (21%), Hetero (13%), Natco (8%) and Mylan (8%). Overall, the
patients were 87% male with a mean age of 46 years; 59% were
genotype 1, and mean baseline HCV RNA was 6.6 log10 IU/mL. Based
on currently available data, the percentage with HCV RNA BLLOQ
was 100% (33/33) at the end of treatment (EOT) and 100% (23/23) at
SVR 4 (Table 1). All of the patients with data at EOT, irrespective of
their type of treatment, achieved undetectable HCV RNA levels.
Conclusions: In this analysis, treatment with legally imported generic
DAAs achieved excellent rates of HCV RNA undetectability at the EOT,
and SVR in all 23 patients evaluated so far. The efficacy observed is
similar to phase 3 trials of the branded medicines. Mass treatment
with the current generic DAAs is a feasible and economical
alternative route of accessing curative DAAs, where the high prices
for branded DAAs prevent access to treatment.
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HIV/HCV co-infected patients over and above what is
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analysis
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Introduction: ART-induced toxicity has been frequently reported in
HIV/HCV co-infected individuals. However, there is conflicting
evidence on whether HCV co-infection has a synergistic effect on
Table 1. Summary baseline and outcome data for patients
treated with SOF/LDV, SOF/DCV or SOF/RBV
HCV RNA
SOF/LDV
(N22)
SOF/DCV
(N15)
SOF/RBV
(N25)
% cirrhosis 33% (6/18) 33% (4/12) 32% (7/22)
% genotype 1 91% (20/22) 14% (2/14) 56% (14/25)
% genotype 2  7% (1/14) 
% genotype 3 4.5% (1/22) 79% (11/14) 28% (7/25)
% genotype 4   8% (2/25)
% genotype 6 4.5% (1/22)  
% genotype 2,6   4% (1/25)
% genotype 3,4   4% (1/25)
HCV RNA B25 IU/mL
RVR 86% (6/7) 100% (5/5) 75% (3/4)
Week 12/EOT 100% (12/12) 100% (8/8) 100% (13/13)
SVR 100% (9/9) 100% (4/4) 100% (10/10)
SOF, sofosbuvir; LDV, ledipasvir; DCV, daclatasvir; RBV, ribavirin; RVR,
rapid virological response; SVR, sustained virologic response; EOT,
end of treatment.
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ART-induced toxicity. One way to evaluate this hypothesis is to
compare the risk of alanine aminotransferase (ALT) elevation
associated with the use of ART in HIV mono-infected versus HIV/
HCV co-infected populations.
Materials and methods: We selected individuals in the ICONA
Foundation study cohort with at least one ALT measurement and
known current HCV status. We designed a case-control analysis nested
in the cohort. Cases were defined as individuals who showed liver
enzyme elevation (LEE) 5 x upper limit normal at their last clinical
observation; controls were participants who showed normal liver
enzyme levels over the same calendar time after enrolment in the
cohort. Controls were matched by a predefined set of potential
confounders: age (B20, 2125 and 2630 to 65), CD4 count cells/
mm3 (B350, 351500 and 501), HIV RNA viral load copies/mL
(B1000 and 10015000 to 100,000) and mode of HIV transmis-
sion. A conditional logistic regression model was used to evaluate the
associations between ART exposure and risk of LEE in a univariable
model adjusted for matching factors and after further controlling for
gender, nationality, alcohol use, smoking status and calendar year of
enrolment. Interaction between HIV/HCV co-infection status and ART
exposure were also formally assessed.
Results: We included 2061 (n687 cases) individuals of whom 70%
were males with median calendar year of last clinical visit in 2014 (IQR
20072015). Median age was 35 (IQR 3140) and CD4 count was 386
(IQR 188586), matched in cases and controls. Proportion of HIV/HCV
co-infected individuals was higher in cases than controls 39 and 29%,
respectively (pB0.001). Proportion of ART use was higher in cases
than controls 79 and 72%, respectively (pB0.001). In the model
without interaction, ART use was associated with an increased risk of
LEE (adjusted odds ratio 1.87 (95% CI 1.382.52; pB0.001))
independently of all factors shown in footnote of Table 1. In the
multivariable model, the association between ART use and risk of LEE
was 2.37 (95% CI 1.364.12) in HIV/HCV co-infected individuals and
1.84 (95% CI 1.242.73) in HIV mono-infected (p0.60).
Conclusions: Using a nested case-control study approach, we found
no evidence that ART use has a synergistic effect with HIV/HCV co-
infection on the risk of ALT elevation. These results are consistent
with those obtained in other studies including those of a previous
analysis of this cohort.
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Introduction: Interferon-free hepatitis C virus (HCV) therapies with
second-generation direct-acting antiviral agents (DAAs) are highly
effective and well tolerated. For that reason they have the potential
to substantially increase treatment eligibility and efficacy in HIV-
infected patients. We assessed the impact of DAAs on treatment
uptake, efficacy as well as its impact on liver disease burden in the
Swiss HIV Cohort Study (SHCS).
Materials and methods: We prospectively collected data on all SHCS
participants who started HCV therapy since January 2009. HCV
treatment uptake and efficacy as well as the stage of liver fibrosis
was compared between three different time periods: period 1,
January 2009 to August 2011 (prior to the availability of DAAs);
period 2, September 2011 to March 2014 (first-generation DAAs);
period 3, April 2014 to December 2015 (second-generation DAAs).
Results: Treatment uptake (4.5/100 patient years (py), 5.7/100 py
and 22.4/100 py) and efficacy ((SVR 12): 54%, 70% and 90%)
continuously increased through the different periods (Figure 1).
Treatment uptake increased across all HCV genotypes in period 3. At
the beginning of the third period, 876 SHCS participants had a
chronic HCV infection and of those, 186 started HCV therapy with a
second-generation DAA. Eighty-eight of 98 patients who reached the
end of follow-up, and from whom complete data were already
available, achieved an SVR: three patients died (two of liver
decompensation and one of sepsis), four had viral relapses (three
SOF/RBV and one SOF/LDV), one had a virologic breakthrough (SOF/
RBV) and two were lost to follow-up. The majority of treated patients
were Caucasian (95%) male (77%) PWIDs (59%) on ART (96%) with
advanced liver fibrosis (69% with F4). Patients treated for HCV-
genotype 1 during period 3 had significantly higher liver fibrosis
stages (44/61, 72% with F4) than those treated during period 2 (21/
58, 36% with F4). The proportion of SHCS participants remaining to
be treated with liver cirrhosis declined during the last two periods
from 18% to 10%.
Abstract P263Table 1. Multivariable conditional logistic regression models for ALT elevation
Elevated ALT N687
(%)
No elevated ALT
N1374 (%)
Total N2061
(%) Unadjusted OR (95% CI); p aAdjusted OR (95% CI); p
HCV status (time-dependent)
HCV
negative
418 (60.8) 971 (70.7) 1389 (67.4) 1.00 1.00
HCV
positive
269 (39.2) 403 (29.3) 672 (32.6) 2.89 (2.103.97); B0.001 2.95 (2.094.16); B0.001
ART status (time-dependent)
ART naı¨ve 144 (21.0) 389 (28.3) 533 (25.9) 1.00 1.00
On ART 543 (79.0) 985 (71.7) 1528 (74.1) 1.82 (1.392.37); B0.001 1.87 (1.382.52); B0.001
aBesides HCV status and ART use, the model was further adjusted for age, CD4 cell count, HIV RNA viral load, mode of HIV transmission, gender,
nationality, alcohol use, smoking status and calendar year of enrolment.
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Conclusions: The introduction of interferon-free second-generation
DAA treatments in the SHCS increased treatment uptake and efficacy
across all HCV genotypes. Because of treatment priorities and
limitations in reimbursement, most patients treated with second-
generation DAAs had advanced fibrosis or cirrhosis. The treatment of
these patients was made possible because of the favourable safety
profile of new drugs, and resulted in a significant reduction of the
number of cirrhotic patients with replicating HCV infection in the SHCS.
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Effectiveness of all-oral DAAs for HCV genotype 4 in HIV/
HCV co-infected subjects with compensated liver disease:
real-world experience from the MADRID-CoRe study
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Abstract P264–Figure 1. Treatment uptake and efficacy over the 3 periods.
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Introduction: We evaluated therapeutic outcomes of all-oral direct-
acting antivirals (DAAs) for HCV genotype 4 (GT4) in HIV/HCV
co-infected patients with compensated liver disease.
Methods: The Madrid co-infection registry (MADRID-CoRe) is a
prospective registry of all co-infected adults (]18 years) undergoing
DAA therapy (Rx) for HCV in hospitals from the Madrid Regional
Health Service (SERMAS). We assessed SVR12, viral relapse and
failure due to Rx discontinuation. Between November 2014 and May
2016, 2402 co-infected individuals have initiated DAA Rx within
MADRID-CoRe. Herein, we present data of co-infected patients with
GT4 and compensated liver disease with programmed Rx finalization
censored to 31 December 2015.
Results: We evaluated 243 co-infected individuals who met the
inclusion criteria. DAA regimens used included (1) sofosbuvir/
ledipasvir (SOF/LDV) 190 patients (181 without ribavirin (RBV) (8
weeks 2, 12 weeks 123 and 24 weeks 56) and nine with RBV (12
weeks 8 and 24 weeks 1)); (2) ombitasvir/paritaprevir/ritonavir
(OBV/PTV/r) 33 patients (one without RBV for 12 weeks and 32 with
RBV (12 weeks 24 and 24 weeks 8)); (3) simeprevir/sofosbuvir (SMV/
SOF) 10 patients (eight without RBV (12 weeks six and 24 weeks
eight) and two with RBV (12 weeks one and 24 weeks one)); (4)
daclatasvir/sofosbuvir (DCV/SOF) 10 patients (seven without RBV (12
weeks one and 24 weeks six) and three with RBV (12 weeks two and
24 weeks one)). Patients’ characteristics and treatment outcomes
categorized by DAA regimens are shown in Table 1.
Conclusions: High effectiveness was found with LDV/SOF and OBV/
PTV/r for GT4 in co-infected patients with compensated liver disease.
Small sample size and very high liver stiffness preclude any
conclusion about the effectiveness of SMV/SOF and DCV/SOF.
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Continued increase of recent hepatitis C virus infections
amongst HIV-positive patients in Taiwan
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Introduction: We previously have shown that the rate of recent
hepatitis C virus (HCV) infection in HIV-positive patients seeking HIV
care at the National Taiwan University Hospital (NTUH), Taipei, had
increased from 0 in 19942000 and 2.29 in 20012005 to 10.13 per
1000 person-years of follow-up (PYFU) in 20062010. This study
aimed to investigate whether the increasing trend of recent HCV
infection continued between 2011 and 2015.
Materials and methods: Between January 2011 and December 2015,
HIV-positive patients seeking care at the NTUH were prospectively
observed, and serologic tests for HCV were provided at baseline during
their first visit and subsequently on an annual basis or to those who
acquired syphilis or had elevated aminotransferases according to the
national HIV treatment guidelines. Antibodies to HCV were deter-
mined with a third-generation enzyme immunoassay (Ax SYM HCV III;
Abbott Laboratories, North Chicago, IL). HCV RNA load was deter-
mined, and HCV was genotyped. Recent HCV seroconversion was
defined as the first positive anti-HCV detected within 1 year after the
last negative anti-HCV. The date of seroconversion was assigned as the
midpoint between the date of the last negative and that of the first
positive anti-HCV result. All patients were followed until 30 April 2016.
Results: During the 5-year study period, 3483 HIV-positive patients
aged 15 years or older sought HIV care at NTUH. After excluding 29
patients without anti-HCV data at baseline and 371 testing positive
for HCV (prevalent HCV infections), 3083 were included for
prospective follow-up. A total of 140 (4.5%) had recent HCV infection
(incident HCV infections) during a total observation duration of
9900.51 PYFU, giving an overall incidence rate of 14.14 per 1000
PYFU. The rate was 12.64, 13.81, 13.27, 11.77 and 18.55 per 1000
PYFU in 2011, 2012, 2013, 2014 and 2015, respectively. Compared
with 2695 patients without HCV seroconversion, patients with recent
HCV seroconversion were more likely to be male (100.0% vs. 96.1%,
p0.009), younger (mean age, 32.4 vs. 35.9 years, p0.0004) and
Abstract P265Table 1. Baseline characteristics and outcome in patients coinfected with HIV and HCV genotype 4 treated with all-
oral direct-acting antivirals for HCV
LDV/SOF OBV/PTV/r SMV/SOF DCV/SOF
Baseline variables N190 N33 N10 N10
Age, median (IQR) 51 (4754) 51 (4653) 52 (4754) 50 (4853)
Male, n (%) 146 (76.8) 24 (72.7) 8 (80.0) 6 (60.0)
Cart, n (%) 183 (96.3) 30 (90.9) 8 (80.0) 8 (80.0)
Log HCV RNA, median (IQR) 6.3 (5.96.7) 6.0 (5.86.6) 6.3 (6.06.6) 6.0 (5.56.5)
Cirrhosis, n (%) 76 (40.0) 8 (24.2) 9 (90.0) 9 (90.0)
Liver stiffness, median (IQR) 11.0 (8.118.6) 9.5 (8.412.3) 48.0 (25.766.4) 31.2 (20.948.0)
HCV-naı¨ve, n (%) 108 (56.8) 11 (33.3) 4 (40.0) 6 (60.0)
Outcomes
SVR12, n (%) 177 (93.2) 32 (97.0) 5 (50.0) 6 (60.0)
% SVR, 95% CI 88.696.3 84.299.9 18.781.3 26.287.8
Relapse, n (%) 10 (5.3) 1 (3.0) 5 (50.0) 2 (20.0)
Discontinuation, n (%) 3 (1.5) 0 0 2 (20.0)
SOF, sofosbuvir; LDV, ledipasvir; DCV, daclatasvir; SVR, sustained virologic response; OBV, ombitasvir; PTV/r, paritaprevir/ritonavir; SMV,
simeprevir.
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men who have sex with men (85.7% vs. 78.4%, p0.007) and to
have recent syphilis (37.1% vs. 11.1%, pB0.0001). The mean plasma
HCV RNA load was 6.07 log10 copies/mL. Of the 76 HCV strains
submitted for genotyping, genotype 1 accounted for 40.8%.
Conclusions: The increasing trend of recent HCV infection continued
in HIV-positive patients seeking HIV care at the university hospital in
Taiwan from 2011 to 2015.
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Treatment failure with DAAs in chronic hepatitis C: a
Portuguese multicentre report
Cristina Valente1; M Isabel Casella2; Domitilia Faria3; M Joa˜o Aleixo4;
Ineˆs Vaz Pinto5; Margarida Mota6; Amparo Mingo7;
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8Immunodeficiency Unit, Hospital Braga, Braga, Portugal.
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Introduction: Either in clinical trials or in real-life studies, cure rates
with oral direct-acting antivirals (DAAs) in the treatment of chronic
hepatitis C virus (HCV) are greater than 90%. However, as these
drugs become more widely used, clinicians are beginning to report
occasional cases of treatment failure.
Materials and methods: GEPCOI is a multicentre group that involves
several sites in Portugal. For this study, 10 centres participated, and
all cases of DAA failure were collected. Treatment failure was
considered in case of relapse, virologic failure during treatment,
discontinuation or death. All co-infected HIV/HCV patients that
started oral DAA drugs were included in this analysis.
Results: A total of 573 chronic hepatitis co-infected patients started a
course of oral DAAs since the beginning of 2015. All but 23 patients
(4%) achieved sustained virologic response: 16 (2.8%) had a relapse
or failure during treatment, 2 discontinued treatment and 5 died. All
except one were male (95.6%) with an average age of 47 years. They
were naı¨ve (65.2%) or null responders (21.7%) and relapsers (4%) in
previous treatment with pegIFNribavirin (RBV). All patients were
under ART, and only two had detectable viremia. Only three patients
changed ART schedule due to HCV treatment (pIs to IIs and TDF/FTC
to ABC/3TC). Regarding HCV, genotype 1 was the predominant
(60.8%) and the degree of fibrosis was respectively: F0F2, 21.7%;
F3; 21.7%; and F4, 56.5%. Those who have relapse or virologic failure
were G1 10, G2 two, G3 three and G4 one. All HCV G1/4 were
treated with SOF/LDVRBV 12 weeks or 24 weeks without RBV. In
all, G2/3 SOFRBV was used, except in one patient classified initially
as G1, who completed 12 weeks with asunaprevirdaclatasvirRBV
(G3). Deaths (five) occurred during or after the end of treatment,
due to hepatic decompensation or related complications: they were
all F4, with a MELD score ranging from 9 to 27. All of these patients
had both albumin level B3.5 gr/dL and platelets B100,000 mcL.
Conclusions: Failures in this real-life study occurred in 4%, with
relapses or virologic failures accounting for 70% of the total. They
were mainly patients with advanced fibrosis (F3/F4 74.9%). Those
who died were cirrhotic, and all of them had both low level of
albumin and platelets. HCV drugs did not have any impact on HIV
outcome at the end of treatment. Treatment in co-infected patients
with advanced disease should have a very close monitoring.
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Seroepidemiology of hepatitis A virus among HIV-positive
patients in Taiwan in the setting of acute hepatitis A
outbreak from 2015 to 2016
Guan-Jhou Chen; Kuan-Yin Lin; Hsin-Yun Sun; Wang-Huei Sheng;
Szu-Min Hsieh; Yu-Chung Chuang; Chien-Ching Hung and
Shan-Chwen Chang
Department of Internal Medicine, National Taiwan University
Hospital, Taipei, Taiwan
Introduction: Since June 2015, an ongoing outbreak of acute
hepatitis A virus (HAV) infection is occurring amongst men who
have sex with men (MSM) in Taiwan, with more than 440 cases
reported to the Taiwan Centres for Disease Control as of 30 June
2016. This study aimed to describe the seroepidemiology of HAV
infection among HIV-positive patients in northern Taiwan, where
three-fourths of the patients in the outbreak reside.
Materials and methods: We reviewed the medical records of HIV-
positive patients seeking HIV care at the National Taiwan University
Hospital, Taipei. Information on demographics and clinical character-
istics was collected, which included age, risk group for HIV
transmission, plasma HIV RNA load, CD4 count and serologies of
hepatitis viruses and syphilis at baseline and during follow-up, and
dates of HAV vaccination administered. A case-control study was
conducted to identify the associated factors with acute HAV
infection. Case patients were those who received a diagnosis of
acute HAV infection between June 2015 and 2016, and four controls
were identified that were matched with case patients by age (95
years), HIV risk factor and similar observation duration.
Results: During the study period, 2029 HIV-positive patients, with a
mean age of 38.4 years and 83.3% being MSM, had baseline HAV
serologic data and 33.6% (n682) tested seropositive for HAV. The HAV
seroprevalence was 15.4% in those aged B35 years. As of June 2016,
52.9% (n713) of HAV-seronegative patients were vaccinated with
HAV vaccine by following the current recommendations of vaccination
for adults, and most of the patients (681; 95.5%) received HAV vaccines
only after the outbreak was taking place. Among the unvaccinated
individuals, a total of 37 patients, all being MSM, developed acute HAV
infection during the follow-up, giving an incidence rate of 4.76 cases per
100 person-years of follow-up as of 30 June 2016. In the case-control
study, acute HAV infection was significantly associated with recent
syphilis that had occurred within 3 months of acute HAV infection, with
an adjusted odds ratio of 2.3 (95% CI 1.33.2).
Conclusions: With a low HAV seroprevalence among HIV-positive
MSM aged B35 years in Taiwan, the adherence to HAV vaccination
in this at-risk group was low before this HAV outbreak. In the
outbreak, patients with acute HAV infection in our cohort were
significantly associated with recent syphilis, suggesting risky sexual
behaviour contributing to this acute HAV outbreak in the at-risk
group in Taiwan.
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Different impact of DAA on innate and adaptive cellular
immunity in HIV/HCV co-infected and HCV mono-infected
patients
Paola Zuccala`; Miriam Lichtner; Serena Vita; Raffaella Marocco;
Claudia Mascia; Stefano Savinelli; Michela Campagna;
Fabio Mengoni; Tiziana Tieghi; Irene Pozzetto; Gabriella D’Ettorre;
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Introduction: HIV/HCV co-infected patients have higher HCV loads
and generally more rapid progression to fibrosis, end-stage liver
disease and death. HIV and HCV viral infections are both character-
ized by systemic immune activation that plays an important role in
disease progression. In the direct-acting antiviral (DAA) era, little is
known about the immune-pathological response in HCV mono-
infected and in HCV/HIV co-infected patients. The aim of the study
was to analyze activation of T lymphocytes, DCs and Mo subsets in
HCV and HCV/HIV patients under effective ART that receiving anti-
HCV therapy.
Material and methods: In our study, we assessed 75 samples from
26 patients (13 HCV/HIV patients under effective ART and active HCV
replication and 13 HCV patients) undergoing IFN-free regimens DAA
based. Samples were collected before starting anti-HCV therapy (TO)
and 12 weeks after the end of treatment when they obtained a
sustained virologic response (SVR 12). Fourteen healthy donors (HD)
were used as controls. We analyzed whole blood samples evaluating
mDC, pDC, slanDC and typical, atypical and intermediate monocytes
with a cytofluorimetric method based on seven fluorochromes. HLA-
DR/CD38 CD4 and CD8 lymphocytes were also evaluated. Liver
fibrosis was measured using FibroScan and FIB-4 score. ANOVA with
Dunn’s test, MannWhitney test, Wilcoxon test and Spearman
correlation test were used for statistical analysis.
Results: All patients in both groups obtained SVR12. Activation of
CD8 T cells was significantly higher in HIV/HCV and HCV patients than
control (p0.0002 and p0.0041, respectively). Interestingly, a
decrease in both groups was found (comparing SVR12 in HIV/HCV
and HCV patients to HD, p0.0186 and p0.0479, respectively) up
to a normalization after anti-HCV therapy. HLA-DR/CD38 CD4 levels
were elevated only in co-infected patients (p0.0003) without
modification during therapy (comparing SVR to control p0.0385).
Intermediate Mo were increased in patients with HCV infection
compared to HD (p0.0654) and normalized after therapy.
Considering the sub-population of DCs, Mdc and pDC were reduced
only in HIV/HCV patients (pB0.001 and pB0.01, respectively), and
normalize after therapy, while MDC8 were decreased both in HIV/
HCV and HCV patients compared to HD (pB0.001 and pB0.01,
respectively); this decreases persist after therapy.
Conclusions: A different pattern of immune dysfunction was found in
HIV/HCV co-infected and HCV mono-infected subjects. IFN-free
treatments seem to reverse some of these alterations that should
be monitored with a longer follow-up.
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Real-life renal impact of ledipasvir/sofosbuvir on a cohort of
HIV-infected patients treated with tenofovir combined with
a boosted protease inhibitor
Joa˜o Cabo; Ana Raquel Garrote; Pedro Simo˜es; Diana Po´voas;
Rita Gonc¸alves; Freddy Ramirez; Stepanka Betkova; Diana Seixas;
Liliana Alves; Maria Jose´ Manata; Nidia Garrido; Orlando Cardoso;
Sara Cardoso; Sara Lino; Teresa Martins and Fernando Maltez
Infectious Diseases Department, Hospital Curry Cabral  Centro
Hospitalar Lisboa Central, Lisboa, Portugal
Introduction: Regarding the treatment of HIV/HCV co-infected
patients, we still have some concerns about the renal safety of the
interaction between ledipasvir (LDV)/sofosbuvir (SOF) and an ARV
regimen including tenofovir and a boosted protease inhibitor (PI).
Data are lacking from clinical trials to support this co-administration,
since these patients were excluded from the main studies in co-
infected patients. Increased levels of tenofovir and risk of renal
impairment might prompt preventive ARV therapy switch recom-
mendations, not possible in all patients due to their history of
previous ARV regimens.
Methods: An observational study was conducted among the co-
infected on an ARV regimen including tenofovir and boosted PI, who
started HCV treatment with DAAs, between 1 January 2015 and 20
May 2016. Data on demographic, clinical and virological features
were collected by analysis of clinical files.
Results: A total of 149 patients were treated with tenofovir/
emtricitabine, from which 68 with SOF/LDV and an antiretroviral
regimen that included a boosted PI: 30 on DRV/r, 22 on LPV/r, 14 on
ATV/r, 1 on SQV/r and 1 on FPV/r. Mean age was 47 years, 72%
males. Regarding HIV infection, 85% of the patients had undetect-
able viral load (B20 copies/mL), ranging below 100 copies/mL in the
remaining, with a median of 582 T CD4 cells/mL (1411570).
Treatment was planned for 24 weeks in 35% (24) of patients,
according to liver fibrosis stage. At baseline, four patients had CKD
stage IIi (Mean EgFR 54 mL/min) and by week 8 three of them had
their FTC/TDF regimen switched (Mean EgFR 44 mL/min). By the end
of treatment, these three patients had egfR 60 mL/min. Only one
of the remaining 64 patients presented with an egfR B60 mL/min
during treatment, requiring no switch on ARV regimen. From the 48
patients with available data at week 12 post-treatment, all but one
had sustained virological response.
Conclusion: In our study, SOF/LDV did not have a major negative
impact in patients on TDF and a boosted PI. In this population, renal
function must be carefully monitored, mainly in patients with other
risk factors for renal impairment.
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Changes in lipid profile during and after hepatitis C virus
(HCV) treatment with direct-acting antiviral (DAA),
interferon-free regimens in patients co-infected with HIV
Lourdes Domı´nguez-Domı´nguez1; Otilia Bisbal1; Marı´a Lagarde1;
Mariano Matarranz1; Asuncio´n Hernando2; Rafael Rubio1 and
Federico Pulido1
1HIV Unit, Instituto de Investigacio´n Hospital 12 de Octubre, Madrid,
Spain. 2Facultad de Ciencias Biome´dicas, Universidad Europea de
Madrid, Villaviciosa de Odo´n, Spain
Introduction: HCV infection is associated with lower lipid levels in
HIV co-infected patients treated or not with ART [1]. This has been
related both to the HCV infection and to the impairment of the liver
function. Some studies have reported increased lipid values after
sustained virological response (SVR) with therapy based on inter-
feron (INF) [2]. We aim to evaluate lipid changes in HIV/HCV co-
infected patients receiving all-oral HCV therapy.
Methods: Retrospective longitudinal study in a cohort of HIV/HCV co-
infected patients treated with direct-acting antiviral (DAA) and INF-
free therapy. All patients whose treatment finished on 30 December
2015 or before, and whose 24-week post-treatment evaluation was
on or before 15 June 2016, were included. The values of triglycerides
(TG), total cholesterol (TC), high-density lipoprotein (HDL) cholesterol
(HDL-c) and low-density lipoprotein (LDL) cholesterol (LDL-c) were
collected at three time points: (1) 12 weeks before starting DAAs (pre-
treatment); (2) between week 4 and the final day of treatment (on-
treatment); (3) weeks 12 to 24 after the end of HCV therapy (post-
treatment). Means were compared with the repeated measures
ANOVA test. Results have been adjusted by a general linear regression
which includes the following variables: age, gender, basal HCV RNA,
presence of a protease inhibitor (PI) drug in the DAA regimen,
presence of a PI drug in the ART regimen and estimated liver fibrosis
(cirrhosis has been considered when liver stiffness ]14.6 kPa).
Results: Two hundred and fifty patients had reached week 24 post-
treatment on 15 June 2016. Only 130 patients had available lipid data
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before, during and after HCV therapy. Table 1 shows baseline char-
acteristics. SVR was achieved in 127 patients (97.7%). TC and LDL-c
values statistically increased on and after treatment (pB0.001) versus
pre-treatment. There were no significant changes when comparing TC
and LDL-c values on versus after-treatment, nor between TG and HDL-c
values pre-treatment versus on-treatment or post-treatment (Table 2).
Changes in TC and LDL-c values are not influenced by gender (p0.55
and p0.86, respectively), age (p0.07 and p0.06), basal HCV RNA
(p0.21 and p0.1), presence of PI in the ART regimen (p0.50 and
p0.46) nor cirrhosis (p0.41 and p0.19). Moreover, changes
between LDL-c values are not influenced by the presence of PI in the
DAA regimen (p0.18), but DAA regimens including a PI were
associated with increased TC values (p0.005).
Conclusion: TC and LDL-c values increase during the HCV treatment
using DAA, INF-free regimens, and remain increased after stopping
the HCV therapy.
References
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HIV/hepatitis C co-infection: successfully treating hepatitis C
with direct-acting antivirals and managing those who do not
access traditional care
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Introduction: In our HIV/hepatitis C virus (HCV) co-infected cohort,
we are successfully treating HCV with direct-acting antivirals (DAAs)
regardless of genotype, regimen, disease stage or prior treatment
exposure. However, we recognize a proportion of patients for whom
we are unable to provide treatment, because they do not engage in
the traditional care setting. We report on the efficacy and safety of
DAA therapy in our cohort of HIV/HCV co-infected individuals, the
demographics of those not engaging in care and the strategies
employed to tackle this population.
Methods: All patients co-infected with HIV and HCV in our cohort
were included, and case notes were reviewed. Those who sponta-
neously cleared HCV infection, transferred care or died were excluded.
Results: At May 2016, the HIV/HCV co-infected cohort comprised 181
patients, of whom 89 (49%) had commenced HCV treatment. Thirty-
three of these patients were treated successfully with interferon and
ribavirin. Fifty-seven patients received ]1 dose second-generation
DAA, including 20 patients with cirrhosis, six in clinical trials. The
majority were male (46/57) with a history of injecting drug use (35/
57). The majority were HCV genotype 1 infected (48/57). Most were
treatment naı¨ve (43/57); six prior null responders; four relapsers after
previous IFN/RBV; none were DAA experienced. Fifty-five of 57 were
on a suppressive HIV antiretroviral regimen. At the time of writing, 52/
57 patients had reached end of treatment. Forty-two had achieved
SVR12 (42/42, 100%). Despite high success rates with those engaged
in care, 92 (51%) patients remain untreated, of whom the majority are
not attending scheduled hospital appointments, and many are
currently struggling with addictions. Some are recently diagnosed as
part of an ongoing outbreak of HIV and HCV amongst people who
inject drugs. To target this population, we are implementing service
change. New strategies will include local pharmacy ‘‘directly observed
therapy’’ dispensing, specialist nurse-led service in the community and
in addiction services. We show the area of residence of those who
have over 50% non-attendance rates, in relation to the hospital where
care is traditionally delivered to highlight the need for local services.
Conclusions: In those who access care, we observe excellent SVR
rates in HIV-infected patients receiving DAAs for HCV. Serious
adverse events with DAAs are rare and delivering treatment in the
community to difficult-to-treat populations will increase engagement
in HIV care and HCV cure rates. Poor engagement in care should be
tackled by service redesign to reach out to these populations.
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Improving of glycaemic control associated with DAAs HCV
treatment persists at SVR12
Table 1. Baseline characteristics
Age, mean (SD) 50.9 (5.5)
Gender: male/female, n (%) 93 (71.5)/37 (28.5)
Risk group: PWID/heterosexual/MSM,
n (%)
113 (86.9)/13 (10.0)/4
(3.1)
CDC (93) classification system’s C stage,
n (%)
48 (36.9)
Basal HCV RNA, medIAn (UI/mL) (IQR) 2,047,181.5
(3,879,143.0)
Prior INF-based therapy: none/failure/
relapse/intolerance, n (%)
79 (60.8)/35 (26.9)/8
(6.2)/8 (6.2)
Liver fibrosis assessed by transient
elastography: F01, F2, F3, F4, n (%)
1 (0.8)/54 (41.5)/14
(10.8)/61 (46.9)
MSM, men who have sex with men; PWID, people who inject drugs.
Abstract P271Table 2. Means of the values in mg/dL with standard deviation
Pre-treatment On-treatment After-treatment p* p$ p%
TG 156.4 (79.7) 142.7 (68.1) 161.5 (85.2) 0.073 1.000 0.011
TC 176.0 (37.9) 199.5 (55.0) 196.1 (51.9) B0.001 B0.001 1.000
HDL-c 49.3 (20.5) 52.0 (23.4) 49.9 (18.4) 0.100 1.000 0.751
LDL-c 97.6 (37.1) 121.1 (46.8) 114.2 (44.7) B0.001 B0.001 0.107
Statistical significance p-value established in 0.05. Bonferroni correction has been done. *compares values pre-therapy versus on-treatment;
$compares pre-therapy versus after-treatment; %compares on-treatment versus after-treatment.
TG, triglycerides; TC, total cholesterol; HDL-c, HDL cholesterol; LDL-c, LDL cholesterol.
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Introduction: Association between HCV infection and insulin resis-
tance and type 2 diabetes has been widely postulated. Our group
already reported a rapid improving of glycaemic control associated
with DAAs [1]. Aim of our study was to evaluate if improving of
glycaemic control persists after the end of DAAs treatment.
Materials and methods: We retrospectively evaluated 39 HCV-
infected patients (10 HIV) with type 2 diabetes who were treated
with different IFN-free regimens, including sofosbuvir, simeprevir,
ledipasvir, daclatasvir, dasabuvir and ombitasvir/paritaprevir/ritonavir.
To evaluate general improving of glycaemic control, we investigated
for reduction of fasting glucose (FG) or glycated haemoglobin (A1C) or
modification of insulin/metformin dosing during and after anti-HCV
treatment. Statistical analysis was performed with the paired t-test,
Kruskal-Wallis test and Welch one-way ANOVA procedure (R software).
Results: The mean age of the patients was 60 years (32 M, 7 F). The
HCV genotypes were different but with type 1 prevalence (n24). All
the patients had HCV RNA undetectable at end of treatment (B15 UI/
mL, if still on treatment). CD4 were above 14%, and HIV RNA was
undetectable in all patients. Pretreatment FG was reported in 38
patients, mean value 168 mg/dL (min. 81, max. 455), pretreatment
A1C in 22 patients, mean value 7% (min. 5.1%, max. 11.8%). Nine
patients (24%) needed to reduce or stop (n2) hypoglycaemic drugs.
One patient with basal A1C value of 11.8% needed to stop insulin
treatment and is off-therapy with A1C B5% at SVR 12. Three patients
needed to increase insulin dosing, one of these patients died after
HCV relapse. Their FG and A1C values were excluded from analysis. FG
values during treatment were available for 35 patients, and analysis
showed a statistically significant reduction (p0.01), reduction mean
value (mv) was 27 mg/dL; at SVR12, FG values were available in 18
patients, with a reduction mv of 44.5 mg/dL (p0.0031). A1C during
treatment was available for 17 patients, and analysis showed a
statistically significant reduction (p0.01), reduction mv was 1.14%;
at SVR12, A1C values were present in 12 patients, reduction mv was
0.5% (p0.09). FG and A1C reductions were not correlated to the
drug regimen, HCV genotype, BMI, ALTt0/ALTt1 and HIV status. No
cases of symptomatic hypoglycaemia were found.
Conclusions: HCV suppression following DAA treatment is often
associated with rapid and persisting improving of glycaemic control.
Patients undergoing DAAs should be closely monitored for eventual
modifications of hypoglycaemic drugs. Eradication of HCV might
result in diabetes cure in some patients.
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Ledipasvir/sofosbuvir for 12 or 24 weeks in HCV genotype 1
in HIV/HCV co-infected subjects with compensated liver
disease: real-world experience from the MADRID-CoRe
study
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Abstract P274Table 1. Patients’ characteristics and treatment outcomes categorized by subtypes, treatment duration and use of ribavirin
G1a G1a G1a G1a G1b G1b G1b
No-RBV No-RBV RBV RBV No-RBV No-RBV RBV
12 weeks 24 weeks 12 weeks 24 weeks 12 weeks 24 weeks 12 weeks
Baseline variables N197 N51 N33 N3 N57 N22 N14
Age years, median 51 51 50 51 50 52 54
Male, % 82.2 78.4 87.9 100 77.2 68.2 64.3
cART, % 97.5 98.0 93.4 100 100 90.9 92.9
Log HCV RNA, median 6.4 6.3 6.3 6.7 6.4 6.0 6.5
Cirrhosis, % 25.4 90.2 90.9 66.7 45.6 100 92.9
Liver stiffness kPa, median 10.0 18.3 20.0 24.0 11.8 20.6 19.8
HCV-naı¨ve, % 67.0 54.9 36.4 0 50.9 10.9 64.3
Outcomes
SVR12, n (%) 183 (92.9) 50 (98.0) 30 (90.9) 3 (100) 56 (98.2) 20 (90.9) 13 (92.9)
% SVR, 95% CI 88.496.1 89.699.9 75.798.1  90.699.9 70.898.9 66.199.8
Relapse, n (%) 7 (3.5) 0 2 (6.1) 0 0 1 (4.5) 0
Breakthrough, n (%) 0 0 0 0 0 0 0
D/C due to AEs, n (%) 1 (0.5) 0 0 0 0 0 0
D/C other reasons, n (%) 6 (3.0) 1 (2.0) 1 (3.0) 0 1 (1.8) 1 (4.5) 1 (7.1)
RBV, ribavirin; SVR, sustained virologic response; D/C, discontinuation; AEs, adverse events.
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Introduction: We evaluated therapeutic outcomes LDV/SOF for HCV
genotype 1 (GT1) in HIV/HCV co-infected patients with compensated
liver disease.
Materials and methods: The Madrid co-infection registry (MADRID-
CoRe) is a prospective registry of all co-infected adults (]18 years)
undergoing DAA therapy (Rx) for HCV in hospitals from the Madrid
Regional Health Service (SERMAS). We assessed SVR12, viral relapse
and failure due to Rx discontinuation. Between November 2014 and
May 2016, 2402 co-infected individuals have initiated DAA Rx within
MADRID-CoRe. Herein, we present data of co-infected patients with
GT1a or GT1b and compensated liver disease that were treated with
LDV/SOF with or without ribavirin (RBV) for 12 or 24 weeks, and
with programmed Rx finalization censored to 31 December 2015.
Results: We evaluated 377 co-infected individuals who met the
inclusion criteria: 284 infected with GT1a and 93 infected with GT1b.
Patients characteristics and treatment outcomes categorized by
subtypes, treatment duration and use of RBV are shown in Table 1.
Conclusions: High effectiveness and safety were found with LDV/SOF
for 12 or 24 weeks in GT1 co-infected patients with compensated
liver disease.
P275
Seroepidemiology of hepatitis B virus (HBV) infection
among HIV-positive men who have sex with men born in
the era of nationwide neonatal HBV vaccination in Taiwan
Yi-Chia Huang1; Shang-Ping Yang2; Wen-Chun Liu1; Pei-Ying Wu2;
Hsin-Yun Sun1; Wang-Huei Sheng1; Szu-Min Hsieh1; Chien-
Ching Hung1 and Shan-Chwen Chang1
1Department of Internal Medicine, National Taiwan University
Hospital, Taipei City, Taiwan. 2Center of Infection Control, National
Taiwan University Hospital, Taipei City, Taiwan
Introduction: Previous studies have demonstrated a waning immu-
nity against hepatitis B virus (HBV) 15 years after vaccination in
individuals born after 1986 when nationwide HBV vaccination
program was implemented in Taiwan [1], where the prevalence of
chronic HBV infection was 15 to 20% among those born before 1984.
We aimed to assess the HBV seroepidemiology and serologic
response to booster vaccination for HBV among HIV-positive men
who have sex with men (MSM) born after 1986.
Materials and methods: Medical records of HIV-positive MSM who
were born after 1986 and sought HIV care at the NTUH between 2000
and 2016 were reviewed, and information on clinical characteristics
and antiretroviral therapy containing tenofovir disoproxil fumarate
(TDF) and emtricitabine (FTC) or lamivudine (3TC) was collected.
Results: During the 16-year study period, 632 HIV-positive MSM
were included, with a mean age of 23.0 years. About 83% were
receiving cART containing TDF plus FTC or 3TC. Twenty patients
(3.2%) had anti-HCV antibody and 197 (31.2%) had syphilis at
baseline. Eighty-two patients (13%) were excluded from analysis due
to lack of the result of anti-HBc antibody at baseline. Among 550
patients, 18 (3.3%) had chronic HBV infection and 271 (49.3%) had
lost HBV seroprotection (anti-hbS B10 mIU/mL). During the follow-
up, 135 patients received at least one dose of HBV vaccine and 75
patients (56%) with follow-up of serologic response after vaccination
achieved anti-HBs titERS 10 mIU/mL. Among the vaccine-respon-
ders, 47 had repeat testing at week 52 of booster vaccination and 22
(47%) had a sustained serologic response. For those who had lost
HBV seroprotection at the beginning of this study, three incident
cases of HBV infection occurred after 754.7 person-years of follow-up
(PYFU), accounting for an incidence rate of 4.0 per 1000 PYFU. Two
cases of anti-HBc antibody seroconversion occurred in patients with
an anti-HBs titer ]10 mIU/mL at baseline (incidence rate, 3.0 per
1000 PYFU). During the same period of observation, the incidence of
HCV infection and syphilis was 13.4 per 1000 PYFU and 96.4 per 1000
PYFU, respectively.
Conclusions: Despite impaired immunity from HIV infection and poor
response to HBV booster vaccination, the seroprevalence of chronic
HBV infection has significantly declined in the HIV-positive MSM
born after 1986. In this high-risk group for acquisition of sexually
transmitted infections and with waning immunity against HBV, the
risk of incident HBV infection remains low.
Reference
1. Sun HY, Cheng CY, Lee NY, Yang CJ, Liang SH, Tsai MS, et al.
Seroprevalence of hepatitis B virus among adults at high risk for HIV
transmission two decades after implementation of nationwide
hepatitis B virus vaccination program in Taiwan. PLoS One. 2014;
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after sustained virologic response with HCV direct-acting
antivirals
Ana Arias; Gemma Lledo´; Ana Trevin˜o; Laura Benitez-Gutierrez;
Itziar Carrasco; Valentı´n Cuervas-Mons and Carmen De Mendoza
Internal Medicine, Puerta de Hierro Hospital, Madrid, Spain
Introduction: The hepatitis C virus (HCV) field has been revolutio-
nized following the introduction of new direct-acting antivirals (DAA).
HCV eradication with peginterferon-ribavirin already was shown to
be associated with significant improvements in liver function and
hepatic fibrosis. Information on the extent of liver fibrosis regression
is lacking in HIV-HCV co-infected indivudals, in whom hepatic fibrosis
more rapidly develops.
Methods: All HIV-HCV co-infected patients treated with DAA at our
clinic until March 2016 were examined. Transient elastometry
(FibroScan) was performed at baseline and after 12 weeks of
completion of therapy, at the time of sustained virologic response
(SVR12). Liver fibrosis regression was defined as a shift from
advanced fibrosis (METAVIR F3F4 [9.5 kPa]) to null-mild fibrosis
(F0F2) and/or 30% reduction on kPa from any baseline value.
Results: A total of 50 HIV-HCV co-infected individuals with SVR12
were identified. Overall, 79.2% were male and median age 52 years.
Baseline serum HCV RNA was 6.2 Log IU/mL. Distribution of HCV
genotypes: G1a (25), G1b (nine), G3 (eight) and G4 (eight). A total of
52.8% of patients had unfavourable IL28B genotypes (CT/TT).
Elevated AST/ALT at baseline was seen in 77.4% of patients. Patients
were treated with SOF-LED (31), 3D (eight), SOF-DCV (eight) and
SOF-SMV (eight). Median length of therapy was 12 weeks. Up to 54%
received RBV. At baseline, 65.4% had F3 to F4 being significantly
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higher in those with IL28B-CC compared with IL28B CT/TT (80% vs.
52%; p0.044). Mean FibroScan value was 20.1 kPa. At the time of
SVR12, a significant regression in liver fibrosis was found in 38.5%.
The mean reduction was of 4.81 kPa (pB0.001). A trend towards
higher improvement was seen in patients with baseline F3 to F4
compared with F0 to F2 (47% vs. 22%; p0.08, respectively). No
relationship was found between significant improvement in liver
fibrosis and IL28B-CC, baseline serum HCV RNA, HCV genotype, DAA
treatment modality and ribavirin use.
Conclusion: Cure of hepatitis C with DAA in HIV-HCV co-infected
patients is associated with significant and rapid improvement in
hepatic fibrosis measured by FibroScan. At least 38% of patients
experience significant liver fibrosis regression after SVR12. Thus, DAA
therapy should be prioritized in the HIV-HCV co-infected population.
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Treatment rate for HCV in the DAAs era in HIV co-infected
patients: data from an Italian cohort
Gianluca Cuomo1; Cinzia Puzzolante1; Cristina Mussini2 and
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Introduction: New drugs (DAAs) are now effective in HCV infection,
and no difference in sustained virological response (SVR) was
observed between HCV mono-infected and HIV co-infected patients.
Despite major advances in HCV therapy, persons living with HIV
(PLHIV) were undertreated. The aim of this study was to describe the
management of HCV treatment in an HIV/HCV cohort during a 15-
year period.
Methods: An electronic chart review of all HIV patients with 1
observation at our department from the year 2000 was made.
Demographic, virological and treatment data were collected.
Results: From 2000 to 2015, 2353 PLHIV were enrolled; 67.8% were
males, median age was 48 years and 19.2% were not Italian. HIV
transmission due to intravenous drug use (IDU) was reported in 681
people (28.9%), in 573 (24.4%) was in men who had sex with men
(MSM), heterosexual transmission in 1007 (42.8%) and other risk in
92 (3.9%). Seven hundred and ninety-five patients’ (33.8%) result
was HCVAb positive. HCV patients were mostly Italian (94.3%), IDU
in 72.0% and MSM in 6.5%. Only 596 HCV patients had detectable
HCV RNA in the blood (75%); this mostly related to patients that
obtained an SVR before the year 2000. HCV genotypes were tested in
516 patients; 55.8% were genotype 1, 31.8% were 3 subtype; 12.4%
were genotype 2 or 4. The percentage of HCVAb patients amongst
the total of HIV population significantly decreased from the 49.2% of
2000 to the 30.7% of 2015 (pB0.001). Year-per-year analysis showed
the stability of treatment rate for HCV, with a significant increase in
2015 (20.6% vs. 8.5% of 2014, p0.001). SVR rate was significantly
improved in 2015 (79.9% vs. 50% of 2014, p0.02). The number of
re-treatments significantly increased in 2014 and 2015 (58.8% and
61.2% of the total of treatments respectively, p0.001 vs. 2013).
The number of HCVAb patients with HCV RNA not relievable
(cured) significantly increased during years. At 2015, 50.4% of
patients resulted to be HCV RNA negative (18.1% in 2000,
pB0.001) (Figure 1).
Conclusions: In the DAAs era, a significant increase in the number of
treatments was observed. SVR rate was significantly higher. Treat-
ment rate remains quite low maybe related to the availability of
DAAs only for patients with advanced liver disease (in Italy). More
than half of our population of HCV co-infected patients’ results to be
cured for HCV.
P278
The elderly and direct antiviral agents (DAAs): constraint or
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Claudia Fabrizio; Giuseppe Bruno; Eugenio Milano;
Raffaele Dell’Acqua; Laura Monno; Sergio Lo Caputo; Michele Milella;
Annalisa Saracino and Gioacchino Angarano
Clinic of Infectious Diseases, University of Bari, Bari, Italy
Introduction: New IFN-free regimens based on direct antiviral agents
(DAAs) in patients with HCV-related chronic hepatitis showed high
rates of sustained virological response (SVR) and good safety profile.
So far, few data are available about the impact of these therapies on
elderly patients, who are often not included in clinical trials. Aim of
this study was to evaluate the efficacy and safety profile of DAAs in
elderly patients.
Materials and methods: In this prospective, single-centre observa-
tional study, all patients aged ]65 years, who initiated a DAA-based
regimen, were enrolled from February 2015 to May 2016, then
divided according to age (group A: 6574 years; group B: ]75
Abstract P277Figure 1. Number of HCV treatments (naı¨ve, re-treatment) during the years (from 2000 to 2015), and percentage of HCV-
RNA negative patients amongt the HCVAb positive population during the same period.
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years). Baseline clinical, anamnestic and laboratory data were
collected (Table 1).
Results: In the study period, 289 patients started a DAA-based
regimen, including 167 patients (males: 87, 52.1%) aged ]65 years
(group A: 99 patients, 59.3%; group B: 68 patients, 40.7%). The
following regimens were administered: sofosbuvir-based: 38 patients
(22.7%), simeprevir-based: 25 (15%), ledipasvir-based: 33 (19.8%),
daclatasvir-based: three (1.8%), paritaprevir, ombitasvir/ritonavir 9
dasabuvir-based: 68 (40.7%). Ribavirin was used in 49 patients
(29.3%). In 38 patients (22.8%), an adjustment of comedications was
necessary due to drug interactions. Safety was assessed for 134
patients who reached end of treatment (EOT) during the study
period (Table 2).
At least one AE occurred in 93 patients (69.4%), of whom seven
(5.2%) had serious AEs (World Health Organization grade 3/4).
Treatment discontinuation because of AEs occurred in six patients
(4.5%), including one death due to oesophageal varices bleeding. The
following AEs were observed: neurological/psychiatric symptoms
(headache, dizziness, insomnia and mood disorders) (23.9%); skin
reactions (23.1%); anaemia with Hb B10 g/dL (12.7%), requiring
hospitalization in four patients; gastrointestinal toxicity (12.7%);
other AEs (13.4%). The presence of two or more comorbidities and a
pill burden of comedications ]4 were observed in subjects with
concurrent AEs, in particular in older patients (group B). A 12-week
follow-up after EOT was available for 88 patients, and SVR12 was
obtained in all subjects.
Conclusions: The heavy burden of comorbidities and comedications
in elderly patients complicates the management of DAA-based
therapies. However, despite a considerable amount of AEs, drug-
related toxicity did not significantly impair the completion and the
effectiveness of treatment. Further studies, based on larger popula-
tions and prolonged follow-up, are warranted to assess the optimal
real-life management of these peculiar patients.
P279
Treating HCV-positive Italian inmates with direct-acting
antivirals: the clinical experience in three major correctional
houses of Milan
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Epidemiologic studies report high HCV positivity rates in prisons (3
40%) with high unawareness rates, resulting in a substantial risk of
Abstract P278–Table 1. Clinical and laboratory baseline features of the 167 enrolled patients
Tot patients (N167) A (6574 years, N99) B (]75 years, N68)
Genotype, n8 (%)
1a 2 (1.2) 0 (0.0) 2 (2.9)
1b 95 (56.9) 45 (45.5) 50 (73.5)
2 37 (22.2) 23 (23.2) 14 (20.6)
3 1 (0.6) 1 (1.0) 0 (0.0)
4 6 (3.6) 5 (5.1) 1 (1.5)
Cirrhosis, n8 (%) 112 (67.1) 62 (62.6) 50 (73.5)
Previous failure of anti HCV therapy, n8 (%) 87 (52.1) 57 (57.6) 30 (44.1)
HCV RNA IU/mL, median (range) 1.296.000 (4.50127.590.025) 1.302.000 (4.50117.140.000) 1.150.000 (13.00027.590.025)
ALT UI/L, median (range) 72 (18434) 77 (18368) 63 (15434)
Total bilirubin mg/dL, median (range) 0.8 (0.22.9) 0.8 (0.22.9) 0.8 (0.42.9)
Serum creatine mg/dL, median (range) 0.83 (0.401.66) 0.81 (0.461.30) 0.88 (0.401.66)
Platelets (109/L), median (range) 136 (38347) 154 (50347) 123 (38342)
Body mass index, median (range) 25.9 (17.838.8) 25.3 (19.338.8) 26.5 (17.831.2)
Patients with at least 1 comorbidity, n8 (%) 138 (82.6) 81 (81.8) 57 (83.8)
Hypertension, n8 (%) 101 (60.5) 60 (60.6) 41 (60.3)
Diabetes, n8 (%) 38 (22.8) 24 (24.2) 14 (20.6)
Oesophageal varices/portal hypertension,
n8 (%)
16 (9.6) 5 (5.1) 11 (16.2)
Other comorbidities, n8 (%)
Thyreopathies 13 (7.8) 14 (14.1) 9 (13.2)
Dyslipidemia 18 (10.8) 16 (16.1) 2 (2.9)
Psychiatric disorders 16 (9.6) 10 (10.1) 6 (8.8)
Neoplasms 10 (6.0) 6 (6.1) 4 (5.9)
Cardiopathies 24 (14.4) 12 (12.1) 12 (17.6)
Prostatic hypertrophy 19 (11.4) 8 (8.1) 11 (16.2)
Others 32 (19.2) 18 (18.2) 14 (20.6)
Pill burden of comedications, median (range) 3 (014) 3 (014) 3 (013)
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HCV transmission. For this, treating HCV-positive prisoners could
impact on both individual and public health. Though international
guidelines have emphasized that prisoners must be treated as well as
general population, HCV treatment eligibility in prisons has always
been suboptimal due to poor adherence, psychiatric comorbidities,
side effects and legal issues. The availability of highly effective, short-
course DAAs could increase inmates’ treatment opportunities [1,2].
Our study was performed in 2015 in three prisons of Milan (Opera,
San Vittore and Bollate) harbouring yearly 3400 prisoners overall.
Every new inmate was proposed HIV, HCV, HBV, PPD and syphilis
testing. HCV RNA prisoners were submitted to an infectious
disease visit, HCV genotyping, ultrasonography and fibroscan. Legal
issues and patient’s motivation were considered. All motivated
prisoners with advanced liver fibrosis (F3/F4) and at least 3 months
end of sentence were selected for DAA treatment according to Italian
guidelines. Three thousand three hundred and fifty-four tests were
performed: HCV-Ab positivity was found in 10% (n314) of inmates.
Seventy percent of HCV-Ab inmates were IDUs. HCV RNA was
detected in 60% of HCVAb inmates. Thirty percent of HCV RNA
patients had advanced liver fibrosis (F3/F4). Sixty percent of them
were treated with first- and second-generation DAAs. The main
reasons for treatment deferral were transfer to other prison or
release (33%), low compliance (19%) and end of sentence B3
months (15%); seven patients (33%) are under evaluation. We
treated 25 patients with second-generation DAAs; the higher the
fibrosis the higher the rate of treated patients. In Table 1, we report
the characteristics of the treated patients. Eighty percent of them
were naı¨ve to previous treatments; 16% were HIV co-infected; the
main genotypes were 1 (48%) and 3 (44%), child-turcotte-pugh (CTP)
score was between A5 and B7. No treatment discontinuations were
observed. SVR12 was reached in 83.3% of the treated patients. Two
patients relapsed. The relapsers were genotype 3 cirrhotic patients
who underwent, in early 2015, a 24-week sofosbuvir  ribavirin
regimen that nowadays is considered suboptimal for this category of
patients. Our data show high rates of F3/F4 treated patients as
compared to previous studies. Inmates showed a strict adherence
Abstract P278Table 2. Safety profile of the 134 patients who reached the end of treatment
Tot pts, N:134
A (6574 years),
N:78
B (]75 years),
N:56
Tot pts with any AE, n8 (%) 93 (69.4) 56 (71.8) 37 (66.1)
Tot pts with ]2 AEs 32 (23.9) 21 (26.9) 11 (19.6)
Tot pts with serious AE (WHO grade 3/4) 7 (5.2) 2 (2.6) 5 (8.9)
Tot pts with serious AE leading to therapy
discontinuationa
6 (4.5) 2 (2.6) 4 (7.1)
Deaths before EOT 1 (0.7) 0 (0.0) 1 (1.8)
AEs according to sex
Male sex 43/65 (66.2) 26/36 (72.2) 17/29 (58.6)
Female sex 50/69 (72.5) 30/42 (71.4) 20/27 (74.1)
AEs according to comorbidities
Pts without comorbidities 19/29 (65.5) 12/17 (70.6) 7/12 (58.3)
Pts any comorbidity 74/105 (70.5) 44/61 (72.1) 30/44 (68.2)
Pts with ]2 comorbidities 52/72 (72.2) 32/41 (78.0) 20/31 (64.5)
Pts with cirrhosis 65/93 (69.9) 36/51 (70.6) 29/42 (69.0)
Pts with obesity (BMI ]30) 15/21 (71.4) 12/18 (66.7) 3/3 (100.0)
AEs according to comedications
Pts with no comedications 20/33 (60.6) 15/22 (68.2) 5/11 (45.5)
Pts with pill burden between 1 and 3 29/43 (67.4) 17/25 (68.0) 12/18 (66.7)
Pts with pill burden ]4 44/57 (77.2) 24/30 (80.0) 20/27 (74.1)
Pts with changes in comedications due to
drug interactions
19/27 (70.4) 9/14 (64.3) 10/13 (76.9)
AEs according to type of DAA therapy
with RBV 65/89 (73.0) 41/54 (75.9) 24/35 (68.6)
without RBV 28/45 (62.2) 15/24 (62.5) 13/21 (61.9)
of which:
SMV based 9 RBV 18/25 (72.0) 14/17 (82.4) 4/8 (50.0)
SOF based  RBV 21/29 (72.4) 13/17 (76.5) 8/12 (66.7)
LDV based 9 RBV 19/25 (76.0) 10/13 (76.9) 9/12 (75.0)
DAC based  RBV 1/1 (100.0) 1/1 (100.0) 0/0 (0.0)
3ABT/2ABT based 9 RBV 34/54 (63.0) 18/30 (60.0) 16/24 (66.7)
3ABT/2ABT, paritaprevir, ombitasvir/ritonavir 9 dasabuvir; AE, adverse event; DAA, direct antiviral agents; DAC, daclatasvir; LDV, ledipasvir;
RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; EOT, end of treatment. adiscontinuations were due to: skin reaction (one patient),
cardiological adverse events (AEs) (one patient), diarrhoea (one patient), oesophageal varices bleeding (one patient) and severe anaemia (two
patients).
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and satisfaction and none of them discontinued treatment. In
conclusion, short-course, highly effective and well-tolerated DAAs
are a feasible and strongly recommended HCV treatment strategy
in prison settings that could improve both individual and public
health.
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Introduction: We evaluated therapeutic outcomes of DSVOBV/
PTV/r for HCV genotype 1 (GT1) in HIV/HCV co-infected patients with
compensated liver disease.
Methods: The Madrid co-infection registry (MADRID-CoRe) is a
prospective registry of all co-infected adults (]18 years) undergoing
DAA therapy (Rx) for HCV in hospitals from the Madrid Regional
Health Service (SERMAS). We assessed SVR12, viral relapse and
failure due to Rx discontinuation. Between November 2014 and May
2016, 2402 co-infected individuals have initiated DAA Rx within
MADRID-CoRe. Herein, we present data of co-infected patients with
GT1 and compensated liver disease with programmed Rx finalization
censored to 31 December 2015, who were treated with DSVOBV/
PTV/r with or without ribavirin (RBV).
Results: We evaluated 132 co-infected individuals who met the
inclusion criteria; 72 infected with GT1a and 60 infected with GT1b.
Patient characteristics and treatment outcomes categorized by
subtypes, treatment duration and use of RBV are shown in
Table 1.
Conclusions: High effectiveness and safety were found with
DSVOBV/PTV/r with or without RBV for GT1 in co-infected patients
with compensated liver disease.
Abstract P279–Table 1. Characteristics of the treated patients
and treatment schedule
Opera/San Vittore/Bollate correctional houses Patients, N (%)
Treated inmates, N 25
Age, years, median (range) 50 (4556)
History of drug addiction, N (%) 15 (60)
Co-infection with HIV, N (%) 4 (16)
HCV genotype, N (%)
1a1b 12 (48)
3 11 (44)
4 2 (8)
CTP classification for cirrhotic patients, N (%)
A5 14 (56)
A6 3 (12)
B7 4 (16)
MELD, median (range) 8.5 (710)
METAVIR fibrosis score, N (%)
F4 21 (84)
F3 3 (12)
F2 1 (4)
Fibrosis 4 score, N (%)
B1.45 1 (4)
1.453.25 5 (20)
3.25 19 (76)
HCC, N (%) 1 (4)
Previous HCV treatment history, N (%)
No 20 (80)
Yes 5 (20)
Current HCV treatment duration, N (%)
12 weeks 11 (44)
24 weeks 14 (56)
HCV treatment schedule, N (%)
SOFRBV 6 (24)
SOFDCV 1 (4)
SOFLDV 2 (8)
SOFP/R 1 (4)
SOFSIMRBV 4 (16)
SOFLDVRBV 5 (20)
SOFDCVRBV 4 (16)
3DRBV 1 (4)
2DRBV 1 (4)
EOTR, N (%) 21 (87)
SVR12, N (%) 10 (83)
Relapse, N (%) 2 (8)
2D, ombitasvirparitaprevir/ritonavir; 3D, ombitasvirparitaprevir
dasabuvir/ritonavir; DCV, daclatasvir; LDV, ledipasvir; P/R, peg-interferon
plus ribavirin; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir, EOTR,
end-of-treatment response; HCC, hepatocellular carcinoma; CTP, child-
turcotte-pugh.
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P281
Response to DAA-based regimens in genotype 4 chronic
HCV/HIV co-infected patients in real life: COINFECOVA-2-
SEICV study
Carlos Minguez1; Miguel Garcı´a-Deltoro2; Juan Flores3;
Marta Montero4; Jorge Carmena5; Maria-Jose´ Galindo6; Sergio Reus7;
Jose-Emilio Ballester2; Jorge Uso´1; Enrique Ortega2 and for the
Coinfecova-2 Seicv Study Group
1Internal Medicine/Infectious Diseases Unit, Hospital General
Universitario de Castello´n, Castello´n, Spain. 2Infectious Diseases Unit,
Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
3Internal Medicine/Infectious Diseases Unit, Hospital Arnau de
Vilanova, Valencia, Spain. 4IInfectious Diseases Unit, Hospital
Universitari i Politecnic La Fe, Valencia, Spain. 5Internal Medicine/
Infectious Diseases Unit, Hospital Universitario Dr Peset, Valencia,
Spain. 6Infectious Diseases Unit, Hospital Clinico Universitario,
Valencia, Spain. 7Infectious Diseases Unit, Hospital General
Universitario de Alicante, Alicante, Spain
Introduction and aims: Because genotype 4 (GT-4) HCV/HIV co-
infected patients with advanced liver fibrosis are generally under-
represented in clinical trials, and their prevalence in developed
countries is low, little data are currently available on use of DAAs in
this setting. The aim of this study was to assess in the clinical
practice, the efficacy and safety of interferon-free DAA therapy in GT-
4 HCV co-infected patients.
Methods: COINFECOVA-2 is an observational, multicentre study
accomplished in hospitals of a region of eastern Spain, including co-
infected patients treated with all oral DAA on routine practice. GT-4
HCV/HIV co-infected patients were included in this analysis, if
interferon-free DAA therapy was initiated before 1 September
2015 (24-week regimen) or before 1st December 2015 (12-week
regimen), allowing a sufficient follow-up to evaluate efficacy.
Epidemiologic and clinical data were retrospectively collected by
their responsible physicians and investigators.
Results: We included 102 patients in 14 outpatient clinics with a
median age of 50 years (IQR 4654), 74% men and 94% on
antiretroviral therapy. HIV viral load was B50 copies/mL in 82%,
median CD4 nadir was 184 cells/mm3 (IQR 99299) and mean
CD4 at baseline 682 cells/mm3 (95% CI 603761). Fifty-six percent
of the patients were naı¨ves to HCV therapy, 47% were cirrhotic and
22% had an F3 degree of fibrosis (METAVIR). Fifty percent of cirrhotic
had a liver stiffness (LS) measured by elastometry ]21 kPa. The
employed combinations of DAA with or without ribavirin (RBV)
included: sofosbuvir (SOF)/ledipasvir (LDV) (59%); ombitasvir (OMB)/
paritaprevir/ritonavir (PTV/r) (20%); SOFsimeprevir (SMV) (14%);
and SOFdaclatasvir (DCV) (7%). RBV was employed in 32% of the
patients, and therapy was scheduled to 24 weeks in 5%. Efficacy
results are displayed in Table 1. There were five patients with
treatment failure (four relapses and one breakthrough), and two
losses of follow-up. Adverse events (AEs) were reported in 29
patients (28%), three of which were serious (3%), and mainly related
Abstract P280–Table 1. Baseline characteristics and outcome in patients coinfected with HIV and HCV genotype 1 treated with
dasabuvir and ombitasvir/paritaprevir/ritonavirribavirin
Genotype
1a
Genotype
1a
Genotype
1a
Genotype
1a
Genotype
1a
Genotype
1b
Genotype
1b
Genotype
1b
Genotype
1b
No RBV No RBV RBV RBV No RBV No RBV RBV
12 weeks 24 weeks 12 weeks 24 weeks Total 12 weeks 24 weeks 12 weeks Total
Baseline variables N3 N1 N42 N26 N72 N37 N1 N22 N60
Age, years, median 51 47 50 51 50 50 50 49 50
Male, % 66.7 100 76.2 92.3 81.9 67.6 0 72.7 68.3
cART, % 100 100 100 100 100 100 100 100 100
Log HCV RNA, median 6.2 5.5 6.5 6.6 6.5 6.5 5.2 6.1 6.3
Cirrhosis, % 66.7 100 4.8 96.2 41.7 13.5 100 86.4 41.7
Liver stiffness kPa,
median
14.4 64.0 8.6 18.0 10.4 9.3 17.5 20.4 11.2
HCV naı¨ve, % 66.7 100 52.4 65.4 58.3 67.6 0 45.4 58.3
Outcomes
SVR12, n (%) 3 (100) 0 40 (95.2) 24 (92.3) 67 (93.1) 34 (91.9) 1 (100) 21 (95.4) 56 (96.3)
% SVR, 95% CI   83.899.4 74.999.1 84.599.7 78.198.3  77.299.9 83.898.2
Relapse, n (%) 0 1 (100) 1 (2.4) 0 2 (2.8) 1 (2.7) 0 1 (4.5) 2 (3.3)
Breakthrough, n (%) 0 0 0 0 0 1 (2.7) 0 0 1 (1.7)
D/C due to AEs,
n (%)
0 0 0 1 (3.8) 1 (1.4) 1 (2.7) 0 0 1 (1.7)
D/C other reasons,
n (%)
0 0 1 (2.4) 1 (3.8) 2 (2.8) 0 0 0 0
RBV, ribavirin; SVR, sustained virologic response; D/C, discontinuation; AEs, adverse events.
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to anaemia in patients treated with RBV (13/33 patients treated with
RBV had anaemia). No patient stopped therapy for AEs.
Conclusions: In a real-world setting, this cohort of GT-4 co-infected
patients, mostly with an advanced liver fibrosis, presented a rate of
SVR over 90%, excepted for cirrhotic patients with high LS (]21 kPa)
who tended to have a worse response, especially if treated with SOF/
LDV. Results in cirrhotic patients with LS B21 kPa are similar to
patients with F3 degree of fibrosis.
P282
The role of two noninvasive tests to evaluate the liver
fibrosis (FIB-4 and transient elastography) and its
implications in the different HCV genotypes in a cohort of
HIV/HCV co-infected patients
Laura Perez Martinez1; Carlos Lapresta2; Maria Gracia3;
Javier Moreno2; Alvaro Cecilio4; Teresa Rubio5; Carmen Irigoyen3;
Gloria Samperiz2; Isabel Sanjoaquin4 and Jose Ramon Blanco1
1Infectious Diseases Department, Hospital San Pedro-Center for
Biomedical Research of La Rioja (CIBIR), Logron˜o (La Rioja), Spain.
2Infectious Diseases, Hospital Universitario Miguel Servet, Zaragoza,
Spain. 3Infectious Diseases, Complejo Hospitalario de Navarra,
Pamplona (Navarra), Spain. 4Infectious Diseases, Hospital Clı´nico
Universitario Lozano Blesa, Zaragoza, Spain. 5Infectious Diseases,
Hospital Reina Sofia de Tudela, Tudela (Navarra), Spain
Introduction: End-stage liver disease caused by chronic HCV infection
is the leading cause of morbidity and mortality in HIV patients.
Several factors such as duration of infection, age, male gender,
consumption of alcohol and transmission path have been associated
with a faster fibrosis progression rate. The aim of this study was to
evaluate the FIB-4 score, a noninvasive test for the assessment of
liver fibrosis, and to compare it with transient elastography (TE) in
order to predict the fibrosis degree, and its implications in the
different genotypes (GTs).
Materials and methods: Observational and multicentre study was
conducted in five hospitals of the northern of Spain (20142015).
HIV/HCV patients ]18 years on stable cART (]6 months) were
selected to analyze their liver fibrosis using two noninvasive
biomarkers: TE and FIB-4 index calculation.
Results: A total of 584 HIV/HCV patients were included (median age
49.5 years; male 71.2%; 86.9% people who inject drugs). Median CD4
was 620 cells/mL; 82% of them had a VL B50 copies/mL. HCV GT
distribution was as follows: GT1 59.2% (72.3% of them GT1a), GT2
2.1%, GT3 22.1% and GT4 16.5%. Median liver fibrosis was 7.8 kPa; it
was F0F1 in 46.1%, F2 in 15.6%, F3 in 18.1% and F4 in 20.1%.
Median FIB-4 was 1.7: B1.45, 1.453.25 and 3.25 in 36.5%,
43.4% and 20.1%, respectively. There was a significative correlation
between fibrosis degree and FIB-4 score (pB0.0001). FIB-4 score
was significantly lower in GT2 (median 1.3 vs. 1.8; p0.04) but
higher in GT3 (1.9 vs. 1.7; p0.04). Comparing GT1a and GT1b,
GT1a had a faster fibrosis degree (p0.037).
Conclusions: The prevalence of severe fibrosis is high in these
patients (20.1%). Compared with TE, FIB-4 has a good correlation.
GT3 has a faster fibrosis grade, so an early therapeutic intervention
in these patients is necessary. In the same way, GT1a has a higher
fibrosis degree.
P283
Diversity of hepatitis C virus envelope associated with
fibrosis in treatment-naı¨ve patients
Leontina Banica1; Simona Paraschiv1; Emil Neaga1;
Valeriu Gheorghita2; Ionelia Batan1; Ovidiu Vlaicu1; Costin Ioan
Popescu3 and Dan Otelea1
1Molecular Diagnostic Laboratory, Prof. Dr. Matei Bals National
Institute for Infectious Diseases, Bucharest, Romania. 2Clinical
Department, Prof. Dr. Matei Bals National Institute for Infectious
Diseases, Bucharest, Romania. 3Viral Glycoproteins, Institute of
Biochemistry of the Romanian Academy, Bucharest, Romania
Introduction: Hepatitis C virus (HCV) continues to be a serious global
health problem despite the introduction of direct acting antiretrovir-
al drugs. The limitations in surveillance that contribute to high
transmission rates as well as the emergence of drug resistance argue
for vaccine development both for prophylactic and therapeutic
purposes. High evolution rate of HCV due to high error rates of viral
polymerase combined with constant immune pressure from the host
generates major challenges for vaccine development. Herein, we
evaluated inter-/intra-host diversity of HCV in the E1E2 region in
relationship with fibrosis in treatment-naı¨ve patients.
Materials and methods: Blood samples from nine treatment-naı¨ve
HCV genotype 1b infected patients, five with no/low fibrosis (F0, F1)
and four with high fibrosis (F4) were collected. HCV full length E1E2
region was reverse transcribed and amplified in two rounds of PCR.
The amplicon was cloned in the mammalian expression vector
pcDNATM3.1/V5-His TOPO TA and 10 clones were sequenced using
3500 ABI instrument. BioEdit, Mega 7 and FastTree software tools
Abstract P281–Table 1. SVR stratified by treatment regimens and degree of fibrosis
SOF/LDV9RBV
(N60)
OMB/PTV/rRBV
(N20)
SOFSMV9RBV
(N14)
SOFDCV9RBV
(N7)
Overall
(N102)a
N (%) N (%) N (%) N (%) N (%)
All degrees 56/60 (93) 20/20 (100) 13/14 (93) 5/7 (71) 95/102 (93)
Fibrosis 3 14/14 (100) 9/9 (100) 3/3 (100) 1/2 (50) 27/28 (96)
Cirrhosis 26/30 (87) 6/6 (100) 7/8 (87) 2/3 (67) 41/47 (87)
Cirrhosis LSB21
kPa
15/15 (100) 2/2 (100) 0/1b (0) 2/2 (100) 19/20 (95)
Cirrhosis LS]21
kPa
11/15 (73) 4/4 (100) 6/6 (100) 0/1 (0) 21/26 (81)
LDV, ledipasvir; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; OMB, ombitasvir; PTV/r, paritaprevir/ritonavir; LS, liver stiffness.
aOne patient was treated with SOFRBV and achieved SVR; bone patient (not included) had a diagnostic of cirrhosis by clinical criteria and
achieved SVR.
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were used to analyze the genetic evolution and the intra- and inter-
host viral diversity.
Results: Intra-host variability was relatively low in patients with high
fibrosis (F4), while for those with no/low fibrosis (F0, F1) the viral
diversity varied, being high in those with older infection and low in
acute infection. The impact of positive (immune-mediated) or negative
(virus adaptation) selection on viral diversity was evaluated based on
non-synonymous to synonymous substitution rates per site (dN/dS
ratio). dN/dS ratio showed a reduced immune pressure on E1E2
glycoprotein of HCV-infected patients with high fibrosis, while those
with chronic infection and low fibrosis showed a strong positive
selection pressure in hypervariable region 1 of E2 glycoprotein.
Conclusion: Advanced fibrosis was associated with low intra-host
viral diversity and reduced selection pressure; apparently viral
populations that are structurally conserved and tolerated by the
immune system are being stably selected during late stages of
disease.
Acknowledgments: This work was supported by ANCSI; grant EEA-
JRP-RO-NO-2013-1-0022, GreenVac Project.
P284
Ledipasvir/sofosbuvir for 8 or 12 weeks in GT1 HCV-
infected, treatment-naı¨ve and non-cirrhotic patients with
HIV infection: real-world experience from the MADRID-
CoRe study
Juan Berenguer1; A´ngela Gil-Martin2; Ana Moreno3;
Francisco Moreno4; Lourdes Dominguez5; Teresa Alda´miz-
Echevarrı´a1; Encarnacio´n Cruz-Martos2; Vicente Estrada6;
Ignacio Santos7; Laura Benı´tez8; Jose´ Sanz9; Pablo Ryan10;
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Juan Jose´ Jusdado14; Carlos Barros15; Eduardo Malmierca16;
Marı´a Jose´ Calvo2; Marta Alcaraz2; Inmaculada Jarrin17 and
Juan Gonza´lez-Garcı´a4
1Infectious Diseases, Hospital General Universitario Gregorio
Maran˜o´n, Madrid, Spain. 2Pharmacy, Servicio Madrilen˜o de Salud,
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Introduction: We evaluated therapeutic outcomes of LDV/SOF for 8
or 12 weeks in HCV genotype 1 (GT1) HCV-infected, treatment-naı¨ve
(TN) and non-cirrhotic patients with HIV infection.
Materials and methods: The Madrid co-infection registry (MADRID-
CoRe) is a prospective registry of all co-infected adults (]18 years)
undergoing DAA therapy (Rx) for HCV in hospitals from the Madrid
Regional Health Service (SERMAS). We assessed SVR12, viral relapse
and failure due to Rx discontinuation. Between November 2014 and
May 2016, 2402 co-infected individuals have initiated DAA Rx within
MADRID-CoRe. Herein, we present data of co-infected patients with
GT1, TN and non-cirrhotic that were treated with LDV/SOF for 8 or 12
weeks without ribavirin, and with programmed Rx finalization
censored to 31 December 2015.
Results: We evaluated 192 co-infected individuals who met the
inclusion criteria: 134 treated with LDV/SOF for 12 weeks and 58
treated for LDV/SOF for 8 weeks. Patients’ characteristics and
treatment outcomes are shown in Table 1.
Conclusions: In real-life clinical practice, no significant differences
were found in effectiveness and safety with LDV/SOF for 8 or 12
weeks for GT1 in TN, non-cirrhotic co-infected patients.
P285
Effect of mono/dual antiretroviral therapy on HCV and HIV
suppression during HCV treatment in HIV/HCV co-infected
patients
Luz Martı´n-Carbonero1; Lourdes Dominguez2; Lucı´a Bailo´n1;
Rafael Torres3; Rafael Rubio2; Raquel Ron1; Mikel Rico1;
Inmaculada Jime´nez-Nacher4; Francisco Moreno4; Juan Gonza´lez1;
Federico Pulido2 and Marisa Montes1
1HIV Unit, Internal Medicine, Hospital Universitario La Paz, IdiPAZ,
Madrid, Spain. 2HIV Unit, Internal Medicine, Hospital Universitario
Doce de Octubre, IMAS12, Madrid, Spain. 3HIV Unit, Internal
Abstract P284Table 1. Patients’ characteristics and treatment outcomes
LDV/SOF 8 weeks (N58) LDV/SOF 12 weeks (N134) P
Baseline variables G1a40, G1b12, non-subtyped6 G1a95, G1b36, non-subtyped3
Age, years, median 49 (4553) 51 (4754) 0.030
Male, % 43 (74.1) 105 (78.4) 0.520
cART, % 55 (94.8) 132 (98.5) 0.140
Log HCV RNA, median 6.1 (5.76.6) 6.4 (6.06.8) 0.004
Liver stiffness kPa, median 7.7 (7.29.0) 8.8 (7.710.3) 0.002
Outcomes
SVR12, n (%) 52 (89.7) 122 (91.0) 0.760
% SVR12, 95% CI 78.896.1 84.995.3
Relapse, n (%) 4 (6.9) 7 (5.2) 0.650
Breakthrough, n (%) 0 0 
D/C due to AEs, n (%) 0 1 (0.7) 0.510
D/C other reasons, n (%) 2 (3.4) 4 (3.0) 0.870
SOF, sofosbuvir; LDV, ledipasvir; SVR, sustained virologic response; D/C, discontinuation; AEs, adverse events.
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Introduction: New HCV treatment combinations have been studied
only with few HIV drugs and always in triple therapy. In the clinical
setting, many times we have to use non-conventional combinations,
such as mono- or dual therapy, due to resistance or toxicity. The
effect of non-conventional ART combinations on both HCV and HIV
suppression needs to be assessed.
Material and methods: Retrospective review of HIV/HCV co-infected
patients has initiated DAA-based HCV treatment from November
2014 to 2015 in three different hospitals in Madrid. HIV viral
suppression was assessed at the beginning and at the end of HCV
treatment and compared between groups that have received triple
therapy versus mono- or dual antiretroviral treatment. Values are
given as percentage and median (interquartile range) for qualitative
and quantitative variables, respectively. Chi-square and non-parametric
(U de Mann-Whitney) test were used for comparisons.
Results: Overall, 596 patients initiated HCV treatment. Of them, 393
were receiving a triple antiretroviral combination, 66 PI/r mono-
therapy, 51 PI/r3TC, 32 other dual therapies and 40 other
combinations. Mono-/dual therapy groups were older than patients
on triple therapy. However, the rest of baseline characteristics were
similar between groups (Table 1).
HCV sustained virologic response (SVR) 12 weeks after the end of
therapy were 93.2% (520/560) and 94.6% (522/552) in intention-to-
treat (ITT) and on-treatment analysis, respectively. No differences in
SVR were seen in patients on triple therapy or mono-/dual therapy:
ITT (92.9% vs. 95.3%; D2.4; 95% CI 6.3 to 1.5; p0.3), OTT
(93.6% vs. 96.1%; D2.5; 95% CI 6.6 to 1.66; p0.2). HIV viral
load B50 copies/mL rate at the end of HCV treatment was 96% and
97.6% with conventional and non-conventional HAART (D1.6; 95%
CI 1.4 to 5.36; p0.4). Neither were differences seen 12 weeks
after (94.5% vs. 95%; D0.1; 95% CI 4.49 to 5.51; p0.9).
CD4 cell count did not significantly change during HCV treatment: 16
(95% CI 68 to 104) versus 18 (95% CI 138 to 100) in triple
versus mono-/dual groups, respectively; p0.1.
Conclusion: Mono- and dual ART maintain HIV suppression during
DAA-based HCV treatment. HCV SVR at week 12 is very high in HIV/
HCV co-infected patients independently of using triple ART or non-
conventional combinations.
P286
Health resources use in patients with HIV: evidence from
Italian administrative databases
Valentina Perrone; Diego Sangiorgi; Elisa Crovato; Stefano Buda and
Luca Degli Esposti
CliCon S.r.l. Health, Economics and Outcomes Research, Ravenna,
Italy
Introduction: The success of ART has changed HIV from a life-
threatening disease to a manageable lifelong disease. Today HIV
patients have a life expectancy approaching that of the general
population, but are exposed to a higher risk of developing
comorbidities as a consequence of ageing and exposure to highly
Abstract P285–Table 1. Baseline characteristics of patients with triple versus mono/dual ATR
All Triple Therapy Mono-Dual therapy
N596 N393 N149 p
Male gender 450 (75.4) 300 (76.3) 109 (73.2) 0.2
Age 51 (4854.2) 50.5 (47.454.3) 52 (49.354.3) 0.03
Genotype 0.1
1a 240 (44.1) 167 (46.9) 47 (35.1)
1b 90 (16.5) 56 (15.7) 30 (22.4)
3 78 (14.3) 48 (13.4) 23 (17.2)
4 133 (24.4) 84 (23.5) 33 (24.6)
RNA-HCV 6.2 (5.86.6) 6.2 (5.86.6) 6.3 (5.96.7) 0.1
Liver Stiffness (kPa) 0.6
B7 62 (10.4) 43 (11) 12 (8.1)
7.19.5 181 (30.4) 118 (30.2) 42 (28.2)
9.614 124 (20.8) 77 (19.7) 35 (23.5)
14 228 (38.3) 153 (39.1) 60 (40.3)
Previous HCV treatment 248 (41.5) 174 (44.3) 54 (36.2) 0.09
HCV treatment 0.2
Sofosbuvir/Ledipasvir 410 (68.8) 261 (66.4) 105 (70.5)
Ombitasvir/Paritaprevir/r /- DasabuvirAbbvie 87 (14.6) 64 (16.3) 21 (14.1)
Sofosbuvir/Daclatasvir 76 (12.7) 48 (12.3) 21 (14.1)
Ribavirin 168 (28.2) 38 (25.5) 121 (30.8) 0.2
Treatment duration 0.1
8 weeks 22 (3.7) 10 (2.5) 9 (6)
12 weeks 367 (61.6) 240 (61.1) 92 (61.7)
24 weeks 207 (34.7) 143 (36.4) 48 (32.2)
Baseline HIV-RNA B50 copies/mL 554 (94.5) 367 (94.6) 146 (98) 0.08
Baseline CD4 cell count 593 (399832) 582 (379829) 613 (433895) 0.3
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active ART. Currently, scarce evidence is available on comorbidities in
HIV patients and the related burden on the healthcare systems.
This study aimed to evaluate the prevalence of comorbidities among
HIV patients and estimate the associated healthcare costs.
Materials and methods: An observational retrospective cohort
analysis, using administrative and laboratory test outcomes data-
bases from seven local health units (LHUs) in Italy, was designed.
Currently, data from one LHU are presented in this analysis. Records
of patients diagnosed with HIV (identified through hospitalizations,
specific treatments or blood test results) between 1 January 2013
and 31 December 2015 were extracted. The date of the first HIV-
related healthcare consumption was used as the index date. Clinical
characteristics of patients were investigated in the year before the
index date. All patients were followed up for one year after the index
date (only patients with one year follow-up were included).
Results: The preliminary analyses from one LHU included 366 HIV
patients. Mean age was 53.6 years, 66% were male and 5% had AIDS.
Twenty-five percent of patients had one comorbidity, 11% had two
and 6% had three or more. Thirty-two percent of patients had
rheumatologic diseases (anti-inflammatory/anti-rheumatic drugs
prescribed), 7% had chronic kidney disease (CKD; defined as GFR
B60 mL/min, from laboratory outcomes database). Seventeen
percent of patients were prescribed statins and 2% of patients
were prescribed osteoporosis drugs. Three percent were hospitalized
for cardiovascular disease (heart failure, myocardial infarction,
cerebrovascular event) and 1% experienced a hospitalization for
fracture. On average, the annual healthcare cost of a patient without
comorbidities was 8400t, the cost of a patient with one comorbidity
9400t, and the cost of a patient with two comorbidities or three or
more were 9700t and 10,600t, respectively.
Conclusions: In this cohort, 42% of HIV patients were shown to
have at least one comorbidity. In addition, healthcare costs were also
shown to increase with the number of comorbidities. Evidence from
this study suggests that a multidisciplinary approach to HIV
patients is required to optimize care and healthcare consumption.
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HCV and HIV/HCV patients treated with direct antiviral
agents (DAAs): to what extent do they differ?
Giuseppe Bruno; Claudia Fabrizio; Raffaele Dell’Acqua;
Eugenio Milano; Michele Milella; Annalisa Saracino; Laura Monno
and Gioacchino Angarano
Clinic of Infectious Diseases, University of Bari, Bari, Italy
Introduction: DAA treatment has been associated with high rates of
sustained virological response (SVR) and a good safety profile both in
HCV and HIV/HCV individuals. We aimed to assess the efficacy
and safety of DAAs in HIV/HCV compared with HCV patients in a
large single-centre.
Methods: All HCV-infected patients, with or without HIV infection,
who received an IFN-free regimen with DAAs from February 2015
throughout June 2016, were enrolled. Clinical, virological and
laboratory data were collected.
Results: A total of 449 patients received DAAs, and 339 (54 HIV/
HCV and 285 HCV) completed their treatment. A follow-up ]3
months after the end of treatment (EOT) was available for 184
HCV and 40 HIV/HCV subjects. HIV/HCV individuals were
younger (median age 52 vs. 68 years), mostly male (90.9% vs. 57.2%)
and more commonly infected with genotypes 1a (52.7% vs. 6.4%), 3
(25.5% vs. 6.8%) and 4 (14.5% vs. 3.1%). Two hundred and twenty-
four (63.4%) patients were cirrhotic and 188 (53.7%) had a previous
therapy failure. HCV patients were more likely to have ]2
comorbidities (27.8% vs. 9%; p0.003). Type of therapy, effective-
ness and safety were analyzed for 350 patients, including 11 subjects
who discontinued treatment (Table 1).
Table 1. Type of DAAs therapy, effectiveness data and safety
profile of the 350 patients
Total number of patients
Total HCV HIV-HCV
evaluated 350 % 295 % 55 % p*
Type of therapy
SOFRBV 78 22.3 66 22.4 12 21.8 0.93
SOFSIM9RBV 56 16.0 39 13.2 17 30.9 0.001
SOFLDV9RBV 56 16.0 46 15.6 10 18.2 0.63
SOFDCV9RBV 25 7.1 21 7.1 4 7.3 0.96
OMBPTV/
RDAS9RBV
129 36.9 118 40.0 11 20.0 0.005
OMBPTV/R RBV 6 1.7 5 1.7 1 1.8 0.94
Use of ribavirin 234 66.8 204 69.2 30 54.5 0.03
Effectiveness
Patients with EOT 339 96.8 285 96.6 54 98.1 0.54
Drop-out 11 3.1 10 3.3 1 1.8 0.54
Patients with at least 3m
of follow-up post EOT
224 49.8 184 62.3 40 72.7 0.14
SVR12 207 92.4 171 92.9 36 90 0.52
Most common side effects
Headache 30 8.6 26 8.8 4 7.3 0.71
Insomnia 13 3.7 11 3.7 2 3.6 0.97
Fatigue 44 12.6 34 11.5 10 18.2 0.17
Dizziness 14 4.0 12 4.1 2 3.6 0.88
Mood disorders 13 3.7 11 3.7 2 3.6 0.97
Gastrointestinal
disorders
22 6.3 20 6.8 2 3.6 0.38
Jaundice 8 2.3 4 1.4 4 7.3 0.007
Rash, pruritus or
photosensitivity
59 16.9 53 18.0 6 10.9 0.19
Haematological
abnormalities
Anaemia 46 13.1 40 13.6 6 10.9 0.59
Haemoglobin B10 g/dl 29 8.3 23 7.8 6 10.9 0.44
Haemoglobin B8 g/dl 5 1.4 5 1.7 0 0.0 0.33
Blood transfusion 5 1.4 5 1.7 0 0.0 0.33
Reduction RBV 27 7.7 26 8.8 1 1.8 0.07
EPO use 17 4.9 14 4.7 3 5.5 0.82
At least two adverse events 73 20.9 68 23.1 5 9.1 0.02
Severe adverse events 9 2.6 8 2.7 1 1.8 0.7
Gastrointestinal
haemorrhage
5 1.4 4 1.4 1 1.8 0.79
Severe anaemia 1 0.3 1 0.3 0 0.0 0.66
Encephalopathy 2 0.6 2 0.7 0 0.0 0.54
Ascites 1 0.3 1 0.3 0 0.0 0.66
Results are presented as frequencies (%) for qualitative variables.
DAS, dasabuvir; DCV, daclatasvir; EOT, end of treatment; LDV,
ledipasvir; OMB, ombitasvir; PTV/r, paritaprevir/r; RBV, ribavirin;
SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response.
*pB0.05.
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Most common adverse events were rash (16.9%), fatigue (12.6%),
anaemia (13.1%) and headache (8.6%). Severe adverse events (SAE)
occurred in eight HCV (2.3%) and in one HIV/HCV patient (1.8%).
HCV patients experienced more frequently ]2 adverse events
(23.1% vs. 9.1%, p0.02) and underwent a larger ribavirin use
(69.2% vs. 54.5%, p0.03). Therapy was discontinued due to liver
transplantation (one patient), SAE (nine patients, including one death
because of oesophageal varices bleeding), breakthrough (one HIV/
HCV genotype 4 patient). SVR12 was achieved in 92.4% patients
overall, 92.9% HCV versus 90% HIV/HCV (p0.52). Relapse was
observed in five genotype 3 patients (three HCV and two HIV/
HCV) treated with sofosbuvir and ribavirin and one genotype 4 HIV/
HCV patient treated with sofosbuvir and simeprevir.
Conclusion: A worse safety profile pertained HCV patients with a
higher burden of comorbidities. However, an overall high rate of
SVR12 was obtained independent of HIV infection.
P288
Renal safety of boosted PI in HIV/HCV patients on SOF/LDV
Maria J Vivancos-Gallego; Ana Moreno; Maria J Perez Elias;
Carmen Quereda; Jose Luis Casado; Matilde Sanchez-Conde;
Enrique Navas; Santos Del Campo and Santiago Moreno
Infectious Diseases, Hospital Ramon y Cajal, Instituto Ramon y Cajal
de Investigacio´n Sanitaria, Madrid, Spain
Objectives: To better describe safety of PI-boosted (ritonavir/
cobicistat) plus ledipasvir/sofosbuvir (LDV/SOF) in routine clinical
care.
Methods: A retrospective HIV/HCV cohort study of patients from a
tertiary centre in Madrid, Spain, starting LDV/SOF with PI-boosted
with complete renal function and overall safety follow-up data during
therapy. Paired baseline and at the end of treatment eGFR (CKD-EPI)
comparisons were made regarding cobicistat or ritonavir boosted PI
use (plus TDF or not).
Results: From a DAA cohort of 424 co-infected patients, 83 were on
protease inhibitor-based regimen for HIV. Of these, 47 patients on
LDV/SOF (57%) were included (83% men, age 51 years (4751)). HCV
genotypes: 1 (68.1%); 3 (10.6%); 4 (21.3%). DAA duration was: 8
weeks (five patients); 12 weeks (33 patients); 24 weeks (nine
patients). Twenty-eight patients without cirrhosis (59.6%), 19 with
cirrhosis (40.4%). PI distribution was: darunavir/ritonavir (25 pa-
tients); darunavir/cobicistat (11 patients); lopinavir/ritonavir (six
patients); and atazanavir/ritonavir (five patients). Antiretrovirals
associated with PI were: Kivexa (six patients) and Truvada (nine
patients); lamivudine (16 patients) and PI monotherapy (16 patients).
Median time between the baseline and the last eGFR was 24 weeks
(2226). Mean baseline eGFR (CKD-EPI) in darunavir/cobicistat group
was 94.4 mL/min meanwhile in the others boosted PI was 91.2 mL/
min (p0.6). After the end of LDV/SOF mean eGFR was 94.2 mL/min
versus 83.4 mL/min, respectively (p0.2). In the boosted TDF group
mean baseline eGFR was 95.4911.5 mL/min versus 74.5932.2 mL/
min in the last observation (p0.15). The observed changes in eGFR
were not statistically significant, of small magnitude and non-clinically
relevant. No adverse events were reported during treatment.
Conclusion: In a population of HCV/HIV co-infected patients no
impact on kidney function or safety considerations was observed
during the short 8 to 24 weeks DAA treatment duration with
cobicistat/ritonavir boosted PI and LDV/SOF therapy.
P289
Entecavir plus lamivudine as an alternative treatment for
co-infected HBV/HIV patients with toxicity on tenofovir
therapy
Marı´a Fontecha-Ortega1; Vanesa Mun˜oz-Mendoza1;
Marta Monsalvo1; Marisa Mateos2; Miguel Angel Rodrı´guez-
Sagrado3; Cristina Go´mez1 and Jose Luis Casado1
1Infectious Diseases, Hospital Ramo´n y Cajal, Madrid, Spain.
2Microbiology, Hospital Ramo´n y Cajal, Madrid, Spain.
3Pharmacology, Hospital Ramo´n y Cajal, Madrid, Spain
Introduction: Combination of lamivudine (LAM) or emtricitabine
with tenofovir disoproxil fumarate (TDF) is the recommended first-
line regime for treatment in chronic hepatitis B virus (HBV)/HIV co-
infection. However, little is known about the best strategy in patients
who developed tenofovir toxicity. We report the outcome of HBV co-
infected patients who switched from TDF to entecavir (ETV) due to
renal or bone toxicity with maintenance of LAM.
Materials and methods: Retrospective case series (20092015) of
HBV/HIV co-infected patients who developed TDF toxicity and
switched to ETV together with LAM. HBV suppression (HBV DNA)
and renal and bone toxicity were evaluated during follow-up.
Results: Overall, 12 patients switched to ETVLAM because TDF
toxicity. Mean age was 54.9 years, and 83% male. Patients showed
chronic replicative HBV co-infection (Ag-HBe positive in four cases,
Ac-HBe in six cases; median HBV DNA level at baseline was 104.146
UI/mL) suppressed while receiving HBV therapy with LAM for a
median of 122 months (49.6170.3), along with TDF for 67 months
(34136.2). Thus, at the time of change, HBV DNA was undetectable
in all the cases except one patient with lack of adherence (1,700,000
UI/L). Patients showed additional cases of renal or bone toxicity (two
HTA, two DM, two liver transplantation, one renal transplant, one
patient on dialysis, four patients receiving antineoplastic chemother-
apy and one patient with Fanconi syndrome suspicion). At the time
of switch, mean estimated glomerular filtration rate (eGFR) was 87.3
mL/min (49103.3) and six patients were below 60 mL/min. Urine
analysis showed a protein-creatinine ratio (PCR) of 112 mg/gr (40
189) and fractional excretion of phosphate was 35.4% (13.579.9%).
Also, two patients showed severe osteoporosis and three patients
had vertebral fractures. During a median follow-up of 29.4 months
on ETV (3.981; 7.3 patient-years), HBV remained suppressed in all
the patients, with normalization of transaminases. In addition, there
was improvement in eGFR (from 75.6 to 90.6 mL/min; 0.16), serum
phosphate (from 2.7 to 3.11; p0.06) and FE of phosphate in urine
(from 59.2 to 74.3; p0.21).
Conclusions: The switch to entecavir together with lamivudine could
be an alternative to TDF in HBV/HIV co-infected patients in case of
toxicity or intolerance.
P290
Direct-acting antiviral drugs (DAAs) for the treatment of
chronic HCV infection in HIV co-infected patients: a
monocentric experience in real life
Ilaria Izzo1; Salvatore Casari1; Andrea Vavassori1; Paola Nasta1;
Silvia Odolini1; Filippo Castelnuovo2; Alberto Bergamasco2; Issa El
Hamad2; Giuseppe Paraninfo1; Angiola Spinetti1; Serena Zaltron1;
Lucia Urbinati1; Luciano Biasi1; Emanuele Foca`1; Elena Festa1;
Graziella Cristini2 and Francesco Castelli1
1Department of Infectious and Tropical Diseases, University of
Brescia and Spedali Civili General Hospital, Brescia, Italy.
2Department of Infectious Diseases, Spedali Civili General Hospital,
Brescia, Italy
Introduction: There are few data on the real-world experience of
hepatitis C virus (HCV) direct-acting antivirals (DAAs) in HIV/HCV co-
infected patients. The aim of the study was to evaluate the efficacy
of DAA therapies in a cohort of HIV/HCV patients in the Infectious
Diseases Department in Brescia, Northern Italy.
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Materials and methods: We retrospectively analyzed data of all HIV/
HCV patients who started treatment with DAAs from February 2015
to March 2016. The primary outcome was to evaluate sustained
virologic response at 12 weeks after DAAs completion (SVR12).
Results: Hundred and fifty-three HCV/HIV co-infected patients
started treatment in the study period. Most patients were male
(121, 79.1%) and HCV genotypes 1a, 3 and 4 were the most
represented (55, 36.0%; 37, 24.2% and 33, 21.6%, respectively). cART
was modified before starting DAA in 35/153 patients (22.9%), to
avoid PK interactions. Sixty-four (41.8%) patients had received prior
treatment with an IFN-containing regimen; 126 (82.4%) of patients
presented with cirrhosis, 25 (16.3%) presented with moderate
fibrosis at transient elastography (F3) and one (0.65%) was treated
according to Agenzia Italiana del Farmaco (AIFA) inclusion criteria no.
3 (extra-hepatic HCV manifestations). Ribavirin was included in the
vast majority of regimens (109 patients, 71.2%). The following
regimens were prescribed: sofosbuvir/ledipasvir (9ribavirin) 68
(44.5%), sofosbuvir/daclatasvir (9ribavirin) 52 (34%), sofosbuvir/
ribavirin nine (5.9%), sofosbuvir/simeprevir (9ribavirin) eight (5.2%),
ombitasvir/paritepravir/ritonavir/dasabuvir (9ribavirin) eight (5.2%)
and ombitasvir/paritepravir/ritonavir (9ribavirin) eight (5.2%).
Among the 72 patients who completed therapy and had a 12-week
follow-up by the end of the study, the overall SVR12 rate was 95.8%
and 3/72 (4.2%) patients faced virologic failure. No significant
differences in SVR12 rate were observed according to gender, age,
fibrosis grade and baseline HCV viral load. Anyway the three failed
patients were males with cirrhosis.
Conclusions: Treatment with DAAs was highly effective (cure rate of
95.8%) in our cohort of co-infected patients, the majority of whom
(82.4%) presented with cirrhosis. Neither HIV co-infection nor
advanced liver disease should be considered as a barrier to HCV
treatment. However, DAAs-cART interactions are a real challenge
during therapy and in some cases (22.9% in our experience) cART
needs to be modified before DAA treatment.
P291
Daclatasvir (DCV) pharmacokinetics in HCV/HIV co-infected
patients co-administered with rilpivirine and other
antiretroviral drugs
Ambra Barco1; Letizia Marinaro1; Marco Merli2; Chiara Alcantarini1;
Chiara Montrucchio1; Giulia Vendemiati1; Maurizio Milesi1;
Francesca Patti1; Fabio Favata1; Alessandra Ariaudo1; Hamid Hasson2;
Antonio D’Avolio1; Caterina Uberti-Foppa2; Giovanni Di Perri1 and
Stefano Bonora1
1Unit of Infectious Diseases, Ospedale Amedeo di Savoia, Torino,
Italy. 2Infectious Diseases Clinic, San Raffaele Hospital, Milano, Italy
Introduction: Due to potential drug-drug interaction, DCV dose
reduction to 30 mg is required when co-administered with
atazanavir/ritonavir (ATV/r), while no data are available for un-
boosted atazanavir (ATV). Moreover, no data on rilpivirine (RPV) and
DCV interaction are currently available. The aim of our study was to
describe DCV pharmacokinetics when co-administered with different
protease inhibitors (PIs) and RPV in a real-life cohort of HIV/HCV-
positive patients.
Materials and methods: HIV/HCV co-infected patients treated with
DCV plus sofosbuvir (SOF) for at least 4 weeks and receiving ART
were enrolled. Assuming a comparable effect of ATV and ATV/r,
patients treated with ATV received a reduced DCV dose of 30 mg.
DCV plasmatic levels (DCVpl) (2292 hours after last intake) were
evaluated using UPLC-MS/MS validated method and reported as ng/
mL. Data are expressed as numbers (percentage) and median (IQR).
Results: Twenty-nine patients were enrolled: 86.2% males, age 52
(IQR 4954), BMI 25 kg/m2 (22.527.7). Metavir score was 4, 3 and
1 in 22 (76%), 6 (21%) and 1 (3%), respectively. Child-Pugh score was
A and B in 93% and 7%, respectively. Twenty-four patients had HCV
genotype 3 and five had genotype 1. ART was PI-based in 13 (48%)
patients (six ATV/r, two ATV, five DRV/r), RPV-containing in eight
(26%) and INI-containing in eight (26%). Twenty-seven DCV determi-
nations were obtained at week 4. Median DCVpl in study population
was 212 ng/mL (103299). In patients co-administered with
RPV, DCVpl was 216 ng/mL (61383) and no significant statistical
difference was found in DCVpl of patients receiving other ARVs
(p1). Patients receiving PI showed a DCVpl of 280 ng/mL (224.5
369.75), with no statistical difference compared with DCVpl of RPV
group (p0.36). DCVpl of subjects in ATV/r (280 ng/mL, 212283)
and DRV/r (315 ng/mL, 277315) showed no significant difference
(p0.29), as well as DCVpl of those in ATV/r or ATV (237 ng/mL,
212237) (p0.37).
Conclusions: DCV plasmatic concentrations in our cohort of patients
administered with different ARV regimens resulted comparable to
values reported from literature. This is the first report on DCV
exposures in HIV/HCV patients co-administered with RPV. Results
show that standard DCV dose of 60 mg provides adequate DCV
levels, comparable to those reported with other regimens. Moreover
our findings confirm the appropriateness of reduced DCV dose of
30 mg both in individuals treated with ATV/r and in patients receiving
unboosted ATV.
P292
Chronic HCV genotype 4 infection in a Portuguese cohort of
co-infected HIV patients: treatment with sofosbuvir-based
regimens
Pedro Brogueira; Virginia Moneti; Ana Miranda; Fernando Ventura;
Teresa Baptista; Fernando Borges; Jaime Nina; Susana Peres;
Isabel Aldir; Maria Campos; Isabel Antunes; Joa˜o Pereira and
Kamal Mansinho
Infectious Diseases, Hospital Egas Moniz, Lisbon, Portugal
Introduction: HCV genotype 4 infection has an estimated prevalence
of 10 to 20% worldwide. In Europe the number of infections has
been rising due to several epidemiologic variations. In Portugal its
incidence reaches 7% [1]. The high rates of cure seen with oral-based
regimens brought the need to well characterize genotype 4 infection
in terms of its epidemiology, natural history and response to
treatment in a real-life experience basis.
Materials and methods: At our Infectious Disease Center, since 1
January 2015 until 31 March 2016, 416 patients were eligible to
engage HCV treatment with DAA regimens.
Inclusion criteria: Included all chronically HCV-infected patients, with
or without HIV infection, followed at our service, and proposed to
DAA treatment. Epidemiologic, demographic, clinical, laboratory and
therapeutic data were collected.
Data analysis: This was performed by using Microsoft Excel and SPSS
version 15.0.
Results: Of the 416 patients proposed for DAA treatment, 281
patients were HIV co-infected (68%) and 135 were HCV mono-
infected (32%). The global prevalence of HCV genotype 4 was 17%
(n72), 20% in co-infected (HIV/HCV) versus 11% in HCV mono-
infected patients. The 72 patients with genotype 4 infection included
57 (79%) patients co-infected with HIV, 77% with TCD4 cell count
500 cells/mL, all of them under cART with viral suppression. The
demographic analysis of co-infected versus HCV mono-infected
patients revealed: male gender 80% versus 82%, mean age 48 years
versus 56 years, injectable drug use being the more frequent route of
transmission 78% versus 45%, mean time since diagnosis 15 years
versus 11 years. Chronic liver disease stage was Child-Pugh A in 91%
versus 100%; MELD B9 in 87% versus 100%. Serum markers of
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fibrosis: FIB-4 3.25 in 10% versus 36% and APRI 0.7 in 20%
versus 36%. Real-time elastography was performed and revealed
fibrosis stage 5F2 in 39% versus 20%. Stage F4 was detected in four
patients (7%) versus one (7%). The proposed treatment was SOF/LED
in 97% of patients (n70); SOF/LEDRBV (n1); SOFPEGRBV
(n1). At the present date, 64 patients started treatment, 80%
(n51) HIV/HCV versus 20% (n13) HCV mono-infected. The
preliminary sustained virologic response rate was 95%. There was
one death due to hepatocellular carcinoma.
Conclusions: Our cohort reveals a genotype 4 prevalence above that
estimated for general population, especially in the HIV co-infected
patients reaching 20%. This analysis suggests that co-infected
patients have an earlier diagnosis of HCV infection, as they were
younger and presented earlier in time.
Reference
1. Anjo J, Cafe´ A, Carvalho A, Doroana M, Fraga J, Gı´ria J, et al. The
burden of hepatitis C in Portugal. GE Jornal Portugueˆs de Gastren-
terologia. 2014;21:4454. [Article in Portuguese]. doi: http://dx.doi.
org/10.1016/j.jpg.2014.03.001
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Mortality during direct-acting antiviral therapy in HCV/HIV
patients with cirrhosis
Maria J Vivancos-Gallego; Ana Moreno; Maria J Perez Elias;
Carmen Quereda; Jose Luis Casado; Cristina Gomez Ayerbe;
Matilde Sanchez-Conde; Santos Del Campo and Santiago Moreno
Hospital Ramon y Cajal, Instituto Ramon y Cajal de Investigacio´n
Sanitaria, Infectious Diseases, Madrid, Spain
Introduction: Direct antiviral agents (DAAs)-based therapy has
dramatically changed outcomes among patients with cirrhosis, but
the benefits in advanced liver disease are unclear.
Materials and methods: From April 2013, we consecutively included
181 HIV/HCV cirrhotics patients treated with DAAs. Baseline
characteristics, sustained virologic response (SVR12) and disconti-
nuations for any reason were recorded.
Results: The baseline characteristics are in Table 1. Most were GT1
(61%) and treatment experienced (58%). The rate of SVR12 obtained
for our cohort was 85% (149/175). There was a statistically significant
difference in the SVR12 rate in non-GT4-infected patients compared
with GT4-infected patients (88.9% vs. 67.7%, p0.009). Simeprevir
(SMV)-including DAA therapy was associated with treatment failure
p0.009. The premature discontinuation rate was 4.4% (8/181) in
our study, of whom five patients (62.5%) died. Reasons for
discontinuation in the remaining three patients included intracranial
haemorrhage (n1), upper gastrointestinal bleeding (n1) and
liver transplantation (n1). On-treatment mortality rate was 2.76%
and the baseline demographics and HCV characteristics of these five
patients are described. The median age was 52 years and received
treatment with DCV/SOF in three patients and LDV/SOF in two
patients. Genotypes distribution was 1a (two patients), 1b (one
patient) and 3 (two patients). The mean model for end-stage liver
disease (MELD) score, platelet counts, bilirubin and albumin levels
were not statistically different from those patients who survived
treatment. The causes of death for the five patients were
hepatocarcinoma (n3), upper gastrointestinal bleeding (n1)
and sepsis (n1). Two of three patients with hepatocarcinoma
developed a multicentric HCC ‘‘de novo’’ with rapid progression
(Table 2). Of note, while there were five on-treatment deaths there
Table 1. Baseline characteristics
Baseline demographics
Total
n181
Died on treatment
n5
Median age (range), years 52 (3673) 52.6 (4457)
Male, n (%) 149 (82%) 5 (100%)
History of decompensation,
n (%)
14 (8%) 3 (60%)
MELD score (range)
09, n (%) 94 (57%) 2 (40%)
1015, n (%) 60 (37%) 2 (40%)
1621, n (%) 9 (5%) 0 (0%)
21, n (%) 1 (1%) 1 (20%)
HCV genotype
1a, n (%) 73 (41%) 2 (40%)
1b, n (%) 37 (20%) 1 (20%)
1 (nosubtype), n (%) 51 (39%) 2 (40%)
2, n (%) 1 (0.6%) 0 (0%)
3, n (%) 37 (20.4%) 2 (40%)
4, n (%) 33 (18%) 0 (0%)
Treatment experienced
Dual therapy, n (%) 21 (11.6%) 1 (20%)
PI/PR, n (%) 105 (58%) 4 (80%)
Child-Pugh score
A, n (%) 124 (68.5%) 1 (20%)
B, n (%) 43 (25.3%) 3 (60%)
C, n (%) 3 (1.7%) 1 (20%)
Median baseline HCV RNA
IU/mL
6.18 MUI 1.5 MUI
Treatment duration (weeks)
12 93 (51.4%) 0 (0%)
24 82 (45%) 0 (0%)
48 1 (0.6%) 0 (0%)
Others 5 (3%) 5 (100%)
RBV use, n (%) 61 (34%) 2 (40%)
Abstract P293–Table 2. Cases of multicentric and fatal HCC
HCV
FBS
(kPa)
Compensated
cirrhosis Previous Tx DAAs AFP Clinical presentation Exitus
Case 1 GT 3a
ILB28 CT
36 Yes PI/PR (1) 04/22/2015 LDV/
SOFRBV
6,48 Multicentric HCC. Portal
vein thrombosis and ascites
27 days after
admission/4 m DAA
Case 2 GT 1b
ILB28 CT
45 Yes PI/PR (2) Dual
therapy
01/27/15 SOF/
DCV
63751 Multicentric HCC. Portal
vein thrombosis and ascites
6 days after
admission/4 m DAA
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was no mortality in the 12 weeks post-treatment. Three patients with
premature discontinuation reached SVR12.
Conclusions: We did not find a high mortality rate although close
monitoring on direct-acting antiviral therapy is essential. DAAs
effectively cured HCV in patients with advanced liver disease. The
longer-term impact of HCV treatment in patients with cirrhosis
remains to be determined.
P294
Characteristics and effectiveness in HCV mono-infected
and HIVHCV co-infected cirrhotic patients receiving oral
direct-acting antiviral (DAA) regimens interferon-free
therapies in southern Spain
Begon˜a Alcaraz1; Francisco Vera1; Paloma Escribano1; Rocio Rojano1;
Amaya Jimeno1; Elena Ruiz1; Ana Garcia1; Javier Trujillo1;
Nazaret Cobos1; Enrique Bernal2; Mar Alcalde1; Josefina Garcia1;
Onofre Martinez1; Maria Carolina Capozzi1 and Lorena Martinez1
1Medicina Interna, Hospital General Universitario Santa Lucia,
Cartagena, Spain. 2Medicina Interna, Hospital General Universitario
Reina Sofia, Murcia, Spain
Introduction: Patients with liver cirrhosis due to hepatitis C virus
(HCV) are a priority treatment group due to the risk of developing
clinical decompensation and hepatocellular carcinoma. Oral direct-
acting antiviral (DAA) interferon (IFN)-free therapies have simplified
regimens and reduced adverse effects (AE), not being exempt from
drug interactions. Cirrhotic patients, with more comorbidities and
polymedication, could have higher risk of AE during the treatment
with DAA, with compromised effectiveness.
Objectives: 1) To describe and analyze clinical, virologic and
elastographic characteristics in cirrhotic HCV mono-infected and
HIVHCV co-infected patients who receive treatment with DAA, and
2) to describe and analyze the effectiveness and safety of DAA in the
patients included.
Methods: Retrospective descriptive observational study of a cohort
of cirrhotic HCV mono-infected and HIVHCV co-infected patients on
DAA IFN-free therapies in the Infectious Diseases Unit of the General
Hospital Universitario Santa Lucia (Cartagena), from 1 January 2015
to 30 April 2016. The variables analyzed were: clinical and elasto-
graphic characteristics, comorbidities, routine treatment, efficacy
rate, AE and therapeutic failures.
Results: From 116 patients with HCV chronic infection who initiated
treatment with DAA, 31 (26.7%) were cirrhotic. Twenty-three
patients were male (74%), and the mean age was 53.898 years.
Nineteen patients (61.3%) were co-infected with HIV. The most
frequent HCV genotype was 1a. The elastography median result was
20.4 kPa (p25p75: 1733 kPa). The mean HCV viral load (log) was
6.1890.73 (3.757.19). Eighty-four percent had at least three
comorbidities. Twenty-two patients consumed three or more drugs
(71%), and most frequently: benzodiazepines (61%), antihyperten-
sives (50%), proton pump inhibitors (50%), antidepressants (32%)
and antipsychotics (29%). Thirteen percent of patients were on
methadone program. Effectiveness analysis: 23 patients (74.2%)
reached week 12 post-treatment; intention-to-treat analysis: 21
patients (91%) achieved SVR; observed data: 17 patients (74%)
with SVR. Six patients presented AE (19%), of which two (33%)
resulted in failure due to toxicity/intolerance. One patient had
severe hepatic decompensation and deceased. Four patients failed
treatment, due to virologic failure (two) and lack of adherence
(two).
Conclusions: Patients with liver cirrhosis receiving DAA IFN-free
therapies present high comorbidity and use of polypharmacy. A
higher rate of severe AE was observed without a significant reduction
in the virologic efficacy.
P295
Chronic hepatitis C treatment with direct antiviral drugs in
mono- and HIV co-infected patients: a real-life experience in
an infectious diseases department at a hospital in Portugal
Joa˜o Cabo; Teresa Martins; Nidia Garrido; Stepanka Betkova;
Maria Jose´ Manata; Liliana Alves; Sara Cardoso; Orlando Cardoso;
Rita Gonc¸alves; Ana Raquel Garrote; Pedro Simo˜es; Freddy Ramirez;
Diana Seixas; Sara Lino; Fernando Maltez and Diana Po´voas
Infectious Diseases Department, Hospital Curry Cabral  Centro
Hospitalar Lisboa Central, Lisboa, Portugal
Background and aims: Hepatitis C (HCV) treatment with direct
antiviral agents (DAAs) showed high rates of sustained virological
response in clinical trials. The aim of this study is to evaluate the
efficacy and safety of DAAs in a real-world setting, and compare the
results in HCV mono-infected and HCV/HIV co-infected patients.
Methods: Observational study including all HCV-infected patients
starting treatment with DAAs between January 2015 and May 2016.
Data were collected by review of clinical files. Liver fibrosis was
evaluated by indirect methods (real time elastography, ultrasono-
graphy and biochemical markers).
Results: Three hundred and eighty-five patients were included, 295
(78%) HIV co-infected, 76% male and 69% aged 40 to 59 years. Mode
of transmission was intravenous drugs use in 76%. Genotype (Gt)
distribution was: Gt1 244 (63%); Gt2 seven (2%); Gt3a 66 (17%); and
Gt4 68 (18%). Liver cirrhosis was present in 10% (38/385). Regimens
used were: SOF/LDV in 298 (77%); SOFRBV in 50 (13%); SOF/
LDVRBV in 26 (7%); other in 11 (3%). Duration of treatment was 8,
12, 16 or 24 weeks, depending on genotype, fibrosis stage and
history of previous treatment, according to EASL guidelines. At the
time of this analysis, 295 (76%) patients had completed treatment
and data for SVR12 were available for 248 (64%). Overall SVR12 was
96%. SVR12 with SOF-based regimens was: Gt1 99% (164/166), Gt2
86% (6/7), Gt3 85% (23/27) and Gt4 91% (40/44). Regimens without
SOF, used in haemodialysis patients, had 100% (4/4) SVR12. Cirrhotic
patients (32/248) had 94% SVR12; average variation on MELD score
for Child-Pugh A and B/C patients with SVR12 was, respectively,
0.9 and 1.4. Eleven patients experienced treatment failure: six
treatment experienced; one F4; no relation with HIV infection status
 4% (8/189) in HIV versus 5% (3/59) non-HIV patients. Treatment
was well tolerated. Thirty-six percent reported at least one adverse
event (AE), the most common being asthaenia (12%) and headache
(9%). None discontinued. ART was changed in 10 patients before or
during HCV treatment, in seven due to renal AEs. Tenofovir-based
regimens were used in 149 HIV-infected patients starting SOF or SOF/
LED therapy, prompting changes on ART in six (4%).
Conclusions: HCV treatment with DAAs showed high efficacy and
good tolerability. SVR12 rate (96%) was consistent with data from
clinical trials. High rate of SVR12 and improvement in liver function
was observed in cirrhotic patients. Failure was not related with HIV
co-infection. Regular monitoring of renal function is needed in
patients on tenofovir starting SOF or SOF/LDV.
P296
Chronic HCV treatment with DAA: what changes when
treating cirrhotic patients  a Portuguese cohort real-life
experience
Ana Claudia Miranda1; Telma Azevedo1; Ineˆs Cruz2;
Fernando Ventura1; Teresa Baptista1; Fernando Borges1;
Susana Peres1; Isabel Aldir1; Jaime Nina1; Isabel Antunes1; Maria Jose´
Campos1; Joa˜o Pereira3 and Kamal Mansinho1
1Servic¸o de Infecciologia e Medicina Tropical, Hospital Egas Moniz 
Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal. 2Servic¸o de
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Lisboa Ocidental, Lisbon, Portugal. 3Servic¸o de Medicina Interna 1,
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Introduction: Cirrhosis and hepatic carcinoma represents the
ultimate stage of HCV infection implying a negative impact on
patients’ quality of life, increase morbidity and mortality. Hepatic
cirrhosis present as a wide histopathologic findings and early HCV
infection diagnosis and treatment are major objectives in order to
treat infection before hepatic severe fibrosis establishment. Since
early 2015, Portugal is living a favourable scenario that allows the
prescription of reimbursed DAA regimens, including sofosbuvir (SOF),
sofosbuvir/ledipasvir (SOF/LDP) coformulation, and most recently,
ombitasvir/pariteprevir/ritonavir plus dasabuvir combination (3D),
with or without ribavirin (RBV) association.
Material and methods: Demographic, epidemiologic, clinical, virolo-
gic and treatment response data of HCV chronic infected cirrhotic
patients, who were eligible to start treatment with DAA regimens,
were collected, during the period between 1 January 2015 and 30
June 2016. Hepatic fibrosis was assessed by real-time elastography
together with APRI and FIB-4 serum biomarkers determination.
Cirrhosis was considered for those with METAVIR F4 and for those
with F3 plus high APRI or FIB-4 scores.
Results: During the inclusion period, 153 chronically HCV-infected
cirrhotic patients started treatment with DAAs: 100 (65%) HCV/HIV
co-infected and 53 (35%) HCV mono-infected. Demographic and
epidemiologic characterization of both groups (HCV/HIV vs. HCV)
revealed: male predominance in 80% versus 64%, mean age of 49
years versus 55 years, parenteral HCV transmission in 74% versus
56% and mean time since HCV diagnosis of 15 years versus 9.8 years.
HCV infection staging evidenced (HCV/HIV vs. HCV): genotype 1 was
the most frequent (68% vs. 60%); CC IL28B gene polymorphism in
39% vs. 32% and mean HCV plasma RNA of 6.48 log10 versus 6.4
log10. Clinical scores Child-Pugh and MELD evidenced compensated
hepatic disease in the vast majority of patients: 83% versus 96%
Child-Pugh A and 77% versus 89% MELD B10. Co-infected patients
presented a mean TCD4 count of 601 cells/mm3 and 88% had
undetectable HIV plasma RNA. At the present time, 72% versus 42%
patients completed treatment and 53% versus 34% performed HCV
RNA determination at 12 weeks after treatment ending, revealing a
SVR12 of 93% versus 95%. The reported rate of adverse events was
36% versus 44%, with one death considered not related with
pharmacologic reasons, documented in a HCV/HIV patient.
Conclusion: Our cohort of chronically HCV-infected patients, with
advanced liver disease, achieved high rates of SVR12. HCV/HIV co-
infected patients presented with a younger age and with a longer
time since HCV diagnosis, eventually corresponding to an earlier
refer to healthcare.
P297
Chronic hepatitis C in HIV-infected patients: treatment in
real-life with new generation direct-acting antivirals in a
Portuguese centre
Andre´ Silva-Pinto; Roge´rio Ruas; Isabel Abreu; Filipa Ceia;
Cristo´va˜o Figueiredo; Ana Clau´dia Carvalho; Ana Sofia Santos;
Jorge Soares; Carmela Pin˜eiro; Rosa´rio Serra˜o and Anto´nio Sarmento
Infectious Diseases, Centro Hospitalar Sa˜o Joa˜o, Porto, Portugal
Introduction: The direct-acting antivirals (DAA) revolutionized the
hepatitis C virus (HCV) infection treatment. Since 2015, DAA
became available in Portugal due to a universal access policy.
Its use in HIV-infected patients has some peculiarities, especially
due to drug interactions. Our aim is to assess the DAA efficacy in real
life and to monitor fibrosis and alpha-fetoprotein (AFP) changes
with treatment.
Methods: We performed a retrospective study of HCV-HIV patients
treated with DAA between February 2015 and June 2016. The
primary outcome was sustained virological response (SVR) at week
12 after treatment and the secondary outcomes were changes in
fibrosis, transaminases and AFP. We used the most appropriate
measures of central tendency/distribution and statistical test.
Results: We included 236 patients that completed 12 weeks after
treatment evaluation (from 402 patients with chronic HCV-HIV, 275
started the DAA treatment). Ninety percent (n212) were men and
the mean age was 47.4 (SD 6.6). The majority acquired the infection
through drug abuse (91.5%) and 64% were HCV treatment naı¨ve. The
most frequent HCV genotype was 1 (77.1%), followed by 3 (10.2%).
The cirrhotic rate was 30%. Concerning the HIV treatment, 99% of
patients were on treatment. In 68 patients (28.8%) the HIV
treatment had to be changed due to drug interactions: efavirenz
(38.3%), boosted atazanavir (27.9%), boosted lopinavir (23.5%),
nevirapine (8.8%) and boosted elvitegravir (1.5%). The patients
changed the HIV treatment to raltegravir, rilpivirine, boosted
darunavir or dolutegravir. Regarding HCV treatment, the majority
did sofosbuvir/ledipasvir (83.9%), followed by sofosbuvir/ribavirin
(9.3%), sofosbuvir/ledipasvir/ribavirin (5.9%) and sofosbuvir/dacla-
tasvir/ribavirin (0.8%). The duration of treatment was 12 weeks in
49.6% and 24 weeks in 50.4%. Our SVR rate was 97% (229 patients
cured the infection): four patients did not cure the infection owing to
lack of adherence, in two patients the treatment was stopped (acute
renal failure and alveolar haemorrhage, respectively) and one patient
had a relapse. There were no statistically significant differences in the
HIV viral load or CD4 count during the treatment (evaluated at 0, 4
and 12 weeks, end of treatment and 12 weeks after treatment)
(Friedman test). The elastography stiffness, AFP and transaminases
decreased in a statistically significant manner comparing before and
after treatment (Wilcoxon test).
Conclusion: Our results confirm in real life the efficacy of these DAA
with improvement of fibrosis, hepatic cytolysis and AFP.
P298
Impact of HCV RNA kinetics in SVR12 in a cohort of HIV/HCV
co-infected patients treated with DAAs in a ‘‘real-life’’
setting
Silvia Cavinato1; Silvia Zuin1; Giulia Marini1; Francesco Barbaro1;
Saverio Parisi2 and Annamaria Cattelan1
1Infectious and Tropical Diseases Unit, Azienda Ospedaliero-
Universitaria di Padova, Padua, Italy. 2Department of Molecular
Medicine, University of Padua, Padua, Italy
Introduction: Direct-acting antiviral (DAA) drugs created a major
paradigm shift in the treatment of chronic hepatitis C in HIV/HCV co-
infected patients. The aim of this study was to evaluate the
effectiveness and safety of DAA therapy and the role of on-treatment
HCV RNA kinetics on virological outcome in a ‘‘real-life’’ setting.
Materials and methods: All consecutive HIV/HCV co-infected
patients starting DAAs from May 2015 to March 2016 at our HIV
Outpatient Clinic were evaluated. Baseline characteristics, safety
data, sustained virological response at 12 weeks after end of
treatment (SVR12) and HCV RNA at 8 hours/48 hours/week 1/
week 2/week 4/week 8 and monthly thereafter were assessed.
Results: Forty-nine patients were treated. Demographic, clinical/
virological characteristics at baseline and DAA regimens are shown in
Table 1.
To date, 31 patients completed 12 weeks of follow-up after end of
treatment. Thirty patients (97%) achieved SVR12 and one patient
(3%) failed to obtain HCV RNA undetectability at 12 weeks after end
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Abstract P298–Table 1. Demographic, clinical and virological characteristics of patients at baseline and DAAs regimens
Demographic characteristics Total number of 49 patients
Male gender 35 (72%)
Age (years) 52 (range 2664)
HIV/HCV risk factor
PWIDs 39 (80%)
Transfusion 2 (5%)
MSM 2 (5%)
Vertical transmission 1 (2%)
Unknown 4 (8%)
HIV characteristics
CDC stage
A 9 (19%)
B 17 (35%)
C 23 (46%)
Under antiretroviral treatment 49 (100%)
HIV RNA B20 copies/mL 46 (93%)
CD4 count (mean, cells/mL) 607 (9103)
Change of antiretroviral treatment before start of
DAAs
29 (60%)
Antiretroviral regimens during DAAs
Raltegravir based 28 (58%)
PI based 11 (21%)
Tenofovir/emtricitabine/rilpivirine 7 (14%)
Dolutegravir based 3 (7%)
HCV characteristics
HCV treatment-experienced 24 (49%)
Liver fibrosis (FibroScan)
F0F1 0 (0%)
F2 10 (21%)
F3 10 (21%)
F4 29 (58%)
HCV genotype
GT1a 15 (30%)
GT1b 9 (19%)
GT1 1 (2%)
GT2 1 (2%)
GT3 9 (19%)
GT4 14 (28%)
HCV RNA (mean, UI/mL) 234,1817 (9754,312)
DAA regimens
Ombitasvir/paritaprevir/ritonavirdasabuvir
(3D) ribavirin
21 (42%)
Ledipasvir/sofosbuvir (9ribavirin) 15 (30%)
Daclatasvir sofosbuvir ribavirin 9 (19%)
Ombitasvir/paritaprevir/ritonavir (2D) ribavirin 3 (7%)
Sofosbuvir ribavirin 1 (2%)
Use of ribavirin in DAA regimens 41 (84%)
Duration of DAA therapy
12 weeks 22 (44%)
24 weeks 27 (56%)
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of treatment. Thirteen patients achieved HCV RNA B12 UI/mL at the
end of treatment and are still waiting for SVR12. Three patients died
during treatment; one patient died for recurrence of hepatocellular
carcinoma after end of treatment, one patient discontinued therapy
at week 3 for a severe adverse event (psychotic syndrome). The other
most common side effects were asthaenia 28%, insomnia 26% and
anaemia 10%. HCV RNA declined rapidly after the initiation of DAAs
with significant decay at 8 and 48 hours from first dose of therapy;
mean HCV RNA at 8 hours was 370.039 UI/mL (80.6% from
baseline), at 48 hours was 2.592 UI/mL (99.6% from baseline;
pB0.05). No significant correlation was found between viral load
decay during first hours of therapy and time of first HCV RNA
undetectability (r: 0.095 at 8 hours, 0.18 at 48 hours). Different
patterns of viral response were observed: (a) rapid response: HCV
RNA B12 UI/mL at week 4: 10 patients (21%), (b) HCV RNA 12 UI/
mL at week 4 and HCV RNA B12 UI/mL at week 8: 7 patients (15%),
(c) slow response: HCV RNA 12 UI/mL at week 8 and HCV RNA
B12 UI/mL at week 12 or end of treatment: 27 patients (60%).
Conclusions: In our HIVHCV co-infected patients, DAAs confirmed
to be highly effective and well tolerated both in treatment-naı¨ve and
treatment-experienced, including those with cirrhosis. A significant
decay of HCV RNA during first hours of therapy did not correlate with
time of HCV RNA undetectability as well as different patterns of HCV
RNA kinetics did not show a relation with subsequent achievement
of SVR12.
P299
CD4 cell count before chronic hepatitis C (HCV) treatment
with direct-acting antivirals (DAAs) and at the end of follow-
up in HCV/HIV co-infected patients
Josefina Mendez; Cristina Soeiro; Marta Marques; Celina Gonc¸alves;
Ana Paula Tavares; Ana Horta; Olga Vasconcelos; Joa˜o Seabra;
Miguel Abreu and Rui Sarmento e Castro
Infectious Diseases, Centro Hospitalar do Porto, Porto, Portugal
Introduction: Treatment of chronic hepatitis C (HCV) with interferon-
based regimens was associated with a decrease in the CD4 cell count
in HCVHIV co-infected patients, which returned to baseline after
the end of treatment. HCV cure with those regimens was associated
with a progressive increase in CD4 cell count.
Aim: To assess the impact of HCV treatment with DAAs on CD4 cell
count.
Methods: Prospective study of HCV/HIV co-infected patients treated
with DAAs for chronic hepatitis C. CD4 cell counts at baseline, at the
end of treatment and 12 weeks after treatment were compared. The
patients were randomized based on CD4 count at baseline lower or
equal and higher than 350 CD4/mm3.
Results: We included 133 patients: 88.7% were male, the mean age
was 46 years old and the acquisition of HCV was by intravenous drug
use in 94%. The most frequent genotype was G1 (79.7%), followed by
G4 (11.3%), G3 (8.3%) and G2 (0.8%). Overall, 41.4% were treatment
experienced. Mean value of fibrosis was 18.4 kPa and 52.6% of
patients were cirrhotic. All patients were receiving antiretroviral
treatment and all had undetectable HIV RNA. The mean baseline CD4
count was 603/mm3. Of the patients with B350 CD4/mm3, 78%
were cirrhotic. Sofosbuvir and ledipasvir 9 ribavirin was prescribed
in 88.7% of patients. Other regimens were sofosbuvir  ribavirin
(6.8%), ombitasvir/paritaprevir/ritonavir  dasabuvir (2.3%), sofos-
buvir  daclatasvir  ribavirin (1.5%) and sofosbuvir  pegylated
interferon (0.8%). SVR12 rate was 97% (four patients relapsed). The
evolution of the CD4 count during treatment is shown in Table 1.
The evolution of the CD4 count at the end of follow-up is shown in
Table 2.
Conclusion: There is a global increase in the mean CD4 cell count
during and after HCV treatment. The increase of CD4 cell count after
treatment is greater in patients with less than 350 CD4 cells/mm3
possibly due to the higher proportion of cirrhotic patients (78%) in
this group.
P300
Testing for HCV and HIV at baseline visit due to post-
exposure prophylaxis
Justyna Kowalska1; Ewa Pietraszkiewicz2; Ewa Firlag-Burkacka2;
Karolina Pyziak-Kowalska2 and Andrzej Horban1
1Hospital for Infectious Diseases in Warsaw, Medical University of
Warsaw, Warszawa, Poland. 2HIV Outpatient Clinic, Hospital for
Infectious Diseases in Warsaw, Warszawa, Poland
Introduction: People consulted for post-exposure prophylaxis (PEP)
can be at higher risk for HCV and/or HIV infection due to earlier
exposures, lifestyle or occupation. Here, we evaluate the positivity
rate of anti-HCV and anti-HIV/p24 in this population, as well as
factors related to it.
Methods: We performed retrospective analyzes of consultations due
to PEP in HIV Outpatient Clinic in Warsaw. Data were obtained from
electronic database, which collects all medical information since
2007. Logistic regression models were used to identify factors related
to positive anti-HCV test (all with pB0.01 in univariate included in
final model). Due to low positivity rate, HIV was not included in the
model.
Results: In total, 3928 persons were tested for both HIV and HCV in
2008 to 2016, 2231 (56.8%) women, median age 33.4 (26.343.4)
Table 1. CD4 cell count evolution during HCV treatment with
DAAs
Mean
baseline CD4
cell count
(mm3)
Mean end of
treatment CD4
cell count (mm3) p
Total (n87) 629 646 0.408
5350 CD4/mm3 (n13) 253 285 0.196
350 CD4/mm3 (n74) 695 710 0.547
Table 2. CD4 cell count evolution at the end of follow-up
Mean
baseline CD4
cell count
(mm3)
Mean end of
follow-up CD4
cell count
(mm3) p
Total (n126) 597 638 0.408
5350 CD4/mm3
(n27)
242 290 B0.05
350 CD4/mm3
(n99)
694 732 0.063
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years. Hundred and fifty (4.9%) persons had elevated ALT level (of
3032 measured at baseline), 161 (5.4%) had elevated AST (of 2961
measured), median PLT was 248 (213296) 103/mL (for 484
measured). Eighty-one (2.1%) persons were anti-HCV positive, 34
(1.0%) HBsAg positive and 4 (0.1%) anti-HIV/p24 positive. Two
persons were both HCV and HBsAg positive, one both anti-HIV/p24
and HCV positive. The final multivariate model included 3912
patients (80 HCV positive) and is presented in Table 1.
Conclusions: The rate of positive anti-HCV tests at baseline PEP visit
was comparable with the one observed in general Polish population,
despite higher baseline risks in this group of patients. Positive HCV
test was associated with traditional factors, namely age and elevated
liver enzymes. The next step in the project is to review possible risk
behaviours described at baseline visit in order to optimize HCV
testing patterns.
CLINICAL PHARMACOLOGY
P301
Interactions between HIV and HCV therapies: how common
and who wins?
Adele Torkington1; Justine Barnes2; Sarah Cripps3; Karen Lee4;
Neal Marshall5; Helen Morgan6; Anthony Pratt7; Ian Sayers1;
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Foundation Trust, Oxford, UK. 12Hepatology, Royal Free London,
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University Hospital Southampton NHS Foundation Trust,
Southampton, UK. 16Infectious Diseases, North West ID Unit, North
Manchester General Hospital, Manchester, UK
Introduction: The current era of HCV direct-acting antivirals (DAAs)
has allowed HIVHCV co-infected patients to achieve similar rates of
response to HCV mono-infected patients [1]. Managing HIVHCV
therapy is complex, often involving drugdrug interactions (DDIs)
between the DAAs, ARVs and other medicines. We evaluated the
incidence of DDIs in co-infected patients and its impact on choice of
preferred HCV therapy as recommended by NHS England.
Material and methods: Retrospective evaluation of all HIVHCV co-
infected patients receiving DAAs seen across nine UK centres from
June 2015 till May 2016. Data were collected on demographics, HCV
genotype, choice of DAA and ARVs and any changes made to these
or additional monitoring required. The Liverpool hep-druginteractions.
org website [2] was used to evaluate the presence and severity of
potential drug interactions.
Results: Hundred and eighty-three patients were identified of which
163/183 (89%) were male and median 49 years old. Hundred and
forty-eight of 183 (81%) were HCV genotype 1, 17 (9%) genotype 4,
15 (8%) genotype 3 and two with genotype 2, with 78/183 (43%)
reporting cirrhosis. Eighty-eight of 183 (48%) were non-responders
or relapses to prior HCV therapy. The HIV and HCV regimens are
listed in Tables 1 and Table 2, respectively. Twenty-nine of 183 (16%)
required alteration to their HIV regimen prior to DAA therapy (Table
3). Twenty-two of 29 (76%) of which received Abbvie 2D/3D
(ritonavir)-based DAA. Six of 183 (3%) required adaptation of HCV
regimen due to current ART regimen. Six hundred and ninety-four
comedicines were identified in 146/183 (80%) patients (median 3.5/
patient). Hundred and seventy-two of 694 (25%) amber DDIs (close
monitor/dosage adjustment required) were identified in 56/183
(31%) of patients, with 17/694 (2%) red (do not co-administer)
observed for 14/183 (8%) of patients. The need for additional
monitoring was reported for 61/183 (33%) of patients due to
Abstract P300–Table 1. Logistic regression odds ratios for having anti-HCV positive test at baseline screening
Univariate Multivariate
Effect OR (95% CI) p OR (95% CI) p
Female gender 0.44 (0.280.69) 0.0004 0.63 (0.341.18) 0.148
AST  ULL 9.18 (4.8517.4) B0.0001 5.15 (2.2211.9) 0.0001
ALT  ULL 8.62 (4.5216.4) B0.0001 3.01 (1.257.28) 0.014
Age of first visit per each 10 years older 1.19 (1.011.42) 0.039 1.36 (1.081.71) 0.009
Year 20112013 versus 20082010 0.93 (0.461.90) 0.131 0.56 (0.191.65) 0.068
Year of test 20142016 versus 20082010 1.98 (1.043.76) 0.002 1.31 (0.493.49) 0.092
HBsAg positive versus negative 3.17 (0.7413.5) 0.173  
HBsAg unknown versus negative 1.31 (0.752.29) 0.497  
All with pB0.01 in univariate included in final model. HIV test not included due to low number of events.
Table 1. HIV regimens
HIV regimen
Number (%)
patients
Integrase inhibitor 72 (39)
Protease inhibitor (PI) 55 (30)
Non-nucleoside reverse transcriptase inhibitor (NNRTI) 39 (21)
Complex regimens 15 (8)
Not on treatment 2 (1)
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potential DDIs with the DAA chosen, including renal monitoring for
tenofovir/ledipasvir co-administration, monitoring of INR for warfar-
in, blood pressure and lipids.
Conclusion: Managing HIVHCV co-infected patients is clearly
complex requiring review and modification of both HIV and HCV
therapy with additional monitoring. The majority received what was
deemed first-line HCV therapy as per national prescribing guidelines
at the time of initiation of HCV treatment. The role of the specialist
pharmacy team is key to managing this cohort.
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Introduction: Increasingly, women in Sub-Saharan Africa are choos-
ing etonogestrel (ENG) contraceptive implants because they are
highly effective and well tolerated. However, implantable contra-
ceptive failures are reported in HIV-positive women due to drug-
contraceptive interactions with efavirenz (EFV)-based ART [13]. We
characterized ENG pharmacokinetics in HIV-positive Ugandan women
receiving ENG implants plus EFV- or nevirapine (NVP)-based ART
compared with ART-naı¨ve women. To explore the potential for a
bidirectional interaction, we compared EFV and NVP concentrations
before and after ENG implant insertion.
Material and methods: This non-randomized, parallel-group study
included three arms: ART-naı¨ve, EFV- or NVP-based ART (N20 per
group). Participants in the ART groups were on stable ART with an
undetectable HIV RNA at entry. Sparse pharmacokinetic sampling of
ENG, EFV and NVP were performed at screening, entry and then 1, 4,
12 and 24 weeks post-implant insertion. In the ART groups, plasma
was collected 12 to 14 hours post-EFV or 11 to 13 hours post-NVP
dose. Participants on EFV-based ART had copper intrauterine devices
in place at entry. ART and ENG concentrations were quantitated
using validated HPLC and HPLC-MS/MS methods, respectively. Data
are compared as geometric mean ratio (GMR), with 90% CI.
Results: At entry, study groups were similar in age, weight and CD4
count. Data from 58 participants are included; one participant each
was excluded from the EFV (ART non-adherence) and NVP (proces-
sing error) groups. Geometric mean (GM) ENG area under the curve
(AUC) from 0 to 24 weeks (AUC024) were 11.12, 1.80 and
10.47ng*wk/mL in the ART-naı¨ve, EFV and NVP groups, respectively
(AUC024 GMR: EFV: ART-naı¨ve 0.162 (0.1600.163); NVP: ART-naı¨ve
0.941 (0.9380.944)). EFV and NVP concentrations were lower at
week 24 compared with pre-implant (EFV: GM 3.6 vs. 4.7 mg/L,
respectively, GMR 0.76 (0.710.79), p0.009; NVP: GM 5.7 vs. 6.9
mg/L, respectively, GMR 0.83 (0.780.88), p0.227). No participant
in the EFV group and one participant in the NVP group had
concentrations below the suggested threshold for virologic suppres-
sion at week 24 (EFV B1 mg/L and NVP B3 mg/L).
Conclusions: Over 24 weeks of combined use, ENG exposure was
84% lower in women using EFV-based ART compared with ART-naı¨ve
women. In contrast, NVP did not significantly impact ENG exposure.
Similar to findings with the levonorgestrel implant [1], decreased
ENG exposure in combination with EFV raises concerns about
reduced implantable contraceptive effectiveness for women on
EFV-based ART. Although statistically lower EFV concentrations
were observed after ENG insertion, all participants in the EFV group
had therapeutic concentrations at week 24.
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Dolutegravir plasma concentrations according to
companion antiretroviral drug: unwanted drug interaction
or desirable boosting effect?
Table 2. HCV regimens
HCV regimen Number (%) of patients
Harvoni9ribavirin 102 (56)
Abbvie 3D9ribavirin 32 (17)
Sofosbuvir/pegIFN/ribavirin 27 (15)
Sofosbuvir/daclatasvir9ribavirin 9 (5)
Abbvie 2D9ribavirin 8 (4)
Other 5 (3)
Table 3. ARV changes
ARV change
Number (%)
of patients
Omit ritonavir on Abbvie 2D/3D 12 (7)
NNRTI to unboosted integrase 10 (5)
PI to unboosted integrase 2 (1)
Boosted integrase converted to unboosted integrase 1 (1)
PI changed 1 (1)
Other 3 (2)
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Introduction: Main pharmacologic advantages of dolutegravir com-
pared with other integrase inhibitors are its suitability for once-daily
administration, no need for pharmacokinetic boosting, a high barrier
to resistance and its modest drug-to-drug interaction profile. It
should be pointed out, however, that most of these features derive
from studies in healthy volunteers. Here we aimed to characterize
the pharmacokinetics of dolutegravir in a real-life setting.
Materials and methods: Consecutive HIV-infected patients treated
with dolutegravir for at least one month with a request for
monitoring of dolutegravir plasma concentrations were considered.
Drug concentrations were assessed by a validated HPLC-UV method.
Dolutegravir trough concentrations were estimated using the interval
between last dose intake and blood sampling and the drugs
elimination half-life and clustered according to the companion
antiretroviral drug.
Results: Sixty HIV-infected adult patients were included in the study.
All patients had good immunologic status (CD4 cell count 6609325
cells/mL) with no clinical signs of liver or kidney dysfunction. Patients
were given dolutegravir at 50 mg once daily, with mean sparse and
trough drug concentrations of 255391932 and 150791283 ng/mL,
respectively. Dolutegravir was given in combination with atazanavir
(n25), darunavir (n13), a non-nucleoside reverse transcriptase
inhibitor (n12, rilpivirine or etravirine) or abacavir/emtricitabine
(n10). By multivariate analyzes, only companion antiretroviral
drug resulted significantly associated with dolutegravir plasma
trough concentrations (p0.012). Indeed, patients given dolutegra-
vir with atazanavir had three- to four-fold higher drug concentrations
compared with those given darunavir, a non-nucleoside reverse
transcriptase inhibitor or abacavir/emtricitabine (291891411 vs.
6179286, 9329965 or 11689822 ng/mL, pB0.001 for all
comparisons, Figure 1).
Conclusions: Here we have documented that co-administration of
atazanavir resulted in highly significant increased dolutegravir
concentrations compared with other antiretroviral drugs. These
results partially challenge previous findings in healthy volunteers
which showed that concomitant atazanavir/ritonavir intake produced
only modest, non-clinically significant increase in dolutegravir
exposure. This drug-to-drug interaction (related to the atazanavir-
mediated inhibition of UDP-glucuronosyltransferase 1A1, the main
enzyme involved in the metabolism of dolutegravir) could become
relevant in all clinical conditions which require higher than conven-
tional dolutegravir exposure. Moreover, the administration of
dolutegravir with atazanavir/ritonavir might also improve the
exposure of poorly compliant patients to antiretroviral therapy. No
association between high dolutegravir concentrations and the
development of drug-related adverse events or toxicity has been
reported to date. Therefore, it remains to be established whether the
increased dolutegravir exposure observed in HIV-infected patients
might eventually translate in late tolerability to treatment.
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Introduction: Dolutegravir (DTG) is the latest available integrase
strand transfer inhibitor. It is primarily metabolized via UGT1A1 with
CYP 3A4 as a minor pathway and it is substrate of p-glycoprotein.
Few drug-to-drug interactions have been observed but data on DTG
pharmacokinetics (PK) in the clinical setting are limited.
Materials and methods: The Torino Therapeutic Drug Monitoring
(TDM) registry was used and patients on DTG, with fully available
data (demographic, time after dose and concomitant medications),
were included; patients on rifampin were excluded. Data are
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Figure 1. Dolutegravir plasma trough concentrations clustered according to the companion antiretroviral.
Boxplots and whiskers represent the 5th, 25th, 50th, 75th and 95th percentiles, respectively. **pB0.001 versus other groups. Dashed lines
depict the protein-adjusted 90% inhibitory concentration for wild-type and resistant viruses (64 and 640 ng/mL, respectively).
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described as medians (interquartile ranges) and analyzed through
non-parametric tests. A multivariate linear regression analysis was
performed including variables with p-values below 0.10 at univariate
tests.
Results: Three hundred and sixty-three samples were available from
149 patients (median 1, range 119 per patient). Median age and
body mass index were 49.3 years (46.454.5) and 24.2 kg/m2 (20.8
27.7); 102 patients (68.4%) were male and 50 (33.5%) were HCV
positive. Samples were withdrawn 22.5 hours (10.824.2) after drug
intake (198 (54.5%) were trough values) and DTG median concentra-
tions were 1107 ng/mL (3992549). Three hundred and twenty-four
(91.3%) and 31 (8.7%) samples were from patients on once-daily or
twice-daily DTG: respective trough values were 660 ng/mL (255
1237) and 2674 ng/mL (10003474). Inter-patient variability was
high (102%) and lower in patients on twice-daily DTG (56.9% vs.
108%); intra-patient variability (calculated in 10 patients with 4
trough samples, all on once-daily DTG) was 64.7%. A moderate
significant correlation was observed between DTG concentrations
and age (rho 0.21 and pB0.001, rho 0.58 and pB0.001 considering
Cmax). Higher concentrations were observed in patients on atazanavir
(2321 vs. 922 ng/mL, pB0.001) while borderline lower in those on
valproic acid (n7, 829 vs. 1132 ng/mL, p0.08). At multivariate
linear regression analysis age, post-dose time, atazanavir use
(pB0.001) and, borderline, valproic acid use (p0.06) were
independent predictors of DTG concentrations explaining approxi-
mately 46% of its variability.
Conclusions: DTG PK in the clinical setting showed significant
variability although resulted in the range of efficacy. Significant
higher exposure was confirmed with atazanavir, while unexpected
higher drug exposure in older patients and lower concentrations in
valproic acid intakers need to be confirmed in further studies.
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Introduction: Limited prospective PK data are available on DRV/RTV
once daily (OD) and RAL twice daily (BD) in ARV-naı¨ve HIV-infected
individuals. We here present the PK analysis performed in the
NEAT001/ANRS143 study.
Materials and methods: NEAT 001/ANRS143 96-week randomized
study demonstrated non-inferiority of first-line ART with DRV/RTV
(800/100 mg OD) plus RAL (400 mg BD) compared with DRV/RTV
plus TDF/FTC (245/200 mg OD). However, higher failure rates in the
RAL arm were seen in those with low CD4 counts and high viral load
(VL) at baseline. Blood for PK analysis of study drugs (TFV, FTC, DRV,
RTV, and RAL) was collected 4 and 24 weeks after ARV initiation. Only
samples drawn between 5 and 30 hours post-dose were included in
this analysis. Drug concentrations were log-transformed, and linear
regression analysis was used to examine possible determinants of
DRV concentrations (age, gender, weight, ethnicity, RTV, RAL),
adjusted for time post-dose. We also examined if DRV concentration
was lower in patients with CD4 B200 cells/mL or VL ]100,000
copies/mL at baseline. Cox regression was used to associate week 4
drug levels with virological failure at or after week 32 (defined as
confirmed VL ]50 copies/mL), adjusting for baseline VL.
Results: Six hundred and sixty participants provided 1146 plasma
samples with DRV concentrations (317 on RAL plus DRV/RTV, 343 on
TDF/FTC plus DRV/RTV). Eighty-nine percent were males, 83% white;
median (IQR) age and weight were 37 (3146) years and 72 (6580)
kg, respectively. Two hundred and ninety-nine participants provided
483 RAL measurements, 658 provided 1138 RTV measurements. No
associations were observed between DRV concentration and sex,
age, ethnicity or weight. We did not see lower DRV concentrations in
the subgroups with baseline CD4 B200 cells/mL or VL ]100,000
copies/mL. Higher DRV concentrations were associated with both
higher RTV and (in RAL arm) higher RAL concentration (pB0.001).
No association was found between DRV concentration at week 4 and
virological failure at or after week 32 in analyses of both arms
together or separately for each arm. RAL concentration at week 4
was also not associated with VL failure.
Conclusion: DRV exposure was not affected by age, gender, weight or
ethnicity but showed a positive association with RTV and RAL
concentrations. There was no evidence of an association between
DRV concentrations and virological failure at or after week 32.
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Introduction: Elvitegravir/cobicistat/emtricitabine/tenofovir alafena-
mide (EVG/COBI/FTC/TAF (150/150/200/10 mg); E/C/F/TAF; Gen-
voya) is a single-tablet regimen approved for HIV treatment.
Atorvastatin (AVA; Lipitor), a HMG-CoA reductase inhibitor, is a
commonly prescribed medication for lipid lowering in HIV-infected
individuals. AVA is metabolized by CYP3A and is a substrate of Pgp
and OATP1B1/1B3. COBI, a pharmacokinetic (PK) enhancer in E/C/F/
TAF, is an inhibitor of CYP3A, P-gp and OATP1B1/1B3. This study
evaluated the DDI potential between E/C/F/TAF and AVA.
Materials and methods: This was a randomized, three-period and
open-label study. Healthy subjects (n16) received the following
treatments in a fixed sequence: AVA 10 mg on day 1; E/C/F/TAF on
days 4 to 13; E/C/F/TAFAVA 10 mg on day 14. PK assessments were
performed on the last day of each period (days 1, 13 and 14).
Statistical comparisons of EVG, COBI, TAF, TFV and AVA exposures
were made using geometric mean ratios (GMRs) and associated 90%
CI bounds of 70 to 143% (EVG, COBI, TAF, TFV AUC, Cmax and Ctau;
AVA AUC) and 50 to 200% (AVA Cmax), with E/C/F/TAFAVA serving
as the test (day 14) and E/C/F/TAF or AVA alone serving as the
reference (day 13 or 1, respectively).
Results: All subjects completed the study and treatments were
generally well tolerated. The majority of adverse events (AEs) were
mild in severity and no grade 3 or 4 AEs were observed. Following
co-administration of E/C/F/TAFAVA, relative to AVA alone, the
GMRs of the PK parameters of AVA were 2.3- to 2.9-fold higher
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(Table 1) and its active ortho- and parahydroxylated metabolites
were undetectable, indicating a DDI attributed the COBI-mediated
effect of E/C/F/TAF on AVA. In contrast, and as expected due to the
limited liability of AVA as a perpetrator of DDI, following co-
administration of E/C/F/TAFAVA, relative to E/C/F/TAF alone, the
90% CIs about the GMRs of the PK parameters of EVG, COBI, TAF and
TFV were within the prespecified bounds and consistent with
historical data.
Conclusions: All treatments were generally well tolerated. An
increase in AVA exposures was observed following co-administration
with E/C/F/TAF, consistent with intestinal Pgp inhibition and the
inhibition of the CYP3A-mediated metabolism of AVA by COBI. AVA
did not result in changes in the PK of the components of E/C/F/TAF.
These findings are aligned with the prescribing information of E/C/F/
TAF regarding AVA, which recommends initiating AVA treatment with
the lowest starting dose and titrate with clinical monitoring.
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Introduction: Data on protease inhibitors (PI) persistence in plasma
are limited to ritonavir (RTV)-boosting, and data with cobicistat-
boosting are unavailable. The object of this study was to investigate
the PK of darunavir (DRV)cobicistat and atazanavir (ATV)cobicistat
once-daily dosing over 72 hours following drug intake cessation.
Materials and methods: Healthy volunteers received a fixed-dose
combination of atazanavir 300 mg cobicistat 150 mg once daily for
10 days, followed by a 10-day washout period and then a fixed-dose
combination of darunavir 800 mg cobicistat 150 mg once daily for
10 days. Full PK profiles were assessed for each phase for the 72
hours following day 10. PK parameters were determined over 24
hours in plasma and to the last measurable concentration in plasma
and urine (2472 hours post-dose) by non-compartmental methods.
Results: Sixteen subjects completed the study. Geometric mean (GM)
terminal elimination half-life to 72 hours of darunavir was 6.35 hours,
lower than the 0 to 24 hours half-life (10.41 hours). The terminal
elimination half-life of atazanavir was 6.77 hours, lower than the 0 to
24 hours half-life (9.69 hours). These values did not remarkably differ
from those measured with RTV [1]. Thirteen of 16 subjects had
darunavir concentrations higher than the target of 550 ng/mL for
protease-resistant HIV isolates (equivalent to 10 times the protein
binding corrected minimum inhibitory concentration (IC50) for wild-
type virus) [2] at 24 hours post-dose, and 5/16 subjects had
concentrations higher than the target at 30 hours post-dose (GM of
1033 and 381 ng/mL). All subjects had atazanavir concentrations
above the suggested minimum effective concentration of 150 ng/mL
(equivalent to 10 times the protein binding corrected IC50 for wild-
type virus) [2] 24 hours post-dose and 14/16 subjects had concentra-
tions higher than the target at 30 hours post-dose (GM of 759 and 407
ng/mL). At 48 hours post-dose, no subject had concentrations above
targets with darunavir-cobicistat whilst 3/16 subjects did for atazana-
vir-cobicistat. Cobicistat half-life to 72 hours was 3.62 hours with
darunavir and 4.21 hours with atazanavir (both were shorter than
RTV’s) [1]. GM urine C24 darunavir and atazanavir concentrations
were 11,878 ng/mL and 24,857 ng/mL respectively. Urine concentra-
tions decay mirrored plasma concentration decay for both drugs.
Conclusions: This study investigated the PK forgiveness of two
cobicistat-boosted protease inhibitors in plasma. Different concentra-
tion decay patterns and relationships with cut-offs used to define
therapeutic concentrations were seen for DRV and ATV, which may be
partially explained by cobicistat half-life (shorter with DRV than ATV).
For the first time, we also measured drug PK forgiveness in urine,
which can be an easier marker of adherence. Further clinical data are
warranted to inform on whether drug doses can be delayed or missed.
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Introduction: Darunavir (DRV) is metabolized by cytochrome P450
3A4 (CYP3A4) and CYP3A5 and is a substrate for the hepatic influx
transporter, OATP1B1 (encoded by SLCO1B1). The pregnane X
receptor (PXR; NR1I2) and constitutive androstane receptor (CAR;
Table 1. Summary of AVA PK parameters and statistical comparisons
AVA PK Parameter E/C/F/TAFAVA (test) N16 mean (% CV) AVA (reference) N16 mean (% CV) GMR (90% CI) test/reference
AUCinf (ng*h/mL) 38.4 (32) 14.6 (27) 260 (231293)
AUClast (ng*h/mL) 34.9 (33) 12.0 (30) 291 (263322)
Cmax (ng/mL) 3.0 (51) 1.3 (56) 232 (191282)
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NR1I3) play important roles in transcriptional regulation of enzymes
and transporters. The effect of polymorphisms within these genes on
the pharmacokinetics of DRV was investigated in participants from
the NEAT 001/ANRS 143 study.
Methods: NEAT 001/ANRS 143 was a randomized study that demon-
strated non-inferiority of first-line ART with DRV/ritonavir (DRV/r; 800/
100 mg once daily) plus raltegravir (RAL; 400 mg twice daily)
compared with DRV/r plus tenofovir/emtricitabine (TDF/FTC; 245/
200 mg once daily). Blood samples were collected at week 4 post-
therapy initiation at any time 5 hours post-dose. DNA was extracted
from whole blood and genotyping for CYP3A4 (rs35599367), CYP3A5
(rs776746), SLCO1B1 (rs4149056; 521TC), CAR (rs2307424) and PXR
(rs2472677) polymorphisms was conducted. Plasma drug concentra-
tions were log transformed and genetic associations were assessed
using linear regression. Analysis was conducted in the entire cohort
(pooled), as well as independently in each arm.
Results: A total of 1278 plasma concentrations were available from
653 participants. In week 4 pooled analysis, SLCO1B1 rs4149056 was
associated with DRV plasma concentrations (p0.025). SLCO1B1
rs4149056 was significantly associated with DRV plasma concentra-
tions in the TDF/FTC arm (p0.036), but not the RAL arm (p0.38).
In the TDF/FTC arm, plasma DRV concentrations were 293695256
ng/mL, 312192160 ng/mL and 252091296 ng/mL, in TT, TC and CC
genotype groups, respectively. NR1I3 rs2307424 was significantly
associated with ritonavir plasma concentrations in TDF/FTC arm
(p0.001) but not the RAL arm (p0.57). Plasma concentrations
for ritonavir in the TDF/FTC arm at week 4 were 2079256 ng/mL,
1929333 ng/mL and 1119117 ng/mL for GG, AG and AA,
respectively. No other associations were observed.
Conclusions: Lower DRV plasma concentrations were observed in C
homozygotes for SLCO1B1 521TC in patients receiving a TDF/FTC
backbone but not those receiving RAL. This association is different to
that previously reported for lopinavir and statins, where concentra-
tions were higher in C homozygotes. This may indicate an indirect
effect of this polymorphism on DRV concentrations (e.g. mediated by
an interacting drug) but confirmatory studies are required and the
underlying mechanism needs to be elucidated.
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Introduction: In the product monograph of Stribild, it is recom-
mended that the formulation should be administered under fed
conditions to optimize drugs exposure. Here we assessed to what
extent this advice is applied in the real-life scenario by measuring
drugs plasma trough concentrations in HIV-infected patients given
Stribild alone or as part of antiretroviral therapy as per their daily
routine practice.
Materials and methods: Consecutive HIV-infected patients treated
with Stribild for at least one month, with no clinical evidence of
gastrointestinal impairment and not given drugs known to affect
elvitegravir or tenofovir pharmacokinetics, were considered. Drug
concentrations were assessed by a validated LC-MS/MS method
(lower limit of quantification (LOQ): 25, 10, 5 and 100 ng/mL for
elvitegravir, tenofovir, cobicistat and darunavir, respectively).
Results: Thirty-six percent of our patients (n65) took Stribild in the
evening with food, and the remaining were distributed as follows: 23%
in the morning with breakfast, 9% middle in the morning, 17% at
lunchtime and 15% late in the evening. Nine out of the 65 patients
had elvitegravir concentrations below the LOQ of the method,
whereas in the remaining the levels were largely distributed (Figure
1). All patients with suboptimal elvitegravir exposure took Stribild
under fasting conditions. Wide inter-individual variability in the
tenofovir and cobicistat levels was also observed, with 13 out of the
65 patients having cobicistat concentrations BLOQ. Of these, patients
given Stribild with darunavir had drug concentration significantly
lower compared with values measured in patients with quantifiable
cobicistat levels (4029547 vs. 321592435; pB0.001).
Conclusions: In a real-life context a significant proportion of patients
took Stribild in fasting conditions. This resulted in a wide inter-
individual variability of elvitegravir and tenofovir plasma trough
concentrations. It is likely that suboptimal tablet disintegration and
poor drug absorption may have taken place in these patients.
Conversely, the intake of Stribild with food increases the resident
time of the drug in the stomach, the disintegration of the
pharmaceutical formulation, the increased dissolution of the com-
ponents and their higher systemic absorption. Food-related altered
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Figure 1. Distribution of elvitegravir (right panel), tenofovir (middle panel) and cobicistat (left panel) trough concentrations in 65 HIV-
infected patients given Stribild as maintenance antiretroviral therapy.
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absorption of cobicistat may become particularly relevant when
darunavir is co-administered in order to reinforce the antiretroviral
therapy, because the cobicistat-related boosting effect is lost,
eventually resulting in sub-therapeutic darunavir concentrations. To
avoid the risk for patients to experience suboptimal drug exposure, it
is important that physicians more convincingly advise their patients
to take Stribild in fed conditions.
P310
Impact of food on the bioavailability of darunavir,
cobicistat, emtricitabine and tenofovir alafenamide
(DCFTAF), the first protease inhibitor-based complete
HIV-1 regimen
Herta Crauwels1; Bryan Baugh2; Erika Van Landuyt1;
Simon Vanveggel1; Anja Hijzen1 and Magda Opsomer1
1Janssen Infectious Diseases BVBA, Beerse, Belgium. 2Janssen
Research & Development LLC, Raritan, NJ, USA
Introduction: DCFTAF is the first single-tablet, once-daily protease
inhibitor-based complete HIV-1 regimen containing darunavir (DRV, D
800 mg), cobicistat (COBI, C 150 mg), emtricitabine (FTC, F 200 mg)
and the novel prodrug of tenofovir, tenofovir alafenamide (TAF, 10
mg). TAF has an improved renal and bone safety profile compared
with tenofovir disproxyl fumarate. The efficacy and safety of DCFTAF
is under investigation in two international, fully randomized phase 3
studies, AMBER (NCT02431247) and EMERALD (NCT02269917). This
study evaluated the impact of food on the pharmacokinetics of the
DCFTAF components.
Methods: This was a phase 1, open-label, randomized, two-period,
single-centre, crossover study in 24 HIV-negative, healthy volunteers
(NCT02475135). In two treatment sessions, participants received a
single oral dose of DCFTAF under fasted conditions or 30 minutes
after a standardized high-fat breakfast, with a ]7-day washout
period in between. Pharmacokinetic profiles were determined over
72 hours for DRV and COBI, 48 hours for FTC and 12 hours for TAF.
Plasma concentrations of DRV, COBI, FTC and TAF were determined
using validated LC-MS/MS assays. Pharmacokinetic parameters were
determined using non-compartmental analysis (WinNonlin) and
evaluated using least square (LS) means ratios and 90% CIs. Safety
and tolerability were assessed throughout the study.
Results: When administered as DCFTAF, DRV exposure was 30 to 45%
lower and COBI exposure was 16 to 30% lower, in fasted (test)
compared with fed conditions (reference) (Table 1). For FTC, Cmax
was 26% higher in fasted compared with fed conditions, while
AUClast was comparable under both conditions (Table 1). For TAF, the
Cmax was 82% higher, while AUCinf was 20% lower, in fasted than in
fed conditions. The TAF AUClast was comparable under both
conditions (90% CI of the LS mean ratio was within the 80 to
125% boundaries of no effect) (Table 1). Administration of DCFTAF
was generally well tolerated under fed and fasted conditions. No new
safety issues, grade 3/4 or serious adverse events or deaths
occurred. There were no discontinuations due to adverse events.
Table 1. DRV, COBI, FTC and TAF pharmacokinetic parameters and statistical analysis
Parameter, mean (SD)a DCFTAF fasted (test) n24 DCFTAF fed (high-fat breakfast) (reference) n24 LS means ratio,% 90% CI,%
DRV
Cmax, ng/mL
b 4089 (1846) 6629 (1543) 54.99 46.7364.71
Tmax, hours
b 3.00 (1.008.02) 5.00 (1.508.00) ND ND
AUClast, ng.h/mL
b 67,504 (35,642) 93,541 (39,730) 65.65 56.7675.92
AUCinf, ng.h/mL
c 72,147 (36,009) 94,686 (40,882) 70.25 59.4982.95
t1/2term, hoursc 7.0 (2.3) 7.8 (3.5) ND ND
COBI
Cmax, ng/mL
b 704 (368) 711 (164) 76.96 55.70106.33
tmax, hoursb 3.00 (1.006.00) 5.00 (2.006.10) ND ND
AUClast, ng.h/mL
b 5771 (3206) 6168 (2260) 70.90 51.1398.30
AUCinf, ng.h/mL
d 6136 (3064) 6258 (2268) 84.39 68.52103.95
t1/2term, hoursd 4.1 (0.9) 3.9 (0.6) ND ND
FTC
Cmax, ng/mL 2247 (573) 1785 (486) 125.99 112.85140.65
tmax, hours 1.00 (0.502.00) 2.00 (0.755.00) ND ND
AUClast, ng.h/mL 11,593 (2573) 11,499 (2055) 100.12 96.29104.10
AUCinf, ng.h/mL
e 12,286 (2729) 10,029 (1079)g ND ND
t1/2term, hourse 10.8 (1.2) 10.7 (1.2)g ND ND
TAF
Cmax, ng/mL 180 (90.6) 107 (65.2) 182.29 140.50236.50
tmax, hours 0.50 (0.250.75) 0.88 (0.255.00) ND ND
AUClast, ng.h/mL 106 (44.7) 117 (51.5) 89.54 81.2098.72
AUCinf, ng.h/mL
f 109 (47.7) 125 (57.3) 80.38 73.0488.45
t1/2term, hoursf 0.3 (0.2) 0.5 (0.1) ND ND
aExcept tmaxmedian (range);
bn23 for test and n24 for reference; cn20 for test and reference; dn22 for test and n24 for reference;
en16 for test and n7 for reference; fn21 for test and n16 for reference; gAccurate determination not possible for more than 50% of
participants; interpret with caution.
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Conclusions: When administered as the DCFTAF tablet, DRV exposure
was decreased in fasted conditions versus fed conditions, similar to
other (co)formulations of DRV. Differences in the exposures to COBI,
FTC and TAF in fasted conditions versus fed conditions are not
considered to be clinically relevant. Consistent with other DRV
formulations, it is recommended the DCFTAF tablet be taken with
food, which is also the recommendation in the ongoing phase 3
AMBER and EMERALD trials in HIV-1-infected adults.
SD, standard deviation; LS, least square; CI,confidence interval; Cmax,
maximum plasma concentration; tmax, time to Cmax; AUClast, area
under the plasma concentration-time curve (AUC, calculated by
linear-linear trapezoidal summation) from time of administration up
to the last timepoint with a measurable concentration post-dose;
AUCinf, AUC from time of administration to infinity; t1/2term,
terminal elimination half-life; ND, not determined.
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durability among patients receiving elvitegravir/cobicistat/
emtricitabine/tenofovir (EVG/C/F/T) and concomitant
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Introduction: Cobicistat, a component of single-treatment regimen
EVG/C/F/T, is a potent cytochrome P450 inhibitor [1], so many DDI
are expected. From the real practice perspective, we evaluated the
clinical impact of DDI associated with the use of EVG/C/F/T and
concomitant medication (CM).
Methods: From July 2014 to January 2016, we retrospectively
reviewed all patients starting a new EVG/C/F/T regimen, both in
naı¨ve and switching scenarios, in six hospitals of Spain. CM was
recorded since EVG/C/F/T was started, and categorized, according to
the Liverpool HIV Drug Interactions (LHDI) tool (no interactions
expected, potential interactions/use with caution and formally
contraindicated). The highest degree of DDI found was applied.
Time and reasons to change EVG/C/F/T were compared according to
CM status (no DDI, if patient has no CM or no interactions were
expected, and DDI present, if CM has been identified by LHDI tool
with potential interactions or contraindicated) [2].
Results: Overall 243 patients, followed for a median time of 13.7
years before starting EVG/C/F/T, were included, 75% men, with a
median age of 47 years, route of HIV transmission (IDU 35%, MSM
34%), AIDS stage 28%, baseline CD4 count 521 and HIV RNA fully
suppressed in 73%. Among 198 (82%) pre-treated patients, main
reasons for starting EVG/C/F/T were simplification 57% and toxicity
18%. Thirty-seven percent of patients did not received CM, while 152
(63%) received a median of 2 (24) CM that were classified as no DDI
26%, potential DDI 73% or contraindicated 2% (domperidone and
ivadravina). After a median exposure of 278 days to EVG/C/F/T, 13%
of patients changed its therapy due to toxicity 6.2%, DDI 2.1%, failure
0.8%, simplification 0.8% and other reasons 3.3%. No differences
were observed in median time to change EVG/C/F/T according to DDI
status, neither in the univariate log rank test p (0.69) nor in the Cox
regression analysis p (0.64).
Conclusions: In clinical practice, despite a large number of drug-drug
interactions are predicted for EVG/C/F/T and concomitant medica-
tion, these did not influence a shorter durability.
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Introduction: Dolutegravir (DTG) is a second-generation integrase
inhibitor used for the treatment of HIV-1-infected patients. DTG has
shown anti-HIV effects non-inferior to those of other drugs in phase
3 trials and can be conveniently taken once daily. The characteristic
side effects of DTG include central nervous system side-effects
(CNSSEs) leading to drug discontinuation in cases. Furthermore, DTG
is primarily metabolized by UGT1A1, and there is a weak correlation
between DTG plasma-trough concentrations and UGT1A1 genetic
polymorphisms. The principal aim of the study was to explore DTG
plasma-trough concentrations association with CNSSEs. Moreover,
we considered whether UGT1A1 genetic polymorphisms could
predict of DTG CNSSEs.
Materials and methods: We included 101 Japanese HIV-1-infected
patients given DTG at Osaka National Hospital from June 2014 to
March 2016. Their DTG trough levels were measured by liquid
chromatography-mass spectrometry. UGT1A1 was genotyped using
the sequence method. We compared the frequency of CNSSEs
among three groups: A (with homozygous mutations in UGT1A1*6/
*28 or compound heterozygous mutations in *6/*28); B (patients
with heterozygous mutations in *6/*28); and C (wild-type).
Results: Side-effects developed in 37 of 101 patients (37%), and of
these, CNSSEs were evident in 21 patients (21%): headache in eight
(38%); insomnia in six (29%); irritability in three (14%); light-
headedness in two (9%); depression in one (1%); and dizziness in
one (1%). The median DTG plasma-trough concentration was
significantly higher in patients with CNSSEs (1.34 mg/mL) than in
those without CNSSEs (1.06 mg/mL) (pB0.05).The frequencies of
CNSSEs in the three groups were: A, 23%; B, 25% and C, 18%. No
significant difference in the frequency of CNSSEs was evident in
terms of UGT1A1 genetic polymorphisms.
Conclusion: Although UGT1A1 genetic polymorphisms are not
predictive of DTG CNSSEs, the data suggest that a relationship may
exist between DTG plasma-trough concentrations and CNSSEs.
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Introduction: There is expanding evidence that redox-imbalance
plays a role in viral, inflammatory and immunological response
of HIV infection [1]. Albumin circulates as S-thiolated form (RSSP) in
near of 25%, and S-thiolation by disulfide bond with low molecular
weight thiols, such as glutathione (GSH) generating glutathionylated
proteins (GSSP), cysteine (cysSH; CysSSP), homocysteine (HCysSH;
HCysSSP) and cysteinylglycine (CysGlySH; CysGlySSP) is a common
reversible oxidative modification. This process protects protein
thiols from irreversible oxidation, is a relevant redox-buffer in blood
and has a regulatory function [2]. The RSSP-profile might represent a
pharmacodynamics biomarker for assessing the redox-modulating
effects of drugs. The antiretrovirals, as efavirenz (EFV) and nevirapine
(NVP), were implicated with protein adducts formation and oxidative
stress induction [3]. This work is aimed to investigate the RSSP-
profiling in a cohort of HIV-infected patients and additionally the
redox-modulating response to EFV and NVP.
Methods: The study protocol received prior approval from hospitals
ethics committee. Patients gave their written informed consent. A cross-
sectional analysis was performed. Patients were stratified according to
cART use: naı¨ve, on NVP-cART and EFV-cART. Anthropometric and clini-
cal data (age, CD4 cell count, viral load, kidney and liver function para-
meters, hepatitis B and C co-infection) were recorded for each patient.
Exclusion criteria included kidney and hepatic dysfunction. Patients with
detectable viral load in cART groups were also excluded. Thiols were
quantified by an HPLC-FD method and the RSSP-profiles were obtained.
Results: A total of 135 patients were included (70% male, 44911
years old; CD4 cell count 606922 cells/mL). Patients’ characteristics
and data obtained from thiol-omic analyses are summarized in
Table 1. Among naı¨ve patients, there was no association between
viral load and any type of RSSP. Conversely, CD4 cell count was
associated with CysSSP (r0.5390, p0.014), GSSP (r0.4930,
p0.044) and CysGlySSP (r0.4508, p0.046). Multivariable
analysis of the entire cohort showed that GSSP levels were
associated with age (B: 0.04; 95% CI 0.060.02; p0.001)
and cART (B: 1.7; 95% CI 1.12.2; pB0.001). CysSSP levels were only
influenced by age (B: 1.3; 95% CI 0.81.9; pB0.001). When
compared with naı¨ve patients, EFV-cART increases GSSP and
decreased CysSSP, whereas NVP-cART influenced GSSP and CysSSP
in opposite way (Table 1).
Conclusions: Immunological status of patients is related to their RSSP-
profile, which is influenced by age and cART. EFV-cART and NVP-cART
showed an inverted GSSP and CysSSP profile. This data support the use
of RSSP-profile for the assessment of redox-modulating effects of
antiretroviral drugs.
Financial support: EXPL/DTP-FTO/1792/2013; PD/BD/105892/2014
(CGD); SFRH/BD/86791/2012(NMG).
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Table 1. Patient characteristics and data attended from thiol-omics analysis
Variable Healthy volunteersa Naı¨ve NVP EFV p
N 63 22 30 83 
Age (years) NA 41.699.9 47.9910.1 43.30911.1 ns
CD4 cell count (cell/mL) NA 478.69192.2 600.29300.5 641.79239.0 0.025b
Viral load (copies/mL)  43,096955,670 BQL BQL 
Total Hcys (mM) 11.394.4 10.593.7 11.493.6 12.694.9 ns
HcysSSP (mM) 9.393.6 8.293.4 9.993.4 10.594.5 0.039c
Total Cys (mM) 237.1936.6 215.7938.7 223.9935.0 193.3938.4 B0.001b
CysSSP (mM) 156.8928.4 166.9929.2 180.6931.6 145.9936.3 B0.001b
Total GSH (mM) 5.891.8 2.491.2 1.790.5 3.991.9 B0.001c
GSSP (mM) 2.391.2 1.590.8 0.990.4 2.791.5 B0.001c
Total CysGly (mM) 19.793.9 24.695.6 27.495.9 32.996.3 B0.001b
CysGlySSP (mM) 11.993.0 17.894.9 21.495.0 24.795.0 B0.001b
Data are presented as mean9SD. BQL, below quantification limit; NA, not available; ns, not significant. aData from Rossi et al., 2009 [4];
bone-way ANOVA; cKruskalWallis test.
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Introduction: EVG/COBI has shown high rates of efficacy and when
combined in the single-tablet regimen (STR) with emtricitabine/
tenofovir-alafenamide (F/TAF) improved bone and renal safety in
treatment-naı¨ve and treatment-experienced participants compared
with F/tenofovir disoproxil fumarate (F/TDF).We evaluated the clinical
consequences of use of the PIM amlodipine, a medication which has a
caution and recommendation for clinical monitoring when adminis-
tered with EVG/COBI/FTC with either TDF or TAF, in nine large phase 3
clinical trials.
Materials and methods: We retrospectively pooled data from five
treatment-naı¨ve studies (GS-US-292-0104, GS-US-292-0111, GS-US-
236-0102, GS-US-236-0103, GS-US-236-0128) and four treatment-
experienced studies (GS-US-292-0109, GS-US-292-0112, GS-US-236-
0115, GS-US-236-0121) to assess AEs associated with concomitant
use of amlodipine. All participants received EVG/COBI/emtricitabine
combined in an STR with either TDF or TAF. Drug-specific AEs were
obtained from Micromedex and Lexi-Comp. We evaluated the
following: (1) AEs occurring in 10% of participants, (2) AEs leading
to premature discontinuation and (3) drug-specific grade 24 AEs.
Statistical comparisons between users and non-users of the PIM
were conducted using two-sided Fisher exact tests.
Results: Of the 4667 participants, there were 153 who received
amlodipine (mean age 50 years, 75% male and 46% Caucasian). See
Table 1.
Although there was no difference in all-grade adverse events between
amlodipine users and non-users, amlodipine users had higher rates of
drug-specific AEs: (1) peripheral edema (4.6% with and 0.4% without
amlodipine, pB0.001) and (2) nervous system disorders (2.6% vs.
0.8% with and without amlodipine, p0.035). Although participants
on amlodipine had a higher overall STR discontinuation rate than non-
users, only one discontinuation event could be considered due to an
amlodipine-specific AE (local swelling).
Conclusions: Overall AEs and discontinuations due to drug-specific
AEs were similar in participants who did or did not use concomitant
amlodipine. Amlodipine-specific AEs were higher for participants
using amlodipine, but only one participant discontinued EVG/COBI/
F/TDF or EVG/COBI/F/TAF due to an amlodipine AE. Because EVG/
COBI/F/TDF or EVG/COBI/F/TAF can increase the level of amlodipine
when co-administered, clinical monitoring is recommended.
P315
Real-world antiretroviral plasma levels in HIV-positive
patients treated with sofosbuvir-containing DAA for
hepatitis C infection
Massimo Tempestilli1; Gabriele Fabbri2; Laura Timelli2;
Mauro Zaccarelli2; Rita Bellagamba2; Stefania Cicalini2;
Federico Lupi2; Anna Gallo2; Raffaella Libertone2; Simone Fazio1;
Andrea Antinori2 and Adriana Ammassari2
1Clinical Immunology and Pharmacology Laboratory, National
Institute for Infectious Diseases, Rome, Italy. 2Clinical Department,
National Institute for Infectious Diseases, Rome, Italy
Introduction: Drugdrug interactions (DDI) between hepatitis C
direct-acting antiviral agents (DAA) and HIV ARVs are frequent. To
date, most information has been obtained from phase 1 DDI studies
in healthy volunteers and drug combinations permitted in phase 2
and 3 HIV/HCV co-infection trials [1,2]. Aim of this study was to
investigate ARV plasma trough levels before and during sofosbuvir
(SOF)-based treatment in HCV/HIV co-infected patients treated in the
real-world setting.
Material and methods: This study is a monocentre, prospective, open-
label, observational cohort study. HIV/HCV co-infected persons under-
going HCV treatment with standard dose of DAA and antiretrovirals
are enrolled. Patients also need to receive the same ARVs for at least
2 weeks before starting DAA treatment and to have HIV RNA B40
copies/mL at baseline. Antiretroviral regimen is prescribed by clinical
care providers based on antiretroviral treatment history, previous HIV
genotypic resistance testing, tolerability and recommendations for
management of HCV/HIV co-infected persons in need of HCV
treatment. The Ctrough of ARVs is measured using a validated high-
performance liquid chromatography (HPLC). Blood samples are
collected before and after 2 months of DAA treatment. For the
purpose of this analysis, estimated change of Ctrough from before to
during DAA was obtained by using a random effect linear regression. A
minimum of seven Ctrough coupled values for each ARV were required
for final statistical analysis.
Results: To date, 66 out of 91 enrolled patients were analyzed: 27
received SOFLDV (40.9%), 16 SOFdactatasvir (24.4%), 6
SOFsimeprevir (9.1%) and 17 SOFribavirin (25.8%). Concurrent
ARVs included atazanavir (n8), darunavir (n19), raltegravir
(n19), efavirenz (n7), etravirine (n8) and rilpivirine (n8).
No statistically significant difference in Ctrough of considered ARVs was
found in samples obtained before and during SOF-based treatment
(Figure 1). In 2/66 patients (3.0%), at least one HIV RNA detectable
40 copies/mL during SOF-based treatment was observed. Con-
sequences of loss of virological suppression, such as resistance
development or treatment change, are still under observation.
Conclusions: In this large HIV/HCV co-infected patient population
observed in the real-world setting, no significant modifications in
Table 1. Frequency of adverse events between amlodipine
users and non-users
All-grade AEs
occurring in
10% of
participants
Drug-specific
grade 24
treatment-
emergent AEs
Treatment-
emergent AEs
leading to
premature DC
Amlodipine
(n153)
49% 14% (22) 5.2% (8)
No amlodipine
(n4514)
47% 5.3% (237) 2.3% (105)
p NS B0.001 0.031
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ARV concentrations during SOF-based DAA treatment were observed
for the most commonly used antiretrovirals. Nonetheless, loss of
virological suppression does occur during DAA treatment and thus
monitoring of plasma drug levels and viral load is advisable.
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Introduction: Regarding the published data, the overall medication
error rate in HIV patients admitted to a hospital varies between 5.8%
and 86% [1], depending on the methodology and study duration.
Admission of an HIV-infected patient by a physician not specialized
in infectious diseases could be a risk factor for drug-related
problems. Most of the described errors are prescribing errors [2,3],
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Figure 1. Median Ctrough plasma concentration of atazanavir, darunavir, efavirenz, rilpivirine, etravirine and raltegravir before and during
SOF-based treatment.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
224
highlighting the need for a detailed and accurate medication
reconciliation on admission.
Materials and methods: Descriptive observational study. HIV-
infected patients with any ART admitted to a hospital ward were
included. The study lasted 5 months (MarchJuly 2015).The primary
outcome was the ART error rate. Secondary outcomes included the
following: type of ART error; omission of treatment, wrong schedule,
wrong dose, wrong drug, pharmacologic interaction (classified as
potential interaction or forbidden co-administration according to the
University of Liverpool classification of interactions); error rate in
each type of ward (medical or surgical); number of times error reach
to patient; time until correction of medication errors. A clinical
pharmacist reviewed prescriptions of all hospitalized HIV patients
with ART on a daily basis. Medication reconciliation was made
comparing outpatient medication records with the treatment
prescribed to the patient at admission. The pharmaceutical inter-
vention was carried out through a text message associated with the
electronic prescription and a phone call to the physician in charge of
the patient. Subsequently, the degree of acceptance of interventions
was evaluated.
Results: In total, 105 HIV patients were admitted to our hospital
during follow-up period, with a total of 124 admissions. Patients had
a mean (SD) age of 49 years (98.48) and 73.4% were male. A total of
32 patients (30.5%) had at least one error. We detected a total of 41
errors (Table 1).
A total of 13 forbidden co-administration and 505 potential
interactions were detected. However, pharmacist intervention was
necessary only in two patients with contraindicated combinations
(protease inhibitorstatins), the rest was controlled by HIV
physicians. Error rate was similar in both surgical and medical wards
(34% and 33%, respectively). A total of 29% of errors reached to
patients. Patients were exposed to errors a median time of 54 hours.
In total, 46.3% of pharmaceutical interventions were accepted.
Conclusions: Error rate was as high as in other studies. Medication
reconciliation on admission by a pharmacist helps to correct these
errors. Collaboration between hospital pharmacists and HIV unit with
physicians not specialized in infectious diseases, and the develop-
ment of strategies are needed to prevent medication errors in HIV
patients at admission.
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Introduction: Tenofovir (TDF) is one of the most widely used
antiretroviral drugs. Despite the high degree of tolerability, a small
percentage of patients experienced alteration in tubular function
during TDF use. Intracellular TDF disposition is regulated by ATP-
binding cassette (ABC) drug efflux transporters, and a reduced
transport activity may be implicated in accumulation of TDF into the
cells. The aim of our study was to assess the major determinant of
TDF-associated tubular dysfunction in a real-life setting including the
usefulness of single-nucleotide polymorphisms (SNPs) mapping into
ABCC2, ABCC4 and ABCC10 genes.
Materials and methods: We retrospectively analyzed all HIV-positive
patients who were followed at the Infectious Diseases Unit, DIBIC
Luigi Sacco, University of Milan from April 2013 to June 2015. All
patients treated with TDF during their antiretroviral history were
evaluated for the functional variants mapping in ABCC2 (24 CT/
rs717620 and 4544 GA/rs8187710), ABCC4 (3463 AG/
rs1751034) and ABCC10 (rs2125739 TC). Kidney tubular dysfunc-
tion (KTD) was defined as the presence of urine phosphate wasting
and/or proteinuria at 24-hour urine analysis.
Results: During the period of observation, 158 patients were selected
and genotyped; 42 (26.6%) patients experienced a KTD and 116
(73.4%) had a normal tubular function. No statistically significant
differences were observed among these two groups of patients
regarding age, gender and ethnicity; non-Caucasian patients were two
(4.8%) and three (2.6%), respectively. No differences were also
observed in the distribution of hypertension and diabetes among
groups. Patients who experienced KTD had a longer median duration
of therapy in TDF than patients without KTD (6.3 years (interquartile
range (IQR) 2.59.2) vs. 4.9 (IQR 1.97.9); p0.09) and a higher
prevalence of bone disease (23 (54.8%) vs. 32 (27.6%); p0.002). The
percentage of patients with KTD was higher among those with ‘‘GG’’
genotype at rs1751034 of ABCC4 compared to patients with normal
tubular function (6 (14.3%) vs. 4 (3.5%), p0.01) (Figure 1).
No statistically significant differences were observed regarding the
distribution of ABCC2 and ABCC10 SNPs. Carriers of ‘‘G’’ allele in
homozygous status at rs1751034 of ABCC4 showed a significant
association with KTD (odds ratio 4.67, 95% CI 1.2517.46, p0.02)
Abstract P316Table 1. Medication errors detected during the study
Type of errors (%) Description
Example of drugs
affected (ratio)
Wrong dose (34) It was prescribed to be taken one tablet instead of two. Or it was prescribed to be taken 300
mg/24h in patients with CrCl B50 mL/min
LPV/r (4/14) or 3TC (3/14)
Wrong schedule (29) It was prescribed to be taken once daily instead of twice daily, or vice versa ETR (5/12); RAL (2/12)
Omission (22) The rest had partial omission of treatment All treatment (4/9)
Wrong drug (15) It was prescribed TDFFTC ABC3TC (4/6)
3TC, lamivudine; ABC, abacavir; CrCl, creatinine clearance; ETR, etravirine; FTC, emtricitabine; LPV, lopinavir; r, ritonavir; RAL, raltegravir; TDF,
tenofovir.
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in bivariate analysis, but this association was lost in multivariable
analysis.
Conclusions: In our real-life cohort, 26% of patients treated with TDF
manifested signs related to kidney tubular dysfunction. According to
our results, ABCC4 rs1751034 should be a genetic determinant of
KTD; however, further validation studies are needed for therapy
personalization.
P318
Prevalence of drugdrug interactions involving
antiretroviral treatment: impact of the integrase inhibitor
class
Peter Messiaen; Charlotte Baecke and Jeroen van der Hilst
Department of Infectious Diseases & Immunity, Jessa Hospital,
Hasselt, Belgium
Introduction: ARV agents pose a high risk for drugdrug interactions
(DDIs) with other ARV and non-ARV drugs. Induction or inhibition of
different cytochrome P450 enzymes by protease inhibitors (PI) or
non-nucleoside reverse transcriptase inhibitors (NNRTI) is one of the
major but not exclusive metabolic pathways potentially leading to an
increased risk of toxicity or loss of efficacy of ARV and non-ARV
drugs. Partly metabolized by other pathways, the integrase inhibitor
(INI) class might show a more favourable profile. The aim of this
study was to investigate the prevalence of potential DDIs in patients
who recently started ARV and to evaluate the effect of INI
introduction.
Materials and methods: The study population comprised all patients
starting ART in our centre from 2009 till April 2016. All prescribed
comedications since start of ARV were recorded retrospectively from
the medical files. The complete treatment was screened for DDIs
using the most recent version of the University of Liverpool HIV
Drug Interactions database (www.hiv-druginteractions.org). DDIs
were scored as absent, potential, contra-indicated or not assessable
due to lack of data.
Results: Of the 145 patients included, 28% (n41) were treated on
an NNRTI-based regimen, 30% (n44) on a PI-based regimen and
42% (n61) on an INI-based regimen. Dolutegravir (69%, n42)
and elvitegravir (30%, n18) were the most prescribed INIs. A total
of 78% (n113) of the patients took comedication. Polypharmacy
(]5 comedications) was seen in 26% of patients, significantly
correlated with age (p0.024). Potential DDI was seen in 63%
(n71) of the patients with comedication and in 32% (160/503) of
all non-ARV prescriptions. These involved mainly antimicrobial drugs
(33%), cardiovascular drugs (19%) and central nervous system drugs
(19%). Contra-indicated prescriptions were detected in 1% (n6),
disproportionally more involving gastro-intestinal drugs (66%). PI-
based ART was an independent risk factor for potential or contra-
indicated DDI (odds ratio (OR) 2.36; 95% CI 1.144.90; p0.030).
There was no higher risk associated with NNRTI-based ART (OR 0.66;
95% CI 0.321.36) as well as for INI-based regimens (OR 0.64; 95% CI
0.331.25). A significantly lower risk for drug interaction was seen
with dolutegravir-based treatment (OR 0.47; 95% CI 0.220.98;
p0.046), though not for elvitegravir-based ART (OR 1.76; 95% CI
0.644.82).
Conclusions: Integrase inhibitor use did not result in lower or higher
risk for drugdrug interactions in our patient cohort. However,
dolutegravir-based treatment showed a significantly lower risk for
DDIs, which was not the case for elvitegravir.
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Introduction: Efavirenz (EFV) is primarily metabolized by hepatic
cytochrome P450 (CYP) 2B6, which is genetically polymorphic.
Genotype 516TT is associated with decreased plasma clearance of
EFV and a higher incidence of neurologic complications. The
pharmacokinetic difference between 516GG and 516GT after long-
term use of EFV has however received less attention.
Methods: Therapeutic drug monitoring (TDM) is available as a
supplemental clinical service to HIV patients receiving HAART in
Hong Kong. A high-performance liquid chromatography system has
been in operation for about 10 years. Mid-dose plasma level of EFV of
patients started on an EFV-based treatment regimen at year 1 (defined
asmore than 2months and less than 2 years) were evaluated. As a sub-
study, EFV-treated patients of Integrated Treatment Centre with blood
tests done at two or more time points were analyzed.
Results: TDM results of 95 patients were examined in the first part of
the study. The mean age at diagnosis of these patients was 40.0 years
(SD 11.7), of which, 93 (97.9%) were male. Their CYP2B6-516
genotypes were as follows: GG 48 (50.5%), GT 37 (38.9%) and TT
10 (10.5%), the distribution of which was in HardyWeinberg
equilibrium. At year 1, the mean EFV level of GT was high at 8.78
mg/L (SD 2.66). The difference between GG and GT was statistically
significant (2.8991.26 mg/L vs. 3.6591.26 mg/L, t test pB0.01). No
significant difference in EFV level between GG and GT could be seen
over time when exploring data from 62 patients in the sub-study.
Conclusion: EFV level in patients with GT genotype of CYP2B6-516 is
generally higher than those with GG genotype in the first 2 years
after initiation of EFV regimen. Nevertheless, the difference of EFV
level between two genotypes is not significant when temporal
changes were evaluated. Differential pattern of auto-induction may
explain the results elicited in this study. Extrapolation of the results is
however cautioned in view of the small number of patient samples
tested, which may also be compounded by the high inter- and intra-
individual variation of plasma EFV levels.
COMMUNITY INITIATIVES
P320
European survey on doctorpatient relationship
Figure 1. Distribution of different genotypes at rs1751034 of
ABCC4 in patients with or without KTD. *x square.
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Introduction: The European AIDS Treatment Group (EATG) conducted
a survey in February 2016 to provide a snapshot on patient
experience with their HIV clinicians. During 1 week, 357 responses
from 34 countries were received (74% male, 23% female, 1% trans,
2% N/A, all age groups 1880 were represented in the responses).
Method: A pan-European online survey consisting of 37 questions
was undertaken using existing networks from across Europe to
promote the survey in order to better understand the current care
continuum from across the region.
Results: While there generally is a high level of trust  88% of the
survey participants have answered ‘‘yes’’ to the question ‘‘do you
trust your HIV doctor?’’  the survey results reveal areas where
further efforts on the European level are necessary. Figure 1 shows
what topics are being addressed during patients’ appointments with
their doctors. In this light, ‘‘Treatment Options’’ (73%), ‘‘Side Effects’’
(65%) and ‘‘Diagnostics’’ (62%) are the most frequently addressed
topics.
Given the high importance of the topics of ‘‘Adherence’’ and ‘‘Sexual
Health,’’ it is particularly surprising that only 35% and 39% of the
participants, respectively, indicated that they discuss these topics
with their doctors. Even much less frequently social or psychological
issues such as ‘‘Recreational Drug Use,’’ ‘‘Legal Rights,’’ ‘‘Reproduc-
tive Choices,’’ ‘‘Social Concerns’’ or ‘‘Mental Health’’ are being
discussed. Almost all the topics are addressed less when patients do
not trust their HIV doctor. When asked if test results are being
explained to them, 57% of participants replied that test results are
explained to them very well, 30% replied that this is only sometimes
the case and 13% either never receive an explanation or do not
understand it. With regard to treatment options, only 56% of the
survey participants indicated that they are given a choice between
treatment options while this was not the case with 44%.
Conclusion: Understanding test results and having a voice in the choice
of treatment and care options are central elements for an empowered
patient. Whilst the outcome shows that in general patients trust their
doctors, there appears to be missed opportunities to identify what
really matters to patients and the long-term management of good
health. Whilst limited time is a pressure, a broader conversation is
needed by both doctors and patients to address the medical, social and
psychological aspects of living with HIV.
P321
HIV testing in the community: responding to the Glasgow
outbreak
Lee Middleton
NHS Greater Glasgow and Clyde Addiction Service, South West
Community Addiction Team, Glasgow, UK
Introduction: In 2015, an outbreak of HIV was noted in the
population of people who inject drugs (PWID) in Glasgow [1]. By
August 2015, over 40 individuals had been identified, where previous
years had an annual average of 10 [2]. Dry blood spot testing (DBST)
is a non-invasive way to diagnose HIV which can be quickly
completed in a community setting.
Aims: Increase access to HIV testing for opiate replacement therapy
(ORT) patients linked to the South West Community Addiction Team
(SWCAT), via DBST, improve acceptability and uptake of HIV testing
among target group; increase awareness amongst staff and patients
of the outbreak and importance of prevention and testing.
Materials and methods: This project used a two-pronged approach.
Awareness campaign. Briefing delivered to SWCAT integrated staff
team (NHS Greater Glasgow and Clyde and Glasgow City Council);
this encompassed both raising awareness of the outbreak and the
importance of increasing testing rates. Poster campaign in clinic
premises in conjunction with European HIV-Hepatitis Testing Week; a
dialogue began with patients regarding the benefits of screening and
to begin to move away from focusing on risk-taking behaviour and
any sense of stigma. DBST. Testing period identified (initially 1 week
 extended to 4 due to high uptake rate). Targeted approach by staff
to promote testing to patients. Identified medical officer available
throughout testing period at each ORT clinic. Instant access to DBST
for those accepting the test.
Results: A total of 148 ORT patients were identified attending clinics
at SWCAT in November/December 2015. All 148 were offered HIV
tests at their clinic appointments. Of this group, 146 (98.6%)
accepted the tests, which were completed at the same appointment.
Conclusions: The uptake of HIV tests in SWCAT significantly exceeded
all expectations. The results show that HIV testing in a community
setting, when offered instantly with a ‘‘no-wait’’ approach during an
awareness campaign, can be made both highly accessible and
acceptable to a population engaged with an ORT programme. By
switching the focus of the test away from risk-taking behaviour
towards health promotion, it allowed patients to actively make
decisions about their health and fully engage with the process.
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Introduction: HIV testing rates are low among men who have sex
with men (MSM) and transgender (TG) individuals who contribute
50% of new HIV infections in Thailand [1,2]. Online supervised,
finger-prick, HIV self-testing and counselling (eHTC) is an innovative
strategy to expand early testing among Thai MSM and TG. We
studied acceptability and uptake of this strategy.
Methods: In December 2015, the Thai Red Cross AIDS Research Centre
(TRCARC) launched an Online Test and Treat implementation research
project to explore approaches to engage and retain ‘‘hard-to-reach’’
MSM and TG, in HIV testing and care. Participants recruited and
enrolled online via TRCARC’s Adam’s Love (www.adamslove.org) could
choose between (1) eHTC with real-time guidance from counsellors or
(2) online counselling followed by private clinic-based testing.
Questionnaires assessed reasons for choosing eHTC over clinic-based
testing, and feelings post-eHTC utilization.
Results: Between December 2015 and May 2016, 99,110 MSM and TG
were reached via online study promotions, 264 were screened, 153
(58%) passed the eligibility criteria and 97 (36.7%) were successfully
enrolled. Among 97 individuals, 25 (25.8%) selected eHTC while 72
(74.2%) opted for online counselling followed by clinic-based testing.
YoungerMSM/TG, (median age 25 vs. 29 years, p0.006), less frequent
(previous test 1 year) and first time testers (47.37% vs. 17.74%,
p0.01) and those having previous STIs (20% vs. 11.11%, p0.015)
were more likely to prefer eHTC than clinic-based testing. High-risk
behaviours were similar in both groups, with high social media sex-
seeking80% and consistent condom use in the past 6monthsB28%.
HIV prevalence was significantly higher among eHTC than clinic-based
testing participants (16% vs. 1.4%, p0.02). Preference for eHTC was
guided by logistic/time convenience (79%), scheduling flexibility (7%),
confidentiality (7%) and altruism (7%). Reasons for declining eHTC
included stigma of receiving self-testing kit at home (40%), fear of one’s
own lack of understanding of self-testing and receiving results alone
(28%), fear of finger-prick (24%) and fear of internet glitches while video
chatting with counsellors during guidance (8%). Positive perceptions
(‘‘it’s good and convenient,’’ ‘‘it’s amazing,’’ ‘‘HIV testing is normal now’’)
increased pre- and post-HIV self-testing from 38% to 85% and negative
perceptions (‘‘I feel anxious,’’ ‘‘I am scared’’) decreased from 38% to 8%.
Conclusions: eHTC is feasible to reach high-risk Thai MSM and TG
who never or infrequently previously tested for HIV. eHTC has high
potential to be scaled up to reach harder-to-reach populations for
the first target of UNAIDS 909090 targets [3,4].
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with HIV, Amsterdam, Netherlands. 3OptTEST, CHIP, University of
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Introduction: Recent HIV continuum of care data from the European
Centre for Disease Prevention and Control [1] shows 78% of
responding countries had significant break points relating to
diagnosis, 41% in linkage to care and 48% in subsequently accessing
treatment. Break points involving care/treatment are far greater in
non-EEA countries but exist across Europe. Two-thirds of countries
identified legal or policy issues contributory to such gaps.
Methods: A literature review done between January and October
2015 for Optimizing Testing and Linkage to Care for HIV across Europe
(OptTEST) [2] included 54 documents, including academic and grey
literature, identifying a wide range of legal and regulatory barriers.
Results: Legal barriers identified included criminalization of HIV
transmission and perceived exposure; criminalization of key popula-
tions, for example, drug users and sex workers; failure to provide legal
protections for these and others, for example, MSM and transgender
people. These acted to deter access to HIV services and to impede
disclosure of risk activities which might otherwise trigger TasP.
Immigration law deterred official access to healthcare for many
undocumented migrants and denial of/poor access to ART existed in
a number of prison and immigration detention systems. Drug laws in
particular were shown to act to increase HIV and decrease access to
care, while their reform can directly act to reduce HIV transmission (e.g.
in Portugal) [3]. Regulatory barriers were less well documented but
there was extensive coverage of testing. Outdated guidelines alongside
restrictive practices and regulations acted to hinder proven new testing
technologies and settings, including restrictions on who can administer
tests; requirement of extensive pre-/post-test counselling; refusal to
accept referrals from community testing into care; limited testing sites
and restricted types of test. Wider barriers to improving the continuum
of care included separation of healthcare into vertical specialities (e.g.
drugs care separate from HIV and from TB); lack of case management
systems; failure to integrate healthcare and social support; disruption of
care between civil and detention authorities. Complex entitlement
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regulations and charging systems deterred migrants, including even
those entitled to healthcare sometimes.
Conclusion: Findings suggest a need for consistent, updated
evidence-based guidelines for testing and care across Europe and
guideline implementation; for reform of laws based on stigma rather
than evidence and practices based on custom rather than current
knowledge; for better dialogue between policymakers, clinicians,
NGOs and people with HIV/in key populations about the actual legal
and regulatory barriers which hinder achievement of 90/90/90.
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Introduction: In the World Health Organization European Region, it is
estimated that approximately 2.5 million people are living with HIV
(PLHIV) [1] and around 13 and 15 million are living with hepatitis B
(HBV) and C viruses (HCV), respectively [2]. Around one in three is
unaware that they are living with HIV [3,4] and one in three people
has been exposed to either HBV or HCV [2]. European HIV-Hepatitis
Testing Week (ETW) is a partnership between civil society, healthcare
professionals, governmental and other policy organizations. A
dedicated website (www.testingweek.eu) provides a hub for inter-
ested organizations to sign up and download materials to support
planned activities.
Materials and methods: ETW 2015 took place from 20 to 27
November 2015. All participating organizations were invited to
complete an online evaluation survey with questions about their
carried out ETW activities. Data were entered into the Research
Electronic Data Capture system (REDCap) hosted at CHIP, Rigshospi-
talet, University of Copenhagen. Five electronic survey reminders
were sent prior to the survey deadline, 15 January 2016. Data were
extracted in Excel format from REDCap and descriptive statistics were
produced as frequencies and respective proportions in Excel.
Results: Of the 417 organizations that signed up, 194 from 39
countries submitted the evaluation survey (46.5%). The majority of
respondents were NGOs (65.5%) followed by healthcare profes-
sionals/hospitals/clinics (18.0%) and governmental and other policy
organizations (9.3%). The majority of respondents carried out testing
activities (Figure 1) and awareness-raising activities.
Several respondents reported testing for more than one of the three
conditions during ETW (Table 1).
The percentage of respondents reporting increase in testing during
ETW compared to an average week was 78% for HIV, 74% for HBV
and 70% for HCV. ETW has brought forward many innovative best
practice examples from all over Europe of how testing and awareness
raising can be done. Examples include designing of coffee cup sleeves
promoting HIV testing distributed to coffee shops throughout
Dublin, dissemination sessions in the streets, use of rapid tests, for
example, via a mobile clinic in Kiev doing outreach testing to MSM
and collaboration across sectors and between organizations and
institutions.
Conclusions: Several organizations tested for HIV, HBV and HCV (35)
and reported significant increases in testing during ETW. ETW has
proven to be an efficient initiative in uniting Europe in promoting
testing and in increasing testing for HIV, HBV and HCV through
innovative activities carried out by ETW participants.
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Figure 1. Activities during ETW (N194).
Table 1. Organizations carrying out testing activities during
ETW (N194)
HIV
testing
HIV &
HBV
testing
HIV &
HCV
testing
HBV &
HCV
testing
HIV, HBV
& HCV
testing
Organizations,
N (%)
158 (81) 37 (19) 59 (30) 36 (19) 35 (18)
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Introduction: The HIV epidemic remains a major global health issue.
Data from cost-effectiveness analyses are usually based on CD4
counts and morbidity. Here, we evaluate the impact of sexual HIV
transmission due to delayed cART on the cost effectiveness of care.
Methods: A lifetime Markov model (1-month cycle) was developed
to estimate lifetime costs, clinical outcomes and cost per quality
adjusted life years (QALY) gained for 1- and 3- year delay in starting
cART (as compared to staring immediately at linkage to care). Health
states included into the model were asymptomatic HIV, AIDS defining
condition (mild, moderate, severe) [1], Hodgkin’s Lymphoma and
non-AIDS defining condition (20 illnesses/events in total). Mor-
tality rates and utility values were obtained from published
literature. The number of new infected persons was estimated based
on sexual orientation, number of sexual partners per year, number of
sex acts per month, frequency of condom use and use of cART [2].
We assumed that patients had HIV RNA B50 copies/ml immediately
since starting cART and for a lifetime. Transmission risk was
presented for three scenarios: low, medium and high (Table 1).
For the input data Test and Keep in Care (TAK) project, cohort pre-
clinical and clinical information was used [3]. Costs of care, cART and
potential life-years lost were based on estimated total costs and the
difference in expected QALY gained between HIV positive and
average person in Polish population. Analysis was performed from
the public payer perspective therefore costs were based on real
expenditures of Ministry of Health (MoH), National Health Fund,
available studies [1618] and expert’s opinion. Costs and effects
were discounted at rates of 5% and 3.5%, respectively. Cost-
effectiveness threshold for incremental cost-utility ratio (ICUR) was
set to 125 955 PLN (29 312 EUR) according to MoH requirements.
Results: Input data were available for 141 patients from TAK cohort.
Estimated number of new HIV infections for low, medium and high-
risk scenarios were 0.28, 0.61, 2.07 and 0.82, 1.80, 6.11 with 1-year
and 3-year delay, respectively. This reflected QALY loss due to cART
delay of 0.52, 1.13, 3.84 and 2.02, 4.43, 15.03 for 1 and 3-year delay,
respectively. If additional costs of treatment and potential life-years
lost due to new HIV infections were not taken into account, initiating
cART immediately at linkage to care was not cost effective
irrespective of cART delay. When additional costs and QALY lost
were included, immediate cART initiation was dominant (cheaper
and more effective) regardless of the chosen scenarios (Table 1).
Conclusions: Accounting for HIV transmission in cost-effectiveness
analysis provides further evidence supporting immediate-initiation of
HIV treatment from a public payer perspective.
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Introduction: Targeted HIV testing has been proposed as the most
efficient strategy for HIV diagnosis in low prevalence populations. We
aimed to compare cost effectiveness of three HIV testing targeted
approaches, previously validated, to predict HIV infection.
Methods: All participants in DRIVE study (non-targeted HIV testing
program in emergency department and primary care centre (PCC))
were tested for HIV and filled out a self-administered HIV Risk
Exposure and Clinical Conditions Questionnaire (RE&CI-Q). The
RE&CI-Q included six questions to evaluate risk of exposure to HIV
and 14 HIV-associated clinical indicators (from HIV Indicator Diseases
across Europe Study (HIDES) list [1]). One affirmative answer defined
the person as being at risk. The other two tools evaluated were as
follows: Denver HIV Risk Score (DHRS) with a cut-off 30 and HIDES
using only 14 clinical indicators. Using DRIVE study database, we
calculated sensitivity (Sn), specificity (Sp), positive predictive value
(PPV) and negative predictive value (NPV) of the three tools,
considering the gold standard confirmed cases of HIV infection
with EIA/WB. Number of missed HIV infections (NMHI), tests avoided
and incremental costs/effectiveness ratio (ICER) were also calculated.
Results: A total of 5329 participants of age 1860 years completed
RE&CI-Q and rapid HIV test in the DRIVE study (69.3% in PCC). In
total, 50.4% women and median age 37 years (2847). Confirmed
new HIV infection was detected in 22 (0.41%) with this non-targeted
strategy. The percentages of population identified at risk for HIV
infection by a positive RE&CI-Q, DHRS 30 and at least one item of
14 HIDES list selection were 51.2%, 39.7% and 26.9%, respectively.
Sn, Sp, PPV, NPV, NMHI and test avoided were 100%, 49%, 0.80%,
100%, 0 and 2601, respectively in RE&CI-Q approach, 72.7%, 60.41%,
0.76%, 99.8%, 6 and 3212 in DHRS, and 91%, 74.4%, 1.4%, 99.9%, 2
and 3948 in 14 items of HIDES list. The cost per new HIV diagnosis
was 552t (HIDES), 992t (RE&CI-Q) and 1058t (DHRS). ICER per new
HIV diagnosis -66t for RE&CI-Q and -506t for HIDES respect DHRS
strategy.
Conclusions: All approaches avoided HIV tests compared with
routine strategy, but only RE&CI-Q captured all HIV-infected subjects
detected by the non-targeted strategy. Cost of each NHIVD obtained
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Abstract P327Table 1. Lifetime Markov model results for the cost per quality adjusted life years (QALY) for 1- and 3-year delay in starting cART
Without
transmission Low risk Medium risk High risk
Number of sexual
partners per year
 3 10 50
Number of monthly
sex acts
 10 20 20
Condom use per acts
pct
 90% 50% 0%
Delay treatment Category Immediate
cART
Delayed
cART
Difference Immediate
cART
Delayed
cART
Difference Immediate cART Delayed
cART
Difference Immediate
cART
Delayed
cART
Difference
1 year Sexual HIV transmission Infected person 0.00 0.00 0.00 0.01 0.28 0.27 0.03 0.61 0.59 0.09 2.07 1.99
Total treatment costs PLN 516,333 473,560 42,773 516,333 473,560 42,773 516,333 473,560 42,773 516,333 473,560 42,773
Cost of treatment new
infections
PLN 0 0 0 5,895 125,975 120,080 12,646 277,067 264,421 42,181 939,075 896,894
Total costs (total treatment
costs  cost of new
infections)
PLN 516,333 473,560 42,773 522,228 599,536 77,307 528,979 750,627 221,648 558,515 1,412,636 854,121
QALY QALY 11.29 11.15 0.14 11.29 11.15 0.14 11.29 11.15 0.14 11.29 11.15 0.14
QALY lost QALY 0.00 0.00 0.00 0.02 0.52 0.50 0.04 1.13 1.09 0.15 3.84 3.70
QALY (adj) QALY 11.29 11.15 0.14 11.27 10.64 0.63 11.25 10.02 1.23 11.14 7.31 3.83
ICUR PLN per QALY 313,484 dominates dominates dominates
3 year Sexual HIV transmission infected person 0.00 0.00 0.00 0.04 0.82 0.78 0.08 1.80 1.73 0.25 6.11 5.86
Total treatment costs PLN 516,333 369,129 147,204 516,3333 369,129 147,204 516,333 369,129 147,204 516,333 369,129 147,204
Cost of treatment new
infections
PLN 0 0 0 5,947 262,526 246,580 34,208 577,394 543,186 114,103 1,956,986 1,842,882
Total costs (total treatment
costs  cost of new
infections)
PLN 516,333 369,129 147,204 532,280 631,656 99,376 550,541 946,523 395,982 630,437 2,326,115 1,695,678
QALY QALY 11.29 10.35 0.94 11.29 10.35 0.94 11.29 10.35 0.94 11.29 10.35 0.94
QALY lost QALY 0.00 0.00 0.00 0.06 2.02 1.96 0.12 4.43 4.31 0.41 15.03 14.62
QALY (adj) QALY 11.29 10.35 0.94 11.23 8.33 2.90 11.17 5.91 5.25 10.88 4.68 15.56
ICUR PLN per QALY 156,335 dominates dominates dominates
Dominates  cheaper and more effective.
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using RE&CI-Q compared to HIDES list is low with respect to the
benefit obtained.
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Introduction: Linkage to care is one of the essential steps in HIV
cascade of care. To evaluate the impact of an active intervention
aimed to shorten time from first HIV EIA result to first HIV outpatient
clinic visit.
Methods: From 1 January to 30 June 2015 (first period) and 2016
(second period), we identified all first positive HIV EIA (HIV) results
obtained in the Microbiology Laboratory Department of Ramo´n y
Cajal Hospital (RyC). All samples came from two main settings:
hospital departments (HD) or primary health area (PHA). In 2015
period, HIV results were electronically informed and when possible
prescriber physician was alerted by phone, that a second sample
needs to be sent to confirm serology. In the 2016 period addition to
the above mentioned, all HIV results were weekly identified, and
we phoned the requesting physician informing the HIV result and
recommending that the confirmation and the first HIV visit should be
done as soon as possible at the HIV RyC outpatient clinic. Number and
result of HIV tests, linkage to care at RyC HIV clinic or other clinic (rate
and time to first visit) were compared between the two periods.
Results: Overall 21,049 first tests were requested (9969 and 11,072
in first and second period). Absolute number and rate of new HIV
diagnoses (NHIVD) were 111 (0.53%) (60 (0.61%) and 51 (0.46%);
p0.16). No differences were observed in NHIVD in first and second
period according to sex (women 20% vs. 12%; p0.3), age (38 vs. 37
mean years; p0.6) or setting (HA 35% vs. 35%; p1) between first
and second periods. From patients with at least 1 month of follow-up
(108), unadjusted rate of linkage to care was 50/60 (83.3%) versus
46/48 (95.8%); p0.04, for first and second period. Mean time to
linkage to care was (829157 and 27931 days; p0.019). In an
unadjusted analysis, age and setting (HD or PHA) presented same
rate of linkage to care, while women had lower rates. In an
estimative model, only a trend towards a higher probability to
linkage to care was observed for second period (OR 4.6 (09;22.3);
p0.07), when it was adjusted by sex.
Conclusions: A higher rate of linkage to care was observed in the
intervention period, but the effect was attenuated by sex.
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Retention of motherbaby pairs in care and treatment
through motherbaby care point initiative in Eastern
Uganda
Mary Abwola Olwedo; Noah Lukoda and Bud Crandall
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Introduction: The Ugandan Ministry of Health adopted Option B in
2013 for the elimination of mother-to-child transmission of HIV. This
required the mother to attend multiple services delivery points for
eMTCT program and ART clinic for her care and treatment as well as
the baby’s EID services after birth. The mothers didn’t want to visit
the ART clinic after birth because of stigma. The MoH became
concerned over high loss-to-follow-up rates and introduced mother
baby care point within the MCH department.
Methods: In 2014, the MoH recommended the establishment of
motherbaby care points within MCH departments, where midwives
provide daily one-stop services to mothers receiving Option B with
their HIV-exposed infants until child is 18 months old, when mother
and child, if HIV positive, are transferred to the ART clinic.
Strengthening TB and HIV & AIDS Responses in Eastern Uganda
(STAR-E), a USAID project funded by PEPFAR and implemented by
Management Sciences for Health, supported the MoH to establish
motherbaby care points at MCH departments in 154 health
facilities in Eastern Uganda from October 2014 to February 2015
and also did an operational research to understand the impact of
MBCP as compared to the old model of implementation.
Lessons learned: STAR-E assessed for retention among 496 mother
baby pairs enrolled into Option B program during when the MBCP
had not been established in 34 health facilities and found the
following: 52% were retained at 3 months and 44% at 6 months. And
at 3 months, post-delivery period when they were transferred and
receiving services at the ART clinic, only 20% were retained. After
MBCP were established, the project reviewed records in the same
facilities from October 2014 to March 2016 and found higher
retention after delivery than earlier research. Of the 277 mother
baby pairs enrolled, 72% were retained at 3 months post-partum,
64% at 6 months, 55% at 9 months and 41% by 12 months, as most
of the babies are weaned by then, second DNA PCR done to
determine if baby has been protected.
Conclusion: Motherbaby care points, where HIV and MCH services
are integrated, improved retention of motherbaby pairs in Option
B during the post-delivery period. This enabled more of the HIV-
exposed infants to access DNA PCR twice, nutritional assessment,
cotrimoxazole prophylaxis and nevirapine prophylaxis. More HIV-
positive infants into care and treatment since they were in contact
with the health system more often and mothers were retained on
ART.
MODELS OF CARE: EVALUATION OF ARV
DELIVERY AND COVERAGE
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Efficiency of antiretroviral therapy in Russia
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Introduction: Free ART is available in Russia for PLH, who visit special
AIDS centres. According to current guidelines, ART is eligible for
patients with CD4 B350 cells/mL. At the beginning of the year 2015,
more than 200,000 PLH were on ART. The aim of this study was to
characterize the basic aspects of antiretroviral therapy among PLH
who visited AIDS centres in Russia in order to develop recommenda-
tions for new treatment guidelines.
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Methods: Multicentre, open-label study with the inclusion of a
retrospective model. We analyzed medical records and question-
naires of 7000 adult patients, who visited AIDS centres and signed an
informed consent form in 27 regions of Russia in April to July 2014.
Funding support for this study was provided by Bristol-Myers Squibb.
Results: A total of 3406 (49%) of all recruited participants were
females, one was transgender. A total of 4445 (60%) of all
participants were on ART which was initiated at mean CD4 
224.69138.9; median  216 (11400) cells/mL. Termination of
therapy in the time of the study was recorded in 10.1% of patients.
Brand name ART drugs were mainly used in the period of the study.
The most commonly prescribed ART combinations for naı¨ve patients
were as follows: ZDV3TCEFV (26.6%), ZDV3TCLPV/r
(21.7%), ZDV3TCATV/r (8.9%). The average duration of ART
was 34 months (max.  16 years), 18.7% of study participants were
on ART over 5 years. A total of 52.3% of patients received the first
ART combination, 29.1%  the second (max.  nine ART regimens in
patient). The main causes of treatment regimens change were
adverse events  43.3%, simplification (reducing the number of pills
and multiplicity)  27%, pregnancy  11.2%. Virologic failure was the
cause of ART change only in 3% of patients. A total of 83.9% of
patients in the study reached HIV RNA B1000 copies/mL and 69.1%
 less 400 copies/mL at the end of the first year of treatment.
Among patients, who have a serodiscordant regular sexual partner,
only 66.7% were on ART.
Conclusions: The majority of patients receiving ART in Russia have
not yet a very long treatment experience. CD4 level at the moment
of ART initiation was low. Though old-fashioned ART combinations
were effective and tolerable in a part of the patients, the number of
adverse effects were significant. Measures are needed to encourage
earlier ART initiation and use drugs with lower toxicity.
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Closing the gap of perinatal HIV infection in Hong Kong
Chun Kwan Bonnie Wong; Wai Chi Ada Lin and Ka Hing Wong
Special Preventive Programme, Department of Health, HKSAR,
Hong Kong
Introduction: To achieve the ultimate goal of eliminating perinatal
transmission, we reviewed and identified gaps of the current public
health programme for the prevention of mother-to-child transmis-
sion (PMTCT) of HIV in Hong Kong, a region with low HIV
seroprevalence of B0.01% in the antenatal population. The
Universal Antenatal HIV Testing Programme (UATP) was introduced
in 2001, with an aim to interrupt MTCT through timely diagnosis and
management of infected expectant mothers. The programme was
strengthened with implementation of rapid HIV testing component
in 2008 to offer rapid HIV test in labour wards for women who did
not receive testing in early antenatal period.
Materials and methods: We reviewed the programme performance,
and matched with perinatal infections reported.
Results: UATP has high coverage rate of 98% in recent years. From
2001 to 2014, 3 perinatal infections were identified out of 72 infants
born to HIV-infected mothers. All were detected before 2007, two of
which were due to late presentation to antenatal care without
participation in UATP. The other was due to failure of intra-partum
and post-partum intervention when the mother presented 6 days
prior to her preterm delivery. The incorporation of rapid HIV testing
in 2008 had filled the gap for late-presenting pregnant women so
that interventions could be offered to HIV-infected women not
identified by UATP. Since 2008, the percentage of women with HIV
test results known prior to delivery remained above 98.6%; and 97%
of HIV-positive mothers and their babies had received either three-
part or two-part ART. However, five cases of HIV-infected children
born to their infected mother who were tested negative by UATP in
the early antenatal period were reported in 20092015. Unprotected
sex during pregnancy was the common risk factor. All five mothers
and all but one of the spouses/partners were either non-Hong Kong
residents or originated from Asian or African countries where the HIV
prevalence was higher than Hong Kong, highlighting its unique
epidemiological pattern.
Conclusions: The gap in PMTCT in Hong Kong lies in the HIV-infected
women who seroconverted after they were tested negative in the
early antenatal period. Partner counselling and testing, enhancement
of safer sex, targeted HIV retesting at third trimester for pregnant
women based on their epidemiological and behavioural risks are
options to close the gap.
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‘‘The first 90’’: how close can we get with home-based HIV
testing? First results from recruitment for the CASCADE trial
in rural Lesotho
Niklaus Daniel Labhardt1; Isaac Ringera2; Thabo Ishmael Lejone2;
Josephine Muhairwe3; Christiane Fritz4; Thomas Klimkait5 and
Tracy Renee Glass6
1Medical Services and Diagnostic, Swiss Tropical and Public Health
Institute, Basel, Switzerland. 2Towards 909090 Project,
SolidarMed, Swiss Organization for Health in Africa, Butha-Buthe,
Lesotho. 3Towards 909090 Project, SolidarMed, Swiss
Organization for Health in Africa, Maseru, Lesotho. 4SolidarMed,
Swiss Organization for Health in Africa, SolidarMed Headquarters,
Lucerne, Switzerland. 5Molecular Virology, Department of
Biomedicine, University of Basel, Basel, Switzerland. 6Epidemiology
and Public Health, Swiss Tropical and Public Health Institute, Basel,
Switzerland
Introduction: The first of the UNAIDS 909090 targets aims at 90%
coverage of HIV testing and counselling (HTC) [1]. Studies on HTC at
the homes of individuals report HTC uptake (individuals tested/
individuals encountered at home) of 90% [2]. However, HTC
coverage (individuals knowing their status/individuals living in
targeted area) remains below 90% because of persons absent during
home-based HTC [3]. This study assesses the HTC coverage achieved
in Lesotho after two consecutive home visits in order to achieve
maximal coverage and to cover presence during the week and on
weekends.
Materials and methods: The study was conducted in Lesotho,
Southern Africa. Data were derived from home-based HTC cam-
paigns serving to recruit HIV-infected individuals for the CASCADE
trial (NCT02692027). Assessment of HTC coverage after two home
visits is a nested study in the published CASCADE trial protocol [4].
The primary outcome of interest was the HTC coverage in targeted
areas after two visits. Counsellors visited randomly selected villages
or urban areas moving door to door and offering HTC to all
household members. Each area was visited twice, once during the
week and once over the weekend. Household members were
defined as spending at least one night at least twice a month in
that household. The duration of the HTC campaigns was from 22
February to 3 July 2016. Data were captured on tablet computers
and synchronised daily [5].
Results: Counsellors visited 6429 occupied households with 17,887
household members in 60 rural villages and 17 urban areas; 1988
(30.9%) households were revisited because of members absent at
first visit. Among individuals encountered at home, 1381 (9.5%) were
already known to be HIV infected. Among the 13,193 with unknown
HIV status, 11,268 (85.4%) accepted HTC. HTC coverage in visited
areas increased from 62.7%, after the first visit, to 70.5%, after the
second visit (Figure 1). Table 1 shows HTC uptake and HTC coverage
after two visits, stratified by age and gender. HTC uptake was similar
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
233
among men and women, but coverage was lower among men due to
a lower proportion encountered at home.
Conclusions: A second catch-up visit on a weekend increased the
proportion of persons knowing their HIV status by 8%, but home-
based HTC still fell short of the targeted 90% coverage. Future
strategies need to combine home-based HTC with approaches
specifically tailored to frequently absent household members, such
as testing at the workplace or school-based HTC or self-testing.
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Characterization of an inmate population followed in an
infectious diseases department in the centre of Portugal
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Introduction: HIV and HCV monitoring among prison inmates is
essential in countries with a high HIV/HCV prevalence. Recent studies
on this topic are sparse in Portugal and other European countries.
The monitoring of HIV and HCV prevalence among inmates, and the
characterization of this population, might be a useful measure to
study the epidemiological situation.
Materials and methods: The HIV and HCV prevalence was estimated
among inmates of two male prisons in the centre of Portugal
(Pinheiro da Cruz and Setu´bal), followed in a medical appointment in
an infectious diseases department between 2014 and 2016. Data
were obtained from the hospital medical records. Collected informa-
tion included variables such as age, country of birth, transmission
risk, serological status and adherence to consultation and therapy.
Patients were considered as refractory to consultation if they had
fewer than two consultations per year.
Results: Approximately 1000 men were incarcerated in those prisons
at the time of data collection. In total, 82 (8%) were under follow-up in
our hospital. A total of 36 (44%) of the inmates were co-infected with
both HIV and HCV, 31 (38%) had solely HCV infection and only 15
(18%) had HIV monoinfection. In total, 91% had history of intravenous
drug abuse, although only 10 were on methadone maintenance
treatment. In total, 43% of the 67 HCV-positive inmates were being or
had been treated for HCV infection, and 18 (62%) had already
obtained sustained virological response. Out of a total of 51, only 6 of
the HIV-positive patients were not under HAART at the moment. In
total, 38 (84%) of the patients undergoing treatment had undetectable
viral load. In total, 62 (79%) were adhering to both HIV and HCV
medication as prescribed. A total of 13 patients were considered as
refractory to the consultation. At the time of data collection, only
three of these refractory patients were still incarcerated.
Conclusion: HIV and HCV prevalence in the inmate population was
513 times higher than the general population in Portugal, which is a
major public health issue. Adhesion to HAART is higher than in the
general population, probably due to controlled medication distribution
in prison facilities. The prevalence of patients undergoing treatment
Figure 1. HTC coverage after first (weekday) and second visit
(weekend). Individuals with missing data on HIV status were
excluded (n157).
Table 1. Proportion of individuals encountered at home, HTC
uptake and HTC coverage stratified by age and gender. Individuals
with missing data on age, gender were excluded (n170)
Total n (%)
Odds ratio
(95% CI) p
Encountered at
home
Women ]15
years
8115 7211 (88.9) 1
Men ]15 years 5209 3668 (70.4) 0.30 (0.270.33) B0.001
Children B15
years
4393 3534 (80.5) 0.52 (0.470.57) B0.001
HTC uptake
Women ]15
years
7211 6204 (86.0) 1
Men ]15 years 3668 3116 (85.0) 0.92 (0.821.03) 0.13
Children B15
years
3534 3048 (86.3) 1.02 (0.911.14) 0.77
HTC coverage
Women ]15
years
8115 6204 (76.5) 1
Men ]15 years 5209 3116 (59.8) 0.46 (0.430.49) B0.001
Children B15
years
4393 3048 (69.4) 0.70 (0.640.76) B0.001
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for HCV is approximately the same as in general population. National
data on HIV and HCV prevalence in prison facilities are essential to
implement prevention interventions and to improve screening and
treatment for these two chronic conditions, as well as to implement
measures to increase adherence to follow-up.
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Rationales for indicator conditions-based HIV testing data
from the Emergency Department in the Hospital for
Infectious Diseases in Warsaw
Karolina Pyziak-Kowalska1; Justyna Kowalska2 and Andrzej Horban2
1Emergency Department, Hospital for Infectious Diseases, Warsaw,
Poland. 2Department for Adults Infectious Diseases, Medical
University of Warsaw, Warsaw, Poland
Introduction: HIDES study has shown that indicator conditions-based
HIV testing may offer better results than standard approach. It has
also been proven that populations with the HIV prevalence of
0.1% should be routinely screened for HIV. Currently, routine HIV
testing for indicator conditions is not covered by public healthcare in
Poland, which may delay or miss the opportunity for HIV diagnosis.
The aim of this study was to evaluate HIV testing patterns among
patients presenting with specific indicator condition, that is, ongoing
mononucleosis-like illness in the Emergency Department (ED) and
referred for further diagnostics to hospital.
Materials and methods: We conducted retrospective analysis of
medical records of patients referred from the ED with ongoing
mononucleosis-like illness to the Hospital for Infectious Diseases in
Warsaw for further diagnosis within past 12 months (1 May 201430
April 2015). Patients were eligible if being 18 years up.
Results: In total, 173 patients were consulted at the ED with a
mononucleosis-like illness, 94 men and 79 women, with a median
age of 26 years; 72 (41.6%) were admitted to hospital; 54 (75%) were
offered HIV test and all expressed consent; 4 (5.5%) patients were
diagnosed with HIV infection, referred to HIV clinic and linkaged to
care. The continuum of care for mononucleosis-like illness is
presented in Figure 1.
Conclusion: The rate of HIV diagnosis among patients hospitalized
due to mononucleosis-like illness was high (5.5%), confirming clear
benefit in routine testing of this group of patients. According to our
analyses, 58% patients missed the opportunity for HIV testing in ED
due to the lack of such healthcare program.With presented rate, this
translated to six HIV patients who may still remain unaware of
HIV infection. Standards of care for mononucleosis-like illness should
include routine HIV testing, which needs additional financing
and attention from public healthcare representatives and other
stakeholders.
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The changing epidemiology of newly diagnosed HIV-infected
adults in New York City
Benjamin Patterson; Jason Zucker; Tanya Ellman; Ellen Morrison and
Magdalena Sobiesczcyk
Division of Infectious Diseases, Columbia University Medical Center,
New York, NY, USA
Introduction: In keeping with the US National HIV/AIDS strategy,
New York City has attained a 90% rate of persons living with HIV
who know their serostatus over the years 2008 to 2012. To maintain
this high standard, it is imperative to target HIV testing and linkage
to care to the highest risk groups. We investigated a cohort of newly
diagnosed individuals at an academic hospital in Northern Manhattan
to evaluate changes in the epidemiology and clinical characteristics
with a focus on men who have sex with men (MSM) and those over
the age of 50 years.
Materials and methods: This was a retrospective review of all new
HIV diagnoses between 1 January 2006 and 1 August 2015. Eligible
patients were 18 years old, had a new positive HIV test and a CD4
cell count within 90 days of diagnosis. Univariate and multivariate
analyses were performed to compare clinical and demographic
characteristics of individuals diagnosed in 2006 to 2010 (early) and
2011 to 2015 (late) periods.
Results: There were a total of 578 new HIV diagnoses: 294 in 2006 to
2010 with mean age 38 years and mean CD4 254 cells/mL; 284 in
2011 to 2015 with mean age 37 years, mean CD4 286 cells/mL. The
proportion of HIV diagnoses made in the ED increased from 9% to
34% in the early compared to late period with a concomitant
decrease in inpatient diagnoses from 44% to 19% (pB0.0005). There
were more diagnoses among individuals self-reporting as MSM in
2011 to 2015 compared to earlier (46.5% vs. 29.6%, pB0.0005);
overall MSM tended to be younger with higher mean CD4 cell count
than non-MSM (384 vs. 284 cells/mL, p0.0025). Individuals ]50
years were more likely to have CD4 B200 cells/mL compared to their
younger counterparts and this persisted in 2011 to 2015 (45.3% vs.
29.0%, p0.009).
Conclusion: We noticed a shift in the epidemiology and setting of
new HIV diagnoses in an academic medical centre. Increasing new
diagnoses among MSM may reflect local and city-wide public health
campaigns focused on HIV testing and pre-exposure prophylaxis
awareness. Also notable are individuals aged ]50 years who
continue to be diagnosed with advanced disease. This group needs
to be a focus of HIV prevention and testing campaigns.
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Reasons for transferring HIV care in London
Nadia Ahmed1; Duncan Scott2; Laura Waters1; Nashaba Matin2 and
Gary Whitlock3
1HIV/GU, Mortimer Market Centre, London, UK. 2HIV, Barts Health
NHS Trust, London, UK. 3HIV/GU Medicine, 56 Dean Street, London,
UK
Introduction: In England, people living with HIV (PLHIV) can access
care at any centre, regardless of geographical location. Non-UK born
and individuals without residency are also entitled to free HIV care at
any service. There are no data currently available on reasons patients
transfer their HIV management and care from one service to another.
We aimed to investigate reasons for transfer amongst PLHIVFigure 1. Continuum of care for mononucleosis-like illness.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
235
transferring their care to one of three London HIV units in London,
UK.
Materials and methods: Patients transferring their HIV care to one of
three London clinics between December 2015 and June 2016 were
asked to fill in a questionnaire. The questionnaire was designed to
explore reasons for leaving their previous centre and reasons for
choosing the new service.
Results: A total of 111 patients completed the questionnaire; 47%
(n52) transferred from services abroad, 37% (n41) within
London and 16% (n18) transferred from outside of London.
Reasons for leaving the previous HIV clinic included location (75%,
n83), problems at the clinic (10%, n11) and confidentiality (5%,
n5). Other reasons (n12) included services offered (e.g.
specialist services for HCV treatment), finance and employment.
Reasons for choosing the service patients transferred to included
location (31%, n34), good reputation (20%, n22), friend/partner
attending the service (14%, n6). A total of 21% (n22) gave a
combination of these reasons and 15% (n17) gave other reasons
including previously attending the service, recommendation by a
doctor. Only one patient mentioned using the internet to find their
clinic. Current BHIVA guidelines recommend a medical summary
should be received within 2 weeks of transferring to a new service.
And 27% (26 of 95) of patients were aware of the summary being
received at the time of their first appointment of whom 11/26 had
transferred their care within the United Kingdom; 36 stated it had
not been received and 33 did not know.
Conclusions: Most patients transferred their care to another HIV
service for geographical reasons. Reasons for choosing their new
clinic included a combination of location, reputation or a friend/
partner already attending the service. Reassuringly, a minority cited
problems at their old clinic as a reason to transfer care. However, this
could have been due to sampling bias, patients with problems may
have been less likely to complete the questionnaire. In the age of
digital media, it is also interesting that only one patient found their
chosen clinic via the internet. Patients seem to base their choice on
recommendation.
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Introduction: Decentralization of HIV care and treatment has played
a critical role in scaling up services across sub-Saharan Africa [1,2].
However, little is understood about the implications for people living
with HIV (PLHIV) in having care closer to their communities. This
qualitative study examined patient experiences of challenges and
advantages of receiving care at decentralized clinics.
Materials and methods: Four decentralized clinics in small commu-
nity hospitals in Plateau State, North Central Nigeria, served as study
sites. In total, 39 patients took part in individual open-ended
interviews; 23 participated in four focus groups. All participants
had transferred from a large, urban HIV clinic. Interview topics
addressed access to and preferences for care, services received,
perceived impact of decentralization and experiences of decentrali-
zation. Resulting data were analyzed to identify recurrent themes
and develop descriptive categories.
Results: Receiving care at clinics located in local communities shapes
the experience of care for patients. Because decentralized sites have
fewer HIV patients, HIV clinics take place on specific days of the
week. This creates a situation of predictable clinic attendance for
PLHIV that can alternately lead to unwanted disclosure of HIV status
or promote a ‘‘family-like’’ atmosphere of support within the clinic.
Underlying factors determine whether a decentralized HIV clinic
creates an atmosphere of risk or family-like support. These include
the following: physical layout of the clinic, whether ‘‘ground rules’’
for confidentiality are established and enforced by staff and whether
staff foster social interaction among patients by offering patient-
centred care and organizing activities such as group meetings and
positive living discussions.
Conclusion: Decentralized clinics embedded within communities can
pose the risk of unwanted disclosure. However, with patient-specific
provider management, clinics can use local positioning to promote
family-like relationships. These relationships may positively impact
patient interpretations of quality of care, thereby improving reten-
tion rates in decentralized clinics.
Funding: US National Institute of Mental Health (K24MH090894, NC
Ware, PI)
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High mortality attributable to late presentation and delayed
ART initiation in HIV-infected adults receiving care in Latin
America
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Introduction: Late presentation and late ART initiation for HIV
infection is common in Latin America. Here, we estimated the
proportion of deaths among HIV-infected adults receiving care at
CCASAnet sites that could be attributed to late presentation (LP) to
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care, late ART initiation (LI) and no-ART initiation (NI) to highlight the
potential impact of implementing strategies that reduce the time
between HIV infection and diagnosis, linkage to care, and ART
initiation.
Methods: In this observational, multicentre, cohort study including
adults enrolled at six centres in Latin America from 2001 to 2014, we
estimated the population attributable fraction (PAF) for mortality
due to LP, LI and NI. LP was defined as CD4 B200 cells/mL or AIDS at
clinic enrolment. LI was defined as failing to start ART before CD4
B200 cells/mL or AIDS. The primary endpoint was all-cause
mortality. We compared mortality in LP versus non-LP; LI versus
non-LI among non-LP; and ART initiation versus NI among LP. We
used weighted Cox regression and marginal structural models to
estimate survival probabilities used in calculating the PAF.
Results: Of 9,229 patients, 5,162 (56%) were LP (Figure 1). Median
CD4 at enrolment was 198 cells/mL (IQR, 68381); 32% had an AIDS
defining illness. Survival probability at 10 years was 84% (95%
CI82%, 86%) for LP and 93% (95% CI9294%) for non-LP. The
PAF of mortality for LP was 78% (95% CI7086%), 58% (95%
CI49%, 67%), and 43% (95%CI33%, 54%) at 1, 5 and 10 years
after enrolment, respectively, meaning 78% of deaths during the first
year after enrolment would have been prevented if individuals had
been non-LP (Figure 2). Of 4,067 patients who were non-LP, 77%
started ART after a median of 8 months. The proportion of deaths
among these non-LPs that would have been prevented by initiating
ART before CD4 B200 or AIDS was 46% (95% CI077%), 55%
(95% CI086%), and 47% (95% CI1080%) at 1, 5 and 10 years
after enrolment (Figure 3). Among LP, starting ART decreased the
hazard of death by 63% (95% CI4372%). However, 93% of LP
started ART, so universal and immediate initiation of ART among LP
would only result in an estimated 12% (95% CI626%) decrease in
mortality after 1 year.
Conclusion: Earlier presentation to care and earlier initiation of ART
would substantially reduce mortality among HIV-infected subjects in
Latin America, mainly during the first year after enrolment.
Interventions to improve early diagnosis and linkage to care are
particularly needed.
Figure 1. Progression of all HIV-infected patients included in the analysis (N9,229) from status at enrolment (late presentation vs. non-
late presentation) to early (non-LI) versus late antiretroviral therapy initiation (LI) among late presenters, and ART initiation (non-NI) versus
no ART initiation (NI) among late presenters and total deaths by treatment group.
Figure 2. Attributable risk of death (left) and population attribu-
table fraction (right) of death due to late presentation (CD4B200
or AIDS) over time (and 95% confidence intervals).
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Figure 3. Estimated survival probabilities and 95% confidence
intervals for patients entering care in not advanced stages of disease
(non-LP) and starting ART before progression to AIDS in comparison
to those who started after advancing to late stages of disease.
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newly diagnosed patients referred for HIV care to a Swiss
teaching hospital between 2010 and 2015
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Katharine Darling
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Switzerland
Introduction:Missed opportunities (MOs) for HIV testing occur when
a patient with undiagnosed HIV infection presents to a healthcare
provider and is not offered an HIV test. Some late presenters (LPs),
defined as patients first presenting for care with a CD4 count below
350 cells/mm3, have presented several MOs before an HIV test is
performed. The aim of this study was to examine the characteristics
of newly diagnosed patients presenting for care to our clinic and the
extent to which MOs for HIV testing occur in our hospital.
Materials and methods: Medical records of all patients newly
presenting to our infectious diseases outpatient clinic for HIV care
between 2010 and 2015 were examined. Demographic character-
istics, HIV stage at diagnosis and reasons for HIV testing were
recorded. For each patient, inpatient and outpatient visits to our
teaching hospital during the 5 years preceding the HIV diagnosis
were reviewed to determine whether HIV testing had been indicated
according to the 2015 Swiss HIV testing recommendations. MOs
were defined as visits at which HIV testing was indicated but not
performed.
Results: In total, 201 patients were included. Patient characteristics
are summarized in Table 1. A total of 106 patients (53%) were late
presenters, and94 patients (47%) had presented at least one MO
(range 117) at our teaching hospital during the 5 years preceding
diagnosis. Figure 1 shows the distribution of the type of MOs.
Multivariate analysis revealed that MOs occurred more frequently
among patients from sub-Saharan Africa (SSA) (aOR 3.5, 95% CI 1.4
8.6), men who have sex with men (MSM) (aOR 3.3, 95% CI 1.29.4)
and patients with chronic disease (aOR 4.5, 95% CI 1.811.1). In
multivariate analysis, MOs were not associated with increased risk of
late presentation (aOR 0.6, 95% CI 0.31.4). Median CD4 count
(cells/mm3) at HIV diagnosis was significantly higher among patients
presenting at least one MO (351 vs. 244, pB0.01).
Conclusions: Almost half our patients presented at least one MO
before HIV diagnosis. The increased MO frequency among patients
from SSA and MSM suggests that rates of HIV testing should be
improved in key groups at higher risk of HIV acquisition. LPs had
fewer MOs than non-LPs. As our data on MOs relate to hospital
visits, it remains to be determined whether LPs in our population
have reduced access to healthcare if they present MOs in the
primary care sector.
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national testing guidelines were published
Muge Cevik1; Durba Raha2; Callum Mutch1 and Clifford Leen1
1Infectious Diseases, Western General Hospital, Edinburgh, UK.
2GUM, Chalmers Sexual Health Centre, Edinburgh, UK
Introduction: In the United Kingdom, almost 90% of patients
diagnosed with HIV had initiated ART, with 93% of those on ART
having a suppressed viral load. However, approximately one-third of
all HIV infections in adults still remain undiagnosed and one-fourth of
newly diagnosed individuals are late presenters. We aim to assess
the newly diagnosed individuals in Lothian where prevalence is over
0.2% with no agreed policy to screen for HIV in order to understand
current testing practice.
Methods: Using our dedicated HIV database, we included all new
presenters to our services between April 2015 and April 2016. Data
were retrospectively collated through electronic patient records.
Descriptive statistics were performed to examine demographics,
baseline characteristics and treatments.
Results: We identified 51 individuals (3 females) who were newly
diagnosed with HIV. Median age was 35 years (2073) with three
individuals 65 years. A total of 17 individuals were diagnosed in
Table 1. Patient demographic characteristics and mode of HIV
acquisition
Number of patients
(%) without MOs
Number of patients
(%) with MOs
Age (years)
1829 23 (41) 33 (59)
3049 59 (53) 53 (47)
50 25 (76) 8 (24)
Sex
Female 41 (54) 34 (46)
Male 66 (52) 60 (48)
Geographical origin
Europe, North America,
Australasia
58 (55) 48 (45)
Sub-Saharan Africa 32 (48) 34 (52)
Other 17 (59) 12 (41)
Mode of HIV
acquisition
Heterosexual 67 (59) 47 (41)
Men who have sex with
men (MSM)
29 (43) 39 (57)
Injecting drug users
(IVDU)
3 (33) 6 (67)
Other 8 (80) 2 (20)
Time since previous
HIV test
None 72 (61) 47 (39)
51 year 12 (43) 16 (57)
1 year ago 23 (43) 31 (57)
Figure 1. Distribution of the type of MOs in our study population.
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GUM clinic, 14 in GP practice, 10 in secondary care, 6 through
outreach services and 3 using self-testing kit. A total of 21 individuals
diagnosed through routine screening, 5 contact tracing and 24
individuals presented with clinical symptoms. Median nadir CD4 cell
count was 326 cells/mL. However, we observed significant differ-
ences in those diagnosed in various settings (Table 1).
Individuals diagnosed in secondary care and those who used home
testing kit had significantly lower median CD4 counts, 81 and 114
cells/mL, respectively. More than half of our cohort (28) had CD4
count B350 cells/mL, 10 (36%) of those presented with AIDS-
defining illness and 11 individuals (39%) presented to a healthcare
facility in the past year before the diagnosis with a clinical indicator
of HIV infection. Overall 13 (25%) individuals had CD4 B200 cells/
mL, 4 (8%) out of those died within 3 months after diagnosis due to
an AIDS-defining illness.
Conclusion: Early diagnosis is critical to improve morbidity and
mortality, and also for the prevention of onward transmission. Late
diagnosis has been associated with longer hospital stay and
increased cost to healthcare services. In this cohort, one-fourth of
patients had CD4 count B200 cells/mL and more than half had CD4
B350 cells/mL. In total, 39% of late presenters had contact with
healthcare prior to HIV diagnosis representing missed opportunities
for earlier diagnosis. We believe routine testing in all relevant
settings should be offered as per national guidelines in order to
reduce undiagnosed HIV infection at late diagnosis.
P343
HIV late presenters: a retrospective cohort study on an
outpatient clinic in Lisbon, 20102014
Fa´bio Cota-Medeiros; Cla´udia Afonso; Alexandra Zagalo and
Luı´s Caldeira
Infectious Diseases, Centro Hospitalar Lisboa Norte  Hospital Santa
Maria, Lisbon, Portugal
Introduction: The diagnosis of HIV late presenter is associated with a
worse clinical condition, increased rate of HIV transmission and
higher healthcare cost burden. Recognition of this population could
change this outcome. Our aim was to analyze the characteristics,
factors and risk predictors associated with being late presenter
among newly HIV-infected patients in an outpatient clinic in Lisbon
during a 5-year period.
Materials and methods: Retrospective analysis of the clinical records
of patients older than 18 years, newly diagnosed with HIV infection
admitted to our outpatient clinic between January 2010 and
December 2014. Epidemiologic, immunologic, clinical and laboratory
data were recorded. European Late Presenter Consensus definition
criteria for late presentation [1] were used.
Results: A total of 347 newly HIV-infected patients were admitted to
our outpatient clinic, 149 (42.9%) meet the criteria for late
presenters (LP) and 88 (25.4%) were late presenters with advanced
disease (LPWAD). The majority of LP were male (68.5%), with a
median age of 41 (62.5% were aged between 31 and 50 years),
Caucasians (71.1%) and 66.4% were Portuguese. Heterosexual
transmission was the main route of infection (57.7%). The main
trigger of HIV infection diagnosis on the LP group was clinical
investigation due to symptoms (55%) followed in 18.1% by screening
due to behaviour risk mainly in the MSM and IVDU groups. A total of
52 (34.9%) patients were asymptomatic and 95 (63.8%) fulfilled AIDS
criteria according to the CDC classification. The median CD4 count
was 195 cells/mm3 (4.2724 cells/mm3); the median viral load was
159,200 copies/mL (3037,578,000 copies/mL) and 55.7% patients
had viral load higher than 5 log10. Almost half of the new HIV
diagnosed patients were foreign (48.5%) and 53.2% of the patients of
African origin were LP. There was a higher number of heterosexual
males who were LP than men who have sex with men (49.1% vs.
30.3%). Although only 4.6% of newly diagnosed patients were IVDU,
75% of these were LP.
Conclusions: There was a high percentage of late diagnosis of HIV
infection in our cohort. These results emphasize the need to promote
a better access to care not only to the classic behavioural risk groups
like MSM and IVDU but mainly to the foreign population and
heterosexual males.
Reference
1. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J,
et al. Late presentation of HIV infection: a consensus definition.
HIV Med. 2011;12:614. doi: http://dx.doi.org/10.1111/j.1468-1293.
2010.00857.x
P344
Clinical characteristics of newly diagnosed HIV-infected
patients and risk factors for late presentation: a Portuguese
cohort
Rita Veiga Ferraz; Francisco Almeida; Raquel Duro; Nuno Pereira;
Carmela Pinero; Ca´tia Caldas; Rosa´rio Serra˜o and Anto´nio Sarmento
Infectious Diseases, Centro Hospitalar de Sa˜o Joa˜o, Porto, Portugal
Introduction: The epidemiology of HIV infection changed dramati-
cally in the last few years; however, late diagnosis, associated with
increased disease burden and risk of transmission as well as a
reduction of the benefits of antiretroviral therapy, continues to be a
major issue. The main objectives of this study were to identify risk
factors related to late presentation and describe the evolution of
clinical characteristics of newly diagnosed HIV-infected patients.
Abstract P342Table 1. Demographics and baseline characteristics of individuals diagnosed with HIV in various settings
Outreach GUM GP Home testing Secondary care Total
Median age (years) 35 (2747) 28 (2250) 36 (2573) 31 (2646) 45 (2064) 35 (2073)
MSM:HSM 5:1 17:0 9:2 3:0 11:0 45:3
Female 0 0 3 0 0 3
Median CD4 count (cells/mL) 490 (275659) 386 (2341166) 385 (40885) 114 (68659) 81 (6570) 326 (61166)
CD4 count B350 (n) 2 8 7 3 8 28 (55%)
CD4 count B200 (n) 0 0 2 3 8 13 (25%)
Survival at 1 year 100% 100% 100% 100% 63% 92%
Number/percentage 6 (12%) 17 (33%) 14 (27%) 3 (6%) 11 (22%) 51 (100%)
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Methods: Retrospective observational cohort study of all newly
diagnosed HIV-infected patients admitted to our Infectious Diseases
Department between 2006 and 2015. Data were collected after chart
review. For a temporal trend analysis patients were categorized into
five time periods: 2006 to 2007; 2008 to 2009; 2010 to 2011; 2012 to
2013; 2014 to 2015. Continuous variables were expressed as median
and standard deviation, and categorical variables were expressed as
number (percentage). Patient characteristics were compared using
chi-square test, independent samples t-test or ANOVA, as appro-
priate. Risk factors for immunity depression were initially investi-
gated through univariate analysis; with the factors identified, a
multiple logistic regression model was performed. The level of
significance considered was pB0.05. Analyses were carried out
using SPSS version 22.0.
Results: We identified 972 newly diagnosed HIV-infected people
between 2006 and 2015. The majority of the patients were male
(73.6%) and the mean age was 41913 years. The main mode of
transmission was unprotected heterosexual sex (62.0%). Late
presenters represented more than half of the patients (58.3%) and
41.8% already had an opportunistic infection when first observed in
HIV clinic. Clinical characteristics and its temporal analysis are
summarized in Table 1.
In univariate analysis, the risk factors for late presentation identified
were older age, risk of acquisition, site of referral to HIV clinic and
previous opportunistic infection. In multivariate analysis, the risk
factors identified were age (OR 1.021; 95% CI 1.0091.034) and
referral from infectious diseases ward/emergency room/other hos-
pital wards/other hospitals.
Conclusion: This study reveals that despite the changing epidemiol-
ogy of HIV infection late presentation is still a major issue in HIV
patients. These data put in question the efficacy of campaigns
targeting specific groups to improve early diagnosis and raise the
question of universal testing of HIV infection.
V IROLOGY AND IMMUNOLOGY:
BIOMARKERS/TROPISM
P345
Immune recovery in acute and chronic HIV infection and the
impact of thymic stromal lymphopoietin
Marco Gelpi1; Hans Jakob Hartling1; Kristina Thorsteinsson2;
Jan Gerstoft1; Henrik Ullum3 and Susanne Dam Nielsen1
1Infectious Diseases, Rigshospitalet, Copenhagen, Denmark.
2Infectious Diseases, Hvidovre Hospital, Hvidovre, Denmark. 3Clinical
Immunology, Rigshospitalet, Copenhagen, Denmark
Introduction: Symptomatic primary HIV infection is associated with
faster decline in CD4 T cells count and progression to AIDS, and
immediate initiation of combination antiretroviral therapy (cART) is
recommended. However, little is known about immunological
predictors of immune recovery. Thymic stromal lymphopoietin
(TSLP) is a cytokine that promotes homeostatic polyclonal prolifera-
tion of CD4 T cells and participates in regulating Th17/regulatory T-
cell balance, immunological functions known to be affected during
primary HIV infection. The aim of this study was to describe immune
recovery in primary and chronic HIV infection and possible impact of
TSLP.
Materials and methods: Prospective study including 100 HIV-
infected individuals (primary HIV infection (N14), early presenters
(350 CD4 T cells/mL, N42), late presenters without advanced
Table 1. Clinical characteristics of newly diagnosed HIV patients: temporal trend analysis
Clinical characteristics Total
20062007
(n226)
20082009
(n239)
20102011
(n182)
20122013
(n179)
20142015
(n146) p
Gender
Male 715 (73.6%) 164 (72.6%) 158 (66.1%) 138 (75.8%) 133 (74.3%) 122 (83.6%) 0.005
Female 257 (26.4%) 62 (27.4%) 81 (33.9%) 44 (24.2%) 46 (25.7%) 24 (16.4%)
Age (mean9SD) 40.78 (13.4) 40.90 (13.3) 42.48 (14.3) 40.74 (13.9) 39.56 (12.3) 39.19 (12.6) 0.101
Risk for HIV acquisition (MSM,
heterosexual, IDU, other)
284 (29.2%)
603 (62%)
70 (7.2%)
15 (1.5%)
41 (18.1%)
146 (64.6%)
39 (17.3)
0
51 (21.3%)
173 (72.4%)
9 (3.8%)
6 (2.5%)
53 (29.1%)
118 (64.8%)
11 (6.0%)
0
76 (42.5%)
95 (53.1%)
7 (3.9%)
1 (0.6%)
63 (43.2%)
71 (48.6%)
4 (2.7%)
8 (5.5%)
B0.001
Site of referral 374 (38.5%) 88 (38.9%) 89 (37.2%) 72 (39.6%) 65 (36.3%) 60 (41.1%) B0.001
ID ward/ER/other
Ambulatory
Serodiscordant couple/drug
centre/jails
Voluntary testing
Blood donation/pregnancy
Unknown
344 (35.4%)
90 (9.3%)
110 (11.3%)
39 (4.0%)
15 (1.5%)
72 (31.9%)
41 (18.1%)
13 (5.8%)
5 (2.2%)
7 (3.1%)
87 (36.4%)
27 (11.3%)
24 (10%)
12 (5%)
0
74 (40.7%)
13 (7.1%)
19 (10.4%)
4 (2.2%)
0
65 (36.3)
5 (2.8%)
34 (19%)
9 (5%)
1 (0.6%)
46 (31.5%)
4 (2.7%)
20 (13.7%)
9 (6.2%)
7 (4.8%)
CD4 cell count (mean9SD) 322 (252.0) 342.33 (305.1) 306.82 (269.8) 308.33 (225.2) 306.10 (199.7) 355.18 (258.5) 0.208
CD4 cell count categorized
B350
350
567 (58.3%)
405 (41.7%)
132 (58.4%)
94 (41.6%)
150 (62.8%)
89 (37.2%)
102 (56%)
80 (44%)
109 (60.9%)
70 (39.1%)
74 (50.7%)
72 (49.3%)
0.177
Clinical stageAIDSNon-AIDS 406 (41.8%)
566 (58.2%)
100 (44.2%)
126 (55.8%)
118 (49.4%)
121 (50.6%)
72 (39.6%)
110 (60.4%)
64 (35.8%)
115 (64.2%)
52 (35.2%)
94 (64.4%)
0.021
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
240
disease (200350 CD4 T cells/mL, N24) and late presenters with
advanced disease (B200 CD4 T cells/mL, N20). Plasma TSLP was
determined using ELISA and CD4 T cell subpopulations (recent
thymic emigrants, naı¨ve and memory cells) were measured using
flow cytometry at baseline and after 6, 12 and 24 months of cART.
Results: Immune recovery was comparable in all groups, and no
differences in immune homeostasis were found between primary
HIV infection and early presenters (Figure 1b). In primary HIV
infection group, lower thymic output compared to late presenters
without advanced disease was found. However, lower proportion of
effector memory and higher proportion of late differentiated CD4
T cell were found in primary HIV infection compared to late
presenters. TSLP was elevated in primary HIV infection at baseline
and after 24 months of cART (Figure 1c and Table 1). Interestingly,
TSLP was negatively associated with proportion of recent thymic
emigrants (correlation coefficient 0.60, p0.030). However, TSLP
was not associated with immune recovery in primary HIV infection.
Finally, higher plasma TSLP was associated with lower CD4 T cell
recovery in the late presenters non-advanced disease group
(correlation coefficient 0.50, p0.034).
Conclusions: Immune recovery was comparable in primary and
chronic HIV infection whereas differences in absolute counts and
proportions of CD4 T cell subpopulations were found between
primary HIV infection and late presenters supporting early initiation
of cART. Higher plasma TSLP was found in primary HIV infection.
Association between TSLP and a lower thymic output, but not with
immune recovery was found in primary HIV infection. These findings
indicate a possible role of TSLP in immune homeostasis in HIV
infection but do not support TSLP to affect immune recovery in
primary HIV infection.
P346
Neuroasymptomatic cerebrospinal fluid (CSF) viral escape
(aCVE) is associated with increased intrathecal immune
activation but not with CSF signs of neuronal injury and
alteration of CSF/serum albumin ratio
Carmela Pinnetti1; Valentina Fedele2; Stefania Carta2;
Patrizia Lorenzini1; Valentina Mazzotta1; Veronica Bordoni3;
Francesco Baldini1; Susanna Grisetti1; Maria Rosaria Capobianchi3;
Federico Martini4; Francesca Ceccherini-Silberstein5;
Adriana Ammassari1; Carlo Federico Perno2 and Andrea Antinori1
1Clinical Department, National Institute for Infectious Diseases,
Rome, Italy. 2Antiretroviral Drug Monitoring Unit, National Institute
for Infectious Diseases, Rome, Italy. 3Laboratory of Virology, National
Institute for Infectious Diseases, Rome, Italy. 4Laboratory of
Immunology, National Institute for Infectious Diseases, Rome, Italy.
5Experimental Medicine and Surgery, University of Rome Tor Vergata,
Rome, Italy
Introduction: aCVE is of rising interest in the HIV setting, although
preliminary data described it as an uncommon finding. CSF viral
escape (CVE) predictors are not definitively assessed. Pathogenesis
Figure 1. CD4 count (a), immune recovery (b) and plasma TSLP (c) before cART and during 24 months of follow-up.
MannWhitney was used to compare PHI group with the chronic groups. Significant differences are marked: aPHI versus late presenters [s1]with
advanced disease; bPHI versus late presenters without advanced disease; cPHI versus early presenters.
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and clinical significance of aCVE remain uncertain, particularly
regarding intrathecal immune activation/inflammation and neuroin-
jury markers during aCVE.
Materials and methods: Single-center retrospective study on CSF/
plasma paired samples collected on neurologically asymptomatic
HIV-positive patients undergoing lumbar puncture (LP) for CNS
staging of lymphoma during ART exposure. aCVE was defined: a)
detectable CSF HIV RNA with concurrent plasma levels B50 copies/
mL, or b) CSF HIV RNA 1.0 log higher than concomitant plasma HIV
RNA level. CSF neopterin, and neurofilament light-chain (NFL)
concentrations were determined by ELISA assays. aCVE adjusted
ORs were calculated by fitting a logistic multivariate regression
model.
Results: Two hundred and ninety-one CSF/plasma pairs from 92
patients were included: 88% male, median age 42 years, hetero-
sexual 47%, MSM 26%, IDU 21%. CD4 cells/mm3 was B200 in 48%
and 500 in 22%; 98% CDC stage C. CSF was collected in 44% during
2004 to 2008, in 56% during 2009 to 2014. At LP, all patients were
Abstract P345Table 1. Proportion of CD4 T cell subsets in HIV-infected individuals with either primary HIV infection or chronic
HIV infection according to CD4 T cell count before initiation of cART
PHI, N14
LP-AD B200 cells/mL,
N20
LP-nonAD 200-350 cells/mL,
N24
EP 350 cells/mL,
N42
Gender, males/females (% males) 13/1 (92.9) 18/2 (90.0) 21/3 (87.5) 39/3 (92.9)
Age, years, median (IQR) 47 (12) 42 (16) 38 (16) 44.5 (12)
Time since diagnosis, days, median (IQR) 2 (3) 3 (9) 18 (269) 24 (983)
CD4 nadir, cells/mL, median (IQR) 540 (335) 45 (113) 290 (95) 480 (170)
CD4 at baseline, cells/mL, median (IQR) 550 (327) 55 (110) 290 (97) 510 (172)
CD4 at 24 months of cART, cells/mL,
median (IQR)
680 (240)a 269 (160)a 695 (290) 820 (317)
RTE at baseline, %, median (IQR) 14 (11) 11 (16) 20 (15) 18 (14)
RTE at 24 months of cART, %, median (IQR) 18 (9)b 17 (10) 28 (11)b 17 (16)
Naive at baseline, %, median (IQR) 43 (20)a 23 (30)a 40 (26) 44 (21)
Naive at 24 months of cART, %, median
(IQR)
36 (12)b 30 (16) 55 (16)b 37 (15)
EM at baseline, %, median (IQR) 12 (7) 17 (14) 16 (12) 12 (6)
EM at 24 months of cART, %, median (IQR) 9 (4)a 15 (6)a 6 (7) 7 (5)
CM at baseline, %, median (IQR) 26 (6) 20 (22) 24 (10) 24 (10)
CM at 24 months of cART, %, median (IQR) 24 (14) 30 (23) 24 (8) 32 (16)
LD at baseline, %, median (IQR) 5 (4)b 3 (12) 1 (2)b 5 (8)
LD at 24 months of cART, %, median (IQR) 9 (16)a,b 1 (1)a 3 (2)b 9 (13)
TSLP at baseline, pg/mL, median (IQR) 2.8 (2.3)a,b,c 1.7 (0.8)a 2.1 (1.4)b 1.9 (0.7)c
TSLP at 24 months of cART, pg/mL, median
(IQR)
3.9 (2.8)a,c 1.3 (1.4)a 2.4 (2.9) 2.1 (1.0)c
Abbreviations: LP-AD, late presenters with advanced disease; LP-nonAD, late presenters without advanced disease; EP, early presenters; PHI,
primary HIV infection. Comparing the four HIV groups by using KruskalWallis test. If significant (B0.05) then MannWhitney was used to
compare PHI group with the other chronic groups. Only significant differences are marked: aPHI versus LP-AD; bPHI versus LP-nonAD; cPHI versus
EP.
Abstract P346Figure 1. Cerebrospinal fluid (CSF) neurofilament light protein (NFL) and neopterin concentration by the presence of an
asymptomatic CSF viral escape (CVE).
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receiving cART: 67.7% TDF/FTC, 11% ABC/3TC, 2.8% ZDV/3TC, 40%
EFV, 33% LPV/r, 9% ATV/r and 6.5% DRV/r. Hundred and forty-nine
(51.2%) had HIV RNA B50 copies/mL, 206 (70.8%) B200 copies/mL.
CVE was detected in 24/291 samples (8.2%): 62.5% diagnosed with
criterion a); 37.5% with criterion b). Mean CSF HIV RNA log was 1.95.
At multivariable analysis, male gender (OR 0.20; 95% CI 0.040.90 vs.
female), CD4 350 (0.11; 0.020.82 vs. CD4 B200) and 2009 to
2014 period (0.10; 0.030.38 vs. 20042008) were all independently
associated with a decreased risk of CVE. Using TDF/FTC as reference,
receiving ABC/3TC at LP (OR 4.38; 1.1316.96) was independently
related to an increased CVE risk. Age, nadir CD4 B200, duration of
cART, 2010 CSF CNS penetration effectiveness score, third ARV drug
received, and CSF/serum albumin ratio were not associated with
CVE. Patients with CVE showed a higher concentration of CSF
neopterin (p0.015) comparing to patients without, while no
significant difference for CSF NFL level (Figure 1). No difference
was found in CSF/plasma albumin ratio.
Conclusions: In 291 CSF/plasma paired samples obtained from HIV-
positive asymptomatic patients on cART, CVE occurred in 8.2% of
cases. Higher CD4 at LP was associated with a lower CVE probability,
while use of ABC/3TC is associated with increased risk of CVE, but
this finding needs further investigation. An increased intrathecal
immune activation, but not neuroinjury, was found, suggesting that
an inflammatory response concomitant with aCVE does not im-
mediately translate into ongoing axonal injury and BBB damage.
P347
Cardiovascular risk in HIV-positive subjects: analyses of
T-cell phenotype and CD49d expression
Maria Antonella Zingaropoli; Alessandra D’Abramo; Marco Iannetta;
Alessandra Oliva; Gabriella d’Ettorre; Miriam Lichtner; Claudio Maria
Mastroianni; Maria Rosa Ciardi and Vincenzo Vullo
Department of Public Health and Infectious Diseases, Sapienza
University of Rome, Rome, Italy
Introduction: It is well known that HIV-positive subjects have a higher
risk of non-AIDS-related comorbidities than general population.
Chronic immune activation of T-cells plays an important role in HIV
pathogenesis and related comorbidities. In this context, the integrin-
alpha4 (CD49d), a transmembrane co-stimulatory molecule, is in-
volved in the lymphocyte homing from peripheral compartment to the
gut (alpha4beta7) and to the central nervous system (alpha4beta1).
The aim of the study was to evaluate CD49d expression in T-
lymphocyte subsets and the relationship with cardiovascular damage
in HIV individuals on effective cART.
Materials and methods: Thirty HIV subjects (6 females and 24
males) with a mean age (9standard deviation (SD)) of 52910.1
years on effective cART and 15 age- and sex-matched healthy donors
(HD) were enroled. T-lymphocyte immunophenotype and CD49d
expression, measured as median fluorescence intensity (MFI), were
assessed by flow cytometry. Carotid intima-media thickness (c-IMT)
was measured with ultrasonography. Normal and pathological c-IMT
were defined as IMT B0.9 mm and 0.9 mm, respectively.
Results: HIV subjects showed a lower count of CD4 T-lympho-
cytes (p0.04) and increased levels of immune activation (CD4 and
CD8 HLA-DRCD38, pB0.001 and pB0.001, respectively) and
immunosenescence (CD4 and CD8 CD28CD57, p0.02 and
pB0.001, respectively) than HD. A decrease in CD4 and CD8
naı¨ve (N) (p0.02 and p0.01) and an increase in CD8 effector
memory (EM) (p0.007) percentages were observed in HIV
subjects, compared to HD. In HIV subjects, CD49d expression was
increased on CD4 (N: p0.01; central memory (CM): pB0.001;
EM: pB0.001; effector (E): p0.05) and CD8 (N: p0.0006; CM:
pB0.001; EM: pB0.001; E: p0.003; and intermediate (I):
pB0.001) T-lymphocyte subsets, compared to HD. A positive correla-
tion between CD49d expression in CD4 T-cells and CD4 HLA-
DRCD38 (p0.0012) was observed in HIV subjects. c-IMT was
higher in the HIV group than HD (mean9SD: 0.8590.17 vs.
0.2890.24 mm, pB0.001). Among HIV patients, 15 (50%) had a
normal c-IMT and 15 (50%) a pathological c-IMT. CD4T-cell CD49d
expression and CD4HLA-DRCD38 positively correlated with c-
IMT (p0.04, p0.085, respectively). Moreover, HIV subjects with
pathological c-IMT showed higher levels of CD4CM CD49d expres-
sion (p0.02) than HIV subjects with normal c-IMT.
Conclusions: The increase of CD49d expression in T-lymphocytes
could be considered an early marker of immune activation during
HIV infection. Furthermore, integrin-alpha4 could represent a
potential therapeutic target for the immune system modulation in
the context of HIV infection aiming to reduce non-AIDS-related
comorbidities, especially cardiovascular diseases.
P348
Baseline myeloid and lymphoid activation markers can
predict time to viral load reduction under 50 copies/mL and
CD4 recovery, respectively, after highly active antiretroviral
therapy initiation
Marco Iannetta; Miriam Lichtner; Raffaella Rossi; Stefano Savinelli;
Serena Vita; Claudia Mascia; Paola Zuccala`; Raffaella Marocco;
Maria Antonella Zingaropoli; Maria Rosa Ciardi; Gabriella d’Ettorre;
Claudio Maria Mastroianni and Vincenzo Vullo
Public Health and Infectious Diseases, Sapienza University, Rome, Italy
Introduction: During HIV infection myeloid and lymphoid activation
has been reported [1], together with elevation of monocyte/
Abstract P348Figure 1. a) Correlation between activated CD8HLA-DRCD38 T-lymphocytes and CD4 recovery after 1 year of ART
(Spearman r: 0.5; p0.005). b) Kaplan-Meier analysis with endpointviral load B50 copies/mL over a period of 150 days (log-rank test p0.03).
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macrophage inflammation markers, such us soluble (s)CD14 and
sCD163 [2,3]. We evaluated both myeloid and lymphoid activation
markers and correlated them with CD4 recovery after 12 months of
ARV treatment, and the time (in days) needed to achieve a viral load
below 50 copies/mL.
Materials and methods: HIV treatment-naı¨ve patients were
enroled and followed up for 1 year after treatment initiation. Blood
samples were collected before treatment initiation (T0). Monocyte
(Mo), dendritic cell (DC) and lymphocyte phenotypes were assessed
by flow-cytometry using a lyse-no-wash protocol. sCD14 and sCD163
were measured in plasma with ELISA. Seventeen age- and sex-
matched healthy donors (HD) were enroled.
Results: We recruited 34 naı¨ve patients (eight women, nine AIDS
presenters). Fifteen, ten and six patients started an ARV therapy
containing a protease, a non-nucleoside reverse-transcriptase and an
integrase inhibitor, respectively. Three patients did not start any
treatment. No differences in HIV viral load and CD4 cell counts were
observed at T0, according to ARV therapy. At T0, HIV subjects
showed lower levels of pDC (3976 vs 7043 cells/mL, pB0.001),
slanDC (11,644 vs 24,538 cells/mL, p0.02) and higher levels of
CD14CD16 Mo (19,369 vs 7157 cells/mL, pB0.001) compared
to HD. HLA-DR was reduced on mDC of HIV subjects (22,556 vs
37,358, pB0.001) and increased on slanDC (13,680 vs. 9979,
p0.005) compared to HD. Levels of CD4 and CD8 T-
lymphocyte immune-activation were higher in HIV subjects than
HD (6.0% vs. 1.8%, pB0.001 and 9.4% vs. 1.1%, pB0.001). Myeloid
activation soluble markers sCD14 and sCD163 were higher in HIV
subjects compared to HD (2163 vs. 1363 ng/mL, pB0.001 and 272.6
vs. 149.1 ng/mL, p0.08). CD14CD16 Mo and CD8 immune-
activation were not correlated with the clinical stage of HIV subjects,
but positively correlated with HIV viral load. After 1 year of ARV
therapy, CD4 recovery positively correlated with basal levels of CD8
immune-activation (Figure 1a), while the choice of protease, non-
nucleoside reverse-transcriptase or integrase inhibitor did not affect
CD4 recovery. The Kaplan-Meier analysis showed that higher baseline
CD14CD16 Mo counts were predictive of a lower rate of
subjects with a viral load B50 copies/mL, within 150 days from ARV
therapy initiation (p0.03) (Figure 1b).
Conclusions: Global evaluation of lymphoid and myeloid activation
markers can be useful in predicting time to undetectable viral load
and immunological recovery in HIV patients starting ARV therapy.
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Introduction: Several sex differences have been described in the
natural course of HIV-1 disease [1]. Higher levels of TLR 7-mediated
IFN-alpha production together with greater levels of activated CD8-T
cells were described in women compared with men for a given HIV
viral load [2]. The role of sexual hormones in antiretroviral treatment
(ART)-treated women is not completely understood and seems to be
crucial to individualize possible eradication strategy in women that
could be different than in men [3]. The aim of this study was to
investigate the role of sexual hormones in determining innate
immunity and immune activation in a cohort of HIV-infected subjects
undergoing effective ART.
Materials and methods: Seventy-four HIV-infected (41 F, 33 M)
subjects receiving stable ART were studied. Immunological test
including plasmocytoid and myeloid dendritic cells (DC) count, slan
DC and typical, atypical and intermediate monocytes and T cell
activation (HLA-DR/CD38CD4 and HLA-DR/CD38CD8).
Sex hormones (oestradiol, progesterone and testosterone) were
determined using CLIA kit. HIV RNA zenith, delta of CD4, years of
disease and CD4/CD8 ratio were also collected. Non-parametric
MannWhitney test and Spearman coefficient correlation were
used.
Results: There were no significant differences in levels of circulating
DC (mDC, pDC) between HIV women and men; however, a positive
correlation was found between mDC and serum oestradiol (p0.03,
r0.30). We did not observe statistically significant differences
among the sub-populations of monocytes and MDC-8, but there was
a trend of increased number of atypical inflammatory monocytes
and MDC-8 in women. Interestingly, a significant augmentation of
DR38 CD4 T cells was found in men (p0.02), and a negative
correlation between DR38CD8 T cells and serum oestradiol
levels in all HIV subjects and in women was observed (respectively
p0.0002; r0.67; p0.006, r0.50). Moreover, only in
women a negative correlation between mDC and DR38CD8 T
cells was found (p0.02; r0.43). Progesterone and testoster-
one levels were not associated with the immune variables con-
sidered. Regarding soluble markers of monocytes activation, we did
not observe differences although women have lower levels of sCD14
than men (pg/mL, median 2249 and 2685 pg/mL).
Conclusions: In HIV aviraemic ART-treated subjects, high levels of
oestrogens seem to be associated with an expansion of mDC and a
lower activation of CD8 T cells, underlying the importance of
considering hormonal status and not only gender and age in
designing immunological and therapeutic studies.
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Introduction: Studies have demonstrated that cytokine-mediated
non-cytopathic suppression of viral replication may provide an
alternative therapeutic strategy for the treatment of viral infection.
We hypothesized that active transforming growth factor (TGF)-b1
cytokine response is involved in HIV-1 suppression during ART.
Methods: Fifty-nine HIV-1 infected individual categorized according
to virologic and immunologic outcomes after ART as, virologic
responder (VR), immune-virologic failure (IVF) and viral suppressed
(VS) were included in this cross-sectional study. For comparison, 12
ART-naı¨ve long-term non-progressors (LTNPs) and 10 healthy controls
were also included in the study. CD4 T cell counts and plasma HIV-
1 RNA were measured using flow cytometry and HIV-1 TaqMan
assays, respectively. Plasma levels of active TGF-b1 were determined
using MILLIPLEX† MAP TGF-b1 single plex magnetic bead kit on
LuminexMAP† 200 system.
Results: Whereas LTNPs had high HIV-1 RNA and CD4 cell counts,
plasma TGF-b1 was low. In patients on ART, VR had high CD4 cell
counts and low HIV-1 RNA contrasted with high TGF-b1 while IVF
exhibited high HIV-1 RNA with low CD4 cell count and TGF-b1. Of
note, VS had undetectable HIV-1 RNA with high CD4 cell counts
and plasma concentration of TGF-b1. Furthermore, a negative
correlation was observed between HIV-1 RNA and TGF-b1 in patients
on ART.
Conclusions: Overall, plasma concentration of active TGF-b1 was not
significantly different between healthy controls and LTNPs. However,
VR and VS displayed a significantly high TGF-b1 and a significantly
low and undetectable HIV-1 RNA, respectively. Compared to VR, IVF
had low TGF-b1 and higher HIV-1 RNA. This suggests immunoregu-
latory mechanisms to be involved in suppressing HIV-1 in HIV-
infected patients on ART.
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Introduction: Maraviroc is a coreceptor antagonist that prevents HIV
cell entry by blocking the CCR5-coreceptor. Before initiating treat-
ment with maraviroc, viral coreceptor usage should be determined
to ensure that HIV can use only the CCR5 coreceptor (R5) and cannot
evade the drug by using the CXCR4 coreceptor (X4-capable).
Although maraviroc is a treatment option for individuals infected
with HIV-2, no online tool for the genotypic identification of HIV-2
coreceptor usage was available until now. Therefore, our research
was concerned with developing, validating and implementing a data-
driven web service for the prediction of HIV-2 coreceptor usage from
the V3 loop of the HIV-2 glycoprotein.
Methods: Several support vector machines (SVMs) were trained and
validated on a data set of 73 R5 and 52 X4-capable V3 amino acid
samples with known phenotypic coreceptor usage. We compared the
nested cross-validation predictions from SVMs with the results from
the rules-based method developed by Visseaux et al. [1] using
McNemar’s test and investigated the predictive performance of
individual discriminatory features in the V3 loop using Fisher’s exact
test with multiple hypothesis correction (Benjamini-Hochberg meth-
od at a false discovery rate of 5%).
Results: After comparing the predictive performance of all trained
SVMs using 10 runs of 10-fold cross-validation, we selected a linear
SVM as the model for geno2pheno (coreceptor-hiv2), because it
performed best (area under the ROC curve of 0.95). In our
evaluations of predictive performance using 10-fold nested cross-
validation, SVMs had a sensitivity of 73.5% and a specificity of 96%
for identifying X4-capable variants. We found that the predictive
performance of SVMs was not significantly different (p0.37) from
the rules-based approach developed by Visseaux et al. Moreover, on
a test set containing nine new V3 sequences together with the
corresponding coreceptor usage phenotypes, geno2pheno (coreceptor-
hiv2) achieved a predictive accuracy of 100% and outperformed the
rules-based approach. Using SVMs, we could not only reproduce the
established markers of CXCR4-usage but could also identify novel
markers: the substitutions 27K, 15G and 8S were significantly
predictive of CXCR4-usage.
Conclusions: In this study, we developed geno2pheno (coreceptor-
hiv2), the first online tool for the prediction of HIV-2 coreceptor
usage from the V3 loop. The tool can aid clinicians in deciding
whether maraviroc is a treatment option and allows for broader
epidemiological studies on HIV-2 coreceptor usage. Moreover, our
research indicates that HIV-2 coreceptor usage is not only influenced
by the V3 loop but also by the V1/V2 regions. Geno2pheno
(coreceptor-hiv2) is available at www.coreceptor-hiv2.geno2pheno.
org.
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Introduction: Until a recent change in guidelines, HIV-infected
patients on antiretroviral therapy (ART) in Uganda were monitored
using CD4 cell counts only. So far, little is known about prevalence of
drug resistance among HIV-infected patients with virological failure
(VF) after immunological treatment monitoring in Uganda.
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Methods: From 4 June to 30 September 2015, viral load measure-
ments were done in HIV-infected adults (18 years) on ART for at least
6 months presenting to the infectious diseases institute (IDI) in
Kampala. In case of VF (1000 copies/mL), HIV genotyping was
requested. Sequencing of partial polymerase gene was conducted
using an in-house protocol. All sequences were submitted to the
Stanford University HIV Drug Resistance database, and the surveil-
lance drug resistance mutations were identified using the 2009
World Health Organization mutations list. HIV-1 subtypes were
determined using REGA version 3.0.
Results: Viral load measurements were done in 2511 patients, who
had been on ART for a median time of 4.7 years (interquartile range
(IQR) 2.58.7). A total of 199 patients (7.9%) had VF with a median
viral load of 4.4 log10 copies/mL (IQR 3.94.9). The majority of
patients with VF (140, 70.4%) were on first-line ART, 138 (69.3%)
were female and the median age was 37 years (IQR 3043). HIV
genotyping tests were available in 163 (81.9%). HIV-1 subtypes A
(46%) and D (34%) were most common. Relevant drug resistance
mutations were observed in 135 (82.8%), of which 103 (63.2%) had
resistance to two drug classes, and 11 (6.8%) had resistance to all
three drug classes available in Uganda (Figure 1).
Conclusions: With 92% of all patients virologically suppressed, the
overall prevalence of VF was low and is in line with the third of the
909090 UNAIDS targets. However, the majority of failing patients
had developed resistance to more than one drug class, suggesting
that failing regimens - not identified as such by CD4 monitoring - had
been in place for a prolonged period of time.
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Introduction: Transmitted drug resistance (TDR) in new HIV infec-
tions has significant clinical consequences for the treatment success.
Therefore, monitoring of TDR in currently circulating HIV strains is an
important public health issue. We aim to estimate the prevalence of
TDR to protease and reverse transcriptase inhibitors (PIs; RTIs) and to
assess the impact on antiretroviral treatment according to the
currently recommended first-line regimens (European AIDS Clinical
Society (EACS) HIV Guidelines version 8.0[1]).
Materials and methods: Diagnostic laboratories provided dried
serum spots (DSS) of 60% of all newly diagnosed HIV infections
in Germany reported to the Robert Koch Institute (20132015). HIV-
1 genotyping was performed from ‘‘recent infections’’ (B155 days)
as classified by the commercial BED HIV-1 Incidence EIA (Sedia
Biosciences Corporation, Oregon USA); exclusive cases with
CD4B100 cells/L, CDC C) to identify resistance-associated mutations
according to the WHO surveillance drug resistance mutations [2].
Results: Between 2013 and 2015, 3,114/9 and 799 DSS were
classified as recent infection and 1460 were sequenced. Overall
prevalence of TDR was 10.8% (102/1460), comprising 3.8% NRTI-,
2.8% NNRTI-, 2.9% PI-mono-resistance and 1.2% multi-class-resis-
tance. 80% (82/102) of NRTI mutations were thymidine analogue
mutations (TAMs) and T215 revertants, namely M41L (1.4%, 20/
1460), K219NQR (1.0%, 15/1460), D67EGN (0.7%, 10/1460), T215Y,
K70R, L210W (each 1/1460) and T215CDEIS (2.3%, 34/1460),
conferring intermediate resistance to zidovudine and stavudine.
60% of NNRTI-resistance was caused by K103NS (38/1460) conferring
resistance to efavirenz and nevaripine. The most frequent PI
mutations M46IL (1.5%; 22/1460) and V82FL (0.8%; 12/1460) are
associated with low/intermediate resistance to tipranavir, nelfinavir
and/or fosamprenavir. Considering only primary resistance mutations
which impact to drugs currently recommended in first-line regimens
[1], the prevalence of TDR was only 5.4% (0.8% NRTI; 3.1% NNRTI;
0.6% PI; 0.9% multi-drug-resistance).
Conclusions: TDR prevalence in recent HIV-1 infections in Germany
(20132015) remained stably high (10%) and is comparable to
other European countries. TDR was mainly caused by the first-
generation NNRTI-selected K103NS, by long-term persisting TAMs
and the PI-selected M46IL and V82FL.While the K103NS is associated
with failure of current efavirenz-containing first-line regimens, the
impact of TAMs and frequent PI-mutations on the success of current
first-line therapies is predicted to be low and halves the TDR
prevalence (10.8% to 5.4%). However, to allow an optimal ther-
apeutic sequencing genotypic resistance testing prior to treatment
initiation is important and should also include the HIV-integrase.
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Figure 1. Type and frequency of most prevalent resistance-
associated mutations observed.
NNRTI, non-nucleoside/nucleotide reverse transcriptase inhibitors;
NRTI, nucleoside/nucleotide reverse transcriptase inhibitors; PI,
protease inhibitors; TAM, thymidine analogue mutation
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Introduction: We have previously found that the most prevalent
NNRTI-resistant mutations among HIV-1 drug-naı¨ve individuals in
Southern Greece were E138A and K103N. Our aim was to estimate
the transmission dynamics of E138A- and K103N-resistant strains and
to investigate for potential differences in these dynamics between
subtypes A and B.
Materials and methods: We analyzed all sequences with E138A from
179 and 68 HIV-1 treatment-naı¨ve individuals sampled in Southern
Greece infected with subtype A and B, respectively. Similarly, we
analyzed 56 and 18 sequences with K103N from subtypes A and B.
Phylodynamic analyses were performed using the birth-death model
(BDM) in BEAST version 1.8.
Results: The distributions of transmission risk groups were similar for
subtypes A and B for both E138A and K103N. Men who have sex with
men (MSM) represented 69% (N124) and 63% (N43) of
infections with E138A in subtypes A and B, respectively
(p0.586). Similarly, MSM comprised 68% (N38) and 61%
(N11) of individuals with K103N in subtypes A and B, respectively
(p0.355). The time of the most recent common ancestor (tMRCA)
for E138A was estimated in 1992.0 (95% HPD 1987.61995.6) and
1982.6 (95% HPD 1973.71990.6) for subtypes A and B, respectively.
For K103N, the tMRCA was in 1999.0 (95% HPD 1994.72002.5) and
1991.8 (95% HPD 1979.12000.8) for subtypes A and B, respectively.
Notably, the slope of the number of lineages (transmissions) over
time estimated at the exponential phase of the BDM skyline for
E138A sequences of subtype A (10.13, 95% CI 9.3010.90) was 10
times that of subtype B (1.04, 95% CI 0.961.11) (Figure 1a). For
K103N, the slope for subtype A transmissions was approximately 2.5
times (6.16, 95% CI 5.806.52) that for subtype B (2.50, 95% CI
2.452.55) (Figure 1b).
Conclusions: Our study suggests that E138A and K103N HIV-1
resistant mutations are transmitted at higher rates in subtype A
than in subtype B strains. Given that the distributions of transmission
risk groups were similar between the two clades, observed
differences in transmission dynamics could be due to higher
transmissibility of subtype A or different risk behaviour of the
individuals infected with this subtype. This is one of the few studies
highlighting differences in transmission dynamics of resistant strains
belonging to different subtypes.
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Introduction: Dolutegravir (DTG) is an integrase strand transfer
inhibitor (INSTI) against which drug resistance in first-line therapy
has never been observed. However, a R263K mutation that confers
low-level resistance (34-fold) to DTG was selected by us in culture
and also developed in several patients who received DTG as an INSTI
after having failed other drugs. The absence of resistance to DTG is
due to a high fitness cost that is exacted by the R263K mutation, and
the fact that compensatory mutations for R263K have not occurred.
Methods: We measured levels of integrated HIV DNA in cells
infected by HIV containing R263K and other INSTI and non-INSTI
resistance mutations. We also monitored immune responsiveness to
HIV in patients receiving DTG-based therapy.
Results: The R263K substitution alone conferred an approximate 3-
fold level of resistance to DTG, a 40% loss inviral replicative capacity
and a 40% drop in recombinant integrase activity. A continuation of
DTG drug pressure led to secondary mutations at positions H51Y,
E138K or T66I that did not individually affect DTG resistance or
enzyme activity. However, the combination of R263K with H51Y or
E138K slightly increased DTG resistance but also caused a 90% loss in
each of viral replication capacity and integrase activity as measured
both biochemically and by PCR. Most importantly, the continued
propagation in culture of viruses containing both R263K and H51Y
yielded progressively less integrated viral DNA in successive infec-
tions, beginning at 30% of wild-type and dramatically decreasing to
non-detectability thereafter. In addition, our data show that HIV that
is subjected to DTG pressure is unable to evolve and remains durably
Figure 1. Transmission dynamics of resistant strains with E138A
for subtypes A and B. (b) Transmission dynamics of resistant strains
with K103N for subtypes A and B.
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susceptible to anti-HIV neutralizing antibodies and Tcell immune
responses.
Conclusions: Our findings explain why drug resistance to DTG has not
been observed after first-line therapy for more than 3 years since its
approval by regulatory agencies. The use of DTG in first-line therapy
may be compatible with treatment interruption strategies aimed at
attaining a functional HIV cure because of the non-development of
drug resistance.
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Introduction: Previous studies on pre-treatment drug resistance
from sub-Saharan Africa have shown the highest prevalence in
Uganda, particularly in Kampala, with a prevalence of 12.3%.
Antiretroviral therapy (ART) has been publicly available in Uganda
since 2000, with initial use - although limited - of mono/dual
thymidine analogues. This study aims to describe type and frequency
of pre-treatment resistance in HIV-infected Ugandan adults seeking
care at one of the largest public-sector providers in Kampala,
Uganda.
Methods: From 4 June to 30 September 2015, ART-naı¨ve adults (18
years) presenting to the Infectious Diseases Institute (IDI) in Kampala
and willing to participate in this study were asked to give a plasma
sample for pre-treatment HIV genotyping. Sequencing of partial
polymerase gene was conducted using an in-house protocol. All
sequences were submitted to the Stanford University HIV Drug
Resistance database, and the surveillance drug resistance mutations
were identified using the 2009 World Health Organization mutations
list.
Results: Pre-treatment drug resistance testing was available from
152 ART-naı¨ve HIV-infected adults, of which 96 (63.2%) were female
with a median age of 33 years (interquartile range (IQR) 2641), and
a median CD4 cell count of 511 cells/mL (IQR 284713). Mutations
associated with HIV drug resistance were found in 9/152 (5.9%)
patients. Five patients (5/152, 3.3%) harboured nucleoside reverse
transcriptase inhibitors (NRTI) mutations, and 8/152 (5.3%) had non-
nucleoside reverse transcriptase Inhibitors (NNRTI) mutations. Five
(3.3%) patients had one-class mutations, and four (2.6%) showed
double class resistance. Protease inhibitor mutations were not
observed (for specific mutations see Table 1).
Conclusions: Contrary to previous reports we found a low prevalence
of pre-treatment drug resistance among Ugandan adults in Kampala.
We hypothesize that the use of mono/dual thymidine analogues in
the past contributed to a higher circulation of thymidine analogue
mutations (TAMs), as observed in developed settings. The subse-
quent swift scale-up of triple ART in the region may have reduced
pre-treatment resistance over time.
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Introduction: According to many reports, the prevalence of resis-
tance mutations to non-nucleoside reverse transcriptase inhibitors
(NNRTIs) in antiretroviral-naı¨ve patients is increasing; and reaches or
exceeds 10% in some regions. Recently, a surveillance study
performed in Argentina determined that the prevalence of resistance
to first-generation NNRTIs among people starting ART and no history
of previous exposure was 10%. However, some mutations conferring
resistance to newer-generation NNRTIs were not considered since
these are not yet recommended as first-line therapy in this country.
Rilpivirine-based regimens are now preferred or alternative first-line
regimens according to many guidelines. The aim of this study was to
analyze the prevalence of resistance mutations to newer-generation
NNRTIs (rilpivirine and etravirine) in the population starting ART in
Argentina.
Methods: We analyzed the prevalence of resistance mutations
obtained through a nationally representative pretreatment HIV-
drug resistance (PDR) surveillance study performed in Argentina
from 2014 to 2015. Briefly, 30 ART-dispensing sites throughout the
country were randomly chosen to enrol 330 adults starting ART
(without prior exposure or re-starting ART); to generate a point
prevalence estimate of resistance-associated mutations (RAMs) with
a maximum 5% confidence interval (for both the total population
and for those without ARV exposure). Samples were processed with
Trugene (Siemens†), and analyzed using the Stanford algorithm
HIVdb Program, Genotype Resistance Interpretation, version 6.3.1.
This report incorporated in the analysis the mutations that, according
to the IAS list [1], confer resistance to rilpivirine or etravirine (and
were not considered for the original analysis).
Results: Between August 2014 and March 2015, we obtained 330
samples from people starting ART in the selected sites. Mean (SD)
age was 35 (11.0) years; 63.4% were male; median (IQR) CD4 count
was 275/mm3 (106461) and 16.6% had prior ARV exposure. For the
population without prior exposure, the prevalence of RAMs was 13%
(94%), and prevalence of first-generation NNRTI RAMs was 10%
(94%). The prevalence of resistance mutations for second-genera-
tion NNRTIs was 7% (93%) (17 samples with mutations out of 239
successfully sequenced samples). The most frequent mutations
Table 1. Observed pre-treatment drug resistance mutations
Drug class and mutations Total N152 (%)
Any NRTI mutation 5 (3.3)
K65R 1 (0.7)
M184V 2 (1.3)
Other (M41L, T215I) 2 (1.3)
Any NNRTI mutation 8 (5.3)
K101E 3 (2.0)
Y181C 2 (1.3)
K103N 2 (1.3)
Other (M230L, G190A/S, Y188L) 4 (2.6)
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
248
conferring resistance to rilpivirine or etravirine were: E138A (n6)
and E190A (n4).
Conclusions: This PDR surveillance study showed concerning levels
of HIVDR in Argentina, not only for first-generation NNRTIs but also
to rilpivirine and etravirine. In our setting, performing resistance
testing would be necessary before prescription of ART even if the
person would start a second-generation NNRTI-based regimen.
Reference
1. Wensing AM, Calvez V, Gu¨nthard HF, Johnson VA, Paredes R, Pillay
D, et al. 2015 update of the drug resistance mutations in HIV-1. Top
Antivir Med. 2015;23(4):13241.
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Frequency of additional resistance relevant mutations in 2%
and 1% population proportions in next-generation
sequencing (NGS) in routine HIV-1 resistance diagnostics
Robert Ehret; Andrew Moritz; Marcel Schuetze and
Martin Obermeier
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Germany
Introduction: NGS technologies have made their way into routine
diagnostics in HIV-1 resistance testing. The report of mutations of at
least 10% of the viral population is chosen by many laboratories due
to its equivalency to Sanger sequencing minority detection. The
relevance of mutation detected in lower frequencies is still a subject
of debate. We here report the frequency of additional mutations in
population proportions of greater than 2% and 1% in routine
laboratory testing.
Materials and methods: All HIV-1 resistance tests (RTI and PI)
performed between October 2014 and April 2016 with an in-house
PCR followed by NGS (Illumina MiSeq, sequences reported with
100 reads only) were analyzed. Sequences were interpreted by
HIV-GRADE (www.hiv-grade.de) for resistance mutations using 10%,
2% and 1% minority cut-offs. Besides the subtype and the overall
increase in mutations, a specific focus were differences in reported
resistance-associated mutations. We analyzed potential increase in
resistance levels (e.g. additional drug class or further drugs in the
same class).
Results: We performed 645 NGS resistance tests for HIV-1 reverse
transcriptase/protease. Four hundred and eighty-three (74.9%) were
identified as subtype B. No drug resistance-associated mutations
were reported by HIV-GRADE for 44% with a 10% cut-off, 29.5% and
19.7% with 2% and 1%, respectively. With a cut-off of 10% in 148
samples (105 non-B subtype), only PI relevant mutations were
detected. We found mutations only relevant for NRTIs in 21 samples
and for NNRTIs in 100 samples. At a cut-off of 2%, we detected
mutations in 94 more samples increasing to 157 samples when
utilizing a cut-off of 1%. A relevant increase in resistance levels
compared with a 10% cut-off was observed for 102 samples at a cut-
off of 2% and for 229 samples in the 1% cut-off group. The increase
of resistance when lowering the cut-off could be shown for all drug
classes with the highest proportions in the NNRTI drug class.
Conclusions: A relative high portion (56%) of investigated sequences
showed resistance mutations at a minority cut-off of 10%. Even
removing the non-B subtype sequences, containing only secondary
or subtype specific mutations, still left 50% with resistance-
associated mutations. This high percentage of resistance increases
substantially lowering the cut-off range to 2 or 1%. That’s true not
only for the numbers of mutations but also regarding resistance-
levels. There is a clear need for clinical evaluation of the relevance of
mutations in the low percentage range in NGS for resistance
interpretation due to its broader use in clinical routine.
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Introduction: NNRTIs are prone to baseline resistance and potential
treatment failure. We investigated the NNRTI resistance profiles of
antiretroviralnaı¨ve patients in a large urban clinic setting and
assessed their response to initial ART.
Materials and methods: This was a retrospective clinical chart
review of ART-naı¨ve patients with baseline genotypes available. We
assessed the frequency of NNRTI mutations. Of those who started
ART, we conducted Cox regression to determine correlates of
virologic suppression (defined as viral load (VL) 540 or 50 copies/
mL by 6 months) with presence of baseline NNRTI resistance as the
primary correlate. Of those with virologic suppression, we conducted
Cox regression to determine correlates of virologic rebound (defined
as VL ]200 copies/mL). Censoring occurred for those who did not
have any follow-up VLs and at last VL or visit date for those without
evidence of viral suppression.
Results: Of the 1338 that fit the inclusion criteria, 90 (8.4%) had
baseline NNRTI resistance (39 with 103N, 20 with 138A/G/K, 17 with
181C and 8 with 101E/H/P). Of the 90, nine (10%) had 184V, 23
(26%) had NRTI mutations and six (7%) had PI mutations. One
thousand two hundred and eighteen (91%) of the ART-naı¨ve patients
were started on ART. Patients without NNRTI mutations were most
commonly started on NNRTI-based regimens (41%), followed by PI-
based (30%) and integrase inhibitor (INI)-based regimens (11%).
Patients with baseline NNRTI resistance (n83) were most com-
monly started on PI-based regimens (41%), followed by INI-based
regimens (19%). Virologic suppression was observed for 963 out of
1218 individuals (79%) that started ART. Eighty-five percent and 90%
of patients with and without NNRTI mutations achieved suppression,
respectively. In univariate Cox regression, the presence of baseline
NNRTI resistance did not impact virologic suppression (HR 0.98; 95%
CI 0.761.24). In multivariable analysis, adjusting for age, gender,
baseline VL and CD4 count, duration of HIV and baseline PI
mutations, the presence of NNRTI mutations still did not impact
virologic suppression (aHR 0.96; 95% CI 0.741.24). For virologic
rebound, the presence of baseline NNRTI resistance also did not
impact its occurrence (HR 1.11; 95% CI 0.681.81). In multivariable
analysis, after adjusting for age, gender, baseline VL and CD4 count,
duration of HIV and baseline PI mutations, the presence of NNRTI
mutations also did not impact virologic rebound (aHR 1.09; 95% CI
0.661.78).
Conclusions: Baseline NNRTI mutations were present in 8.4% of our
antiretroviral-naı¨ve patients. Despite having baseline NNRTI muta-
tions, the majority of the patients reached virologic suppression and
did not experience changes in virologic rebound.
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Enhanced surveillance to study HIV-1 drug resistance among
naı¨ve individuals in Southern Greece: the added value of
molecular epidemiology to public health
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Introduction: The prevalence of resistance to NNRTI was previously
estimated to be 16.9% among drug-naı¨ve individuals in Greece. Our
aim was to investigate the dispersal patterns of HIV-1 resistant
strains and to estimate the effective reproductive number (Re) and
transmission dynamics for locally transmitted resistance.
Materials and methods: We analyzed sequences from 3428 HIV-1
treatment-naı¨ve individuals sampled in Southern Greece during 1
January 2003 to 31 June 2015. Phylogenetic analysis was performed
on subtype A (N235) and B (N86) sequences with NNRTI
resistance (K103N and E138A), along with sequences isolated from
seropositives without resistance from Greece sampled during 1998
to 2013 (subtype A: N904; subtype B: N1615) and a randomly
selected global dataset (subtype A: N5907; subtype B: N3984).
Phylogenetic trees were inferred by maximum likelihood method as
implemented in RAxML. Phylodynamic analyses were performed
using birth-death models (BDM) as implemented in BEAST2.
Results: Phylogenetic analyses revealed that for subtype A, the
majority of individuals infected with resistant strains (209 out of 235,
88.9%) belonged to monophyletic clusters (local transmission net-
works, LTNs). Specifically, 48 out of 56 (85.7%) of sequences with
K103N, and 148 out of 179 (82.7%) with E138A belonged to one and
four LTNs, respectively. These findings suggest that the viruses with
the most prevalent resistance mutations spread locally. For subtype
B, either non-clustered sequences or small LTNs (26 sequences),
were identified. The time of the most recent common ancestor
(tMRCA) was in 2007 (95% HPD: 20042009) for the K103N cluster
versus 1995 (95% HPD: 19911999), 1996 (95% HPD: 19892000),
1997 (95% HPD: 19912001) and 2004 (95% HPD: 20002007) for
E138A LTNs (Figure 1). For the K103N sub-outbreak the Re was
higher than 1 between 2008 and the first half of 2013 (maximum
value of median Re2.8) (Figure 1). On the contrary, for all E138A
LTNs the Re was higher between 2011 and 2015, except the most
recent one where the Re was approximately equal to 1.
Conclusions: Our study suggests that the most prevalent mutations
associated with resistance to NNRTIs were transmitted through local
networks in Greece. Notably, phylodynamic analysis allows estimat-
ing that resistance in the last few years has been actively propagated
with an increasing incidence. Those belonging to the active TDR
networks are the priority population for prevention (TasP). Our study
highlights the added value of the latest advances in molecular
epidemiology to public health since these allow us to estimate
critical epidemiologic parameters and therefore the priority popula-
tion to intervene.
P361
Transmission patterns of HIV-1 subtype A resistant strains
across Greece: evidence for country and regional level
transmission networks
Figure 1. Phylodynamic characteristics of the major sub-outbreaks with resistant mutations in Southern Greece.
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Introduction: The prevalence of mutations conferring resistance to
NNRTIs was previously reported to be higher than 15% among drug-
naı¨ve individuals both in Northern and Southern Greece. The most
prevalent resistance mutations were E138A, K103N and Y181C
associated mostly with subtype A1. Our aim was to investigate the
dispersal patterns of HIV-1 resistant strains across Greece.
Materials and methods: We analyzed sample of subtype A1
sequences (N1104) obtained between 1999 and middle-2015
from both areas in Greece. We included sequences only from Greece
since we have shown previously that subtype A1 sequences have
been mostly found within a single monophyletic cluster. Phylogenetic
trees were inferred by maximum likelihood method as implemented
in RAxML using the GTRG as nucleotide substitution model with
bootstrapping.
Results: Phylogenetic analyses revealed that E138A and K103N
resistant strains have spread through large monophyletic clusters
spanning both Northern and Southern Greece, suggesting that all
transmissions within these clusters occurred regionally. Conversely,
Y181C formed a subnetwork (monophyletic cluster) limited in
Northern Greece with only a single spill over to Southern Greece.
Specifically, for K103N strains we found a large (N49) and a small
cluster (N5) including sequences from both areas. Sequences from
Northern Greece formed two specific subnetworks, suggesting local
dispersal. Similarly sequences with E138A from Northern Greece
formed two specific subnetworks within the E138A monophyletic
clades found for Greece. The latter consisted of four major clades of
53, 41, 29 and 25 sequences from both regions. Overall, we found
that E138A and K103N spread through common networks across the
country with evidence of local transmissions in Northern Greece. On
the contrary, Y181C has spread only in Northern Greece with very
limited dispersal to Southern Greece.
Conclusions: A high prevalence of NNRTI resistance mutations was
previously reported for the subtype A1 strains circulating in Greece
and especially in Northern Greece. Our study provides evidence that
the majority of these resistant viruses were transmitted within
common transmission networks. Notably, significant clustering of
sequences from Northern Greece as well as the existence of a
regional cluster suggest high transmission networking of the
population in this area; a finding that might explain the higher
prevalence of transmitted drug resistance (TDR) in Northern Greece.
Our study highlights the priority population to prevent TDR in the
future.
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Introduction: In Europe, country-specific treatment guidelines often
do not advocate testing for integrase inhibitor resistance-associated
mutations (IRAM) before initiation of first-line ART given the
extremely low prevalence of mutations found in older surveillance
studies. However, increased use of integrase inhibitors (INSTI) might
have led to the emergence of treatment-limiting mutations in more
recent years. We aimed to determine the prevalence of IRAM in
Austria in the 5 years following introduction of INSTI and to analyze
trends and factors associated with their detection.
Methods: Samples of antiretroviral treatment-naı¨ve patients in
Austria between 2008 and 2013 were analyzed for the existence of
IRAM using bulk sequencing with published primers and drug-
resistant mutation penalty scores (DPS, Stanford HIVdb algorithm)
were calculated to estimate response to antiretroviral drugs.
Demographic and virologic data including age, sex, viral subtype,
drug resistance-associated mutations to PI and RTI were extracted
from a database. Comparative statistics and logistic regression
models were used to analyze risk factors for the occurrence of IRAM.
Results: A total of 303 samples were analyzed. Seventy-eight percent
were male and median age was 36 years. HIV subtype B was most
common (62%) followed by subtype C (12%). Overall prevalence of
IRAM was 2.3%. Six percent had a DPS ]10 for raltegravir or
elvitegravir, respectively, indicating at least potential low-level
resistance. One percent had a DPS ]10 for dolutegravir. One major
mutation was observed (F121Y) in a patient sample from 2012
leading to 5- to 10-fold reduced susceptibility to raltegravir and
elvitegravir. Two patients carried the major accessory mutations
E138K and G140A, respectively, which both lie on the Q148 pathway.
No temporal trend was observed (p0.16). Presence of any IRAM
was not significantly associated with male sex (OR 0.78, 95% CI 0.14
4.30), older age (OR 0.98, 95% CI 0.911.05), calendar year (OR 1.28,
95% CI 0.802.03) or occurrence of any other drug resistance
mutations (OR 1.41, 95% CI 0.1612.23) in a multivariable logistic
regression.
Discussion: Major primary IRAM are rarely found despite increasing
use of INSTI in Austria but there is potential for reduced suscept-
ibility to these drugs in selected patients. In the absence of
predictors for occurrence of IRAM routine resistance testing seems
prudent to avoid the consequences including accumulation of further
mutations and therapeutic failure.
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Introduction: The HIV-1 infected population in Israel is unique in its
diversity. Until recently, the rate of transmitted drug-resistance
mutations (TDRs) was relatively highmainly to NNRTIs.The prevalence
of TDRs is regularly evaluated in treatment-naı¨ve patients in Tel Aviv.
Methods: All blood samples obtained from treatment-naı¨ve patients
between 2010 and 2015 were analyzed for reverse transcriptase (RT)
and protease resistance-associated mutations. Phylogeny on 614
sequences of subtypes A, B and C viruses (the main subtypes
represented) was inferred by pol sequences.
Results: Viral sequences from 672 patients were tested. Men who
have sex with men (MSM) was the major exposure risk category
group (n375), 76% among them were born in Israel, and 88%
harbor subtype B viruses. Other groups include intravenous drug
users (IVUs) (n99); 78% of them were born in the former Soviet
Union countries and 86% harbour subtype A viruses. The hetero-
sexuals group is very heterogeneous and includes patients born in
Israel, Ethiopian immigrants, former Soviet Union and worker
immigrants or refugees mainly from Africa. The resistance rate
decreased from 15.9% in 2010 to 5.9% in 2013 (pB0.05). In 2014
and 2015, it increased to 13.8% and 14.2% respectively. Same
pattern was observed among MSM. Phylogenetic analysis of subtype
B viruses supported clustered transmission among MSM. In 2010 to
2011 a cluster represented by the protease inhibitor mutation L90M
was observed, and in 2014 to 2015 a cluster represented by NNRTIs
(K103N)-associated mutations. In subtype A, a cluster among IVUs
was found at 2012 during an outbreak, without resistance-associated
mutations. However, a cluster harboring resistance mutation at
position 103 in RT was observed in four MSM with subtype A virus.
Subtype C viruses were not represented by specific clusters.
Conclusions: TDRs among patients followed in Tel Aviv were
represented by clusters in MSM. These clusters were containing
resistance-associated mutations to drugs less prescribed in recent
years in Israel. Although the integrase inhibitor (InI) region is not
analyzed routinely in treatment-naı¨ve patients low rate of InI TDRs is
reported in other studies. Regular assessment of genotyping in
treatment-naı¨ve populations including the integrase region is
essential in order to understand the potential epidemiologic
transmission of HIV clusters and effect of resistance on current
ARV strategies.
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Introduction: As second-generation integrase inhibitor (INI), dolute-
gravir (DTG) has shown a superior barrier to resistance as compared
with profiles of raltegravir (RAL) or elvitegravir (EVG). Current fin-
dings suggest that resistance mutations against INIs extreme rarely
occur under DTG-containing first-line ART. However, this case report
unveils a possible development of a T66I-mediated cross-resistance
against EVG under DTG first-line regimen.
Methods: A first-line treatment with lamivudine/abacavir, lopinavir
and dolutegravir was initiated by a 44-year-old man with a diagnosis
of HIV in November 2015 (CDC status B2, CD4 nadir 219/mL, HIV-1
RNA 350,000 copies/mL). Ultra-deep sequencing was performed
by using population sequencing and ultra-deep sequencing (UDS,
Illumina MiSeq) at baseline and at time of therapy failure. Resistance
interpretation was estimated by using the HIV-Grade 12/2015,
Stanford HIVdb version 7.0.1, Rega version 9.1.0 and the ANRS
25_09/2015 database. Viral load was quantified with Abbott
Realtime.
Results: Before start of therapy, no resistance-associated variants
could be detected neither by population nor by UDS in HIV protease,
reverse transcriptase and integrase. After start of DTG first-line
therapy, HIV viral load dropped from 300,000 copies/mL to 2400
copies/mL within 4 weeks of follow-up and was undetectable at
week 8. CD4 cell counts increased from 219/mL to 479/mL (13.4%).
However, 20 weeks after initiation of ART, HIV viral load increased to
105 copies/mL and maintained low viremic 4 weeks later at 112
copies/mL most likely due to inadequate adherence although plasma
drug levels turned out to be above critical limits. More importantly,
the development of the INI resistance mutation T66I was then
verified by UDS showing a minority population of 36.1%. The variant
T66I is a non-polymorphic mutation and reduces EVG susceptibility
by 15-fold while susceptibility to RAL or DTG is reported to be
unaffected. There was no evidence for protease or reverse tran-
scriptase resistance mutations at this time. Twenty-eight weeks after
start of therapy the viral load decreased to undetectable levels
without any changes.
Conclusion: Although being extreme rarely observed, INI-resistant
HIV variants may also occur under DTG first-line treatment. The T66I
alone does not necessarily limit the susceptibility to DTG itself but
could be a first step of resistance development against DTG. It is
reported that T66I confers high-level resistance against EVG and may
also putatively lower the resistance barrier against RAL.
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containing regimens in Taiwan: a multicentre cohort study
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Introduction: Non-nucleoside reverse-transcriptase inhibitor (NNRTI)-
containing ART remains the recommended first-line regimens for
adults infected with HIV in many resource-limited countries. Increas-
ing trends of resistance-associated mutations (RAMs) to NNRTIs have
caused concerns about the effectiveness of the regimens in national
programs in these regions. In this multicentre study, we aimed to
investigate the incidence of emergent RAMs of HIV-1 to ARVs in HIV-
positive adults who developed virologic failure to first-line NNRTI-
containing ART in Taiwan.
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Materials and methods: Between June 2012 and March 2016,
ARV-naı¨ve HIV-positive adults who initiated two NRTIs plus NNRTI
at participating hospitals were included for analysis. Plasma HIV
RNA load (PVL) was determined at baseline, and week 4 to 6 and
subsequently every 12 to 16 weeks after ART initiation. Virologic
failure was defined as a decrease of PVL B1.0 log10 copies/mL in
4 to 6 weeks of ART initiation; or PVL 200 copies/mL at 6 months
of ART initiation; or confirmed HIV RNA ]200 copies/mL after viral
suppression (PVL B50 copies/mL). Population sequencing was used
to detect RAMs. Detection of RAMs at baseline was performed
retrospectively. RAMs were interpreted using the IAS-USA 2015
mutations list.
Results: During the 3.5-year study period, 1642 patients initiated
NNRTI-containing regimens, and 454 (27.4%) had to switch first-line
ART because of adverse effects or intolerance (n323, 19.7%),
retrospective detection of RAMs at baseline (41, 2.5%) and virologic
failure (83, 5.1%). Virologic failure to two NRTIs plus nevirapine,
efavirenz and rilpivirine was 9.7% (41/422), 4.2% (40/946) and 0.7%
(2/277), respectively. In 68 patients, (3.8%) emergent RAMs were
identified: 42 patients (62.7%) with NRTI RAMs; 28 (41.2%), one
(1.5%) and 48 patients (71.6%) with NNRTI, protease inhibitors (PI)
and any ARV RAMs, respectively, and 21 (31.3%) with resistance to
two or more classes of ARV. The common emergent RAMs to NRTIs
were K65R (25%), M184I (10.3%) and M184V (36.8%), and RAMs to
NNRTIs included V90I (5.9%), K101E (5.9%), K103N (19.1%), V108I
(7.4%), Y181C (11.8%) and G190A (5.9%) (Figure 1).
Conclusions: While a substantial proportion of the patients discon-
tinued first-line NNRTI-containing regimens due to adverse effects,
virologic response to NNRTI-containing regimens remained good in
patients who were able to tolerate the regimens in Taiwan. Most
common RAMs in those with virologic failure were related to
exposure to tenofovir disoproxil fumarate, lamivudine, nevirapine
and efavirenz.
P366
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Introduction: The German-Austrian guidelines for the treatment of
HIV infection define therapeutic success as the reduction of the HIV-
1 viral load (VL) below 50 copies/mL. Low-level viremia (LLV) is
defined as repeated VL measurements between 50 and 200 copies/
mL after initial therapeutic success. LLV has been previously
associated with virologic failure (VF). Here, we provide an indepen-
dent analysis of the association of LLV and other factors with VF.
Materials and methods: The Arevir database comprises clinical and
virologic data of therapy-naı¨ve and therapy-experienced HIV-1-
infected patients in North Rhine-Westphalia, Germany, including
the data of the RESINA cohort. We queried the Arevir database for
patients who attained confirmed therapeutic success under ART
and who experienced confirmed LLV thereafter. We constrained our
query to therapies in which the VL was measured at least once every
24 weeks. We define VF as a confirmed VL greater than 200 copies/
mL following therapeutic success. P-values were calculated with
Fisher’s exact and Wilcoxon rank sum test.
Results: The database query resulted in 2485 first-line and 3657
further-line therapies. LLV occurred in 294 (4.8%) of these therapies,
specifically in 47 (1.9%) first-line and in 247 (6.8%) further-line
therapies. The mean time to LLV was 27 months (s20.7), with
no significant differences between first- or further-line therapies
(p0.4597). The majority of patients showing LLV were treated with
PI-based therapies (165/294; 56%), followed by NNRTI-based
regimes (76/294; 26%). Fifty-three out of 294 (18%) patients ex-
perienced VF after LLV with a median VL at failure of 472 copies/mL
(range 203116,590 copies/mL) after a mean LLV episode of 77.4
weeks (s68.0). The failure rate was increased in therapy-
experienced patients (48/247; 19.4%), as compared with therapy-
naı¨ve patients (5/47; 10.4%; p0.2129). There was no difference in
VF between PI-based and NNRTI-based therapies regardless of the
backbone (33/165; 20% and 13/76; 17.1%, respectively; p0.6049).
Among all drug classes, VF was never related to entry inhibitors,
integrase inhibitors or the more recently approved compounds DRV,
TPV and RPV (45/204 vs 0/83, respectively; pB0.0001).
Conclusions: The prevalence of LLV in patients on suppressive ART is
low (4.8%). Nevertheless, 18% of patients with LLV experienced VF
thereafter. The strongest predictor for VF after LLV was a treatment
regimen exclusively containing drugs of the older generations.
Therefore, episodes of LLV in patients treated with drugs with high
potency and a high barrier to resistance are not predictive of VF.
Figure 1. Patterns of emergent resistance-associated mutations
after initiation of three different non-nucleoside reverse-transcrip-
tase inhibitor-containing regimens.
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Introduction: cART has resulted in significant reduction of mother-
to-child-transmission (MTCT) from 40% to 1 to 2% in the last
2 decades. Choosing an individualized cART is one key factor for
successful suppression of viral load until delivery. Thus, drug resis-
tance testing during pregnancy before cART initiation or in case
of increasing viral load is recommended. The prevalence of drug
resistance mutations (DRM) in pregnant women in Germany has not
been characterized yet.
Materials and methods: Between January 2009 and March 2016, HIV
drug resistance of all HIV-positive pregnant women was analyzed.
Resistance testing was performed by using Sanger sequencing and
next generation sequencing (NGS) by means of Illumina MiSeq-
technology. Resistance interpretation was performed by the HIV-
GRADE HIV-1-Tool (www.hiv-grade.de).
Results: Data of 85 HIV-positive pregnant women and 103 live births
were analyzed. In 64/85 cases (75%), resistance testing was
requested, with 61/64 successful analyses. The majority of patients
were migrants (88%), 75% of these women had their origin in Sub-
Saharan Africa (SSA). The majority of the patients were infected with
non-B-subtypes (54/61, 88%), mainly 02_AG (23/61, 38%), followed
by C (8/61, 13%) and A (7/61, 11%). In 14/61 (23%) resistance tests,
DRM were found, in 9/14 due to ART history whereas five patients
were therapy-naı¨ve with presumably transmitted DRM (tDRM) or
DRM due to immunological mechanisms like APOBEC3G/F (e.g. M184I,
M230I) [1]. Five of 14 patients contained a two-class resistance
against NRTI/NNRTI (Figure 1). Most common mutations were:
M184VI (5/14), T215Y/F/N (4/14), Y181C (3/14) and K103N (3/14).
NGS analysis showed additional mutations in 4/14 patients. No MTCT
has been observed.
Conclusions: In 23% (14/61), of all HIV-positive pregnant women
in our study DRM have been observed, in 8% tDRM (5/61). The
prevalence of tDRM in pregnant women is lower than in general
German population of HIV-positive individuals. Using resistance
testing by NGS resulted in the identification of additional relevant
DRM compared to Sanger. Considering the importance of viral load
suppression in pregnancy and the limited amount of time to achieve
this goal, the choice of cART should be optimal and take these
mutations into account. Genotypic resistance testing should be
therefore considered for all pregnant women to optimize the success
of cART and hence prevent mother-to-child transmission.
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Introduction: Combination antiretroviral therapy has greatly reduced
the rate of morbidity and mortality among HIV-1 infected patients.
However, high mutation and recombination rates of HIV-1 lead to the
emergence of various subtypes and drug resistance viruses, render-
ing first-line ARV therapy ineffective in many patients. The aim of this
sub-study is to describe the prevalence of HIV-1 subtypes and the
patterns of drug resistance mutations among ARV-naı¨ve HIV-1
infected patients from six different countries participating in the
GARDEL study [1].
Materials and methods: A total of 543 naı¨ve patients from six
countries (Argentina, Chile, Spain, Mexico, Peru and US) were
screened between December 2010 and May 2012, and 534 HIV
Figure 1. Drug resistance mutations in pregnancy.
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sequences were analyzed following the IAS-USA 2014 Drug Resis-
tance Mutations Panel [2]. Genotypic assays performed at screening
visit were: PhenoSense HIV assay (Monogram Biosciences, San
Francisco, CA, USA), ViroSeq HIV-1 (ViroSeq HIV-1 Genotyping System
version 2.0, Celera, Alameda, CA, USA) and TRUGENE† HIV-1
Genotyping Assay (Siemens Healthcare Diagnostics, Munich, Ger-
many), according to availability at each site.
Results: Of the 534 patients screened, 74% were Hispanic/Latino.
Median time of infection at SCR was 10.5 months. CDC stage A: 82%.
Of 450 viral subtypes available, the most frequent was subtype B in
all three regions (Latin America (LA): 72% B, 17.6% BF; US/Mexico:
92% B; Spain: 91.2% B). A total of 113 samples (21.2%) had major
resistant mutations; 22 samples (4.1%) had major protease muta-
tions (M46I was the most common mutation: 1.5%), 85 samples
(15.9%) had NNRTIs mutations (K103N/S was the most common
mutation: 4.9%) and 17 samples had mutations to NRTIs (3.2%) and
M41L (1.3%) was the most common mutation. PIs: only two patients
had more than one major mutation (2/22). The more frequent minor
mutations were: M36I/L/V (216/534), L63P (120/534), L10I/F/V/R
(115/534) and K20R/M/I: 59/534. The global resistance analysis by
regions showed 21% for LA, 22.8% for US/Mexico and 14.7% for
Spain, being NNRTI resistance by regions 16.4%, 15.4% and 11.8%
respectively. PI resistance was 3.1% for LA and Mexico/US and NRTI
resistance was 3.1% for LA, 3.4% for US/Mexico and 2.9% for Spain.
No Q151M, 69ss or K65R were identified.
Conclusions: In our study, we found a primary resistance rate of
21.2%, similar in LA and US/Mexico. Levels of NNRTI resistance are
similar in the three analyzed regions, as previously reported in naı¨ve
populations, and reinforce the need of performing genotypic testing
in ARV-naı¨ve patients, especially in LA where the first-line therapy is
still based on NNRTI drugs.
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Introduction: The highly effective antiretroviral therapy has changed
the natural history of HIV/AIDS, delaying the disease progression and
improving the quality of life of the infected individuals. In treated
HIV-1 population in Cuba, several factors might have contributed
to high drug resistance levels such as prescription of suboptimal
regimens containing non-boosted PI, prolonged exposure to failing
therapies due to limited access to laboratory monitoring and limited
options for antiviral drug substitutions if required. This might also
result in the subsequent spread of drug-resistant strains. The
performed studies in untreated population have shown high levels
of HIV resistance to the antiretroviral therapy ranging from 12 to
21%. The aim of this study is to determine the levels of primary HIV
drug resistance in newly diagnosed Cuban patients on a representa-
tive sample of the country.
Materials and methods: Demographic, clinical and laboratory data
were collected from 263 recently HIV-1 diagnostic patients from April
2013 to April 2014. The HIV-1 pol gene was sequenced using Sanger
sequencing and drug resistance was interpreted according to the
World Health Organization surveillance drug-resistance mutations
(SDRM) list, version 2009. HIV-1 subtyping was performed using the
Rega subtyping tool, version 3.
Results: Experiments were successful for 189. The mean age at
sampling was 33.5 years (1774), 80.9% of the patients were men
and the major transmission route was MSM (80.3%). 72.4% had
recent infection and 38.6% were from Havana. The median value viral
load was 58,000 RNA copies/mL and CD4 count value was 371 cells/
mm3. In 17.4% (33/189) of the studied viruses, transmitted
resistance mutations were detected, 22 (66.6%) were HSH, 26
(78.8%) were a recent HIV-1 infection, 13 (39.4%) were from Havana
and 9 (27.2%) were infected with CRF19_cpx. Simple non-nucleoside
mutants contributed the highest amount (45.5%), followed by
double class resistance against NRTI and NNRTI (27.3%) and single
mutants to the IP (12.1%). The most common mutation associated
with resistance to NRTI was M184V (24.2%), for NNRTI was K103N
(45.4%) and Y181C (30.3%) and for PI was D30N (6%).
Conclusions: This study confirms the high levels of resistance in
untreated population, it demonstrates the commitment of first-line
therapies used in the country and could put at risk future therapies.
It highlights the need for studies to elucidate the factors that are
influencing detected high levels of resistance in newly diagnosed
population. It also shows the need for resistance testing in patients
who are starting the therapy.
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Introduction: Genotypic resistance testing is paramount for the
monitorization of the emergence of antiretroviral drug-resistant
virus. The Viroseq HIV-1 genotyping system version 2.0 is an IVD
assay for sequencing of HIV-1 from plasma but only feasible if the
viral load is at least 1000 copies/mL. However, some patients have a
persistent low HIV-1 viremia inferior to 1000 copies/mL, being
resistance testing and antiretroviral therapy hampered by this. So,
for their clinical management, resistance testing solutions must be
made available [1]. With this regard, we developed an in-house assay
adapting the Viroseq version 2.0 with a nested-PCR protocol.
Materials and methods: Blood samples from 36 patients on HAART
with a viral load between 20 copies/mL and 1000 copies/mL (range
36934 copies/mL; mean 357 copies/mL) were collected in K3EDTA
and the plasma separated 6 hours after sampling and stored at
808C. HIV-1 was concentrated by centrifugation of 1 mL of plasma
at 24,000 g for 1 hour at 48C. After removal of the supernatant, 1 mL
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of plasma was added and the sample thoroughly homogenized. RNA
extraction was performed in the QIASymphonySP equipment from
QIAGEN (Hilden, Germany) using the QIAsymphony Virus/Pathogen
Mini Kit and an in-house protocol, rendering a final volume of 30 mL.
The Viroseq protocol was performed according to the manufacturer
instructions, followed by a nested-PCR protocol previously described
by Mackie et al. [2]. The 50 mL PCR mix contained 0.5 mM of each
primer, 1x Incomplete NH4 Reaction Buffer (DFS-Taq DNA Poly-
merase, Bioron Life Science), 0.2 mM of deoxyribonucleotide, 2.5
units of DFS-Taq DNA Polymerase and 5 mL from the products of the
first PCR. The PCR was performed on a Perkin Elmer PE9700
thermocycler and consisted on an initial denaturation for 5 minutes
at 958C, followed by 40 cycles of 958C for 30 seconds; 558C for 30
seconds, 728C for 120 seconds and a extension at 728C for 7 minutes.
PCR products were sequenced on the 3130xl DNA Analyzer (Applied
Biosystems) and analyzed in Viroseq version 2.8.
Results: Sequencing and drug resistance testing was successful in
70% (9/13) of the samples with a viral load 36 to 200 copies/mL; in
93% (13/14) of the samples comprising 200 to 500 copies/mL and in
100% (9 /9) of the samples with 500 to 1000 copies/mL.
Conclusion: Genotypic resistance testing is essential for the mon-
itorization of the emergence of antiretroviral drug-resistant virus
being necessary for the development of assays for patients with low
viral loads.
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Introduction: Presepsin, a newly discovered soluble fragment of
CD14, has been studied as a sepsis biomarker. The mechanism of its
secretion is involved in the TLR4 activation cascade and it is related
to mCD14 and sCD14, which are monocyte activation markers,
indirectly representing the presence of bacterial translocation.
Therefore presepsin could be employed as an immune activation
marker, and it could allow for the estimation of bacterial transloca-
tion rates [1]. The aim of this study was to assess the correlations
between presepsin serum concentration and bacterial translocation,
immune activation and fibrosis markers in subjects with HIV and
hepatitis C virus (HCV) mono-infections and in HIV/HCV co-infection,
compared to healthy controls.
Materials and methods: This cross-sectional study included patients
with HCV and HIV mono-infections, HIV/HCV co-infection and healthy
controls (20 subjects/group). Peripheral blood was analyzed to
determine the levels of presepsin, Forkhead box 3 (Foxp3) T cells,
TGF-b1, CD14 (soluble and surface isoforms), IL-17 and bacterial
translocation products. These measurements were correlated to the
severity of liver fibrosis, measured with the FIB-4 score and transient
elastography.
Results: Presepsin concentration was significantly higher in the HIV
patients (HIV mono-infected and HIV/HCV co-infected). The same
group showed increased levels of sCD14 and mCD14, expression of
immune activation. Statistical analysis shows a significant correlation
between presepsin and both forms of CD14 only in HIV/HCV
group, where the percentage of bacterial translocation and chronic
inflammation is high, as shown by the significant increase in bacterial
DNA levels, sCD14, mCD14 and IL-17. Presepsin is associated with
FIB-4 values in the HCV group.
Conclusions: Presepsin is a biomarker of chronic immune activation,
as demonstrated by its correlations with sCD14, mCD14 and
CD4CD25Foxp3 lymphocytes, particularly in HIV infection.
Its concentration is correlated to liver fibrosis markers, such as FIB-4,
particularly in HCV mono-infected patients. Considering presepsin
and a direct correlation between the levels of fibrosis and an inverse
correlation with Treg cells in this group, the low levels of Treg cells
may be involved in increasing the state fibrosis in chronic HCV
patients.
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Introduction: HIV CRF19_cpx has been described as a highly patho-
genic recombinant from Cuba [1]. Furthermore, these infections are
typically associated to higher viral load (VL) at diagnosis and rapid
progression to AIDS [2]. Here, we describe the emergence of this
CRF19_cpx variant in southern Spain, clustering in men having sex
with men (MSM).
Materials and methods: The study was undertaken at the Virgen de
la Victoria Hospital, a reference centre for the analysis of HIV-1
genotypic drug resistance in Malaga (Spain). The subtype for each
FASTA sequence provided was assigned through REGA version 3.0.
Sequences consigned as a CRF19_cpx variant were confirmed by
phylogenetic analysis with other 195 reference sequences retrieved
from LANL. Protease and reverse transcriptase (RT) genes were
aligned by ClustalX and the phylogenetic reconstruction inferred by
maximum likelihood method (RAxML). The reliability of the clades
was supported on bootstrapping, with 1000 replications. For analysis
of RT and protease resistance mutations, Standford algorithm version
7.1.1 was used. Additionally, we collected epidemiologic, clinical and
immunologic data.
Results: Genotypic test was performed in 2298 naı¨ve patients from
four hospitals during 2011 to 2016, finding the CRF19_cpx variant in
49 of them (2.1%). These recombinants, except one, were clustered
together (bootstrap93%), with phylogenetic relation to CRF19_cpx
from Israel, Bulgaria and Cuba. Seven well-supported subclusters
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with different number of patients were also found: A, D, F and G
(n2); B and E (n8); and C (n3) (Figure 1). Non-nucleoside RT
inhibitor G190A resistance mutation was found in 24 patients
(48.9%), among them, clades C, D, E and F. All the patients were
MSM, 21 of them (42.8%) had a prior negative HIV test, with a
median time of seroconversion of 15 months (IQR 10.722.8). All
were Spanish, except for two patients from Argentina and one from
France. The mean age was 35.0 years (26.341.5), the initial CD4
count was 361/mL (254416) and VL 4.9 log (4.55.4), being lower in
patients with G190A mutation (4.6 vs 5.1, p0.02). Three cases of
AIDS (6.1%) and one death occurred (acute myocardial infarction). All
the patients treated with first-line combination ART responded.
Conclusions: CRF19_cpx variant has emerged affecting MSM naı¨ve
patients from southern Spain; all cases but one are related to a local
cluster. Half of patients showed the G190A resistance mutation.
Unlike previous studies, the variant from Malaga seems less patho-
genic, with few cases of AIDS and excellent response to ARV.
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One-step real-time PCR for HIV-2 group A and B RNA plasma
viral load in LightCycler 2.0
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Marina Ferreira1; Dina Hortela˜o1; Carolina Rocha1; Claudia Vaz1;
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Anto´nio Sarmento2
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Porto, Portugal. 2Infectious Diseases, Sa˜o Joa˜o Hospital, Porto,
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Introduction: Although with a lower prevalence than HIV-1, HIV-2 is
responsible for localized epidemics, being Portugal the non-African
country with the greatest expression of the infection. Clinical
management of the infection is hampered by the lack of validated
commercial RNA viral load assays, thus there an in-house develop-
ment using the available equipment is mandatory.
Materials and methods: HIV-2 was confirmed by Innolia# (Innoge-
netics, Gent, Belgium). Blood samples were collected in K3EDTA and
the plasma separated 6 hours after sampling and stored at 808C.
The BIOQ HIV-2 RNA group A quantification panel (Biocentric) was
used as an external standard. RNA extraction was performed from
1000 mL of plasma in the QIASymphonySP equipment from QIAGEN
(Hilden, Germany) using the QIAsymphony Virus/Pathogen Mini
Kit and an in-house protocol, rendering a final volume of 60 mL. RNA
from the samples and standards was isolated under the same
conditions. The protocol was based on the previously described by
Avettand-Fenoel et al. [1]. The forward and reverse primers for the
LTR region were 5’TCTTTAAGCAAGCAAGCGT GG-3 and 5’-AGCAGG-
TAGAGCCTGGGTGTT-3 and for the gag region F3 5’-GCGCGA-
GAAACTCCGTCTTG-3 and R1 5’-TTCGCTGCCCACACAATATGTT-3. The
probe for the LTR region was 5’FAM-CTTGGCCGGYRCTGGGCAGA-BHQ1-
3 and for the gag region S65GAG2 5’FAM-TAGGTTACGGCCCGGCG-
GAAAGA-BHQ1-3. The one-step RT-PCR was performed on the
LightCycler 2.0 (Roche Diagnostics, Mannheim, Germany). The Light-
Cycler RNA Virus Master Kit from Roche (Roche Molecular Biochem-
icals) was used. The 20 mL reaction mixture contained 0.5 mM of each
primer, 0.25 mM of each probe, 0.4 mL of Enzyme Blend and 7.5 mL of
the isolated RNA. The thermocycling consisted of 10 minutes at 608C
Figure 1. Phylogenetic tree with CRF19_cpx reference sequences, and subtree containing the clustering of our 49 patients obtained by
maximum likelihood. Only support values ]70% are shown.
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and 60 seconds at 958C, followed by 50 cycles of 958C for 5 seconds,
608C for 50 seconds and 728C for 10 seconds.
Results: The standard curve generated by the LightCycler software
(version 4.05) presented an efficiency of 2.079 and an error of
0.0657. This RT-PCR provides an increment in sensibility to 50 copies/
mL and the detection of HIV-2 B subtypes. In comparison to the RT-
PCR previously used in routine, no deviation higher than 0.5 log was
found in the testing of 21 clinical samples and several dilutions of the
NIBSC HIV-2 NIH-Z strain.
Conclusions: This assay allows us to quantificate HIV-2 A and B
subtypes with satisfactory sensibility and linearity, supporting the
clinical management of the infection.
Reference
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The association between high pre-HAART CD8 counts and
poorer immunological outcome following antiretroviral
therapy
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1Special Preventive Programme, Department of Health, Hong Kong
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Introduction: Nadir CD4 counts, advanced age and hepatitis C co-
infections are known predictors of poorer immune recovery follow-
ing HAART. As a high CD8 count was associated with inflammatory
non-AIDS-related clinical events, it could be another useful marker
for prognostic monitoring.
Methods: Anonymous clinical data from Integrated Treatment
Centre, the largest HIV service in Hong Kong, were accessed. Adult
HIV patients with available negative HIV testing result within 3
years before HIV diagnosis were targeted for the collection of the
following data: (a) CD4, CD8 and viral loads at all time points of
testing, (b) timing of AIDS diagnosis, as appropriate, (c) antiretroviral
treatment date and regimens. Cumulative viral load was estimated.
All eligible patients were divided into two groups by their pre-HAART
CD8 counts, that is, either 800/L or 5800/L, followed by multi-
variable logistic regression.
Results: As of the end of 2012, records of 199 treatment-naı¨ve
patients (median age 36) who had been on HAART continuously
for ]4 years were analyzed. A majority (90%) were male with men
who have sex with men (MSM) accounting for 58% of the study
population. Their median interval from diagnosis to the latest
assessment was 12.7 years. Either a protease inhibitor-based (70%)
or non-nucleoside reverse transcriptase inhibitor-based (30%) regi-
men was prescribed. The pre-HAART median CD4 and CD8 counts
were 158/L and 790/L, which were positively correlated (r0.51,
pB0.001). The median treatment duration was 78 months (IQR 57
112). At the end of a 4-year observation period, about half (56%) had
CD4 reaching 500/L or above, of which 45 (40.5%) gave a CD4:CD8
ratio of ]0.8. After adjusting for baseline CD4, patients with low
pre-HAART CD8 (5800/L) had a higher chance of achieving a higher
CD4 count (aOR 1.002, 95% CI 1.001.004). A low pre-HAART CD8
was also associated with optimal immune outcome defined as a CD4
count ]500/L in conjunction with a CD4:CD8 ratio ]0.8, with an
increased odds (aOR 6.64, 95% CI 2.5317.40) after adjusting for pre-
HAART CD4. Cumulative viral load from the time of estimated
seroconversion was not associated with pre-HAART CD8 count.
Conclusion: A pre-HAART CD8 count of 800/L gave a high odds of
poorer immune outcome. Pre-HAART CD8 count is an independent
predictor of an outcome measure comprising CD4 count and CD4:
CD8 ratio. While CD4 is a useful prognostic marker, the strength of
prediction increased with the addition of baseline CD8 count using a
cutoff of 800/mL.
Abstracts of the HIV Glasgow supplement
Journal of the International AIDS Society 2016, 19 (Suppl 7)
http://www.jiasociety.org/index.php/jias/article/view/21487 | http://dx.doi.org/10.7448/IAS.19.8.21487 Poster Abstracts
258
Abstract P258Figure 1. Molecular clock analysis of the 193 sequences from the Group 1 maximum likelihood phylogenetic tree. Produced
using a Bayesian Markov Chain Monte Carlo (MCMC) approach. Branches are coloured by location; AT  Austria, CN  China, DE  Germany, ES 
Spain, FR  France, GB  United Kingdom, IT  Italy, NL  Netherlands, PT  Portugal, US  United States of America. The MSM and IDU clusters
identified from this analysis are labelled on the figure. The sequences obtained from a Dutch MSMwho also reports injecting drug use is indicated
by a red arrow.
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